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The book Research on Melanoma: A Glimpse into Current Directions and Future 
Trends, is divided into sections to represent the most cutting-edge topics in melanoma 
from around the world. The emerging epigenetics of disease, novel therapeutics 
under development and the molecular signaling aberrations are explained in detail. 
Since there are a number of areas in which unknowns exist surrounding the complex 
development of melanoma and its response to therapy, this book illuminates and 
comprehensively discusses such aspects. It is relevant for teaching the novice 
researcher who wants to initiate projects in melanoma and the more senior researcher 
seeking to polish their existing knowledge in this area. Many chapters include visuals 
and illustrations designed to easily guide the reader through the ideas presented.
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Preface 
This is an exciting time for the field of melanoma research. So far in 2011 the FDA has
approved two new immunotherapies against this malignancy and is likely to vote on a 
targeted therapeutic soon. The clinical trials evaluating BRAF inhibitors are being 
discussed at major symposia and appearing in popular news media. There hasn’t been 
this much activity on melanoma therapeutics since 1998. For researchers it is particularly
exciting to see years of studying aberrant molecular mechanisms in the laboratory 
translate into the clinic. The goal of scientists who tirelessly study mechanisms of disease 
is this – to contribute to developing lifesaving interventions. Now is the time when this
dream is coming to fruition. Although the ability to cure every melanoma patient may 
still be elusive, exploiting melanoma’s molecular weaknesses and observing dramatic
effects provides hope and confidence to researchers that it can be done.
Thus, this book on melanoma research provides a glimpse of many diverse scientific
aspects that are currently underway in melanoma research laboratories around the
world. Although the topics are different they all have the same goals, to develop better 
understandings of malignancy and treatment methods. The sections of this book are
organized to reflect emerging trends in research, starting with epigenetics. The role of 
epigenetics is under investigation in melanoma as well as other types of cancers. There
is much progress to be made in this complex area to help explain the etiology of 
disease, a topic that patients always ask when attempting to pinpoint the source of 
their cancer. In addition, a subsequent section contains work discussing emerging,
promising and much‐needed therapeutics. Although newer drugs have an enhanced
ability for treatment, they also suffer from chemoresistance development, a huge
clinical problem among other cancer types. Thus, there is still much work to be done in 
the area of melanoma therapeutics. 
In the section on Molecular Signaling, the manuscripts cover a broad range of areas. 
The classical pathways are discussed, including BRAF, along with some emerging
proteins that are likely highly relevant to melanoma. This theme is continued with the
final section on Tumor Progression and the Microenvironment. Manuscripts organized 
in this section are focused on angiogenesis, the tumor microenvironment and
metastasis. All of these reflect clinical problems in need of additional research, 
whereby contributions aimed towards melanoma are likely to be translatable to 
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This book would not have been possible without the help of several wonderful people. 
These include Ana Pantar, Petra Nenadic, Juliet Eneh and Molly Altman. I would also 
like to thank my spouse, Gary Rollie, who has always been incredibly supportive of 
my career and dealt with me this past year as I worked on this project. I think he knew 
when I said, “This will only take a few more minutes”, that  it  wasn’t  true,  but  he 
patiently understood that at some point I would finish. 
Sincerely, 
 
Mandi Murph, Ph.D. 
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Predictive Capacity and Functional  
Significance of MicroRNA in  
Human Melanoma 
Xiaobo Li and Yaguang Xi 
Mitchell Cancer Institute, University of South Alabama, 
USA 
1. Introduction 
Melanoma is one of the most serious forms of cutaneous malignancies with an incidence of 
over two million people worldwide1. During 2010, an estimated 68,130 new patients were 
diagnosed with melanoma, and 8,700 deaths were attributed to the development of 
metastatic disease in the United States2. Compared to earlier stages of melanoma, the 
prognosis for patients with metastatic (stage IV) melanoma is very poor with six out of 
every seven skin cancer-related deaths being attributed to melanoma. However, our 
diagnostic and prognostic methods for melanoma are primarily histologic, such as Breslow’s 
depth of invasion, falling far short of being able to accurately predict the overall survival, 
recurrence risk, or clinical outcomes for patients3. There are several methods of treatment for 
metastatic melanoma, including radiation therapy, immunotherapy, chemotherapy, and 
palliative surgery2, 4, 5. However, there exists a clear and unfortunate understanding that 
these therapies are only minimally effective in treating patients with advanced disease6.  
MicroRNAs(miRNAs) are a set of small, average 22 nt in length, single-stranded, non-protein-
coding RNA molecules that can recognize and bind 3’-untranslated regions (UTR) of mRNA, 
blocking translation of the gene or inducing cleavage of the mRNA7, 8. To date, a total of 15,172 
miRNAs (Version 16.0), including 1,049 human miRNAs, have been registered in the miRbase 
database. The biogenesis of miRNA is similar to the other RNA starting from DNA 
transcription. A primary miRNA (pri-miRNA) is an independent transcript processed by RNA 
polymerase II (Pol II), which are bound in the nucleus by the microprocessor complex 
consisting of the RNase III-type endonuclease, Drosha, and its co-factor, Pasha (DGCR8).  
These enzymes can crop the pri-miRNA into a hairpin loop, cleaving off 3’ and 5’ regions of 
excess mRNA to give precursor miRNA (pre-miRNA) ~70 nt in length. Pre-miRNA is then 
actively transported to the cytoplasm by exportin-5 where it is bound by the RNAse III-type 
endonuclease, Dicer, which removes the loop, resulting in a duplex of complementary, mature 
miRNA sequences. One strand is bound by the RNA-induced silencing (RISC) complex, which 
guides mature miRNA to target mRNA for subsequent silencing. The remaining strand is 
usually degraded, but it may be bound by RISC and target its own mRNAs, which are denoted 
with an asterisk (i.e., miR-10b and miR-10b*)9, 10.  
In both plants and animals, miRNAs are capable of mediating gene expression by 
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miRNA can potentially bind hundreds to thousands of its cognate mRNA 3’UTR sequences. 
It is predicted that miRNAs may regulate upwards of 30% of all mammalian genes’ 
expression, due to their critical function in gene regulation and expression8. Thus, it is 
meaningful to understand their roles and significance in the essential cellular events, such as 
development, differentiation, proliferation, and apoptosis, which account for carcinogenesis, 




Fig. 1. MicroRNA biogenesis and biological functions 
Following a pilot study connecting B-cell chronic lymphocytic leukemia (CLL) and 
deregulated expression of miR-15a and miR-16-117, it has been demonstrated that more than 
50% of miRNA genes are located in cancer-associated genomic regions or within fragile 
sites18, and more and more miRNAs have been identified to play a central role in the 
pathogenesis of human cancers. Although it was in 2006 that the first study on miRNA in 
melanoma has reported that 86% of primary melanoma cell lines had DNA copy number 
alterations in genomic loci containing miRNA genes19, studies focusing on the roles of 
miRNA in the pathogenesis and development of melanoma have bloomed since 2008. 
Figure 2 illustrates the miRNAs reported by more than two studies or confirmed by 
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functional studies in the progression of melanoma20-26, suggesting that miRNAs play an 
important role in melanocyte and melanoma biology. To date, there are 77 publications that 
can be retrieved in PUBMED when using keywords “melanoma and miRNA”; more than 
99% of them were published in the latest three years, and half of them were published from 
2010 to 2011, which is evidence that this research field is rapidly expanding. However, a few 
knowledge and understanding gaps need to be filled before taking full advantage of miRNA 
signatures in melanoma research. In 2010, we were invited to author a review summarizing 
the accomplishments on the research of miRNA and melanoma27. Here, based on the 
previous review, we will highlight the latest progress in this field.  
 
 
Fig. 2. Representative miRNAs involved in the progression of melanoma 
2. Oncogenic miRNAs in melanoma 
The role of miRNAs in tumorigenesis depends on their target genes’ classification and 
abundance. When targeting tumor suppressor genes, these over-expressed miRNAs will 
play the promoting tumor roles as oncogenes; likewise, when targeting oncogenes, these 
miRNAs will have the characteristics of tumor suppressors. Kitago et al. reported that miR-
532-5p directly targeted the runt-related transcription factor 3 (RUNX3) tumor suppressor 
during the progression from melanocyte to metastatic melanoma28. MiR-532-5p was shown 
to be significantly up-regulated in melanoma cells compared to normal melanocytes and in 
metastatic melanoma tissue compared to primary melanoma tissue. The transfection of anti-
miR-532-5p molecules to the melanoma cells rescued the expression of RUNX3. Methylation 
analysis of the RUNX3 promoter region showed that transcriptional regulation was not a 
major regulatory mechanism for the down-regulation of RUNX3 expression in melanoma, 
suggesting miR-532-5p induced post-transcriptional regulation played an important role in 
melanoma progression. 
Zhang et al. demonstrated that the expression of miR-210, the most prominent miRNA up-
regulated by hypoxia and a direct transcriptional target of hypoxia inducible factors (HIFs), 
was elevated in multiple cancer types and correlated with breast cancer and melanoma 
metastases, respectively. MiR-210 over-expression in cancer cells bypassed hypoxia-induced 
cell-cycle arrest by directly targeting the expression of MNT, which is a gene known as one of 
the Myc antagonists. The miR-210-mediated abolishment of hypoxia-induced cell-cycle arrest 
was restored by the loss of Myc5. This finding indicated that miR-210 influenced the hypoxia 
response in tumor cells by triggering a Myc-like response by targeting MNT expression. 
The miR-200 family has received much attention for suppressing epithelial-mesenchymal 
transition (EMT) as well as their down-regulation in some tumors promotes invasion and 
metastasis. Interestingly, Elson et al. showed that levels of miR-200 are increased in 
melanoma cell lines compared to normal melanocytes. In melanoma cell lines, the 
expression of miR-200 members has no significant effect on suppressing invasion but 
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metastases, respectively. MiR-210 over-expression in cancer cells bypassed hypoxia-induced 
cell-cycle arrest by directly targeting the expression of MNT, which is a gene known as one of 
the Myc antagonists. The miR-210-mediated abolishment of hypoxia-induced cell-cycle arrest 
was restored by the loss of Myc5. This finding indicated that miR-210 influenced the hypoxia 
response in tumor cells by triggering a Myc-like response by targeting MNT expression. 
The miR-200 family has received much attention for suppressing epithelial-mesenchymal 
transition (EMT) as well as their down-regulation in some tumors promotes invasion and 
metastasis. Interestingly, Elson et al. showed that levels of miR-200 are increased in 
melanoma cell lines compared to normal melanocytes. In melanoma cell lines, the 
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instead leads to a switch between modes of invasion. For example, miR-200c results in a 
higher proportion of cells thus adopting the rounded, amoeboid-like mode of invasion by 
reduced expression of myristoylated alanine-rich protein kinase C substrate (MARCKS); 
meanwhile, miR-200a results in a protrusion-associated elongated mode of invasion by 
reduced actomyosin contractility. This study improved our understanding of the impacts of 
the miR-200 family on suppressing invasion and metastasis, and implied a novel insight of 
these miRNAs in melanoma29.  
3. Tumor suppressor miRNAs in melanoma 
Recently, miR-34 was identified as a target and a potential key responder of the tumor 
suppressor gene product, p53. Ectopic expression of miR-34a induced a G1 cell-cycle arrest, 
senescence, and apoptosis, which suggested that miR-34 was a potential tumor suppressor12. 
The altered expression of miR-34 was also found in melanoma progression22, 24, 30. Lodygin 
et al. reported that miR-34a expression is silenced in several types of cancer due to the 
aberrant CpG methylation of its promoter. Reportedly, 43.2% of melanoma cell lines and 
62.5% of primary melanoma samples displayed CpG methylation of the miR-34a promoter 
and loss of miR-34a expression, whereas the two samples of normal melanocytes included in 
the study did not show promoter methylation30. Migliore et al. identified three miRNAs, 
miR-34b, miR-34c, and miR-199a*, in melanoma cells that negatively regulate the expression 
of MET, which is an oncogene that encodes the tyrosine kinase receptor for hepatocyte 
growth factor24. MET is frequently over-expressed in many human tumors and promotes the 
‘invasive growth’ that results from the stimulation of cell motility and protection from 
apoptosis. Exogenous expression of these miRNAs in primary melanoma cells led to a 
decreased MET protein expression and resulted in the impairment of MET-mediated 
motility in these cells24. Recently, Yan et al. detected the expression level of miR-34a in uveal 
melanoma cells and melanocytes and found that miR-34a had been actively expressed in 
melanocytes but not in uveal melanoma cells. Additionally, the transfection of miR-34a into 
melanoma cells led to a significant repression of their growth and migration by down-
regulating the expression of c-Met directly and the expression of phosphorylated Akt (p-
Akt) and other cell-cycle-related proteins indirectly 22.  
Mazar et al. found the levels of miR-211 were reduced in melanoma cell lines compared 
with expression levels in melanocytes. Ectopically expressing miR-211 in different 
melanoma cell lines caused significant growth inhibition and reduced invasiveness by 
cleaving the mRNA and inhibiting the translation of KCNMA1, a highly expressed protein 
in metastasizing melanoma, prostate cancer, and glioma31. Another research study resulted 
in a similar but more interesting conclusion. MiR-211 is encoded within the sixth intron of 
TRPM1, which is known as melastatin and is greatly down-regulated in metastatic 
melanomas; it is widely believed to function as a melanoma tumor suppressor. Levy et al. 
reported that the tumor suppressive activity of TRPM1 in melanoma is not mediated by this 
gene itself but instead by miR-211 hosted within an intron of TRPM1 because of the 
increasing expression of miR-211 but not a TRPM1 reduced migration and invasion of 
invasive human melanomas cells. This result implicates miR-211 as a suppressor of 
melanoma invasion whose expression is silenced or selected against via the suppression of 
the entire TRPM1 locus during human melanoma progression. Additionally, they also 
identified three central node genes, IGF2R, TGFBR2, and NFAT5, as the target of miR-21132. 
Notably, the micropthalmia-associated transcription factor (MITF), which is important for 
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melanocyte development and function, is needed for high TRPM1 expression31, and thus, 
MITF contributes to miR-211 expression, suggesting that the tumor-suppressor activities of 
MITF may at least be partially executed through miR-211's tumor suppressing effect.  
MiR-196a is another documented tumor suppressor in melanoma by Dr.Bosserhoff’s group 
33, 34. First, they found that miR-196a was significantly down-regulated in malignant 
melanoma cell lines and tissue samples when screening differential miRNAs. Re-expressing 
miR-196a in vitro can dramatically reduce the invasive behavior of melanoma cells, which is 
partially believed to account for the negative regulating expression of the transcription 
factor HOX-C8, which is a member belonging to the homeobox genes family. By 
investigating a potential “miR-196a → HOX-C8 → target gene” model, they further 
identified cadherin-11, calponin-1, and osteopontin as the downstream targets of miR-
196a34. Additionally, they elucidated that down-regulated miR-196a in melanoma cells leads 
to enhanced HOX-B7 mRNA and protein levels, another member of the homeobox genes 
family, which subsequently raise Ets-1 activity, another transcription factor, by inducing 
basic fibroblast growth factor (bFGF). Ets-1 eventually up-regulates bone morphogenetic 
protein 4 (BMP-4)  playing an important role in melanoma progression33. 
Chen et al. reported that the over-expression of miR-193b in melanoma cell lines repressed 
cell proliferation by down-regulating cyclin D1 (CCND1). They identified 31 miRNAs that 
are differentially expressed (13 up-regulated and 18 down-regulated) in metastatic 
melanomas relative to benign nevi by profile-analyzing tissue samples from benign nevi and 
metastatic melanomas. Notably, miR-193b was significantly down-regulated in the 
melanoma tissues examined. Functional studies revealed miR-193b is a tumor suppressor in 
melanoma. Their study indicates that miR-193b is able to repress cell proliferation and 
regulate CCND1 expression, suggesting that the deregulation of miR-193b may play an 
important role in melanoma development35. 
4. Molecular mechanism of microRNA associated with melanoma 
The development of rational treatments for melanoma will depend on our taking advantage of 
its clinical features’ molecular basis. The necessary understanding of the molecular genetics 
underlying melanoma is gradually emerging36. Many key genes and signaling pathways have 
been characterized for their functions associated with melanoma. For example, the 
micropthalmia-associated transcription factor (MITF) is one of the most recognizable 
oncogenes in melanoma, which regulates cell proliferation and apoptosis, and is over-
expressed in 10-20% of human melanoma32. Also, it is a member in Myc supergene family of 
basic helix-loop-leucine-zipper transcription factors, which are necessary for functional 
melanocyte formation37. Because MITF’s critical role in melanoma progression, several recent 
studies have explored miRNAs’ impact on melanoma through MITF mediated pathways.   
4.1 MicroRNAs targeting MITF  
MicroRNA.org, an online database for miRNA targets prediction, provides more than 300 
miRNA candidates that putatively target MITF. However, only few of them have been 
verified.  
MiR-137 is located in the chromosomal region, 1p22, which is known to harbor an allele for 
melanoma susceptibility. The bioinformatics and in vitro analyses verified that miR-137 had 
targeted MITF in melanoma cells20. Most recently, Chen et al. reported the down-regulation 
of MITF by miR-137 in uveal melanoma cells38. Additionally, the over-expression of miR-137 
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in a similar but more interesting conclusion. MiR-211 is encoded within the sixth intron of 
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reported that the tumor suppressive activity of TRPM1 in melanoma is not mediated by this 
gene itself but instead by miR-211 hosted within an intron of TRPM1 because of the 
increasing expression of miR-211 but not a TRPM1 reduced migration and invasion of 
invasive human melanomas cells. This result implicates miR-211 as a suppressor of 
melanoma invasion whose expression is silenced or selected against via the suppression of 
the entire TRPM1 locus during human melanoma progression. Additionally, they also 
identified three central node genes, IGF2R, TGFBR2, and NFAT5, as the target of miR-21132. 
Notably, the micropthalmia-associated transcription factor (MITF), which is important for 
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melanocyte development and function, is needed for high TRPM1 expression31, and thus, 
MITF contributes to miR-211 expression, suggesting that the tumor-suppressor activities of 
MITF may at least be partially executed through miR-211's tumor suppressing effect.  
MiR-196a is another documented tumor suppressor in melanoma by Dr.Bosserhoff’s group 
33, 34. First, they found that miR-196a was significantly down-regulated in malignant 
melanoma cell lines and tissue samples when screening differential miRNAs. Re-expressing 
miR-196a in vitro can dramatically reduce the invasive behavior of melanoma cells, which is 
partially believed to account for the negative regulating expression of the transcription 
factor HOX-C8, which is a member belonging to the homeobox genes family. By 
investigating a potential “miR-196a → HOX-C8 → target gene” model, they further 
identified cadherin-11, calponin-1, and osteopontin as the downstream targets of miR-
196a34. Additionally, they elucidated that down-regulated miR-196a in melanoma cells leads 
to enhanced HOX-B7 mRNA and protein levels, another member of the homeobox genes 
family, which subsequently raise Ets-1 activity, another transcription factor, by inducing 
basic fibroblast growth factor (bFGF). Ets-1 eventually up-regulates bone morphogenetic 
protein 4 (BMP-4)  playing an important role in melanoma progression33. 
Chen et al. reported that the over-expression of miR-193b in melanoma cell lines repressed 
cell proliferation by down-regulating cyclin D1 (CCND1). They identified 31 miRNAs that 
are differentially expressed (13 up-regulated and 18 down-regulated) in metastatic 
melanomas relative to benign nevi by profile-analyzing tissue samples from benign nevi and 
metastatic melanomas. Notably, miR-193b was significantly down-regulated in the 
melanoma tissues examined. Functional studies revealed miR-193b is a tumor suppressor in 
melanoma. Their study indicates that miR-193b is able to repress cell proliferation and 
regulate CCND1 expression, suggesting that the deregulation of miR-193b may play an 
important role in melanoma development35. 
4. Molecular mechanism of microRNA associated with melanoma 
The development of rational treatments for melanoma will depend on our taking advantage of 
its clinical features’ molecular basis. The necessary understanding of the molecular genetics 
underlying melanoma is gradually emerging36. Many key genes and signaling pathways have 
been characterized for their functions associated with melanoma. For example, the 
micropthalmia-associated transcription factor (MITF) is one of the most recognizable 
oncogenes in melanoma, which regulates cell proliferation and apoptosis, and is over-
expressed in 10-20% of human melanoma32. Also, it is a member in Myc supergene family of 
basic helix-loop-leucine-zipper transcription factors, which are necessary for functional 
melanocyte formation37. Because MITF’s critical role in melanoma progression, several recent 
studies have explored miRNAs’ impact on melanoma through MITF mediated pathways.   
4.1 MicroRNAs targeting MITF  
MicroRNA.org, an online database for miRNA targets prediction, provides more than 300 
miRNA candidates that putatively target MITF. However, only few of them have been 
verified.  
MiR-137 is located in the chromosomal region, 1p22, which is known to harbor an allele for 
melanoma susceptibility. The bioinformatics and in vitro analyses verified that miR-137 had 
targeted MITF in melanoma cells20. Most recently, Chen et al. reported the down-regulation 
of MITF by miR-137 in uveal melanoma cells38. Additionally, the over-expression of miR-137 
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in uveal melanoma cells can lead to a significant decrease in cell growth through inducing 
G1 cell cycle arrest, which might be due to its suppression on oncogenic tyrosine kinase 
protein receptor c-Met, cell cycle-related protein CDK6, and MITF38.  
Segura et al. described miR-182 also as a negative regulator of MITF expression25. MiR-182 is 
located in 7q31-34, a chromosomal region frequently altered in melanoma. MiR-182 was 
demonstrated to increase the invasive potentials of melanoma cells by repressing MITF and 
FOXO3, a Forkhead family transcription factor. Importantly, 7q31-34 also harbors c-Met 
(encodes hepatocyte growth factor receptor with tyrosine-kinase activity) and BRAF 
(member of the raf/mil family of serine/threonine protein kinases), two important 
regulators in the MAPK/ERK signaling pathway39. They found that miR-182 was over-
expressed not only in human melanoma cell lines but also in tissue specimens. These results 
were inversely correlated with MITF and FOXO3 expression in the prediction of melanoma 
progression and development. Moreover, miR-182 ectopic expression in melanoma cells 
stimulated the anchorage-independent growth and invasion using an in vitro extracellular 
matrix assay, and promoted melanoma lung metastasis in a mouse model, whereas miR-182 
down-regulation impeded invasion and triggered apoptosis of melanoma cells.  
MiR-340 is capable of causing mRNA degradation by interacting with its 3'-UTR of MTIF. 
Interestingly, the RNA-binding protein coding region determinant-binding protein (CRD-
BP) is highly expressed in melanoma and can directly bind the 3'-UTR of MITF mRNA thus 
preventing miR-340 access, resulting in the stabilization of the MITF transcript and the 
elevation the transcription of MITF40.  
4.2 MiRNAs regulated by MITF in transcription 
As described earlier, miRNA has a similar transcription and regulatory process to other 
RNA molecules. MITF has been demonstrated as a transcriptional factor37.  Ozsolak et al. 
identified a number of miRNAs that were regulated by MITF in melanoma cells using 
nucleosome mapping and linker sequence analyses41. These miRNAs included some 
members of let-7 family (let-7a-1, -7d, -7f-1 and -7i), miR-221/222, miR-17-92 cluster, miR-
106-363 cluster, miR-29, miR-146a, miR-148b and miR-125b41. A few of them, such as let-7, 
miR-17-92, miR-221/222, and miR-148, have been documented for their abilities to connect 
many key genes and to signal pathways to melanoma. Here, we will illustrate a MITF-
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The Let-7 family is highly conserved across species in sequence and function, which were 
first validated to be involved in tumorigenesis42. Schultz et al. revealed five members of the 
let-7 family (let-7a, -7b, -7d, -7e, and -7g) as being significantly down-regulated in primary 
melanoma when compared with benign nevi, which suggested that the let-7 family might be 
tumor suppressors in melanoma43. The ectopic over-expression of let-7b diminished the 
anchorage-independent growth ability of melanoma cells and inhibited the cell-cycle 
progression. The over-expression of let-7b eventually repressed cyclins (D1, D3 and A) and 
cyclin-dependent kinase (CDK4) all of which had been described to play a role in melanoma 
development. Most recently, another study showed that the over-expression of let-7b in the 
melanoma cell line B16-F10 exhibited an inhibition of both cellular proliferation and colony 
formation. Let-7b can reduce lung metastasis by repressing the expression of basigin, which 
is a stimulator for tumor cells producing matrix metalloproteinases (mmps) and is highly 
expressed on the surface of tumor cells44. 
Let-7a is considered lost in melanoma when one is comparing primary melanocytes to 
malignant melanoma cell lines. Sequencing analysis suggested Let-7a had an interaction 
with the 3'UTR of integrin β3 mRNA26. Integrin β3 is highly related to melanoma 
progression and leads to an enhanced migratory and an enhanced invasive potential of 
melanoma cells45. The transfection of melanoma cells with let-7a pre-miR molecules resulted 
in the down-regulation of integrin β3 mRNA and protein expression, which suggested that 
the loss of let-7a expression might be one of the essential regulatory mechanisms leading to 
an increase integrin β3 expression in melanoma cells26. Muller et al. also proved that the 
over-expression of let-7a in melanoma cells reduced their invasive potential by 
approximately 75%; meanwhile transfection with let-7a anti-miRs and anti-sense 
oligonucleotides that directly binds and inhibits the actions of miRNAs, resulted in the 
induction of the integrin β3 expression and induced the migration of anti-let-7a-transfected 
melanocytes. These findings revealed let-7a to be an important integrin β3 regulator, and the 
loss of let-7a is thus involved in the development and progression of malignant melanoma. 
The miR-17-92 cluster locates to chromosome 13 and contains 6 members (miR-17, -18a, -19a, 
-20a, -19b-1 and -92a-1), while another  miRNA cluster, miR-106-363that shares many 
similarities with the miR-17-92 cluster locates to the X chromosome; it also consists of 6 
members (miR-106a, -18b, -20b, -19b-2, -92a-2 and -363). Both miRNA clusters are described 
as being oncogenic and found to be highly expressed in a variety of cancers46, 47. Muller et al. 
compared the miRnomes of normal human melanocytes and well characterized melanoma 
cell lines derived from primary tumors and melanoma metastases and showed that all 
members of the miR-17-92 cluster were up-regulated in primary tumor cell lines compared 
with normal melanocytes. The expression of the miR-17-92 cluster was even higher in 
metastatic cell lines with an approximately two-fold up-regulation as compared to primary 
melanoma cell lines. The expression of the miR-106-363 cluster was similar to the expression 
of the miR-17-92 cluster in melanocytes and melanoma cells. They detected a strong up-
regulation of miR-106a expression in primary tumor cells and a further increase in 
expression levels in metastatic melanoma cells48. In addition to finding miR-17-5p, miR-18a, 
miR-20a, and miR-92a over-expressed and miR-146a, miR-146b, and miR-155 down-
regulated in the majority of melanoma cell lines with respect to melanocytes, Levati et al. 
found that ectopic expression of miR-155 in melanoma cells inhibits the proliferation49. 
These results imply that the miR-17-92 cluster would be involved in melanoma progression. 
Both miR-221 and miR-222 are regulated by MITF at the transcription level21. These two 
miRNAs are clustered on the X chromosome, are transcribed as a common precursor, and 
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The Let-7 family is highly conserved across species in sequence and function, which were 
first validated to be involved in tumorigenesis42. Schultz et al. revealed five members of the 
let-7 family (let-7a, -7b, -7d, -7e, and -7g) as being significantly down-regulated in primary 
melanoma when compared with benign nevi, which suggested that the let-7 family might be 
tumor suppressors in melanoma43. The ectopic over-expression of let-7b diminished the 
anchorage-independent growth ability of melanoma cells and inhibited the cell-cycle 
progression. The over-expression of let-7b eventually repressed cyclins (D1, D3 and A) and 
cyclin-dependent kinase (CDK4) all of which had been described to play a role in melanoma 
development. Most recently, another study showed that the over-expression of let-7b in the 
melanoma cell line B16-F10 exhibited an inhibition of both cellular proliferation and colony 
formation. Let-7b can reduce lung metastasis by repressing the expression of basigin, which 
is a stimulator for tumor cells producing matrix metalloproteinases (mmps) and is highly 
expressed on the surface of tumor cells44. 
Let-7a is considered lost in melanoma when one is comparing primary melanocytes to 
malignant melanoma cell lines. Sequencing analysis suggested Let-7a had an interaction 
with the 3'UTR of integrin β3 mRNA26. Integrin β3 is highly related to melanoma 
progression and leads to an enhanced migratory and an enhanced invasive potential of 
melanoma cells45. The transfection of melanoma cells with let-7a pre-miR molecules resulted 
in the down-regulation of integrin β3 mRNA and protein expression, which suggested that 
the loss of let-7a expression might be one of the essential regulatory mechanisms leading to 
an increase integrin β3 expression in melanoma cells26. Muller et al. also proved that the 
over-expression of let-7a in melanoma cells reduced their invasive potential by 
approximately 75%; meanwhile transfection with let-7a anti-miRs and anti-sense 
oligonucleotides that directly binds and inhibits the actions of miRNAs, resulted in the 
induction of the integrin β3 expression and induced the migration of anti-let-7a-transfected 
melanocytes. These findings revealed let-7a to be an important integrin β3 regulator, and the 
loss of let-7a is thus involved in the development and progression of malignant melanoma. 
The miR-17-92 cluster locates to chromosome 13 and contains 6 members (miR-17, -18a, -19a, 
-20a, -19b-1 and -92a-1), while another  miRNA cluster, miR-106-363that shares many 
similarities with the miR-17-92 cluster locates to the X chromosome; it also consists of 6 
members (miR-106a, -18b, -20b, -19b-2, -92a-2 and -363). Both miRNA clusters are described 
as being oncogenic and found to be highly expressed in a variety of cancers46, 47. Muller et al. 
compared the miRnomes of normal human melanocytes and well characterized melanoma 
cell lines derived from primary tumors and melanoma metastases and showed that all 
members of the miR-17-92 cluster were up-regulated in primary tumor cell lines compared 
with normal melanocytes. The expression of the miR-17-92 cluster was even higher in 
metastatic cell lines with an approximately two-fold up-regulation as compared to primary 
melanoma cell lines. The expression of the miR-106-363 cluster was similar to the expression 
of the miR-17-92 cluster in melanocytes and melanoma cells. They detected a strong up-
regulation of miR-106a expression in primary tumor cells and a further increase in 
expression levels in metastatic melanoma cells48. In addition to finding miR-17-5p, miR-18a, 
miR-20a, and miR-92a over-expressed and miR-146a, miR-146b, and miR-155 down-
regulated in the majority of melanoma cell lines with respect to melanocytes, Levati et al. 
found that ectopic expression of miR-155 in melanoma cells inhibits the proliferation49. 
These results imply that the miR-17-92 cluster would be involved in melanoma progression. 
Both miR-221 and miR-222 are regulated by MITF at the transcription level21. These two 
miRNAs are clustered on the X chromosome, are transcribed as a common precursor, and 
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are over-expressed in a variety of cancers with the function of repressing the c-Kit receptor. 
In normal melanocytes, stem cell factor (SCF)-dependent c-Kit-mediated signaling supports 
proliferation, migration, and differentiation of cells50. Constitutive activation of c-Kit receptor 
tyrosine kinase (RTK) alone does not induce a tumorigenic transformation of the melanocytes 
in neither in vitro nor in vivo51; however, cutaneous melanoma are often characterized with a 
loss of c-Kit expression52. The inhibition of c-Kit RTK in c-Kit-positive melanoma showed an 
increased apoptosis and G1 phase cell-cycle arrest52, while the re-expression of c-Kit in the c-
Kit-negative melanoma cells restored c-Kit-mediated apoptosis and resulted in a loss of 
tumorigenic potential53. In accordance with these observations, Felicetti et al. found that up-
regulated miR-221/222 repressed the expression of the c-Kit receptor and p27Kip1 (cyclin-
dependent kinase inhibitor 1B, CDKN1B) tumor suppressor during melanoma progression 
from a weakly invasive primary tumor to a more invasive phenotype21. The over-expression of 
miR-221/222 in melanoma cells led to an increase in their proliferation and invasion in vitro 
and accelerated tumor growth in a mouse melanoma model. Conversely, treatment with anti-
miRs against both miRNAs resulted in a reduced proliferation rate and migration of 
melanoma cells with a high level of miR-221/222 abilities. They also found that the elevated 
expression of miR-221/222 in melanoma cells was caused by the loss of a transcription factor, 
promyelocytic leukemia zinc finger (PLZF). PLZF binds to the miR-221/222 promoter and 
inhibits their transcription in normal melanocytes.  
Cyclin-dependent kinase 2 (CDK2) has been reported to phosphorylate PLZF, triggering its 
ubiquitination and subsequent degradation54. Furthermore, p27Kip1 is important for the 
efficient induction of G1 cell-cycle arrest by PTEN and is necessary for PTEN-induced 
down-regulation of CDK2 55, 56. Additionally, PTEN is an inhibitor for Ha-ras-mediated 
astrocyte elevated gene-1 (AEG-1) transactivation 57. AEG-1 directly binds PLZF, preventing 
it from binding its target promoters58, including those of miR-221/222. Therefore, PTEN 
may be an important negative regulator of miR-221/222 in melanoma as it is capable to 
maintain PLZF levels to bind the miR-221/222 promoters, preventing their transcription. 
Although there are no miRNAs currently described to target PTEN in melanoma, recent 
reports highlighted miR-221/222 in aggressive non-small cell lung cancer (NSCLC) and 
hepatocarcinoma as oncomirs capable of directly targeting and inhibiting the expression of 
the tumor suppressor, PTEN 59, 60. As a result, there may be a positive feedback loop for 
miR-221/222 expression, promoting melanoma progression through the joint inhibition of 
PTEN and p27Kip1 and blocking PTEN/AEG-1/PLZF and/or p27Kip1/CDK2/PLZF-
mediated repression of miR-221/222. 
Additionally, Igoucheva et al. confirmed that c-Kit was down-regulated by miR-221/222 
and revealed that c-Kit regulation was mainly based on miRNA-dependent post-
transcriptional mechanisms instead of an AP-2-dependent transcriptional mechanism50. 
Recently, mutations have been identified in both miRNAs and target genes that disrupt 
regulatory relationships. Godshalk et al. described a genetic variant in the 3' UTR of the KIT; 
this KIT variant results in a mismatch in the seed region of a miR-221 complementary site 
and thus leads to an increased expression of the KIT oncogene 61. 
Haflidadóttir et al. suggested that miR-148 affects MITF mRNA expression in melanoma 
cells through a conserved binding site in the 3'UTR sequence of mouse and human MITF37. 
Interestingly, it seemed that MITF transcriptionally regulated the expression of miR-148b in 
melanoma cells41, which showed that there was a negative feedback regulation between 
miR-148 and MITF to control their balance.  
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5. Clinical applications of miRNA in melanoma  
5.1 Diagnostic miRNAs 
Several years ago, we and other groups independently demonstrated that miRNAs were 
relatively more stable and tolerate RNAases better than mRNAs in both archived tissue 
samples and in blood samples27, 41, 62, which suggests that miRNAs have the potential to be 
valuable, practical, and reliable biomarkers for disease states.  
Recently, several groups employed a high through-put microarray technique to discover 
miRNA biomarkers from formalin-fixed and paraffin-embedded (FFPE) melanoma 
samples9, 63, 64. A number of miRNAs have shown the potential to become diagnostic 
markers for melanoma based on data from clinical samples and array analysis9, 63, 
64.Radhakrishnan et al. examined the presence of oncogenic miRNA (oncomirs) in uveal 
melanoma using FFPE specimens by comparing miRNA expression profiles between non-
invasive tumor and melanoma metastatic to the liver. They revealed 19 miRNAs that were 
expressed in non-metastatic melanoma but were absent in metastatic melanoma, and they 
revealed 11 miRNAs with the opposite expression pattern65.  
In addition to FFPE samples, blood samples have been used to identify the melanoma tumor 
biomarkers66. Leidinger et al screened almost 900 human miRNAs, 55 blood samples, 
including 20 samples of healthy individuals, 24 samples of melanoma patients as test set, 
and 11 samples of melanoma patients as independent validation set. They identified 51 
altered miRNAs (21 down-regulated miRNAs and 30 up-regulated miRNAs) that can 
potentially distinguish melanoma patients from healthy controls. More excitingly, the panel 
consisting of 16 deregulated miRNAs can reach a classification accuracy of 97.4%, a 
specificity of 95%, and a sensitivity of 98.9%. Therefore, this study again demonstrates that 
signatures of miRNA expression can act as useful biomarkers for melanoma66  
Kanemaru et al, in particular, indentified the serum level of miR-221 as a new tumor marker 
in patients with malignant melanoma67. MiR-221 is usually up-regulated in malignant 
melanoma cells as we discussed earlier. By measuring the miR-221 levels in serum from 94 
malignant melanoma patients and 20 healthy controls, they found that the circulating miR-
221 was detectable and could be quantified in serum samples; the serum levels of miR-221 
were significantly increased in malignant melanoma patients when compared to healthy 
controls. Among the malignant melanoma patients, the miR-221 levels were significantly 
increased in patients with advanced melanoma compared to those with melanoma in situ, 
and the levels were correlated with tumor thickness. Moreover, they also revealed a 
decreasing tendency for the miR-221 levels along with the surgical removal of the primary 
tumor, but miR-221 was found to increase again at recurrence, which strongly suggested 
that circulating miR-221 may be useful not only for diagnosing malignant melanoma and for 
differentiating melanoma with different stages, but it could also be useful as a prognostic 
marker for patients with malignant melanoma67. 
5.2 Prognostic miRNAs 
Like miR-221, some other miRNAs have been reported for their prognostic signatures in 
melanoma. Worley et al. were the first to use a genome-wide, microarray-based approach to 
investigate the value of miRNA expression patterns in predicting metastatic risk in uveal 
melanoma. They found the most significant discriminator to classify low and high 
metastatic risk was let-7b and miR-199a expression. A classifier system that included the top 
six miRNA discriminators accurately distinguished melanoma patient tissues with high 
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metastatic propensity with 100% sensitivity and specificity23. Satzger et al. found that miR-
15b and miR-210 were significantly up-regulated in parallel with the down-regulation of 
miR-34a in melanoma compared to nevi. These three miRNAs were then analyzed in 128 
primary melanoma patients, including detailed clinical follow-up information; only the high 
expression of miR-15b was significantly correlated with the poor recurrence-free survival 
and overall survival by the univariate Kaplan-Meier and the multivariate Cox analyses. 
Furthermore, the transfection of anti-miR-15b into melanoma cells led to a reduced tumor 
cell proliferation and an increased apoptosis. Their results showed that miR-15b might be a 
novel melanoma biomarker contributing to poor prognosis and tumorigenesis68. Segura et 
al. identified the signature of a panel of miRNAs for predicting post-recurrence survival in 
metastatic melanoma by analyzing 59 formalin-fixed paraffin-embedded melanoma 
metastasis samples. Eighteen over-expressed miRNAs are significantly correlated with 
longer survival (>18 months). The signature of a six-miRNA panel (miR-150, miR342-3p, 
miR-455-3p, miR-145, miR-155, and miR-497) can have a better advantage to classify stage III 
patients into different  prognostic categories because it is an independent predictor of 
survival69. Additionally, the down-regulation of miR-191 and the up-regulation of miR-193b 
were reported to be associated with poor melanoma-specific survival70.  
5.3 Therapeutic miRNAs 
Since miRNAs are critical in regulating many cellular events and are highly deregulated in 
various cancers, including melanoma, it is likely that miRNAs could be effective targets for 
treatment. The basic strategies of miRNA-based therapeutics are: first, delivering highly 
expressed miRNAs that are tolerated in normal tissues but are lost in diseased cells , which 
may provide a general strategy for miRNA replacement therapies71; and second, using specific 
compounds targets aberrant oncogenic miRNAs, especially for over-expressed miRNAs. 
Sun et al. recently found that genistein, an isoflavone isolated from soybeans, inhibited 
human uveal melanoma cells growth in vitro and in vivo and altered the expression of miR-
27a and its target gene zinc finger and BTB domain containing 10 (ZBTB10), hinting at the 
contributions of miR-27a to genistein’s inhibitory effect on melanoma growth72. Das et al. 
found that human polynucleotide phosphorylase (hPNPase(old-35)), a type I IFN-inducible 
3'-5' exoribonuclease, can specifically down-regulate the expression of miR-221, a regulator 
of p27(kip1) and usually over-expressed in melanoma, as stated previously. This study 
implied that targeting over-expression of hPNPase(old-35) might provide an effective 
therapeutic strategy for miR-221-overexpressing and IFN-resistant tumors, such as 
melanoma73. MiR-137 acted as a tumor suppressor and usually decreased in uveal 
melanoma as previously described. Chen et al described one avenue to increase the 
expression levels of miR-137 through treatment with a DNA hypomethylating agent, 5-aza-
2'-deoxycytidine, or a histone deacetylase inhibitor, trichostatin A, for down-regulating its 
cognate target genes MITF and CDK638. MiR-182 is a pro-metastatic miRNA frequently 
over-expressed in melanoma. Huynh et al. assessed the effect of anti-miR-182 
oligonucleotides in a mouse model with melanoma liver metastasis and confirmed that miR-
182 levels were effectively down-regulated in the tumors of anti-miR-treated mice. This 
study implies that anti-miR may be a promising therapeutic strategy for metastatic 
melanoma74. Targeted delivery of RNA-based therapeutics for cancer therapy remains a 
challenge. By developing an improved liposome-polycation-hyaluronic acid (LPH) 
nanoparticle vehicle, Chen et al. reported that miR-34a was successfully delivered to B16-
F10 melanoma lung metastasis-bearing mice, and it could specifically suppress the 
surviving expression in the metastatic tumor and reduced tumor load in the lung75.  
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There were approximately 40 publications from the past year and a half that reported the 
involvement of miRNA in melanoma research from both laboratory and clinical settings, 
which evidences the perspective of miRNA as one of the most valuable biomarkers and 
therapeutic targets in current melanoma research. We are pleased to find the that research 
trend of miRNA and melanoma has changed from solely searching altered specific miRNAs 
to exploring molecular networks and connections between miRNAs and signaling pathways 
involved in the progression of melanoma (Table 1). Certainly, a better understanding of the 
biological machinery of miRNA function will allow us to visibly observe the genetic impacts 
on carcinogenesis and to explore effective therapeutic strategies for conquering melanoma 
in the near future. 
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1. Introduction 
Melanoma is responsible for 80% of all skin cancer deaths (Miller & Mihm, 2006), and it is 
the most common cause of cancer deaths between the age of 20 and 35 years old (Houghton 
& Polsky, 2002). Melanoma is a highly heterogeneous cancer that is caused by the 
accumulation of genetic and epigenetic defects allowing the cell to escape normal cellular 
controls. Genetic changes are caused by irreversible alterations in the DNA sequence, 
including chromosomal amplification or deletions and gene mutations that culminate in 
aberrant cellular functions, such as activation of oncogenes and inactivation of tumor 
suppressors. However, recent progress in cancer research has shown that epigenetic events 
may play a major role in establishing the correct program of gene expression. Epigenetics is 
defined as heritable changes in gene expression that are not due to any changes in the DNA 
sequence. Currently, four epigenetic drugs, vorinostat (Marks & Breslow, 2007), romidepsin 
(Campas-Moya, 2009), azacitidine (Mani & Herceg, 2010; Wijermans et al., 2005), and 
decitabine (Mani & Herceg, 2010), have been approved for the treatment of hematologic 
malignancies in the United States by the Food and Drug Administration (U.S. FDA).  
In a human cell, there are approximately two meters of diploid DNA that are packaged 
inside the nucleus with a volume of about 1000 μm3 (Kamakaka & Biggins, 2005). This 
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1. Introduction 
Melanoma is responsible for 80% of all skin cancer deaths (Miller & Mihm, 2006), and it is 
the most common cause of cancer deaths between the age of 20 and 35 years old (Houghton 
& Polsky, 2002). Melanoma is a highly heterogeneous cancer that is caused by the 
accumulation of genetic and epigenetic defects allowing the cell to escape normal cellular 
controls. Genetic changes are caused by irreversible alterations in the DNA sequence, 
including chromosomal amplification or deletions and gene mutations that culminate in 
aberrant cellular functions, such as activation of oncogenes and inactivation of tumor 
suppressors. However, recent progress in cancer research has shown that epigenetic events 
may play a major role in establishing the correct program of gene expression. Epigenetics is 
defined as heritable changes in gene expression that are not due to any changes in the DNA 
sequence. Currently, four epigenetic drugs, vorinostat (Marks & Breslow, 2007), romidepsin 
(Campas-Moya, 2009), azacitidine (Mani & Herceg, 2010; Wijermans et al., 2005), and 
decitabine (Mani & Herceg, 2010), have been approved for the treatment of hematologic 
malignancies in the United States by the Food and Drug Administration (U.S. FDA).  
In a human cell, there are approximately two meters of diploid DNA that are packaged 
inside the nucleus with a volume of about 1000 μm3 (Kamakaka & Biggins, 2005). This 
packaging of DNA is facilitated by histones. Histones are a group of highly conserved, basic 
(positively-charged) proteins that are rich in arginine and lysine residues. This DNA-protein 
complex is called the chromatin. In chromatin, proteins account for more than half of the 
weight, from which, histone proteins being the most abundant. There are five distinct 
families of histones, each with numerous variants or individual genes. DNA is packaged 
into nucleomes comprising a histone octamer of two copies of each core histones (H2A, H2B, 
H3, and H4) (Luger et al., 1997). The core histones interact in pairs. Two H3:H4 dimers 
interact together forming a tetramer, and two H2A:H2B dimers associate with the H3:H4 
tetramer to form a nucleosome. About 146 bp of DNA is wrapped around a histone octamer. 
One molecule of histone H1 associates at the position where the DNA enters and exits the 
nucleosome core, thus sealing the two turns of DNA (Luger et al., 1997).  
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These core histones contain a conserved C-terminal histone fold domain and unique N-
terminal tails. The histone N-terminal tails protrude from the nucleosome core and provide 
sites for posttranslational modifications, including acetylation, methylation, 
phosphorylation, and ubiquitination (Jenuwein & Allis, 2001). These distinct patterns of 
posttranslational modifications make up the histone code that is read by multiprotein 
chromatin remodelling complexes to determine the transcriptional status of the target gene 
(Strahl & Allis, 2000).  
2. Histone acetylation and histone deacetylases 
Epigenetic phenomena can be viewed as changes in the packaging and modifications of the 
DNA. In the case of DNA, it is modified only by methylation. Changes in the packaging of 
DNA include both histone modifications and chromatin remodeling. Histones can be 
modified by methylation, acetylation, phosphorylation, biotinylation, ubiquitination, 
sumoylation, and ADP-ribosylation. Lysine residues in the histone tails can be acetylated or 
methylated. Arginine residues can be methylated (Howell et al., 2009). 
Among all of the posttranslational modifications on histone tails, histone acetylation is 
among the most extensively studied. In normal cells, acetylation and deacetylation exist in 
equilibrium. Acetylation is a reaction that is catalyzed by histone acetyltransferases (HATs), 
and the deacetylation reaction is catalyzed by histone deacetylases (HDACs). These two 
families of enzymes regulate the delicate balance needed for maintaining the states of 
chromatin and chromatin dynamics (Figure 1).  
Acetylation is a reversible reaction occurring on lysine residues within the N-terminal 
tails of core histones H3 and H4. For histone acetylation, one of the hydrogens in the free 
amino group of internal lysine is substituted with an acetyl (CH3CO) group. The addition 
of an acetyl group removes the positive charge from the NH3+ group on lysine, thus 
neutralizing the basic charge of the histone tails. This modification is suggested to reduce 
the affinity between histones and DNA, which, in turn, correlates with active gene 
expression. Acetylated histone is usually associated with transcriptionally active 
chromatin (Hebbes et al., 1992; Kouzarides, 2007; Turner, 1993). In addition, it is involved 
in many processes, such as replication, nucleosome assembly, higher-order chromatin 
packing and interactions of nonhistone proteins (Grant & Berger, 1999). Lysine at amino 
acid positions 9, 14, 18, and 23 for histone H3 and at amino acid positions 5, 8, 12, 16 for 
histone H4 are frequent targets for acetylation. These histone modifications facilitate 
access and binding of transcription factors. 
Histone deacetylation is associated with an inactive (closed) state of chromatin and 
transcriptional repression (Kouzarides, 2007; Strahl & Allis, 2000). Deacetylation is catalyzed 
by histone deacetylases (HDAC). HDACs catalyze the removal of acetyl groups from lysine 
residues. HDACs and HATs are either part of a multiprotein transcriptional complex or 
interact with DNA binding proteins (Haberland et al., 2009; Jenuwein & Allis, 2001). 
Deregulation in the activity of HDACs and HATs may lead to alterations in gene expression 
and has been linked to diseases, particularly cancers.  Fraga et al (2005) found that the loss of 
acetylation of histone H4 at K16 and K20 is a common hallmark of human cancer. Recently, 
Kondo et al. (2008) found, 5% of the genes are silenced by trimethylation of H3K27 
independent of DNA methylation. 
 





Fig. 1. The states of chromatin and regulation of gene expression. HAT: Histone 
acetyltransferase; HDAC: Histone deacetylase. 
To date, 18 HDACs have been identified in humans. They are divided into four classes 
based on their homology to yeast HDACs (Table 1). Class I enzymes, which included 
HDACs 1, 2, 3, and 8, are related to the yeast RPD3 (de Ruijter et al., 2003; Paris et al., 2008). 
Class I HDACs 1, 2, and 3 are ubiquitously expressed and are almost exclusively found in 
the nuclei of cells in various cell lines and tissues (de Ruijter et al., 2003; Paris et al., 2008). 
Unlike HDACs 1-3, HDAC 8 is found only in cells with smooth muscle/myoepithelial 
differentiation. HDAC8 expression was found in smooth muscle cells where its expression is 
suggested to play a role in regulating the dynamics of smooth muscle cytoskeleton 
(Waltregny et al., 2004). These class I HDACs are involved in the regulation of proliferation, 
apoptosis, cardiac morphogenesis, and interferon (INF) expression through regulating gene 
expressions (Bernstein et al., 2000; Foglietti et al., 2006; Zupkovitz et al., 2006). Class II 
proteins, which included HDACs 4, 5, 6, 7, 9, and 10, share domains with the yeast HDAC-1 
(de Ruijter et al., 2003; Paris et al., 2008). Class II HDACs can shuttle between the nucleus 
and the cytoplasm (Paris et al., 2008). Class II HDAC 6 is not seen in lymphocytes, stromal 
cells, and vascular endothelial cells (Yoshida et al., 2004; Zhang et al., 2004). It is localized 
mainly in the cytoplasm. This HDAC6 enzyme is also found on the perinuclear and leading-
edge subcellular regions of cells. It is a microtubule-associated deacetylase (Hubbert et al., 
2002). HDAC 7 inhibits the expression of Nur77, which is involved in the regulation of 
apoptosis and negative selection during developing thymocytes (Dequiedt et al., 2005). 
Unlike class I HDACs, class II HDACs are found only in some tissues. The recently 
described class IV, comprised solely of HDAC 11 enzyme, shares features of classes I and II 
HDACs, such as the dependence on zinc for their enzymatic activity. Classes I, II and IV are 
zinc dependent proteases (de Ruijter et al., 2003; Gao et al., 2002; Glozak & Seto, 2007). Class 
III HDACs (sirtuins) have been identified based on sequence homology with the yeast 
transcription repressor Sir2. To date, seven different sirtuins have been identified, and all of 
the enzymes of class III require NAD+ for their activity. This class of enzymes is localized in 
the nucleus (de Ruijter et al., 2003; Glozak & Seto, 2007). HDACs can deacetylase non-
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histone proteins, such as tumor suppressors (e.g., p53), and signaling molecules (e.g., STAT1 
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2.1 Clinical applications of histone modifications 
Given the association between HDAC enzymes and cancers, there is growing interest in 
using HDAC inhibitors (HDACI) as antitumor agents. Inhibition of HDAC activity should 
lead to chromatin decondensation and an increase in gene transcription (Figure 1) 
(Karagiannis & El-Osta, 2006). HDACIs have been shown to have pleiotropic effects, 
including cell cycle arrest, growth inhibition and chromatin decondensation. They interfere 
directly with the mitotic spindle checkpoint, differentiation, and apoptosis in cancer cell 
types (Choi et al., 2007; Marchion & Munster, 2007; Stearns et al., 2007; Xu et al., 2005). Imre 
et al. (2006) showed that HDACIs reduce the responsiveness of tumor cells to the tumor 
necrosis factor-α (TNF-α) mediated activation of the nuclear factor-kappa B (NF-kappa B). 
All HDACIs upregulate p21, an important mediator of growth arrest (Richon et al., 2000). 
Studies in clinical trials have attempted to use HDACIs in combination therapy with some 
successes (Johnstone, 2002). This combined strategy has shown promise in some 
malignancies (Bishton et al., 2007).  
To date, more than 18 HDACIs have been tested in clinical trials for cancer therapy (Carew 
et al., 2008; Paris et al., 2008). In the United States, two histone deacetylase inhibitors, 
namely vorinostat (Zolinza) and romidepsin (Istodax), have been approved for the 
treatment of cutaneous T-cell lymphoma. HDACIs are usually classified into various groups 
based on their structures, including hydroxamic acids, cyclic peptides, short chain fatty 
acids, and benzamides. Hydroxamic acid derived compounds (trichostatin A, oxamflatin) 
have been used in clinical trials for treating both hematologic malignancies and solid 
tumors. These compounds contain an acid moiety that can fit into the catalytic site and bind 
to the zinc atom, thus inhibiting the HDAC enzyme (Marchion & Munster, 2007; Marks et 
al., 2000). For cyclic peptide group (depsipeptide, trapoxin), HDACIs are effective in 
nanomolar range. On the other hand, short chain fatty acid compounds (butyrate, 
trybutyrin) require relatively high concentrations for their action. A member of this group, 
valproic acid has been used in antiepileptic treatment. The use of valproic acid as an anti-
epileptic underlines the wide functional distribution of HDACs, contributing to problems 
targeting the cancer treatments using histone deacetylase inhibitors. The benzamide group 
molecules (MS-275, CI-994) exert their action at micromolar concentrations. Since the 
enzymatic pocket is highly conserved in nature, most HDACIs do not selectively inhibit 
individual HDAC enzymes. Rather, HDACIs inhibit several HDAC enzymes 
simultaneously. They target mainly classes I and II HDACs (Marks & Xu, 2009; Paris et al., 
2008). Table 2 shows the histone deacetylase inhibitors. 
Histone deacetylase inhibitors have been investigated in clinical trials for melanoma (Table 
3). A multicenter, phase II clinical trial was conducted to evaluate the efficacy, safety, and 
pharmacokinetics of the histone deacetylase inhibitor, pyridylmethyl-N-{4-[(2-
aminophenyl)-carbamoyl]-benzyl}-carbamate (MS-275) in 28 patients with pretreated 
metastatic melanoma. MS-275 is an oral benzamide HDACI. In the study, patients with 
unresectable American Joint Committee on Cancer (AJCC) stage IV melanoma, refractory to 
at least one earlier systemic therapy, were randomized to receive MS-275 3 mg bi-weekly or 
7 mg weekly on a 28-day cycle. The primary endpoint of the study was objective tumor 
response, and the secondary study endpoints were safety and time-to-progression. No 
objective responses were observed in pretreated metastatic melanoma patients. The median 
time-to-progession was comparable in both arms of the study. MS-275 was well tolearted, 
with nausea, diarrhea, and hypophosphatemia as the most frequently reported adverse 
events (Hauschild et al., 2008).  
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Due to the low response rates of HDACIs as single-agent therapies, HDACIs have also been 
investigated in combination with other therapeutic agents (Table 3).  In a phase I/II clinical 
trial for patients with stage IV melanoma, the combination of valproic acid and the 
topoisomerase I inhibitor karenitecin associated with disease stabilization in 47% of patients. 
The median overall survival and time-to-progression were 32.8 and 10.2 weeks, respectively. 
In addition, histone hyperacetylation was observed in peripheral blood mononuclear cells 
(Daud et al., 2009). 
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HDACIs have also been investigated in combination with other treatment modalities. A 
phase I/II study of HDACI valproic acid with standard chemoimmunotherapy in patients 
with advanced melanoma was conducted to evaluate its clinical activity and to assess 
toxicity. In the study, patients were treated initialy with valproic acid alone for 6 weeks. 
After the treatment with valproic acid alone, dacarbazine plus interferon-α therapy was 
started in combination with the valproic acid. However, the results showed that the 
combination of valproic acid and chemoimmunotherapy did not produce superior results as 
compared to standard therapy (Rocca et al., 2009). 
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3. DNA methylation 
DNA methylation is carried out by different DNA methyltransferases (DNMT). DNMT1 
involves in the maintenance of established methylation patterns. DNMT3a and DNMT3b are 
implicated in de novo DNA methylation (Bestor, 2000; Okano et al., 1999; Rothhammer & 
Bosserhoff, 2007). This epigenetic event takes place at the C5 position of cytosine on the CpG 
dinucleotide rich regions (CpG islands) that are distributed throughout the genome. Proper 
DNA methylation patterns are essential for human development and normal functioning. In 
normal cells, CpG islands located in the promoter regions are mainly unmethylated; 
however, in melanoma cancer cells, aberrant hypermethylation occur. In addition, genome-
wide hypomethylation occurs in melanoma cancer cells (Jones & Baylin, 2007). This 
epigenetic modification results in silencing the transcription of selected tumor suppressor 
genes (Robertson, 2005; Rothhammer & Bosserhoff, 2007). Aberrant DNA hypermethylation 
of promoter regions has been shown to result in the silencing of at least 50 genes (Fulda et 
al., 2001; Gallagher et al., 2005; Mori et al., 2005; Muthusamy et al., 2006; Paz et al., 2003; 
Rothhammer & Bosserhoff, 2007; Soengas et al., 2001; van der Velden et al., 2003). Table 4 
shows some genes affected by promoter DNA hypermethylation in melanoma. For example, 
CDKN2A is a major gene involved in the pathogenesis of melanoma. It is the most 
frequently mutated gene inherited in familial cutaneous melanoma (Palmieri et al., 2009; 
Sigalotti et al., 2010). Freedberg et al (2008) showed that aberrant promoter DNA 
hypermethylation at CDKN2A locus independently affects the tumor suppressors p16INK4A 
and p14ARF, which function in the pRB and p53 pathways, respectively. In human 
melanoma, p16INK4A and p14ARF are methylated.  
 
Gene Pathway Reference
APAF1(apoptotic protease activating 
factor 1) Apoptosis (Soengas et al., 2001)  
MT2A (methallothionein 2A) Apoptosis (Gallagher et al., 2005) 
HSPB1 (heat shock 27 kDa protein) Apoptosis (Gallagher et al., 2005)  
MAGE-A1(melanoma antigen, family A1) Immune recognition (De Smet et al., 1996; Karpf et al., 2004; Sigalotti et al., 2010) 
ER-α (estrogen receptor alpha) Signaling (Mori et al., 2006) 
WFDC1 (wap 4-disulfide core domain 1) Proliferation (Muthusamy et al., 2006) 
CDKN1B (cyclin-dependent kinase 
inhibitor 1B Cell cycle (Worm et al., 2000) 
CDKN1C (cyclin-dependent kinase 
inhibitor 1C) Cell cycle (Shen et al., 2007) 
APC (adenomatous polyposis coli gene) Cell fate determination (Worm et al., 2004) 
GDF15 (growth/differentiation factor 15) Differentiation (Muthusamy et al., 2006) 
TPM1 (tropomyosin 1) Anchorage-independent growth (Liu et al., 2008) 
MIB2 (skeletrophin) Cell fate determination (Takeuchi et al., 2006) 
MGMT (06-methylguanine-DNA-
methyltransferase) DNA repair (Hoon et al., 2004) 
CDH1 (E-cadherin) Invasion/metastasis (Liu et al., 2008)
CDH8 (cadherin 8) Invasion/metastasis (Muthusamy et al., 2006) 
Table 4. Genes with an altered DNA methylation status in melanoma 
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3.1 Clinical applications of DNA methylation 
DNA methylation is a reversible epigenetic event and can be nullified by specific DNA 
demethylating agents (DNA methyltransferase inhibitors).  Several ongoing clinical trials 
are conducted to investigate their clinical effectiveness and safety in melanoma patients 
(Table 3). In these studies, DNA demethylating agents 5-azacytidine (Vidaza) and 5-aza-2-
deoxycytidine (decitabine, Dacogen) are the most intensively studied. Azacytidine is a 
pyrimidine nucleoside analog of cytidine, and decitabine is a cytosine nucleoside (cytidine) 
analog. These epigenetic agents were approved by the FDA for the treatment of 
myelodysplastic syndromes and acute myeloid leukemia. Agents that inhibit DNA 
methyltransferases can reactivate silenced genes and induce apoptosis of cancerous cells 
(Howell et al., 2009). Since epigenetic modifications affect cellular pathways, epigenetic 
agents also display pleiotropic activities (Howell et al., 2009). In a phase I trial, Gollob et al. 
(2006) found that a low dose of 5-aza-2'-deoxycytidine (decitabine) can be safely 
administered with high-dose interleukin to cancer patients and has antitumor activity in 
melanoma. The inclusion of decitabine resulted in DNA hypomethylation. In addition, 
Appleton et al. (2007) showed that decitabine reduces DNA methylation and can be 
combined safely with carboplatin for the treatment of melanoma. 
In addition to therapeutic applications, modifications of DNA methylation may serve as 
biomarkers in clinical use for melanoma (Howell et al., 2009). Mori et al. (2006) showed that 
methylated ER-α can be detected in paraffin-embedded primary and metastatic melanoma 
tumors. In addition, methylated ER-α DNA was detected in the serum of melanoma patients 
with AJCC stage I to IV disease. Methylated ER-α was detected in 42% of stage III and 86% 
of stage IV metastatic melanomas. Serum methylated ER-α is an unfavorable prognostic 
factor. Liu et al (2008) found that SOCS1, SOCS2, RARβ2, DcR1, and DcR2 genes were the 
most frequently methylated genes in melanoma. The investigators also found that RECK, 
IRF7, PAWR, DR5, and Rb were not methylated in melanoma although these genes were 
found to be highly methylated in other cancers (Howell et al., 2009; Liu et al., 2008), 
suggesting that different cancers have distinct methylated genes. This is important since 
biomarkers must be specific and be able to differentiate between different forms of 
malignancies.  
4. Conclusions and future perspectives 
Melanoma is a complex disease that is caused by aberrant genetic and epigenetic events. 
Epigenetic modifications play a significant role in the biology of melanoma, and epigenetic 
therapy emerges as a promising treatment modality for melanoma as well as for dignostic 
developments for the malignancy. A major difference between the two events is that 
epigenetic changes can be reversed by chemical and/or environmental modalities. Histone 
modifications and DNA methylation are extensively studied epigenetic events that affect the 
expression of genes. Currently, four epigentic agents have been approved by the U.S. FDA 
for hematologic malignancies and many HDACIs and DNMTIs are being investigated in 
clinical trials for solid tumors, such as melanoma. However, there have not been any FDA-
approved epigenetic agents for solid tumors. Consequently, further investigations are 
required to find successful treatment strategies or protocols involving epigenetic agents. 
Future developments would address the issues of systemic toxicities, nonspecific epigenetic 
effect, and low bioavailability. In addition, a promising strategy is combination therapy. In 
tumors, DNA methylation and histone acetylation can act synergistically to silence tumor 
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suppressor genes. This approach could potentially enhance the reversal of epigenetic 
silencing. Although in its infancy, epigenetic therapy has been shown to be an effective 
treatment modality for cancers, as evident by the approval of 4 epigenetic drugs by the U.S. 
FDA. Encouraging results from preclinical and clinical trials prompts further investigations 
into designing new drugs or strategy that are more suitable for epigenetic therapies for 
melanoma patients, with the goal of improving patient outcomes. 
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1. Introduction 
The last two decades have registered a progressive decline of both the incidence and 
mortality rates for some human cancers, worldwide (Jemal et al., 2010). However, in the 
same time interval, the incidence of cutaneous melanoma (CM), has progressively increased 
(Gallagher et al., 2005; Jemal et al., 2010), up to an epidemic level in Western countries and 
Australia (Beddingfield et al., 2003; Cancer facts & Figures, 2009). To date, the average 
lifetime risk for developing melanoma ranges from 1/50 in the United States (men and 
women) (Meyle & Guldberg, 2009; Horner et al. 2011) up to 1/25 for Australian men 
(Hocker et al., 2008). CM is an extremely aggressive skin cancer, and constitutes one of the 
most lethal human malignancies, notwithstanding the progressive increase of early 
diagnosis and surgical excision registered from 1990s. This poor prognosis may be due, at 
least in part, to the possible occurrence of metastasis even in early phases of melanoma 
progression, as well as to the very low response to current systemic therapy. The 5 year-
survival rate for patients with disseminated disease is about 10%, with death for disease 
ultimately occurring within 2 years from metastases (Balch et al., 2000; Chin et al., 2006; 
Zbytek et al., 2008; Ugurel et al., 2009; Cancer facts & Figures, 2009). This underscores the 
need to uncover the mechanisms underlying melanoma biology, with the aim to identify 
reliable early markers of response and to select patients eligible for new rational avenues for 
therapy (Siena et al., 2009). The formidable aggressive potential of CM is thought to 
represent the result of multiple intersecting molecular alterations of the control pathways 
governing cell proliferation, cell death, DNA-repair, and tumor-stromal interaction. These 
molecular alterations are thought to be involved also in the peculiar histomorphological 
features and different biological behavior of the four “classical” types of CM. Three of them 
(superficial spreading melanoma, SSM; malignant lentigo melanoma, LM; acral melanoma, 
AM) are characterized by the sequential progression from junctional (radial) and pagetoid 
(intraepithelial) growth phase, to invasive (vertical) growth. The radial growth phase (RGP) 
is characterized by lateral melanocyte growth at the dermo-epidermal interface (junctional 
area), whereas the vertical growth phase (VGP) shows the spreading of melanoma cells into 
the dermis and subcutis, this being correlated with the occurrence of metastasis. The fourth 
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type of CM, the “nodular” melanoma (NM), shows an ab initio invasive growth, and a more 
aggressive clinical course. Considerable insights have recently been made with respect to 
these topics. An impressive number of putative biomarkers of CM progression and drug 
response are being increasingly proposed, and new hypotheses concerning the 
interrelationship between histopathological features and clinical behavior are in progress. 
To date, however, we have to face with an “overload” of research data, which has already 
had a great impact on our understanding of melanoma progression, but is only beginning to 
unravel the real complexity of CM biology. Further work is required before we definitively 
know how we can use correctly these data to fight melanoma. We here review the more 
recent advances in molecular events involved in melanoma progression, drawing on a 
limited set of examples focused on the seminal findings of several research groups that have 
provided insight on melanoma biology. We discuss also the surprising interactions between 
some of these molecular pathways, both at genetic and epigenetic level, with particular 
attention to their role in defining potential markers for prognosis and therapeutic 
management of melanoma patients. 
2. Genetics 
Since the announcement of the completion of the Human Genome Project in 2003 (Noble, 
2003), the first comprehensive analysis of cancer genomes has been completed: the entire 
genome of cutaneous melanoma and lung cancer has been sequenced. This formidable 
amount of information concerning the specific mutations of these cancer types will be of 
paramount importance in our understanding of the key molecular events that determine 
cancer evolution in every single patient. In tumors, most mutations are "passengers", 
meaning that they do not contribute to oncogenesis. Still, they provide information about 
the various steps leading to the oncogenic transformation of cells, as occurs, for example, for 
UV-exposure in skin cancer. This kinds of mutation, then, are very useful to study the 
pathogenesis of cancer. Only a small subset of somatic mutations is made of "driver 
mutations", which confer the oncogenic stigmata to cancer cells, being thus eligible for 
diagnosis and molecular therapy (Stratton et al, 2009). To date, more than 300 "driver" genes 
have been identified across all human cancers. Not surprisingly, they all converge over the 
few key cellular pathways which regulate cell life and differentiation (Vogelstein, 2010). The 
development and progression of melanoma is characterized by the acquisition of 
chromosomal deletions, amplification and gene mutations (Chin et al., 2006). The many gene 
expression profile studies performed up to now have evidenced that melanomas show 
significant genetic heterogeneity (Fecher et al., 2007; Ryu et al., 2007). Overall, large regions 
of the genome exhibiting DNA copy number changes and genes relevant for melanoma 
progression (Lin et al., 2008) as the Wnt5a, which misregulation results in increased motility 
in melanoma, have been identified (Lin et al., 2008). This also occurs for genes fundamental 
for basic melanocyte biology, such as Rab38, involved in melanosomal protein trafficking. 
We here refer to several genetic changes specifically linked to particular aspects of 
melanoma biology.  
2.1 UVR 
The dominant mutational signature emerging from sequencing the entire genome of 
cutaneous melanoma (Stratton et al, 2009) reflects DNA damage due to ultraviolet light 
exposure. Ultra-Violet Radiation (UVR) exerts direct or indirect damaging effects on nucleic 
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acids and proteins (Kyrgidis et al., 2010). UVA mutate DNA indirectly, via absorption by 
non-DNA endogenous sensitizers which generate Reactive Oxygen Species (ROS) 
responsible for DNA damage (Lund & Timmins, 2007).  UVB directly cause two types of 
DNA lesions: cyclobutane pyrimidine dimers (CPDs), arising between adjacent thymine(T) 
or cytosine(C) residues, and -pyrimidine 4-pyrimidone photoproducts (6-4PP) . The ‘‘UVB 
signature mutations” are characterized by CT→T and CC→TT transitions. Variants in 
MC1R, ASIP, TYR and TYRP1 have been identified as independent low-penetrance 
susceptibility genes for UV-induced melanomagenesis. These genes seem to contribute to 
the interrelation between pigmentation, cutaneous phototypes and exposure to UV light in 
affecting predisposition to melanoma (Thompson et al., 2009). Moreover, in melanomas of 
photoexposed skin, we have found defective expression of the mismatch-repair genes 
MHS2, which constitutes the phototype of mismatch-repair genes. It is actually thought that 
this may trigger microsatellite instability, thus contributing to the development of UV 
related skin tumors. In a previous study, we have shown also in oral melanomas that a 
deregulating expression of both hMSH2 and hMLH1 (mut L homologue 1) occurs. hMLH1 
is frequently silenced in tumors with microsatellite instability. Both these genes can actually 
predispose to mutational events during tumor progression. We hypothesized that the 
altered expression of both HMSH2 and hMLH1 contributes to the mutagenic effect of UVR 
on melanocytes and, in turn, may be also involved in  melanoma resistance to DNA 
damaging agents (Lo Muzio et al., 2000; Staibano et al., 2001). 
2.2 BRAF 
Alteration of the RAF/MEK/ERK pathway influences proliferation, invasion and survival 
of melanoma cells in vitro. For this reason it emerges then that B-Raf mutation has a pivotal 
role in determining melanoma biology, even if its exact function in melanoma progression 
remains still controversial. BRAF is a serine/threonine kinase that signals downstream of 
RTKs and RAS protein. Point mutations of B-Raf alter its auto-regulatory activation (Rother 
& Jones, 2009). The frequency of B-Raf mutations in melanoma and nevi is really impressive, 
being detectable in 30 to 80% of cases. Very interestingly, melanomas have a BRAF 
mutational spectrum different from other tumours, this probably reflecting the UVR 
environmental exposure (Thomas et al., 2006). This idea is further supported by the frequent 
occurrence of these mutations in SSM or NM of intermittently sun-exposed skin and in 
younger patients, whereas they are rare in AM (5-10%) and non-cutaneous melanomas 
(Platz et al., 2008). Over 30 distinct BRAF mutations, varying in biological activity, have 
been found and may be predictive of clinically relevant tumour differences (Thomas et al., 
2006). The most common is constituted by a glutamic acid (glu) for valine (val) substitution 
at residue 599 (V600E) in the activation segment. At present, in spite of all these technical 
information, we are far away to the understanding of the real meaning of BRAF mutation in 
melanoma. It seems to correlate with distinct histopathologic features, such as 
intraepidermal “pagetoid” spreading of cohesive nests of malignant melanocytes, and 
“pushing” rather than infiltrative border of the tumor, as well as with the younger age and 
lymph node metastasis at diagnosis (Rother & Jones, 2009). However, these hypotheses 
show considerable inconsistencies, if we consider that benign nevi show even higher rates of 
V600E BRAF mutation and cell line or transgenic mouse models of melanoma have failed to 
unequivocally demonstrate the transforming ability of this mutation (Rother J et al, 2009). 
Recently, Dhomen N et al. have developed a mouse model of BRAFv600E-driven 
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type of CM, the “nodular” melanoma (NM), shows an ab initio invasive growth, and a more 
aggressive clinical course. Considerable insights have recently been made with respect to 
these topics. An impressive number of putative biomarkers of CM progression and drug 
response are being increasingly proposed, and new hypotheses concerning the 
interrelationship between histopathological features and clinical behavior are in progress. 
To date, however, we have to face with an “overload” of research data, which has already 
had a great impact on our understanding of melanoma progression, but is only beginning to 
unravel the real complexity of CM biology. Further work is required before we definitively 
know how we can use correctly these data to fight melanoma. We here review the more 
recent advances in molecular events involved in melanoma progression, drawing on a 
limited set of examples focused on the seminal findings of several research groups that have 
provided insight on melanoma biology. We discuss also the surprising interactions between 
some of these molecular pathways, both at genetic and epigenetic level, with particular 
attention to their role in defining potential markers for prognosis and therapeutic 
management of melanoma patients. 
2. Genetics 
Since the announcement of the completion of the Human Genome Project in 2003 (Noble, 
2003), the first comprehensive analysis of cancer genomes has been completed: the entire 
genome of cutaneous melanoma and lung cancer has been sequenced. This formidable 
amount of information concerning the specific mutations of these cancer types will be of 
paramount importance in our understanding of the key molecular events that determine 
cancer evolution in every single patient. In tumors, most mutations are "passengers", 
meaning that they do not contribute to oncogenesis. Still, they provide information about 
the various steps leading to the oncogenic transformation of cells, as occurs, for example, for 
UV-exposure in skin cancer. This kinds of mutation, then, are very useful to study the 
pathogenesis of cancer. Only a small subset of somatic mutations is made of "driver 
mutations", which confer the oncogenic stigmata to cancer cells, being thus eligible for 
diagnosis and molecular therapy (Stratton et al, 2009). To date, more than 300 "driver" genes 
have been identified across all human cancers. Not surprisingly, they all converge over the 
few key cellular pathways which regulate cell life and differentiation (Vogelstein, 2010). The 
development and progression of melanoma is characterized by the acquisition of 
chromosomal deletions, amplification and gene mutations (Chin et al., 2006). The many gene 
expression profile studies performed up to now have evidenced that melanomas show 
significant genetic heterogeneity (Fecher et al., 2007; Ryu et al., 2007). Overall, large regions 
of the genome exhibiting DNA copy number changes and genes relevant for melanoma 
progression (Lin et al., 2008) as the Wnt5a, which misregulation results in increased motility 
in melanoma, have been identified (Lin et al., 2008). This also occurs for genes fundamental 
for basic melanocyte biology, such as Rab38, involved in melanosomal protein trafficking. 
We here refer to several genetic changes specifically linked to particular aspects of 
melanoma biology.  
2.1 UVR 
The dominant mutational signature emerging from sequencing the entire genome of 
cutaneous melanoma (Stratton et al, 2009) reflects DNA damage due to ultraviolet light 
exposure. Ultra-Violet Radiation (UVR) exerts direct or indirect damaging effects on nucleic 
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acids and proteins (Kyrgidis et al., 2010). UVA mutate DNA indirectly, via absorption by 
non-DNA endogenous sensitizers which generate Reactive Oxygen Species (ROS) 
responsible for DNA damage (Lund & Timmins, 2007).  UVB directly cause two types of 
DNA lesions: cyclobutane pyrimidine dimers (CPDs), arising between adjacent thymine(T) 
or cytosine(C) residues, and -pyrimidine 4-pyrimidone photoproducts (6-4PP) . The ‘‘UVB 
signature mutations” are characterized by CT→T and CC→TT transitions. Variants in 
MC1R, ASIP, TYR and TYRP1 have been identified as independent low-penetrance 
susceptibility genes for UV-induced melanomagenesis. These genes seem to contribute to 
the interrelation between pigmentation, cutaneous phototypes and exposure to UV light in 
affecting predisposition to melanoma (Thompson et al., 2009). Moreover, in melanomas of 
photoexposed skin, we have found defective expression of the mismatch-repair genes 
MHS2, which constitutes the phototype of mismatch-repair genes. It is actually thought that 
this may trigger microsatellite instability, thus contributing to the development of UV 
related skin tumors. In a previous study, we have shown also in oral melanomas that a 
deregulating expression of both hMSH2 and hMLH1 (mut L homologue 1) occurs. hMLH1 
is frequently silenced in tumors with microsatellite instability. Both these genes can actually 
predispose to mutational events during tumor progression. We hypothesized that the 
altered expression of both HMSH2 and hMLH1 contributes to the mutagenic effect of UVR 
on melanocytes and, in turn, may be also involved in  melanoma resistance to DNA 
damaging agents (Lo Muzio et al., 2000; Staibano et al., 2001). 
2.2 BRAF 
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remains still controversial. BRAF is a serine/threonine kinase that signals downstream of 
RTKs and RAS protein. Point mutations of B-Raf alter its auto-regulatory activation (Rother 
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mutational spectrum different from other tumours, this probably reflecting the UVR 
environmental exposure (Thomas et al., 2006). This idea is further supported by the frequent 
occurrence of these mutations in SSM or NM of intermittently sun-exposed skin and in 
younger patients, whereas they are rare in AM (5-10%) and non-cutaneous melanomas 
(Platz et al., 2008). Over 30 distinct BRAF mutations, varying in biological activity, have 
been found and may be predictive of clinically relevant tumour differences (Thomas et al., 
2006). The most common is constituted by a glutamic acid (glu) for valine (val) substitution 
at residue 599 (V600E) in the activation segment. At present, in spite of all these technical 
information, we are far away to the understanding of the real meaning of BRAF mutation in 
melanoma. It seems to correlate with distinct histopathologic features, such as 
intraepidermal “pagetoid” spreading of cohesive nests of malignant melanocytes, and 
“pushing” rather than infiltrative border of the tumor, as well as with the younger age and 
lymph node metastasis at diagnosis (Rother & Jones, 2009). However, these hypotheses 
show considerable inconsistencies, if we consider that benign nevi show even higher rates of 
V600E BRAF mutation and cell line or transgenic mouse models of melanoma have failed to 
unequivocally demonstrate the transforming ability of this mutation (Rother J et al, 2009). 
Recently, Dhomen N et al. have developed a mouse model of BRAFv600E-driven 
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melanoma, showing that V600E BRAF mutation alone stimulates proliferation of 
melanocytes but cannot induce full transformation, which presumably requires the 
acquisition of additional mutations (Dhomen N, et al., 2009). Nevertheless, the BRAFV600E 
has evolved into the most important target in melanoma. First-generation non-selective RAF 
inhibitor (Sorafenib) as a single therapy or in combination with carboplatin and paclitaxel 
(Hauschild et al., 2009), iinhibitors of the MAPK pathways with activity for either BRAF or 
MEK (as PLX4032, Flaherty et al., 2010), induction of specific cellular immunity against 
BRAFV600E, BRAFV600E inhibitors based on the crystal structure of BRAFV600E complexes, are 
providing conflicting results in patients with metastatic melanoma. New potent small 
molecule inhibitors of mutant BRAF, combined to the immunotherapy agent ipilimumab 
have demonstrated promising clinical activity. However, despite initial high response rates, 
in most cases these results persist for a short time and melanomas recur after a few months, 
showing resistance to the previously effective B-RAFv600E inhibitors (Nazarian et al., 2010; 
Villanueva et al., 2010). One invoked mechanism which can influence the clinical response 
to antineoplastic therapy could be the pharmacogenomic variation in both the tumor and 
the patient's genome (Wang et al., 2011). Recently, high-throughput screening methods have 
been proposed to uncover the mechanisms of resistance in these tumors (Garraway, 2010). 
However, further studies on B-RAF mutant melanomas are needed before definitive results 
will be reached. A recent genome-wide RNA-interference screening targeting 28,000 genes, 
identified 17 genes able to block uncontrolled proliferation of melanocytes in the presence of 
BRAFV600E, among them a relevant role seems to be played by IGFBP7 (insulin-like growth 
factor binding protein 7 ), which is often epigenetically silenced in primary melanomas. The 
functional relevance of these genes in human melanoma remains unclear.  Overall, it seems 
evident that several mechanisms act together during malignant transformation and 
progression of melanoma. Activating or inactivating mutations of members of the Akt 
signalling pathway (phosphatidylinositol 3-kinase CA, PI3KCA and Akt kinase) and 
mutations of tumor suppressor phosphatase and tensin homolog (PTEN) are frequently 
found in melanomas. Hopefully, targeting these molecular pathways will change the 
standard of care of metastatic melanoma in the future, but further studies focused on 
identifying predictors of chemotherapeutic response are needed. 
2.3 PTEN/AKT 
PTEN is a phosphatase that acts as a tumor suppressor gene, regulating the activation of the 
global regulators of cell proliferation serine/theronine kinases AKT1/2-3. Complete PTEN 
loss (usually due to genomic deletion) is found in 20-25% of melanomas, sometimes in 
combination with BRAF mutation, and leads to high-level AKT activation (Rother & Jones, 
2009). Rare activating mutations of the AKT1 or AKT3 isoforms have been found in sun-
exposed melanoma subtypes. Moreover, AKT overexpression may be associated with 
melanoma growth in situ. 
2.4 Timing of melanoma progression 
The central theme of melanoma research actually focuses on changes in gene expression 
occurring at the RGP/VGP shifting. We are now in a conceptual transition phase, in which 
the Clark model of neoplastic progression of melanocytes is being questioned. Basing upon 
the growing body of molecular data and considering the finding that many melanomas arise 
de novo on normal skin instead of from pre-exsisting melanocytic nevi, the biology of 
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melanocytic lineage could be examined from a point-of-view alternative to the postulated 
classical Clark model. This latter postulated that melanoma derives from (Takata et al., 2009) 
benign melanocytic nevus, which usually temporarily undergoes proliferation via oncogenic 
BRAF signalling, followed by growth arrest due to senescence induced by p16INK4/Rb. 
When a disruption of p16INK4a-retinoblastoma (Rb) pathway occurs, mostly by the 
inactivation of CDKN2A, the nevus become “dysplastic” and progressively more atypical, 
up to the RGP melanoma. At this stage, melanoma cells are dependent on growth factors 
secreted from keratinocytes, such as endothelin-1 (Murata et al., 2007), and are immortal, 
due to the activation of human telomerase reverse transcriptase (hTERT). In the vertical 
growth phase (VGP), mutations repressing apoptosis and favouring invasion (as PTEN loss, 
RAS activation, b-catenin activation) allow neoplastic melanocytes to survive in the absence 
of keratinocytes (Bennett 2003).  
According to this theory, the interaction between melanoma cells and stromal fibroblasts 
further promotes tumor growth, migration, and angiogenesis (Li et al. 2003), but recently it 
has been proposed to revise this model of neoplastic progression of melanocytes, basing on 
the same evidences. Firstly, melanocytic nevi often consist of polyclonal population of either 
wild-type BRAF and BRAF mutated-nevus cells; moreover as before mentioned, many 
melanomas arise de novo (Takata et al., 2009). The p16INK4a-Rb inactivation (by deletion, 
mutation or promoter methylation of the CDKN2A gene, amplification of CCND1 or CDK4, 
or Rb mutation) (Bennett, 2008) has been demonstrated in early RGP melanomas (Takata et 
al., 2009), which in turn acquire a proliferative mutation, such as BRAFV600E, and clonally 
proliferate, maintaining a minimum telomere length through activation of hTERT. The full 
oncogenic transformation to VGP melanoma requires additional genetic or epigenetic 
changes, suppressing apoptosis, altering cell-cell adhesion, and leading to 
hyperproliferation and stromal invasion, for example via up-regulation of genes coding for 
cell surface and secreted proteins, as Neuropilin-2 (NRP2), which plays a critical role in 
mediating melanoma-endothelial interactions (Stine et al., 2011). 
2.5 HIF1/ROS and melanoma-microenvironment 
ROS are mutagenic molecules. Most of apoptosis regulators are known to be potentially 
mutated or functionally altered by ROS: BRAF (RAS, MEK, and ERK within the MAPK 
pathway), PTEN, Rb and AKT (Wittgen & van Kempen, 2007; Fruehauf & Trapp, 2008). 
Melanoma cells generate large intracellular amounts of ROS (Sander et al., 2003) and excrete 
them into the extra cellular space. An upgraded ROS production has also been observed in 
dysplastic nevi (Pavel et al., 2004). ROS emerging as bio product during physiological 
melanin synthesis are neutralized within melanosomes by the anti-oxidant melanin. 
Melanosomes of malignant melanocytes produce excessive amounts of ROS (Gidanian et al., 
2008; Josse et al., 2010) and in addition produce, instead of the regular eumelanin, 
pheomelanin, which is associated with more oxidative stress. In view of these unique 
melanoma properties, elevated production of ROS seems to be a melanoma- specific defect 
(Fruehauf and Trapp, 2008). Other factors may contribute to elevate ROS levels around the 
primary tumor: the skin is a hypoxic tissue, leading to ROS production (Wittgen & van 
Kempen, 2007) and exogenous attacks (e.g. UV-radiation) further increase oxidative stress. 
In addition, tumor-associated immune cells also excrete ROS (Nishikawa, 2008). Reactive 
oxygen species derived from immune cells have been proposed to exert a ‘selective 
pressure’ on MM cells to develop ROS-resistance (Wittgen & van Kempen, 2007). Following 
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melanoma, showing that V600E BRAF mutation alone stimulates proliferation of 
melanocytes but cannot induce full transformation, which presumably requires the 
acquisition of additional mutations (Dhomen N, et al., 2009). Nevertheless, the BRAFV600E 
has evolved into the most important target in melanoma. First-generation non-selective RAF 
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(Hauschild et al., 2009), iinhibitors of the MAPK pathways with activity for either BRAF or 
MEK (as PLX4032, Flaherty et al., 2010), induction of specific cellular immunity against 
BRAFV600E, BRAFV600E inhibitors based on the crystal structure of BRAFV600E complexes, are 
providing conflicting results in patients with metastatic melanoma. New potent small 
molecule inhibitors of mutant BRAF, combined to the immunotherapy agent ipilimumab 
have demonstrated promising clinical activity. However, despite initial high response rates, 
in most cases these results persist for a short time and melanomas recur after a few months, 
showing resistance to the previously effective B-RAFv600E inhibitors (Nazarian et al., 2010; 
Villanueva et al., 2010). One invoked mechanism which can influence the clinical response 
to antineoplastic therapy could be the pharmacogenomic variation in both the tumor and 
the patient's genome (Wang et al., 2011). Recently, high-throughput screening methods have 
been proposed to uncover the mechanisms of resistance in these tumors (Garraway, 2010). 
However, further studies on B-RAF mutant melanomas are needed before definitive results 
will be reached. A recent genome-wide RNA-interference screening targeting 28,000 genes, 
identified 17 genes able to block uncontrolled proliferation of melanocytes in the presence of 
BRAFV600E, among them a relevant role seems to be played by IGFBP7 (insulin-like growth 
factor binding protein 7 ), which is often epigenetically silenced in primary melanomas. The 
functional relevance of these genes in human melanoma remains unclear.  Overall, it seems 
evident that several mechanisms act together during malignant transformation and 
progression of melanoma. Activating or inactivating mutations of members of the Akt 
signalling pathway (phosphatidylinositol 3-kinase CA, PI3KCA and Akt kinase) and 
mutations of tumor suppressor phosphatase and tensin homolog (PTEN) are frequently 
found in melanomas. Hopefully, targeting these molecular pathways will change the 
standard of care of metastatic melanoma in the future, but further studies focused on 
identifying predictors of chemotherapeutic response are needed. 
2.3 PTEN/AKT 
PTEN is a phosphatase that acts as a tumor suppressor gene, regulating the activation of the 
global regulators of cell proliferation serine/theronine kinases AKT1/2-3. Complete PTEN 
loss (usually due to genomic deletion) is found in 20-25% of melanomas, sometimes in 
combination with BRAF mutation, and leads to high-level AKT activation (Rother & Jones, 
2009). Rare activating mutations of the AKT1 or AKT3 isoforms have been found in sun-
exposed melanoma subtypes. Moreover, AKT overexpression may be associated with 
melanoma growth in situ. 
2.4 Timing of melanoma progression 
The central theme of melanoma research actually focuses on changes in gene expression 
occurring at the RGP/VGP shifting. We are now in a conceptual transition phase, in which 
the Clark model of neoplastic progression of melanocytes is being questioned. Basing upon 
the growing body of molecular data and considering the finding that many melanomas arise 
de novo on normal skin instead of from pre-exsisting melanocytic nevi, the biology of 
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melanocytic lineage could be examined from a point-of-view alternative to the postulated 
classical Clark model. This latter postulated that melanoma derives from (Takata et al., 2009) 
benign melanocytic nevus, which usually temporarily undergoes proliferation via oncogenic 
BRAF signalling, followed by growth arrest due to senescence induced by p16INK4/Rb. 
When a disruption of p16INK4a-retinoblastoma (Rb) pathway occurs, mostly by the 
inactivation of CDKN2A, the nevus become “dysplastic” and progressively more atypical, 
up to the RGP melanoma. At this stage, melanoma cells are dependent on growth factors 
secreted from keratinocytes, such as endothelin-1 (Murata et al., 2007), and are immortal, 
due to the activation of human telomerase reverse transcriptase (hTERT). In the vertical 
growth phase (VGP), mutations repressing apoptosis and favouring invasion (as PTEN loss, 
RAS activation, b-catenin activation) allow neoplastic melanocytes to survive in the absence 
of keratinocytes (Bennett 2003).  
According to this theory, the interaction between melanoma cells and stromal fibroblasts 
further promotes tumor growth, migration, and angiogenesis (Li et al. 2003), but recently it 
has been proposed to revise this model of neoplastic progression of melanocytes, basing on 
the same evidences. Firstly, melanocytic nevi often consist of polyclonal population of either 
wild-type BRAF and BRAF mutated-nevus cells; moreover as before mentioned, many 
melanomas arise de novo (Takata et al., 2009). The p16INK4a-Rb inactivation (by deletion, 
mutation or promoter methylation of the CDKN2A gene, amplification of CCND1 or CDK4, 
or Rb mutation) (Bennett, 2008) has been demonstrated in early RGP melanomas (Takata et 
al., 2009), which in turn acquire a proliferative mutation, such as BRAFV600E, and clonally 
proliferate, maintaining a minimum telomere length through activation of hTERT. The full 
oncogenic transformation to VGP melanoma requires additional genetic or epigenetic 
changes, suppressing apoptosis, altering cell-cell adhesion, and leading to 
hyperproliferation and stromal invasion, for example via up-regulation of genes coding for 
cell surface and secreted proteins, as Neuropilin-2 (NRP2), which plays a critical role in 
mediating melanoma-endothelial interactions (Stine et al., 2011). 
2.5 HIF1/ROS and melanoma-microenvironment 
ROS are mutagenic molecules. Most of apoptosis regulators are known to be potentially 
mutated or functionally altered by ROS: BRAF (RAS, MEK, and ERK within the MAPK 
pathway), PTEN, Rb and AKT (Wittgen & van Kempen, 2007; Fruehauf & Trapp, 2008). 
Melanoma cells generate large intracellular amounts of ROS (Sander et al., 2003) and excrete 
them into the extra cellular space. An upgraded ROS production has also been observed in 
dysplastic nevi (Pavel et al., 2004). ROS emerging as bio product during physiological 
melanin synthesis are neutralized within melanosomes by the anti-oxidant melanin. 
Melanosomes of malignant melanocytes produce excessive amounts of ROS (Gidanian et al., 
2008; Josse et al., 2010) and in addition produce, instead of the regular eumelanin, 
pheomelanin, which is associated with more oxidative stress. In view of these unique 
melanoma properties, elevated production of ROS seems to be a melanoma- specific defect 
(Fruehauf and Trapp, 2008). Other factors may contribute to elevate ROS levels around the 
primary tumor: the skin is a hypoxic tissue, leading to ROS production (Wittgen & van 
Kempen, 2007) and exogenous attacks (e.g. UV-radiation) further increase oxidative stress. 
In addition, tumor-associated immune cells also excrete ROS (Nishikawa, 2008). Reactive 
oxygen species derived from immune cells have been proposed to exert a ‘selective 
pressure’ on MM cells to develop ROS-resistance (Wittgen & van Kempen, 2007). Following 
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this hypothesis, the entire ‘ROS-saturated environment’ in and around the primary tumor 
may exert a selective pressure on MM cells, causing the selection of those with the highest 
ROS resistance, whereas unfit cells die of ROS-induced apoptosis. After acquiring ROS 
resistance to block apoptosis, MM cells can also use high ROS levels to further stimulate 
their metastatic potential (Nishikawa and Hashida, 2006) through an impressive variety of 
pathways; from induction of DNA changes and activation of cell proliferation, to 
destruction of surrounding tissue, induction of adhesion molecules, activation of metastatic 
processes and escaping immune surveillance. In summary, ROS act as pro-metastatic agents 
through a wide range of pathways (Josse et al., 2010), which in melanoma cells accumulates 
early in tumor progression due to the alteration of melanin produced by characteristically 
abnormal melanosomes (Fruehauf & Trapp, 2008; Meyskens, 2001; Gidanian et al., 2008). 
HIF-1 activity is highly regulated by hydroxyl radicals and other reactive oxygen species 
(ROS) (Kietzmann & Gorlach, 2005; Wittgen & van Kempen, 2007, Kuphal et al., 2010) HIF-1 
molecular complex is the major transcriptional regulator of the cellular and systemic 
response to a hypoxic environment, and is involved in cancerogenesis, regulating the 
expression of factors fundamental for angiogenesis (VEGF) and tumour invasion (glycolytic 
enzymes) (Forsythe et al., 1996; Wenger, 2002; Wiesener & Maxwell, 2003; Erler et al., 2006). 
HIF-1 contributes also to the induction of vasculogenic mimicry (Sun et al., 2007). In 
melanoma cells HIF-1 expression is also regulated both at the translational and 
transcriptional level by various other molecular ways, comprising the 
AKT/phosphatidylinositol 3-kinase (PI3K) pathway, (Jiang et al., 2001) enhanced by the 
hypoxic skin environment, and by V600E BRAF (Minet et al., 2000; Galabova-Kovacs et al., 
2006) and the transcription factor NFkappaB (Bonello et al., 2007, Rius et al., 2008). This 
latter, in turn, is constitutively upregulated in melanoma cell lines (Kuphal et al., 2004) and, 
in addition, may be regulated by ROS and/or JNK, either induced by UVR or directly 
triggered by the activation of the RAS/RAF/MEK pathway (Tobar et al., 2008; Bonello et al., 
2007; Li & Karin, 1999; Kuphal et al., 2010). HIF-1 activity is modulated also by mTOR. In 
particular, it has been shown that downregulation of HIF-1 by the mTOR inhibitor 
rapamycin prevents transformation under hypoxia, this suggesting that Rapamycin may be 
proposed as a therapeutic approach in melanoma treatment (Bedogni et al., 2005; Michaylira 
& Nakagawa, 2006). This is of particular interest, considering that Rapamicin has been 
shown to stimulate apoptosis in melanoma cell lines through the specific inhibition of 
FK506-binding protein 51 (FKBP51) isomerase activity (Romano et al., 2004).This protein 
belongs to a family of immunophilins physiologically expressed in lymphocytes, involved in 
the regulation of several fundamental biological processes and over-expressed in cancers 
and premalignant lesions. FKBP51 has been associated to the apoptosis resistance of 
malignant melanoma. In a recent study, we demonstrated that the expression of FKBP51 is 
markedly increased in vertical growth phase of melanomas and in metastatic lesions, 
providing evidence that FKBP51 is a marker of melanocyte malignancy (Romano et al., 
2010a, 2010b). In addition we found that FKBP51 is a factor of resistance to genotoxic agents, 
including anthracyclins and ionizing radiations, through NF-kB activation. 
2.6 cKIT 
KIT encodes a receptor tyrosine kinase (RTK), which is recognized as a ligand for a stem cell 
factor (SCF) (Takata et al., 2009). Dysregulation of KIT plays a role in systemic mastocytosis, 
acute myelogenous leukaemia, gastrointestinal stromal cell tumors (GISTs) and germ cell 
tumors (Patnaik et al., 2007). A critical role for c-Kit for normal neural crest and normal 
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melanocyte development, (Rother & Jones, 2009) differentiation, proliferation, survival and 
migration (Wehrle-Haller, 2003) has been recognized, but its function in melanoma remains 
somewhat unclear. As a rule, c-Kit expression is lost during melanoma progression, but a 
subset of melanomas has been found to overexpress it and mutations activating c-Kit, 
mostly constituted by L576P (up to 50% of mutations), have recently been identified in some 
mucosal and AL melanoma subtypes (5-20% of cases), but not in cases arising from chronic 
sun-damaged skin (Rother & Jones, 2009; Monsel et al., 2010). KIT is expressed at maximum 
level at the invading edge of tumors, this suggesting a role for dynamic RTK activation in 
metastasis (Handolias et al., 2010). Monsel et al (Monsel et al., 2010) demonstrated that c-Kit 
mutated melanocytes require a specific epigenetic environment to be transformed in 
melanoma cells. c-Kit mutants cause in fact a strong activation of the phosphatidyl-inositol-3 
kinase (PI3K) pathway, which, per se, is not sufficient to promote transformation of 
melanocytes. However, in the chronic hypoxic skin microenvironment, and/or when a 
constitutively active form of hypoxia-inducible factor 1alpha (HIF-1alpha) is coexpressed, c-
Kit mutants activate also the Ras/Raf/Mek/Erk pathway, transforming the melanocytes, 
(Monsel et al., 2010). This scenario is extremely interesting, considering that KIT mutations 
are mutually exclusive with BRAF and NRAS, to identify a subset of melanomas arising 
from a distinct molecular mechanism of transformation, which may be specifically targeted 
by KIT inhibitors, such as imatinib or sorafenib (Monsel et al., 2010).  
2.7 Plexin B1 
Plexin B1 interacts with small G proteins to regulate cell proliferation, migration, and 
apoptosis, and is repressed by oncogenic B-RAF signalling; its loss of expression in vivo has 
been documented in breast cancer and renal cell carcinoma (Stevens et al., 2010). Plexin B1 
functions as a tumor suppressor in melanoma cells, as it has been recently shown in a mouse 
model (Stevens et al., 2010; Argast et al., 2009). Introduction of plexin B1 into melanoma cell 
lines suppresses tumor formation in mice (Rody et al., 2009; Gomez Roman et al., 2008; 
Argast et al., 2009), this being thought to be due, at least in part, to suppression of c-Met 
signalling and c-Met-dependent migration. Recently, it has been evidenced that plexin B1 is 
lost in metastatic and deeply invasive melanoma in patient samples in vivo (Stevens et al., 
2010), whereas it is generally hyperexpressed in benign nevi and thin melanomas. This 
finding suggests that the loss of plexin B1 contributes to late stages of melanoma 
progression, including invasion and metastasis. Recent evidences indicate that plexin B1 can 
also activates the PI3-kinase-Akt pathway, thus functioning as a tumor promoter and 
inhibitor of apoptosis in melanomas not driven by c-Met activation (Stevens et al., 2010). 
These results require further investigation. If confirmed, they could indicate that the final 
action of plexin B1 on melanoma progression may depend on the balance between c-Met 
receptor blockade and the interaction of plexin B1 receptor to downstream targets 
independent of c-Met signalling, such as Akt.  
2.8 Tumor-stromal interactions 
Mutant BRAF melanomas show high levels of constitutively activated Erk 1,2 (Houben et 
al., 2004). Consequences of Erk 1,2 pathway activation include induction of cell proliferation, 
expression of melanoma transcription factors, matrix metalloproteinases, specific integrin 
subunits, and resistance to apoptosis (Rubinstein et al., 2010). Melanoma chondroitin sulfate 
proteoglycan (MCSP) is a plasma membrane-associated proteoglycan which interacts with 
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ROS resistance, whereas unfit cells die of ROS-induced apoptosis. After acquiring ROS 
resistance to block apoptosis, MM cells can also use high ROS levels to further stimulate 
their metastatic potential (Nishikawa and Hashida, 2006) through an impressive variety of 
pathways; from induction of DNA changes and activation of cell proliferation, to 
destruction of surrounding tissue, induction of adhesion molecules, activation of metastatic 
processes and escaping immune surveillance. In summary, ROS act as pro-metastatic agents 
through a wide range of pathways (Josse et al., 2010), which in melanoma cells accumulates 
early in tumor progression due to the alteration of melanin produced by characteristically 
abnormal melanosomes (Fruehauf & Trapp, 2008; Meyskens, 2001; Gidanian et al., 2008). 
HIF-1 activity is highly regulated by hydroxyl radicals and other reactive oxygen species 
(ROS) (Kietzmann & Gorlach, 2005; Wittgen & van Kempen, 2007, Kuphal et al., 2010) HIF-1 
molecular complex is the major transcriptional regulator of the cellular and systemic 
response to a hypoxic environment, and is involved in cancerogenesis, regulating the 
expression of factors fundamental for angiogenesis (VEGF) and tumour invasion (glycolytic 
enzymes) (Forsythe et al., 1996; Wenger, 2002; Wiesener & Maxwell, 2003; Erler et al., 2006). 
HIF-1 contributes also to the induction of vasculogenic mimicry (Sun et al., 2007). In 
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AKT/phosphatidylinositol 3-kinase (PI3K) pathway, (Jiang et al., 2001) enhanced by the 
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and premalignant lesions. FKBP51 has been associated to the apoptosis resistance of 
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providing evidence that FKBP51 is a marker of melanocyte malignancy (Romano et al., 
2010a, 2010b). In addition we found that FKBP51 is a factor of resistance to genotoxic agents, 
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2.6 cKIT 
KIT encodes a receptor tyrosine kinase (RTK), which is recognized as a ligand for a stem cell 
factor (SCF) (Takata et al., 2009). Dysregulation of KIT plays a role in systemic mastocytosis, 
acute myelogenous leukaemia, gastrointestinal stromal cell tumors (GISTs) and germ cell 
tumors (Patnaik et al., 2007). A critical role for c-Kit for normal neural crest and normal 
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melanocyte development, (Rother & Jones, 2009) differentiation, proliferation, survival and 
migration (Wehrle-Haller, 2003) has been recognized, but its function in melanoma remains 
somewhat unclear. As a rule, c-Kit expression is lost during melanoma progression, but a 
subset of melanomas has been found to overexpress it and mutations activating c-Kit, 
mostly constituted by L576P (up to 50% of mutations), have recently been identified in some 
mucosal and AL melanoma subtypes (5-20% of cases), but not in cases arising from chronic 
sun-damaged skin (Rother & Jones, 2009; Monsel et al., 2010). KIT is expressed at maximum 
level at the invading edge of tumors, this suggesting a role for dynamic RTK activation in 
metastasis (Handolias et al., 2010). Monsel et al (Monsel et al., 2010) demonstrated that c-Kit 
mutated melanocytes require a specific epigenetic environment to be transformed in 
melanoma cells. c-Kit mutants cause in fact a strong activation of the phosphatidyl-inositol-3 
kinase (PI3K) pathway, which, per se, is not sufficient to promote transformation of 
melanocytes. However, in the chronic hypoxic skin microenvironment, and/or when a 
constitutively active form of hypoxia-inducible factor 1alpha (HIF-1alpha) is coexpressed, c-
Kit mutants activate also the Ras/Raf/Mek/Erk pathway, transforming the melanocytes, 
(Monsel et al., 2010). This scenario is extremely interesting, considering that KIT mutations 
are mutually exclusive with BRAF and NRAS, to identify a subset of melanomas arising 
from a distinct molecular mechanism of transformation, which may be specifically targeted 
by KIT inhibitors, such as imatinib or sorafenib (Monsel et al., 2010).  
2.7 Plexin B1 
Plexin B1 interacts with small G proteins to regulate cell proliferation, migration, and 
apoptosis, and is repressed by oncogenic B-RAF signalling; its loss of expression in vivo has 
been documented in breast cancer and renal cell carcinoma (Stevens et al., 2010). Plexin B1 
functions as a tumor suppressor in melanoma cells, as it has been recently shown in a mouse 
model (Stevens et al., 2010; Argast et al., 2009). Introduction of plexin B1 into melanoma cell 
lines suppresses tumor formation in mice (Rody et al., 2009; Gomez Roman et al., 2008; 
Argast et al., 2009), this being thought to be due, at least in part, to suppression of c-Met 
signalling and c-Met-dependent migration. Recently, it has been evidenced that plexin B1 is 
lost in metastatic and deeply invasive melanoma in patient samples in vivo (Stevens et al., 
2010), whereas it is generally hyperexpressed in benign nevi and thin melanomas. This 
finding suggests that the loss of plexin B1 contributes to late stages of melanoma 
progression, including invasion and metastasis. Recent evidences indicate that plexin B1 can 
also activates the PI3-kinase-Akt pathway, thus functioning as a tumor promoter and 
inhibitor of apoptosis in melanomas not driven by c-Met activation (Stevens et al., 2010). 
These results require further investigation. If confirmed, they could indicate that the final 
action of plexin B1 on melanoma progression may depend on the balance between c-Met 
receptor blockade and the interaction of plexin B1 receptor to downstream targets 
independent of c-Met signalling, such as Akt.  
2.8 Tumor-stromal interactions 
Mutant BRAF melanomas show high levels of constitutively activated Erk 1,2 (Houben et 
al., 2004). Consequences of Erk 1,2 pathway activation include induction of cell proliferation, 
expression of melanoma transcription factors, matrix metalloproteinases, specific integrin 
subunits, and resistance to apoptosis (Rubinstein et al., 2010). Melanoma chondroitin sulfate 
proteoglycan (MCSP) is a plasma membrane-associated proteoglycan which interacts with 
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distinct Erk-binding sites (Yang et al., 2009). As for Erk 1,2, its functions range from 
remodelling tumor microenvironments, facilitating the growth, invasion and motility of 
tumor cells to modify the organization of the cytoskeleton by modulating the activity of Rho 
family. Normal melanocytes express little or no MCSP, while the protein expression 
increases from benign and dysplastic nevi (Campoli et al., 2004) to melanoma. In RGP 
melanoma, MCSP expression enhances integrin function and constitutive activation of Erk 
1,2. As already shown in acral lentiginous melanoma (such as in acute lymphoblastic 
leukaemia) MCSP expression is thought to be associated with a poor prognosis (Kageshita et 
al., 1991). These evidences indicate that MCSP, as a member of the Erk 1,2 pathway, may be 
considered as a promising therapeutic target in the treatment of melanoma. 
3. Epigenetics 
Epigenetics refers to changes in phenotype or gene expression without alterations of the 
DNA sequence. These changes occur at a much higher frequency compared to gene 
mutation, and may persist for the entire cell life and even for multiple generations (Kyrgidis 
et al., 2010). These “epimutations”allow the cell to modulate the transcriptional activity of a 
given gene, from high-level expression to complete silencing. Transcription results from the 
activity of the RNA polymerase machinery and depends on the ability of transcription 
activators and repressors to access chromatin at specific promoters (Santos-Rosa & Caldas, 
2005). Chromatin is the dynamic scenario in which all the genomic functions take place; its 
structure is governed by the interplay of complex regulatory systems, which guarantee the 
maintenance of higher order chromosomal organization. Our understanding of how 
modulation of chromatin influences cell fate in normal as in neoplastic cells has been greatly 
improved during the last two decades. DNA replication, repair and transcription are 
achieved through the interplay of DNA modification and alteration in DNA packaging 
(Rountree et al., 2001). These mechanisms cooperate to establish the pattern of gene 
expression (Hashimshony et al., 2003) concerning every fundamental cell function, from cell 
growth and differentiation, to DNA repair and apoptosis. They operate through the 
induction of changes in chromatin architecture induced by histones (Dong & Bode, 2006) 
and “chromatin modifiers” (Kyrgidis et al., 2010). Histones are the main protein components 
of chromatin. Covalent post-translational modifications of the amino termini of the core 
histones in nucleosomes consist of methylation, acetylation, phosphorylation, ubiquitination 
and SUMOylation, and determine the “histone code” (Berger, 2002). 
3.1 DNA methylation 
DNA methylation occurs on lysine and arginine residues on histone tails. One preferred site 
of methylation is the C5 position of cytosine in the context of CpG dinucleotides. The latter 
may be found throughout the genome but are frequently clustered in short regions of 0.5–
4kb, known as CpG islands (Bird, 2002), mostly located at the promoter regions of genes and 
unmethylated in normal cells. Hypermethylation of these regions causes the “silencing” of 
the target gene. DNA methylation is carried out by different DNA methyltransferases 
(DNMT) that use s-adenosyl-methionine as a methyl donor to replace a hydrogen atom with 
a methyl group (Board et al., 2008) and have distinct substrate specificities: DNMT1 
(Pradhan et al., 1999), DNMT3a and 3b (Okano et al., 1999). All these DNMTs cooperate in 
establishing and maintaining DNA methylation patterns (Rhee et al., 2000; Kim et al., 2002). 
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In normal cells, methylation of CpG sites within promoter regions is used for controlling 
gene expression (Klose & Bird, 2006). In cancer cells, hypermethylation of the promoter 
regions of growth-regulatory genes leads to transcriptional silencing (Eden et al., 2003; Bonazzi 
et al., 2009), whereas hypo/demethylation results in de-repression of proto-oncogenes and 
genome wide hypomethylation leads to increased mutation rates and chromosome instability, 
which constitutes an early hallmark of tumour cells (Feinberg et al. 2002; Robertson, 2005; 
Martinez et al., 2009). The peculiar changes in DNA methylation patterns of human cancers 
are commonly constituted by reduced levels of DNA methylation and aberrantly 
hypermethylated CpG islands (Bird, 2002), which has been termed “the CpG island 
methylator phenotype” (CIMP) (Board et al., 2008). In cancer, epigenetic silencing through 
methylation occurs at even greater frequency than mutations or deletions and may be a 
more frequent cause of loss of function of tumor-suppressor genes than genetic defects (Jones 
& Baylin, 2002; Herman, 1999), suggesting that epigenetic changes have a major role in every 
step of tumor progression (Baylin, 2005). The genes that are known to be frequently 
hypermethylated and silenced in cancers frequently reside in chromosome regions that 
commonly show loss of heterozygosity, and their loss-of-function provides a selective growth 
advantage to neoplastic cells, and/or are implicated in tumor metastasis and angiogenesis 
(Baylin, 2005). Among these genes, we found most of them frequently mutated in cancers, as: 
ATM, ataxia telangiectasia mutated; APC, adenomatosis polyposis coli; BRCA1/2, breast 
cancer1/2; CDKN2A/B, cyclin-dependent kinase inhibitor 2A/B; GSTP1, glutathione S-
transferase pi; MLH1, mutL homologue 1, colon cancer, non-polyposis type 2; MSH2, mutS 
homologue 2, colon cancer, non-polyposis type 1; NF12PTCHPTEN, phosphatase and tensin 
homologue; RB1, retinoblastoma 1; SWI/SNF-related, matrix-associated, actin-dependent 
regulator of chromatin, subfamily A, member 3/subfamily B, member 1; TIMP3, tissue 
inhibitor of metalloproteinase 3; TP53/73, tumour protein p53/p73. 
3.2 Histone acetylation 
In an opposite manner respect to methylation, acetylation of histones reduces the positive 
charge, relaxing chromatin and making DNA in a transcriptionally active state, mediated 
mainly by the binding of transcriptional factors and histone acetylates. By a simplified 
point-of-view, we can assume that hyper acetylated histones are mostly associated with 
activated genomic regions, whereas deacetylation/hypoacetylation results in 
repression/silencing. In addition, histone acetylation allows also the binding of some 
regulatory transcriptional co-activators (Baylin, 2005), as the SWI/SNF adenosine 
triphosphatase (ATP)-dependent chromatin remodelling complex. Chromatin remodelling 
complex (“chromatin modifiers”) is large protein complexes with enzymatic activity able to 
modify the structure and transcriptional activity of the chromatin. In an indirect manner, 
then, histone acetylation cooperates also to the regulation of gene expression mediated by 
the modification of higher-order chromatin folding (Verdone et al., 2006). 
3.3 Phosphorylation 
Other chromatin modifications, in concert with DNA methylation and acetylation, regulate 
gene transcription, in normal as in cancer cells, by affecting local chromatin structure. One 
of these modifications is constituted by phosphorylation of serines and threonines (Dong & 
Bode, 2006). Berger (Berger, 2002) showed that phosphorylation of histone (Ser10) is 
fundamental for neoplastic cell transformation. 
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distinct Erk-binding sites (Yang et al., 2009). As for Erk 1,2, its functions range from 
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melanoma, MCSP expression enhances integrin function and constitutive activation of Erk 
1,2. As already shown in acral lentiginous melanoma (such as in acute lymphoblastic 
leukaemia) MCSP expression is thought to be associated with a poor prognosis (Kageshita et 
al., 1991). These evidences indicate that MCSP, as a member of the Erk 1,2 pathway, may be 
considered as a promising therapeutic target in the treatment of melanoma. 
3. Epigenetics 
Epigenetics refers to changes in phenotype or gene expression without alterations of the 
DNA sequence. These changes occur at a much higher frequency compared to gene 
mutation, and may persist for the entire cell life and even for multiple generations (Kyrgidis 
et al., 2010). These “epimutations”allow the cell to modulate the transcriptional activity of a 
given gene, from high-level expression to complete silencing. Transcription results from the 
activity of the RNA polymerase machinery and depends on the ability of transcription 
activators and repressors to access chromatin at specific promoters (Santos-Rosa & Caldas, 
2005). Chromatin is the dynamic scenario in which all the genomic functions take place; its 
structure is governed by the interplay of complex regulatory systems, which guarantee the 
maintenance of higher order chromosomal organization. Our understanding of how 
modulation of chromatin influences cell fate in normal as in neoplastic cells has been greatly 
improved during the last two decades. DNA replication, repair and transcription are 
achieved through the interplay of DNA modification and alteration in DNA packaging 
(Rountree et al., 2001). These mechanisms cooperate to establish the pattern of gene 
expression (Hashimshony et al., 2003) concerning every fundamental cell function, from cell 
growth and differentiation, to DNA repair and apoptosis. They operate through the 
induction of changes in chromatin architecture induced by histones (Dong & Bode, 2006) 
and “chromatin modifiers” (Kyrgidis et al., 2010). Histones are the main protein components 
of chromatin. Covalent post-translational modifications of the amino termini of the core 
histones in nucleosomes consist of methylation, acetylation, phosphorylation, ubiquitination 
and SUMOylation, and determine the “histone code” (Berger, 2002). 
3.1 DNA methylation 
DNA methylation occurs on lysine and arginine residues on histone tails. One preferred site 
of methylation is the C5 position of cytosine in the context of CpG dinucleotides. The latter 
may be found throughout the genome but are frequently clustered in short regions of 0.5–
4kb, known as CpG islands (Bird, 2002), mostly located at the promoter regions of genes and 
unmethylated in normal cells. Hypermethylation of these regions causes the “silencing” of 
the target gene. DNA methylation is carried out by different DNA methyltransferases 
(DNMT) that use s-adenosyl-methionine as a methyl donor to replace a hydrogen atom with 
a methyl group (Board et al., 2008) and have distinct substrate specificities: DNMT1 
(Pradhan et al., 1999), DNMT3a and 3b (Okano et al., 1999). All these DNMTs cooperate in 
establishing and maintaining DNA methylation patterns (Rhee et al., 2000; Kim et al., 2002). 
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In normal cells, methylation of CpG sites within promoter regions is used for controlling 
gene expression (Klose & Bird, 2006). In cancer cells, hypermethylation of the promoter 
regions of growth-regulatory genes leads to transcriptional silencing (Eden et al., 2003; Bonazzi 
et al., 2009), whereas hypo/demethylation results in de-repression of proto-oncogenes and 
genome wide hypomethylation leads to increased mutation rates and chromosome instability, 
which constitutes an early hallmark of tumour cells (Feinberg et al. 2002; Robertson, 2005; 
Martinez et al., 2009). The peculiar changes in DNA methylation patterns of human cancers 
are commonly constituted by reduced levels of DNA methylation and aberrantly 
hypermethylated CpG islands (Bird, 2002), which has been termed “the CpG island 
methylator phenotype” (CIMP) (Board et al., 2008). In cancer, epigenetic silencing through 
methylation occurs at even greater frequency than mutations or deletions and may be a 
more frequent cause of loss of function of tumor-suppressor genes than genetic defects (Jones 
& Baylin, 2002; Herman, 1999), suggesting that epigenetic changes have a major role in every 
step of tumor progression (Baylin, 2005). The genes that are known to be frequently 
hypermethylated and silenced in cancers frequently reside in chromosome regions that 
commonly show loss of heterozygosity, and their loss-of-function provides a selective growth 
advantage to neoplastic cells, and/or are implicated in tumor metastasis and angiogenesis 
(Baylin, 2005). Among these genes, we found most of them frequently mutated in cancers, as: 
ATM, ataxia telangiectasia mutated; APC, adenomatosis polyposis coli; BRCA1/2, breast 
cancer1/2; CDKN2A/B, cyclin-dependent kinase inhibitor 2A/B; GSTP1, glutathione S-
transferase pi; MLH1, mutL homologue 1, colon cancer, non-polyposis type 2; MSH2, mutS 
homologue 2, colon cancer, non-polyposis type 1; NF12PTCHPTEN, phosphatase and tensin 
homologue; RB1, retinoblastoma 1; SWI/SNF-related, matrix-associated, actin-dependent 
regulator of chromatin, subfamily A, member 3/subfamily B, member 1; TIMP3, tissue 
inhibitor of metalloproteinase 3; TP53/73, tumour protein p53/p73. 
3.2 Histone acetylation 
In an opposite manner respect to methylation, acetylation of histones reduces the positive 
charge, relaxing chromatin and making DNA in a transcriptionally active state, mediated 
mainly by the binding of transcriptional factors and histone acetylates. By a simplified 
point-of-view, we can assume that hyper acetylated histones are mostly associated with 
activated genomic regions, whereas deacetylation/hypoacetylation results in 
repression/silencing. In addition, histone acetylation allows also the binding of some 
regulatory transcriptional co-activators (Baylin, 2005), as the SWI/SNF adenosine 
triphosphatase (ATP)-dependent chromatin remodelling complex. Chromatin remodelling 
complex (“chromatin modifiers”) is large protein complexes with enzymatic activity able to 
modify the structure and transcriptional activity of the chromatin. In an indirect manner, 
then, histone acetylation cooperates also to the regulation of gene expression mediated by 
the modification of higher-order chromatin folding (Verdone et al., 2006). 
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Other chromatin modifications, in concert with DNA methylation and acetylation, regulate 
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3.4 Ubiquitination and SUMOylation 
The other histone post-translational modifications include ubiquitination and SUMOylation. 
Ubiquitin is a highly conserved protein associated with most of fundamental cellular 
processes and its deregulated activity is thought to contribute to cancer onset or 
progression.  SUMOylation directly affects nucleosomal structure, but the exact molecular 
mechanism is still not clear (Gill, 2004). Recently it has been shown that histone H4 is 
modified by SUMO, and SUMO-modification of histones has been suggested to contribute 
to transcriptional repression (Shiio & Eisenman, 2003), regulation of protein–protein 
interactions and activity of many factors involved in maintenance of the genome stability. 
Many factors and enzymes associated with DNA replication and repair including PCNA, 
and Topoisomerases I and II, are post-translationally modified by SUMO (Muller et al., 
2004). The activity and/or localization of several tumor supressors and oncogenes are 
regulated by SUMO modification, and this has been hypothesized to provide new chances 
for new target therapy for cancer (Gill, 2004). 
3.5 Interplay between different post-translational modifications 
It has to be pointed out that single histone modifications may have distinct biological effects 
depending on their context. Methylation of H3 on K9, for example, is largely associated with 
silencing and repression. Methylation of lysine 9 on histone H3 is associated with 
epigenetically silenced chromatin, and loss of the H3K9me3 mark results in genomic instability 
(Cloos et al., 2006). Methylation of H3 on K4, by reverse, is most often associated with active or 
permissive chromatin regions. Moreover, demethylation of H3-K4 occurs at both inactive and 
active euchromatic genes, whereas tri-methylation is present exclusively at active genes. 
Similarly, the phosphorylation of H3 at S10 has been implicated not only in transcriptional 
activation, but also in mitotic chromosome condensation. This led to the suggestion that 
multiple readouts of a certain covalent mark could be obtained by various combinations of 
different modifications in the same chromatin region. Particular sets of modifications might 
occur concomitantly on the same histone tail. Mounting evidence suggests that different 
histone modifications can influence or ‘communicate’ with each other at several levels (Fischle 
et al., 2003). Moreover, as a rule, histone acetylation/deacetylation and methylation operate 
synergistically in cancer cells (Rountree et al., 2001), but competition for lysines may create 
crosstalk between SUMO and other modifiers. Acetylation may enhance SUMOylation of 
histone H4 (Gill, 2004); HATs and HDACs (that respectively add and remove acetyl groups) 
are post-translationally modified by SUMO, which regulates also their localization and/or 
activity (Girdwood et al., 2003). Cross-talk between the SUMOylation, ubiquitination, and 
acetylation occurs during signal-dependent regulation of several proteins (Hoege et al., 2002; 
Ross et al., 2002). From these data it emerges that the epigenetic framework which regulates 
gene expression is an extremely complex process, constituted by a multitude of intersecting 
molecular factors converging on chromatin. 
3.6 miRNA 
MicroRNAs (miRNAs) are recently discovered endogenous non-coding RNAs, about 22 
nucleotide long (Guil & Esteller, 2009; Sigalotti et al., 2010). They play a role as mediators of 
epigenetic gene regulation, by interacting with mRNA, either by inhibiting mRNA 
translation or causing mRNA degradation (Sood et al., 2006). Their regulatory nature, as 
well as the large number of presumptive target genes, candidate them as regulators of 
several fundamental cellular processes, in normal as in cancer cells. 
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3.7 Melanoma epigenetics 
3.7.1 Methylation 
At present, it is not clear if UVR can initiate melanomagenesis through an epigenetic 
mechanism. Nevertheless, epigenetic changes, as mutations, increase after ultraviolet 
radiation (UVR) (Kyrgidis et al., 2010). This is of a great interest, considering that 
intermittent, intense exposure to UVR, especially during childhood, is major environmental 
risk factor in the etiology of melanoma (Maddodi & Setaluri, 2008). Deregulation of gene 
expression in melanoma progression requires epigenetic mechanisms which are currently 
uncompletely characterized, but  have a potential great impact on the process of melanoma 
tumorigenesis and metastatic potential (Howell et al., 2009; Schinke et al., 2010). To date, 
more than 50 genes have been shown to be silenced through epigenetic changes during 
melanoma development, progression, and metastasis, mainly by promoter CpG island 
hypermethylation (Rothhammer & Bosserhoff, 2007; Howell et al., 2009), as it has been 
reported for MAGEA1 (Karpf et al.,2004). Most of these genes are not specific for melanoma, 
being involved in the control of cell cycle, cell signalling, immune recognition, angiogenesis, 
apoptosis, tumor cell invasion and metastasis in almost all cancer types (Rothhammer & 
Bosserhoff, 2007). Among these, there are CDKN2A, PTEN, APAF-1, TPM1 and TIMP3, 
several human leukocyte class I antigens and CASP8. Recently, have been found methylated 
in melanoma other genes linked to apoptosis (DAPKb, HSPB6, HSPB8, TMS1, TP53INP1, 
TRAILR1, XAF1), anchorage-independent growth (TPM1; cell cycle: CDKN1B, CDKN1C, 
CDKN2A, TSPY); chromatin remodeling (NPM2); differentiation (HOXB13, ENC1, GDF15); 
DNA repair (MGMT); invasion/metastasis (CCR7, CXCR4, SERPINB5); signaling 
(PGRbeta); transcription (RUNX3) (Sigalotti et al., 2010). In several cases, these aberrant 
hyper-methylations are recognizable in an high percentage of melanomas, as for 
Suppressors of cytokine signaling SOCS-1 (75%), SOCS-2 (75%),  SOCS-3 (60%) (Liu et al., 
2008), ER-α Estrogen receptor alpha (42%–86%) (Mori et al., 2006), p101(PIK3R5) 
Phosphoinositide-3-kinase, regulatory subunit 5 (88%), TNFRSF10C (DcR1) Tumor necrosis 
factor receptor superfamily, member 10c (55%) and TNFRSF10D (8 5%) (Liu et al., 2008), 
THBS4 Thrombospondin 4 (63%), RASSF1A RAS association domain family protein 1A 
(involved in apoptosis: its expression negatively correlates with lymph node metastasis, 
55%), (Yi et al., 2010), HSP11, Heat shock protein H11 (60%), and RARβ2, Retinoic acid 
receptor, beta isoform 2 (70%, linked to the low retinoid sensitivity of melanoma) (Hoon et 
al., 2004). Up to 100% of melanoma cases show hyper-methylated CYP1B1 (Cytochrome 
P450, subfamily 1, polypeptide 1, linked to drug metabolism) and QPCT (Glutaminyl-
peptide cyclotransferase) (Muthusamy et al., 2006). Recently, in cutaneous melanoma the 
loss of expression/methylation of gene promoter for Tumor suppressor in lung cancer 1 
(TSLC1), encoding a member of the immunoglobulin superfamily, has been described (You 
et al., 2010). In some cancer types, this phenomenon leads to poor prognosis, and in 
melanoma it is significantly associated with advanced tumor stage and shorter disease-
related survival, thus appearing as an important event in the pathogenesis of CM and a 
marker of poor prognosis (You et al., 2010). Similarly, recent findings indicated that a 
frequently aberrant methylated region in CM resides within the Zygote arrest 1 (ZAR1) 
gene, demonstrating a distinct methylation pattern between melanoma and nevus, thus 
hypothesizing that the aberrant methylation of ZAR1 may be a useful tumor biomarker to 
distinguish nevus from melanoma for early diagnosis (Shinojima et al., 2010). As well, there 
is an increasing body of evidence that, indicating the inactivation of the dimeric 14-3-3σ 
proteins member of the oncogene RAS/RAF/MEK/Erk pathway, involved in DNA damage 
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regulated by SUMO modification, and this has been hypothesized to provide new chances 
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(Cloos et al., 2006). Methylation of H3 on K4, by reverse, is most often associated with active or 
permissive chromatin regions. Moreover, demethylation of H3-K4 occurs at both inactive and 
active euchromatic genes, whereas tri-methylation is present exclusively at active genes. 
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occur concomitantly on the same histone tail. Mounting evidence suggests that different 
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acetylation occurs during signal-dependent regulation of several proteins (Hoege et al., 2002; 
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nucleotide long (Guil & Esteller, 2009; Sigalotti et al., 2010). They play a role as mediators of 
epigenetic gene regulation, by interacting with mRNA, either by inhibiting mRNA 
translation or causing mRNA degradation (Sood et al., 2006). Their regulatory nature, as 
well as the large number of presumptive target genes, candidate them as regulators of 
several fundamental cellular processes, in normal as in cancer cells. 
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3.7 Melanoma epigenetics 
3.7.1 Methylation 
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tumorigenesis and metastatic potential (Howell et al., 2009; Schinke et al., 2010). To date, 
more than 50 genes have been shown to be silenced through epigenetic changes during 
melanoma development, progression, and metastasis, mainly by promoter CpG island 
hypermethylation (Rothhammer & Bosserhoff, 2007; Howell et al., 2009), as it has been 
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Bosserhoff, 2007). Among these, there are CDKN2A, PTEN, APAF-1, TPM1 and TIMP3, 
several human leukocyte class I antigens and CASP8. Recently, have been found methylated 
in melanoma other genes linked to apoptosis (DAPKb, HSPB6, HSPB8, TMS1, TP53INP1, 
TRAILR1, XAF1), anchorage-independent growth (TPM1; cell cycle: CDKN1B, CDKN1C, 
CDKN2A, TSPY); chromatin remodeling (NPM2); differentiation (HOXB13, ENC1, GDF15); 
DNA repair (MGMT); invasion/metastasis (CCR7, CXCR4, SERPINB5); signaling 
(PGRbeta); transcription (RUNX3) (Sigalotti et al., 2010). In several cases, these aberrant 
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Suppressors of cytokine signaling SOCS-1 (75%), SOCS-2 (75%),  SOCS-3 (60%) (Liu et al., 
2008), ER-α Estrogen receptor alpha (42%–86%) (Mori et al., 2006), p101(PIK3R5) 
Phosphoinositide-3-kinase, regulatory subunit 5 (88%), TNFRSF10C (DcR1) Tumor necrosis 
factor receptor superfamily, member 10c (55%) and TNFRSF10D (8 5%) (Liu et al., 2008), 
THBS4 Thrombospondin 4 (63%), RASSF1A RAS association domain family protein 1A 
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P450, subfamily 1, polypeptide 1, linked to drug metabolism) and QPCT (Glutaminyl-
peptide cyclotransferase) (Muthusamy et al., 2006). Recently, in cutaneous melanoma the 
loss of expression/methylation of gene promoter for Tumor suppressor in lung cancer 1 
(TSLC1), encoding a member of the immunoglobulin superfamily, has been described (You 
et al., 2010). In some cancer types, this phenomenon leads to poor prognosis, and in 
melanoma it is significantly associated with advanced tumor stage and shorter disease-
related survival, thus appearing as an important event in the pathogenesis of CM and a 
marker of poor prognosis (You et al., 2010). Similarly, recent findings indicated that a 
frequently aberrant methylated region in CM resides within the Zygote arrest 1 (ZAR1) 
gene, demonstrating a distinct methylation pattern between melanoma and nevus, thus 
hypothesizing that the aberrant methylation of ZAR1 may be a useful tumor biomarker to 
distinguish nevus from melanoma for early diagnosis (Shinojima et al., 2010). As well, there 
is an increasing body of evidence that, indicating the inactivation of the dimeric 14-3-3σ 
proteins member of the oncogene RAS/RAF/MEK/Erk pathway, involved in DNA damage 
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repair or arrest of cell cycle after severe damage, plays an important role in primary melanoma 
development. This has been reported for several malignant tumors (Schultz et al., 2009). 
Moreover, enhanced 14-3-3σ gene methylation in lymph node and cutaneous melanoma 
metastases compared with primary tumors was associated with significant 14-3-3σ 
downregulation. Treatment of melanoma cells with methylation and histone deacetylase 
inhibitors has led to the increase of 14-3-3σ expression, inhibition of cell proliferation, and 
induction of melanoma cell senescence. Epigenetic profiling showed, in addition, that multiple 
metastases after a single primary melanoma either share similar methylation patterns for 
many genes, or show differences in methylation between the lesions for several genes, as for 
PTEN, TFAP2C, and RARB (Harbst et al., 2010). Less is known on the presence and role of 
demethylation in CM, this reflecting the state-of-the art of the research on genome-wide 
demethylation in cancer, which has been overshadowed, to date, by studies of gene-specific 
hypermethylation events. It is generally thought that global demethylation early in 
tumorigenesis might predispose cells to genomic instability and further genetic changes, 
whereas gene-specific demethylation frequently constitutes a later event that favours the 
establishment of metastasis (Robertson, 2005). Recent study report that MAGE-A1, A2, A3, A4, 
which are involved in immune recognition and belong to the melanoma antigen family of 
cancer–testis genes, encoding tumour antigens of mostly unknown function,  are frequently 
demethylated and re-expressed in cancer (Robertson, 2005) and hypomethylated in 44% of CM 
(MAGEA1) (Sigalotti et al., 2010; Tellez et al., 2009). This is very interesting, if we consider that 
the same family of genes, as before reported, may be found frequently hypermethylated in 
melanoma. This is also the case for the Testis-specific protein, Y-encoded (TSPY) (Oram et al., 
2006; Howell et al., 2009), and maspin, a mammary serine protease inhibitor, acting as a TSG in 
breast cancer (Wada et al., 2004) that is repressed in normal melanocytes. 
3.7.2 Phosphorylation 
Phosphorylation of histone H3 at serine 28 and 10 is strongly induced by UV irradiation 
(Dong et al., 2006), and is mediated by the MAP kinase cascades (Zhong SP et al., 2000). 
UVA and UVB differentially induce the MAP kinase pathways at different levels (Bode & 
Dong, 2003): ERKs and p38 kinase mediate UVB-induced H3 (Ser10) phosphorylation in 
mouse epidermal skin cells and in vitro. It has been hypothesized that the p53 protein may 
directly regulate this phosphorylation by serving as a link or a bridge between these kinases 
and histone H3. Moreover, it has been found that also (He Z et al., 2005). Fyn, a member of 
the Src kinase family, and Aurora B kinase overexpression are involved in the UVB-induced 
phosphorylation of histone H3 (Ser10) (Ota et al., 2002). Recent data suggest that H3 histone 
phosphorylation plays a role in UV-mediated carcinogenesis. 
3.7.3 Acetylation 
Three members of the HATs family, the transcriptional coactivators, GNAT (general control 
non-depressible 5 (Gcn5)-related N-acetyltransferase), MYST (family members: MOZ, Ybf2-
Sas3, Sas2, and Tip60) and p300/CBP-adenoviral E1A-associated protein, 300 kDa, (CREB-
binding protein), have been recently found linked to melanoma progression. Members of the 
GNAT family (including GCN5, HAT1) and PCAF (p300/CREB-binding associated factor) 
acetylate histones H3 and H4 and non-histone transcriptional activators. P300 and CBP are 
global transcription coactivators that acetylate core histones and non-histone proteins such as 
p53, Rb, and E2F, involved in regulation of cellular proliferation, differentiation and apoptosis 
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(Shiama et al., 1997). Both CBP and p300 have been also shown to associate with 
microphthalmia-associated transcription factor (MITF), a melanocyte lineage survival 
oncogene (Garraway et al., 2005), which regulates melanoma proliferation, apoptosis and 
invasiveness (Dynek et al., 2008), and is mostly upregulated in metastatic melanomas (Lomas 
et al., 2008) being associated with decreased survival of patients (Ugurel et al., 2007). 
3.7.4 Ubiquitination/SUMOylation 
Accumulating evidence confirms the involvement of ubiquitin and ubiquitin–related 
pathways in melanomagenesis. Transcription factors such as MiTF, beta-catenin and IkB, 
which regulate the proliferation and differentiation of melanocytes, are subjected to this 
process (Wu et al., 2000). In normal melanocytes, MITF may be in turn subjected to 
ubiquitination or SUMOylation. In melanoma, ubiquitination leads to the corresponding 
elevated activity of MITF (Nakayama, 2010). In addition, melanoma cells show an alterated 
ubiquitination-dependent degradation of IKB, with consequent high rate of nuclear 
translocation of free NF-kB and activation of its target genes (Nakayama, 2010). Notably, 
also B-catenin is a target of the ubiquitin–proteasome pathway in melanoma. Several beta-
catenin mutants lack sites of ubiquitination and, consequently, become stabilized because of 
the inhibition of proteasome-mediated proteolysis; thus promoting proliferation and 
survival of melanoma cells (Aberle et al., 2007; Rubinfeld et al., 1997; Widlund et al., 2002). 
3.7.5 Chromatin texture 
The neoplastic growth-induced modification of composition and distribution of histone and 
non-histone nuclear proteins provokes alterations of the distribution of heterochromatin in the 
nucleus. This reflects on the characteristics of the nuclear architecture, as seen on routinely 
stained histopathological sections, and has suggested as prognostic markers in cancer 
(Montironi et al., 2007). The determination of fractality characterizes the complexity of a 
structure not revealed by classical morphometry. The fractal nature of nuclear chromatin and 
of the surrounding nucleoplasmic space (Lieberman-Aiden et al., 2009; Bancaud A et al., 2009) 
are of prognostic importance in neoplasias (Goutzanis et al., 2008; Mashiah et al., 2008). 
Unstable, aggressive tumors with a high number of genetic or epigenetic changes, are 
characterized by a complex chromatin rearrangement, with an increased number of darker 
and lighter areas. The increased nuclear fractal dimension found in the most aggressive 
melanomas is the mathematical equivalent of this complex chromatin architecture, 
constituting a new and promising variable in prognostic models (Bedin et al., 2010), able to 
provide prognostic information independent from the invasion level of melanomas.  
3.7.6 Chromatin assembly 
Nuclear structure and function interact reciprocally at all the three hierarchical nuclear 
levels (coordination of nuclear processes, higher-order chromatin fiber organization, and 
spatial arrangement of genome) (Misteli, 2007). The chromatin template undergoes 
structural reorganizations during DNA replication and cell cycle progression (Fischle et al., 
2003). Nucleosomes, made of 146 base pairs of DNA wrapped around a histone octamer 
core comprising two copies each of histones H2A, H2B, H3 and H4, represent the basic 
functional units of chromatin. Each histone contains flexible N-terminal tails protruding 
from the nucleosomes, which are extensively targeted by post-translational modifications, 
including acetylation and methylation (Sigalotti et al., 2010). When in open configuration, 
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repair or arrest of cell cycle after severe damage, plays an important role in primary melanoma 
development. This has been reported for several malignant tumors (Schultz et al., 2009). 
Moreover, enhanced 14-3-3σ gene methylation in lymph node and cutaneous melanoma 
metastases compared with primary tumors was associated with significant 14-3-3σ 
downregulation. Treatment of melanoma cells with methylation and histone deacetylase 
inhibitors has led to the increase of 14-3-3σ expression, inhibition of cell proliferation, and 
induction of melanoma cell senescence. Epigenetic profiling showed, in addition, that multiple 
metastases after a single primary melanoma either share similar methylation patterns for 
many genes, or show differences in methylation between the lesions for several genes, as for 
PTEN, TFAP2C, and RARB (Harbst et al., 2010). Less is known on the presence and role of 
demethylation in CM, this reflecting the state-of-the art of the research on genome-wide 
demethylation in cancer, which has been overshadowed, to date, by studies of gene-specific 
hypermethylation events. It is generally thought that global demethylation early in 
tumorigenesis might predispose cells to genomic instability and further genetic changes, 
whereas gene-specific demethylation frequently constitutes a later event that favours the 
establishment of metastasis (Robertson, 2005). Recent study report that MAGE-A1, A2, A3, A4, 
which are involved in immune recognition and belong to the melanoma antigen family of 
cancer–testis genes, encoding tumour antigens of mostly unknown function,  are frequently 
demethylated and re-expressed in cancer (Robertson, 2005) and hypomethylated in 44% of CM 
(MAGEA1) (Sigalotti et al., 2010; Tellez et al., 2009). This is very interesting, if we consider that 
the same family of genes, as before reported, may be found frequently hypermethylated in 
melanoma. This is also the case for the Testis-specific protein, Y-encoded (TSPY) (Oram et al., 
2006; Howell et al., 2009), and maspin, a mammary serine protease inhibitor, acting as a TSG in 
breast cancer (Wada et al., 2004) that is repressed in normal melanocytes. 
3.7.2 Phosphorylation 
Phosphorylation of histone H3 at serine 28 and 10 is strongly induced by UV irradiation 
(Dong et al., 2006), and is mediated by the MAP kinase cascades (Zhong SP et al., 2000). 
UVA and UVB differentially induce the MAP kinase pathways at different levels (Bode & 
Dong, 2003): ERKs and p38 kinase mediate UVB-induced H3 (Ser10) phosphorylation in 
mouse epidermal skin cells and in vitro. It has been hypothesized that the p53 protein may 
directly regulate this phosphorylation by serving as a link or a bridge between these kinases 
and histone H3. Moreover, it has been found that also (He Z et al., 2005). Fyn, a member of 
the Src kinase family, and Aurora B kinase overexpression are involved in the UVB-induced 
phosphorylation of histone H3 (Ser10) (Ota et al., 2002). Recent data suggest that H3 histone 
phosphorylation plays a role in UV-mediated carcinogenesis. 
3.7.3 Acetylation 
Three members of the HATs family, the transcriptional coactivators, GNAT (general control 
non-depressible 5 (Gcn5)-related N-acetyltransferase), MYST (family members: MOZ, Ybf2-
Sas3, Sas2, and Tip60) and p300/CBP-adenoviral E1A-associated protein, 300 kDa, (CREB-
binding protein), have been recently found linked to melanoma progression. Members of the 
GNAT family (including GCN5, HAT1) and PCAF (p300/CREB-binding associated factor) 
acetylate histones H3 and H4 and non-histone transcriptional activators. P300 and CBP are 
global transcription coactivators that acetylate core histones and non-histone proteins such as 
p53, Rb, and E2F, involved in regulation of cellular proliferation, differentiation and apoptosis 
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(Shiama et al., 1997). Both CBP and p300 have been also shown to associate with 
microphthalmia-associated transcription factor (MITF), a melanocyte lineage survival 
oncogene (Garraway et al., 2005), which regulates melanoma proliferation, apoptosis and 
invasiveness (Dynek et al., 2008), and is mostly upregulated in metastatic melanomas (Lomas 
et al., 2008) being associated with decreased survival of patients (Ugurel et al., 2007). 
3.7.4 Ubiquitination/SUMOylation 
Accumulating evidence confirms the involvement of ubiquitin and ubiquitin–related 
pathways in melanomagenesis. Transcription factors such as MiTF, beta-catenin and IkB, 
which regulate the proliferation and differentiation of melanocytes, are subjected to this 
process (Wu et al., 2000). In normal melanocytes, MITF may be in turn subjected to 
ubiquitination or SUMOylation. In melanoma, ubiquitination leads to the corresponding 
elevated activity of MITF (Nakayama, 2010). In addition, melanoma cells show an alterated 
ubiquitination-dependent degradation of IKB, with consequent high rate of nuclear 
translocation of free NF-kB and activation of its target genes (Nakayama, 2010). Notably, 
also B-catenin is a target of the ubiquitin–proteasome pathway in melanoma. Several beta-
catenin mutants lack sites of ubiquitination and, consequently, become stabilized because of 
the inhibition of proteasome-mediated proteolysis; thus promoting proliferation and 
survival of melanoma cells (Aberle et al., 2007; Rubinfeld et al., 1997; Widlund et al., 2002). 
3.7.5 Chromatin texture 
The neoplastic growth-induced modification of composition and distribution of histone and 
non-histone nuclear proteins provokes alterations of the distribution of heterochromatin in the 
nucleus. This reflects on the characteristics of the nuclear architecture, as seen on routinely 
stained histopathological sections, and has suggested as prognostic markers in cancer 
(Montironi et al., 2007). The determination of fractality characterizes the complexity of a 
structure not revealed by classical morphometry. The fractal nature of nuclear chromatin and 
of the surrounding nucleoplasmic space (Lieberman-Aiden et al., 2009; Bancaud A et al., 2009) 
are of prognostic importance in neoplasias (Goutzanis et al., 2008; Mashiah et al., 2008). 
Unstable, aggressive tumors with a high number of genetic or epigenetic changes, are 
characterized by a complex chromatin rearrangement, with an increased number of darker 
and lighter areas. The increased nuclear fractal dimension found in the most aggressive 
melanomas is the mathematical equivalent of this complex chromatin architecture, 
constituting a new and promising variable in prognostic models (Bedin et al., 2010), able to 
provide prognostic information independent from the invasion level of melanomas.  
3.7.6 Chromatin assembly 
Nuclear structure and function interact reciprocally at all the three hierarchical nuclear 
levels (coordination of nuclear processes, higher-order chromatin fiber organization, and 
spatial arrangement of genome) (Misteli, 2007). The chromatin template undergoes 
structural reorganizations during DNA replication and cell cycle progression (Fischle et al., 
2003). Nucleosomes, made of 146 base pairs of DNA wrapped around a histone octamer 
core comprising two copies each of histones H2A, H2B, H3 and H4, represent the basic 
functional units of chromatin. Each histone contains flexible N-terminal tails protruding 
from the nucleosomes, which are extensively targeted by post-translational modifications, 
including acetylation and methylation (Sigalotti et al., 2010). When in open configuration, 
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they allow access of transcription factors. By converse, when they are in a hyper-compacted 
state, as in heterochromatin, inhibit transcription (Jones & Baylin, 2002; Jenuwein & Allis, 
2001; Noma et al., 2001). Nucleosome structure and histone acetylation/methylation equally 
affect chromatin structure, regulating gene transcription (Baylin, 2005). Among molecules 
responsible of the chromatin assembly, a pivotal role is exerted by the Chromatin Assembly 
Factor-1 (CAF-1), a protein complex, formed of three subunits with different molecular 
weight: p48, p60 and p150. CAF-1 deliveres histones H3 and H4 to DNA during DNA 
replication and DNA repair, and CAF-1/p60 has been found overexpressed in a series of 
human malignancies, including breast, prostate, oral squamous and salivary glands cancers, 
in close association with their biological aggressiveness. We have evaluated by 
immunohistochemistry the expression of CAF-1/p60 in a selected series of cutaneous 
melanomas paraffinized tissue (Mascolo et al., 2010), comparing results with the clinical and 
pathological features of each tumor and with patient’s outcome. We found a significant 
association between hyperexpression of CAF-1/p60 and the occurrence of node and/or 
distant metastases in SM patients. These findings indicate that CAF-1 may have a role as 
novel, sensible proliferation and prognostic marker for CM. CAF-1 overexpression can be 
easily evaluated by immunohistochemistry on formalin-fixed, paraffin-embedded tissue, 
and may constitute a potential useful adjunctive tool for pathologists for predicting the 
individual prognosis of melanoma patients. 
3.7.7 Remodeling proteins 
Recent studies have shown that SWI/SNF ATP dependent chromatin remodeling enzymes 
are involved in the molecular alterations occurring in melanoma (Saladi et al., 2010) and 
regulate the expression of genes important for tumor metastasis. SWI/SNF enzymes 
promote neural crest migration and differentiation and interact with Microphthalmia –
Associated Transcription Factor (MITF), a known lineage survival oncogene in melanoma 
(de la Serna et al., 2006; Matsumoto et al., 2006; Saladi et al., 2010). SWI/SNF are 
multisubunit complexes that contain either BRG1 or BRM as the catalytic subunit (Li B et al., 
2007) regulating important aspects of melanoma phenotype. While BRM expression is 
variable in melanoma (cell lines), BRG1 expression is increased at the protein levels in 
primary melanoma tumors compared to dysplastic nevi, and in most melanoma cell lines 
(Keenen et al., 2010; Vachtenheim et al., 2010). A BRG1 expression increases during 
melanoma progression and is thought to play an important role in melanoma metastasis, as 
it promotes melanoma invasive ability in vitro. This is supported by the ability of BRG1 to 
modulate the expression of a subset of cell surface receptors, adhesion proteins, and 
extracellular matrix remodeling enzymes in normal as in cancer cells, interacting with a 
transcriptional regulator of MMP2, the SP1 transcription factor, being also recruited to the 
matrix metalloproteinase (MMP2) promoter. However, up to date there was found no 
significant difference in BRG1 levels between primary and metastatic melanoma samples, 
but there has been evidenced a tendency for negative to weak BRG1 expression in the cases 
with a better patient survival (Lin et al., 2010). 
3.7.8 miRNA 
As before outlined, microRNAs (miRNAs) may act as either oncogenes or tumor suppressor 
genes. Recently, it has been shown that miRNAs act as tumor suppressors in uveal 
melanoma cells through downregulation of MITF and CDK6, and, particularly, that miR-137 
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is frequently silenced in this tumor (Chen et al., 2011). Up to now, limited data are available 
on miRNA deregulation in CM, almost all relative to small series of cases (Mueller et al., 
2009; Sigalotti et al., 2010). However, a recent specific miRNA profiling study reports 
extensive modifications of miRNA patterns in CM as compared to normal melanocytes, and 
identifyies modifications of miRNA expression potentially associated to the different phases 
of CM progression (Mueller et al., 2009). Another study reports that miR-17-5p, miR-18a, 
miR-20a and miR-92a are over-expressed, while miR-146a, miR-146b, and miR155 are down-
regulated in the majority of the examined CM cell lines as compared to normal melanocytes 
(Levati et al., 2009). Of particular interest, the master regulator of melanocytes biology, 
transcription factor MITF, has been found to be regulated by at least 2 different miRNAs, miR-
137 and miR-182, which showed opposite alterations (Bemis et al., 2008). Other miRNAs have 
been found overexpressed in CM cell lines and tissues. Among them, miR-182 appeared to be 
involved in CM progression, being increasingly over-expressed from primary to metastatic 
disease. Its action has been related to the repression of MITF and FOXO3 (Segura. et al., 2009). 
The overexpression of miR-29c has been recently reported to be inversely correlated to 
DNMT3A and DNMT3B protein expression (Nguyen et al., 2011) and predictive of overall 
survival in AJCC stage III melanoma patients by multivariate analysis.  On the contrary,  
members of the let-7 family of miRNAs are significantly downregulated in primary 
melanomas compared with benign nevi (Schultz et al., 2008). As in normal cells let-7 miRNAs 
exhert a regulatory activity on the expression of cyclins D1, D3, and A, as well as cyclin-
dependent kinase (Cdk) 4, all of which have been described to play a role in melanoma 
development, (Müller & Bosserhoff, 2008). It appears evident that the loss of let-7a expression 
may contribute in the development and progression of melanoma.  
3.7.9 Epigenetic drugs 
DNA methylation inhibitors (as azacitidine and decitabine), along with inhibitors of histone 
deacetylation, have improved the therapeutic options of some cancer types, and particularly 
of several hematologic malignancies, where gene hypermethylation typically occurs (Baylin, 
2005). The potential reversibility of epigenetic changes via pharmacologic manipulation, 
confers to this area of research particular relevance for the alternative therapeutic treatment 
of patients with advanced melanoma. New agents affecting epigenetic alterations in 
melanoma are thus being increasingly produced. The treatment of CM with these 
“epigenetic drugs” generally produce multiple effects, due to the reactivation and/or 
suppression of many of intersecting pathways that became altered during melanoma 
progression (Sigalotti et al., 2007). There is a tendency to combine epigenetic intervention 
with conventional and/or innovative therapeutic approaches that would take specific 
advantages from the epigenetically-restored pathways. As an example,  strategies to restore 
the loss of expression of spindle checkpoint proteins, such as RASSF1A, by use of 
demethylating agents may be of utility in reversing genetic instability associated with 
melanoma progression (Rother & Jones, 2009). Indeed, in advanced stage melanoma, 
RASSF1A appears to correlate at some degree with response to chemotherapy. As a result, 
profiling of the activation state or degree of mitotic spindle dysfunction using these 
markers, shows promise in identifying those patients who would benefit from spindle 
toxins. The drugs typically used as multi-agent chemotherapy regimens to treat melanoma 
include carboplatin and cisplatin, alkylating agents, and mitotic spindle poisons such as 
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they allow access of transcription factors. By converse, when they are in a hyper-compacted 
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replication and DNA repair, and CAF-1/p60 has been found overexpressed in a series of 
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in close association with their biological aggressiveness. We have evaluated by 
immunohistochemistry the expression of CAF-1/p60 in a selected series of cutaneous 
melanomas paraffinized tissue (Mascolo et al., 2010), comparing results with the clinical and 
pathological features of each tumor and with patient’s outcome. We found a significant 
association between hyperexpression of CAF-1/p60 and the occurrence of node and/or 
distant metastases in SM patients. These findings indicate that CAF-1 may have a role as 
novel, sensible proliferation and prognostic marker for CM. CAF-1 overexpression can be 
easily evaluated by immunohistochemistry on formalin-fixed, paraffin-embedded tissue, 
and may constitute a potential useful adjunctive tool for pathologists for predicting the 
individual prognosis of melanoma patients. 
3.7.7 Remodeling proteins 
Recent studies have shown that SWI/SNF ATP dependent chromatin remodeling enzymes 
are involved in the molecular alterations occurring in melanoma (Saladi et al., 2010) and 
regulate the expression of genes important for tumor metastasis. SWI/SNF enzymes 
promote neural crest migration and differentiation and interact with Microphthalmia –
Associated Transcription Factor (MITF), a known lineage survival oncogene in melanoma 
(de la Serna et al., 2006; Matsumoto et al., 2006; Saladi et al., 2010). SWI/SNF are 
multisubunit complexes that contain either BRG1 or BRM as the catalytic subunit (Li B et al., 
2007) regulating important aspects of melanoma phenotype. While BRM expression is 
variable in melanoma (cell lines), BRG1 expression is increased at the protein levels in 
primary melanoma tumors compared to dysplastic nevi, and in most melanoma cell lines 
(Keenen et al., 2010; Vachtenheim et al., 2010). A BRG1 expression increases during 
melanoma progression and is thought to play an important role in melanoma metastasis, as 
it promotes melanoma invasive ability in vitro. This is supported by the ability of BRG1 to 
modulate the expression of a subset of cell surface receptors, adhesion proteins, and 
extracellular matrix remodeling enzymes in normal as in cancer cells, interacting with a 
transcriptional regulator of MMP2, the SP1 transcription factor, being also recruited to the 
matrix metalloproteinase (MMP2) promoter. However, up to date there was found no 
significant difference in BRG1 levels between primary and metastatic melanoma samples, 
but there has been evidenced a tendency for negative to weak BRG1 expression in the cases 
with a better patient survival (Lin et al., 2010). 
3.7.8 miRNA 
As before outlined, microRNAs (miRNAs) may act as either oncogenes or tumor suppressor 
genes. Recently, it has been shown that miRNAs act as tumor suppressors in uveal 
melanoma cells through downregulation of MITF and CDK6, and, particularly, that miR-137 
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is frequently silenced in this tumor (Chen et al., 2011). Up to now, limited data are available 
on miRNA deregulation in CM, almost all relative to small series of cases (Mueller et al., 
2009; Sigalotti et al., 2010). However, a recent specific miRNA profiling study reports 
extensive modifications of miRNA patterns in CM as compared to normal melanocytes, and 
identifyies modifications of miRNA expression potentially associated to the different phases 
of CM progression (Mueller et al., 2009). Another study reports that miR-17-5p, miR-18a, 
miR-20a and miR-92a are over-expressed, while miR-146a, miR-146b, and miR155 are down-
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vinblastine and paclitaxel. Since therapeutic activity of alkylating agents and DNA-
damaging agents requires tumor cell division, melanomas with high proliferative rate or 
those with genetic alterations in checkpoint function may be more likely to respond (Rother 
& Jones, 2009). Similarly, a particular clinical benefit might be expected from the synergistic 
effect of the pharmacologic inhibition of DNA methyltransferases and/or of histone 
deacetylases with chemo-, radio-, and immuno-therapeutic approaches in melanoma 
patients (Sigalotti, 2010). The introduction of new epigenetic drugs in this context is  
 
 
a) RTK-RAS-RAF-MEK-ERK pathway. When activated, RAS triggers a phosphorylation cascade of RAF, 
MEK and ERK. MEK, when phosphorylated, activates Jun N-terminal kinase (JNK) cascade; ERK 
translocates to the nucleus, where it activates transcription factors for cell proliferation. VEGFR is a RTK 
and, therefore, when activated, leads to activation of this pathway. b) PI3K-AKT pathway. Activation of 
RTKs leads to activation of PI3K and, subsequently, of PDK1 that phosphorylates and activates AKT. 
AKT regulates several proteins affecting cell growth and survival. c) ROS signaling pathway. ROS 
production can induce HIF-1a (hypoxia-inducible transcription factors 1) under normoxia in response to 
some factors. Intracellular ROS activates also the NFkB (nuclear factor-kappa route B). d) DNA-repair 
pathways. PARP1 (Poly [ADP-ribose] polymerase 1) has a role in repair of single-stranded DNA 
(ssDNA) breaks, modifying nuclear proteins by polyADP-ribosylation. Component of the post-
replicative DNA mismatch repair system (hMSH2 and hMLH) binds to DNA mismatches thereby 
initiating DNA repair. e) The Chromatin Assembly Factor-1 (CAF-1) promotes also the first step of 
nucleosome assembly during DNA replication, driving the incorporation of different histones into DNA 
to the sites where chromatin has to be newly formed or remodeled. CAF-1 promotes chromosome 
assembly during resetting of the chromatin structure after DNA repair (d). 
Fig. 1. Crosstalks between signaling pathways involved in melanomagenesis and 
progression 
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GENETIC CHANGES  
Mutations 
ASIP, β-catenin, BRAF, CCND1, CDKN2A, CDK4, Rb, 
cKIT, HIF1/ROS, IGFBP7, MC1R, NEUROPILIN2, NFkB, 
NRAS, PI3KCA, p16INK4, PLEXIN B1, PTEN/AKT, 




ATM, APAF-1, APC, BRCA1, BRCA2, CASP8, CCR7, 
CXCR4, CDKN1B, CDKN1C, CDKN2A, CDKN2B, 
CYP1B1, DAPKb, ENC1, ER-α, GDF15, GSTP, H3, HLA 
class I, HOXB13, HSPB6, HSPB8, HSP11, MAGE-A1, 
MGMT, MLH1, MSH2, NF12PTCHPTEN, NPM2, 
p101(PIK3R5), PGRbeta, PTEN, QPCT, RARβ2, RASSF1A, 
RB1, RUNX3, SERPINB5, SOCS1, SOCS2, SOCS3, Stratifin 
(14-3-3sigma), SWI/SNF, TFAP2C, THBS4, TIMP3, TMS1, 
TNFRSF10C (DcR1), TNFRSF10D, TP53INP1, TP53/73, 
TPM1, TRAILR1, TSCL1, TSPY, XAF1, ZAR1 
Hypomethylation MAGE-A1, MAGE-A2, MAGE-A3, MAGE-A4, Maspin, TSPY,  
Phosphorylation H3 (ser 28), H3 (ser 10) 
Acethylation E2F, H3, H4, MITF, p53, Rb, SWI/SNF (ATP)-dependent chromatin remodelling complex, 
Ubiquitination/SUMOylation H4, PCNA, Topoisomerase 1, Topoisomerase 2, MiTF, IkB, β-catenin 
Chromatin assembly Chromatin Assembly Factor-1  (CAF-1) 
Remodelling proteins SWI/SNF chromatin remodelling enzymes 
miRNA overexpressed miR-29c, miR-17-5p, miR-18a, miR-20a, miR-92a, miR-182 
miRNA downregulated miR137, miR-146a, miR-146b, miR155, miRNA let-7a 
Tumor-stromal interactions MCSP/NG2 
Table 1. Summary of major genetic and epigenetic alterations in melanoma. 
expected to reduce systemic toxicities of traditional therapies. Histone deacetylase (HDAC) 
inhibitors represent a promising therapeutic option for melanoma treatment (Facchetti F et 
al., 2004) and are particularly interesting with this regard. It has been shown, in fact, that 
HDAC inhibitors enhance the response of human tumor cells to ionizing radiation (Munshi 
et al., 2006) and synergize with radiation, reducing the clonogenic survival of CM cells. This 
beneficial effect seems to be related to their ability to sensitize CM cells to radiation-induced 
apoptosis, impairing also the ability of CM cells to repair DNA damages through the down-
regulation of the repair proteins Ku70, Ku80, Ku86 and Rad50) (Munshi et al., 2006). These 
exciting results support the idea that combined epigenetic chemo/radiotherapies might 
overcome the resistance of CM to traditional therapies. In addition, HDAC inhibitors have 
been shown to sensitize melanoma cells to retinoid treatment, leading to the increase of tsg 
p16INK4A, either mutated or with homozygous deletion in most of late-stage melanoma 
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cells, thus correlating with their increased senescence. A further interesting example of 
possible integration between “old” and “new, epigenetic” therapies, is offered by the major 
polyphenolic constituent of green tea, the epigallocatechin-3-gallate (EGCG), which has anti-
proliferative, pro-apoptotic and chemopreventive effects against cancer cells, including 
melanoma (Nihal et al., 2010), mediated through its demethylating activity. EGCG sensitizes 
melanoma cells to interferon in mouse models of human melanoma, by down-regulating NF-
κB promoter activity, induced by reactive oxygen species (Fried & Arbiser, 2008). EGCG 
synergizes with the HDAC inhibitory action of vorinostat to help de-repress silenced tumor-
suppressor genes regulating key functions, such as proliferation and survival. Lastly, it has to 
be outlined the potential beneficial effect of therapeutically restoring miRNA activity in CM.  
4. Conclusions 
Cross-talk between different signaling cascades has emerged as a paradigm of cell biology, 
in that they direct the local and global cell functions (Fischle et al., 2003). The epigenetic 
code is made of post-translational marks which correlate with specific transcriptional states 
and may influence one another (Berger, 2002), their combinations ultimately directing 
downstream functions. We are beginning to unravel the complexities of gene expression, 
which is conditioned by a myriad of diverse stimuli, acting in a multidimensional fashion 
(Dong & Bode, 2006), with histone modification and ATP-dependent chromatin remodeling 
being functionally connected for gene regulation. DNA methylation is controlled at several 
different levels in normal and tumor cells, directly by DNA methyltransferases (DNMTs), 
and indirectly by nucleosome spacing and histone deacetylases (HDACs) (Baylin, 2005; Bird 
A, 2002; Bird & Wolffe, 1999). Synergism/antagonism of adjacent modifications in the same 
histone tail is the rule (‘cis’ effects), but modifications on different histones affect each other 
(‘trans’ effects) (Fischle et al., 2003). Overall, it is now clear that each specific genetic or 
epigenetic alteration may impact the biology of CM cells by concurrently affecting multiple 
proteins/pathways. Further study will determine which panels of genes are most effective 
as biomarkers for prediction of response to therapy and prognosis and may be translated 
into clinically applicable tests. The different methylation or acetylation patterns may 
indicate important differences in tumorigenesis and may help identify subsets of patients 
with different clinical behaviour. The reported correlation of alterations in tumour DNA 
with circulating tumour DNA allows the basis for the development of biomarker blood tests 
for early detection of melanoma metastasis and prediction of response to therapy. Being a 
relatively rare event in normal melanocytes, specific hypermethylations of CpG islands are 
ideal candidate as biomarkers for early melanoma metastasis detection in body fluids 
(Howell et al., 2009). In line with this hypothesis, it has been recently reported that estrogen 
receptor A (ER-A) methylation can predicts melanoma progression, and serum methylated 
ER-A constitutes an unfavorable prognostic factor and negative predictor of progression-
free survival in patients treated with biochemotherapy (Mori et al., 2006; Satzger I, 2009). 
Many studies are investigating the methylation status of several genes in sera of CM 
patients (Satzger I, 2009). We have now summarized only a selection of the hot topics 
concerning the genetic and epigenetic alterations that contribute to the development and 
progression of melanoma. Many questions remain unanswered. Cancer research is moving 
away from an histology-based view of cancer toward a genomic concept of the neoplastic 
disease (Garraway, 2010), and therapy is shifting toward pharmacogenomics, engineered to 
hit the specific genetic and epigenetic profile (the "genomic grade") of the single tumor in 
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each single patient, (Kim et al., 2010; Piccart-Gebhart, 2010). These goals are necessary for 
ultimately improve melanoma patient outcomes and increase drug efficacy against this 
lethal cancer. Further work is required to improve our understanding of the precise role of 
interlinked modifications that dictate specific genomic states, such as gene activation, 
repression, DNA repair in melanoma progression. Bioinformatics-based tools are being 
currently used to generate complex fingerprints based on a combination of genetic and 
epigenetic markers. Recent mathematical modeling of the dynamics of transcriptional 
control of gene expression will be relevant to a full understanding of MITF, SOX10, and 
PAX3 functions (Ben-Tabou de-Leon & Davidson, 2009). An unconditioned approach to the 
importance of the yet known key molecules involved in melanocyte development and 
function, under the light of the growing body of newly discovered interrelationships 
between new and old members of the most relevant pathways involved in melanoma 
progression, will be fundamental to improve the chances of the pigment research 
community to fight melanoma. The shift occurring towards personalized therapy in cancer 
is also beginning to be seen in melanoma, and new generation epigenetic drugs are be 
expected to reduce systemic toxicities with more specific effects (Sigalotti et al., 2010), even if 
additional pre-clinical studies are required to define even more precisely their consequences 
on normal cells and to predict their safety when used on patients. Convincing evidence that 
we are on the right way to truly understand melanoma biology already exists. A 
comprehensive point-of-view, considering simultaneously the phenotype, genotype and 
epigenotype of melanoma cells with respect to the differences in clinical behavior 
(Shackleton & Quintana, 2010) will help us to guide treatment and target those patients with 
specific, personalized therapies. 
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1. Introduction  
The incidence of melanoma continues to rise, in particular among adult males residing in 
the U.S. (Jemal, Siegel et al. 2010). Although this disease is treatable in its early stages, 
diagnosis of or progression to an advanced, metastatic disease stage drastically reduces the 
prognosis, with few patients surviving 5 years. It is especially disturbing that there is a lack 
of FDA-approved therapeutics that can adequately treat the disease and very low 
percentages (5-15%) of patients who will respond to these traditional chemotherapeutics 
(Thompson, Morton et al. 2004). Even among responders, the response to therapy is usually 
unsustainable over the long-term, with approximately 10.8% of patients achieving long-term 
survival (Kim, Lee et al. 2010). Dacarbazine or DTIC is considered the most appropriate 
cytotoxic chemotherapy, but response rates are poor. Many other single-agents have been 
tried with response rates ≤18%, these include temozolomide, lomustine, carmustine, 
cisplatin, carboplatin, vincristine, vinblastine, vindesine, paclitaxel, docetaxel, gemcitabine 
and topotecan. (Thompson, Morton et al. 2004) 
Without patient selection to decipher who belongs to the small portion of responders, the more 
common approach to therapy is to enroll patients into a clinical trial. Recent trials examining 
more targeted and selective agents like PLX4032 (Flaherty, Puzanov et al. 2010) and 
ipilimumab (Hodi, O'Day et al. 2010) have further reinforced this clinical ideology due to the 
successes observed among some patients. Although the development of chemoresistance is an 
impediment to achieving cure using these novel agents, they represent the current ideal and a 
hopeful future for promising targeted therapeutics. Thus, more specific drugs are desirable to 
increase the options for therapy and improve overall outcomes. 
A recently discovered and highly “druggable” method to target melanoma cells is through 
inhibition of a G protein-coupled receptor (GPCR) that is responsible for viability among 
melanomas that predominantly express it (Altman, Gopal et al. 2010). This GPCR is called 
the Lysophosphatidic Acid (LPA) receptor 3 or the LPA3 receptor (Bandoh, Aoki et al. 1999) 
and is found along the cell surface of specific types of melanomas. In addition, the high-
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affinity ligand that binds to this GPCR is lysophosphatidic acid (Aoki, Bandoh et al. 2000). 
Interestingly, the lysophospholipase D that is responsible for the vast majority of the 
production of LPA from lysophosphatidylcholine is also expressed extracellularly and is a 
major target in melanoma (Altman et al. 2010; Liu, Murph et al. 2009). This enzyme, autotaxin 
(ATX), was first isolated from the conditioned medium of melanoma cells and was thought to 
be responsible for melanoma cell motility (Stracke, Krutzsch et al. 1992). Recent studies have 
shown that targeting either the LPA3 receptor or ATX effectively reduces melanoma cell 
viability (Altman et al. 2010). Furthermore, research devoted to producing inhibitors and 
antagonists targeting the ATX-LPA receptor axis has yielded a large variety of compounds 
(Albers, Dong et al. 2010; Altman et al. 2010; Baker, Fujiwara et al. 2006; Block, Duff et al. 2010; 
Hoeglund, Bostic et al. 2010; Hoeglund, Howard et al. 2010; North, Howard et al. 2010; Xu, 
Yang et al. 2009), suggesting the critical role of this pathway in cancer. 
Herein we tested the in vitro capability of another antagonist of the LPA3 receptor and the 
lysophospholipase D activity of autotaxin, BrP-LPA, among the MeWo melanoma cell line. 
This compound inhibits the growth of in vivo lung carcinoma and angiogenesis (Xu and 
Prestwich 2010), but was untested in melanoma, a disease in dire need of additional 
therapeutics. We compared the BrP-LPA anti diastereoisomer to the BrP-LPA 
diastereomeric mixture and observed a slight enhancement of activity against MeWo cells 
using the mixture. Surprisingly, this effect was reduced or absent in the presence of a 24-
hour pretreatment with dacarbazine, a traditional alkylating chemotherapeutic agent, 
suggesting that single-agent therapy is superior. We have observed an in vivo effect on 
reducing the number of metastatic melanoma lesions in the lungs of mice treated with BrP-
LPA, in comparison to control (data not shown). It is unclear whether our in vitro results 
would extend to in vivo treatment, but if so, then the implications of this study would 
require naïve patients for clinical trials, an extremely difficult group to have available. 
2. Materials and methods 
MeWo fibroblast malignant melanoma cells were acquired from ATCC (Manassas, VA) and 
maintained in Cellgro RPMI (Mediatech, Inc., Manassas, VA) supplemented with 5% fetal 
bovine serum (Sigma-Aldrich, St Louis, MO). BrP-LPA compounds, the anti diastereoisomer 
and diastereomeric mixture, were synthesized as previously described (Zhang, Xu et al. 
2009) and reconstituted in water prior to use. The alkylating agents temozolomide (TMZ) 
and dacarbazine (DTIC) were purchased from Sigma-Aldrich. 
2.1 Cell viability 
MeWo cells were examined for viability by seeding cells (10 x 103) in quadruplicates in 96-
well plates. Cells were allowed to attach to the 96-well plate overnight in 5% FBS containing 
medium prior to the indicated drug treatment and concentration for 36 hours. CellTiter™ 
Blue reagent (Promega, Madison, WI) was added to plates and cells were incubated at 37°C 
to assess viability as previously described (Altman et al. 2010; Hasegawa, Murph et al. 2008).  
2.2 High-throughput proliferation imaging 
To examine the effects of cell proliferation in the presence of monotherapy, 10 x 103 MeWo 
cells were plated in quadruplicates in 96-well plates. After overnight incubation at 37 °C, the 
indicated drug and concentration was administered to the cells and the plates were 
incubated for another 30-40 h. After this incubation the cells were fixed in 2% formaldehyde 
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and stained using the Multiparameter Cytotoxicity II kit (ThermoScientific, Pittsburgh, PA), 
according to the directions provided by the manufacturer. To obtain the results, the plates 
were then quantified and visualized using the ArrayScan®VTI HCS Reader (Thermo 
Scientific). For combination drug treatments, approximately 2,500 MeWo cells were plated 
in 96-wells and allowed to attach overnight. DTIC was added at the indicated concentration 
for 24 h followed by the addition of BrP-LPA for 24 h. The cells were fixed and stained using 
the Multiparameter Cytotoxicity III kit and then following the directions given in the 
manufacturer’s protocol (Thermo Scientific). 
2.3 Statistical analysis 
Statistical differences in experimental data was determined using analysis of variance 
(ANOVA) followed by either Tukey’s test or Bonferroni’s multiple comparison test between 
groups. Alternatively, single comparisons were calculated using the student’s t-test. 
GraphPad Prism (La Jolla, CA) was used to facilitate the statistical tests performed. *p < 0.05 
**p < 0.01 and ***p < 0.001 indicate the levels of significance.  
3. Results  
Figure 1 shows the chemical structures of the two BrP-LPA compounds used. Figure 1A 
shows the relative anti-configuration of the bromo substituent relative to the natural 
configuration of the sn-2 hydroxyl of LPA, while Figure 1B shows the diastereomeric 
mixture of syn- and anti-bromo substituents.  
 
 
The structures of the anti diastereoisomer of 16:0 BrP-LPA (A) and its diastereomeric mixture (B) are 
depicted. 
Fig. 1. Chemical structures.  
We compared these two preparations in a viability curve, which accounts for both 
proliferation and metabolism, using MeWo melanoma cells. In the viability assay, we 
measured IC50 values of 17.68 μM and 16.76 μM for the anti diastereoisomer and the 
diastereomeric mixture, respectively (Figure 2A and 2B). Upon further analysis, the mixture 
(Figure 1B) consistently demonstrated increased ability to reduce cell viability over anti-BrP-
LPA (Figure 1A), especially at the highest concentration (100 μM) tested (Figure 2C).  
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Cell viability assays using MeWo cells treated with increasing doses of the BrP-LPA anti 
diastereoisomer (A) or diastereomeric mixture (B) are log transformed and depicted here. (C) A bar 
graph showing the range of concentrations used in MeWo cells compares the reduction in viability 
achieved between the two BrP-LPA reagents. (D) Comparison between the two BrP-LPA reagents and 
other single-agent treatment with dacarbazine (DTIC) or temozolomide (TMZ) demonstrates potency of 
the BrP-LPA diastereomeric mixture (100 μM and 10μM) surpasses that achieved by either DTIC or 
TMZ at higher doses (1000 μM and 100 μM). Similar results are also seen with the BrP-LPA anti 
diastereoisomer. Brackets at the top indicate which single-agent was used. *p<0.05, **p<0.01 or 
***p<0.001, compared to DMSO control-treated MeWo cells. 
Fig. 2. Single-agent treatment with BrP-LPA compounds reduces cell viability at lower doses 
than dacarbazine or temozolomide.  
We next sought to evaluate how these agents measured up against chemotherapy. In 
comparison to single-agent BrP-LPA treatment versus traditional alkylating chemotherapy, 
the BrP-LPA compounds showed more activity in reducing cell viability, even at lower 
concentrations than the chemotherapy (Figure 2D). For example, 100 μM or 10 μM of BrP-
LPA (Figure 1B) was more effective at reducing viability than 1000 μM of dacarbazine 
(DTIC) or temozolomide (TMZ). At 100 μM of DTIC or TMZ, the modest reduction in 
viability was not statistically different than diluent control (DMSO). Similar observations 
occurred with the anti-BrP-LPA (Figure 1A)  as well. 
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(A) MeWo cells were either untreated, or treated with 12.5 μM BrP-LPA reagents for 36 hours, fixed, 
processed and stained for immunofluorescence visualization. (B) The average number of cells per field 
was calculated by automated measurements of quadruplicate well samples using the ArrayScan®VTI 
HCS Reader, as a measurement of the cell proliferation achieved in the presence of either 0, 1.6, 3.1, 6.25 
or 12.5 μM of the BrP-LPA diastereomeric mixture or the anti diastereoisomer. (C) Using a nuclear 
permeability dye, the increase in fluorescence intensity was automatically measured by the 
ArrayScan®VTI HCS Reader using quadruplicate samples. *p<0.05, **p<0.01 or ***p<0.001, compared to 
0 μM or untreated MeWo cells. 
Fig. 3. MeWo cell proliferation is reduced after treatment with BrP-LPA reagents. 
Since the assay measuring cell viability accounts for both the proliferation and metabolism 
of cells, we sought to discriminate these two features by looking solely at the rate of in vitro 
growth or proliferation in the presence of BrP-LPA. After treating MeWo cells for 36 hours 
in the presence of increasing concentration of drug (Figure 3A), we assessed the number of 
surviving cells using high-throughput imaging for quantification. Strikingly, even the 
lowest concentration of the mixture BrP-LPA (Figure 1B) (1.6 μM) showed a significant 
decrease in the number of cells captured per field compared with untreated cells (Figure 3B). 
At the highest dose (12.5 μM), an obvious shift in cell number was visually observed (Figure 
3A) and was also quantified as statistically significant versus untreated cells (Figure 3B). 
Although a reduction in cell number was detected among cells treated with the anti-BrP-
LPA (1A), the reductions were significant only at 6.25 μM and 12.5 μM. Dying cells display 
many morphological changes, including nuclear condensation and permeabilization that 
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Fig. 2. Single-agent treatment with BrP-LPA compounds reduces cell viability at lower doses 
than dacarbazine or temozolomide.  
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comparison to single-agent BrP-LPA treatment versus traditional alkylating chemotherapy, 
the BrP-LPA compounds showed more activity in reducing cell viability, even at lower 
concentrations than the chemotherapy (Figure 2D). For example, 100 μM or 10 μM of BrP-
LPA (Figure 1B) was more effective at reducing viability than 1000 μM of dacarbazine 
(DTIC) or temozolomide (TMZ). At 100 μM of DTIC or TMZ, the modest reduction in 
viability was not statistically different than diluent control (DMSO). Similar observations 
occurred with the anti-BrP-LPA (Figure 1A)  as well. 
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(A) MeWo cells were either untreated, or treated with 12.5 μM BrP-LPA reagents for 36 hours, fixed, 
processed and stained for immunofluorescence visualization. (B) The average number of cells per field 
was calculated by automated measurements of quadruplicate well samples using the ArrayScan®VTI 
HCS Reader, as a measurement of the cell proliferation achieved in the presence of either 0, 1.6, 3.1, 6.25 
or 12.5 μM of the BrP-LPA diastereomeric mixture or the anti diastereoisomer. (C) Using a nuclear 
permeability dye, the increase in fluorescence intensity was automatically measured by the 
ArrayScan®VTI HCS Reader using quadruplicate samples. *p<0.05, **p<0.01 or ***p<0.001, compared to 
0 μM or untreated MeWo cells. 
Fig. 3. MeWo cell proliferation is reduced after treatment with BrP-LPA reagents. 
Since the assay measuring cell viability accounts for both the proliferation and metabolism 
of cells, we sought to discriminate these two features by looking solely at the rate of in vitro 
growth or proliferation in the presence of BrP-LPA. After treating MeWo cells for 36 hours 
in the presence of increasing concentration of drug (Figure 3A), we assessed the number of 
surviving cells using high-throughput imaging for quantification. Strikingly, even the 
lowest concentration of the mixture BrP-LPA (Figure 1B) (1.6 μM) showed a significant 
decrease in the number of cells captured per field compared with untreated cells (Figure 3B). 
At the highest dose (12.5 μM), an obvious shift in cell number was visually observed (Figure 
3A) and was also quantified as statistically significant versus untreated cells (Figure 3B). 
Although a reduction in cell number was detected among cells treated with the anti-BrP-
LPA (1A), the reductions were significant only at 6.25 μM and 12.5 μM. Dying cells display 
many morphological changes, including nuclear condensation and permeabilization that 
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can be visualized by an intense increase in the fluorescence intensity of cell nuclei. We 
quantified nuclear permeability and detected an initial reduction (1.6 μM and 3.1μM), 
followed by a significant increase at higher concentrations (6.25 μM and 12.5 μM) in MeWo 
cells treated with the BrP-LPA mixture (Figure 1B) (Figure 3C). Although the results from 
the anti-BrP-LPA (Figure 1A) were not significant, there did appear to be an increasing 
trend at higher concentrations (6.25 μM and 12.5 μM).  
Due to the favorable results we observed thus far in our analysis, we hypothesized that the 
combinatorial treatment of BrP-LPA compounds with the alkylating agent DTIC would 
have superior activity to reduce MeWo cell viability than single-agent BrP-LPA treatment. 
In contrast, we observed an increase in the number of remaining MeWo cells after 24 hours 
treatment with DTIC, followed by 24 hours of the BrP-LPA compounds (Figure 4A). We 
quantified the changes in the loss of cells and determined monotherapy of BrP-LPA to be 
superior in comparison with combinatorial treatment (Figure 3B and 3C).  
Only when DTIC was reduced to 50 μM did the significance return, suggesting that a low 
enough concentration eliminated the combined inhibition. Similarly, we detected plasma 
membrane permeability only among DTIC 1000 μM and single-agent anti or mix (10 μM). 
There was a slight increase in the permeability at 50 μM DTIC and 10 μM of anti or mix, 
further supporting the observation that the low dose of DTIC eliminates the combined 
inhibition. Since the drugs were administered 24 hours apart, we hypothesize this is due to 
the molecular and cellular response to the compound, within the context of proliferation or 
an effect related to chemoresistance. This could suggest that the BrP-LPA compounds would 
require chemonaïve patients to achieve therapeutic efficacy, and this group would be 
incredibly difficult to find. 
4. Discussion 
Our data suggests, at least in an in vitro comparison, that single-agent or monotherapy 
using the anti-BrP-LPA (Figure 1A) or the mixed diastereomers BrP-LPA (Figure 1B) is 
superior at reducing the viability and proliferation of MeWo primary cutaneous melanoma 
cells than dacarbazine or temozolomide. Although we hypothesized that the mechanism of 
action for these two different agents would create a synergistic response as others have seen 
using combinations of dacarbazine with unrelated agents (Jin, Gong et al. 2011), in fact that 
is not what was observed. While unexpected, our results are similar to what others have also 
observed using BrP-LPA. Using an in vivo breast cancer model, Zhang et al. reported that 
the mixed diastereomers BrP-LPA (Figure 1B) alone (10 mg/kg) was superior at reducing 
tumor burden, compared with taxol alone (10 mg/kg) or taxol followed by BrP-LPA (Zhang 
et al. 2009). This corroborates our observations and further predicts that similar effects are 
likely to occur in an in vivo model of melanoma. Indeed, we have tested single-agent BrP-
LPA against metastatic melanoma in vivo and measured a significant reduction in the 
number of lesions in the lungs of animals (data not shown).  
The concern over reduced response with combination treatment of a novel agent together 
with dacarbazine is a major concern since most chemotherapy is now given in combination, 
even in clinical trials (Chu and DeVita 2008). In our study, we staged the drugs 24 hours 
apart, yet we still observed a reduction in overall efficacy. Our results are also in agreement 
with other publications suggesting that dacarbazine selects for a more aggressive phenotype 
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(A) Fluorescent images of MeWo cells treated with the indicated reagents for 24 or 48 h. The 
combination treatments were staged so that the dacarbazine (DTIC) was added for 24 h prior to the 
addition of BrP-LPA for an additional 24 h, for a total of 48 h of dacarbazine. The single-agent 
treatments were for 24 h. (B and C) Cell loss was calculated by measuring the average number of cells 
lost per field from quadruplicate samples and at least 4 images taken per sample for N=16. The BrP-
LPA diastereomeric mixture was used in ‘B’ and the anti diastereoisomer was used in ‘C’. (D) Plasma 
membrane permeability was calculated after staining the MeWo cells with a fluorescent dye capable of 
penetrating the membrane when small pores or holes provide access for the dye to enter the cell. An 
increase in the membrane permeability was achieved in the single-agent conditions or when DTIC was 
very low (50 μM), although statistical significance (***p<0.001) was calculated for only the BrP-LPA 
diastereomeric mixture (10 μM) in comparison with DMSO (1 μM) control using the student’s t-test. 
Fig. 4. Combination treatment of BrP-LPA reagents with dacarbazine inhibits the reduction 
in cell loss and proliferation achieved using single-agents. 
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action for these two different agents would create a synergistic response as others have seen 
using combinations of dacarbazine with unrelated agents (Jin, Gong et al. 2011), in fact that 
is not what was observed. While unexpected, our results are similar to what others have also 
observed using BrP-LPA. Using an in vivo breast cancer model, Zhang et al. reported that 
the mixed diastereomers BrP-LPA (Figure 1B) alone (10 mg/kg) was superior at reducing 
tumor burden, compared with taxol alone (10 mg/kg) or taxol followed by BrP-LPA (Zhang 
et al. 2009). This corroborates our observations and further predicts that similar effects are 
likely to occur in an in vivo model of melanoma. Indeed, we have tested single-agent BrP-
LPA against metastatic melanoma in vivo and measured a significant reduction in the 
number of lesions in the lungs of animals (data not shown).  
The concern over reduced response with combination treatment of a novel agent together 
with dacarbazine is a major concern since most chemotherapy is now given in combination, 
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apart, yet we still observed a reduction in overall efficacy. Our results are also in agreement 
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of melanoma, which may occur through the upregulation of ERK signaling pathways, 
cytokine release or increased vascular endothelial growth factor (Lev, Onn et al. 2004). In 
this study  we also observed what others have reported in that melanomas are notoriously 
resistant to therapeutic intervention. Indeed, we also found this to be true after only 24 
hours of exposure to dacarbazine, which was unexpected given the short timecourse. 
Herein we showed a reduction in cell viability using BrP-LPA compounds over the 
traditional chemotherapy alkylating agents, even when using BrP-LPA at lower 
concentrations. This highlights two important points concerning current therapeutics of 
melanoma. First, the traditional alkylating agents lack sufficient potency against this type of 
tumor, even when drug delivery is removed from the equation through the use of an in 
vitro tissue culture model. Second, single-agent BrP-LPA could be far better in generating a 
reduction in tumor burden and clinical usage than the alkylating agents.  
In comparison with other agents that we have tested, the BrP-LPA compounds can generate 
a more robust effect against certain types of melanoma than thio-ccPA 18:1, which requires a 
higher dosage in vitro (Altman et al. 2010). Furthermore, in a direct comparison between 
anti-BrP-LPA (Figure 1A) and the mixed diastereomers BrP-LPA (Figure 1B), we repeatedly 
observed an enhanced effect of the mixture. Thus far, in vivo studies have not detected any 
known cytotoxicity of this compound (data not shown), which further indicates its utility. 
Taken together, this is suggestive of the clinical potential of BrP-LPA in advanced 
melanoma. 
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1. Introduction 
Metastasis is a spread of cancer cells to a distant location from the primary tumor. This 
process involves a complex series of events similar to those that occur during inflammation. 
The events of metastasis can be divided into four major steps. First, cancer cells proliferate 
and transform to acquire motility and ability to invade basement membrane to reach blood 
vessels. Second, cancer cells penetrate blood vessels due to increased vascular permeability 
facilitated by inflammatory mediators and enter the circulation. Third, in the circulation 
cancer cells are shielded by host cells (platelets and neutrophils) to escape surveillance by 
immune cells and survive shear forces of the bloodstream. Next, integrin-mediated arrest of 
circulating cancer cells occurs on the endothelial surface before extravasation. Once cancer 
cells extravasate, heparanase from cancer cells degrades heparan sulfates of the extra 
cellular matrix. The cleavage of heparan sulfates release growth factors that stimulate cancer 
cell growth as well as angiogenesis. 
The Receptor for Advanced Glycation Endproducts (RAGE) belongs to the immunoglobulin 
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accumulate in physiological (aging) and pathological disorders such as diabetes (Schmidt et 
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(Kuniyasu et al., 2002). In contrast, RAGE levels are down-regulated in lung cancer relative 
to levels in the normal lung tissue. These observations have led to studies to delineate the 
pathophysiologic involvement of RAGE in cancer. Notably, AGEs are involved in 
development and progression of cancers (Abe et al., 2007; Sebekova et al., 2007).  
 
 
Fig. 1. RAGE domains and ligands involved in cancer. RAGE has ligand-binding V-domain 
followed by two C-domains of similar to immunoglobulins, a transmembrane region and 
cytoplasmic tail.  
Heparin was discovered in 1916 (McLean, 1916)}, and has been used almost exclusively as 
an anticoagulant in medicine. However, shortly after its initial discovery, it was reported 
that heparin had an inhibitory effect on tumor growth in animals (Goerner, 1930). This 
initial observation led to intensive investigation with regard to heparin’s anticancer and 
anti-metastatic properties (Casu et al., 2010; Casu et al., 2008; Hettiarachchi et al., 1999; 
Kragh et al., 2005; Kragh & Loechel, 2005; Lapierre et al., 1996; Lever & Page, 2002; Ono et 
al., 2002; Ornstein & Zacharski, 1999; Smorenburg et al., 1996; Stevenson et al., 2005; 
Stevenson et al., 2007; Vlodavsky et al., 2006; Yip et al., 2006; Yoshitomi et al., 2004). The 
usefulness of heparin as an anticancer drug has been hindered by its anticoagulant effect at 
therapeutic doses required to inhibit cancer growth and spread. The potential of heparin as 
an anticancer and anti-inflammatory agent led to discovery of a number of low or 
nonanticoagulant heparins produced by chemical modifications of the heparin polymer 
itself (Irimura et al., 1986; Lundin et al., 2000; Vlodavsky et al., 1994), sulfation of other 
natural polymers (Borgenstrom et al., 2007; Kaeffer et al., 1999; Miao et al., 1999) and 
sulfated heparin-like polymers produced synthetically (Wellstein et al., 1991; Zugmaier et 
al., 1992). Studies with heparanoids have been limited to animal models. In human studies, 
heparin has proven beneficial in cancer treatment but its anticoagulant activity has limited 
its use.  
Herein we describe a nonanticoagulant 2-O, 3-O desulfated heparin (ODSH) that retains the 
anti-inflammatory activities of heparin, including inhibition of P- and L-selectins, 
heparanase, cationic neutrophil proteases, activation of nuclear factor-κB (NF-κB) and 
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ligation of RAGE by HMGB-1, AGEs and S100 calgranulins (Barry et al., 2010; Lapierre et al., 
1996; Rao et al., 2010; Thourani et al., 2000). Also, we describe the first clinical experience 
with this modified heparin, which has proven safe and low in anticoagulant activity in 137 
humans tested to date. Moreover, we present studies demonstrating that ODSH does not 
cause heparin-induced thrombocytopenia (HIT), a thrombotic syndrome occurring in 3% of 
individuals receiving heparins (Arepally & Ortel, 2010).  
2. Methods 
2.1 Production of ODSH 
ODSH is a heparin derivative produced for human use under cGMP conditions by the 
leading U.S. commercial manufacturer of bulk pharmaceutical grade USP heparin, Scientific 
Protein Laboratories (Wanaukee, WI). It is synthesized by cold alkaline hydrolysis of USP 
porcine intestinal heparin, as reported (Fryer et al., 1997), which removes the 2-O sulfate 
groups from iduronic acid residues and the 3-O sulfate groups from the glucosamine 
residues of the heparin backbone, The N-sulfates,  6-O sulfates, and carboxylates remain 
intact (Fig.2).  
 
 
Fig. 2. Sulfate position in disaccharide units of ODSH in comparison to heparin. 
2.2 Phase I clinical trials 
Two INDs have been opened for intravenous ODSH:  #71,356 (under which Phase I safety 
trials were conducted and pediatric protein losing enteropathy is being studied) and #72,247 
(inactive, for a phase II trial in exacerbations of COPD). In the 137 humans who have 
received intravenous ODSH by bolus and constant infusion for up to 5 days, there have 
been no serious adverse events, and no decrease in platelet count in any subject to suggest 
occurrence of HIT, which might have been expected in 2-4 (2-3%) subjects. In Phase I human 
safety studies (Rao et al., 2010) bolus ODSH was administered safely in doses as high as 20 
 
Research on Melanoma – A Glimpse into Current Directions and Future Trends 
 
82
(Kuniyasu et al., 2002). In contrast, RAGE levels are down-regulated in lung cancer relative 
to levels in the normal lung tissue. These observations have led to studies to delineate the 
pathophysiologic involvement of RAGE in cancer. Notably, AGEs are involved in 
development and progression of cancers (Abe et al., 2007; Sebekova et al., 2007).  
 
 
Fig. 1. RAGE domains and ligands involved in cancer. RAGE has ligand-binding V-domain 
followed by two C-domains of similar to immunoglobulins, a transmembrane region and 
cytoplasmic tail.  
Heparin was discovered in 1916 (McLean, 1916)}, and has been used almost exclusively as 
an anticoagulant in medicine. However, shortly after its initial discovery, it was reported 
that heparin had an inhibitory effect on tumor growth in animals (Goerner, 1930). This 
initial observation led to intensive investigation with regard to heparin’s anticancer and 
anti-metastatic properties (Casu et al., 2010; Casu et al., 2008; Hettiarachchi et al., 1999; 
Kragh et al., 2005; Kragh & Loechel, 2005; Lapierre et al., 1996; Lever & Page, 2002; Ono et 
al., 2002; Ornstein & Zacharski, 1999; Smorenburg et al., 1996; Stevenson et al., 2005; 
Stevenson et al., 2007; Vlodavsky et al., 2006; Yip et al., 2006; Yoshitomi et al., 2004). The 
usefulness of heparin as an anticancer drug has been hindered by its anticoagulant effect at 
therapeutic doses required to inhibit cancer growth and spread. The potential of heparin as 
an anticancer and anti-inflammatory agent led to discovery of a number of low or 
nonanticoagulant heparins produced by chemical modifications of the heparin polymer 
itself (Irimura et al., 1986; Lundin et al., 2000; Vlodavsky et al., 1994), sulfation of other 
natural polymers (Borgenstrom et al., 2007; Kaeffer et al., 1999; Miao et al., 1999) and 
sulfated heparin-like polymers produced synthetically (Wellstein et al., 1991; Zugmaier et 
al., 1992). Studies with heparanoids have been limited to animal models. In human studies, 
heparin has proven beneficial in cancer treatment but its anticoagulant activity has limited 
its use.  
Herein we describe a nonanticoagulant 2-O, 3-O desulfated heparin (ODSH) that retains the 
anti-inflammatory activities of heparin, including inhibition of P- and L-selectins, 
heparanase, cationic neutrophil proteases, activation of nuclear factor-κB (NF-κB) and 
 
Low-Anticoagulant Heparins in the Treatment of Metastasis 
 
83 
ligation of RAGE by HMGB-1, AGEs and S100 calgranulins (Barry et al., 2010; Lapierre et al., 
1996; Rao et al., 2010; Thourani et al., 2000). Also, we describe the first clinical experience 
with this modified heparin, which has proven safe and low in anticoagulant activity in 137 
humans tested to date. Moreover, we present studies demonstrating that ODSH does not 
cause heparin-induced thrombocytopenia (HIT), a thrombotic syndrome occurring in 3% of 
individuals receiving heparins (Arepally & Ortel, 2010).  
2. Methods 
2.1 Production of ODSH 
ODSH is a heparin derivative produced for human use under cGMP conditions by the 
leading U.S. commercial manufacturer of bulk pharmaceutical grade USP heparin, Scientific 
Protein Laboratories (Wanaukee, WI). It is synthesized by cold alkaline hydrolysis of USP 
porcine intestinal heparin, as reported (Fryer et al., 1997), which removes the 2-O sulfate 
groups from iduronic acid residues and the 3-O sulfate groups from the glucosamine 
residues of the heparin backbone, The N-sulfates,  6-O sulfates, and carboxylates remain 
intact (Fig.2).  
 
 
Fig. 2. Sulfate position in disaccharide units of ODSH in comparison to heparin. 
2.2 Phase I clinical trials 
Two INDs have been opened for intravenous ODSH:  #71,356 (under which Phase I safety 
trials were conducted and pediatric protein losing enteropathy is being studied) and #72,247 
(inactive, for a phase II trial in exacerbations of COPD). In the 137 humans who have 
received intravenous ODSH by bolus and constant infusion for up to 5 days, there have 
been no serious adverse events, and no decrease in platelet count in any subject to suggest 
occurrence of HIT, which might have been expected in 2-4 (2-3%) subjects. In Phase I human 
safety studies (Rao et al., 2010) bolus ODSH was administered safely in doses as high as 20 
 
Research on Melanoma – A Glimpse into Current Directions and Future Trends 
 
84
mg/kg, resulting in lower activated partial thromboplastin times (aPTT) than the usual 
anticoagulation bolus of unfractionated heparin (80 U/kg, i.e., 0.5 mg/kg at the usual 160 
U/mg anti-Xa activity of USP heparin). As part of the Phase I evaluation, ODSH was 
infused as a bolus of 8 mg/kg followed by continuous intravenous infusion of 0.5 mg/kg/h, 
adjusted to maintain an aPTT between 40 and 45 seconds (0.64 to 1.39 mg/kg/h final 
infusion rate). 
2.3 Cell culture 
U937 monocytes were grown in suspension culture at 37° C in humidified 5% CO2-95% air 
in RPMI-1640 supplemented with 10% heat inactivated FBS, 2 mM L-glutamine, 1 mM 
sodium pyruvate, 0.1 mM MEM non-essential amino acids, 100 units/mL penicillin and 100 
μg/mL streptomycin. Experiments were performed on cells from passages 1-5. B16F10.1 
melanoma cells were grown in Dulbecco’s modified Eagle’s medium, 10% fetal bovine 
serum, 100 U/mL penicillin, 100 U/mL streptomycin, 2 mM glutamine and 1 mM sodium 
pyruvate. 
2.4 Adhesion assays 
2.4.1 Cell surface binding assays   
The effect of heparinoids on binding of U937 monocytes to P-selectin or RAGE was studied 
in high-bind micro plates coated with 8 μg/mL protein A (50 μL/well) in 0.2 M carbonate-
bicarbonate buffer (pH 9.4). Plates were washed with phosphate buffered saline (PBS) 
containing 1% BSA (PBS-BSA), and P-selectin-Fc or RAGE-Fc chimera (50 μL containing 1 
μg) was added to each well and incubated for 2 h at room temperature or overnight at 4° C, 
respectively. Following incubation, wells were washed twice with PBS-BSA. Fifty μL of 
heparinoids (0 to 1,000 μg/mL) serially diluted in 20 mM HEPES buffer (containing 125 mM 
NaCl, 2 mM calcium and 2 mM magnesium) were added to each well and incubated at 
room temperature for 15 min. As a negative control, 50 μL of 10 mM EDTA was added to 
select wells to prevent cell binding through sequestration of calcium. At the end of the 
incubation period, 50 μL of U937 cells (105 cells/well, calcein-labeled according to 
manufacturer’s instructions) were added to each well and plates were incubated an 
additional 30 min at room temperature. The wells were then washed thrice with PBS, and 
bound cells were lysed by addition of 100 μL of Tris-Triton X-100 buffer. Fluorescence was 
measured on a microplate reader using excitation of 494 nm and emission of 517 nm.  
2.4.2 Solid phase binding assays  
Two types of ELISAs were performed, one to observe the binding between RAGE and its 
ligands, including CML-BSA, HMGB-1 and S100b, and a competitive ELISA to study the 
ability of ODSH to inhibit/compete for RAGE binding to its ligands.  
To confirm RAGE binding to its ligands, polyvinyl 96-well plates were coated with 5 
μg/well of specific ligand (CML-BSA, HMGB-1 or S100b calgranulin). Plates were incubated 
overnight at 4° C and washed thrice with PBS-0.05% Tween-20 (PBST). Next, 50 μL of RAGE 
from the dilution series ranging from 0.001 to ~ 6 nM was transferred to each respective 
ligand-coated well and incubated at 37° C for 1 h. Wells were then washed four times with 
PBST. To detect bound RAGE, 50 μL of anti-RAGE antibody (0.5 μg/mL) was added to each 
well, the mixture was incubated for 1 h at room temperature, and wells were washed again 
four times with PBST. HRP-conjugated secondary antibody (50 μL per well) was added, 
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wells were incubated for 1 h at room temperature, and then washed once with PBST. A 
colorimetric reaction was initiated by addition of 50 μL of TMB and terminated after 15 min 
by addition of 50 μL of 1 N HCl. Absorbance at 450 nm was read using an automated 
microplate reader. Binding affinity (KD) was determined from the plot of absorbance values 
versus concentrations of RAGE.  
RAGE binding to glycated ECM proteins, collagen-I, collagen -IV, fibronectin and laminin 
coated plates were used. Plates were incubated with 100 µL of 0.15 M glyoxylic acid + 0.45 
M sodium cyanoborohydride mixture at 37 °C for 24 hours. At the end of incubation period, 
the plates were washed with PBST and used for RAGE binding as described above. 
For studies of the effect of ODSH or heparin on RAGE binding to its ligands, polyvinyl 96-
well plates were coated with specific ligand as described above. Separately, a constant 
amount of RAGE-Fc chimera (100 μL containing 0.5 μg/mL in PBST containing 0.1% BSA) 
was incubated with an equal volume of serially diluted ODSH or heparin (0.001 to 1,000 
μg/mL in PBST-BSA) overnight at 4° C. The following day, 50 μL of RAGE-heparinoid mix 
was transferred to each respective ligand-coated well and incubated at 37° C for 2 h. Wells 
were then washed four times with PBST. Bound RAGE was detected as described above. 
Absorbance at 450 nm was plotted against concentration of ODSH or heparin. The IC50 
values were obtained using non-linear regression analysis.  
2.5 Elastase and cathepsin G activity assay 
The inhibitory activity of heparin and ODSH against HLE and cathepsin G was monitored 
using the specific chromogenic substrates Suc-Ala-Ala-Val-pNA and Suc-Ala-Ala-Pro-Phe-
pNA, respectively, according to methods previously described (Fryer et al., 1997).  
2.6 Mouse model of melanoma lung metastasis 
Lung metastasis from melanoma was studied using protocols previously reported by the 
Varki group (Stevenson et al., 2005). Animal use and husbandry followed protocols 
approved by the IACUC at the University of Utah. Confluent B16F10 melanoma cells (70-
80%) were harvested by brief exposure to trypsin, and washed twice with serum-free 
medium prior to injection. Living cells were counted with Trypan blue staining prior to 
injection to insure > 95% viability. Female C57BL/6J mice (n = 6 per group) were injected 
subcutaneously with 100 μL PBS, heparin (30 mg/kg) or ODSH (30 mg/kg). Thirty min 
later, 5 x 105 B16F10 cells in 200 μL medium were injected intravenously into the lateral tail 
vein. Mice from each group were injected in alternating order, and cells were resuspended 
by gently flicking the tube before aspirating the sample for each injection. Twenty-seven 
days after injection, surviving mice were euthanized. The lungs were removed, perfused 
intra-tracheally with 10% buffered formalin and photographed. Visible tumor foci were 
counted independently by two different laboratory personnel blinded with regard to 
treatment groups, and metastasis quantified in terms of the number of black spots.  
3. Results and discussion 
3.1 ODSH is a non-anticoagulant heparin that is manufactured at industrial scale and 
safe from heparin induced thrombocytopenia 
The ODSH was manufactured as described in Methods section. Seven serial 1-2 kg batches 
of material have shown an average molecular mass of 11.7 ± 0.3 kg kDa. ODSH has low 
affinity for anti-thrombin III (KD = 339 μM or 4 mg/mL vs. 1.56 μM or 22 μg/mL for 
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heparin) consistent with its low anticoagulant activity. Serial batches of ODSH 
demonstrated consistently reduced USP (7 ± 0.3 U of anticoagulant activity/mg), anti-Xa 
(1.9 ± 0.1 U/mg), and anti- IIa (1.2 ± 0.1 U/mg) activities, compared with those of heparin 
(165-190 U/mg activity for all 3 assays). The current clinical formulation that was used in 
137 humans (54 normal and 83 ill patients) is a sterile-filled 20 mL glass vial containing an 
isotonic 50 mg/mL solution of ODSH in buffered saline. This formulation is cGMP 
manufactured by Pyramid Laboratories (Costa Mesa, CA). Chemistry and Manufacturing 
processes are already on file with the FDA in two INDs. A complication of heparin is HIT, 
which occurs in subjects who produce an activating antibody to the heparin-platelet factor 4 
(PF4) complex on the platelet surface, causing thrombocytopenia and thromboembolism 
(Arepally & Ortel, 2010). In standard serotonin release assays (SRA) performed with human 
antibodies to the heparin-PF4 complex, heparin triggered release of 14C-serotonin from 




Fig. 3. ODSH does not trigger platelet activation in the serotonin release assay. Normal 
platelets were loaded with 14C-serotonin and incubated with serum from 3 patients with 
heparin-PF4 antibodies. Platelets were activated by heparin as a positive control (≥ 20% 
serotonin release). Rao et al., Am J Physiol Cell Physiol (2010) Am Physiol Soc, used with 
permission. 
3.2 ODSH is safe to use in humans 
Two INDs have been opened for intravenous ODSH:  #71,356 (under which Phase I safety 
trials were conducted and pediatric protein losing enteropathy is being studied) and #72,247 
(inactive, for a phase II trial in exacerbations of COPD). In the 137 humans who have 
received intravenous ODSH by bolus and constant infusion for up to 5 days, there have 
been no serious adverse events, and no decrease in platelet count in any subject to suggest 
occurrence of HIT, which might have been expected in 2-4 (2-3%) subjects (Arepally & Ortel, 
2010). In Phase I human safety studies (Rao et al., 2010) bolus ODSH was administered 
safely in doses as high as 20 mg/kg, resulting in lower activated partial thromboplastin 
times (aPTT) than the usual anticoagulation bolus of unfractionated heparin (80 U/kg, i.e., 
0.5 mg/kg at the usual 160 U/mg anti-Xa activity of USP heparin). As part of the Phase I 
evaluation, ODSH was infused as a bolus of 8 mg/kg followed by continuous intravenous 
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infusion of 0.5 mg/kg/h, adjusted to maintain an aPTT between 40 and 45 seconds (0.64 to 
1.39 mg/kg/h final infusion rate). This protocol achieved anti-inflammatory plasma ODSH 
concentrations (≥ 10-20 μg/mL) at doses that did not cause anticoagulation (Fig 4). 
 
      
 
Fig. 4. ODSH infusion in human volunteers achieves anti-inflammatory concentrations 
before producing anticoagulation. A. Mean (± SD) plasma ODSH levels during study drug 
infusion, measured by an automated GLP validated assay (Rao et al., 2010). B. Mean (± SD) 
aPTT and change in prothrombin time (PT) during study drug infusion. C. Relationship 
between plasma ODSH and change in aPTT from baseline during the 3 day infusion of 8 
mg/kg followed by 0.5 mg/kg/h adjusted to maintain aPTT between 40 and 45 seconds. 
Rao et al., Am J Physiol Cell Physiol (2010) Am Physiol Soc, used with permission. 
3.3 ODSH has anti-metastatic and anti-inflammatory activities in vitro 
Despite low anticoagulant activity, ODSH retains the strong, broad anti-inflammatory 
activities and antimetastatic activities of heparin. In metastasis, cancer cells disseminate into 
the blood circulation and interact with other circulating cells like leukocytes and platelets 
and also endothelium of vascular wall by selectin-mediated adhesion. The family of 
selectins includes, P-, L- and E-Selectin, which are expressed on activated platelets, 
leukocytes and endothelium. Tumor cells express mucins, which are the ligands for 
selectins, on the cell surface and facilitate cell-cell adhesion. The involvement of selectins in 
metastasis has been shown in selectin-deficient mouse models (Borsig et al., 2002; Kim et al., 
1998; O et al., 2002). Several studies have shown that heparin and heparinoids inhibit 
selectin-mediated cell adhesion, an important phase of metastasis (Borsig, 2010; Borsig et al., 
2001; Borsig et al., 2002; Gao et al., 2006; Ma & Geng, 2000; Maraveyas et al., 2010; Stevenson 
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heparin) consistent with its low anticoagulant activity. Serial batches of ODSH 
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et al., 2005; Stevenson et al., 2007; Varki, 2007; Wahrenbrock et al., 2003; Wei et al., 2004). To 
investigate the antimetastatic potency of ODSH, we used U937 cells, a human monocytic 
leukemia cells. U937 cells express P-selectin ligand, P-selectin glycoprotein ligand-1 (PSGL-
1), that functions similar to mucins. We tested the ODSH ability to competitively displace 
fluorescent-labeled U937 cells adherence to P-selectin via PSGL-1. ODSH inhibited P-selectin 
with an IC50 of 1.1 μg/mL consistent with that of values reported byWang (Wang et al., 
2002), who demonstrated that ODSH also inhibits L-selectin-mediated adhesion with an IC50 
of 3 μg/mL, versus 0.4 μg/mL for heparin (Wang et al., 2002) (Fig. 5). 
 
 
Fig. 5. Anti-inflammatory and anti-metastatic profile of ODSH. The 50% inhibitory 
concentrations (IC50 values) of ODSH to interrupt the receptor ligand pairs, P-
selectin/PSGL-1, RAGE/Mac-1, RAGE/CML-BSA, RAGE/S100B and RAGE/HMGB1, 
interaction are higher than that of heparin. Nonetheless, the IC50 concentrations of ODSH 
required to inhibit HLE, cathepsin G and heparanase activities, the key enzymes involved in 
the inflammation and metastasis, are similar to the values for heparin. The IC50 values of 
ODSH are higher than that of heparin suggesting that ODSH has lower inhibitory potential 
than heparin, but the values are much lower than achievable plasma concentration (~200 
µg/mL) in humans (see Fig 4). Heparanase data is from (Lapierre et al., 1996). 
Though RAGE binds to disparate ligands, we will discuss only the ligands AGE, HMGB1 
and S100B that have been evaluated for their role in cancer. RAGE and its ligands are co-
expressed in many tumors and the expressed ligands are secreted causing triggering of 
cellular signaling pathways. This results in expression of cytokines, growth factors, 
transcription factors, adhesion molecules and NF-kB (Sparvero et al., 2009). Therefore we 
will focus on the interruption of RAGE-ligand interaction with ODSH. 
Several in vitro studies have shown that AGE stimulates growth, proliferation and invasion 
of cancer cells including melanoma cells (Abe et al., 2004; Yamamoto et al., 1996; Zill et al., 
2003; Zill et al., 2001). AGEs are found in extracellular matrix (ECM) proteins (Ling et al., 
1998; Mizutari et al., 1997) that can interact with RAGE on tumor cells and enhance RAGE 
expression causing damage to surrounding tissues. We therefore tested the binding of 
native and glycated ECM proteins (collagen I, collagen IV, fibronectin and laminin) to 
RAGE. Results indicate that RAGE binds to native ECM protein with a strong affinity but 
the affinity is negligibly decreased with glycated ECM proteins.  Overall, the KD values of 
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RAGE for different ECM proteins are less than 100 ng/mL or <1nM suggesting RAGE on 
tumor cells might play a role in tumor cell spreading (Fig 6).  
 
 
Fig. 6. RAGE binds to AGE-ECM proteins. RAGE binding to ECM proteins was analyzed as 
described in Methods Section. RAGE bound to native Collagen I, Collagen IV and 
fibronectin with same affinity but with a lesser affinity to Laminin. The affinity of RAGE for 
glycated ECM decreased for all the ECM proteins studied but the affinity constants suggest 
that RAGE binds strongly to ECM proteins even in modified conditions. 
In addition, AGE-CML is a common AGE found in vivo (Reddy et al., 1995) and has been 
detected in tumor tissues (van Heijst et al., 2005). Therefore, we tested potential of ODSH to 
disrupt the binding between CML-BSA and RAGE as described in methods section. We 
observed that RAGE bound to CML-BSA with strong affinity (KD 0.43 nM) and ODSH 
inhibited the ligation of CML-BSA with IC50 of 8.6 µg/mL (Fig 5). 
HMGB1 is another ligand for RAGE and both HMGB1 and RAGE have been shown 
elevated in tumors, including melanoma, colon, prostate, breast and pancreatic cancers 
(Brezniceanu et al., 2003; Ellerman et al., 2007; Sparvero et al., 2009). Earlier studies by 
Huttunen et al. suggested that RAGE/HMGB1 signaling might be associated with 
metastasis (Huttunen et al., 1999; Huttunen et al., 2000). Taguchi et al. found that blockade 
of HMGB-RAGE signaling suppressed tumor growth as a result of decreased cell migration 
and invasiveness rather than proliferation or apoptosis (Taguchi et al., 2000). HMGB1 alone 
or by interaction with NF-kBp65 has been shown to bind specific region of melanocyte 
inhibitory activity (MIA) promoter in melanocytes and increase the expression of MIA 
protein, which enhances migration and invasion of tumor cells (Poser et al., 2003; Sasahira et 
al., 2008). HMGB1 was isolated using heparin-sepharose chromatography (Rauvala & 
Pihlaskari, 1987) and later was identified to contain a heparin-binding sequence in its amino 
terminus, suggesting its affinity for heparin (Cardin & Weintraub, 1989). Consistent with 
these observations, HMGB1 also interacted with carbohydrate chain of syndecan and 
facilitated cell migration (Rauvala & Rouhiainen, 2010). Syndecan is expressed in normal 
tissues and tumor tissues but the role of HMGB1 interaction with syndecan in physiological 
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and pathological conditions is not known (Rauvala & Rouhiainen, 2010). Since ODSH is 
derived from heparin, we tested whether ODSH can interrupt the RAGE-HMB1 ligation. 
Though HMGB1 binds to RAGE with high affinity (KD 0.64nM), ODSH inhibited RAGE-
HMGB1 interaction with an IC50 of 0.23 µg/mL (Figs. 5 and 7). 
 
 
Fig. 7. ODSH and heparin inhibit binding of HMGB-1 to RAGE. HMGB-1 binding to RAGE-
Fc chimera was studied using ELISA techniques as described in Methods. RAGE bound to 
immobilized HMGB-1 in a saturable fashion (inset) with a KD of 0.64 nM. ODSH (●) and 
heparin (○) inhibit binding of recombinant HMGB-1 to RAGE with IC50 values of 0.23 and 
0.04 μg/mL, respectively. Rao et al., Am J Physiol Cell Physiol (2010) Am Physiol Soc, used 
with permission. 
S100 proteins are calcium dependent proteins of the EF-hand (helix-loop-helix) type that are 
differentially located and differentially expressed in a wide variety of cells (Donato, 1999; 
Donato, 2001; Donato et al., 2009). Among the 25 S100 protein identified, S100b is unique in 
its location on chromosome 21q22.3 and first one of the group found to ligate to RAGE 
(Hofmann et al., 1999). S100b is highly expressed in melanoma and considered as possible 
biomarker for the prognosis of the disease (Harpio & Einarsson, 2004; Salama et al., 2008). 
We studied the binding affinity of S100b to RAGE. RAGE ligated to S100b with a KD of 0.45 
nM, a value much lower than the affinity range reported (reviewed in (Leclerc et al., 2009)). 
ODSH inhibited the binding of RAGE to S100b with IC50 value of 4.23µg/mL. (Fig 5). 
HMGB-1 is released into extracellular milieu as a result of necrosis, apoptosis and secretion. 
Only HMGB1 released by necrotic cells demonstrates cytokine activity, recruits leukocytes 
and activates endothelial cell adhesion molecules such as selectins (Dumitriu et al., 2005; 
Lotze & Tracey, 2005). In cancer, tumor cells undergoing stress are susceptible to death 
because of factors that include hypoxia, nutrient deprivation and or anticancer treatments 
(Kepp et al., 2009). These dying cancer cells become a source of HMGB1 (Dong Xda et al., 
2007; Scaffidi et al., 2002). Orlova et al (Orlova et al., 2007)) have shown that HMGB1-
induced Mac-1 dependent neutrophil recruitment requires the presence of RAGE on 
neutrophils but not on endothelial cells. Interestingly, three proteins, HMGB1, Mac-1 and 
RAGE bind to heparin (Diamond et al., 1995; Hanford et al., 2004; Rauvala & Pihlaskari, 
1987). We therefore tested Mac-1 dependent binding of U937 cells to immobilized RAGE. 
ODSH inhibited the adherence of U937 cells to RAGE with IC50 values of 0.11 µg/mL  
(Fig 5). 
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3.4 ODSH Prevents metastasis in vivo 
The vitro studies described above suggested that ODSH, similar to heparin, might interrupt 
key receptor-ligand interactions involved in metastasis. We therefore investigated the effects 
of ODSH in experimental melanoma lung metastasis. Heparin significantly decreased lung 
metastasis at 28 days after melanoma injection, but the same dose of ODSH provided 
substantially greater reduction of lung metastasis (Fig 8A). ODSH also significantly 
improved 28-day survival. In contrast to 70% mortality in mice treated with PBS, ~ 70% of 
ODSH-treated mice survived the experiment (Fig 8B). 
 
 
Fig. 8. ODSH inhibits melanoma lung metastasis. Female C57BL/6J mice (n = 6/group) were 
injected SQ with 100 μL PBS, 30 mg/kg heparin, or 30 mg/kg ODSH. Thirty min later, 5 x 
105 B16F10 melanoma cells were injected IV into the tail vein. 27 days later surviving mice 
were euthanized and lungs were removed, fixed, stained and assessed for metastasis by 2 
independent observers. A. Heparin (*P < 0.05 vs PBS) or ODSH (**P < 0.01 vs PBS) 
significantly reduced metastasis. B. SQ heparin showed little effect on lung metastatic 
outgrowth but ODSH suppressed metastatic colonization microscopically. C. ODSH 
improved survival (*P < 0.05 vs PBS). Rao et al., Am J Physiol Cell Physiol (2010) Am 
Physiol Soc, used with permission. 
This model is widely used to test the inhibitory capacity of heparin and heparins with no or 
minimal anticoagulant activity in metastasis (reviewed in (Borsig, 2010). The attenuation of 
metastasis was attributed to P-selectin and L-selectin as the experimental mice were 
deficient in selectin but also suggested that there is a selectin-independent mechanism 
involved. It is not clear whether B16 melanoma cells express mucins on the cells surface to 
interact with P-selectin, but the expression of RAGE is observed in melanoma cells 
(Huttunen et al., 2002; Saha et al., 2010). Further, Huttunen et al showed the attenuation of 
metastasis when B16 cells injected with HMGB1 peptide suggesting the RAGE-mediated 
tumor cell invasion can be inhibited by competition with RAGE binding ligand such as 
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ODSH and heparin.  In summary, because ODSH interacts with the many receptors, ligands 
and inhibits enzymes involved in the metastasis, the attenuation of metastasis in the 
experimental model is due to action of ODSH on multiple sites. 
4. Conclusion 
A number of fully anticoagulant heparins are commercially available, but their use as a 
chronic treatment for cancer is dose-limited by their anticoagulant activity. Therapeutic 
anticoagulant doses of heparin or low molecular weight heparin (Hirsh et al., 2001; Koenig 
et al., 1998) do not provide sufficiently high plasma drug concentrations to reliably inhibit 
the selectin-, heparanase- or RAGE-mediated processes (Koenig et al., 1998; Lapierre et al., 
1996; Rao et al., 2010; Wang et al., 2002) that are now understood to be important for 




Fig. 9. Potential interference of low anticoagulant ODSH in metastasis. ODSH 1) inhibits 
heparanse, the enzyme secreted by tumor cells during intravsation and extravsation thus 
prevent spread of the tumor cells, 2) inhibits the tumor cell mucin (P-selectin ligand) 
binding to P-selectin on endothelial cells and platelets, 3) inhibits tumor cell RAGE 
interaction with leukocyte Mac-1, 4) inhibits tumor cell RAGE interaction with its ligands, 
AGE, HMGB1 and S100b, that are either released by tumor cells within cancer micro 
environment or by the leukocytes thus prevent sustained signaling for tumor progression,  
5) inhibits circulating RAGE  ligand interaction with endothelial RAGE. 
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Of the available low anticoagulant heparin derivatives (Casu et al., 2008; Fryer et al., 1997; 
Kragh et al., 2005; Kragh & Loechel, 2005; Lapierre et al., 1996; Ono et al., 2002; Rao et al., 
2010; Stevenson et al., 2007; Wang et al., 2002; Yoshitomi et al., 2004), only ODSH has been 
proven safe from major adverse events in humans (Rao et al., 2010) data on file with FDA) 
and only ODSH is free from the potential to induce HIT (Rao et al., 2010). The concept that 
P-selectin is the key molecule in metastasis is based on the attenuation of metastasis in 
animal models. Because of the complex biology of cancer metastasis, it is not easy to identify 
the specific mediator(s) involved in development of metastatic disease in patients with 
cancer. In such situation, a compound that can simultaneously target multiple mediators 
involved in the diseases might have substantial therapeutic value. We have described that 
non-anticoagulant ODSH, not only targets P-selectin, but additionally is capable of 
inhibiting the RAGE interaction with its multiple structurally unrelated ligands that play 
many biological roles in metastasis (Fig. 9). Thus, the results described herein support the 
notion that low anticoagulant heparin derivatives such as ODSH might prove useful in 
prevention of metastasis in human cancer. 
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environment or by the leukocytes thus prevent sustained signaling for tumor progression,  
5) inhibits circulating RAGE  ligand interaction with endothelial RAGE. 
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1. Introduction 
Malignant melanoma is a deadly disease in which standard treatment options have remained 
remarkably static over the past 30 years (Sullivan & Atkins, 2009). At present, the incidence of 
melanoma continues to increase despite public health initiatives that have promoted 
protection against the sun. Thus, during the past ten years, the incidence and annual mortality 
of melanoma has increased more rapidly than any other cancer and according to an American 
Cancer Society estimate, there will have been approximately 68,720 new cases of invasive 
melanoma diagnosed in 2009 in the United States, which resulted in approximately 8,650 
deaths (American Cancer Society, 2009). Unfortunately, the increase in incidence has not been 
paralleled by the development of new therapeutic agents with a significant impact on survival. 
Although many patients with melanoma localized to the skin are cured by surgical excision, 
increased time to diagnosis is associated with higher stage of disease, and those with regional 
lymphatic or metastatic disease respond poorly to conventional radiation and chemotherapy 
with 5-year survival rates ranging from 10 to 50% (Tawbi & Buch, 2010). Currently, limited 
therapeutic options exist for patients with metastatic melanomas, and all standard 
combinations currently used in metastasis therapy have low efficacy and poor response rates. 
One example of the complications involved in melanoma chemotherapy is the limited 
effectiveness of antifolates. Although methotrexate (MTX), the most frequently used antifolate, 
is an efficient drug for several types of cancer, it is not active against melanoma (Kufe et al., 
1980). Undoubtedly, unravelling the mechanism of the resistance of melanomas to this drug 
could help to improve current therapeutic approaches. Moreover, it could help to develop a 
novel generation of antifolate drugs that overcome resistance problems and present low 
toxicity for the prophylaxis and treatment of melanoma. 
2. Mechanisms of resistance of melanoma to classical antifolates 
Dihydrofolate reductase (DHFR; 5,6,7,8-tetrahydrofolate: NADP+ oxidoreductase, EC 1.5.1.3) 
catalyzes the reduction of 7,8-dihydrofolate (DHF) to 5,6,7,8-tetrahydrofolate (THF) in the 
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increased time to diagnosis is associated with higher stage of disease, and those with regional 
lymphatic or metastatic disease respond poorly to conventional radiation and chemotherapy 
with 5-year survival rates ranging from 10 to 50% (Tawbi & Buch, 2010). Currently, limited 
therapeutic options exist for patients with metastatic melanomas, and all standard 
combinations currently used in metastasis therapy have low efficacy and poor response rates. 
One example of the complications involved in melanoma chemotherapy is the limited 
effectiveness of antifolates. Although methotrexate (MTX), the most frequently used antifolate, 
is an efficient drug for several types of cancer, it is not active against melanoma (Kufe et al., 
1980). Undoubtedly, unravelling the mechanism of the resistance of melanomas to this drug 
could help to improve current therapeutic approaches. Moreover, it could help to develop a 
novel generation of antifolate drugs that overcome resistance problems and present low 
toxicity for the prophylaxis and treatment of melanoma. 
2. Mechanisms of resistance of melanoma to classical antifolates 
Dihydrofolate reductase (DHFR; 5,6,7,8-tetrahydrofolate: NADP+ oxidoreductase, EC 1.5.1.3) 
catalyzes the reduction of 7,8-dihydrofolate (DHF) to 5,6,7,8-tetrahydrofolate (THF) in the 
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presence of coenzyme NADPH as follows: DHF + NADPH + H+  THF + NADP+. This 
enzyme is necessary for maintaining intracellular pools of THF and its derivatives which are 
essential cofactors in one-carbon metabolism. Coupled with thymidylate synthase (Lockshin et 
al., 1979), it is directly involved in thymidylate (dTMP) production through a de novo pathway. 
DHFR is therefore pivotal in providing purines and pyrimidine precursors for the biosynthesis 
of DNA, RNA and amino acids. In addition, it is the target enzyme (Blakley, 1969) for 
antifolate drugs such as the antineoplastic drug MTX and the antibacterial drug trimethoprim 
(TMP). The mechanisms of resistance to MTX have been extensively studied, mainly in 
experimental tumors propagated in vitro and in vivo (Kufe et al., 1980; Zhao & Goldman, 2003; 
Assaraf, 2007); however, the specific basis for the resistance of melanoma cells to MTX is 
unclear. During decades the mechanism of resistance of melanoma to MTX was associated 
with general mechanisms of resistance detected in other epithelial cancer cell including 
reduced cellular uptake of this drug, high intracellular levels of DHFR and/or insufficient rate 
of MTX polyglutamylation, which diminishes long-chain MTX polyglutamates from being 
preferentially retained intracellularly (Assaraf, 2007). However, recently, a melanoma-specific 
mechanism of resistance to cytotoxic drugs, including MTX, has been described (Chen et al., 
2006; Sánchez-del-Campo et al., 2009a; Xie et al., 2009). Experiments from our laboratory and 
others provide evidences that melanosomes contribute to the refractory properties of 
melanoma cells by sequestering cytotoxic drugs and increasing melanosome-mediated drug 
export. Concretely, we have described that folate receptor  (FR)-endocytotic transport of 
MTX facilitates drug melanosomal sequestration and cellular exportation in melanoma cells, 
which ensures reduced accumulation of MTX in intracellular compartments (Sánchez-del-
Campo et al., 2009a). 
An important observation in this study was that MTX was a cytostatic agent on melanoma 
cells. These cells were resistant to MTX-induced apoptosis but responded to the drug by 
arresting their growth. A similar response was observed when the murine B16/F10 
melanoma cell line was grown in low folate. After 3 days in folate-deficient medium the 
cells had restricted proliferative activity and also increased their metastatic potential 
(Branda et al., 1988). Taking this into consideration, the results indicate that MTX might also 
induce depletion of intracellular reduced folate coenzymes by reducing their transport 
though the FR and/or competing with them for the reduced folate carrier (RFC). 
Melanoma cells may be highly sensitive to intracellular depletion of folate coenzymes, and 
in this situation may enter into a “latent” state. This form of melanoma should indeed be 
highly resistant to MTX, since antifolate drugs are more effective on fast-dividing cells, 
which require continuous DNA synthesis. Most likely, the high increases of DHFR 
expression in cells treated with MTX (Kufe et al., 1980) would represent an adaptation 
mechanism that allows cells to survive with low intracellular concentrations of folate 
coenzymes. Increasing the recycling of folate molecules the cells would maintain other 
cellular functions that are dependent on folate coenzymes, such as the synthesis of purines, 
pyrimidines, amino acids and methylation reactions. The presence of this “latent” form of 
melanoma should be critical for the resistance to MTX during in vivo therapies. Although 
MTX chemotherapy could initially halt the development of the tumor, after clearance of the 
drug from the body the melanoma cells may reinitiate their progression, possibly with an 
increased metastatic potential (Branda et al., 1988). 
A defect in intracellular folate retention is another recognized mechanism of drug resistance 
(Assaraf, 2007; Gaukroger et al., 1983; Kufe et al., 1980; Zhao and Goldman, 2003). In 
addition to a decrease in antifolate polyglutamylation, melanoma cells may also export 
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cytotoxic drugs by melanosome sequestration (Chen et al., 2006). The results presented in 
this study indicated that drug exportation was an operative mechanism of resistance to MTX 
in melanoma cells. Although the mechanism by which cytotoxic drugs are sequestered into 
melanosomes remains unclear, we demonstrated that MTX-melanosome trapping may be a 
consequence of its FR-endosomal transport (Sánchez-del-Campo et al., 2009a). To test the 
importance of this process on the resistance of melanoma to antifolates, we silenced the 
expression of the melanosomal structural protein gp100/Pmel17, which is known to play a 
critical role in melanosome biogenesis (Theos et al., 2005). Recently, Xie and collaborators 
(2009) provided the first direct evidence that disruption of the process of normal 
melanosome biogenesis, by mutation of gp100/Pmel17, increased sensitivity to cisplatin. We 
also observed that effective silencing of gp100/Pmel17 significantly increased the sensitivity 
of melanoma cells to MTX, favouring MTX-induced apoptosis. This observation strongly 
supports the hypothesis which indicates that melanosome biogenesis is a specialization of 
the endocytic pathway (Raposo and Marks, 2002; 2007); however, the exact mechanism by 
which MTX induces abnormal trafficking of early endosomes in melanoma cells, favoring 
the exportation of melanosomes, is still unclear. Whether MTX blocks the formation of 
carrier vesicles operating between early and late endosomes, inhibits the delivery of 
endocytosed material from endosomes to lysosomes, promoting, thus, the generation of 
exosomes (Raposo and Marks, 2007) and/or induces a failure of lysosomal acidification, 
which is essential for normal endocytosis (Liang et al., 2003), remains to be determined.  
To explore the relationship between MTX exportation and melanosome trafficking, we 
studied the possible interaction of MTX with melanin (Sánchez-del-Campo et al., 2009a). 
Such interaction was confirmed by incubating this drug with synthetic 3,4-
dihydroxyphenylalanine (DOPA)-melanin. Importantly, folic acid and 5-methyl-THF, the 
natural source of cellular folates, did not appear to interact with synthetic DOPA-melanin. A 
comparison of the interaction of several folates (folic acid and 5-methyl-THF) and antifolates 
(MTX and aminopterin) with synthetic DOPA-melanin indicated that the double amino 
group of the pterin ring is an important molecular requirement for the drug-melanin 
interaction. Therefore, the physiological importance of the high affinity of melanin for 
antifolates, such as MTX and aminopterin, for drug melanosomal sequestration is also 
another important issue that remains to be addressed. Endocytic transport of molecules 
involves several processes, including the fusion of early and late endosomes and the 
dissociation of receptor-ligand complexes through the acidic pH of preformed vesicles 
(Sabharanjak and Mayor, 2004). After melanosome biogenesis from MTX-loaded 
endosomes, dissociated MTX could be trapped in the melanosomes by its interaction with 
melanins. In contrast, folate substrates would not be sequestered in melanosomes due to 
their low affinities for melanin; facilitated by the acidic pH of this organelle, uncharged 
reduced folates would leave the melanosome by passive diffusion and reach the cytosol, 
where they would become available for cellular functions. Therefore, elucidation of the 
molecular basis for the (anti)folate interaction with melanins could have important 
therapeutic implications, and this study might be used as a guide for the synthesis of new 
antifolates or for using existing antifolates in ways that escape melanin trapping.  
In addition to these cellular mechanisms of resistance to MTX in melanoma, other 
mechanism that includes liver transformation of the drug has also been reported. A 
paradoxical response of malignant melanoma to MTX in vivo and in vitro has been described 
(Gaukroger et al., 1983). The authors observed that MTX showed consistent cytotoxicity for 
melanoma cells in vitro but was ineffective at equivalent concentrations in vivo. MTX 
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cytotoxic drugs by melanosome sequestration (Chen et al., 2006). The results presented in 
this study indicated that drug exportation was an operative mechanism of resistance to MTX 
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therapeutic implications, and this study might be used as a guide for the synthesis of new 
antifolates or for using existing antifolates in ways that escape melanin trapping.  
In addition to these cellular mechanisms of resistance to MTX in melanoma, other 
mechanism that includes liver transformation of the drug has also been reported. A 
paradoxical response of malignant melanoma to MTX in vivo and in vitro has been described 
(Gaukroger et al., 1983). The authors observed that MTX showed consistent cytotoxicity for 
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undergoes oxidation to its primary metabolite 7-hydroxy-MTX (7-OH-MTX) in the liver by 
the enzyme aldehyde oxidase (Assaraf, 2007) and therefore, this transformation has been 
proposed as a novel mechanism of resistance to explain this paradox (Gaukroger et al., 1983; 
Assaraf, 2007). In contrast to the large body of literature available on the multiple modalities 
of MTX resistance, very little is known regarding the ability of 7-OH-MTX to provoke 
antifolate-resistance phenomena that may disrupt MTX activity. Recent studies seem to 
indicate that 7-OH-MTX which exceeds by far MTX in the plasma of MTX-treated patients 
can provoke distinct modalities of antifolate-resistance that severely compromise the 
efficacy of the parent drug MTX (Joerger et al., 2006).  
3. The antifolate activity of tea catechins 
Recent studies have presented data that show a variety of biological activities of tea 
catechins, compounds which constitute about 15% (dry weight) of green tea (Mukhtar & 
Ahmad, 2000; Fujiki et al., 2002). Green tea catechins include: (-)-epigallocatechin gallate 
(EGCG), (-)-epigallocatechin (EGC), (-)-epicatechin gallate (ECG) and (-)-epicatechin (EC). 
EGCG is the most abundant (one 240 mL cup of brewed tea contains up to 200 mg EGCG), 
and many health benefits, including antioxidant, antibiotic and antiviral activities, have 
been attributed to this compound (Yam et al., 1998; Mabe et al., 1999; Hamilton-Miller, 
2001). Some authors consider EGCG alone to be the active anticancer component, while 
others suggest that other tea constituents also have antiproliferative or anticarcinogenic 
properties (Jung & Ellis, 2001). Green tea extracts have been shown in vitro to stimulate 
apoptosis of various cancer cell lines, including prostate, lymphoma, colon, and lung (Yang 
et al., 2000; Mukhtar & Ahmad, 2000; Jung & Ellis, 2001; Gupta et al., 2003). Moreover, 
EGCG was reported to inhibit tumour invasion and angiogenesis, processes that are 
essential for tumour growth and metastasis (Jung & Ellis, 2001). Despite great efforts during 
the last two decades to understand the anticarcinogenic activity of tea, the exact 
mechanism(s) of action are not well defined. Therefore, deciphering the molecular 
mechanism by which green tea or its polyphenols impart their antiproliferative effects could 
be important and may result in improved opportunities for the treatment of cancer. 
Based on the observation that classical (MTX) and non-classical (TMP) antifolate compounds 
possess similar chemical structures to some tea polyphenols (Navarro-Perán et al., 2005a), 
we started to work on the hypothesis that tea catechins could inhibit DHFR activity. 
Suppression of DNA synthesis by tea catechins could explain many of the observed effects 
on cancer inhibition by these compounds. Recently, we have shown that ester bonded 
gallate catechins isolated from green tea, such as EGCG and ECG are potent inhibitors of 
DHFR activity in vitro at concentrations found in the serum and tissues of green tea drinkers 
(0.1–1.0 μM) (Navarro-Perán et al., 2005b). EGCG exhibited the kinetic characteristics of a 
slow-binding inhibitor of DHF reduction with bovine liver DHFR but of a classical, 
reversible, competitive inhibitor with chicken liver DHFR. Structural modelling showed that 
EGCG can bind to human DHFR in a similar orientation to that observed for a number of 
structurally characterized DHFR inhibitor complexes (Fig. 1) (Navarro-Perán et al., 2005a). 
These results suggested that EGCG could act as an antifolate compound in the same way as 
MTX and TMP. Since these first reports describing the inhibition of DHFR by tea 
polyphenols, several studies by us and other laboratories have reported that EGCG inhibits 
DHFR from a variety of biological sources (Navarro-Martínez et al., 2005; 2006; Navarro-
Perán et al., 2007; Hannewald et al., 2008; Kao et al., 2008; Spina et al., 2008; Sánchez-del-
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Campo et al., 2010a). Recently, a screening of DHFR-binding drugs by MALDI-TOFMS 
demonstrated that EGCG is an active inhibitor of DHFR and has a relative affinity between 
that of pyrimethamine and MTX (Hannewald et al., 2008). 
 
 
Fig. 1. View of EGCG modeled into the folate-binding site of human DHFR (Navarro-Perán 
et al., 2005a). Carbon atoms of the ECG ligand and surrounding protein are colored green 
and grey respectively. Residue Phe-31, located behind the EGCG, is unlabelled. Four 
different ligands from human and chicken DHFR crystal structures were used to define a 
binding envelope, shown in cyan; these were placed in a common orientation by 
superimposing backbone atoms from a common set of protein residues located around the 
ligands. Ligands from the following PDB structure files were used; 1DR1 (biopterin), 1S3V 
(TQD), 1S3W, and 1DLR. The figure was prepared using ViewerLite software.  
Other studies have been focused in understand weather the antifolate activity of tea catechins 
could explain their anti-inflammatory and antitumoral properties (Navarro-Perán et al., 2007; 
Navarro-Perán et al., 2008). The most common use of MTX is as an anticancer drug, although 
the drug is also considered to have anti-inflammatory and immuno-suppressive properties 
with accompanying activity against autoimmune disorders (Cutolo et al., 2001). Inflammation 
is central to our fight against pathogens, but if it is not ordered and timely the resulting chronic 
inflammation may contribute to diseases such as arthritis, heart attacks and Alzheimer’s 
disease. A functional link between chronic inflammation and cancer has long been suspected 
(Aggarwal, 2004; Balkwill & Coussens, 2004). This link is of great interest in the context of this 
chapter because green tea has shown remarkable anti-inflammatory activity (Sueoka et al., 
2001). Understanding the mechanisms by which EGCG imparts this effect could be of 
importance for explaining the epidemiological data on the prophylactic effects of diets high in 
gallate polyphenols for certain forms of cancer. Most solid tumors contain many non-
malignant cells, including immune cells and blood-vessel cells, which are important in 
inflammation, although the crucial molecular pathways that permit communication between 
abnormally growing cancer cells and these inflammatory cells remain unknown. A mouse 
model of inflammation-associated cancer now points to the involvement of the gene 
transcription factor NF-κB and the inflammatory mediator known as TNF-α in cancer 
progression (Pikarsky et al., 2004). Several of the anti-inflammatory effects of MTX and other 
antifolates can be explained by the suppression of NF-κB activation, a multisubunit factor 
known to play a role in inflammation, immune modulation and cell proliferation.  
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Although the mechanism by which antifolates modulate NF-B activation has remained 
unclear for some time, recent investigations have demonstrated that MTX could inhibit the 
TNF--induced NF-B activation though the release of adenosine (Cutolo et al., 2001; 
Majumdar & Aggarwal, 2001). By lowering THF cofactors, MTX inhibits two steps of the 
purine synthesis pathway: the conversion of GAR to FGAR and the conversion of AICAR to 
FAICAR. Excess AICAR inhibits the conversion of AMP to IMP by AMP deaminase, while 
AMP is rapidly converted to adenosine by surface expressed ecto-5’ nucleotidase. Adenosine 
is a potent endogenous regulator of a variety of physiological processes through specific 
receptors on the cell surface and binds to four different types of G protein-coupled cell surface 
molecules, termed the A1, A2A, A2B, and A3 adenosine receptors (Linden, 2001). After binding 
to the cell surface receptors, adenosine alters the immune cell production of soluble mediators 
such as cytokines, free radicals, and arachidonic acid metabolites (Majumdar & Aggarwal, 
2001). Although MTX is widely used for the treatment of inflammatory and autoimmune 
diseases, its use as a chemopreventive agent is precluded, even at low doses, due to its adverse 
side effects. However, there is no evidence for such side effects as a result of the regular 
consumption of tea. The finding that EGCG shares mechanisms of action with MTX could be 
of interest, and suggests that the regulation of chronic inflammation by EGCG could 
represents a strong possibility to explain the epidemiological data concerning the green tea’s 
prophylactic effects on certain forms of cancer (Yang et al., 2000). To check our hypothesis that 
the anti-inflammatory properties of EGCG could be related to its antifolate action and whether 
adenosine and its receptors are involved in EGCG action, we investigated the EGCG-induced 
suppression of NF-B in Caco-2 cell monolayer, which acted as a model of the human 
intestinal epithelium (Navarro-Perán et al., 2008). We observed that EGCG, by inhibiting 
DHFR, can disturb the metabolism of this vitamin in Caco-2 cells, producing the release of 
adenosine and the suppression of NF-B. The data suggest that by modulating NF-B 
activation, EGCG might not only combat inflammation, but also cancer. Since by reducing 
chronic inflammation there is a strong possibility of modulating tumorogenesis, these results 
could be of importance for explaining tea’s cancer preventive effects. 
4. Synthetic catechins as antifolate prodrugs against melanoma 
Despite the excellent properties of tea catechins, they have at least one limitation, their low 
bioavailability (Nakagawa & Miyazawa, 1997). Factors influencing this low bioavailability 
could be related to their low stability in neutral or slightly alkaline solutions and their inability 
to cross cellular membranes (Hong et al., 2002). In an attempt to solve such bioavailability 
problems, we first synthesized a 3,4,5-trimethoxybenzoyl analogue of ECG [3-O-(3,4,5-
trimethoxybenzoyl)-(-)-epicatechin, TMECG] (Sánchez-del-Campo et al., 2008). This 
compound was successfully synthesized following the five-step reaction sequence shown in 
Fig. 2, starting from the commercially available catechin. In comparing the antiproliferative 
activity of TMECG on several human and mouse cancer cell lines, we noticed that this 
compound was much more active on melanoma cells than on normal human melanocytes and 
other epithelial cancer cell lines from breast, lung and colon cancers (Sánchez-del-Campo et al., 
2008; Sánchez-del-Campo et al., 2009b). Next, we designed experiments to throw light on the 
elevated activity of TMECG on melanoma cell lines. As one of the most striking differences 
between melanoma and other epithelial cells is the presence of tyrosinase in melanoma, we 
wondered whether TMECG cytotoxicity against melanoma might be mediated by cellular 
tyrosinase activation. The results indicated that tyrosinase oxidized TMECG to its 
corresponding o-quinone, which quickly evolved through a series of chemical reactions to a 
quinone methide (QM), which showed high stability over a wide pH range (Fig. 3).  
 




















Fig. 2. Synthesis of TMECG (6) and TMCG (8). Reagents and conditions: (a) benzyl bromide, 
K2CO3, N,N-dimethylformamide, -10ºC to rt; (b) Dess-Martin periodinane, moist CH2Cl2, rt; 
(c) L-Selectride, n-Bu4NCl, THF, -78ºC; (d) 3,4,5-trimethoxybenzoyl chloride, 4, CH2Cl2, 
























Fig. 3. Reaction sequences indicating the oxidation of TMECG and TMCG by tyrosinase and 
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The TMECG-QM was found to be a potent irreversible inhibitor of human DHFR, and this 
highly stable product may be responsible for TMECG’s high activity against melanoma cells 
(Sánchez-del-Campo et al., 2009b). To explain the irreversibility on the binding of TMECG-
QM to human DHFR, we performed in silico molecular modelling experiments. TMECG 
bound to human DHFR in a similar way to that described for EGCG binding (Navarro-
Perán et al., 2005a), with specific hydrogen bonding interactions, most notably involving 
Glu-30 (Fig. 4). However, the open structure of QM increases its molecular flexibility, and it 
adopts a different conformation in the active site of human DHFR (Fig. 4). QM maintained 
the hydrogen bond with the Glu-30 side chain (O · · · ··O distance 1.99 Å), but three new 
interactions were detected. The other phenolic group of ring A forms a hydrogen bond with 
Ile-7, whereas the other two hydrogen bonds formed between two oxygens of the methoxy 
groups of ring D and Ser-59 and Ile-60. This strong interaction between QM and different 
residues of the protein could explain the irreversibility of the inhibitor-protein complex. 
Prodrugs are compounds that must be transformed before exhibiting their pharmacological 
action. They are often divided into two groups: those designed to increase bioavailability to 
improve the pharmacokinetics of antitumor agents, and those designed to deliver antitumor 
agents locally (Rooseboom et al., 2004). TMECG could, therefore, be considered an 
anticancer prodrug on melanoma since it showed both of these characteristics. Therapies 
with TMECG would increase bioavailability and would achieve high melanoma drug 
concentrations. The soft antifolate character (Graffner-Nordberg et al., 2004) of the prodrug 
(TMECG), its specific activation on melanoma cells and the fact that antifolates are more 
active on fast-dividing cancer cells make this compound ideal for the prevention and 
treatment of this skin pathology.  
However, the synthesis of TMECG is difficult and results in low yields. Therefore, we 
synthesized a related-epimer compound with catechin configuration [3-O-(3,4,5-
trimethoxybenzoyl)-(-)-catechin (TMCG)] (Fig. 2) (Sáez-Ayala et al., 2011). As observed in 
this figure TMECG and TMCG share the first synthesis step, but the yields of the other 
synthetic steps were significantly different. The overall yield of TMCG in the two steps of 
alkylation and deprotection was 88%; however, the overall yield of TMECG in the four steps 
of epimerisation of C-3 (oxidation and reduction), alkylation and deprotection was 16%. The 
difference between these yields was due to the limiting stereoselective reduction of 
compound 2 (Fig. 2), which gives moderate yield and purity and requires further 
purifications lowering the yield. Because of the absence of the limiting reduction step, the 
synthesis of TMCG was simpler (only three steps) and more economical (only common 
reagents). Since the active product of TMECG in melanoma is its QM derivative, we 
hypothesized that both TMECG and TMCG should have similar activity against these 
cancer cells (Sáez-Ayala et al., 2011). Oxidation of TMCG and TMECG by tyrosinase is 
predicted to generate the same final product because proton-catalysed hydrolysis of ring C 
would generate a freely rotating carbon (C-3), which should prevent epimeric differences in 
the QM product (Fig. 3). To confirm that TMECG and TMCG generate the same quinonic 
product after tyrosinase oxidation, both substrates were oxidised in vitro using mushroom 
tyrosinase as a catalyst. The final products of the corresponding oxidations were analysed 
and compared using several spectroscopic techniques. Tyrosinase oxidised TMECG and 
TMCG to stable final products, which varied in colour from yellow to orange depending on 
pH. The products had similar spectroscopic properties, with λmax at 275/412 nm at acidic 
pH and 275/470 nm at higher pH values (pKa = 6.9). Thus, the UV-Vis spectroscopy data 
indicated that, as represented in Fig. 3, both TMEGC and TMCG generated the same QM 
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product after tyrosinase oxidation. Mass spectroscopy confirmed these results, and the 
spectra of both final oxidation products exhibited the same molecular ion peak. High-
performance liquid chromatography-mass spectrometry (HPLC-MS) revealed that the 
molecular weights of the compounds were 498.7 (for TMECG) and 498.8 (for TMCG), which 
correspond to the calculated mass of the QM product depicted in Fig. 3. Both molecules 
were analysed by MS/MS and produced the same daughter ion peaks at m/z 363 and m/z 
287, corresponding to the loss of the dihydroxybenzoyl moiety and the trimethoxybenzoyl 
moiety, respectively.  
 
 
Fig. 4. Molecular modelling for the binding of TMECG and TMECG-QM to human DHFR. 
5. Antitumoral activity of TMECG in melanoma 
5.1 TMECG inhibits folate metabolism and transport in melanoma 
The folate cycle plays a central role in cell metabolism. Among its important functions are 
the delivery of one-carbon units to the methionine cycle for use in methylation reactions, 
and the synthesis of pyrimidines and purines. Several enzymes, including DHFR, TS and 
methyltetrahydrofolate reductase (MTHFR), participate in the activation and regeneration of 
folic acid coenzymes. Several studies have shown that the protein and mRNA levels of TS 
and DHFR are higher in tumor tissues and cancer cells than in their normal counterpart 
(Kufe et al., 1980; Rahman et al., 2004). Tumors with high levels of these enzymes are 
thought to undergo more active cellular proliferation, which, in turn, is associated with 
tumor invasiveness and metastasis. Having demonstrated the strong in vitro inhibition of 
human DHFR by QM, further experiments were designed to test its antifolate activity in 
culture systems. To investigate whether TMECG could interfere with folate metabolism in 
cancer cells, the levels of expression of these folate cycle genes were analyzed in melanoma 
SK-MEL-28 cells using real time PCR (Sánchez-del-Campo et al., 2008). As observed in other 
tumor tissues and cells, the genes involved in the metabolism of folic acid were highly 
overexpressed in melanoma cells compared with normal melanocytes. The levels of DHFR, 
TS and MTHFR mRNAs were calculated to be about 400-, 22- and 4-fold higher, 
respectively, in melanoma cells than in normal melanocytes. Treatment of SK-MEL-28 with 
TMECG produced a substantial and rapid downregulation of these genes, involving 
significant changes in the mRNA levels of the genes at 24 h of treatment. DHFR, TS and 
TMECG TMECG-QM 
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MTHFR mRNA levels were similar to that detected in normal melanocyte cells after 5 days 
of TMECG treatment. The data indicated that TMECG disturbs the folate metabolism in 
melanoma cells and suggest that this might be the mechanism by which TMECG induces 
cell growth inhibition and death. 
It is widely accepted that antifolates block the de novo biosynthesis of thymine, purines and 
pyrimidines by inhibiting the synthesis of THF, an essential cofactor in these biosynthetic 
pathways, and that the administration of exogenous reduced folates, such as leucovorin (5-
formyl-THF), or growing the cells in an HT-medium, effectively prevent antifolate 
cytotoxicity in mammalian cells. We observed that TMECG was more active on cells 
growing in a normal culture medium than in an HT medium (Sánchez-del-Campo et al., 
2009b); however, leucovorin did not “rescue” SK-MEL-28 cells from TMECG-induced death. 
Recently, it has been reported that natural tea catechins inhibit folate transport in Caco-2 
cells, which might be partly responsible for their antifolate activity (Alemdaroglu et al., 
2007). Therefore, to understand the different response of SK-MEL-28 to leucovorin- and HT-
treatments, and to prove or discard the in vivo antifolate activity of TMECG, the status of the 
RFC, the major protein involved in the transport of reduced folates, was analyzed in this cell 
line. RFC mRNA expression was significantly higher in SK-MEL-28 than in normal human 
melanocytes (8.9 times), but treating SK-MEL-28 with TMECG strongly downregulated RFC 
gene expression. The time-dependent effect of TMECG on SK-MEL-28 was studied using RT 
PCR, and the data indicated that cells responded quickly to TMECG treatment with a more 
than 80% reduction in RFC expression 24 h after treatment. Protein levels of this transporter 
correlated with gene expression (Sánchez-del-Campo et al., 2009b). This finding could 
explain why leucovorin did not affect TMECG treatments. As demonstrated, TMECG highly 
down-regulated the RFC and, therefore, SK-MEL-28 cells became practically impermeable to 
leucovorin during TMECG treatment and can not, therefore, restore the reduced folate 
levels in the cells. 
5.2 TMECG downregulates DHFR expression in melanoma 
As described for other cancer cell lines, DHFR is overexpressed in melanoma (Kufe et al., 
1980). The level of DHFR polyA+ mRNA in these melanoma cells was estimated to be 400 to 
500 times higher than in normal human melanocytes, resulting in increased DHFR protein 
content (Sánchez-del-Campo et al., 2009b). An increase in DHFR expression/activity after 
antifolate treatment has been recognized as a mechanism of resistance of cancer cells to 
antineoplastic drugs. As expected, treatment of SK-MEL-28 with MTX resulted in a 
significant increase of DHFR mRNA and protein. However, treatment of SK-MEL-28 with 
TMECG rapidly reduced DHFR mRNA and protein to normal levels. The efficient down-
regulation of DHFR by TMECG is evidence of its proposed antifolate activity. The lack of 
reduced folate coenzyme recycling by DHFR could be one of the reasons for its in vivo 
activity. 
The mechanism by which TMECG-QM downregulates DHFR expression in melanoma has 
been studied in more detail (Sánchez-del-Campo et al., 2010b). TMECG-QM has a dual 
action on these cells. First, it acts as a potent antifolate compound, disrupting folate 
metabolism and increasing intracellular oxidized folate coenzymes, such as DHF, which is a 
non-competitive inhibitor of dihydropterine reductase, an enzyme essential for 
tetrahydrobiopterin (H4B) recycling. Such inhibition results in H4B deficiency, endothelial 
nitric oxide synthase (eNOS) uncoupling and superoxide production. Second, TMECG-QM 
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acts as an efficient superoxide scavenger and promotes intra-cellular H2O2 accumulation. 
We presented evidence that TMECG markedly reduces melanoma H4B and NO 
bioavailability and that TMECG action is abolished by the eNOS inhibitor N-nitro-L-
arginine methyl ester or the H2O2 scavenger catalase, which strongly suggested H2O2-
dependent DHFR downregulation (Sánchez-del-Campo et al., 2010b). It is this duality that 
may be of importance for TMECG action. Classical antifolate compounds are very effective 
in inhibiting DHFR but the lack of an antioxidant property may be the cause of the lack of 
DHFR downregulation. In cells treated with antifolates, the common effect is the 
overexpression of DHFR, which may be responsible for cell resistance to antifolates and is 
probably the reason that these compounds fail to treat melanoma (Zhao & Goldman, 2003). 
In addition, antioxidant therapies have little effect on melanoma. It is interesting to 
speculate that unsatisfactory outcomes of some of these antioxidant therapies are partially 
due to their ineffectiveness in uncoupling the eNOS reaction (Chalupsky & Cai, 2005). 
5.3 TMECG induces apoptosis in melanoma cells 
To investigate whether the metabolic changes induced by TMECG resulted in the apoptosis 
of melanoma cells, melanoma cell lines were treated for seven days with different 
concentrations of this compound and the degree of apoptosis induction was evaluated using 
a DNA fragmentation assay (Sánchez-del-Campo & Rodríguez-López, 2008). The results 
indicated that the reduced viability of melanoma cells in the presence of TMECG was 
indeed due to apoptosis induction. The data also indicated that normal melanocytes were 
highly resistant to TMECG-induced apoptosis, which is a highly desirable feature for 
potential antitumoral agents. TMECG-induced apoptosis was studied in greater detail using 
the SK-MEL-28 cell line. SK-MEL-28 cells exposed to 50 M TMECG for seven days showed 
evident signs of cellular damage. Morphological changes included cell shrinkage, loss of 
cell-cell contact and the fragmentation of plasmatic and nuclear membranes (Fig. 5). 
Another feature of apoptotic cell death, the activation of caspase-3, was evaluated by a 
colorimetric activity assay and Western blot analysis. The cells treated with TMECG showed 
significantly higher caspase-3 activity. Immunoblot analysis confirmed caspase-3 activation 
(Fig. 5). The Bcl-2 family proteins play a critical regulatory role through their interacting 
pro- and anti-apoptotic members, which integrate a wide array of upstream survival and 
distress signals to decide the fate of cells. Bax and Bcl-2 proteins are the key elements of this 
protein family. As reported for EGCG (Nihal et al., 2005), TMECG treatment resulted in a 
decrease in anti-apoptotic Bcl-2 and an increase in proapoptotic Bax at the levels of mRNA 
and protein, thereby resulting in a significant increase in the Bax/Bcl-2 ratio that favors 
apoptosis. Immunohistochemistry results also indicated that TMECG treatment caused 
mitochondrial translocation of Bax, which is a common response of cancer cells subject to 
certain apoptotic stimuli (Choi & Singh, 2005). 
In general, melanoma cells are quite resistant to apoptosis and it has recently been shown 
that these cells can avoid suicide by inactivating the apoptosis protease-activating factor-1 
(Apaf-1) gene, which is one step further on from p53 in the apoptosis pathway (Soengas et 
al., 2001). It was proposed that Apaf-1 inactivation involves the addition of methyl groups to 
cytosine nucleotides in DNA and the removal of acetyl groups from the hystone proteins 
that bundle DNA into the compressed form seen in the nucleus. In vivo, loss of expression of 
Apaf-1 has been associated with tumor progression, suggesting that Apaf-1 inactivation 
may provide a selective survival advantage to neoplastic cells (Soengas et al., 2001). To 
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Fig. 5. Apoptosis of SK-MEL-28 induced by TMECG visualized by the morphological aspect 
of untreated SK-MEL-28 cells compared with those subject to treatment with 50 M 
TMECG. The effect of TMECG on the protein content of caspase-3 in SK-MEL-28 was 
visualized by Western blot analysis in control cells (Sk28) and those treated with TMECG. 
Cells were treated for 7 days with 50 M TMECG 
evaluate the participation of Apaf-1 in SK-MEL-28 apoptosis during TMECG treatment, its 
mRNA and protein levels were determined by PCR and Western blot, respectively 
(Sánchez-del-Campo & Rodríguez-López, 2008). Apaf-1 mRNA and protein were detected 
in SK-MEL-28 and their levels were essentially the same than those detected in normal 
human melanocytes. This data indicated that, although methylation of Apaf-1 has been 
proposed as a mechanism for controlling its expression, TMECG, which decreased cellular 
methylation in SK-MEL-28 cells, was not able to produce Apaf-1 activation. These results are 
in accordance with others which found that drugs acting on different mechanisms did not 
induce or upregulate the expression of Apaf-1 at the levels of mRNA and protein (Zanon et 
al., 2004).  
5.4 TMEGC inhibits growth and metastasis of induced melanoma tumors in mice 
To check whether TMECG was pharmacologically active in in vivo situations and to study 
the possible inactivation of TMECG in the body, we performed experiments to test the 
effectiveness of this compound in induced melanoma tumors in mice. The group receiving 
TMECG therapy showed significantly longer survival times than the control group (Fig. 6).  
Moreover, we observed that tumor growth was significantly reduced by the treatment with 
TMECG but not with MTX (Fig. 6). The observation that TMECG-treated animals survived 
with larger tumors indicated that treatment could also reduce the metastasis of primary 
tumors. To confirm this, a third group was inoculated with B16 melanoma cells and treated 
with TMECG for 21 days (median survival time of the control group). After this time the 
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animals were sacrificed and a post-mortem examination of the lungs was performed to 
search for metastatic lesions. Secondary metastasis in the lungs was more frequent in control 
mice (Fig. 6), while treatment with TMECG drastically reduced lung metastasis. The lungs 
of the control animals showed prominent tumor nodules around the terminal bronchioles. 
These tumour nodules were composed of polygonal tumor cells with a prominent nucleolus. 
Intracellular melanin deposition and clear areas of necrosis were also detected. The lungs of 
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Taken in consideration all these observations a mechanism for the activation, cellular 
distribution and action of TMECG and its products may now be proposed (Fig. 7). Although 
TMECG efficiently binds to DHFR, we hypothesized that this hydrophobic compound 
would cross the cell membrane without needing to bind to folate transporters. Therefore, the 
most plausible transport mechanism for this lipophilic drug is passive diffusion across the 
plasma membrane in a manner driven solely by the concentration gradient (Fig. 7a). Its 
independence from folate transporters means that TMECG may avoid transport-mediated 
resistance mechanisms (Ma et al., 2000). In fact, TMECG downregulated RFC but, far from 
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Fig. 7. Schematic mechanism underlying activation, cellular distribution and action of 
TMECG in melanoma cells (Sánchez-del-Campo et al., 2010b). 
being a disadvantage, this could represent an important advantage for its antiproliferative 
action. Downregulation of RFC would reduce intracellular folate pools, reducing competition 
reactions with the active form of TMECG and the molecular target, DHFR. Subsequent 
transport to the melanosome by a concentration gradient would facilitate its tyrosinase-
catalyzed oxidation and transformation to the corresponding QM (Fig. 7b). Observations from 
our laboratory indicated that TMECG or TMECG-QM did not interact with DOPA-melanins, 
which may avoid melanosomal trapping. Because of the low pH of this organelle, the 
predominant form is QMH, which, due to its high stability and the absence of formal charge, 
would exit the melanosome and enter the cytosol (Fig. 7c). Under the slightly basic pH of the 
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cytosol, the anionic form of QM would be the predominant form, and it would be trapped in 
this compartment due to its formal negative charge. This retention mechanism would 
represent another advantage with respect to antifolates that require polyglutamylation for 
cellular retention. This would be even more essential in cancer cell environments, in which 
folate requirements lead to an increase in the cellular THF-cofactor pools. As the THF-cofactor 
pool is increased, there is a feedback inhibition of folate polyglutamylation, which results in 
the accumulation of easily exported compounds (Tse & Moran, 1998). Once in the cytosol, 
TMECG-QM may inhibit DHFR activity and, in addition, lead to the downregulation of DHFR 
(Fig. 7d-h). The finding that tyrosinase is highly overexpressed in melanoma cells with respect 
to normal melanocytes might also influence the degree, the specificity and the duration of the 
antifolate inhibitory effect of TMECG-QM. Finally, the data on the effectiveness of TMECG in 
mouse melanoma models indicates that TMECG is bioavailable for cancer cells and avoids not 
only cellular mechanisms of resistance to antifolates but also mechanisms related with body 
drug inactivation. 
6. Combined therapies to improve the activity of synthetic catechins in 
melanoma 
The combination of several drugs to improve the clinical efficiency of the treatments is a 
common strategy for the fighting of pathological bacteria. For instance, TMP is used in 
combination with sulphonamides as a therapy against multiple bacterial infections. These 
are treatment based in the metabolic attack of the bacteria, where TMP inhibits the recycling 
of folic acid coenzymes and the sulphonamide inhibits the synthesis of folic acid. 
Conventional chemotherapy treatments against cancer have shown important clinical 
limitations and, therefore, it would be of interest to develop new and more efficient 
strategies for the treatment of this fatal pathology. The metabolic attack of cancer cells could 
be an interesting perspective. The identification of metabolic and signalling pathways 
essential for tumour growth and dissemination, but less important for healthy cells, could 
guide the development of new cancer therapies. The combination of several drugs to target 
several metabolic and/or signalling pathways could increase the efficiency of the 
treatments. Recently, it has been observed that the major catechin presented in green tea, 
EGCG, showed synergic activity with other drugs commonly used for the treatment of 
several cancers and in some cases EGCG sensitizes cancer cells to other treatments (Liu et 
al., 2001; Farabegoli et al., 2007). The identification of synthetic catechins as antifolate 
compounds can help the design of more directed combined therapies against melanoma 
since the folic acid has multiple connections with metabolic and signalling pathways. Thus, 
we started this application targeting the methionine cycle in melanoma using TMECG in 
combination with other drugs (Fig. 8). 
Malignant tumors are characterized by a high rate of growth. Tumor cells drain the energy 
of the host, particularly glucose but also amino acids. Methionine is an essential amino acid 
with at least four major functions (Fig. 8) (Cellarier et al., 2003). First, methionine 
participates in protein synthesis. Second, methionine is a precursor of glutathione, a 
tripeptide that reduces reactive oxygen species, thereby protecting cells from oxidative 
stress (Anderson, 1998). Third, it is required for the formation of polyamines, which have 
far-ranging effects on nuclear and cell division (Thomas & Thomas, 2001). Fourth, 
methionine is the major source of the methyl groups necessary for the methylation of DNA 
and other molecules (Cellarier et al., 2003). It is important to bear in mind the well-
established connection of the methionine cycle with two crucial cell metabolites, folic acid 
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cytosol, the anionic form of QM would be the predominant form, and it would be trapped in 
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represent another advantage with respect to antifolates that require polyglutamylation for 
cellular retention. This would be even more essential in cancer cell environments, in which 
folate requirements lead to an increase in the cellular THF-cofactor pools. As the THF-cofactor 
pool is increased, there is a feedback inhibition of folate polyglutamylation, which results in 
the accumulation of easily exported compounds (Tse & Moran, 1998). Once in the cytosol, 
TMECG-QM may inhibit DHFR activity and, in addition, lead to the downregulation of DHFR 
(Fig. 7d-h). The finding that tyrosinase is highly overexpressed in melanoma cells with respect 
to normal melanocytes might also influence the degree, the specificity and the duration of the 
antifolate inhibitory effect of TMECG-QM. Finally, the data on the effectiveness of TMECG in 
mouse melanoma models indicates that TMECG is bioavailable for cancer cells and avoids not 
only cellular mechanisms of resistance to antifolates but also mechanisms related with body 
drug inactivation. 
6. Combined therapies to improve the activity of synthetic catechins in 
melanoma 
The combination of several drugs to improve the clinical efficiency of the treatments is a 
common strategy for the fighting of pathological bacteria. For instance, TMP is used in 
combination with sulphonamides as a therapy against multiple bacterial infections. These 
are treatment based in the metabolic attack of the bacteria, where TMP inhibits the recycling 
of folic acid coenzymes and the sulphonamide inhibits the synthesis of folic acid. 
Conventional chemotherapy treatments against cancer have shown important clinical 
limitations and, therefore, it would be of interest to develop new and more efficient 
strategies for the treatment of this fatal pathology. The metabolic attack of cancer cells could 
be an interesting perspective. The identification of metabolic and signalling pathways 
essential for tumour growth and dissemination, but less important for healthy cells, could 
guide the development of new cancer therapies. The combination of several drugs to target 
several metabolic and/or signalling pathways could increase the efficiency of the 
treatments. Recently, it has been observed that the major catechin presented in green tea, 
EGCG, showed synergic activity with other drugs commonly used for the treatment of 
several cancers and in some cases EGCG sensitizes cancer cells to other treatments (Liu et 
al., 2001; Farabegoli et al., 2007). The identification of synthetic catechins as antifolate 
compounds can help the design of more directed combined therapies against melanoma 
since the folic acid has multiple connections with metabolic and signalling pathways. Thus, 
we started this application targeting the methionine cycle in melanoma using TMECG in 
combination with other drugs (Fig. 8). 
Malignant tumors are characterized by a high rate of growth. Tumor cells drain the energy 
of the host, particularly glucose but also amino acids. Methionine is an essential amino acid 
with at least four major functions (Fig. 8) (Cellarier et al., 2003). First, methionine 
participates in protein synthesis. Second, methionine is a precursor of glutathione, a 
tripeptide that reduces reactive oxygen species, thereby protecting cells from oxidative 
stress (Anderson, 1998). Third, it is required for the formation of polyamines, which have 
far-ranging effects on nuclear and cell division (Thomas & Thomas, 2001). Fourth, 
methionine is the major source of the methyl groups necessary for the methylation of DNA 
and other molecules (Cellarier et al., 2003). It is important to bear in mind the well-
established connection of the methionine cycle with two crucial cell metabolites, folic acid 
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and adenosine (Fig. 8). Folic acid acts as the fuel for the methionine cycle, which, after 
transformation by folate cycle enzymes such as DHFR, TS and MTHFR, forms 5-methyl-
THF, the cofactor of methionine synthase (MS), the enzyme responsible for methionine 
synthesis (Fig. 8). Adenosine, in contrast, is a product of the methionine cycle, and is 
produced at high concentrations in tumor cells. The efficient intracellular elimination of this 
product by adenosine-transforming enzymes, such as adenosine deaminase (ADA), or its 
transport out of the cells by specific adenosine transporters, including the equilibrate 
nucleoside transporters (ENTs), is of vital importance for cancer cell survival.  
The efficacy of antifolates in treating cancer is widely attributed to the subsequent decrease 
in nucleotide production, but in addition to these effects, antifolate treatment has also been 
linked to a decrease in cellular methylation. We observed that TMECG modulated the 
expression of genes involved in methionine metabolism, cellular methylation and 
glutathione synthesis in melanoma cells (Sánchez-del-Campo & Rodríguez-López, 2008). 
Having elucidated the effects of TMECG on the melanoma folate and methionine cycles, we 
designed therapeutical strategies to increase its effectiveness. Combinations of TMECG with 
S-adenosylmethionine (SAM) or compounds that modulate the intracellular concentration of 
adenosine strongly increase the antiproliferative effects of TMECG. The ability of TMECG to 
target multiple aspects related with melanoma survival, with a high degree of potency, 
points to its clinical value in melanoma therapy. 
 
 
Fig. 8. The methionine cycle and its connections with several metabolic and survival cell 
pathways. Abbreviations: ADA, adenosine deaminase; AHYC, S-adenosylhomocysteine 
hydrolase; COMT, catechol-O-methyltransferase; DHF, dihydrofolate; DHFR, dihydrofolate 
reductase; DNMT, DNA methyltransferase; ENT, equilibrative nucleoside transporter; GCS, -
glutamylcysteine synthetase; MAT, methionine adenosyltransferase; MS, methionine synthase; 
MTHFR, 5,10-methylenetetrahydrofolate reductase; SAH, S-adenosylhomocysteine; SAM, S-
adenosylmethionine; THF, tetrahydrofolate; TS, thymine synthase. 
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6.1 SAM enhances the antiproliferative effects of TMECG 
Having analyzed the ability of TMECG to disrupt the methionine cycle, we designed several 
strategies to completely block this pathway. The first strategy was to inhibit methionine 
adenosyltransferase-2A (MAT2A) enzyme (Fig. 8). MAT2A shows a very low Km for 
methionine (4-10 M) and, in tissues that predominantly express MAT2A, the rate of SAM 
synthesis is near maximal and relatively unaffected by fluctuations in methionine 
concentration and, thus, MAT2A can work even a very low concentration of methionine. 
Another kinetic characteristic of MAT2A is that this enzyme is strongly inhibited by SAM, 
its reaction product (IC50 = 60 M) (Sullivan & Hoffman, 1983). We hypothesized that, by 
increasing intracellular SAM concentration in the presence of TMECG, two consecutive 
steps in the methionine cycle, the synthesis of methionine and the synthesis of SAM, could 
be blocked (Fig. 8). Only high concentrations of SAM (up to 100 M) affected SK-MEL-28 
growth in accordance with its calculated IC50 towards MAT2A. However, in the presence of 
TMECG, lower concentrations of SAM showed a synergistic behavior with this antifolate 
compound. Thus, the combination 20 M SAM with 50 M TMECG efficiently inhibited the 
growth of SK-MEL-28. The results indicated that when MAT2A is working at limiting 
concentrations of methionine in the presence of TMECG, it is highly susceptible to inhibition 
by low SAM concentrations. 
6.2 Strategies to increase the intracellular concentration of adenosine in the  
presence of TMECG 
As observed in Fig. 8, adenosine is a direct product of the methionine cycle, and is produced 
in high concentration when the cycle is highly active. Any resulting excess of adenosine may 
not be a problem for cancer cells. Adenosine is efficiently metabolized by specific enzymes 
such as ADA and adenosine kinase (ADK) before being used for purine nucleotide 
synthesis, which is even more necessary for DNA synthesis in these highly proliferating 
cells. Finally, excess adenosine can be transported out of the cells by ENTs, bidirectional 
transporters that allow adenosine release and uptake by facilitating diffusion along its 
concentration gradient. However, in the presence of an antifolate compound, adenosine 
accumulation might represent a severe problem for the cell. Depletion of 5-methyl-THF 
would result in the production of high concentrations of S-adenosylhomocysteine (SAH), 
which strongly inhibits cellular methyltransferases. This inhibition would produce an 
accumulation of SAM, which would inhibit the MAT2A reaction. We hypothesized that 
accumulation of adenosine in the presence of TMECG may block the methionine cycle at 
three levels: the synthesis of methionine, the methylase reaction and the synthesis of SAM 
(Fig. 8). Adenosine flux across the cellular membrane depends on the concentration 
gradients between extra- and intracellular nucleoside levels (Tabrizchi & Bedi, 2001). 
Therefore, we first tried to increase the extracellular concentration of adenosine. Adenosine 
alone had no detectable effect on SK-MEL-28 growth at the studied concentrations (up to 
500 M) but, in the presence of TMECG, adenosine had a significant synergistic effect, 
enhancing the antiproliferative action of this antifolate compound. A combination of 50 M 
adenosine with 50 M TMECG was seen to completely inhibit the growth of SK-MEL-28.  
Although adenosine is currently used for the treatment of several cardiovascular diseases, 
its use as a therapeutic agent is restricted, since it is rapidly metabolized to inosine and 
AMP, which limits its ability to exert a systemic effect. Therefore, we planned other strategy 
to accumulate adenosine in melanoma cells using dipyridamole. This drug suppresses 
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adenosine transport by inhibiting ENTs. Moreover, it also inhibits the enzyme ADA, which 
normally breaks down adenosine into inosine. We hypothesized that inhibition of ENTs and 
ADA in melanoma cells would result in an intracellular accumulation of adenosine, which, 
in the presence of TMECG-accumulated homocysteine, would produce an effective blockage 
of the methionine cycle. Dipyridamole alone inhibited SK-MEL-28 growth with a calculated 
IC50 (at 5 days) of 20 M. However, in the presence of 50 M TMECG, the IC50-value fell to 
less than 1 M. A combination of 5 M dipyridamole with 50 M TMECG had a deadly 
effect on melanoma cells. The results pointed to the possibility of using this combination 
treatment against malignant melanoma. 
6.3 Methionine depletion for melanoma treatment: Conclusions 
Conventional chemotherapy treatments have shown their limits, especially for patients with 
advancer cancer. New therapeutic strategies must be identified, and the metabolic 
abnormalities of cancer cell open up such opportunities (Cellarier et al., 2003). Many human 
cancer cells lines and primary tumors have an absolute need for methionine, an essential 
amino acid. In contrast, normal cells are relatively resistant to exogenous methionine 
restriction. We show that melanoma cells are highly dependent on methionine. The 
resistance of melanomas to general chemotherapies and their avoidance of cellular suicide 
or resistance to apoptosis is primarily related with the high activity of the methionine cycle 
in these cells, which permits the methylation of specific genes and activation of different 
survival pathways. Blockage of the methionine cycle by the new antifolate, TMECG, is an 
effective therapy for melanoma. The specific activity of TMECG on melanoma methionine 
cycle was confirmed by the high synergy found with compounds that uncoupled adenosine 
metabolism in these cells. In conclusion, our results show that TMECG is a potent antitumor 
agent that modulates multiple aspects of melanoma metabolism and survival, including the 
folic acid and the methionine cycles and the methylation status of the cells. This broad 
spectrum of antitumor activities in conjunction with low toxicity underlies the translational 
potential of TMECG and suggests it may be used as part of a therapeutic strategy against 
melanoma. A combination with other compounds that modulate melanoma methionine 
cycle, such as SAM, adenosine or dipyridamole, represents another promising strategy to 
combat this malignant skin pathology.  
7. Conclusions 
Several investigations indicate that natural and synthetic polyphenols may well be 
beneficial, not only in the prevention but also in the treatment of cancer. Antifolates are 
usually used as chemotherapeutic agents for certain types of cancer. Although antifolates 
such as MTX attack proliferating tissues selectively, they are also toxic to normal cells. 
Deleterious side effects are seen against tissues that proliferate as part of their normal 
function; such tissues include intestinal mucosa, hair cells, and components of the immune 
system. The “soft” character of polyphenols could be developed for use in the treatment of 
cancer with significantly reduced side effects compared to those of the DHFR inhibitors 
currently in use in chemotherapy such as MTX. Moreover, we have demonstrated that 
synthetic derivatives of ECG, TMECG and TMCG, might be considered a treatment for 
melanoma. Disruption of the cell folate cycle by these compounds and their active products 
may explain many of the molecular and cellular effects described for these synthetic 
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polyphenols on melanoma cells because antifolates exert their action by disturbing the 
nucleic acid metabolism of cancer cells, including its synthesis, methylation and stability 
(Navarro-Perán et al., 2007; Sánchez-del-Campo & Rodríguez-López, 2008). We define them 
as new generation antifolates because they maintain the ability to inhibit DHFR and disrupt 
folate metabolism but show significant and important differences from other classical and 
non-classical antifolates. TMECG was seen to be active not only in melanoma cells in culture 
but was also effective in an animal model, where it inhibited growth and metastasis of 
preformed tumors. An additional advantage of these compounds is their prodrug character, 
which would favour its specific activity against melanoma cells and prevent unspecific side 
effects in rapidly dividing healthy cells. In addition, the multiple connections of the folic 
acid cycle with many metabolic and signalling pathways in melanoma cells could open the 
way for the development of new combined and directed therapies against this elusive skin 
pathology. 
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adenosine transport by inhibiting ENTs. Moreover, it also inhibits the enzyme ADA, which 
normally breaks down adenosine into inosine. We hypothesized that inhibition of ENTs and 
ADA in melanoma cells would result in an intracellular accumulation of adenosine, which, 
in the presence of TMECG-accumulated homocysteine, would produce an effective blockage 
of the methionine cycle. Dipyridamole alone inhibited SK-MEL-28 growth with a calculated 
IC50 (at 5 days) of 20 M. However, in the presence of 50 M TMECG, the IC50-value fell to 
less than 1 M. A combination of 5 M dipyridamole with 50 M TMECG had a deadly 
effect on melanoma cells. The results pointed to the possibility of using this combination 
treatment against malignant melanoma. 
6.3 Methionine depletion for melanoma treatment: Conclusions 
Conventional chemotherapy treatments have shown their limits, especially for patients with 
advancer cancer. New therapeutic strategies must be identified, and the metabolic 
abnormalities of cancer cell open up such opportunities (Cellarier et al., 2003). Many human 
cancer cells lines and primary tumors have an absolute need for methionine, an essential 
amino acid. In contrast, normal cells are relatively resistant to exogenous methionine 
restriction. We show that melanoma cells are highly dependent on methionine. The 
resistance of melanomas to general chemotherapies and their avoidance of cellular suicide 
or resistance to apoptosis is primarily related with the high activity of the methionine cycle 
in these cells, which permits the methylation of specific genes and activation of different 
survival pathways. Blockage of the methionine cycle by the new antifolate, TMECG, is an 
effective therapy for melanoma. The specific activity of TMECG on melanoma methionine 
cycle was confirmed by the high synergy found with compounds that uncoupled adenosine 
metabolism in these cells. In conclusion, our results show that TMECG is a potent antitumor 
agent that modulates multiple aspects of melanoma metabolism and survival, including the 
folic acid and the methionine cycles and the methylation status of the cells. This broad 
spectrum of antitumor activities in conjunction with low toxicity underlies the translational 
potential of TMECG and suggests it may be used as part of a therapeutic strategy against 
melanoma. A combination with other compounds that modulate melanoma methionine 
cycle, such as SAM, adenosine or dipyridamole, represents another promising strategy to 
combat this malignant skin pathology.  
7. Conclusions 
Several investigations indicate that natural and synthetic polyphenols may well be 
beneficial, not only in the prevention but also in the treatment of cancer. Antifolates are 
usually used as chemotherapeutic agents for certain types of cancer. Although antifolates 
such as MTX attack proliferating tissues selectively, they are also toxic to normal cells. 
Deleterious side effects are seen against tissues that proliferate as part of their normal 
function; such tissues include intestinal mucosa, hair cells, and components of the immune 
system. The “soft” character of polyphenols could be developed for use in the treatment of 
cancer with significantly reduced side effects compared to those of the DHFR inhibitors 
currently in use in chemotherapy such as MTX. Moreover, we have demonstrated that 
synthetic derivatives of ECG, TMECG and TMCG, might be considered a treatment for 
melanoma. Disruption of the cell folate cycle by these compounds and their active products 
may explain many of the molecular and cellular effects described for these synthetic 
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polyphenols on melanoma cells because antifolates exert their action by disturbing the 
nucleic acid metabolism of cancer cells, including its synthesis, methylation and stability 
(Navarro-Perán et al., 2007; Sánchez-del-Campo & Rodríguez-López, 2008). We define them 
as new generation antifolates because they maintain the ability to inhibit DHFR and disrupt 
folate metabolism but show significant and important differences from other classical and 
non-classical antifolates. TMECG was seen to be active not only in melanoma cells in culture 
but was also effective in an animal model, where it inhibited growth and metastasis of 
preformed tumors. An additional advantage of these compounds is their prodrug character, 
which would favour its specific activity against melanoma cells and prevent unspecific side 
effects in rapidly dividing healthy cells. In addition, the multiple connections of the folic 
acid cycle with many metabolic and signalling pathways in melanoma cells could open the 
way for the development of new combined and directed therapies against this elusive skin 
pathology. 
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1. Introduction  
Malignant melanoma can be currently allocated within the list of the most serious diseases 
with high mortality, every year, over 50,000 patients with this diagnosis die worldwide (Pirard 
& Vries, 2007). In addition, its incidence (200,000 per year worldwide) (Mathers et al., 2001) is 
still increasing due to deteriorating environmental factors (increased exposure to UV light, 
unhealthy lifestyle, pollution etc.). Chemotherapy is one of the most important therapeutic 
modalities of this diagnosis however, despite significant advances in the field of contemporary 
medicine and a broad portfolio of medicaments in use, the treatment success rate is still 
insufficient. For these reasons, scientific and pharmaceutical communities have intensively 
investigated new compounds that could be applied as new drugs for this devastating disease. 
Triterpenes - substances abundant in natural sources belong to a group of isoprenoids, 
compounds made of 6 isoprene building units. They have a wide spectrum of 
pharmacological activities (Dzubak et al., 2006), of which the most noteworthy are: antiviral, 
anti-inflammatory, antiulcerogenic, antimicrobial, anticariogenic and most importantly 
anticancer activity. Betulinic acid (1) and many other triterpenes have been known over a 
century, however, until recently their selective cytotoxic activity against human melanoma 
cells was undiscovered (Cichewicz & Kouzi, 2004; Eiznhamer & Xu, 2004; Salvador, 2010). 
The extract of Vauquelinia corymbosa (Fig. 1) showed significant cytotoxic activity against a 
cell line of lymphocytic leukemia P-388 in the work of Trumbull by 1976 and betulinic acid 
(1) along with uvaol and ursolic acid were supposed to be responsible for it (Trumbull et al., 
1976). Despite that, the fundamental study of selective cytotoxic activity of acid 1 against 
human melanoma cells MEL-1 with IC50 values in the range between 0.5 - 1.5 µg/mL was 
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reported by Pisha and his team (Pisha et al., 1995) incredible 19 years after Trumbull's paper. 
A large number of natural triterpenes have been isolated and many more semi-synthetic 
compounds have been prepared from them since then. Plenty of these derivatives also 
showed cytotoxic activity against melanoma cells (Salvador, 2010). 
In this chapter (Isolated pentacyclic triterpenes and Semi-synthetic triterpenoids), there 
will be a summary of representatives from both natural and semi-synthetic lupane 
triterpenoids with cytotoxic activity against melanoma cells that were studied during the 
past fifteen years. Current knowledge of the mechanisms of action of the leading 
representatives, results and aspects of in vivo tests and clinical trials will be discussed here. 
Betulinic acid (1) will be given the most attention as it is historically the first known 
triterpene with activity against melanoma. Betulinic acid (1) is currently in the second phase 
of clinical trials for treatment of dysplastic nevus and therefore, it has a high potential to be 
used in future clinical practice. 
 
 
Fig. 1. Vauquelinia corymbosa (Photo: Dr. Carlos Gerardo Velazco Macías) 
2. Anticancer effects of triterpenoids used for treatment of melanoma 
To date, several hundred triterpenoid compounds with significant in vitro cytotoxic activity 
against a variety of cancer cell lines have been found (Salvador, 2010) however; few of them 
were screened against human melanoma lines such as MEL-1, -2, -3, -4. Most of the 
triterpenes that actually were tested and showed interesting activity against melanoma cell 
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lines were derivatives of lupane. That is why this chapter will be focused on lupane 
triterpenoids with anti-melanoma activity and they will be divided into two groups 1) 
isolated pentacyclic triterpenoids, meaning they were isolated from a natural source and 2) 
semi-synthetic triterpenoids that were obtained by modification of natural compounds 
using chemical reactions or biotransformations. 
2.1 Isolated pentacyclic triterpenes 
Natural appearance and properties of betulinic acid (1) 
Betulinic acid (1) is a natural triterpene with extraordinarily high activity against human 
melanoma and is found throughout the plant kingdom (e.g. genus Betulla, Ziziphus, Syzigium, 
Diospiros, Paeonia) (Cichewicz & Kouzi, 2004). When isolated as a pure compound, this natural 
pentacyclic triterpene appears to be snow-white crystalline odorless and tasteless powder that 
is almost insoluble in water (Cichewicz & Kouzi, 2004; Glassby, 1982; Simonsen & Ross, 1957). 
 
 
Fig. 2. Gratiola officinalis (photo: http://botanika.wendys.cz); 
 
 
Fig. 3. Platanus acerifolia (photo: www.shutterstock.com); 
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Fig. 5. 
The first isolation of the compound currently known as betulinic acid (1) was described by 
Retzlaff in 1902 (Retzlaff, 1902; Simonsen & Ross, 1957), who extracted the yet unknown 
substance from Gratiola officinalis (Fig. 2) which he called “graciolon”. In 1925, betulinic acid 
(1) was independently obtained from the bark of plane trees Platanus acerifolia (Fig. 3) by 
Zellner and Ziffer (Simonsen & Ross, 1957; Zellner & Ziffer, 1925) using either extraction or 
sublimation. The authors named it after its source “platanolic acid” and did not recognize its 
true identity. Similarly, the same compound was isolated from Florida Cornus (Fig. 6) during 
the dissertation research of Soliman who, in 1939 first called it “cornolic acid”. However, 
soon he and his co-workers identified it correctly as betulinic acid (1) (Robertson et al., 1939). 
In 1944, Barton and Jones used physical constants to correctly identify “graciolon” as 
betulinic acid (1) (Barton & Jones, 1944) and in 1948, Bruckner and co-workers identified 
(Bruckner et al., 1948) “platanolic acid” as betulinic acid (1) as well. Demonstrating, that 
betulinic acid (1) is widely spread throughout nature and that its identification was often 
accompanied with many problems during the 20th century. 
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Acid 1 is accessible from plane tree and birch bark on an industrial scale since both types of 
bark contain several percent of it. In addition to the extraction procedures (Cichewicz & 
Kouzi, 2004; Simonsen & Ross, 1957; Urban et al., 2004), several industrial processes were 
developed to manufacture (Csuk et al., 2006; Krasutsky et al., 2003, 2006; Pezzuto et al., 2007) 
betulinic acid (1) from betulin (3), a triterpene far more abundant (up to 30 %) in birch bark 
(e.g. Betula pendula; Fig. 7) than the acid, which makes it far more profitable process. This is 
especially useful in northern European countries, Russia, Canada, where paper mills mostly 
use birches to produce cellulose pulp and where over 40 tons of birch bark (Krasutsky, 2005, 
2006; Sarek, 2008) is produced daily, with 6 tons a day being burned as a cheap fuel (5-7 
USD per ton; 7-11 MJ/kg). Using birch bark as a cheap source of betulin can provide the 
industry with a less expensive source of betulinic acid (Csuk et al., 2006; Krasutsky, 2003, 
2006; Pezzuto, 2007). With these procedures, there should not be a significant problem with 
manufacturing betulinic acid (1) on a multi ton scale. The best known industrial process to 
convert betulin (3) into betulinic acid (1) is based on conversion of it into aldehyde 4 (Csuk 
et al., 2006; Krasutsky et al., 2006a, 2006b, 2006c) followed by oxidation (Csuk et al., 2006; 
Krasutsky et al., 2006) of aldehyde 4 to betulinic acid (1). Older patented procedures 
(Pezzuto et al., 2007) that use oxidation of betulin (3) with Jones reagent into betulonic acid 
(5) followed by selective reduction are not preferable because they use toxic Cr(VI) 
compounds in large quantities and also a 3-epimeric product originates as a by-product 
(Pezzuto, 2007) which makes the isolation and purification far too expensive. 
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Antitumor activities of acid 1 against human melanoma cells 
Despite acid 1 having been isolated in 1902, its cytotoxic effects were not found until the 
examination of cytotoxicity of various Vaquelinia corymbosa (Fig. 1) extracts against 
lymphocytic leukemia cells P-388 by Trumbull in 1976 (Trumbull et al., 1976). Approximately 
19 years later, Pisha and his co-workers (Pisha et al., 1995) published their findings of selective 
cytotoxic effects of betulinic acid (1) extracted from stem bark of Ziziphus Mauritiana 
(Lamnaceae, Fig. 4) against human melanoma cells Mel-1, -2, -3, -4. Furthermore, this work 
investigated the mechanism of action by flow-cytometry (Pisha et al., 1995), and it was found 
that acid 1 induced selective apoptosis of tumor cells Mel-2, which remained in G0/G1 phase. 
Moreover, induction of apoptosis was evident from the emergence of sub-G1 apoptotic peak 
(Ap) in DNA histograms and its increase between 56-72 h after application. Direct 
perturbation of the mitochondria by betulinic acid (1) was observed by (Fulda et al., 1998) and 
this type of activity was also found when the cancer cells were treated by various triterpene 
scaffolds without limitation to the melanoma cells. Despite extensive research, the molecular 
target of betulinic acid (1) has not yet been identified. Only from some published pathway 
alterations like Bcl-2 and NF-kB modulation and antiangiogenic activity were some 
speculations about the target able to be made (Selzer et al., 2000, 2002). There is a plethora of 
information about the activity of potent derivatives of betulinic acid (1) (e.g. NVX-207, PA-457) 
in in vitro and in vivo models but it seems to be a reality, that small changes in the chemical 
structure could lead to significant differences in specificity and mechanisms of action (Keller et 
al., 2001; Suh et al., 1999; Willmann et al., 2009). 
Another advantage of using acid 1 in cancer therapy is its very low toxicity in a Hippocratic 
screens at doses of 200 and 400 mg per kg body weight in animal models (Pisha et al., 1995). 
In a study published by Pisha, intraperitoneal application of acid 1 to mice in six doses of 
500 mg/kg every fourth day and six doses of 250 mg/kg every third day were accepted 
without any signs of toxicity (Cichewicz & Kouzi, 2004). In vitro studies showed that the 
only symptom of high doses of acid 1 was an increase of intracellular-free calcium, and this 
increase was only associated with a small decrease in cell viability (Cichewicz & Kouzi, 
2004). Very low toxicity and significant antitumor activity give acid 1 a very favorable 
therapeutic index (Cichewicz & Kouzi, 2004). These findings thrust common triterpenes - 
betulinic acid (1) - to the center of interest within scientific groups studying antitumor 
activities and mechanisms of action, and pharmaceutical companies interested in 
chemotherapeutics (e.g. BMS). 
Other anticancer activities and studies 
Acid 1 has presented promising antitumor activity against a variety of tumor cell lines such 
as malignant brain-tumor (Fulda et al, 1999), neuroectodermal (Zuco et al., 2002), human 
chronic myelogenous leukemia (CML) 562 (Gopal et al., 2005) and many other cell lines 
derived from the most prevalent human cancer types (lung, colorectal, breast, prostate and 
cervical cancer (Kessler et al., 2007; Zuco, 2002). Furthermore selective cytotoxicity against 
tumor cell lines in comparison with normal cells has been confirmed (Hata et al., 2002). 
Pulsatilic acid (2), a compound isolated from Pulsatilla chinensis is another example of a 
triterpene highly cytotoxic against mouse melanoma cell line B16 (Bi et al., 2007; Liu et al, 
2004; Zhou et al., 2007). Pulsatilic acid (2) is a little less active than acid 1 (53 mol/L for acid 
1 and 83 mol/L for acid 2) (Bi at al., 2007). 
The last type of natural pentacyclic triterpenes active against melanoma are ochraceolides, 
compounds with modified E-ring. Ochraceolides A (6) and C (7) were isolated together with 
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other lupane derivatives from Kokoona ochracea and their activity against line UISO-MEL-2 
was approximately 15 mol/L (Ngassapa et al., 1991). 
Synergisms of acid 1 with cytostatics and other effects.  
Animal and cell based studies (Sawada et al., 2004; Selzer et al., 2000; Wachsberger et al., 
2002) have focused on investigating the synergic anticancer activities of various doses of 
acid 1 and vincristine (Fig. 8), radio therapy, lowering pH, or hyperthermia. A significant 
increase in the efficiency of radio therapy against human melanoma cells was demonstrated 
when combined with dossing of betulinic acid (1). Response of melanoma cells to betulinic 
acid (1) alone or in combination with irradiation was studied by Selzer and co-workers 
(Selzer et al., 2000). Analysis of tumor cell survival following the treatment by acid 1 
combined with an application of ionizing γ irradiation (dose of 2 Gy, within the range used 
in clinical therapy) indicates that betulinic acid (1) and irradiation have an additive effect on 
the inhibition of colony-forming ability. It is possible that acid 1 can target tumor cells that 


















Fig. 8. Vincristine 
In another study, Japanese authors looked at the influence of combination of betulinic acid 
(1) and vincristine on mice melanoma B16F in vitro and in vivo (Sawada et al., 2004). Based on 
fast apoptosis of those melanoma cells, the authors suggested an existence of a synergic 
effect between acid 1 and vincristine, they found, that each substance causes inhibition of 
cell cycle in different phases: betulinic acid (1) in G1 phase and vincristine in G2/M phase 
(Sawada et al., 2004). An application of both compounds in vivo increased suppression of 
lung metastasis of melanoma cells in a model C57BL/6 in mice, in comparison to vincristine 
only. Authors proclaimed that acid 1 is a suitable complement to the chemotherapy of 
malignant melanoma (Sawada et al., 2004).  
Wachsberger et al reported an influence of antitumor activity of compound 1 together with 
application of hyperthermia and lower pH in human melanoma cells DB-1 (Wachsberger et 
al., 2002). They found that percentage of survived tumor cells during the combined 
application of acid 1 and hyperthermia of 42°C for two hours decreased with respect of used 
pH 7.3, 6.7 and 6.3  from 5 %, 9 %, to 2 %. 
In vivo studies and the clinical trials of betulinic acid (1) 
Based on promising in vitro and in vivo activity of betulinic acid (1) in melanocarcinoma cells 
and tumors in animal models, human clinical trials were induced. Some considerations were 
taken in regard to actinic keratosis (AKs), which represents the initial intraepidermal 
manifestation of keratinocyte abnormal transformation that may potentially progress to 
small cell carcinoma. In a randomised trial, Huyke (Huyke et al., 2009) treated 45 patients 
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(with <10 AKs each) either with a topical betulin-based oleogel twice daily, or cryotherapy, 
or a combination of the two. Treatment with betulin-based oleogel was well-tolerated and 
showed efficacy in treating AKs. Continued controlled studies on larger sample sizes 
investigating the use of betulinic acid for the treatment of nonmelanoma skin cancer are 
warranted. Phase I and II clinical trials evaluating the topical application of betulinic acid (1) 
in the treatment of dysplastic nevi with moderate to severe dysplasia are currently ongoing 
(www.clinicalstrials.gov). Clinical trials with acid (1) have not been completed to date. 
Overview of other biological activities of acid 1 
It should be stated that betulinic acid (1) also has other interesting biological activities, 
especially, anti-HIV (Fujioka et al., 1994; Mayaux et al., 1994) and anti-inflammatory (Huang 
et al., 1995; Mukherjee et al., 1997; Recio et al., 1995a, 1995b; Yasukawa et al., 1991). The anti-
HIV activity of betulinic acid (1) and its derivatives was first described by two independent 
research groups (Fujioka et al., 1994; Mayaux et al., 1994). Since then, several researchers 
prepared, published and often patented a large number of novel derivatives (Jacob et al., 
2010; Salzwedel et al., 2010) with significant activity against HIV (EC50 < 1 nM). Among 
these derivatives, three main groups are worth mentioning. First 3-O-acyl derivatives of 
betulinic acid that inhibit the maturation of HIV virus (Kashiwada et al., 1996). 3-O-3´,3´-
dimethylsuccinylbetulinic acid (8), also known as PA-457 or bevirimat is the most important 




























Fig. 9.  
The companies Panacos (Salzwedel et al., 2010) and Myriad (Jacob et al., 2010) found 
bevirimat to be active against HIV in vivo which sent the compound to phase IIa of clinical 
trials under registry number NCT01026727 (US National Institute of Health). Not only does 
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Bevirimat (Jacob et al., 2010; Kashiwada et al., 1996; Salzwedel et al., 2010) show very high 
anti-HIV activity (EC50 ~ 0.35 nM) but it also has a very low toxicity (typical for betulinic 
acid derivatives) which together puts the value of its therapeutic index over 20,000. Another 
advantage of bevirimat is that to date no resistance to it has been recorded. The second 
group of anti-HIV active compounds are 28-amides (Evers et al., 1996; Soler et al., 1996; Sun 
et al., 2002) of betulinic acid that block the entry of the virion into cells. The most important 
amide derivatives (Holz-Smith et al., 2001; Sun et al., 2002) are compounds 9 and 10 also 
known as RPR103611 and IC9564. The third group is represented by compounds that 
combine both of the previously mentioned mechanizms of activity (Huang et al., 2006) 
because they contain a combination of both pharmacophors – acyl group in the position 3 
and 28-amide group. Those compounds were discovered most recently and the most active 
is ([(N-[3-O-(3´,3´-dimethylsuccinyl)lup-20(29)-en-28-oyl]-7-aminoheptyl)-carbamoyl]me-
thane) (11) which showed activity about 20 times higher than Bevirimat in in vitro tests 
(Huang et al., 2006).  
Yasukawa was the first to describe anti-inflammatory activity of betulinic acid (1) 
(Yasukawa et al., 1991) and relevant inhibition effect against TPA –induced inflammation 
was found at concentration of 5 M (Huang et al., 1995; Mukherjee et al., 1997; Recio et al., 
1995a, 1995b). Promising anti-inflammatory activity has also been found in 3caffeoyl 
betulinic acid (12) by Fuchino group (Fuchino et al., 1995, 1996, 1998). This compound is one 
of the components of birch bark. Last but not least, betulinic acid (1) is commonly used in 
the cosmetic industry. It is usually used in concentrations of 50-500 mg per gram to prevent 
and help treat UV-induced skin cancer, to reduce signs of cellulitide and to stimulate 
collagen synthesis in skin-care products. It’s also used to prevent sunlight-caused signs of 
aging, wrinkles, and blotches and to improve skin homogeneity and pigmentations. 
(Bradbury et al., 1997a, 1997b, 1997c) 
2.2 Semi-synthetic triterpenoids with activity against melanoma 
The very poor solubility of acid 1 in water based media (< 1 mol/L) (Cichewicz & Kouzi, 
2004; Symon et al., 2005), high hydrophobicity (log P) (Srivastava et al., 2002) and unsuitable 
pK parameters (absorption, distribution, metabolism and elimination), along with strong 
antitumor potential (Pisha et al., 1995) and low acute toxicity (Cichewicz & Kouzi, 2004) 
motivated a number of scientific institutions to synthesize derivatives, pro-drugs and 
formulations of betulinic acid (1) that could retain the activity and low toxicity, but improve 
the afore mentioned properties. The following semi-synthetic derivatives might be divided 
into three groups: simple derivatives of natural triterpenes (2.2.1), derivatives obtained by 
biotransformation procedures of betulinic acid (1) (2.2.2) and triterpenoids with 
modification of lupane skeleton (2.2.3). 
2.2.1 Derivatives of natural triterpenes (acids 1, 2 and betulin (3)) 
Several functional groups can be used for the derivatization of acid 1, such as the secondary 
hydroxyl group in the position 3, a neopentyl 28-carboxyl moiety in the location 17 and 
finally, a double bond located between carbons 20 and 29. As both hydroxyl and carboxyllic 
groups are sterically hindered, common derivatization processes usually don’t work very 
well or fail completely. A typical example is the esterification of 28-carboxylic group. The 
reaction does not work with alcohols at all; acid catalysis or use of DCC does not help either. 
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2.2.1 Derivatives of natural triterpenes (acids 1, 2 and betulin (3)) 
Several functional groups can be used for the derivatization of acid 1, such as the secondary 
hydroxyl group in the position 3, a neopentyl 28-carboxyl moiety in the location 17 and 
finally, a double bond located between carbons 20 and 29. As both hydroxyl and carboxyllic 
groups are sterically hindered, common derivatization processes usually don’t work very 
well or fail completely. A typical example is the esterification of 28-carboxylic group. The 
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Using alkyl bromides or iodides and alkali carbonates or DBU as the basis in DMF are the 
most effective conditions to introduce an ester to 28-carboxyl group. Analogously, simple 
alkali hydrolysis of alkyl betulinates does not work and to release a free acid from its ester, it 
is necessary to apply drastic conditions such as reflux with potassium hydroxide in ethylene 
glycol or nucleophilic deprotection using lithium iodide in collidines under reflux. For the 
purposes of this chapter, the compounds that are modified at more than one site of the 
skeleton are classified according to significance of the modification. Also, many cytotoxic 
compounds with no data about their activity on melanoma lines are not included in this 
chapter. 
Derivatization of betulinic (1) and pulsatillic acid (2) in position 28 
Cytotoxicity of various types of esters of betulinic acid (1) is very well researched. In the 
past, researchers found that the cytotoxicity of betulinic acid decreases by forming alkyl or 
aryl esters from 28-carboxylic group. (Kim et al., 1998, 2001; Kvasnica et al., 2005; Urban et al., 
2004, 2005). One of the explanations of this fact is that free carboxyl group is responsible for 
the activity and the hydrolysis of its esters is extremely difficult and requires extreme 
conditions which are caused by sterical hinderance of the neopentyl-type group. Curiously, 
difficulties with the hydrolysis were not observed at similar -unsaturated esters (e.g. 
compound 13, Fig. 10) (Sarek et al., 2005) which suggests that a different reaction mechanism 
might exist to cleave them, so those difficulties are probably specific for alkyl and aryl esters 
and for acids with unmodified E-ring. Very detailed studies of the dependency of 
cytotoxicity on the type of the ester in position 28 of betulinic acid (1) have been published 
in literature (Kvasnica et al., 2005; Urban et al., 2005) The authors demonstrated that methyl, 
ethyl, and benzyl esters are an order of magnitude less active than the free acid 1.  
A different situation was observed at substituted alkyl esters of acid 1 and 2 (Bi et al., 2007; 
Urban et al., 2005). Urban et al. compared the cytotoxicity of methyl-, pivaloyloxymethyl-, 
and acetoxymethyl- esters of betulinic and betulonic acid 15 - 22 on broad scale of cancer cell 
lines. They found that while methyl- and pivaloyloxymethyl- group significantly decrease 
the activity, the Acm-esters were either as active as the starting acids or better. The Acm 
group is therefore a suitable derivatization group that could possibly be useful to synthesize 
prodrugs. Another good property of Acm is that it increases hydrophilicity.  
A completely new type of esters was published by Effenberger et al. who synthesized esters 
from a variety of monoterpenes, sesquiterpenes, and betulinic acid with carboxylic and 
hydroxyethylene derivatives of thymoquinone (Effenberger et al., 2010). However, 28-esteric 
derivative 23 was about 7 times less active against the cell line 518A2 than the free acid 1 
(Effenberger et al., 2010). A SARS study done by Bi et al. who investigated the activity of 
alkenyl, alkynyl and hydroxyalkyl esters of pulsatillic acid 24 - 29 against several tumor cell 
lines. The authors included in vivo experiments using the most active allyl ester 24 and the 
starting acid 2 on mice in H22 and B16 models. The in vitro experiments showed that all 
prepared esters were more active than the starting acid 2 against line B16 and also that 6-
hydroxyethylester was only slightly better than the acid 2 on the same line. In vivo 
experiments brought even more exciting results when they showed that allyl pulsatillate 24 
(applied as intraperitoneal DMSO solution) caused a larger reduction of the mass of a tumor 
than the free acid 2. Its activity was actually comparable to cyclophosphamide which is a 
commercially used cytostatic.  
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15: R1 = Me,       R2 = -H, -OH
16: R1 = Et,         R2 = -H, -OH
17: R1 = Bn,        R2 = -H, -OH
18: R1 = Pom,     R2 = -H, -OH
19: R1 = Acm,     R2 = -H, -OH
20: R1 = Me,       R2 = O
21: R1 = Pom,     R2 = O
22: R1 = Acm,     R2 = O











24:  R = CH2CH=CH2
25:  R = CH2C
26:  R = CH2CH2OH
27:  R = (CH2)4OH
28:  R = (CH2)6OH






13: R1 = Me,  R2 = Ac






Fig. 10.  
Willmann et al. brought even more promising results using the compound 30 - NVX-207 that 
is an ester of acetylbetulinic acid with tris(hydroxymethyl)aminomethane (TRIS). The 
compound was highly active in vitro against 15 cancer cell lines including human melanoma 
518A2 and the activity was between 2.6 mol/L on 518A2 and 5.6 mol/L on fibrosarcoma 
HAT 1080. Those initial experiments were followed by a phase I/II animal clinical study on 
canine patients with spontaneous currently untreatable tumors using intralesional and 
surrounding tissue application of NVX-207. Five dogs bearing tumors of different 
histogenetic origine (squamous cell carcinoma, soft tissue sarcoma, mammary carcinoma 
and adenocarcinoma of the scent gland of the paw) were treated. The complete response to 
the therapy was observed in two dogs, almost complete remission (90% reduction), stable 
disease (50% response) and 30% percent reduction was observed in the remaining cases. No 
systemic side effects and minor local side effects (mild local discomfort) after infiltration of 
the tumors were observed (Willmann et al., 2009). 
Another large group of activated esters are esters with sugars, sometimes improperly called 
glycosides. The cytotoxicity of these compounds has not been studied thoroughly and the 
few examples in literature (Gauthier et al., 2009a, 2009b; Pakulski et al., 2009) do not show 
activity against melanoma cell lines. The only conclusion that can be made is that esters 
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where a terpene is connected to a single saccharide unit are far less active than the free acid. 
An example of this is - -D-glucopyranosyl betulinate (31) (Gauthier et al., 2009a, 2009b) 
which has activity lower than the activity of betulinic acid (1) by an order of magnitude. 
Despite this, a study which researched the cytotoxicity of bidesmosidic saponines showed 
that the saccharide component bound as an ester is an important part of the pharmacophore 
because its removal caused significant drop of activity. The study contained pulsatillic 




































Fig. 11.  
Amides represent another type of carboxylic acid derivative. Their antitumor activity is 
usually high and their hydrophilicity makes their use in in vivo tests very easy (Jeong et al., 
1999; Willmann et al., 2009). Jeong published a very complex SARS study about the cytotoxic 
activity of conjugates of betulinic acid (1) with natural amino acids along with a toxicity 
study on fibroblasts and basic studies of solubility. The best results against MEL-2 cell line 
were found using conjugates of betulinic acid with alanine - 33 and 35; although the 
compounds were somewhat toxic against fibroblasts. While the conjugates of betulinic acid 
with valine 34, 37 and glycine 36 were less active than those with alanine 33 and 35; they 
were completely non toxic. The glycine conjugate 36 was also the most hydrophilic of the 
studied compounds. The authors tested the solubility of the conjugates with a very simple 
method. They prepared solutions of each studied compound in DMSO and kept diluting 
those solutions with water until they started to precipitate. While the most active alanine 
derivative 33 could be diluted up to 50 times, the glycine conjugate 36 could be diluted 100 
times. Despite the fact, that the cytotoxicity of the glycine conjugate 36 was the same as the 
activity of free betulinic acid (1) (4.2 mol/L), the conjugate 36 is far more soluble in water 
and that makes it a very suitable candidate for in vivo testing.  
Another type of derivative that showed cytotoxicity against melanoma lines was quaternary 
ammonium salts (Biedermann et al., 2010; Sarek et al., 2008). The strong antitumor activity of 
quaternary ammonium salts of four terpenic acids (betulinic (1), dihydrobetulinic (38), 
platanic (39) and 21-oxoacid 14) on a panel of 11 cancer cell lines has been demonstrated in 
the literature (Sarek et al., 2008). The salts were obtained by a two step reaction of a terpenic 
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acid with 1,2-dibromoethane followed by a quaternization with a corresponding amine 
(trimethylamine, triethylamine, pyridine). The best cytotoxicity was obtained with 
quaternary salts of triethylamine - compound 40 and 41. The dihydrobetulinic salt 41 is 
currently being tested on melanoma lines and has shown activity between 1.6 mol/L 
against the line UAAC 62 and 14.6 mol/L against the line M14 (see Tab. 4). Salts 40 and 41 
are also very hydrophilic which makes it easy to dissolve them (55 mg/mL of vehiculum) in 
media based on water and moreover, their oral accessibility makes them ideal candidates for 
in vivo testing on animals.  
 
HO
33: R1 = H,     R2 = Me
34: R1 = Me,   R2 = CH(CH3)2
35: R1 = Me,   R2 = Me
36: R1 = H,     R2 = H















40: x = double bond
41: x = single bond
38: R = CH3,H
39: R = O,  
Fig. 13.  
The final group of carboxylic derivatives consists of compounds with aldehydic or 
hydroxymethyl group in position 17 because they can be prepared by simple reduction step 
from carboxylic acids. Those compounds are actually more easily synthesized from betulin 
(3) than from betulinic acid (1). It was shown that the carbonyl group (aldehyde or 
carboxylic acid) is essential for cytotoxicity because while aldehydes are active, 28-
hydroxyderivatives are generally not. This fact was well documented in the work (Hata et 
al., 2003) in which betulinal (4) had activity 10.6 mol/L, and acid 1 6.5 mol/L against 
melanoma cell line SK-MEL-2. However, if another part of the molecule of 28-
hydroxyderivatives is modified, the activity may increase. The best examples are glycosides 
of betulin (3) that are very active on melanoma B-16F, especially when position 3 was 
glycosylated. Curiously, 28-O-glycosides were inactive (Gauthier et al., 2006). Among -D-
glucoside, -D-arabinoside, and -L-rhamnoside 42 – 44 (Fig. 13), the last listed was the most 
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active against B16-F1 cell line (18 mol/L, which is just slightly worse than acid 1 with an 
activity of 16 mol/L) (Gauthier et al., 2006). There are no results for bisdesmosidic 
saponines on melanoma cell lines, however, work of Gauthier describes similar trend on 
another lines (most active is betulin-328-O-bis(-L-rhamnoside) 45 (Gauthier et al., 2009a). 
 
R2O
42: R1 = O-L-Glc,     R2 = H
43: R1 = O-L-Rha,    R2 = H
44: R1 = O-D-Ara,     R2 = H

























46: R1 = OCOCH2X+Br-;            R2 = OH
47: R1 = OCO(CH2)3X+Br-;        R2 = OCOCH2)3X+Br-
48: R1 = OCOCH2X+Cl-;            R2 = OH
49: R1 = OCO(CH2)2X+Cl-;        R2 = OCO(CH2)2X+Cl-
50: R1 = OCOCH(C2H5)X+Br-;  R2 = OCOCH(C2H5)X+Br-
51: R1 = OCOCH(CH3)X+Cl-;    R2 = OCOCH(CH3)X+Cl-
52: R1 = OCOCH2X+Cl-;            R2 = OCOCH2X+Cl-
53: R1 = OCOCH2X+Br-;            R2 = OCOCH2X+Br-
54: R1 = CONHCH2CH3;           R2 = OCONHCH2CH3
55: R1 = Ac;                               R2 = OH
56: R1 = H;                                 R2 = OAc




Dimethylaminopyridine quaternary ammonium derivatives of betulin 46 – 53 showed 
strong activities of 0.3 - 2.6 mol/L on cell lines WM3211 a WM793 and again, the 3,28-
bisfunctional derivatives were more active than the monofunctional (Holy et al., 2010). Also 
bis(carbamoyl) derivatives had strong activity against 518A2 when bis(ethylcarbamate) 54 
was almost as active as betulinic acid (1) (about 8 mol/L). Common acyl derivatives such 
as 55 - 57 acetates cause a complete extinction of any cytotoxic activity (Gauthier et al., 2006). 
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Derivatization of betulinic acid (1) and betulin (3) in position 3
This heterogeneous group of derivatives contains C-3 glycosides, 3-O-acyl derivatives, 3-
oxo compounds and their derivatives (ketones, oximes), and products of reduction of 
nitrogen derivatives (3-amines). As already mentioned in the previous chapter, antitumor 
activity of triterpenoid saponins is relatively well explored (Gauthier et al., 2006, 2009a, 
2009b; Pakulski et al., 2009; Thibeault et al., 2007) however there is not much data for the 
melanoma line (Gauthier et al., 2006; Pakulski et al., 2009). 
The situation with betulinic acid 3-glycosides reminds the situation with esters of betulinic 
acid (1) with sugars. 3-O--L-rhamnopyranoside 59 is the most active glycoside with 
activity of 3.9 mol/L against metastatic murine melanoma line B-16F1. Glycoside 59 is 
approximately 4 times more active than acid 1 itself (Gauthier et al., 2006). Approximately 
the same activity as betulinic acid (1) was found in case of its 3-O--D-arabinopyranoside 
60, while 3-O--D-glucopyranoside 58 was 2 times less active than the 3-O--L-
rhamnopyranoside 59 (Gauthier et al., 2006). In the same work, an inverse relation for 
glycosides of methyl betulinate (15) is also documented; 3-O--glucopyranoside 58 was the 
most active from them. (Gauthier et al., 2006) 
(Pakulski et al., 2009) investigated the antitumor efficacy of mannopyranosides and 3,6-
branched trimannopyranosides, which were stereoselectively prepared from the natural 
triterepenes – betulin (3), and betulinic acid (1). Although it is a synthetically attractive 
method, the mannosylation did not bring any significant effect against melanoma. 3-O--D-
mannopyranoside 61 and 28-O--D-mannopyranoside 62 showed very poor results against 
malign melanoma line G 361 and trimannopyranosides were not active as well. 
2-Deoxygalactosides and 2-deoxyglucosides (Sarek et al., 2009), prepared from a large group 
of highly oxidized lupane hydroxyderivatives by stereospecific additions of corresponding 
glycals, have significant antitumor activity. The above mentioned 2-deoxyglucosides were 
effective against a wide range of cancer cell lines, including MDR (Sarek et al., 2009). 
Recently, we tested the anticancer effectiveness of derivative 64 against melanoma lines 
where activity reached approximately 20 mol/L (Tab. 4). This group of saponins is 
promising because peracetylated analogues have an order of magnitude better activity than 
free 2-deoxyglycosides (Sarek et al., 2009). 2-deoxyglycosides are very hydrophilic in 
character which makes them readily soluble in aqueous media and easily applicable in in 
vivo conditions, e.g. compound 64 up to 68 mg/mL (Sarek et al., 2007). It was shown on mice 
that 2-deoxyglycosides are orally bioavailable which is possibly result of their hydrophilicity 
(Sarek et al., 2007), and that makes them promising candidates for anticancer drugs. An 
example of a natural highly active glycoside of betulinic acid is 3-O--L-arabinopyranoside 
63 isolated from Schefflera rotundifolia, which has an activity of 0.55 mol/L against mouse 
fibrosarcoma line and also shows a combination of glycoside and saccharide ester in 
molecule. 
Acyl derivatives of betulinic acid (1) and betulin (3) are a large group of semisynthetic 
derivatives known especially for their antiviral effects while their cytotoxicity is much lower 
than that of hydroxyderivatives. This fact dramatically improves their therapeutic index for 
testing anti-HIV activity (Krasutsky et al., 2006; Fujioka et al., 1994, Mayaux et al., 1994). A 
comparison of activity of betulinic (1) and dihydrobetulinic acid (38) with their acetates is 
described in (Kim et al., 2001; Mukherjee et al., 2004). Tests with SK-MEL-2 and M14-MEL 
lines showed that the acetylation of hydroxyderivatives causes either a small decrease or no 
change in cytotoxicity (Kim et al., 2001). This fact is in good agreement with the work, where 
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active against B16-F1 cell line (18 mol/L, which is just slightly worse than acid 1 with an 
activity of 16 mol/L) (Gauthier et al., 2006). There are no results for bisdesmosidic 
saponines on melanoma cell lines, however, work of Gauthier describes similar trend on 
another lines (most active is betulin-328-O-bis(-L-rhamnoside) 45 (Gauthier et al., 2009a). 
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Dimethylaminopyridine quaternary ammonium derivatives of betulin 46 – 53 showed 
strong activities of 0.3 - 2.6 mol/L on cell lines WM3211 a WM793 and again, the 3,28-
bisfunctional derivatives were more active than the monofunctional (Holy et al., 2010). Also 
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Derivatization of betulinic acid (1) and betulin (3) in position 3
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the influence of the 3-O-acetyl group on cytotoxicity of broader group of triterpenoides 65 
– 67 was studied (Mukherjee et al., 2004; Sarek et al., 2005). In the work of Chien et al., the 
cytotoxicity of natural 3-O-acyl derivatives of betulinic acid 68 – 71 isolated from Strychnos 
vanprukii Craib was investigated against MEL2 line. Cytotoxicity of feruoyl 68, 69 and 
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The last type of 3-O-acyl derivatives of betulinic acid (1) with described cytotoxicity against 
the human melanoma line SK MEL2 is represented by phthalates 72 - 74 prepared by 
(Kvasnica et al., 2005). A SARS study (Kvasnica et al., 2005) of cytotoxicity of hemiphthalates 
and phthalates of betulinic acid (1) and betulin (3) and their esters against SK MEL2 line 
shows that the more lipophilic the phthalate ester is, the more active the hemiphthalate is 
and thus the difference in the activities of the ester is higher. The best activity was reached 
by derivatives 72 and 74 which was 10 times more active than benzyl betulinate (17) (Fig. 9) 
itself and a little more active than the free acid 1. Another convenient feature of 
hemiphthalates is their high hydrophilicity allowing their easy dissolution in aqueous 
media and their use in in vivo tests (Krasutsky et al., 2006; Sarek et al., 2007). 
The final group consists of derivatives of 3-oxo acids 5, 75, 76 and their mostly nitrogenous 
analogues 77 - 81. It is known that oxidation of the 3-hydroxy group to the oxo group 
increases the cytotoxicity against the human melanoma line MEL-2. (Kim et al., 1998) While 
in the pair of betulinic acid (1) - betulonic acid (5) the change is relatively insignificant (1.2 
vs. 0.9 mol/L), the difference is almost an order of magnitude (5.8 vs. 0.7 mol/L) large in 
the case of dihydrobetulinic acid (38) - dihydrobetulonic acid (75), which makes 
dihydrobetulonic acid (75) about twice more effective against MEL-2 than betulinic acid (1) 
itself (Kim et al., 1998). Analogous results were obtained in cytotoxicity tests of oxidation 
products of pulsatillic acid (2) (Liu et al., 2004; Zhou et al., 2007). Pulsatillonic acid (76) 
showed higher activity against B16 line than the original pulsatillic acid (2) (Liu et al., 2004; 
Zhou et al., 2007). Oxime derivatives of both acids 77 and 80 showed the cytotoxicity against 
MEL-2 an order of magnitude lower than oxo acids 5 and 75, methyloxime analogues 78 and 
81 were two orders of magnitude less active (Kim et al., 1998). In contrast, the 3-amino 
analogue 79 obtained by reductive ammination of betulonic acid (5) showed anti-MEL-2 
activity comparable with betulinic acid (1) (Kim et al., 1998). The nitrogenous derivatives of 
betulinic acid (1) in position 3 can also include carbamoyl derivatives 82 – 84 synthesized 
according to the literature (Kommera et al., 2010). While the 3-phenylcarbamoyl derivative 
of betulinic acid - 83 - was active against 518A2,  3-ethyl carbamates 82, 84 showed activity 
comparable to or better than betulinic acid (1). Strong antitumor activity against a radial-
phase WM3211 and a vertical-phase melanoma WM793 was also found in the case of the 
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77: R = NOH,           x = double b.
78: R = NOCH3,       x = double b.
79: R =-NH2, -H;  x = double b.
80: R = NOH,            x = single b.
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83: R1 = NHPh,          R2 = H 
84: R1 = NHCH3CH2, R2 = CH3
85: R1 = CH2X+Br-,    R2 = H
       where X see Fig. 15  
Fig. 18. 
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Modification of skeleton of betulinic acid (1) on the isopropenyl side chain 
An addition of hydrogen, respectively hydrogenation of 20(29)-double bond, represents the 
simplest modification on the isopropenyl side chain as well as a simple way to isotopically 
label the terpenic skeleton with either deuterium or tritium. Although the hydrogenation of 
a terminal double bond seems easy to be done, experiments show the contrary, because 
20(29)-double bond is disubstituted. Under the standard conditions – using hydrogen on 
Pd/C, it is possible to achieve a selective debenzylation of benzyl betulinate (17), without 
20(29)-double bond to be hydrogenated (Kvasnica et al., 2005). As mentioned above, 
dihydrobetulinic acid (38) is approximately four times less active than betulinic acid (1) 
against the line MEL-2, whereas the cytotoxicity of oxidized forms, such as dihydrobetulonic 
(75) and betulonic acid (5) is almost identical. These data show that 20(29) 
dihydroderivatives are comparably active to their unsaturated analogs (Biedermann et al., 
2010; Sarek et al., 2007). 
Among the other explored addition reaction to 20(29)-double bond, there is the addition of 
halogene (Mukherjee et al., 1997) or dihalocarbene (Symon et al., 2005). In the study of 
Mukherjee’s et al., cytotoxic activity (except melanoma lines) of the products of addition of 
bromine to betulonic (5), betulinic (1), and acetylbetulinic (65) acids (e.g. 86 – 87, Fig. 19) was 
explored and the best results were achieved using 20,29–dibromo-3-O-acetylbetulinic acid 
(87) which activity was about the same as betulinic acid (1). A Russian team tested the 
activity of formerly prepared addition adducts 88 and 89 of dichloro- and dibromocarbene 
to betulinic acid (1) against human melanoma cells Colo 38 and Bro.92. The best results were 
achieved with a dichloroderivative 88 with the activity on Bro line slightly better than the 
activity of acid 1, nevertheless the authors claimed that the high lipophilicity of synthesized 
derivatives complicated in vitro tests, therefore further tests of the derivatization of these 
non-polar compounds were suggested (Symon et al., 2005). 
Another option to modify the isopropenyl side chain is substitution, respectively allylic 
oxidation. Introducing alcohol moieties into the location 30 might be carried out either by 
allylic bromination using NBS followed by nucleofilic substitution (Kim et al., 2001) or allylic 
oxidation followed with reduction (Biedermann et al., 2005). The most unique compound 
among these oxygenated derivatives is the unsaturated aldehyde 90, synthesized by allylic 
oxidation of acid 1 by selenium dioxide. Aldehyde 90 disposes of strong multispectral 
antitumor activity, including melanoma lines B16, B16F, SK-MEL2 a MEL-3 (9.3, 12.4, 17.7 
and 3.7 mol/L; also see Tab. 4), and except for B16F, it is several times stronger than acid 1 
(Sarek et al., 2003). Corresponding allylic alcohol 91 and its methyl ether 92 had a similar 
acitivity of 20 mol/L on SK-MEL2 lines (Kim et al., 2001). 3,30-Diamino derivatives 
synthesized by (Mar et al., 2010) showed strong proapoptotic effect against panel of seven 
tumors lines, include SK-MEL-2. Derivative 93 was reported to have two times better 
cytotoxic effect against SK-MEL2 than acid 1 itself and furthermore this compound is highly 
hydrophilic and therefore it is easily applicable for in vivo tests (Mar et al., 2010). 
Finally, compounds formed by oxidative cleavage of the double bond 20(29) should be 
mentioned (Kim et al., 2001). Evaluated anti SK-MEL2 activity of platanic acid (39) (and its 
derivatives), obtained by the oxidative cleavage of the double bond using ruthenium 
tetraoxide (which provide mostly products expected from ozonolysis under standard 
conditions) was published in Kim’s study. Platanic acid (39), alcohol 94 and oxime 95 did 
not show significant cytotoxicity on SK-MEL2 (Kim et al., 2001). 
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2.2.2 Derivatives obtained by biotransformation procedures of betulinic acid (1) 
Several papers have described the biotransformation (Chatterjee et al., 1999, 2000; Kouzi et 
al., 2000) of betulinic acid (1) and the biological activity of those biotransformation products 
96 - 102. In Fig. 20, the biotransformation products of different bacterial strains are clearly 
shown. 
The bacterial biotransformation usually produces compounds that would be very difficult to 
obtain using classical chemical approaches. An example of such compounds is a group of 
hydroxyderivatives with hydroxyl groups in positions 1, 6, 7, 11 and 15, sometimes the 
hydroxylation is accompanied by an oxidation in position 3 or an esterification in position 
28 by the glucopyranosyl residue. Monohydroxyderivatives 99, 100, as well as betulonic acid 
(5) showed an order of magnitude better activity during cytotoxicity screening against the 
Mel-2 cancer line (pleural fluid) than betulinic acid (1) itself, whereas their activity against 
the Mel-1 cancer line (lymph node) was an order of magnitude worse. 1,7-
Dihydroxyderivative 102, 6,7-dihydroxyderivative 98, and 7,15-dihydroxyderivative 96 as 
well as 7-hydroxyderivative 97 (Kouzi et al., 2000) or glucopyranosyl ester 101 did not show 
any significant activity against either Mel-1 or Mel-2 cancer lines. 
These SARS studies of biotransformation products of acid 1 show that the hydroxylation of 
the lupane skeleton has a positive impact on antimelanoma activity only if it does not occur 
in position 7 or 15. Inactivity of -D-glucopyranosyl ester 101 is possibly caused by the 
difficulties with hydrolysis of this ester function. 
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Fig. 20. Biotransformation of betulinic acid (1) 
2.2.3 Triterpeoids with modification of lupane skeleton (at ring A or E) 
Oxidative modification and cleavage on A-ring of betulinic acid (1) 
A detailed study of the cytotoxicity of the products of oxidation of betulinic acid (1) on A-
ring was published in paper (Urban et al., 2004). The authors firstly oxidized betulinic acid 
(1) using chromium(VI) oxide to obtain betulonic acid (5) that was further oxidized with air 
or oxygen in the presence of potassium tert-butoxide in tert-butylalcohol. That way, either 
diosphenol 103 or lactol 105 was obtained. Diosphenol 103 was then oxidized with 
hydrogen peroxide in basic conditions to give A-seco triacid 106, reduction of this triacid 
afforded A-seco triol 107 and dehydratation of the same triacid gave a 7-membered 
anhydride 108 (Urban et al., 2004). Curiously, diosphenol 103 only occurs in its enolfom 
which had not been known before as some literature displays it as a diketone structure that 
actually does not exist. Derivatives of diosphenol 103, A-seco triol 107 and 7-membered 
anhydride 108 were the most cytotoxic active compounds from this group. Their 
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cytotoxicity was firstly measured on five cancer cell lines (none of them melanoma) and the 
active derivatives of diosphenol 103 was then tested on three more lines including human 
melanoma SK-Mel2. More recent tests of the diosphenol derivatives 104 against three 
melanoma lines in groups of Sarek and Hajduch resulted in activity about 7-10 times worse 
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Condensation reactions at A-ring 
This special chapter will discuss aldehydes and -ketoesters, the products of Claisen 
condensation of triterpenoid 3-oxoderivatives with formates and carbonates. Both aldehydes 
and -ketoesters are in their enolforms probably due to the boat conformation of the A-ring. 
Those -dicarbonyl compounds are a good starting material for synthesis of various 
heterocycles and for many other substitution reactions. A very complex evaluation of activity 
of A-homo derivatives was published in work (You et al., 2003). Probably the most interesting 
was 109 a cytotoxic lupane analogue of a promising anticancer drug CDDO, mainly because 
it’s structural motif seems to be the universal pharmacophor of the cytotoxicity in pentacyclic 
triterpenes (Suh et al., 1999; You et al., 2003). This derivative is the most active compound from 
a group of three very promising structures – chloroderivative 110, aldehyde 111, and nitrile 
109, which activities against melanoma cell lines SK-MEL-2 a B16-F10 were an order of 
magnitude better than the activity of betulinic acid (1) (You et al., 2003). These compounds are 
actually also an exemption from the rule that the 28-alkyl esters are inactive because prepared 
methyl esters are almost as active as free acids (You et al., 2003).  
Heterocyclic derivatives are another type of compounds with homologous carbon atoms 
bound to the A-ring of the terpenic skeleton (Kumar et al., 2008; Urban et al., 2007; You et al., 
2003). You et al. published results of the testing of cytotoxic activity of four isoxazole 
derivatives 112 – 115, prepared by a condensation of aldehydes with hydroxylamine against 
cell lines SK-MEL-2 a B16-F10. The isoxazoles were strongly cytotoxic only when 28-
carboxylic acid was free (compounds 112 and 114). In an article (Urban et al., 2007), a 
 
 



















































Fig. 20. Biotransformation of betulinic acid (1) 
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synthesis of triterpenoid pyrazines from betulonic (5) and dihydrobetulonic acid (75) and 
their cytotoxic activity on 9 cancer cell lines including SK-MEL2 was published. The 
compounds were obtained by a reaction of 3-oxoacids with ethylenediamine, followed by 
aromatization of the intermediate dihydropyrazine (Urban et al., 2007). Despite the fact that 
these pyrazines (e.g. 116) were more cytotoxic against many cancer cell lines than betulinic 
acid (1), they were four fold less active against the melanoma cell line SK-MEL2. A 
conclusion is ambiguous, a 2,3 annealing of a pyrazine cycle to the lupane skeleton increases 
the cytotoxic activity against some cancer cell lines while vanishes the activity against 
others, such as melanoma (Urban et al., 2007). Analogous quinoxalines (benzopyrazines) 
were inactive at all. Urban et al. also confirmed that there is a strong dependence of the 
cytotoxicity on the type of ester at 28 carboxylic group. As mentioned before, the Acm esters 
were generally as active as free acids. Another kind of heterocycles were described in work 
(Kumar et al., 2008), who prepared and performed a large SARS study with 2,3-annealed 
indole derivatives of betulinic (1) and betulonic acid (5), prepared by Fisher reaction. The 
article contains over 30 indole derivatives that were tested on a panel of 8 cancer cell lines, 
however, not including melanoma. Despite that, a general conclusion can be made that an 
introduction of the indol heterocycle to a terpene improves the cytotoxicity when both N-1 
and C-28 positions remain free. An exception from this assumption is the most active 
derivative 117 (Kumar et al., 2008) which is conjugated with glycine through C-28 but that is 








Modification of the ring E 
First semi-synthetic anticancer lupane and 18,19-seco lupane derivatives with modified 
ring E (referred to as Betulinines) to be published were compounds derived from 18-lupene 
that contained either intact E-ring and oxygen functional groups in the positions 21 and 22, 
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or cleaved E-ring and 18,19-diketone system (Sarek et al., 2003). The group of Betulinines 
contains several compounds with significant antitumor activity against wide range of cancer 
cell lines, including MDR and melanoma lines (SK-MEL-2 MEL-3, B-16, B-16F), diketones 
118, and 119 and triketone 126 were among the best. Diketone 118, which is on the other 
tumor lines much more active than the acid 1, has shown activity in melanoma lines about 
three times worse than acid 1; Tab. 2, 4 (Sarek et al., 2003). Compounds with pyrazine and 
quinoxaline heterocycle condensed to the E-ring were not as active as compounds 118, 119, 
and 126 (Urban et al., 2007). Last but not least, we should mention quaternary ammonium 
salt 120 was the most active. 
Taraxastane derivatives - heterobetulinic acid (121) and heterobetulonic acid (122) should be 
formally included in this chapter. The acid 121 was firstly isolated from Calyptranthes pallens, 
(Lobo-Echeverri et al., 2005) but it is also available synthetically from betulin (3) in five steps 
(Bradbury & Mingjun, 2007), which include a rearrangement of lupane skeleton to 
taraxastane. Heterobetulinic acid (121) showed antitumor activity against melanoma lines 
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Fig. 24. 
Des-E lupane derivatives 
Des-E lupane derivatives represent the ultimate synthetic step in the oxidative 
cleavage/degradation of the ring E of the 21,22-dioxolupane compounds using 
ruthenium(VIII) oxide. (Sarek et al., 2003) described several des-E-lupane compounds, most 
important are the -keto and -keto acids 123, 124 and methyleneketone 125. They are also 
named Betulinines. -Keto acid 124 (also called JS8) is the most promising anticancer drug 
within this group, based on the values of cytotoxic activity against more than 30 lines 
including MDR (the cytotoxicity was 1.28 mol/L for MEL-3, 4.3 mol/L for M14, and 1.16 
mol/L for SK-MEL-2; Tab. 4) (Sarek et al., 2003). It is essential to mention that, according to 
data from flow cytometry, JS8 causes selective apoptosis of tumor cells with rate comparable to 
the commercial cytostatic diterpenic drug paclitaxel. It was found that JS8 has a unique and 
new mechanism of action with primary target located in mitochondria. Compound JS8 is also 
very interesting from the chemical point of view, because it is a -keto acid that are known to 
be extremely unstable because they tend to decarboxylate spontaneously. Despite that, JS8 is 
relatively stable compound when stored at reduced temperature and it is probably due to a 
significant steric hindrance of the labile carboxyl group. As a tetracyclic pentanorlupane 
derivative, JS8 is very hydrophilic in comparison to the full-sized triterpenes, and so it is 
readily soluble in aqueous media (maximum solubility is 68 mg/mL) (Sarek et al., 2007). In 
conclusion, JS8 is highly antitumor compound, it has favorable solubility for the in vivo tests; 
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its structure, activity and manufacturing procedure has been patented (Fisher et al., 2003) and 
therefore it has a great chance to become an anticancer drug. Methyleneketone 125, one of the 
two degradation products of JS8, has similarly strong antitumor properties (activity against 
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3. Conclusions and future directions 
Despite the fact that betulinic acid (1) was first isolated in 1902, it took another forty years to 
solve its structure and to identify that several compounds obtained from natural sources by 
other research groups were identical to it. Trumbull et al. was the first to discover the 
interesting cytotoxic activity of betulinic acid (1) in 1976 when he studied a chloroform extract 
of Vauquelinia corymbosa against lymphocytic leukemia cells anti-P-388. He suggested that 
uvaol, ursolic acid, and betulinic acid (1) are the components responsible for the cytotoxicity. 
After that, it took another 19 years until Pisha et al. confirmed that the activity is caused by 
betulinic acid (1) and these authors were first to report that the cytotoxicity is selective against 
human melanoma cells. This fact sparked intensive research and gave the oncologists hope for 
the birth of a new drug to combat the insidious disease with steadily increasing incidence. 
During early 90th of the last century, the scientists stood at the starting line – they had a 
natural substance with a quite complicated structure and available only in limited quantities 
from precious natural sources, however, the compound had strong and selective activity 
against melanoma and very low toxicity. The main disadvantage seemed to be its 
unfavorable pharmacokinetic parameters. After solving the difficulties with the availability 
of acid 1 by developing its synthetic procedure from betulin (3), the use of betulinic acid (1) 
was given a real dimension. As a result, several hundred semi-synthetic lupane analogues 
were published up today, derivatives of betulinic acid (1), pulsatillic acid (2), and betulin (3), 
many of those showed significant anticancer effects. They are more hydrophilic and their 
pharmacokinetic profile is improved. Some of them were tested in vitro on activity against 
human or murine melanoma cells and three of them were tested in vivo. 
There are several tens of derivatives with promising activity against melanoma cells in vitro; 
the most significant are artificially modified compounds as pulsatillates 24 - 29; NVX-207 
(30); conjugates of acid 1 with amino acids 33, 36, 37; quaternary ammonium salts 40, 41 and 
46 – 53, 85; some glycosides (the best showed to be: 32, 58, 59 and 64); hemiphtalates 72, 74; 
carbamate 54; compounds with modified isopropenyl chain (acid 90, 93, methoxyderivative 
92 and alcohol 91); compounds with modified A-ring (most active were compounds that 
have an EWG group in the location 2 of the 3-oxo lupane skeleton or the EWG with a 
multiple bond in conjugation with 3-oxo group – the best are 109 – 112, 114 and 117); 
compounds with modified E-ring where active was diketone 118 and heterobetulinic acid 
(121); and finally, the des-E-derivatives JS8 (124) and methyleneketone 125. 
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Betulinic acid (1) itself is now in phase II of clinical trials against dysplastic nevus, 
compound NVX-207 (30) was tested on dogs with particularly good results and pulsatillate 
24 was successfully tested on the mice models. These in vivo data together with current 
industrial availability of betulinic acid (1) and a variety of its active derivatives with 
improved hydrophilicity and a reasonable solubility in water-based media gives this group 
of natural compounds high potential to become a new generation of cytostatic drugs to 
combat a malignant melanoma. 
4. Tables of activities 
Compound B16 B16-F1 MEL-1 MEL-2 
1 53.5 16.1 6.3 1.3
2 83.0 ── ── ──
3 ── 13.8 ── ──
5 ── ── 31.8 0.1
13 ── 210.1 ── 244.1
14 ── ── ── 160.0
15 ── 26.0 ── ──
16 ── ── ── 217.9 
17 ── ── ── NA
24 80.5 ── ── ──
25 72.9 ── ── ──
26 80.9 ── ── ──
27 66.0 ── ── ──
28 41.1 ── ── ──
29 63.2 ── ── ──
30 ── ── ── ──
31 ── ── NA NA
33 ── ── ── 2.9
34 ── ── ── 4.1
35 ── ── ── 6.8
36 ── ── ── 8.0
37 ── ── ── 18.1
38 - - - 12.7
42 ── >248 ── ──
43 ── >228 ── ──
44 ── >175 ── ──
55 ── ── ── 247.0
56 ── ── ── 223.7
58 ── 7.1 ── ──
59 ── 3.9 ── ──
60 ── 11.0 ── ──
68 ── ── ── 3.4
69 ── ── ── 3.4
70 ── ── ── 4.2
71 ── ── ── 3.7
72 ── ── ── 13.4
73 ── ── ── 24.9
74 ── ── ── 90.0
75 - - - 1.5
77 ── ── ── 2.4
78 ── ── ── 8.3
79 ── ── ── 1.3
80 ── ── ── 2.2
81 ── ── ── NA  
Table 1. 
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Compound B16-F1 MEL-1 MEL-2 M14-MEL
91 - - 18.0 -
92 - - 20.0 -
93 - - 3.0 -
96 - NA NA -
97 - 14.1 14.1 -
98 - 21.5 33.3 -
99 - NA 0.5 -
100 - NA 0.4 -
102 - NA NA -
103 - - 23.0 -
109 2.7 - 1.5 -
110 3.0 - 0.21 -
111 0.55 - 0.50 -
112 6.1 - 31.2 -
114 3.1 - 2.2 -
116 - - 98.0 -
118 67.9 - 65.3 -
119 NA - NA -
123 11.5 - 19.9 -
124 0.4 - 1.2 4.3
125 0.7 - 2.1 -






Compound 518A2 Colo38 Bro WM3211 WM793
15 28.8 ── ── ── ──
30 2.6 ── ── ── ──
46 ── ── ── 0.6 2.5
47 ── ── ── 0.7 1.3
48 ── ── ── 0.3 1.9
49 ── ── ── 0.6 0.8
50 ── ── ── 0.3 0.5
51 ── ── ── 0.5 0.5
52 ── ── ── 0.4 0.4
53 ── ── ── 0.5 0.5
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82 17.8 ── ── ── ──
83 51.5 ── ── ── ──
84 16.7 ── ── ── ──
85 ── ── ── 2.6 5.7
87 ── 10 10 ── ──
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116 41.2 14.7 6.3
118 15.8 14.7 11.3
121 6.2 4.6 3.5
122 45.8 13.9 6.4
124 4.9 3.5 3.8
125 4.3 3.5 3.4  
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Table 1-4: Table 1-3 - cytotoxicity (IC50 in µM) of published compounds against melanoma 
cell lines; Table 4 - cytotoxicity (IC50 in µM) selected semisynthetic lupane derivatives 
against melanoma cell lines which are part of the NCI60 cell lines panel and are therefore 
well characterized and further studied, e.g. cell line M14 is bearing the mutated p53 protein. 
NA is not active. 
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1. Introduction 
Melanoma is one of the most deadly forms of skin cancer. The incidence of melanoma has 
been steadily increasing over the last several decades. It is estimated that in 2010 68,130 adults 
were diagnosed with melanoma, and 8,700 patients died of this disease (Jemal et al.). 
Melanoma is highly curable when it is diagnosed at early stages. However, patients with 
distant metastases have a median overall survival of only 6-8 months (Balch et al. 2009). 
Chemotherapy regimens have not improved survival in patients with metastatic melanoma, 
and immunotherapies have generally benefited only a small percentage of patients (Koon and 
Atkins 2006). Thus, there is a critical need to develop more effective therapeutic approaches 
for this disease. Recently, dramatic results have been reported with agents that specifically 
target proteins or pathways that are aberrant in this disease, such as BRAF and c-KIT (Flaherty 
et al. ; Hodi et al. 2008). These results support the rationale for continued investigation into the 
molecular events that characterize and contribute to melanoma. This review will describe 
existing knowledge about several of the molecules and pathways that have been implicated in 
melanoma, and review the results of clinical studies focused on these targets.  
2. Melanoma molecular targets 
Melanoma has traditionally been classified based on the clinical and pathological features of 
the tumor. The most commonly observed type of melanoma is cutaneous melanoma (CM), 
arising from skin with either intermittent or chronic sun exposure. While ultraviolet 
radiation likely has a significant causative role in these tumors, its role in certain other 
subtypes is less clear. Cutaneous melanomas can arise in areas with limited sun/UV 
radiation exposure such as palms, soles and the area under nails (acral lentiginous 
melanoma). Other melanomas arise from mucosal surfaces of the body, including the upper 
aerodigestive, gastrointestinal, and genitourinary tracts, and are termed mucosal 
melanomas. Melanomas also originate from melanocytes in the uveal tract of the eye 
(uveal/ocular melanoma). In addition to anatomic differences, recent research has 
demonstrated that the different melanoma subtypes are characterized by distinct regions of 
DNA copy number gain and loss (Curtin et al. 2005). This finding suggested that each of 
these tumor types could be characterized by distinct molecular mechanisms, a hypothesis 
that is also supported by the marked variance of recently described oncogenic mutations 
across the different melanoma subtypes.  
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2.1 RAS/RAF/MAPK pathway 
The RAS/RAF/MAPK cascade is a critical growth and survival signaling pathway in cells. 
The pathway is generally triggered by activation of cell surface receptor(s) [i.e., receptor 
tyrosine kinases (RTK), G-protein coupled receptors (GPCR), etc] following ligand binding 
or cell-to-cell contact. The receptors induce activation of RAS through guanine exchange 
factors (GEFs), which promote the exchange of RAS-GDP to RAS-GTP. GTP-bound RAS 
recruits and activates the RAF (A-, B- and C-RAF) family of serine-threonine kinases, which 
then phosphorylate and activate Mitogen Activated Kinase Kinase [MAPKK or MAP/ERK 
kinase (MEK)]. Phosphorylated MEK, which is also a kinase, activates the downstream 
Extracellular Regulatory Kinase (ERK1/2 or P44/42 MAPK) through phosphorylation. Once 
activated, ERK translocates to the nucleus where it regulates the expression of several genes 
involved in differentiation, survival and proliferation by phosphorylating transcription 
factors such as ETS, MYC etc. The MAPK pathway also regulates the apoptotic machinery in 
cells through post-translational regulation of BAD, BIM, MCL-1 and BCL-2 proteins 
(George, Thomas, and Hannan).  
In addition to RAF, the RAS proteins activate several other effectors that contribute to the pro-
survival and proliferative phenotype, including phospholipase C (PLC), phosphatidyl inositol-
3-Kinase (PI3K), Ral, Rac and Rho-GTPases. Mutations in the RAS family genes (HRAS, NRAS 
and KRAS) have been detected in approximately one-third of all cancers, including pancreatic, 
colon, leukemia and thyroid cancers (Bos et al. 1987; Bos et al. 1985; Almoguera et al. 1988; 
Forrester et al. 1987; Padua, Barrass, and Currie 1985). Activating mutations of RAS have been 
reported in 15-20% of melanomas, and almost exclusively involve the NRAS isoform (Tsao et 
al. 2000). NRAS mutations are highly conserved in melanoma, as over 90% of the detected 
mutations occur in codons 12, 13 and 61 (Hocker and Tsao 2007).   NRAS mutations occur in 
26% of cutaneous and 14% of mucosal melanomas, but only in 4% of acral and less than 1% of 
uveal melanomas (Hocker and Tsao 2007). Mutant RAS proteins have very little GTPase 
activity,  and thus remain constitutively active. This results in aberrant regulation of its 
downstream signaling pathways and subsequent uncontrolled cell proliferation and survival. 
RAS also promotes suppression of p16INK4a and p53 in melanoma models, and knockdown of 
mutated H-RAS (H-RasV12G) using siRNAs in an doxycycline inducible melanoma mouse 
model resulted in tumor regression (Chin et al. 1997; Chin et al. 1999).  
Activating mutations in the serine/threonine kinase BRAF were first reported by Davies and 
colleagues in 2002, who demonstrated in a small cohort of tumors and cancer cell lines that 
66% of melanomas harbored somatic mutations in BRAF, which were also detected in 
smaller fractions of gliomas, colon and ovarian cancer samples. A recent meta-analysis 
reported BRAF mutations in 43% of melanoma clinical specimens and 65% of human 
melanoma cell lines (Hocker and Tsao 2007). BRAF mutations were detected most frequently 
in cutaneous melanomas (42.5%), but were markedly less common in acral (18.1%), mucosal 
(5.6%), and uveal (<1%) melanomas. Some studies have also reported significantly lower 
rates of BRAF mutations in cutaneous melanomas with chronic sun damage (Curtin et al. 
2005), but this has not been recapitulated in other studies (Handolias, Salemi et al. 2010). 
Approximately 40 different BRAF mutations have been identified in melanoma. The most 
frequent mutation (approximately 90% of mutations in clinical samples) arises due to a 
T→A transversion in position 1799 of the BRAF gene (T1799A) resulting in the substitution 
of glutamic acid for valine at position 600 (BRAFV600E) of the BRAF protein acid, which has 
markedly increased catalytic activity compared to the wild-type BRAF protein (Davies et al. 
2002; Wan et al. 2004; Hocker and Tsao 2007). Interestingly, some of the BRAF mutations 
that have been detected in cancer do not increase the catalytic activity of the BRAF protein, 
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but still result in hyperactivation of MEK and ERK through efficient dimerization with other 
RAF isoforms (Garnett et al. 2005; Heidorn et al. 2010). 
In melanoma, activating BRAF and NRAS mutations are almost always mutually exclusive, 
but overlap can occur with non-activating BRAF mutations (Heidorn et al. 2010; Tsao et al. 
2004). While BRAF mutations are extremely common in melanoma, there is significant 
evidence that they must be complemented by additional genetic events in melanomagenesis. 
Pollock et al (2002) reported that the BRAFV600E mutation is detectable in 82% of benign nevi, 
which have virtually no malignant potential. In addition, expression of the BRAFV600E 
mutation alone in melanocytes failed to induce transformation in several preclinical models, 
including zebrafish and mice (Patton et al. 2005). Invasive lesions were only seen when 
other molecules were inactivated concurrently, such as p16/Ink4a, p53, and PTEN or p53 
(Dankort et al. 2009; Chudnovsky et al. 2005).  
The dual specificity kinases MEK1/2 that lie downstream of BRAF are activated in majority of 
the cancers with deregulated RAS/RAF/MAPK signaling. The MEK kinases phosphorylate 
ERK1/2 downstream and mediate cell survival signaling through MAPK signaling cascade. 
Emery et al. (2009), using random mutagenesis and massive parallel sequencing approaches 
identified mutations in the drug binding and regulatory domains of MEK1 kinase that led to 
increased phosphorylation of ERK and a MEK inhibitor-resistance phenotype. Subsequently, 
MEK1 point mutations P124L and C121S have been detected in melanoma patients who 
progressed after initial clinical responses to MEK or BRAF inhibitors (Wagle et al. ; Emery et al. 
2009). To date no MEK1 or MEK2 mutations have been reported de novo in melanoma. 
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2.1 RAS/RAF/MAPK pathway 
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but still result in hyperactivation of MEK and ERK through efficient dimerization with other 
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identified mutations in the drug binding and regulatory domains of MEK1 kinase that led to 
increased phosphorylation of ERK and a MEK inhibitor-resistance phenotype. Subsequently, 
MEK1 point mutations P124L and C121S have been detected in melanoma patients who 
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2.2 PI3K/AKT/mTOR pathway 
The PI3K/AKT/mTOR pathway is one of the most important intracellular signaling 
pathways. The pathway regulates many important cellular processes, including proliferation, 
differentiation, motility, metabolism, survival, invasion and intracellular transport (Engelman, 
Luo, and Cantley 2006). The Phosphatidyl Inositol-3 Kinases (PI3K) are a family of lipid 
kinases that are composed of an adaptor/regulatory subunit (i.e. p85) and a catalytic unit (i.e. 
p110). Similar to RAS/RAF/ERK, the PI3K/AKT/mTOR pathway is activated by a variety of 
signals, including receptor tyrosine kinases and RAS proteins. Activation of PI3K results in 
phosphorylation of phosphatidylinositols in the cell membrane at the 3’-hydroxyl group. This 
reaction generates the lipid species PI (3,4)P2 and PI(3,4,5)P3. PI (3,4)P2 and PI(3,4,5)P3 act as 
second messengers, recruiting proteins that contain a pleckstrin homology (PH) domain to the 
cell membrane, such as the serine/threonine kinases AKT and PDK1. Upon recruitment to the 
cell membrane, AKT is phosphorylated at two critical residues, serine 473 and threonine 308. 
Once phosphorylated, the activated AKT translocates to the cytosol where it promotes cell 
proliferation and survival by phosphorylating numerous substrate proteins including mTOR, 
GSK3, FOXO, and BAD, among others. 
The activity of the PI3K/AKT/mTOR pathway is normally controlled by the lipid 
phosphatase PTEN (Phosphatase and Tensin Homolog), which dephosphorylates  
phosphatidyl inositols (PI) at the 3’ position, thereby inhibiting PI3K-mediated signaling 
(Maehama and Dixon 1998). PTEN, which is a tumor suppressor, is inactivated in a variety of 
tumor types, through both genetic and epigenetic mechanisms (Li et al. 1997; Myers et al. 1998; 
Mirmohammadsadegh et al. 2006). Tumors with loss of PTEN are characterized by markedly 
increased basal activation of AKT (Davies et al. 1999; Davies et al. 1998; Davies et al. 2009). 
In melanoma, PTEN loss is observed in up to 20% of tumors and 30% of melanoma cell lines  
(Tsao et al. 1998; Tsao, Mihm, and Sheehan 2003; Tsao et al. 2000). This prevalence is 
primarily defined for cutaneous melanomas; the prevalence in other subtypes is poorly 
described. Similar to BRAF, loss of PTEN appears to be mutually exclusive with the 
presence of an NRAS mutation in melanoma tumors and cell lines. While this pattern 
suggests functional redundancy, quantitative analysis of AKT activation demonstrated that 
PTEN loss correlated with significantly higher levels of phosphorylated AKT than NRAS 
mutations in both clinical specimens and cell lines (Davies et al. 2009). In contrast to NRAS, 
PTEN loss frequently occurs in melanomas with a concurrent activating BRAF mutation 
(Tsao et al. 2000; Goel et al. 2006; Tsao et al. 2004). The functional nature of this pattern is 
supported by mouse studies, which demonstrated that crossing mice with the BRAFV600E 
mutation in melanocytes with mice that harbour PTEN loss resulted in frankly invasive and 
metastatic melanomas, which did not occur with either lesion alone (Dankort et al. 2009). 
In addition to loss of PTEN, the PI3K/AKT/mTOR pathway may also be activated by gene 
amplifications and gain of function mutations in other pathway components. Rare activating 
mutations in PI3KCA have been detected in 2-3% of melanomas (Omholt et al. 2006). Studies 
by Stahl et al, identified activation of AKT3 in 43 to 60% of sporadic melanomas, which was 
associated with an increase in copy number of the AKT3 gene along with a simultaneous 
decreased activity of PTEN, either due to loss or haploinsufficiency of the PTEN gene. 
Knockdown of AKT3 by siRNA induced apoptosis and reduced melanoma tumor 
development (Stahl et al. 2004). Davies et al recently also reported rare gain of function point 
mutations in the regulatory pleckstrin homology domains of AKT1 and AKT3 (AKT1 E17K, 
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AKT3  E17K) in ~2% melanoma cell lines and tumor specimens (Davies et al. 2008). Every 
melanoma with an AKT1 or AKT3 mutation also had a concurrent BRAF mutation. 
2.3 Receptor tyrosine kinases 
Activating mutations or amplifications of receptor tyrosine kinases are implicated in 
multiple tumor types, including gastrointestinal stromal tumors (GIST) (c-KIT), breast 
(HER2/neu), and lung (EGFR) cancers. However, until recently there has been little evidence 
of significant aberrations in melanoma. The relatively low rate of BRAF and NRAS 
mutations in non-cutaneous melanomas led to focused searches for other oncogenic drivers 
in these tumor types. Comparative genome hybridization (CGH) analysis identified 
selective amplification of the 4q12 chromosomal region in acral and mucosal melanomas 
(Curtin et al. 2005). Detailed analysis of the genes in this region identified focal 
amplifications of the c-KIT gene (Curtin et al. 2006). C-KIT is a receptor tyrosine kinase 
which is affected by activating mutations in ~80% of GISTs (Hirota et al. 1998). Subsequent 
to the discovery of gene amplifications, sequencing demonstrated that the c-KIT gene is also 
frequently mutated in the same melanoma subtypes in which amplifications had been 
detected(Curtin et al. 2006). Overall, c-KIT gene amplification or mutation was identified in 
39% of mucosal and 36% of acral melanomas. Among cutaneous melanomas, c-KIT gene 
alterations were also detected in 28% of cutaneous melanomas with chronic sun damage 
(CSD), but no c-KIT gene aberrations were reported in cutaneous melanomas without CSD 
(Curtin et al. 2006). However, other studies have reported lower rates of c-KIT alterations in 
cutaneous melanomas with CSD (Handolias, Salemi et al. 2010). The mutations in c-KIT gene 
generally affect the same exons that are mutated in GIST, although the distribution in 
melanoma shows a higher prevalence of mutations in exons associated with resistance to 
many c-KIT inhibitors. Interestingly, while most c-KIT mutations in GIST are short 
insertions or deletions, the overwhelming majority of changes in melanoma are point 
mutations, with the most common event being the L576P substitution at exon 11 of the 
juxtamembrane region (Beadling et al. 2008). The finding of activating c-KIT mutations was 
surprising, as previous reports had demonstrated that although c-KIT is essential for the 
development of normal melanocytes, c-KIT activation suppressed the growth of melanoma 
cells, and melanoma progression was associated with loss of c-KIT expression (Huang et al. 
1996; Lassam and Bickford 1992). However, the lack of mutations in c-KIT in cutaneous 
melanomas suggests that other lineage-specific genetic or environmental factors in the non-
cutaneous melanocytes may critically interact with the c-KIT mutations. 
More recently, high-throughput sequencing analysis of all protein kinases identified novel 
somatic mutations in 19 different genes (Prickett et al. 2009). The most frequently mutated 
gene was ERBB4 (24 missense mutations in 15 patients; 19% prevalence in the cohort), which 
encodes a receptor tyrosine kinase that is a member of the epidermal growth factor receptor 
family (EGFR, HER2, HER3). ERBB4 mutations have previously been reported in lung, 
colon, stomach and breast cancers (Soung et al. 2006; Ding et al. 2008). Interestingly, the 
mutations in the melanomas were distributed throughout the entire ERBB4 gene. Despite 
this unusual pattern for an activating event, Pickett et al., found that every tumor-derived 
mutation ERBB4 tested had higher levels of receptor tyrosine kinase activity, promoted 
anchorage independent growth, and induced cellular transformation (Prickett et al. 2009). In 
contrast to the distinct patterns seen with other mutations, ERBB4 mutations were not 
mutually exclusive with BRAF or NRAS mutations. Further investigation is needed to gain a 
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cutaneous melanocytes may critically interact with the c-KIT mutations. 
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mutually exclusive with BRAF or NRAS mutations. Further investigation is needed to gain a 
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better understanding of the role of ERBB4 in melanoma, and to understand the therapeutic 
potential of inhibitors against this target. 
2.4 G proteins 
Heterotrimeric guanine nucleotide-binding proteins (G proteins) are a diverse family of 
proteins that regulate and propagate signals from G-Protein Coupled Receptors (GPCRs) 
that are expressed at the cell membrane. The complex of G-proteins and GPCRs activate 
several key signaling pathways involved in cell survival, proliferation, and transformation. 
There is growing evidence that this family of genes may play a significant role in certain 
subtypes of melanoma. 
A role for G proteins in melanoma was first suggested by a preclinical study that was designed 
to identify genes that promote melanin synthesis and pigmentation in mice. Two different G 
protein alpha subunits, GNAQ and GNA11, were identified in this screen (Van Raamsdonk et 
al. 2004). In order to determine the clinical relevance of these genes in patients, panels of 
melanomas and nevi were then screened for alterations in these genes. Remarkably, point 
mutations in GNAQ were identified in ~50% of primary uveal melanomas (Onken et al. 2008; 
Van Raamsdonk, Bezrookove, Green, Bauer, Gaugler, O/'Brien et al. 2009). GNAQ mutations 
were also identified in 50-80% of blue nevi, and in 6% of rare lesions called nevi of Ota, which 
are associated with an increased risk of uveal melanoma (Van Raamsdonk, Bezrookove, 
Green, Bauer, Gaugler, O/'Brien et al. 2009). In contrast, no GNAQ mutations were identified 
in cutaneous melanomas without chronic sun damage, acral melanomas, or mucosal 
melanomas; 1 of 27 cutaneous melanomas with chronic sun damage tested had a mutation. 
Further sequencing identified point mutations of GNA11 in 32% of primary uveal melanomas, 
all of which were mutually exclusive with GNAQ mutations (Van Raamsdonk et al. 2010). 
Interestingly, analysis of a cohort of uveal melanoma metastases identified a higher prevalence 
of GNA11 (56%) than GNAQ (22%) mutations. Overall, somatic  mutations in GNAQ and 
GNA11 were detected in over 80% of all uveal melanomas analyzed (Van Raamsdonk, 
Bezrookove, Green, Bauer, Gaugler, O'Brien et al. 2009).  
Over 90% of the reported mutations in GNAQ and GNA11 affect the Q209 residue. This 
occurs in a RAS-like domain of these proteins, and is specifically analogous to the Q61 
residue that is the most common site of point mutations in the RAS gene. Functional studies 
of the Q209L mutation in both GNAQ and GNA11 demonstrated that this mutation 
promotes anchorage independent growth, tumorigenicity, and activation of the 
RAS/RAF/MAPK pathway (Van Raamsdonk, Bezrookove, Green, Bauer, Gaugler, O/'Brien 
et al. 2009; Van Raamsdonk et al. 2010). These findings suggest that these mutations may 
obviate the requirement for BRAF or NRAS mutations, which are virtually non-existant in 
uveal melanomas (Cohen et al. 2003; Rimoldi et al. 2003). Studies to determine the various 
functions of GNAQ and GNA11 mutations in uveal melanoma, and determine the 
therapeutic potential of inhibiting these genes or their effectors, are currently ongoing. 
In addition to these mutations in uveal melanoma, high-throughput sequencing for 
mutations in G protein family members in cutaneous melanomas identified 18 non-
synonymous somatic mutations in G protein subunits spanning seven genes (Cardenas-
Navia et al.). Mutations were identified in GNA12, GNG10, GNAZ, GNG14, GNA15, GNA11, 
and GNB3 (Cardenas-Navia et al.). Further work needs to be done to understand the 
pathways and processes affected by these mutations.  
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2.5 Other affected genes  
Alterations in several regulators of cell cycle progression have also been implicated in 
melanoma. Allelic alterations in CDK4 and CCND1 have been reported in melanoma (Curtin et 
al. 2005; Smalley et al. 2008). Inactivation of the tumor suppressor p53, which is associated with 
DNA damage and metabolic stress, has also been reported. (Yang, Rajadurai, and Tsao 2005; 
Jonsson et al. 2007). P53 may also be functionally inactivated by loss of function of 
p16INK4a/p14ARF genes (Pomerantz et al. 1998; Stott et al. 1998; Zhang, Xiong, and Yarbrough 
1998). Loss of function of p16INK4a/p14ARF is present in most familial melanomas (Cannon-
Albright et al. 1992; Goldstein et al. 2007). Loss of both p16 and p14 is seen in both melanoma 
cell lines and primary tumors and is a selection factor for the survival of melanoma cells in 
vitro (Daniotti et al. 2004; Rakosy et al. 2008). However, currently there are no therapies in 
place to restore the expression of these tumor suppressors.  
A comparative genetic analysis of melanomas with other tumor types identified selective 
amplifications of the gene encoding the microphthalmia-associated transcription factor 
(MITF) in melanoma (Garraway et al. 2005). MITF is a transcription factor that regulates 
many genes associated with melanin production and melanocyte development (Levy, 
Khaled, and Fisher 2006). Initial studies demonstrated the MITF could function as an 
oncogene, and was able to cooperate with the mutant BRAF gene to induce transformation 
of normal melanocytes (Garraway et al. 2005). Amplification of the MITF locus occurs in 10-
20% melanomas, and subsequent studies have also detected rare somatic mutations in the 
gene in melanomas (Cronin et al. 2009).  
3. Clinical targeting of activated pathways in melanoma 
The treatment of many cancers has changed dramatically due to an improved 
understanding of the genes and pathways that contribute to the aggressive nature of many 
of these diseases. The discovery of activating events in kinase signaling pathways in 
melanoma rapidly led to clinical testing of a number of targeted therapies for this disease. 
The early results illustrate both the promise and challenge of this strategy.  
3.1 The RAS/RAF/MAPK pathway 
The high prevalence of mutations in components of the RAS/RAF/MAPK pathway in 
melanoma, particularly in the most common subtype (cutaneous), strongly supports the 
rationale to test the clinical efficacy of drugs against it. After the discovery of activating BRAF 
mutations (Davies et al. 2002), the first drug against the pathway to be tested clinically was 
sorafenib. Sorafenib is a small molecule that inhibits a number of kinases, including BRAF, 
CRAF, vascular endothelial growth factor receptor (VEGFR), platelet derived growth factor 
receptor (PDGFR), and c-Kit (Strumberg 2005). Preclinical studies demonstrated that sorafenib 
slowed the growth of melanoma xenografts with activating BRAF mutations, but did not result 
in tumor eradication (Karasarides et al. 2004). Subsequently, in a single-agent phase II trial, 
treatment with sorafenib resulted in only 1 clinical response among 34 evaluable patients 
(Eisen et al. 2006). More promising results were observed in a phase I trial that tested the safety 
of combined treatment with sorafenib, carboplatin, and paclitaxel. Ten clinical responses were 
observed, all of which occurred in patients with metastatic melanoma [n=24; 40% overall 
response rate (ORR)] (Flaherty et al. 2008). Of note, the clinical benefit among the melanoma 
patients did not correlate with the presence of activating BRAF mutations. Despite these 
promising results, a subsequent randomized phase III trial of treatment with carboplatin and 
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better understanding of the role of ERBB4 in melanoma, and to understand the therapeutic 
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2.5 Other affected genes  
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receptor (PDGFR), and c-Kit (Strumberg 2005). Preclinical studies demonstrated that sorafenib 
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(Eisen et al. 2006). More promising results were observed in a phase I trial that tested the safety 
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response rate (ORR)] (Flaherty et al. 2008). Of note, the clinical benefit among the melanoma 
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paclitaxel with or without sorafenib definitively showed that sorafenib did not improve the 
ORR or progression-free survival (PFS) that was achieved with the chemotherapy agents alone 
(Hauschild et al. 2009). Combined with preclinical studies that showed the high prevalence of 
BRAF mutations in benign nevi, and induction of cellular senescence only following 
expression of mutant BRAF in normal melanocytes, these results raised doubts about the value 
of BRAF as a therapeutic target. 
The identification of mutant BRAF as a therapeutic target in melanoma has now been 
confirmed by clinical trials with potent, selective second-generation BRAF inhibitors. 
PLX4032 (vemurafenib) is a small molecule that has an in vitro IC50 for the BRAFV600E 
protein of ~ 10 nM. This is one log lower than the IC50 for the wild-type BRAF protein, and 
2-3 logs lower than the IC50 for other related kinases (Tsai et al. 2008). Experiments in 
xenografts models demonstrated that PLX4720, a closely related compound used for 
preclinical studies, eradicated melanomas with a BRAFV600E mutation (Yang et al. 2010). 
More importantly, the phase I trial of PLX4032 in patients with advanced melanoma 
reported an unconfirmed ORR of 81% among patients with the BRAFV600E mutation 
(Flaherty et al. 2010). The selectivity of the agent in vivo is supported by the relatively mild 
toxicity of the drug, which was well-tolerated by patients. In addition, no clinical responses 
were observed in the 5 patients included in the trial who had a wild-type BRAF gene. In fact, 
4 of those patients demonstrated clinical progression of disease at their initial restaging. This 
clinical finding is consistent with work in preclinical models that demonstrated that 
treatment of human melanoma cell lines with a wild-type BRAF gene with PLX4720 and 
other selective BRAF inhibitors resulted in hyperactivation of MEK and MAPK, and 
increased growth of cancer cells in vitro and in vivo (Halaban et al. 2010; Hatzivassiliou et al. 
2010; Heidorn et al. 2010; Poulikakos et al. 2010). A second selective inhibitor of the 
BRAFV600E protein, GSK2118436, has demonstrated similar activity, with a 62% ORR in phase 
I testing in advanced melanoma patients with a BRAF mutation (Kefford et al. 2010). 
While the high response rate with minimal toxicity with PLX4032 and GSK2118436 is 
unprecedented, it is now becoming clear that resistance will be a major problem with these 
agents. In the phase I trial of PLX4032, virtually all patients who responded clinically went 
on to develop disease progression, with a median duration of response of approximately 7 
months (Flaherty et al. 2010). While the experience with resistance to targeted therapies in 
other diseases made it reasonable to hypothesize that secondary BRAF mutations could 
cause this, to date the analysis of tumors and cell lines with secondary resistance to selective 
BRAF inhibitors have failed to identify any such mutations (Nazarian et al. 2010; Villanueva 
et al. 2010). Instead, cells lines and tumors have developed changes that either maintain 
activation of the RAS/RAF/MAPK pathway in the presence of the BRAF inhibitors, or 
changes that allow cells to survive even when that pathway is inhibited. Mechanisms that 
result in continued activation of the RAS/RAF/MAPK pathway include (1) concurrent 
NRAS or MEK1 mutation (Nazarian et al. 2010; Wagle et al.), (2) induction of the serine-
threonine kinase COT1 (Johannessen et al. 2010), or (2) utilization of all 3 RAF isoforms to 
activate MEK (Villanueva et al. 2010). Mechanisms that result in resistance to cell killing 
despite continued inhibition of MEK and MAPK generally implicate activation of the PI3K-
AKT pathway, either through the increased expression of receptor tyrosine kinases or 
through the loss of PTEN (Nazarian et al. 2010; Villanueva et al. 2010). Activation of the 
PI3K-AKT pathway by loss of PTEN also results in de novo resistance to cell killing by BRAF 
inhibitors, but the relationship between PTEN loss and clinical responsiveness in patients 
has yet to be determined (Paraiso et al. 2011). 
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In addition to BRAF inhibitors, MEK inhibitors have shown promise in the treatment of 
metastatic melanoma. The initial presentation of the preliminary results of the phase I trial 
of GSK1120212, an orally available MEK inhibitor with a very long half life, reported a 40% 
ORR response among patients with metastatic melanoma (Infante et al. 2010). This response 
rate is higher than previous reports with other MEK inhibitors, such as AZD6244 (Dummer 
et al. 2008). Preclinical studies demonstrated that, similar to the results with BRAF 
inhibitors, loss of PTEN correlates with increased resistance to cell killing by MEK inhibitors 
(Gopal et al. 2010). Interestingly, several cells with normal PTEN expression but similar 
resistance developed activation of the PI3K-AKT pathway following treatment with MEK 
inhibitors. This compensatory mechanism, which was mediated by the insulin-like growth 
factor-1 receptor, gives further support to the rationale for testing the effects of targeted 
therapy combinations to improve clinical results with both BRAF and MEK inhibitors. 
3.2 c-KIT 
Imatinib, a small molecule inhibitor of a number of kinases, is approved by the FDA for the 
first-line treatment of metastatic GISTs, which are characterized by a high (~80%) prevalence of 
activating mutations in the c-KIT gene. This clinical experience gave cause for optimism for the 
use of imatinib in melanoma, a mesenchymal tumor like GIST with very poor responsiveness to 
cytotoxic chemotherapies. Prior to the identification of c-KIT mutations in acral and mucosal 
melanomas, three different phase II trials with imatinib were conducted in advanced melanoma 
patients (Kim et al. 2008; Ugurel et al. 2005; Wyman et al. 2006). The cumulative ORR was only 
1.5% for these trials. However, the patients overwhelmingly consisted of patients with 
cutaneous primary melanomas, and thus were unlikely to harbor activating c-Kit mutations. 
There are now several case reports describing impressive clinical responses to c-KIT inhibitors 
in melanoma patients with mutations in the c-KIT gene (Handolias, Hamilton et al. 2010; Hodi 
et al. 2008). In addition, relatively large clinical trials are ongoing testing the efficacy of c-KIT 
inhibitors in this patient population. An initial report from one of the imatinib trials reported 
an ORR of approximately 50% among patients with c-KIT mutations, but 0 of 10 patients with 
only gene amplification of the wild-type gene responded (Fisher et al. 2010). In addition, while 
c-KIT inhibitors have induced some durable responses, other dramatic responses have lasted 
for only a few months (Woodman et al. 2009). Thus, the further development of therapies for 
melanoma patients with c-KIT mutations will likely require an improved understanding of 
mechanisms of resistance to these agents, and combinatorial approaches. 
 
Affected Gene Subtypes Affected Classes of Inhibitors 
BRAF Cutaneous >> Acral > Mucosal 
Selective BRAF inhibitors 
Non-Selective BRAF Inhibitors 
MEK inhibitors 




Dual PI3K/mTOR inhibitors 
mTORC1/2 inhibitors 
c-KIT Mucosal > Acral >> Cutaneous c-KIT inhibitors 
ERBB4 (Undefined) HER-family inhibitors 
GNAQ, GNA11 Uveal MEK inhibitors 
Table 1. Molecular Targets in Melanoma 
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The testing and treatment of melanoma patients is evolving rapidly due to an improved 
understanding of the genes and pathways that are genetically altered in this disease. The 
dramatic responses of melanoma patients with BRAF and c-KIT mutations to inhibitors 
against these targets demonstrate the power and benefit of research to uncover the 
underpinnings of cancer. However, the early experience with these targets has also 
illuminated the challenges of this approach.  
There is a clear need to improve our understanding of the factors that are present at baseline 
that allow resistance to occur to BRAF and c-KIT inhibitors, as well as changes that evolve 
over time to manifest the resistance. An improved understanding of pre-treatment factors 
that facilitate the eventual emergence of resistance may suggest rational combinatorial 
approaches that can prevent resistance from developing. Such factors may also serve as 
markers that clinically distinguish patients who need combinatorial treatments, which are 
likely to incur additional toxicities, from those who may achieve significant benefit from 
single-agent therapy. Similarly, determining the changes that evolve over time and correlate 
with functional resistance will also suggest rational combinatorial approaches that can be 
used after single-agent therapies fail. While it is reasonable to hypothesize that many of the 
critical mechanisms that underlie resistance will involve changes in signaling pathways in 
the tumors, the possibility of other factors should not be dismissed. For example, recent 
research has demonstrated that targeted therapies against the RAS/RAF/MAPK pathway 
can influence both the ability of immune cells to recognize melanomas, and their 
proliferation and survival (Boni et al. 2010). As immunotherapies have been associated with 
relatively low response rates but durable benefit when they occur, it is possible that 
strategies that combine such approaches with targeted therapies may have synergistic 
clinical benefit. 
While there are now clearly defined challenges for patients with BRAF and c-KIT mutations, 
the picture remains much less clear for other patients. To date, effective treatment strategies for 
tumors with mutations in RAS family members have not been validated clinically. Research 
clearly needs to be undertaken to develop such approaches for patients with NRAS mutations, 
and perhaps the analogous mutations in GNAQ and GNA11 in uveal melanomas. 
Furthermore, a significant number of patients (i.e. ~30% of cutaneous melanomas) do not have 
a detectable mutation in BRAF, NRAS, or c-KIT. As has been described here, the number of 
other mutations that have been identified in melanoma is now rapidly increasing, but the 
functions and therapeutic implications of many of these events remain poorly characterized. It 
is highly likely that many more events will be identified in the future, as the first whole-
genome sequencing effort revealed almost 200 non-synonymous coding region substitutions in 
a single patient-derived melanoma (Pleasance et al. 2010). Unraveling the functional 
interactions and significance of the multiple mutations that are present in each tumor will 
require extensive testing and innovation. In addition, additional pathways, such as 
metabolism, oxidative stress, and angiogenesis likely play key functional roles, and may be 
important therapeutic targets without being directly involved by genetic alterations. 
Overall, recent discoveries have provided new hope and therapeutic options for patients 
with melanoma. These advances highlight the potential of translational research, and 
provide the impetus for continued research of this highly aggressive disease. 
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1. Introduction  
Cutaneous metastatic melanoma management has recently approached the age of 
individualized therapy (Romano et al., 2011). The discovery that the 1799T>A point 
mutation in the BRAF oncogene (BRAFV600E) occurs in ~50% of melanoma lesions and that 
melanoma cells bearing the mutation are oncogene addicted, i.e., strictly dependent upon 
BRAFV600E activity for growth and survival, have pointed to BRAFV600E as a promising 
target for therapy. Drugs targeting BRAF have been developed, and several clinical trials are 
currently ongoing. Phase I-II results recently reported remarkable tumor regression in the 
great majority of patients bearing disseminated BRAFV600E mutated melanoma disease 
after treatment with BRAFV600E-specific inhibitors. 
In these trials, BRAF mutational status is determined to select patients who may benefit 
from therapy. However, melanoma specimens are not always available to perform this 
analysis; moreover, a negative result in a single tumor biopsy may cover the presence of 
mutation-positive tumor lesions. Because blood has been proven to represent a valuable 
alternative source of tumor-derived cells as well as of tumor-derived DNA, several technical 
approaches have been studied to detect BRAFV600E in RNA/DNA extracted from blood-
derived circulating tumor cells and in circulating free DNA isolated from plasma or serum. 
For these reasons, circulating BRAFV600E has the potential as both a specific melanoma 
molecular marker and a monitoring factor to be used to evaluate clinical response. 
In this chapter, we summarize the clinical and biological features of BRAF mutation in 
melanoma. Furthermore, we report a new BRAFV600E detection assay developed in our lab 
that shows high sensitivity and specificity. 
2. BRAFV600E mutation in melanoma 
Among the genetic lesions that frequently occur in melanoma, BRAF gene mutation is the 
most common and is detected in about 50% of melanoma (Davies et al., 2002). The BRAF 
gene encodes a serine-threonine kinase belonging to the MAPK kinase pathway, also known 
as the RAS/RAF/MEK/ERK pathway. This signaling pathway regulates important cellular 
processes, including cell growth, proliferation and migration; in physiological conditions, 
the signaling is triggered by activated growth factor receptors, which act as binding sites for 
 
Research on Melanoma – A Glimpse into Current Directions and Future Trends 
 
180 
Mary Ellen Simcox, David Heimbrook, Gideon Bollag, and Fei Su. 2010. RG7204 
(PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in 
Preclinical Melanoma Models. Cancer Research 70 (13):5518-5527. 
Zhang, Y., Y. Xiong, and W. G. Yarbrough. 1998. ARF promotes MDM2 degradation and 
stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor 
suppression pathways. Cell 92 (6):725-34. 
9 
BRAF V600E Mutated Gene Variant as  
a Circulating Molecular Marker in  
Metastatic Melanoma Patients 
Viviana Vallacchi, Licia Rivoltini and Monica Rodolfo 
Fondazione IRCCS Istituto Nazionale Tumori 
Italy 
1. Introduction  
Cutaneous metastatic melanoma management has recently approached the age of 
individualized therapy (Romano et al., 2011). The discovery that the 1799T>A point 
mutation in the BRAF oncogene (BRAFV600E) occurs in ~50% of melanoma lesions and that 
melanoma cells bearing the mutation are oncogene addicted, i.e., strictly dependent upon 
BRAFV600E activity for growth and survival, have pointed to BRAFV600E as a promising 
target for therapy. Drugs targeting BRAF have been developed, and several clinical trials are 
currently ongoing. Phase I-II results recently reported remarkable tumor regression in the 
great majority of patients bearing disseminated BRAFV600E mutated melanoma disease 
after treatment with BRAFV600E-specific inhibitors. 
In these trials, BRAF mutational status is determined to select patients who may benefit 
from therapy. However, melanoma specimens are not always available to perform this 
analysis; moreover, a negative result in a single tumor biopsy may cover the presence of 
mutation-positive tumor lesions. Because blood has been proven to represent a valuable 
alternative source of tumor-derived cells as well as of tumor-derived DNA, several technical 
approaches have been studied to detect BRAFV600E in RNA/DNA extracted from blood-
derived circulating tumor cells and in circulating free DNA isolated from plasma or serum. 
For these reasons, circulating BRAFV600E has the potential as both a specific melanoma 
molecular marker and a monitoring factor to be used to evaluate clinical response. 
In this chapter, we summarize the clinical and biological features of BRAF mutation in 
melanoma. Furthermore, we report a new BRAFV600E detection assay developed in our lab 
that shows high sensitivity and specificity. 
2. BRAFV600E mutation in melanoma 
Among the genetic lesions that frequently occur in melanoma, BRAF gene mutation is the 
most common and is detected in about 50% of melanoma (Davies et al., 2002). The BRAF 
gene encodes a serine-threonine kinase belonging to the MAPK kinase pathway, also known 
as the RAS/RAF/MEK/ERK pathway. This signaling pathway regulates important cellular 
processes, including cell growth, proliferation and migration; in physiological conditions, 
the signaling is triggered by activated growth factor receptors, which act as binding sites for 
 
Research on Melanoma – A Glimpse into Current Directions and Future Trends 
 
182 
adapter proteins that subsequently activate a cascade of kinases, including NRAS, BRAF, 
MEK and ERK, via phosphorylation. Activated ERK translocates to the cell nucleus, where it 
phosphorylates and activates many different substrates (Held et al., 2010; Poulikakos & 
Rosen, 2011; Young et al., 2009).  
BRAF mutations identified in melanoma are in the kinase domain, which is encoded by 
exons 11 and 15, and are somatic. Somatic BRAF point mutations have been also detected in 
approximately 8% of other tumor types, including 30-70% of papillary thyroid cancers and 
10% of colorectal cancers, and ovarian, breast and lung cancers (Cantwell-Dorris et al., 2011; 
Davies et al., 2002; Puzanov et al., 2011). No BRAF germline mutations have been found in 
familial or sporadic melanoma patients (Lang et al., 2003; Laud et al., 2003; Meyer et al., 
2003a), although germline mutations have been shown to occur in Noonan, LEOPARD and 
cardio-facio-cutaneous syndromes, which are developmental disorders with overlapping 
features including distinctive facial dysmorphia, reduced growth, cardiac defects, skeletal 
and ectodermal anomalies and variable cognitive deficits (Sarkozy et al., 2009; Tidyman & 
Raouen, 2009). The relationship between BRAF germline polymorphisms and melanoma 
risk has also been investigated, and data obtained suggest that BRAF can be considered a 
low-risk susceptibility gene for melanoma (James et al., 2005; Meyer et al., 2003b). 
It has been reported that melanocortin 1 receptor (MC1R) variants increase the risk of 
melanoma with BRAF mutations (Fargnoli et al., 2008; Landi et al., 2006; Scherer et al., 2010). 
The MC1R gene, which has been identified as a low-risk melanoma susceptibility gene 
(Williams et al., 2010), encodes a seven-pass transmembrane G-protein receptor that binds 
alpha-melanocyte stimulating hormone and plays a key role in the pigmentation process 
(Palmer et al., 2000; Rees, 2004; Valverde et al., 1995). The MC1R gene is highly 
polymorphic, and gene variants determine a partial or complete loss in the ability of the 
receptor to transduce signals, thus impairing the switch from pheomelanin to eumelanin 
production in response to UV radiation exposure (Healy et al., 2000). Further studies are 
needed to elucidate the mechanisms causing MC1R variants to select for BRAF somatic 
mutations (Hacker & Hayward, 2008). 
BRAF mutations result in the constitutive activation of ERK, resulting in proliferation and 
growth advantage of melanoma cells. In 15-30% of melanoma, the RAS/RAF/MEK/ERK 
pathway is constitutively activated through NRAS mutation (Sekulic et al., 2008). As BRAF 
and NRAS mutations are mutually exclusive, hyperactivation of the MAPK pathway is very 
frequent in melanoma. Although the constitutive activation of the MAPK pathway is often 
required to promote the growth and proliferation of neoplastic cells, BRAF mutations are 
prevalent in melanoma, while mutations in tyrosine kinase receptors or in RAS genes are 
prevalent in other tumor types. Chromosomal rearrangements leading to the formation of 
BRAF fusion products, characterized by the lack of the BRAF auto-inhibitory domain and 
the aberrant activation of the MAPK pathway, have also been reported in pilocytic 
astrocytoma, thyroid, prostate and gastric cancer as well as melanoma (Ciampi et al., 2005; 
Cin et al., 2011; Dessars et al., 2007; Palanisamy et al., 2010). 
The substitution of a valine (V) for glutamic acid (E) at position 600 (V600E) accounts for 
>90% of BRAF mutations identified in melanoma. BRAF mutations in melanoma are an 
early event as they can be detected in nevi and in primary melanoma (Figure 1) (Rodolfo et 
al., 2004; Thomas et al., 2006). Even if 60-70% of benign and dysplastic nevi show the 
BRAFV600E mutation, most of them do not progress to melanoma, suggesting that further 
alterations are necessary to promote malignant progression. In particular, it has been 
proposed that BRAF mutations may induce senescence and that abrogation of the 
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mechanisms regulating this cellular process are required to induce tumor progression 
(Michaloglou et al., 2005). In primary melanoma, BRAFV600E mutation is rarely detected in 
lentigo maligna lesions which arise in chronically sun-exposed skin and show a high rate of 
RAS mutations, and in acral and mucosal melanoma that arise in non-exposed skin, which 
may show KIT gene mutation (Platz et al., 2008). Melanoma occurring in childhood and 
adolescence, as well as those occurring in patients with a family history of melanoma, show 
BRAFV600E mutation (Daniotti et al., 2009). Melanoma that arise in intermittently exposed 
body sites, in skin lacking signs of chronic sun-induced damage, and in younger people, 
show a >80% rate of BRAFV600E mutation (Curtin et al., 2005). BRAF mutation frequency 
appears higher in advanced lesions than primary tumors, and it does not seem to be related 
to the site of metastases. Moreover, different studies have reported that BRAF mutation is 
maintained during progression from primary tumor to metastatic lesions or is acquired 
during the development of metastases (Houben et al., 2004; Omholt et al., 2003; Shinozaki et 
al., 2004). These results suggested a possible direct link between mutated BRAF and the 
metastatic potential of melanoma cells. 
 
 
B: Benign nevi; B/S: Blue and Spitz nevi; D: Dysplastic nevi; SS: Superficial Spreading melanoma; N: 
Nodular melanoma; L: Lentigo maligna melanoma; A: Acral lentiginous melanoma; M: Mucosal 
melanoma; No: Nodal metastases; Cu: Cutaneous metastases; V: Visceral metastases; Ce: Cerebral 
metastases. 
Fig. 1. Frequency of BRAFV600E mutation in nevi and melanoma lesions. 
Several authors have studied the effects of BRAFV600E on global gene expression profiles of 
melanoma cells by microarray analysis and reported a BRAF mutation-associated gene 
expression signature (Pavey et al., 2004; Bloethner et al., 2005; Johansson et al., 2007). In 
particular, genes that encoded proteins involved in RAS/RAF/MEK/ERK signaling were 
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adapter proteins that subsequently activate a cascade of kinases, including NRAS, BRAF, 
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Several authors have studied the effects of BRAFV600E on global gene expression profiles of 
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particular, genes that encoded proteins involved in RAS/RAF/MEK/ERK signaling were 
 
Research on Melanoma – A Glimpse into Current Directions and Future Trends 
 
184 
identified among the genes differentially expressed between melanoma cell lines with or 
without BRAF mutation (Bloethner et al., 2005). In addition, a classifier able to discriminate 
between BRAF mutant and BRAF wild-type melanoma with high accuracy was built, 
including genes encoding phosphates and other genes biologically related to melanoma 
progression (Pavey et al., 2004). On the contrary, Hoek et al. failed to find a BRAF signature 
but identified three sample cohorts that represented melanoma groups characterized by 
different metastatic potential (Hoek et al., 2004). This discrepancy could be explained by 
considering the methods used to perform the analysis of array data; in fact, when the data 
by Hoek were re-analyzed with another statistical approach, a BRAF signature could be 
identified in these data (Johansson et al., 2007). Taken together, these results support the 
presence of a gene expression profile associated with BRAF mutation in melanoma and 
point to the genes that are potentially novel therapeutic targets. 
3. BRAFV600E as a therapeutic target 
The frequency and specificity of BRAFV600E mutation, together with the strict dependence 
of melanoma cell growth and survival on BRAFV600E activity (a phenomenon called 
oncogene addiction), have pointed to BRAFV600E as a promising therapeutic target. 
Several BRAF inhibitors have been produced in the last years that have been or are currently 
being clinically tested (Sheperd et al., 2010). The first compound tested in clinical trials was 
Sorafenib (BAY43-9006), a multi-kinase inhibitor that targeted both wild-type and mutated 
BRAF, CRAF and other protein kinases, such as VEGFR2 and -3, PDGF, p38 MAPK, cKIT, 
FMS and RET (Wellbrock & Hurlstone, 2010). Sorafenib showed poor clinical activity when 
tested as a single agent, and in phase III trials in both front- and second-line therapies in 
combination with carboplatin and paclitaxol (Eisen et al., 2006; Hauschild et al., 2009). Other 
multi-kinase inhibitors that show a higher selectivity for BRAF than Sorafenib are currently 
under investigation in clinical trials (Dienstmann & Tabernero, 2011). 
Several compounds that selectively inhibit BRAF have also been developed. Among them, 
GSK2118436 (SB-590885) has been tested in a phase I-II clinical trial and shows clinical 
responses in 60% of melanoma patients with BRAFV600 tumors, including patients having 
BRAFV600K and BRAFV600G mutations, with good tolerability (Kefford et al., 2010). 
Moreover, treatment with GSK2118436 induced a 20-100% reduction in the size of central 
nervous system lesions in patients with previously untreated brain metastases (Long et al., 
2010).  
Recently, the results of a phase I-II study that tested a specific BRAFV600E inhibitor, 
PLX4032 (RO5185426), were reported. Treatment with PLX4032 induced a complete or 
partial tumor regression in 81% of patients who had melanoma with BRAFV600E mutation, 
including progression-free survival for more than 7 months and manageable side effects, 
while patients with BRAF wild-type tumors showed no evidence of tumor regression 
(Flaherty et al., 2010). As a side effect, 31% of patients treated with PLX4032 developed low-
grade squamous cell carcinomas, which were reported to occur also in patients treated with 
Sorafenib (Arnault et al., 2009). This side effect is possibly due to the selective mechanism of 
action of PLX4032 that shuts down only the activity of BRAFV600E while inducing the 
formation of BRAF-RAF1 heterodimers and RAF1-RAF1 homodimers, thus inducing hyper-
activation of the MAPK pathway in both tumor cells and normal skin cells with wild-type 
BRAF (Hatzivassiliou et al., 2010; Heidorn et al., 2010; Poulikakos et al., 2010). 
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4. Mechanisms of resistance to BRAF inhibitors 
Even if BRAFV600E tumors initially respond to PLX4032 treatment, the majority of patients 
relapsed within 2-18 months and developed resistance to the treatment. Furthermore, a subset 
of BRAFV600E tumors showed primary resistance as about 20% of patients did not respond to 
PLX4032 treatment (Flaherty et al., 2010). These findings indicate that the development of new 
therapeutic strategies using PLX4032 in combination with other targeted agents could be 
useful to prevent the acquisition of resistance. Several studies investigating the molecular 
mechanisms that promote resistance to RAF inhibitors have been recently reported. The 
restoration of MEK activity in BRAFV600E melanoma appears to be a crucial event in 
promoting the acquisition of resistance (Poulikakos & Rosen, 2011; Solit & Rosen, 2011; Solit & 
Sawyers, 2010; Tuma, 2011). In particular, MEK activity was restored by overexpressing other 
kinases such as RAF1 and COT/TPL2 (Johannessen et al., 2010) or by the de novo acquisition 
of a mutation in the NRAS gene (Nazarian et al., 2010). The COT gene was amplified in cell 
lines that showed intrinsic resistance to PLX4032 (Johannessen et al., 2010). Surprisingly, no 
secondary BRAF mutations were detected in tumors from patients with acquired resistance 
(Nazarian et al., 2010). Wagle et al. identified an activating mutation at codon 121 of MEK1 in 
the tumor from a patient who relapsed after developing resistance to PLX4032 treatment, thus 
demonstrating for the first time that resistance to PLX4032 is associated with the development 
of activating mutations in kinases downstream of BRAFV600E (Wagle et al., 2011). This 
discovery highlights the importance of establishing new combined therapies using MEK or 
ERK inhibitors with PLX4032 to overcome resistance. In fact, data obtained in preclinical 
studies demonstrated a synergism between BRAF and MEK inhibitors AZD6244 and 
GSK1120212 (Emery et al., 2009; Joseph et al., 2010; Paraiso et al., 2010). However, mechanisms 
that promote the acquisition of resistance independently of MEK activation have been 
described, including the increased activation of the receptor tyrosine kinases PDGFRβ 
(Nazarian et al., 2010) or IGF1R (Villaneuva et al., 2010), suggesting that the combination of 
receptor tyrosine kinase inhibitors with PLX4032 could be effective in the treatment of these 
patients. However in most patients, the mechanisms that promote the acquisition of resistance 
remain unclear (Nazarian et al., 2010).   
5. BRAFV600E as a circulating disease biomarker 
As blood has been proved to represent a valuable alternative source of tumor-derived cells 
and tumor-derived DNA/RNA, circulating BRAFV600E represents a potential circulating 
disease biomarker that could be useful when melanoma specimens are not available to test 
the BRAF mutational status for the selection of patients who will benefit from treatment 
with BRAF inhibitors. In addition, it could be used as a monitoring factor to evaluate clinical 
response. 
Several studies reported that BRAFV600E is detectable in DNA/RNA extracted from 
circulating melanoma cells (CMC) (Kitago et al., 2009; Oldenburg et al., 2008). The 
assessment of CMC for monitoring the efficacy of therapeutic treatment and for predicting 
the disease outcome of melanoma patients has been proposed. Currently, RT-PCR and 
quantitative real-time RT-PCR are the methods most frequently used to detect CMC in 
melanoma. Both techniques are used to amplify genes expressed in melanoma cells, such as 
tyrosinase, MART-1, MAGE-3A and MITF (Koyanagi et al., 2010). Detection of the mutated 
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identified among the genes differentially expressed between melanoma cell lines with or 
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BRAF variant in blood samples requires the efficient isolation of CMC (Kitago et al., 2009) or 
the development of extremely sensitive techniques to detect the mutant sequence in a large 
excess of wild-type BRAF forms (Oldenburg et al., 2008). 
Circulating free DNA (cfDNA) isolated from plasma or serum samples represents an 
alternative source of melanoma-derived DNA. Several studies reported the feasibility of 
detecting BRAFV600E mutation in the cfDNA from patients with melanoma (Board et al., 
2009; Daniotti et al., 2007; De Giorgi et al., 2010; Pinzani et al., 2010; Yancovitz et al., 2007). 
Interestingly, Shinozaki and coworkers reported that the detection of circulating BRAV600E 
in the serum of patients treated with biochemotherapy correlates with poorer outcomes due 
to absence of response to the treatment (Shinozaky et al., 2007). 
Some important limitations should be overcome to consider BRAFV600E as a reliable 
circulating disease biomarker. In fact, the studies previously mentioned demonstrated that 
BRAFV600E is detectable at stage IV and only in a few stage III melanoma patients, 
suggesting that it does not represent a marker for the detection of the disease in early-stage 
patients. Moreover, when matched plasma/serum and tumor samples from melanoma 
patients were tested for BRAFV600E, the concordance between the BRAF mutation rates of 
cfDNA and tumors showed some discrepancies, which could be due to a low sensitivity of 
the techniques used to perform the mutational analysis or to the heterogeneity of the tumor 
for the BRAFV600E mutation. For these reasons, different methods were developed to detect 
BRAFV600E mutation in high levels of BRAF wild-type DNA by increasing the specificity 
and sensitivity of the assays, as shown in Table 1, mainly through enriching the sample for 
the mutant variant or by selectively inhibiting the amplification of the BRAF wild-type form 
(Kitago et al., 2009; Oldenburg et al., 2008; Pinzani et al., 2011; Shinozaki et al., 2007; 
Yancovitz et al., 2007) 
 
Method Detection limit Samples Reference
Allele-Specific PCR 1:400 mut allele in wt alleles Plasma Daniotti et al., 2007
Mutant-specific PCR 0.1 ng of mut DNA in 100 ng of wt DNA Plasma Yancovitz et al., 2007
PNA/LNA clamp Real Time PCR 1X10-4 U mut DNA in 10 U of wt DNA Serum Shinozaki et al., 2007
PBAS-PCR 10 melanoma cells in 1ml of blood CMC Oldenburg et al., 2008
Real Time PCR 1-5 melanoma cells in 5X106 PBC CMC Kitago et al., 2009
ARMS allele-specific Real Time PCR 5 copies of mut DNA in 5000 copies of wt DNA Serum Board et al., 2009
LNA/allele-specific Real Time PCR 0.3% of mut alleles in wt alleles Plasma Pinzani et al., 2010
COLD PCR 3.1% of mut alleles in wt DNA FFPE tissue Pinzani et al., 2011
 
PNA: Peptide Nucleic Acid; LNA: Locked Nucleic Acid; PBAS: Primer-Blocking Allele-Specific; ARMS: 
Amplification Refractory Mutation System; COLD: CO-amplification at Lower Denaturation 
temperature; mut: mutated; wt: wild-type; 1U: amount of target DNA contained in 1 µg/ml of genomic 
DNA; PBC: Peripheral Blood Cells; FFPE: Formalin Fixed Paraffin Embedded 
Table 1. Methods developed to detect BRAFV600E. 
5.1 Other melanoma circulating biomarkers 
Melanoma serum markers that have significant potential both as prognostic indicators and 
for monitoring the treatment response include lactate dehydrogenases (LDH), S100 calcium 
binding protein B (S100B), and melanoma inhibitory activity (MIA) molecule. 
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LDH are cytochrome c- or NAD(P)-dependent enzymes that act on either D- or L-lactate. 
Serum LDH is the only circulating biomarker shown to have a prognostic relevance in 
melanoma. Several studies have shown that high levels of circulating LDH correlate with a 
poor prognosis in stage IV melanoma patients and in other neoplastic diseases (Balch et al., 
2009; Bedikian et al., 2008; Keilholz et al., 2002). For this reason, LDH was included in the 
current AJCC staging system, and its level is currently determined in melanoma patients 
having distant metastasis because patients with elevated LDH are assigned directly to the 
M1C category without considering the site of distant metastasis (Dickson & Gershenwald, 
2011).  
S100B is a protein that belongs to the S100 protein family and is mainly expressed by 
astrocytes, where it acts as a neurotrophic factor to promote neuronal survival. S100B is a 
well-characterized melanoma marker, and it is used as a diagnostic marker of melanocytic 
skin lesions in immunohistochemical staining. Several studies pointed out S100B as a 
prognostic marker of disease progression (Gogas et al., 2009; Jury et al., 2000) as increased 
serum levels in melanoma patients were predictive of disease progression. Even if not 
included in the AJCC staging system, Swiss and German guidelines recommend the 
determination of S100B serum levels in patients with Breslow thickness >1 mm every 3-6 
months (Dummer et al., 2005; Garbe et al., 2007; Garbe et al., 2008). 
MIA is a small protein secreted by malignant melanoma cells that exhibits an inhibitory 
effect on cell growth in vitro (Blesch et al., 1994). Even if a correlation between high MIA 
serum levels and metastatic melanoma progression has been reported (Bosserhoff et al., 
1997; Stahlecker et al., 2000), MIA was shown to have lower sensitivity and specificity as a 
melanoma marker than S100B and LDH (Krahn et al., 2001). 
Recently, microRNAs (miRNAs) have been proposed as a new class of potential circulating 
biomarkers that are detectable in various body fluids. miRNAs are non-coding RNAs 
consisting of 18-24 nucleotides that regulate mRNA and protein levels mainly by inducing 
mRNA degradation or by inhibiting translation (Ambros, 2004; Bartel, 2004). Recently, 
deregulation of a group of miRNAs was found in melanoma lesions in association with 
BRAF mutational status (Caramuta et al., 2010). miRNAs are also released into the 
extracellular space, where they can be found free or contained within vesicles such as 
microvesicles, exosomes, apoptotic vesicles and senescent bodies. The functional role of 
extracellular miRNAs as an intercellular communication system is poorly characterized 
(Reid et al., 2010). Extracellular miRNAs have been identified as ideal tumor circulating 
biomarkers because of their stability and easy quantification (Etheridge et al., 2010). For 
these reasons, circulating miRNAs have been investigated in many tumor types, including 
lung, colorectal, ovarian and pancreatic cancers, to evaluate their prognostic and diagnostic 
value (Reid et al., 2010). Few studies have assessed circulating miRNAs in the context of 
melanoma. Kanemaru et al. demonstrated that miRNA-221 serum levels are higher in 
melanoma patients than in healthy controls; in addition, miRNA-221 levels directly correlate 
with tumor thickness, staging and disease course (Kanemaru et al., 2011). In another study, 
16 miRNAs were identified deregulated in blood cells of melanoma patients by comparison 
of miRNA expression profiles in blood cells of healthy donors; moreover, they were 
sufficient to distinguish melanoma patients from healthy individuals with high accuracy 
(Leidinger et al., 2010). Taken together, these studies suggest that miRNAs potentially could 
be prognostic and diagnostic circulating markers in melanoma, although larger studies and 
the standardization of isolation and detection techniques are needed to confirm these 
results. 
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BRAF variant in blood samples requires the efficient isolation of CMC (Kitago et al., 2009) or 
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Method Detection limit Samples Reference
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PBAS-PCR 10 melanoma cells in 1ml of blood CMC Oldenburg et al., 2008
Real Time PCR 1-5 melanoma cells in 5X106 PBC CMC Kitago et al., 2009
ARMS allele-specific Real Time PCR 5 copies of mut DNA in 5000 copies of wt DNA Serum Board et al., 2009
LNA/allele-specific Real Time PCR 0.3% of mut alleles in wt alleles Plasma Pinzani et al., 2010
COLD PCR 3.1% of mut alleles in wt DNA FFPE tissue Pinzani et al., 2011
 
PNA: Peptide Nucleic Acid; LNA: Locked Nucleic Acid; PBAS: Primer-Blocking Allele-Specific; ARMS: 
Amplification Refractory Mutation System; COLD: CO-amplification at Lower Denaturation 
temperature; mut: mutated; wt: wild-type; 1U: amount of target DNA contained in 1 µg/ml of genomic 
DNA; PBC: Peripheral Blood Cells; FFPE: Formalin Fixed Paraffin Embedded 
Table 1. Methods developed to detect BRAFV600E. 
5.1 Other melanoma circulating biomarkers 
Melanoma serum markers that have significant potential both as prognostic indicators and 
for monitoring the treatment response include lactate dehydrogenases (LDH), S100 calcium 
binding protein B (S100B), and melanoma inhibitory activity (MIA) molecule. 
BRAF V600E Mutated Gene Variant as a  
Circulating Molecular Marker in Metastatic Melanoma Patients 
 
187 
LDH are cytochrome c- or NAD(P)-dependent enzymes that act on either D- or L-lactate. 
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6. Allele-specific real-time PCR-based detection of circulating BRAFV600E 
It is possible to selectively eliminate the BRAF wild-type sequence and thus improve the 
sensitivity of the PCR performed to detect mutated circulating BRAF by taking advantage of 
the presence of a TspRI enzyme restriction site located at codon 600 of the BRAF wild-type 
sequence (Rimoldi et al., 2003). This restriction site is abrogated by BRAFV600E, and 
therefore it is possible to enrich for the BRAV600E allele by selectively eliminating wild-type 
sequences by performing TspRI digestion. We modified the experimental conditions 
described by Rimoldi et al. to improve sensitivity and specificity of an allele-specific 
TaqMan-based real-time method to detect BRAFV600E in colorectal cancer tissues (Benlloch 
et al., 2006). Figure 2 summarizes the steps of the assay developed to screen for BRAV600E 
mutation plasma or melanoma tissue biopsies. 
 
 
Fig. 2. Schematic representation of TaqMan-based Real-Time PCR method developed to 
detect few copies of BRAFV600E in a large amount of wild-type DNA. 
Experimental conditions of each step are reported in paragraph 6.1. 
6.1 Overview of the protocol 
A 224-bp fragment that includes codon 600 of the BRAF gene is amplified from 5 ng DNA in 
a final reaction volume of 50 µl (Figure 2A). Amplification was performed with a pre-cycling 
hold at 95°C for 7 min followed by 37 cycles of PCR (95°C for 1 min, 55°C for 1 min and 72°C 
for 1 min) and a final extension at 72°C for 7 min using primers for exon 15 amplification 
reported by Davies (Davies et al., 2002). Twenty microliters of the PCR product were mixed 
with 1X NEB Buffer 4 supplemented with 100 µg/ml BSA (New England Biolabs) and then 
subjected to restriction digestion at 65°C overnight with 15 U TspRI (New England Biolabs) 
in a final digestion mix volume of 50 µl to enrich samples for the BRAFV600E mutant allelic 
variant (Figure 2B). Two microliters of the digestion product were used to perform an allele-
specific TaqMan-based real-time PCR analysis (Figure 2C). The final reaction volume of 20 
µl contained 10 µl 2X of TaqMan Genotyping Master Mix (Applied Biosystems), 18 pmol of 
each primer (BRAF-51F and BRAF-176R) and 5 pmol of each probe (BRAFmut and 
BRAFwt). The primer and probe sequences were reported previously by Benlloch (Benlloch 
et al., 2006). Amplification and detection were performed with an ABI PRISM 7900HT 
(Applied Biosystems) using the standard thermal profile conditions of the Absolute 
Quantification protocol. Data analysis was performed using the SDS (Sequence Detection 
System) version 2.2.2 software. Each experiment was performed in duplicate.  
6.2 Results 
Specificity of the technique was tested by assaying dilutions of BRAF mutated DNA (5 
ng/µl) in wild-type DNA (5 ng/µl). The mutated DNA was obtained from a heterozygous 
melanoma cell line showing 2 copies of BRAF gene. Therefore, the allelic ratio was 
calculated considering one mutated allele out of 4 total alleles. Results obtained show that 1 
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copy of V600E allele can be detected when diluted in 8X105 copies of wild-type alleles. 
Sensitivity of the technique was assayed by testing progressive dilutions in water of the 
BRAF mutated DNA. Results obtained show that BRAFV600E mutation can be detected 
starting from 6.25X10-5 ng of DNA. 
This method showed an increase in both sensitivity and specificity when compared to the 
assays previously used in our lab to detect BRAFV600E (Daniotti et al., 2007). As shown in 
Figures 3 and 4, the selective elimination of the BRAF wild-type allele is a critical step 
required to increase both parameters. In fact, the BRAF mutated allele became detectable 
only when the wild-type allele was greatly reduced (Figure 3) or eliminated (Figure 4) after 
digestion with TsprRI. 
Taken together, these results indicate that the new assay has an improved sensitivity and 
specificity for detecting BRAFV600E when tested on genomic DNA from melanoma when 
diluted in an excess of wild-type DNA or when present in a few copies as in water dilutions. 
Preliminary results obtained by testing matched plasma and tissues samples indicate that 
more samples test positive for BRAFV600E compared to the previously described technique 
(Daniotti et al., 2007) and suggest a potential clinical application of this technique. 
 
 
Fig. 3. TspRI digestion increases the specificity of BRAFV600E allele-specific real-time PCR. 
 
Research on Melanoma – A Glimpse into Current Directions and Future Trends 
 
188 
6. Allele-specific real-time PCR-based detection of circulating BRAFV600E 
It is possible to selectively eliminate the BRAF wild-type sequence and thus improve the 
sensitivity of the PCR performed to detect mutated circulating BRAF by taking advantage of 
the presence of a TspRI enzyme restriction site located at codon 600 of the BRAF wild-type 
sequence (Rimoldi et al., 2003). This restriction site is abrogated by BRAFV600E, and 
therefore it is possible to enrich for the BRAV600E allele by selectively eliminating wild-type 
sequences by performing TspRI digestion. We modified the experimental conditions 
described by Rimoldi et al. to improve sensitivity and specificity of an allele-specific 
TaqMan-based real-time method to detect BRAFV600E in colorectal cancer tissues (Benlloch 
et al., 2006). Figure 2 summarizes the steps of the assay developed to screen for BRAV600E 
mutation plasma or melanoma tissue biopsies. 
 
 
Fig. 2. Schematic representation of TaqMan-based Real-Time PCR method developed to 
detect few copies of BRAFV600E in a large amount of wild-type DNA. 
Experimental conditions of each step are reported in paragraph 6.1. 
6.1 Overview of the protocol 
A 224-bp fragment that includes codon 600 of the BRAF gene is amplified from 5 ng DNA in 
a final reaction volume of 50 µl (Figure 2A). Amplification was performed with a pre-cycling 
hold at 95°C for 7 min followed by 37 cycles of PCR (95°C for 1 min, 55°C for 1 min and 72°C 
for 1 min) and a final extension at 72°C for 7 min using primers for exon 15 amplification 
reported by Davies (Davies et al., 2002). Twenty microliters of the PCR product were mixed 
with 1X NEB Buffer 4 supplemented with 100 µg/ml BSA (New England Biolabs) and then 
subjected to restriction digestion at 65°C overnight with 15 U TspRI (New England Biolabs) 
in a final digestion mix volume of 50 µl to enrich samples for the BRAFV600E mutant allelic 
variant (Figure 2B). Two microliters of the digestion product were used to perform an allele-
specific TaqMan-based real-time PCR analysis (Figure 2C). The final reaction volume of 20 
µl contained 10 µl 2X of TaqMan Genotyping Master Mix (Applied Biosystems), 18 pmol of 
each primer (BRAF-51F and BRAF-176R) and 5 pmol of each probe (BRAFmut and 
BRAFwt). The primer and probe sequences were reported previously by Benlloch (Benlloch 
et al., 2006). Amplification and detection were performed with an ABI PRISM 7900HT 
(Applied Biosystems) using the standard thermal profile conditions of the Absolute 
Quantification protocol. Data analysis was performed using the SDS (Sequence Detection 
System) version 2.2.2 software. Each experiment was performed in duplicate.  
6.2 Results 
Specificity of the technique was tested by assaying dilutions of BRAF mutated DNA (5 
ng/µl) in wild-type DNA (5 ng/µl). The mutated DNA was obtained from a heterozygous 
melanoma cell line showing 2 copies of BRAF gene. Therefore, the allelic ratio was 
calculated considering one mutated allele out of 4 total alleles. Results obtained show that 1 
BRAF V600E Mutated Gene Variant as a  
Circulating Molecular Marker in Metastatic Melanoma Patients 
 
189 
copy of V600E allele can be detected when diluted in 8X105 copies of wild-type alleles. 
Sensitivity of the technique was assayed by testing progressive dilutions in water of the 
BRAF mutated DNA. Results obtained show that BRAFV600E mutation can be detected 
starting from 6.25X10-5 ng of DNA. 
This method showed an increase in both sensitivity and specificity when compared to the 
assays previously used in our lab to detect BRAFV600E (Daniotti et al., 2007). As shown in 
Figures 3 and 4, the selective elimination of the BRAF wild-type allele is a critical step 
required to increase both parameters. In fact, the BRAF mutated allele became detectable 
only when the wild-type allele was greatly reduced (Figure 3) or eliminated (Figure 4) after 
digestion with TsprRI. 
Taken together, these results indicate that the new assay has an improved sensitivity and 
specificity for detecting BRAFV600E when tested on genomic DNA from melanoma when 
diluted in an excess of wild-type DNA or when present in a few copies as in water dilutions. 
Preliminary results obtained by testing matched plasma and tissues samples indicate that 
more samples test positive for BRAFV600E compared to the previously described technique 
(Daniotti et al., 2007) and suggest a potential clinical application of this technique. 
 
 
Fig. 3. TspRI digestion increases the specificity of BRAFV600E allele-specific real-time PCR. 
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TspRI digestion reduces the excess of the wild-type allele that is detected 9 cycles later 
compared to the undigested sample and allows the detection of the BRAFV600E allele. The 
red line represents the threshold line. wt: wild-type. mut: mutated.  
 
 
Fig. 4. TspRI digestion increases the sensitivity of the BRAFV600E allele-specific real-time PCR. 
The amplification plot shows that the complete elimination of the BRAF wild-type template 
by TspRI digestion improves the sensitivity of mutated allele-specific PCR, anticipating its 
detection of about 14 cycles compared to undigested samples. The red line represents the 
threshold line. wt: wild-type. mut: mutated. 
7. Conclusion 
BRAFV600E currently represents the most specific circulating tumor marker available for 
cutaneous melanoma, although it will only detect about 50% of melanoma. Circulating 
BRAFV600E can be used to select patients to be treated with BRAF inhibitors when the 
tissue samples are not available for the analysis. In addition, detection methods for 
circulating BRAFV600E can be used to monitor the treatment response and evaluate disease 
relapse during follow-up. However, to use BRAFV600E as a blood marker, more sensitive 
technologies must be designed and validated to improve the sensitivity and specificity of 
the assays used to detect this mutation. 
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1. Introduction 
Epidemiological evidence is overwhelming that exposure of the skin to ultraviolet radiation 
(UVR) can increase one’s risk of developing malignant melanoma. However the situation is 
complex, as melanoma development is associated with “intermittent” sun exposure, whereas 
epidermal keratinocyte-based skin cancers like squamous cell carcinoma (SCC) are associated 
with chronic UVR exposure. Thus it is difficult to talk in terms of a classical UVR carcinogenic 
mechanism for melanoma in general. Melanoma risk seems intricately associated with 
pigmentation characteristics. Genome wide association studies identify variants in genes 
involved in pigmentation as risk factors, generally the strongest signal being for the 
melanocortin receptor 1 gene (MC1R). One reason postulated to explain the odd relationship 
between UVR exposure and tumorigenesis is that there may be a unique carcinogenic 
mechanisms at play involving UVA, that is a weak carcinogen for skin cancer in general. 
Evidence for UVA causality in melanoma comes from some epidemiological studies, and to 
some extent from work with animal models. On the other hand, one can argue that there may 
not be a unique carcinogenic mechanism for melanoma, and that there are several factors that 
may help explain the apparent difference from typical mechanism of UVR mutagenesis 
involving classical UVR mutations. Firstly, in terms of normal cellular function, melanocytes 
principal function is to produce melanin pigment while epidermal keratinocytes are 
programmed to proliferate and then die as they generate and maintain the epidermis, a barrier 
for internal tissues and organs. Secondly, there may be genetic differences between individuals 
developing particular subtypes of melanoma and/or form of sun exposure. Thus particularly 
relates to susceptibility to naevus development, a critical factor associated melanoma 
development on the trunk, a site presumably receiving mainly “intermittent” sun exposure.  
2. Epidemiology of melanoma 
Major risk factors for cutaneous melanoma are shown below - approximate relative risk 
(RR) and 95% confidence intervals (CI) are shown in brackets (Gandini et al., 2005a; Gandini 
et al., 2005b):  
1. One atypical naevus (RR 1.60, CI 1.4-1.8) 
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2. Five or more atypical naevus (RR 10.5, CI 5.1-21.5). 
3. Multiple banal melanocytic naevi - 100 vs <15  (RR-6.9, CI 4.6-10.3). 
4. Red versus dark hair (RR 3.6, CI 2.5-5.4). 
5. Sunburns in childhood (RR 2.2, CI 1.73-2.89 
6. Sunburns in adulthood (RR 1.9, CI 1.6-2.7) 
7. Chronic sun exposure (RR 1.0, CI 0.8-1.1) 
Apart from familial predisposition, the strongest risk factor for the development of cancer 
generally, the presence of naevi, especially dysplastic naevi, is the innate, or phenotypic 
factor that most increases the probability of developing a melanoma. Sunlight is the only 
environmental factor that has been consistently implicated as a cause of melanoma, leading 
to a melanoma incidence 10- to 20- fold higher among fair-skinned than dark-skinned 
peoples (Armstrong & Kricker, 1993). Among fair-skinned people, melanoma incidence 
increases with proximity to the equator and several studies have shown that fair-skinned 
migrants moving from high (e.g. UK) to low latitude countries (e.g. Australia, South Africa) 
have lower melanoma rates than native-born residents (Whiteman and Green, 1999; Khlat et 
al., 1992; McCredie et al., 1990; McMichael and Giles, 1988). Individuals with xeroderma 
pigmentosum (XP), a disorder in which sufferers have a gene mutation that diminishes their 
ability to repair UVR-induced DNA damage, have much higher risk of melanoma than the 
population average (Kraemer et al., 1994; Cleaver, 2006). Those with a past history of non-
melanoma skin cancer (caused by high exposures to solar UVR) have a 3-fold higher risk of 
melanoma than the general population (Green et al., 1993). 
3. Genetic basis of melanoma 
3.1 Genes involved in familial melanoma susceptibility 
Although many different genes can be somatically mutated in melanoma, as yet there are 
only two confirmed familial melanoma susceptibility loci, CDKN2A and CDK4. CDKN2A 
encodes INK4A and ARF, which regulate cell cycle progression via the INK4A/CDK4/pRB 
and ARF/MDM2/p53 pathways respectively, although undoubtedly there is significant 
cross talk between these two pathways, and with other pathways. The overwhelming 
majority of CDKN2A mutations in melanoma-prone kindreds affect only the INK4A 
transcript, or both transcripts, but ARF-specific mutations also predispose to melanoma (e.g. 
Randerson-Moor et al., 2001; Rizos et al., 2001). As INK4A mutations generally prevent 
CDK4 from being bound and inhibited by p16INK4A, the mechanism of tumorigenesis with 
INK4A or CDK4 mutations is presumed to be equivalent (via pRB deregulation). Families 
carrying CDKN2A mutations usually, although not always, exhibit a naevus-prone 
phenotype (Goldstein et al., 2000) indicating that relaxation of melanocyte proliferation 
control induced by INK4A (or ARF) loss may be important in naevogenesis. However a 
recent study comparing the influence of sun exposure on melanoma risk in CDKN2A 
mutations carriers in Australia and the United Kingdom (Cust et al., 2011) suggests that they 
have to have the same cumulative risk of melanoma irrespective of the ambient UV 
irradiance in the region in which they live.   
3.2 Genes associated with melanoma in genome wide association studies 
Genome wide association (GWA) studies have been used to discover genes that confer risk 
for skin cancer development (Table 1). Some genes are associated both melanoma and non-
melanoma skin cancer, especially basal cell carcinoma (BCC). Five genes associated with 
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melanoma, SLC45A2, TYRP1, TYR, MC1R, and ASIP, encode proteins that are involved in 
various ways in regulating pigmentation. Little is known about how most of these may 
effect melanoma genesis and we are left to assume that the risk alleles may encode variants 
in these genes that simply result in lower levels of protective pigmentation. Notably, in 
respect to MC1R and ASIP (agouti signaling protein, an MC1R antagonist), there may be 
other explanations, which will be discussed below. The genes that confer the strongest risk 
for the development of naevi, MTAP/CDKN2A and PLA2G6, are not involved in the 
regulation of pigmentation.  
 
Chromosome Candidate gene Pigmentation
Naevus 
count Melanoma BCC SCC 
1p36 PAD15 -  - ++ - 
1q42 RHOU -  - ++ - 
5p13.3 SLC45A2 ++  ++ ++ ++ 
5p13.33 TERT -  ++ ++ - 
6q25 IRF4 ++ +? +? - - 
7q32 KLF14 -  - ++ - 
9p21 CDKN2A -  - ++ - 
9p21 MTAP  ++ ++   
9q23 TYRP1 ++  ++ - - 
11q13.2 TPCN2 ++  - -  
11q14 TYR ++  ++ ++ - 
12q13 KRT5 -  - ++ - 
12q21 KITG ++  - -  
14q23 SLC2A4 ++  - -  
15q11 OCA2 ++  - - - 
15q13.1 HERC2 ++  - -  
15q21 SLC24A5 +  - - - 
16q24.3 MC1R ++  ++ ++  
20q11 ASIP ++  ++ ++ - 
22q13 PLA2G6  ++ ++   
Table 1. Adapted from Gerstenblith et al. (2010). A double plus sign (++) indicates a 
signicant association (P < 10-7) in GWAS. A single plus sign (+) indicates an association (P 
between 0.01 and 10-7). A minus sign (-) indicates a null association (P > 0.01). A blank cell 
indicates that the locus in the left column has not been not tested. BCC=basal cell carcinoma. 
SCC =squamous cell carcinoma. 
3.3 MC1R, melanoma risk and sun exposure  
MC1R, the receptor for melanocyte stimulating hormone, is the most thoroughly studied 
melanoma risk gene. It functions largely to control the switch between red/yellow 
pheomelanin and black/brown eumelanin, hence it is sometimes referred to as the “red 
haired” gene. This gene is highly polymorphic in human populations with >65 variants 
documented. Variants have been classed into two groups based on the strength of their 
association with red hair (Sturm et al., 2003). The R variants (i.e. Asp84Glu, Arg151Cys, 
Arg160Trp, and Asp294His) are most highly correlated with red hair (mean OR 63.3, range 
50.5-118.3) although the r variants are still associated to a lesser degree (mean OR 5.1, range 
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2.4-6.4). MC1R variants are not the sole determinant of hair colour, twin studies have 
observed discordant hair colour but identical MC1R haplotypes (Box et al., 1997). The 
molecular consequences of UVR upon melanocytes with variant melanocortin-1 receptors 
are variable. This has lead to debate over MC1R classification and which variants to include 
in assessing the impact of impaired MC1R function in melanoma (Hacker & Hayward, 
2008). Beaumont et al. (2007) used in vitro studies to examine the functional impact of nine 
common MC1R variants and found that the V60L, D84E, R151C, I155T, R160W and R163Q 
variants showed impairment in cAMP coupling. Normal receptor expression was found for 
R142H and D294H variants, but reduced functional responses were observed, indicating 
that altered G-protein coupling may be responsible for this loss of function. The V92M 
isoform shows similar activity to the wild-type receptor, and along with V60L, is not 
associated with melanoma (Raimondi et al., 2008). Interestingly, melanoma risk due to the 
carriage of MC1R variants is stronger in individuals with dark hair and eyes, who do not 
have freckles, and tan well (Kanetsky et al., 2010). Thus the risk due to MC1R variation is 
certainly not limited to red heads. 
The mechanism by which the carriage of MC1R variants increases melanoma risk is an area 
of intense investigation. The simplest explanation is simply the lower photo-protection 
afforded by red/yellow pheomelanin than brown/black eumelanin. Notably, MC1R 
variants are also associated with increased risk of non-melanoma skin cancer (table 1). In 
addition, pheomelanin is more likely than eumelanin to generate potentially damaging 
reactive oxygen species following UVR exposure (Hill, 1992; Takeuchi et al., 2004; Baldea et 
al., 2009). A popular explanation for the protective role of MC1R comes from cell culture 
experiments showing that melanocytes carrying melanoma-associated MC1R variants have 
less effective repair of both UVR-induced pyrimidine dimers and oxidative damage than 
wild-type cells and are more sensitive to UVR-induced cell death (Kadekaro et al., 2005; 
Bohm et al., 2005; Hauser et al., 2006; Song et al., 2009). Functional MC1R appears to be 
necessary to prevent UV-induced genomic instability within melanocytes.  
4. The epidemiological association between sunlight and melanoma is 
complex 
Despite the persuasive descriptive evidence linking sunlight with melanoma, several 
observations make clear that the association is complex and does not accord with a simple 
model in which the risk of melanoma increases directly with increasing levels of exposure to 
the sun. Melanoma occurs more commonly among indoor than outdoor workers (Beral & 
Robinson, 1981). Even in sunny countries most melanomas develop on sites that are 
habitually covered by clothing (such as the back), as opposed to sites more frequently 
exposed to the sun such as the face (Green et al., 1993). Many case-control studies of 
melanoma incidence report stronger associations with intermittent (short periods of intense 
sun exposure to untanned skin) rather than chronic patterns of sun exposure (Elwood & 
Jopson, 1997). Recreational sun exposure is a risk factor for melanoma on the trunk and 
limbs but not on the head and neck (Chang et al., 2009).  
Chronic sun exposure and a “classical” UVR carcinogenic mechanism involving UVB-
induced DNA damage is accepted to be responsible for the development of SCC. One reason 
frequently proposed for the lack of association of melanoma with chronic sun exposure is 
that there may be a different carcinogenic mechanism for melanoma, possibly involving 
UVA exposure. The potential role of UVA in the induction of melanoma has been reviewed 
elsewhere (e.g. Wang et al., 2001; Moan et al., 2008; Godar et al. 2009). Sunlight at different 
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latitudes contains vastly different rations of UVA/UVB, with a greater proportion of UVB 
nearer the equator, and less closer to the poles. Because the change in melanoma incidence 
with latitude is much smaller than that for SCC (which is dependent upon cumulative UVB 
exposure) it is hypothesized that UVA play a role at least in exacerbating the development of 
melanoma (Godar et al., 2009; Wang et al., 2010). Other ideas revolve around the notion that 
office workers are at higher relative risk possibly due excessive UVA that can penetrate glass 
(Godar et al., 2009). Further, recreational exposure, generally agreed to increase melanoma 
risk, can include solarium use. Depending on the lamp type used, artificial tanning devices 
(sunbeds or solariums) emit higher UVA/UVB ratios and possibly higher UVA doses than 
found in sunlight (Miller et al., 1998; Gerber et al., 2002). A meta-analysis of nineteen studies 
has shown that exposure to sunbeds at a young age is the most damaging, with a relative risk 
for “first exposure under the age of 35” of 1.75 (95% CI, 1.35, 2.26) (International Agency for 
Research on Cancer Working group on artificial UV light and skin cancer, 2007). A large 
prospective cohort study of 106,366 women in Sweden and Norway showed that solarium use 
at ages 30-39 linked to a relative risk of 1.49 (95% CI, 1.11-2.00)(Veierod et al., 2011). Thus 
epidemiological evidence suggests that sunbeds are health hazards in terms of melanoma risk 
and that UVA has a plausible role in the development of this neoplasm. Hence 
epidemiological data is somewhat supportive of the view that the full UVR spectrum may be 
carcinogenic in melanoma. It should be noted that at any point on the earth it is difficult to 
precisely predict the UVA/UVB ratio in sunlight as it can greatly vary with time of day, 
altitude, latitude and climate factors (De Fabo et al., 2004). 
5. Naevus and melanoma subtypes 
From the point of view of basic biology differences between melanoma and non-melanoma 
skin cancer in terms of their relationship with UVR exposure is not surprising. Melanocytes 
are long living cells, resistant to apoptosis, whose principal function is to produce melanin. 
In contrast, the primary function of keratinocytes is to provide a protective barrier, the 
epidermis, which is in a continual state of regeneration, supplied by proliferation of 
epidermal basal layer keratinocytes that initiates a programmed process of differentiation 
and apoptosis as needed. Melanocytes can undergo a form of proliferation, where they form 
senescent groups, or nests, which are termed naevi. Such lesions are negative for 
proliferation markers, but can progress to malignancy, albeit at an extremely low frequency 
(Grichnik, 2008). There are multiple subtypes of naevi. These include dermal (blue naevi), 
compound (common acquired, spitz and congenital naevi) and epidermal (e.g. reed naevi) 
lesions (Grichnik, 2008). These subtypes may be influenced differently by UVR exposure, 
and there may be differences in their propensities for transformation (e.g. which is probably 
much less for dermal naevi). Hence the subtype of naevus can be a confounding factor when 
studying environmental and genetic factors influencing naevo genesis. For instance the 
positive association between naevus count and IRF4 gene variation (Duffy et al., 2010) varies 
greatly for different subtypes (dermal versus compound naevi).   
Likewise there are several major melanoma subtypes, and then subtle forms within each 
group. Superficial spreading melanoma (SSM) is the most common form in Caucasians 
(around 70% of all melanomas). It follows a radial growth phase with atypical melanocytes, 
either as single cells or nests at all levels of the epidermis (Smoller, 2006), followed by an 
invasive vertical growth phase. Nodular melanoma (NM) are primary dermal lesions 
characterized by growth through the dermis, generally lack epidermal involvement, and a 
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2.4-6.4). MC1R variants are not the sole determinant of hair colour, twin studies have 
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latitudes contains vastly different rations of UVA/UVB, with a greater proportion of UVB 
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very sharply circumscribed with virtual lack of radial spread (Smoller, 2006). Lentigo 
maligna melanoma (LMM) is the only subtype unequivocally associated with chronic sun 
exposure. Lesions display confluent spread of melanocytes along the epidermal basal layer 
and in the upper portion of the hair follicle and are invariably associated with solar elastosis 
in adjacent skin (Smoller, 2006). SMM and NM, but not LMM, sometimes have naeval 
remnants present on histopathology. Acral lentiginous and mucosal melanomas are 
epidermal lesions that occur on palmoplantar and mucosal surfaces respectively, and  are 
assumed not to be influenced by UVR exposure. Clearly, any discussion of the effects of 
chronic versus intermittent sun exposure has to consider melanoma subtype.  
6. The divergent pathway model of melanoma 
To assess the effects of chronic versus intermittent sun exposure melanomas have been 
stratified into chronic sun damage (CSD) or non-chronic sun damage (non-CSD) 
melanomas, either histologically by assessing solar elastosis, a measure of chronic exposure 
(e.g. Curtin et al., 2005), or by comparing melanomas developing on the head and neck (an 
anatomical region of high cumulative sun exposure), and the trunk (a region of intermittent 
exposure). While these two methods of classification may create some confounding 
differences, overall the use of either system supports the conclusion of a complex 
relationship between melanoma and sun exposure that has lead to the proposal of a 
“divergent pathway” model (Whiteman et al., 2003). According to this model (Figure 1) the 
pathways diverge after an initial insult that stabilizes the melanocyte. This may be early life 
exposure to UVR given that childhood sunburns are a risk factor for melanoma (Whiteman 
et al., 2001). What happens thereafter depends upon a combination of host characteristics 
and subsequent patterns and doses of UVR exposure. Melanomas that develop on the head 
and neck are associated with solar elastosis (a marker of CSD), low naevus count, and 
relatively late age of onset. In contrast, melanomas developing on the trunk via the 
intermittent UVR (non-CSD) pathway tend to have relatively earlier age of onset and are 
associated with higher naevus count.  
 
 
Fig. 1. Schematic depiction of the divergent pathways model for melanoma development. 
 
Ultraviolet Light as a Modulator of Melanoma Development 
 
203 
Several studies have published findings concordant with the divergent pathway hypothesis 
(Carli and Palli, 2003; Chang et al., 2009; Bataille et al., 1998). Given the strong association 
between truncal (non-CSD) melanomas and naevus development, and the fact that most 
naevi carry BRAF mutations (Pollock et al., 2003), it is not surprising that the non-CSD 
melanomas also tend to carry BRAF mutations (reviewed in Platz et al., 2008). A greater 
tendency for melanocytes to proliferate in this branch of the model has been proposed 
(Whiteman et al., 2001). This may manifest as innate propensity for “proliferation” (a 
tendency to form nests, i.e. naevi), or proliferation in response to UVR exposure. To our 
knowledge inter-individual variation in the latter has only been reported once. Stierner et al. 
(1989) exposed buttock skin (seven UVB exposures with dose gradually increased to give 
slight erythema), and collected biopsies three weeks after last exposure. They found 
variation in the melanocyte proliferative response to UVR. Individuals that showed the 
biggest increase had the lowest pre-existing density. There was no association between 
melanocyte number increase, minimal erythemal dose, or skin type (the presence, or not, of 
naevi was not mentioned). Hence, although the sample size was small, this study does 
indicate different proliferative potential of melanocytes between individuals. We cannot 
know how these responses influence melanoma development except in prospective studies, 
but we can begin to look at genes and other phenotypic measures that may stratify the two 
pathways and allow better predication of risk. There are some suggestions that not only 
naevus risk may be important, but also the propensity of individuals with less naevi to be 
prone to developing solar elastosis (Thomas et al., 2010). Arguing against this, individuals 
with DNA repair defects (e.g. XP patients) frequently develop lentigo melanomas without 
solar elastosis (Spatz et al., 2001), indicating that repeated or unrepaired UVR-induced DNA 
damage in the skin may be more important than the presence of solar elastosis per se.  To 
sum up, the divergent pathway hypothesis provides some basis for explaining why 
melanoma as a whole is most associated with intermittent sun exposure.  
7. Stratification of CSD and non-CSD melanomas by innate phenotypic and 
genetic variation 
7.1 MC1R variants 
Landi et al. (2006) reported that individuals in Italian and U.S. cohorts that developed 
BRAF-mutant melanomas via the “naevus” (non-CSD) pathway tended to carry MC1R 
variants more frequently than those developing CSD melanomas. However studies 
undertaken in cohorts from Australia and North Carolina found no association between 
germline MC1R status and somatic BRAF mutations in melanomas (Thomas et al., 2007; 
Hacker et al., 2010a). More recently, the Italian sample population originally reported in 
Landi et al. (2006) has been expanded to include another 92 melanomas and they reported 
that germline MC1R variants were associated with melanomas carrying BRAF-mutations 
independent of solar elastosis measures (Fargnoli et al., 2008). Conflicting data has 
continued to appear, with results from a German sample of 173 melanoma patients showing 
the opposite effect, with individuals carrying MC1R variants less likely to acquire somatic 
BRAF mutations in tumours (Scherer et al., 2010). MC1R is considered the most important of 
the “moderate” risk genes for melanoma. However its relationship to CSD versus non-CSD 
associated melanoma is a matter of debate. It is possible that the discordant study findings 
reflect that fact that MC1R is extremely polymorphic within and between ethnic 
populations, and that the small sample sizes for each study means that chance association 
with the non-CSD melanoma pathway cannot be excluded.  
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Several studies have published findings concordant with the divergent pathway hypothesis 
(Carli and Palli, 2003; Chang et al., 2009; Bataille et al., 1998). Given the strong association 
between truncal (non-CSD) melanomas and naevus development, and the fact that most 
naevi carry BRAF mutations (Pollock et al., 2003), it is not surprising that the non-CSD 
melanomas also tend to carry BRAF mutations (reviewed in Platz et al., 2008). A greater 
tendency for melanocytes to proliferate in this branch of the model has been proposed 
(Whiteman et al., 2001). This may manifest as innate propensity for “proliferation” (a 
tendency to form nests, i.e. naevi), or proliferation in response to UVR exposure. To our 
knowledge inter-individual variation in the latter has only been reported once. Stierner et al. 
(1989) exposed buttock skin (seven UVB exposures with dose gradually increased to give 
slight erythema), and collected biopsies three weeks after last exposure. They found 
variation in the melanocyte proliferative response to UVR. Individuals that showed the 
biggest increase had the lowest pre-existing density. There was no association between 
melanocyte number increase, minimal erythemal dose, or skin type (the presence, or not, of 
naevi was not mentioned). Hence, although the sample size was small, this study does 
indicate different proliferative potential of melanocytes between individuals. We cannot 
know how these responses influence melanoma development except in prospective studies, 
but we can begin to look at genes and other phenotypic measures that may stratify the two 
pathways and allow better predication of risk. There are some suggestions that not only 
naevus risk may be important, but also the propensity of individuals with less naevi to be 
prone to developing solar elastosis (Thomas et al., 2010). Arguing against this, individuals 
with DNA repair defects (e.g. XP patients) frequently develop lentigo melanomas without 
solar elastosis (Spatz et al., 2001), indicating that repeated or unrepaired UVR-induced DNA 
damage in the skin may be more important than the presence of solar elastosis per se.  To 
sum up, the divergent pathway hypothesis provides some basis for explaining why 
melanoma as a whole is most associated with intermittent sun exposure.  
7. Stratification of CSD and non-CSD melanomas by innate phenotypic and 
genetic variation 
7.1 MC1R variants 
Landi et al. (2006) reported that individuals in Italian and U.S. cohorts that developed 
BRAF-mutant melanomas via the “naevus” (non-CSD) pathway tended to carry MC1R 
variants more frequently than those developing CSD melanomas. However studies 
undertaken in cohorts from Australia and North Carolina found no association between 
germline MC1R status and somatic BRAF mutations in melanomas (Thomas et al., 2007; 
Hacker et al., 2010a). More recently, the Italian sample population originally reported in 
Landi et al. (2006) has been expanded to include another 92 melanomas and they reported 
that germline MC1R variants were associated with melanomas carrying BRAF-mutations 
independent of solar elastosis measures (Fargnoli et al., 2008). Conflicting data has 
continued to appear, with results from a German sample of 173 melanoma patients showing 
the opposite effect, with individuals carrying MC1R variants less likely to acquire somatic 
BRAF mutations in tumours (Scherer et al., 2010). MC1R is considered the most important of 
the “moderate” risk genes for melanoma. However its relationship to CSD versus non-CSD 
associated melanoma is a matter of debate. It is possible that the discordant study findings 
reflect that fact that MC1R is extremely polymorphic within and between ethnic 
populations, and that the small sample sizes for each study means that chance association 
with the non-CSD melanoma pathway cannot be excluded.  
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7.2 Genes controlling the development of naevi 
Given that the “intermittent” exposure arm of the divergent pathway is associated with the 
presence of naevi, we should be able to obtain clues about how to differentiate the pathways 
based on genes that confer naevus risk. Naevi are benign proliferations of melanocytes, and 
the number of naevi individuals tend to develop is under strong genetic control (English & 
Armstrong, 1994; Harrison et al., 1994). Monozygotic, or identical twin pairs, share all genes 
and have extremely highly correlated naevus counts (twin1 vs twin2, r=0.94), whereas 
dizygotic twin pairs share on average only half of their genes, and their naevus counts are 
considerably less correlated (r=0.60) (Zhu et al., 1999). The great majority naevi carry the 
BRAFV600E which seems to be an early event in melanoma development but not sufficient to 
transform naevocytes (Pollock et al., 2003). Instead, the expression of the mutant form in 
melanocytes leads to growth arrest characteristic of senescence (Michaloglou et al., 2005). 
However the presence of BRAFV600E does not inform in terms of how naevi might develop. 
Here we must look to genetic studies that might provide some hints to the molecular 
mechanisms involved. GWAS have also identified variants associated with development of 
naevi at chromosomal regions 9p21 and 22q13 (Falchi et al., 2009; Zhu et al., 2007). The 
strongest signal on 9p21 was located in the MTAP gene, which encodes 
methylthioadenosine phosphorylase, an enzyme involved in nucleoside metabolism. On 
22q13 the SNP with the highest association lies within PLA2G6, a gene belonging to the 
phospholipase A2 superfamily. Notably, the 9p21 locus accounted for 3.0% of nevus count 
variance, whereas the 22q13 locus accounted for only 0.7%. Thus the MTAP/CDKN2A locus 
is the strongest candidate region for naevus susceptibility. Clearly MTAP is an excellent 
candidate, but so is CDKN2A given its historical involvement in melanoma and the fact that 
individuals in families carrying CDKN2A mutations commonly have many naevi. It is 
thought that SNPs in the MTAP gene may confer long-range regulation of the CDKN2A 
locus. The various lines of evidence for long distance regulation of the CDKN2A locus are 
reviewed in Peters (2008). This would be an analogous situation to the OCA2 gene, whose 
influence on eye colour is not due to OCA2 coding variants, but to remote regulation by a 
SNP in the adjacent gene (Sturm et al., 2008). Another study on twins (Duffy et al., 2010) has 
revealed another association, this time with IRF4 (Interferon regulatory factor-4). Here the 
effect is somewhat weaker, and associated only with naevus development in an age-specific 
context (stronger effect in younger individuals). It will be very important to understand the 
mechanisms by which these genes confer naevus susceptibility given that the potential to 
develop naevi is the critical stratifying factor for the divergent pathways.  
The number of naevi an individual develops does not appear to just an innate trait, it may also 
be associated with levels of sun exposure, especially in children (reviewed in Gallagher et al., 
1995; Bauer et al., 2003). Recent studies examining the association of holidays overseas among 
young white English women found an increased in naevus count, particularly on anatomical 
sites intermittently exposed to sunlight, supporting the hypothesis that intermittent sun 
exposure is of relevance in the aetiology of naevi (Silva Idos, et al., 2009).  
7.3 UVR-induced proliferation of melanocytes 
Of possible relevance is how the branches of the divergent pathways differ in terms of the 
propensity of melanocytes in the skin to proliferate after UVR. Early studies in humans 
demonstrated that melanocyte density was correlated with sun exposure (Mitchell, 1963; 
Staricco & Pinkus, 1957; Stierner et al., 1989). Work by Quevedo and Colleagues (1965) 
reported that in mice melanocyte density increased up to 4-fold following repeated UVR 
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exposure, possibly due to increased mitotic activity of melanocytes (Rosdahl, 1978). More 
recent experiments have shown that melanocyte proliferation is greater following exposure 
to UVB than UVA, and that a single dose has a substantially greater effect than the same 
dose fractionated over several days (An et al., 2001; van Schanke et al., 2005). The generation 
of melanoma in mouse models using neonatal UVR is usually, although not always, 
accompanied by a strong proliferative response of melanocytes and their migration to the 
burnt area of the skin (Walker et al., 2009; Ferguson et al., 2010). Melanocyte proliferation 
would seem to be linked to the tanning response, which increases the amount of pigment in 
the skin, and is driven by UVB-induced damage to the skin. This is akin to “delayed tanning”, 
that can occur 1-5 d after exposure, and is primarily due to increased melanin production, 
although multiple exposures induce proliferation of melanocytes resulting in increased 
numbers in human skin (Yamaguchi et al., 2008). This is a long lasting protective 
pigmentation, unlike UVA-induced intermediate pigment darkening (IPD), which results from 
oxidation of pre-existing melanin, fades quickly, and is not protective against subsequent 
exposures. Interestingly, the induction of active melanocytes in mouse skin is also produced 
by chemical carcinogens, and the more carcinogenic the compound the greater the tanning 
response (Iwata et al., 1981). Liver carcinogens that are not metabolically activated in skin are 
ineffective. The compound most effective in inducing melanocyte proliferation was 7,12-
dimethylbenz[a]anthracene (DMBA), a very potent skin carcinogen. Thus the response of 
melanocytes is driven either by UVR or compounds that induce adducts within the DNA of 
skin cells.  
Melanocyte proliferation after UVR is thought to be driven by cytokines released by the 
microenvironment (Figure 2). UVR exposure modulates the production by keratinocytes 
(and probably other cells) of endothelins, Kit ligand (KITL), fibroblast growth factors (FGFs), 
and many others, which are all regulate melanocyte function (Hirobe, 2005; Lin & Fisher, 
2007; Imokawa, 2004). These include α-MSH (alpha melanocyte stimulating hormone), 
ACTH and a range of other growth factors. α-MSH and ACTH both bind to the MC1R on 
the surface of melanocytes, which activates the cyclic-AMP dependent kinase pathway, and 
the production of melanin pigments and possibly melanocyte proliferation. Most of these 
signaling molecules are known to enhance pigmentation, but little is known about how they 
might influence melanocyte proliferation in vivo. Mutations in mice that cause disruption 
keratinocyte function (resulting in epidermal thickening), for instance by germline activating 
keratin 4a or epidermal growth factor mutation (Fitch et al., 2003), or keratinocyte-specific 
ablation of 1-Integrin (López-Rovira et al., 2005), result in increased melanocyte numbers in 
the epidermis. This can also occur without epidermal hyperplasia by keratinocyte-specific 
overexpression of p53 (McGowan et al., 2008), Kit ligand (Kunisada et al., 1998), or, 
surprisingly, deletion of Fgf2 (Weiner et al., 2007). Treating human skin xenografted on to mice 
with exogenous FGF2, endothelin 3, and KITL resulted in the development of pigmented 
lesions, which only required UVB exposures repeatedly for one month for progression to 
melanoma (Berking et al., 2004). Hence signals from DNA damaged keratinocytes may play a 
role in inducing melanocytes to proliferate. To quote Lin and Fisher (2007), “could it be that 
keratinocytes are the primary UV responding population, and melanoma formation is largely a 
consequence of reactive secondary stimulation?” In fact the injection of highly active MSH 
analogues may be naevis promoting (Cardones et al., 2009; Langan et al., 2009). However the 
notion of UVR-induced melanocyte proliferation being melanomagenic is at odds with 
findings that stimulation of melanocytes with factor such as a-MSH (e.g. Bohm et al., 2005; 
Hauser et al., 2006; Abdel-Malek et al., 2009), Endothelin 1, (Kadekaro et al., 2005) and KITL 
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methylthioadenosine phosphorylase, an enzyme involved in nucleoside metabolism. On 
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phospholipase A2 superfamily. Notably, the 9p21 locus accounted for 3.0% of nevus count 
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demonstrated that melanocyte density was correlated with sun exposure (Mitchell, 1963; 
Staricco & Pinkus, 1957; Stierner et al., 1989). Work by Quevedo and Colleagues (1965) 
reported that in mice melanocyte density increased up to 4-fold following repeated UVR 
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exposure, possibly due to increased mitotic activity of melanocytes (Rosdahl, 1978). More 
recent experiments have shown that melanocyte proliferation is greater following exposure 
to UVB than UVA, and that a single dose has a substantially greater effect than the same 
dose fractionated over several days (An et al., 2001; van Schanke et al., 2005). The generation 
of melanoma in mouse models using neonatal UVR is usually, although not always, 
accompanied by a strong proliferative response of melanocytes and their migration to the 
burnt area of the skin (Walker et al., 2009; Ferguson et al., 2010). Melanocyte proliferation 
would seem to be linked to the tanning response, which increases the amount of pigment in 
the skin, and is driven by UVB-induced damage to the skin. This is akin to “delayed tanning”, 
that can occur 1-5 d after exposure, and is primarily due to increased melanin production, 
although multiple exposures induce proliferation of melanocytes resulting in increased 
numbers in human skin (Yamaguchi et al., 2008). This is a long lasting protective 
pigmentation, unlike UVA-induced intermediate pigment darkening (IPD), which results from 
oxidation of pre-existing melanin, fades quickly, and is not protective against subsequent 
exposures. Interestingly, the induction of active melanocytes in mouse skin is also produced 
by chemical carcinogens, and the more carcinogenic the compound the greater the tanning 
response (Iwata et al., 1981). Liver carcinogens that are not metabolically activated in skin are 
ineffective. The compound most effective in inducing melanocyte proliferation was 7,12-
dimethylbenz[a]anthracene (DMBA), a very potent skin carcinogen. Thus the response of 
melanocytes is driven either by UVR or compounds that induce adducts within the DNA of 
skin cells.  
Melanocyte proliferation after UVR is thought to be driven by cytokines released by the 
microenvironment (Figure 2). UVR exposure modulates the production by keratinocytes 
(and probably other cells) of endothelins, Kit ligand (KITL), fibroblast growth factors (FGFs), 
and many others, which are all regulate melanocyte function (Hirobe, 2005; Lin & Fisher, 
2007; Imokawa, 2004). These include α-MSH (alpha melanocyte stimulating hormone), 
ACTH and a range of other growth factors. α-MSH and ACTH both bind to the MC1R on 
the surface of melanocytes, which activates the cyclic-AMP dependent kinase pathway, and 
the production of melanin pigments and possibly melanocyte proliferation. Most of these 
signaling molecules are known to enhance pigmentation, but little is known about how they 
might influence melanocyte proliferation in vivo. Mutations in mice that cause disruption 
keratinocyte function (resulting in epidermal thickening), for instance by germline activating 
keratin 4a or epidermal growth factor mutation (Fitch et al., 2003), or keratinocyte-specific 
ablation of 1-Integrin (López-Rovira et al., 2005), result in increased melanocyte numbers in 
the epidermis. This can also occur without epidermal hyperplasia by keratinocyte-specific 
overexpression of p53 (McGowan et al., 2008), Kit ligand (Kunisada et al., 1998), or, 
surprisingly, deletion of Fgf2 (Weiner et al., 2007). Treating human skin xenografted on to mice 
with exogenous FGF2, endothelin 3, and KITL resulted in the development of pigmented 
lesions, which only required UVB exposures repeatedly for one month for progression to 
melanoma (Berking et al., 2004). Hence signals from DNA damaged keratinocytes may play a 
role in inducing melanocytes to proliferate. To quote Lin and Fisher (2007), “could it be that 
keratinocytes are the primary UV responding population, and melanoma formation is largely a 
consequence of reactive secondary stimulation?” In fact the injection of highly active MSH 
analogues may be naevis promoting (Cardones et al., 2009; Langan et al., 2009). However the 
notion of UVR-induced melanocyte proliferation being melanomagenic is at odds with 
findings that stimulation of melanocytes with factor such as a-MSH (e.g. Bohm et al., 2005; 
Hauser et al., 2006; Abdel-Malek et al., 2009), Endothelin 1, (Kadekaro et al., 2005) and KITL 
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(Serre et al., 2011) improve DNA repair efficiency after UVR and are thus proposed to be 
protective for melanoma. Clearly we are only at the beginning of understanding how 
melanocyte UVR responses influence melanoma development. Whether genetic variation in 
humans that augment the proliferative response of an individual’s melanocytes to UVR could 
increase susceptibility to a particular pathway of melanoma development (as suggested by 
Whiteman et al., 2003, and Rivers, 2004) remains to be determined. 
 
 
Fig. 2. Pathways regulating melanocyte function. 
Keratinocytes expresses various growth factors that bind to melanocyte receptors that  
regulate critical intracellular pathways. Expression of these factors is increased after damage 
to the skin such as after UVR exposure. Germline mutations in p16INK4A and CDK4 (light 
blue) confer susceptibility to familial melanoma. KIT, NRAS and BRAF (white) are mutated 
somatically in melanomas. MC1R and ASIP variants (yellow) confer increased risk for 
melanoma development. In addition, macrophages that infiltrate the skin after UVR may 
stimulate melanocytes. Activation of the pathways depicted result in increased pigment 
production and distribution to adjacent keratinocytes, and increased survival, DNA repair, 
and proliferation of the melanocyte. 
7.4 Stratification of CSD and non-CSD by somatic mutations signatures 
Examination of melanomas of various subtypes by array comparative genome hybridization 
(CGH) has detected significant differences at specific genomic locations such that DNA copy 
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number differences could stratify melanomas into CSD, non-CSD, acral and mucosal 
melanomas (the latter two assumed not associated with sun exposure)(Curtin et al., 2005). 
Subsequently the same group detected activating mutations of KIT in 28% (n=18) of CSD 
melanomas versus 0% (n=18). This raised hopes that KIT mutation status may differentiate 
CSD and non-CSD melanomas, but a subsequent Australian publication (Handolias et al., 
2010) showed that the frequency of KIT receptor gene mutations in CSD melanomas is very 
low. Thus KIT mutation may not a good discriminator of CSD and non-CSD melanomas. In 
contrast, it has consistently been shown that mutation of KIT is much more common in acral 
and mucosal lesions (Curtin et al., 2005; Smalley et al., 2009). As described above we are left 
with fact that BRAF mutations are more common in melanomas arising in the non-CSD 
group, and a tendency for NRAS mutations to be more often present CSD melanomas. 
Notably the frequency of NRAS mutants in this group is relatively low, hence it would be 
only a signature for a small proportion of CSD melanomas. Nonetheless a recent meta-
analysis of all published studies showed that NRAS mutation is found in 24% of CSD 
melanomas and 17% of non-CSD melanomas and calculated that NRAS mutation is 
significantly associated with CSD melanoma (OR 1.9, 95% CI 1.11-3.20)(Lee et al., 2010). 
Despite the significant difference, NRAS mutation appears to be a weak discriminator of the 
CSD and non-CSD pathways. BRAF mutation is a better discriminator, having been found in 
30% of CSD melanomas and 49% of non-CSD melanoma. BRAF mutation is significantly 
associated with non-CSD melanoma (OR 2.4, 95% CI 1.35-3.10). Unlike SSM and NM, few 
LMs (10-20%) harbor BRAFV600E, (Hocker & Tsao, 2007). Hence there does not seem to be a 
strong mutations signature for the non-CSD pathway except for BRAF, which is mutated in 
over 80% of naevi. The stratification of CSD and non-CSD pathways in terms of BRAF 
mutation may have more to do with their differential association with naevus development 
than the forms of UVR exposure.  
8. Vitamin D and potential protective effects of chronic sun exposure on 
melanoma?  
Vitamin D has been shown to inhibit proliferation and induce differentiation in some 
melanoma cells, although melanoma cell lines have demonstrated resistance to vitamin D 
growth arrest (Danielsson et al., 1998,1999; Reichrath et al., 2007). A population-based study 
of 528 melanoma cases found that the presence of solar elastosis (dermal sun damage) was 
associated with a better prognosis for melanoma patients (Berwick et al., 2005). These 
findings have provoked speculation that as chronic sun damage induces a less aggressive 
form of melanoma (LMM), perhaps vitamin D levels might somehow slow melanoma 
growth and/or improve prognosis. To further determine if the anti-proliferative effect of 
vitamin D is modifying outcome for melanoma patients, Downing and colleagues, (2008) 
carried out a study to compare two populations with similar ethnic background but 
potentially different environmental influences. Patients diagnosed with invasive melanoma 
between 1993 and 2003 in Yorkshire (n= 4170) and New South Wales (NSW, n= 30,520) were 
identified from cancer registry databases and prognostic information (age, sex, 
socioeconomic background, tumour site and Breslow thickness) was examined. Five-year 
relative survival was 86.9% (95% CI, 85.2-88.5) in Yorkshire and 88.6% (95% CI, 88.1-89.1) in 
NSW. There was a suggestion of reduced risk for death in Australia, but differences in 
tumour thickness appeared to be the most important factor. The difference in survival may 
be due to the strong health promotion message for screening of skin cancer in Australia 
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(Serre et al., 2011) improve DNA repair efficiency after UVR and are thus proposed to be 
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number differences could stratify melanomas into CSD, non-CSD, acral and mucosal 
melanomas (the latter two assumed not associated with sun exposure)(Curtin et al., 2005). 
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contrast, it has consistently been shown that mutation of KIT is much more common in acral 
and mucosal lesions (Curtin et al., 2005; Smalley et al., 2009). As described above we are left 
with fact that BRAF mutations are more common in melanomas arising in the non-CSD 
group, and a tendency for NRAS mutations to be more often present CSD melanomas. 
Notably the frequency of NRAS mutants in this group is relatively low, hence it would be 
only a signature for a small proportion of CSD melanomas. Nonetheless a recent meta-
analysis of all published studies showed that NRAS mutation is found in 24% of CSD 
melanomas and 17% of non-CSD melanomas and calculated that NRAS mutation is 
significantly associated with CSD melanoma (OR 1.9, 95% CI 1.11-3.20)(Lee et al., 2010). 
Despite the significant difference, NRAS mutation appears to be a weak discriminator of the 
CSD and non-CSD pathways. BRAF mutation is a better discriminator, having been found in 
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associated with non-CSD melanoma (OR 2.4, 95% CI 1.35-3.10). Unlike SSM and NM, few 
LMs (10-20%) harbor BRAFV600E, (Hocker & Tsao, 2007). Hence there does not seem to be a 
strong mutations signature for the non-CSD pathway except for BRAF, which is mutated in 
over 80% of naevi. The stratification of CSD and non-CSD pathways in terms of BRAF 
mutation may have more to do with their differential association with naevus development 
than the forms of UVR exposure.  
8. Vitamin D and potential protective effects of chronic sun exposure on 
melanoma?  
Vitamin D has been shown to inhibit proliferation and induce differentiation in some 
melanoma cells, although melanoma cell lines have demonstrated resistance to vitamin D 
growth arrest (Danielsson et al., 1998,1999; Reichrath et al., 2007). A population-based study 
of 528 melanoma cases found that the presence of solar elastosis (dermal sun damage) was 
associated with a better prognosis for melanoma patients (Berwick et al., 2005). These 
findings have provoked speculation that as chronic sun damage induces a less aggressive 
form of melanoma (LMM), perhaps vitamin D levels might somehow slow melanoma 
growth and/or improve prognosis. To further determine if the anti-proliferative effect of 
vitamin D is modifying outcome for melanoma patients, Downing and colleagues, (2008) 
carried out a study to compare two populations with similar ethnic background but 
potentially different environmental influences. Patients diagnosed with invasive melanoma 
between 1993 and 2003 in Yorkshire (n= 4170) and New South Wales (NSW, n= 30,520) were 
identified from cancer registry databases and prognostic information (age, sex, 
socioeconomic background, tumour site and Breslow thickness) was examined. Five-year 
relative survival was 86.9% (95% CI, 85.2-88.5) in Yorkshire and 88.6% (95% CI, 88.1-89.1) in 
NSW. There was a suggestion of reduced risk for death in Australia, but differences in 
tumour thickness appeared to be the most important factor. The difference in survival may 
be due to the strong health promotion message for screening of skin cancer in Australia 
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resulting in increased detection of early thin lesions with better outcomes. A recent follow-
up study of 872 patients from the Leeds cohort (median follow-up, 4.7 years) has shown that 
higher 25-hydroxyvitamin D3 levels, at diagnosis, were associated with both thinner 
tumours and better survival from melanoma, independent of Breslow thickness (Newton-
Bishop et al., 2009). This data needs to be validated in additional sample sets and the level of 
vitamin D in the follow up period examined. Understanding the balance between optimal 
sun exposure to limit skin cancer risk while maintaining adequate vitamin D levels has been 
further complicated by work from Damian et al. (2010), which found that vitamin D had a 
presumably undesirable immunosuppressive effect when vitamin D analogues were applied 
topically to irradiated skin. On the other hand, Mason et al. (2010) reported that increased 
vitamin D levels reduced DNA damage in vitro following UVR and subsequently reduced 
UVR-induced immunosuppression in mouse and human skin. Currently data do not allow 
us to predict with any accuracy whether there may be a true causal influence of low Vitamin 
D levels on melanoma outcome. Although there is no solid evidence as such, we cannot 
discount that CSD melanomas may have an innately better prognosis because they are not 
associated with naevus susceptibility (certainly this would be the case for LMM which are 
well known to have better outcomes than SSM and NM).  
9. Animals as model systems for melanoma 
To mechanistically link sun exposure and melanoma is very difficult because individual sun 
exposure, especially based on recall, is difficult to assess, and the ratio of UVB/UVA varies 
greatly with geographical location, season, and time of day. This leads to great uncertainty 
in inferences about how different wavelengths influence melanoma development, hence 
sometimes model experimental systems can be useful, and animal models for carcinogenesis 
can provide complementary information when epidemiological studies have difficulty 
avoiding confounding factors. Grey horses and certain strains of pig are models for genetic 
susceptibility to melanoma, although there is no evidence for any effects of UVR exposure 
(Rosengren Pielberg et al., 2008; Seltenhammer et al., 2004). Opossom, guinea pigs and 
Angora goats have also been used as models for melanocytic lesion development (Chan et 
al., 2001; Menzies et al., 2004; Green et al., 1996). However except for goats, UVR exposure is 
not known to play any role in melanoma development in these animals. All of these species 
are very expensive to maintain, and generally limited in terms of the availability of reagents 
such as antibodies, and resources for genetic analyses. Various strains of fish including 
zebrafish (reviewed by Patton et al., 2010) and other fish species such as Xiphophorus 
(discussed in more detail below) are tractable models where UVR exposure can exacerbate 
the development of melanoma. 
9.1 Modeling chronic-induced melanoma in mice  
In contrast to the ability to induce SCC in wild type mice using chronic treatment regimens, 
a pre-existing genetically engineered mutation, and exposure of neonates, is necessary for 
inducing murine melanoma (Noonan et al., 2001). There are three reasons proposed to 
explain why mice develop melanoma after neonatal UVR, but not after chronic exposures to 
adult animals. First, neonatal mice have epidermal melanocytes that are likely to be 
damaged by UVR, whereas adult mice do not. Second, the heightened sensitivity of neonatal 
melanocytes to proliferation following UVR may be destabilizing (Walker et al., 2009), and 
third, the lack of inflammatory response to UVR in neonates may create a tolerant 
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environment for melanocyte transformation (Wolnicka-Glubisz et al., 2007; McGee et al., 
2011). It is thought that murine neonatal UVR may be somewhat analogous to childhood 
sunburn (Noonan et al., 2001). Despite it being a somewhat specialized system, there is 
much we can learn using the neonatal UVR about how UVR results in melanocyte 
transformation. For instance using the Mt-Hgf model (with overexpression hepatocyte 
growth factor throughout the skin) it has been shown that UVB, and not UVA, induces 
melanoma (de Fabo et al., 2004), and that use of sunscreen can attenuate its development 
(Klug et al., 2010).  
The skin of hairless mice contains some epidermal melanocytes, hence the animals represent 
a murine system amenable to chronic UVR exposures. Van Schanke et al. (2006) have carried 
out extensive UVR carcinogenesis studies on such animals carrying Ink4a/Arf deletion, with 
some cohorts also with co-deletion of the nucleotide excision repair gene Xpa. The mice 
developed naevi at a low rate spontaneously which was greatly increased by UVB treatment 
(how much depended upon the protocol and genotype). The naevi occasionally progressed 
to melanoma. Naevus development was dramatically increased by Xpa deletion, implicating 
UVB-induced pyrimidine dimer-type mutations in the pathogenesis of the lesions. 
Consistent with human melanoma, where intermittent exposures are most important, a 
single high dose erythemal exposure was much more effective at inducing naevi than the 
same dose delivered daily in a fractionated regimen (van Schanke et al., 2006).  
In terms of using adult mice for UVR studies, a major problem is that they do not have 
epidermal melanocytes (and murine melanomas that develop are mostly dermal). Mice 
overexpressing Kitl in their keratinocytes (K14-Kitl) have epidermal melanocytes throughout 
life (Kunisada et al., 1998). They do not develop melanoma after chronic UVR exposures 
(Yamazaki et al., 2005). Even when crossed onto a DNA repair defective background (Xpa-
null) no lesions were detected using a standard chronic UVB exposure protocol. But when the 
total UVB dose was increased over one half of the K14-Kitlg::Xpa-/- animals developed 
epidermal lesions reminiscent of lentigo and nodular melanomas (Yamazaki et al., 2005). Thus 
very high (almost physiological irrelevant) doses of UVB, plus a DNA repair defect, is need to 
induce transformation of the epidermal melanocytes in these mice. Interestingly, the animals 
developed very few SCCs, which both the high and low dose regimens do very effectively in 
wild type mice, hence it is thought that the extreme hyperpigmentation may be somewhat 
protective for both forms of skin cancer in this model. Nonetheless, murine epidermal 
melanocytes are apparently not totally resistant to transformation by UVR per se. It is possible 
that albino versions of the K14-Kitl model may have potential as a mouse model for chronic 
UVR-induced melanoma. Chronic UVR is somewhat effective in inducing melanomas in Tyr-
HrasG12V transgenic mice on an albino, but not pigmented strain background (Broome Powell, 
et al., 1999). However in Mt-Hgf transgenics chronic adult exposures do not exacerbate the 
development of melanoma (Noonan et al., 2001).  
10. Mechanisms of UVR carcinogenesis in melanoma 
10.1 Evidence of UVB causality in melanoma 
The ultraviolet spectrum that plays a physiological role in skin cancer development is 
arbitrarily divided into UVB (280-315 nm) and UVA 315-400 nm). Non-melanoma skin 
cancer (especially SCC) is undeniably associated with chronic UVR exposure, and tumours 
carry “classical” UVB signature mutations resulting from mis-repaired cyclobutane 
pyrimidine dimer (CPD) or pyrimidine (6-4) pyrimidone photoproducts (6-4 PPs) adducts. 
The action spectrum for SCC induction in mice, and the inferred action spectrum for SCC in 
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Consistent with human melanoma, where intermittent exposures are most important, a 
single high dose erythemal exposure was much more effective at inducing naevi than the 
same dose delivered daily in a fractionated regimen (van Schanke et al., 2006).  
In terms of using adult mice for UVR studies, a major problem is that they do not have 
epidermal melanocytes (and murine melanomas that develop are mostly dermal). Mice 
overexpressing Kitl in their keratinocytes (K14-Kitl) have epidermal melanocytes throughout 
life (Kunisada et al., 1998). They do not develop melanoma after chronic UVR exposures 
(Yamazaki et al., 2005). Even when crossed onto a DNA repair defective background (Xpa-
null) no lesions were detected using a standard chronic UVB exposure protocol. But when the 
total UVB dose was increased over one half of the K14-Kitlg::Xpa-/- animals developed 
epidermal lesions reminiscent of lentigo and nodular melanomas (Yamazaki et al., 2005). Thus 
very high (almost physiological irrelevant) doses of UVB, plus a DNA repair defect, is need to 
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wild type mice, hence it is thought that the extreme hyperpigmentation may be somewhat 
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cancer (especially SCC) is undeniably associated with chronic UVR exposure, and tumours 
carry “classical” UVB signature mutations resulting from mis-repaired cyclobutane 
pyrimidine dimer (CPD) or pyrimidine (6-4) pyrimidone photoproducts (6-4 PPs) adducts. 
The action spectrum for SCC induction in mice, and the inferred action spectrum for SCC in 
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humans, peaks at 293 nm, firmly within the UVB range (de Gruijl et al., 1993). This overlaps 
with the action spectrum for CPD formation and sunburn. UVB, but not UVA, very 
effectively induces non-melanoma and melanoma skin cancer in mice (De Gruijl et al., 1993; 
De Fabo et al., 2004). Evidence of a critical role for UVB in melanoma induction comes from 
humans (van Steeg & Kramer, 1999) and mice (Yang et al., 2007) carrying nucleotide 
excision repair (NER) enzyme mutations (in XP genes) where melanoma incidence is 
dramatically increased after UVR exposure. XP patients have extreme sun sensitivity and 
burn very easily (van Steeg & Kramer, 1999). Melanomas from these individuals frequently 
carry TP53 and PTEN gene mutations that show classic C-T or CC-TT UVB signatures and 
lesions are similar in body site distribution associated with chronic UVR exposure (Spatz et 
al., 2001; Wang et al., 2009). Further, the majority of melanomas in these individuals appear 
to be of the lentigo type, but they do not exhibit the solar elastosis that is invariably present 
in the same melanoma subtypes developing in DNA repair-proficient individuals (Spatz et 
al., 2001). 
More information about the melanoma UVR mutation signature comes from the first 
melanoma genome sequence (Pleasance et al., 2010). Of 33,000 single point mutations 
detected, nearly 70% were C-T transitions. The only other nucleotide change above levels 
expected by chance were G-T transitions (9%) that can be a marker for UVA-induced damage 
(Agar et al., 2004). Notwithstanding the fact that only one melanoma, a secondary with 
undetected primary, was sequenced (Pleasance et al., 2010), and that some mutations could 
have been acquired by sun exposure during tumour development, these results suggest that 
CPD adducts may be critical driver of melanoma genesis. This is remarkably similar to the 
results of a recent review of all known CDKN2A and TP53 point mutations in melanoma 
(Hocker & Tsao, 2007) which found that the frequency of UVB-signature mutations (65 and 55 
% respectively) in these two genes in melanoma is similar to that found in SCC, a skin cancer 
with well-characterized UVB causality. Despite the presence of these UVR signature 
mutations, the overall mutation rate of these two genes in primary cutaneous melanomas is 
very low (7.9% and 11.8% respectively) (Hocker & Tsao, 2007), accounting for only about 10% 
of all melanomas. By comparison, BRAF or NRAS are mutated in more than 70% of all 
cutaneous melanomas (Hocker & Tsao, 2007). 
Although we usually concentrate on CPDs as the mutagenic adduct, UVB also induces 6-
4PPs, which are larger the CPDs, hence recognized and removed much more rapidly by 
nucleotide excision repair (NER). It has been hypothesized that 6-4PPs may be involved in 
melanoma induction, not via a mutagenic mechanism, rather via their deregulation of 
genome surveillance and transcription mechanisms leading to downstream changes that 
may deregulate the melanocyte (Mitchell et al., 2010). It is known that the two forms of 
UVB-induced photoproduct induce differential effects within cells (Lo et al., 2005). 6-4PP 
lesions are much more important in triggering cell death, whereas the response of the cell to 
CPD lesions mainly involves cell cycle arrest. An important role for 6-4PPs in melanoma is a 
speculative but interesting potential alternate aetiogy. Of note, 6-4PPs play no role in the 
generation of SCC in mice, CPD adducts are necessary and sufficient  (Jans et al., 2005).  
10.2 Evidence of UVA causality in melanoma 
In contrast to UVB, UVA is generally extremely inefficient at inducing CPDs, oxidative 
damage, erythema, and non-melanoma skin cancer in mice (De Gruijl et al., 1993; 
Besaratinia & Pfeifer, 2008; Runger & Kappes, 2008).  However UVA can induce 8-oxo-
guanine (8-oxoG) oxidative adducts that can results in the formation of G-T transversions 
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(Agar et al., 2004). Results of another study suggest that T-G transversion is a UVA 
“signature” (Drobetsky et al., 1995). UVA-specific lesions in the p53 gene have been detected 
in skin constructs and squamous tumours (Agar et al., 2004; Huang et al., 2009). In contrast, 
in vivo studies using “Big Blue” mice, and in vitro data, suggests that UVA-induced 
mutations are mainly of the pyrimidine dimer type (Mouret et al., 2006; Besaratinia & 
Pfeifer, 2008; Runger & Kappes, 2008). An interesting idea regarding the role of UVA in 
melanoma is that UVA and UVB generate a similar DNA mutation spectrum (although 
UVA is much less effective at inducing CPDs), but that UVA-induced cellular stress and 
repair response is not as great, thus lesions may not be as effectively removed (Runger & 
Kappes, 2008). Possibly this would only apply after relatively pure UVA exposures, for 
instance from solaria, or through glass. 
Notably, most of the studies mentioned above have used keratinocytes and fibroblasts, and 
not melanocytes to assess the mutagenicity of UVA. A recent study suggests that UVA is 
much more effective than UVB in inducing reactive oxygen species in melanocytes than in 
the other cell types (Wang et al., 2010). In addition, melanocytes are less efficient in 
removing CPDs and oxidative DNA damage. As discussed by Runger, (2011), these findings 
are at odds with some other studies, but nonetheless are indicative of potential differences 
between the responses of melanocytes and other skin cells to UVR. Runger, (2011) also raises 
the question of why if there is so much oxidative damage induced by UVA why are lesions 
typical for such stress vastly underrepresented in melanoma (e.g. Pleasance et al., 2010)? He 
suggests that this could relate to the low mutagenicity of 8-oxoG adducts.  
The ability of UVA to generate melanoma in Xiphophorus backcross fish is suggestive of a 
role for UVA in melanoma development (Setlow et al., 1989; Setlow, 1999). This has long 
been interpreted to infer UVA causality for melanoma, probably based on melanin 
photosensitization and subsequent oxidative damage to DNA. UVA is about 1000-fold less 
effective than UVB in inducing erythema and SCC, whereas in fish melanoma induction 
there is only about a 10-fold difference between the effects of UVB and UVA. Given the 
overwhelming preponderance of UVA in natural sunlight, if the fish action spectrum held 
up in humans, UVA would dominate melanoma causality. Xiphophorus are a complicated 
model. They carry photolyase, a light-inducible system that very rapidly and specifically 
repairs specific DNA adducts (e.g.. CPD-photolyase removes CDPs). Such repair systems 
are present in most of the plant and animal kingdom except for rodents and primates. Thus 
the fish experiments are carried out in the dark, and activation (by light) of the photolyase 
reduces melanoma incidence to background levels. Recently Timmins and colleagues used 
electron paramagnetic resonance assays to show that the action spectrum for melanoma and 
melanin radical production overlap (Wood et al., 2006), further evidence for melanin radical 
causation. However the notion that UVA is more effective than UVB in inducing melanoma 
in fish has been questioned by Mitchell et al., (2010), after similar experiments using 
apparently the same strain of fish. This conflicting result from the original study (Setlow et 
al., 1989) may be largely explained by the fact that latest study used more animals to make 
the results more statistically significant, and followed the fish for a longer time, allowing for 
later age of onset of some melanomas. Further, the fish also carry nucleotide excision repair 
activity, and melanoma development is exacerbated in fish with defective NER (Mitchell et 
al., 2007). The authors point out that UVA exposure is still potentially very important in the 
induction of melanoma in humans, but it may not be via a melanin radical-based mechanism.  
One would expect that if melanin sensitization were an important mechanism, we would 
not see the huge increase in melanoma risk for patients with XP, unless they also lacked a 
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(Agar et al., 2004). Results of another study suggest that T-G transversion is a UVA 
“signature” (Drobetsky et al., 1995). UVA-specific lesions in the p53 gene have been detected 
in skin constructs and squamous tumours (Agar et al., 2004; Huang et al., 2009). In contrast, 
in vivo studies using “Big Blue” mice, and in vitro data, suggests that UVA-induced 
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melanoma is that UVA and UVB generate a similar DNA mutation spectrum (although 
UVA is much less effective at inducing CPDs), but that UVA-induced cellular stress and 
repair response is not as great, thus lesions may not be as effectively removed (Runger & 
Kappes, 2008). Possibly this would only apply after relatively pure UVA exposures, for 
instance from solaria, or through glass. 
Notably, most of the studies mentioned above have used keratinocytes and fibroblasts, and 
not melanocytes to assess the mutagenicity of UVA. A recent study suggests that UVA is 
much more effective than UVB in inducing reactive oxygen species in melanocytes than in 
the other cell types (Wang et al., 2010). In addition, melanocytes are less efficient in 
removing CPDs and oxidative DNA damage. As discussed by Runger, (2011), these findings 
are at odds with some other studies, but nonetheless are indicative of potential differences 
between the responses of melanocytes and other skin cells to UVR. Runger, (2011) also raises 
the question of why if there is so much oxidative damage induced by UVA why are lesions 
typical for such stress vastly underrepresented in melanoma (e.g. Pleasance et al., 2010)? He 
suggests that this could relate to the low mutagenicity of 8-oxoG adducts.  
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been interpreted to infer UVA causality for melanoma, probably based on melanin 
photosensitization and subsequent oxidative damage to DNA. UVA is about 1000-fold less 
effective than UVB in inducing erythema and SCC, whereas in fish melanoma induction 
there is only about a 10-fold difference between the effects of UVB and UVA. Given the 
overwhelming preponderance of UVA in natural sunlight, if the fish action spectrum held 
up in humans, UVA would dominate melanoma causality. Xiphophorus are a complicated 
model. They carry photolyase, a light-inducible system that very rapidly and specifically 
repairs specific DNA adducts (e.g.. CPD-photolyase removes CDPs). Such repair systems 
are present in most of the plant and animal kingdom except for rodents and primates. Thus 
the fish experiments are carried out in the dark, and activation (by light) of the photolyase 
reduces melanoma incidence to background levels. Recently Timmins and colleagues used 
electron paramagnetic resonance assays to show that the action spectrum for melanoma and 
melanin radical production overlap (Wood et al., 2006), further evidence for melanin radical 
causation. However the notion that UVA is more effective than UVB in inducing melanoma 
in fish has been questioned by Mitchell et al., (2010), after similar experiments using 
apparently the same strain of fish. This conflicting result from the original study (Setlow et 
al., 1989) may be largely explained by the fact that latest study used more animals to make 
the results more statistically significant, and followed the fish for a longer time, allowing for 
later age of onset of some melanomas. Further, the fish also carry nucleotide excision repair 
activity, and melanoma development is exacerbated in fish with defective NER (Mitchell et 
al., 2007). The authors point out that UVA exposure is still potentially very important in the 
induction of melanoma in humans, but it may not be via a melanin radical-based mechanism.  
One would expect that if melanin sensitization were an important mechanism, we would 
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defence against the melanin radicals.However there remains an anomaly that Africans with 
albinism (i.e. no melanin, or low levels), who practice poor sun protection, have been 
consistently shown to only very rarely develop melanoma (reviewed in Wood et al., 2006). In 
164 such patients in Tanzania actinic keratoses were found in 100%, and SCC in 34%, of albino 
individuals over 30 years old, but no melanomas were found (Lookingbill et al., 1995). In these 
cases childhood sunburns do not seem to drive subsequent melanoma development.  
The only other model used as evidence for UVA causality in melanoma is the South 
American opossum, Monodelphis Domestica, although the effect is weak (Mitchell et al., 2007). 
A study on focal pigmented hyperplasia developing in the opossum after UVA (Ley, 2001) 
showed that the action spectrum for the development of these lesions was much closer to 
the SCC action spectrum rather than the fish action spectrum. Nonetheless pure UVA does 
seem able to induce melanocyte proliferations in these animals, albeit not melanomas. 
Another interesting model is the guinea pig. These animals develop naevi after chronic UVB 
but not after chronic UVA exposures (Menzies et al., 2004). Neonatal UVB and not UVA 
induces melanoma in albino Mt-Hgf mice (De Fabo et al., 2004). In short, the fish is the only 
published model for UVA-induced melanoma and the conclusions have been questioned. 
However there is some evidence using pigmented Mt-Hgf mice that UVA can increase 
melanoma penetrance after neonatal exposure (Fisher et al., 2009, meeting report from the 
6th international melanoma congress), but it does not induce melanoma in albino Mt-Hgf 
mice. UVB effectively induces melanoma on both pigmented and non-pigmented 
backgrounds. Because the UVA effect is only seen in pigmented mice, the carcinogenic 
mechanism may involve increased oxidative stress induced by photosensitized melanin. 
Application of inhibitors of melanin synthesis before and after UVR exposure of appropriate 
animal models may provide an avenue to test the melanin radical hypothesis. It appears that 
the debate about the role of UVA in melanoma induction is not over.  
It must be pointed out that the murine and fish studies cannot model cumulative lifetime 
exposure to UVA in sunlight. We cannot rule out a role for UVA given that although the 
genotoxicity (i.e. frequency of dimers) is much higher in the UVB, UVA is far more 
abundant in sunlight (at least 20-fold). Not only are there debates about the role of UVA, 
there are even studies suggesting a protective role for UVA. Here, with UVB dose kept 
constant, increasing UVA dose protects against epidermal apoptosis (Ibuki et al., 2007) and 
SCC induction in mice (Forbes et al., 1978). Which wavelengths are critical for melanoma 
formation? In some ways this is irrelevant, and the real question is what type of adducts are 
needed? The balance of evidence to date suggests that the susceptibility of a melanocytes to 
UVR-induced transformation depends mostly upon the presence of classical CPD type 
adducts that if not properly removed result in C-T or CC-TT mutations. However this has 
not been formally proven.  
10.3 Role of UVR in generating BRAF and NRAS mutations 
The DNA base changes causing activating mutations in BRAF and NRAS do not represent 
classical UVB signatures, thus other mechanisms have been proposed for their causation. 
BRAFV600E is found in several internal malignancies, arguing against a specific role for UVR, 
and more suggestive of a role for generalized oxidative damage, or another mechanism 
(Dhomen et al., 2007). The BRAFV600E mutation is generally caused by a T>A transversion, 
and one theory regarding the possibly role of UVR in the generation of this change relates to 
error prone repair at the V600 mutation site in BRAF caused by adjacent pyrimidine dimers 
(Thomas et al., 2006). On the other hand, Besaratinia, & Pfeifer, (2008) show that there are 
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many types of lesions that can be induced by solar UVR, which although uncommon, could 
explain some of the mutations in detected in BRAF, particularly as there is selection pressure 
for the “required” the amino acid change. As discussed by Lund & Timmins, (2007) bulky 
adducts formed by reactive melanin species may be involved. None of these theories have 
been functionally tested. However in many melanomas the base change resulting in the 
NRAS codon 61 mutations is a G>T transversion (Hocker & Tsao, 2007). It has been 
experimentally confirmed in vitro using murine fibroblasts, that an 8-oxoG-mediated 
transcriptional mutagenesis mechanism greatly enhances the acquisition of such mutations 
(Saxowskya et al., 2008). Using a system that selected for clones carrying mutant HRASQ61 
mutations they showed that these were very rare in wild type murine fibroblasts but 
common in cells lacking the enzyme 8-oxoguanine DNA-glycosylase 1 (Ogg1), which 
repairs 8-oxoG lesions. The mutations were induced by G-T changes in the transcribed 
strand of the HRAS transcript. Thus while NRAS mutations may be induced in melanomas 
following UVB exposure, this mechanistic data best supports a role for oxidative adducts in 
their formation rather then CPDs. There is little mechanistic data to support the genesis of 
the BRAFV600E mutation from oxidative stress, only the observation that it is sometimes 
found in mucosal and acral melanomas, not associated with sun exposure, and in internal 
cancers (thyroid and colorectal) (Dhomen et al., 2007). 
It is difficult to glean much from murine melanoma models regarding the potential role of 
UVR in inducing BRAF or NRAS mutations. Braf mutations have not been detected in 
murine melanomas. One interesting finding comes from work with Ink4a/Arf-/-/Xpc+/- mice. 
These mice, essentially the only example of mice developing melanoma due to UVR 
exposure without carrying an engineered oncogenic mutation, resulted in development of 
melanomas that frequently carried KrasQ61 mutations. Similarly, melanomas induced by 
UVB in Ink4a/Arf-/-/Xpa+/- adult hairless mice occasionally carried an NrasQ61 mutation (van 
Schanke et al., 2006). The RasQ61 mutations in the NER-deficient mice were mainly G-T 
changes, again reflective of mis-repaired 8-oxoG adducts rather than mis-repaired CPDs.  
As suggested by Runger, (2011), oncogenes can only function as such due to very specific 
gain-of-function mutations that can only occur as certain amino acid changes, “thus the DNA 
base change may rather indicate a constraint on the amino acid change than the identity of the 
mutagen”. 
11. UVR, melanoma, and the immune system 
11.1 Immunosuppression 
There is undoubtedly an interplay between damaged melanocytes and immunocytes, 
whether just after UVR exposure or during tumour progression. It has long been known that 
the UVR exposure can suppress the immune system and create an environment tolerant to 
the growth of tumour cells that should be targeted for immunological destruction. Margaret 
Kripke and colleagues (Donawho et al., 1996) described how the growth of implanted 
tumours in mice is enhanced by local photoimmunosuppression. How much of a role it 
plays in melanoma development is unknown. Transplant patients taking 
immunosuppressive drugs are at a particularly heightened risk of skin cancer, particularly 
SCC, but it is a matter of debate whether they are at increased risk of melanoma. Out of nine 
studies recently reviewed (Bastiaannet et al., 2007), five reported between 2 and 4-fold 
increased risk, and four reported no increased risk. If immunosuppressed patients are at 
increased melanoma risk, it is low, and much less than the risk of developing SCC. Despite 
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gain-of-function mutations that can only occur as certain amino acid changes, “thus the DNA 
base change may rather indicate a constraint on the amino acid change than the identity of the 
mutagen”. 
11. UVR, melanoma, and the immune system 
11.1 Immunosuppression 
There is undoubtedly an interplay between damaged melanocytes and immunocytes, 
whether just after UVR exposure or during tumour progression. It has long been known that 
the UVR exposure can suppress the immune system and create an environment tolerant to 
the growth of tumour cells that should be targeted for immunological destruction. Margaret 
Kripke and colleagues (Donawho et al., 1996) described how the growth of implanted 
tumours in mice is enhanced by local photoimmunosuppression. How much of a role it 
plays in melanoma development is unknown. Transplant patients taking 
immunosuppressive drugs are at a particularly heightened risk of skin cancer, particularly 
SCC, but it is a matter of debate whether they are at increased risk of melanoma. Out of nine 
studies recently reviewed (Bastiaannet et al., 2007), five reported between 2 and 4-fold 
increased risk, and four reported no increased risk. If immunosuppressed patients are at 
increased melanoma risk, it is low, and much less than the risk of developing SCC. Despite 
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this, individuals taking immunosuppressive drugs sometimes develop eruptive naevi, and 
this form of melanocyte proliferation is proposed to be due to the effects of 
immunosuppression rather than the drugs that induce it (Zattra et al., 2009).  
An important factor in the initiation of melanoma in mice by neonatal and not adult 
exposure is that neonates exhibit a defective inflammatory response to UVR compared to 
adults (Wolnicka-Glubisz et al., 2007; McGee et al., 2011). There may be ways to investigate 
the role that photoimmunosuppression plays in UVR-induced tumorigenesis. For example, 
(Jans et al. 2005) used mice carrying an inducible photolyase system that very rapidly 
removes CPDs from the skin after UVR exposure. Removal of CPDs from the whole skin 
significantly reduces both SCC development and immunosuppression. However, removal 
of CPDs specifically from the epidermal basal layer (using K14-Photolyase transgenics) 
similarly reduced tumorigenesis, but did not prevent photoimmunosuppression (Jans et al., 
2006). Thus immunosuppression seems to depend upon damage throughout the epidermis 
and dermis, whereas SCC is driven largely by UVR damage to basal layer keratinocytes, 
suggesting that immunosuppression may be important but not essential for the initiation of 
this skin cancer in mice  (at least in terms of UVR damage-driven SCCs). The relative 
contribution of direct DNA damage to melanocytes, and photoimmunosuppression, in 
melanoma needs to be clarified. 
11.2 UVR-induced inflammation 
One of the difficulties in studying UVR causality in melanoma is not only that multiple UVR 
response mechanisms such as DNA repair, proliferation and immune response play a role, 
but they are often not independent of each other. We can look at the normal response of 
melanocytes to UVR (Figure 2), in particular the multiple effects of cytokines that are 
released in the skin to activate melanocytes. Upon UVR-induced damage keratinocytes 
upregulate their expression of the pro-opiomelanocortin (Pomc) gene. Pomc encodes a pro-
peptide that is cleaved to generate α-MSH, ACTH and β-endorphin (Cui et al., 2007). 
Together, these peptides have pleiotropic effects on endocrine and neuroendocrine 
signaling, and the immune system (Brzoska et al., 2008), in addition to the melanotropic 
function of αMSH. Another protein upregulated in the epidermis after UVR exposure, KITL, 
can drive proliferation and migration of both pro-inflammatory mast cells as well as 
melanocytes (Kunisada et al., 1998). Pro-inflammatory cytokines like interleukin 12 (Schwarz 
et al., 2002) and interleukin-18 (Schwarz et al., 2006) can increase DNA repair capability of 
melanocytes after UVR exposure. In the case of interleukin-18, this may be via upregulation of 
KITL (Hue et al., 2005). Another secreted protein, previously known only for its role in 
immune responses to infectious agents, β-Defensin, is upregulated over 50-fold in human 
epidermis after UVR exposure (Enk et al., 2006) and is possibly involved in melanocye 
response to UVR as another ligand for the MC1R (Candille et al., 2007). Thus the release of 
cytokines within the skin not only activates the immune system, but also induces protective 
responses in the melanocye itself (e.g. increased pigmentation, proliferation, and DNA repair).  
The proliferative burst of melanocytes emanating from the upper portion of the hair follicle 
in neonatal mice presents an excellent opportunity to investigate how melanocytes are 
activated by UVR exposure. Zaidi et al. (2011) have cleverly utilized the power of the 
genetically modified mice to look into the mechanism of this melanocyte response. They 
used a genetically engineered mouse model inducibly expressing green fluorescent protein 
(GFP) in melanocytes. GFP was induced immediately after UVB exposure and melanocytes 
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were isolated via fluorescence activated cell sorting at various time-points after neonatal 
UVR. Gene expression array analysis on these cells detected a strong signature of interferon-
gamma (IFN)-induced genes that coincided with the appearance of melanocytes in the 
epidermis. It was subsequently shown that that the melanocyte response is largely driven by 
IFN released from infiltrating macrophages. Further experiments indicated that not only 
can macrophages influence melanocyte proliferation in the context of UVR exposure, but 
that they also contribute to the pro-tumorigenic inflammatory microenvironment of 
melanomas. This is possibly the first study to establish a direct link between the immune 
and melanocytic systems during the immediate skin response to UVR.  
12. Conclusion 
Because, measured on a population basis, melanoma induction by UVR appears to be via a 
very different mechanism (i.e. via intermittent exposure) than for keratinocyte-derived 
cancers (i.e. via chronic exposure), it has been postulated that there are different 
carcinogenic mechanisms at play (Setlow, 1999). Different mutagenic DNA adducts are 
proposed to be involved, including UVA-induced oxidative lesions, UVB-induced 
pyrimidine dimers and 6-4PPs. In studies of human populations individual sun exposure 
level, based on recall, can be difficult to assess, but also the ratio of UVB/UVA varies greatly 
with geographical location, season, and time of day. This leads to uncertainty in inferences 
about how much exposure and which wavelengths most influence melanoma development. 
However epidemiological work has lead to the proposal of the divergent pathway model for 
melanoma, where some melanomas develop as a result of intermittent exposure, others after 
chronic exposures (Whiteman et al., 2003). The major difference between the chronic and 
intermittent branches of the model is the presence of naevi, the great majority of which carry 
BRAF mutations, in the former. Naevi can develop spontaneously. Hence the presence of or 
propensity to develop naevi increases melanoma risk. Even limited sun exposure appears to 
increases this risk, whereas for individuals not prone to develop naevi a relatively high 
cumulative lifetime UVR damage may often be necessary. Nevus cells proliferate strongly, 
and move to a suprabasal (malignant-like) location if subjected to only a single UVB 
exposure in vivo (Carrera et al., 2008). Thus naevus cells, unlike normal melanocytes within 
the skin, are extremely sensitive to UVB-induced damage. It is not known if there is a 
mechanistic difference in UVR mutagenesis between the two CSD and non-CSD pathways. 
However, judging from the mutation spectrum in human melanoma, dominated by 
pyrimidine dimer type mutations, the most parsimonious conclusion may be that it is not 
necessary to invoke a different mutagenic mechanism per se to explain apparent differences 
in UVR causality between melanoma and non-melanoma skin cancer. In both cases 
pyrimidine dimer type DNA lesions are involved.  
If multiple carcinogenic mechanisms are at play, this can be tested in a number of ways. The 
stratification of melanomas into CSD and non-CSD has been critical in enhancing our 
understanding of divergent mechanisms of melanoma genesis, but since the two major 
forms of melanoma, SSM and NM can be associated with either forms of exposure, further 
stratification may be necessary (Of note, LMM clearly has a different aetiology from NM 
and SSM). This may be in the form of the discovery of better somatic mutation signatures, as 
well as further innate genetic differences between the two groups. The development of 
further tests to differentiate between the two groups could help in terms of targeting 
particularly susceptible groups within the population for health education campaigns and 
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further tests to differentiate between the two groups could help in terms of targeting 
particularly susceptible groups within the population for health education campaigns and 
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more frequent screening. High throughput genome sequencing of large numbers of 
melanomas of various subtypes and association with CSD or non-CSD should clarify which 
type of DNA adducts are driving melanoma development, and in doing so might go some 
way towards clarifying the role of UVB versus UVA in the genesis of melanoma. Improved 
animals models should also be informative. 
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1. Introduction 
1.1 General properties and functions of METCAM/MUC18 
Human METCAM (huMETCAM), a CAM in the immunoglobulin-like gene superfamily, is 
an integral membrane glycoprotein. Alternative names for METCAM are MUC18 [1], CD146 
[2], MCAM [3], MelCAM [4], A32 [5], and S-endo 1 [6]. To avoid confusion with mucins and 
to reflect its biological functions, we have renamed MUC18 as METCAM (metastasis CAM), 
which means an immunoglobulin-like CAM that affects or regulates metastasis [7]. The 
huMETCAM  has 646 amino acids that include a N-terminal extra-cellular domain of 558 
amino acids, which has 28 amino acids characteristic of a signal peptide sequence at its N-
terminus, a transmembrane domain of 24 amino acids (amino acid #559-583), and a 
cytoplasmic domain of 64 amino acids at the C-terminus. HuMETCAM has eight putative N-
glycosylation sites (Asn-X-Ser/Thr), of which six are conserved, and are heavily glycosylated 
and sialylated resulting in an apparent molecular weight of 113,000-150,000. The extra-
cellular domain of the protein comprises five immunoglobulin-like domains (V-V-C2-C2-
C2) [1, 7] and an X domain [7]. The cytoplasmic tail contains peptide sequences that will 
potentially be phosphorylated by protein kinase A (PKA), protein kinase C (PKC), and 
casein kinase 2 (CK 2) [1, 7-8].  My lab has also cloned and sequenced the mouse METCAM 
(moMETCAM) cDNA, which contains 648 amino acids with a 76.2% identity with 
huMETCAM, suggesting that moMETCAM is likely to have biochemical properties and 
biological functions similar to the human counter part [9]. The structure of the huMETCAM 
protein is depicted in Fig. 1, suggesting that METCAM, similar to most CAMs, plays an 
active role in mediating cell-cell and cell-extracellular interactions, crosstalk with many 
intracellular signaling pathways, and modulating the social behaviors of cells [7].  
It is now well documented that although tissue specific signatures exist in different cancer 
types, cancers from different tissues also express some common genes [10-12]. One group of 
them is cell adhesion molecules (CAMs). CAMs do not merely act as a molecular glue to 
hold together homotypic cells in a specific tissue or to facilitate interactions of heterotypic 
cells; CAMs also actively govern the social behaviors of cells by affecting the adhesion status 
of cells and modulating cell signaling [13]. They control cell motility and invasiveness by  
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Fig. 1. HuMETCAM protein structure. SP stands for signal peptide sequence, V1, V2, C2, 
C2’, C2’’ for five Ig-like domains (each held by a disulfide bond) and X for one domain 
(without any disulfide bond) in the extracellular region, and TM for transmembrane 
domain. P stands for five potential phosphorylation sites (one for PKA, three for PKC, and 
one for CK2) in the cytoplasmic tail. The six conserved N-glycosylation sites are shown as 
wiggled lines in the extracellular domains of V1, between C2’ and C2”, C2’’, and X. 
mediating the remodeling of cytoskeleton [13]. They also actively mediate the cell-to-cell 
and cell-to-extracellular matrix interactions to allow cells to constantly respond to 
physiological fluctuations and to alter/remodel the surrounding microenvironment for 
survival [14]. They do so by crosstalk with cellular surface growth factor receptors, which 
interact with growth factors that may be secreted from stromal cells or released from 
circulation and embedded in the extracellular matrix [13-14]. Thus an altered expression of 
CAMs affects the motility and invasiveness of many tumor cells in vitro and metastasis in 
vivo [13-14]. CAMs also play an important role in the favorable soil that provides a proper 
microenvironment at a suitable period to awaken the dormant metastatic tumor cells to 
enter into an aggressive growth phase. Actually, the metastatic potential of a tumor cell, as 
documented in many carcinomas, is the consequence of a complex participation of many 
over- and under-expressed CAMs [13-14]. Based on the above information, aberrant 
expression of huMETCAM may also affect the motility and invasiveness of many tumor cells 
in vitro and metastasis in vivo. It is logical to hypothesize that HuMETCAM should play an 
important role in regulating the malignant progression of many cancer types [7, 13]. 
Nevertheless, in this chapter we will only review its positive or negative roles in the 
tumorigenesis and metastasis of human and mouse melanoma cells. 
HuMETCAM is expressed in a limited number of normal tissues, such as hair follicular cells, 
smooth muscle cells, endothelial cells, cerebellum, normal mammary epithelial cells, basal 
cells of the lung, activated T cells, intermediate trophoblast, [15] and normal nasopharyngeal 
epithelial cells [16]. The protein is not expressed in melanocyte, but it is overly expressed in 
most (67%) malignant melanoma cells [1]. Thus it was postulated to play a role in the 
progression of human melanoma. Likewise, the expression of mouse METCAM 
(moMETCAM) was positively correlated with the metastatic ability of several mouse 
melanoma cell lines [9]. Since then, it has been proven that METCAM is not just correlative 
with the progression of melanoma, but also is capable of inducing non-metastatic melanoma 
cell lines to metastasize in various mouse models. First, it was shown that the stable ectopic 
expression of the huMETCAM cDNA gene in three non-metastatic human cutaneous 
melanoma cell lines increases the metastatic abilities of these cell lines in immune-deficient 
xenograft mouse models [3,17].  Second, it was shown that the stable ectopic expression of 
moMETCAM cDNA in two low-tumorigenic and low-metastatic mouse melanoma cell 
lines, K10 (tumor–/metlow) and K3 (tumor+/metlow), increases their metastatic abilities in 
immune-competent syngeneic C3H brown mice [18].  
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However, METCAM enables both human and mouse melanoma cells to metastasize only 
under an experimental metastasis assay (tail vein injection), not under a spontaneous 
metastasis assay (subcutaneous injection). In addition, the ectopic expression of METCAM 
in METCAM-minus melanoma cell lines has no effect or a slight suppressive effect on the 
tumorigenesis. Taken together, this suggests that METCAM promotes the metastasis of 
melanoma cells only at later stages of progression (it has been found that fibroblast growth 
factor-2 initiates the metastatic process) [19]. 
Recently, we further investigated the effect of moMETCAM expression on tumorigenesis 
and metastasis of a different mouse melanoma subline #9 of K1735 (K1735-9 or K9), which is 
also METCAM-minus and lowly metastatic, but has a highly tumorigenic phenotype 
(tumor+++/metlow), in the syngeneic C3H mouse model. We tested the effect of ectopic 
expression of moMETCAM on in vitro growth rate, motility, and invasiveness and in vivo 
subcutaneous tumor growth and pulmonary metastasis. Similar to the two isogenic K10 and 
K3 sublines, ectopic expression of METCAM did not significantly affect in vitro growth rate, 
but greatly increased in vitro motility and invasiveness. Surprisingly, unlike K10 and K3 
sublines, ectopic expression of METCAM in K9 cells decreased tumorigenicity and 
suppressed their ability to establish pulmonary nodules. The suppressive effect of 
METCAM is not limited to the K9 mouse melanoma cell line, but is also observed in two 
human ovarian cancer cell lines (our unpublished results).  
We suggest that METCAM-mediated tumorigenesis and metastasis of melanoma cells and 
other cancer cells is dependent on intrinsic co-factors of different K1735 sublines and cancer 
types. The establishment of an immune-competent syngeneic mouse model for the 
METCAM-mediated progression is physiologically more relevant to and should provide 
knowledge more applicable to clinical melanoma than immune-deficient xenograft mouse 
models. The putative mechanisms of METCAM-mediated promotion/suppression of 
melanoma progression will also be discussed.  
  


























Fig. 2. Effect of over-expression of huMETCAM on tumor formation of two human 
melanoma cell lines, SK and XP-44 [17]. SK-METCAM and XP44-METCAM were two clones 
of human melanoma cell lines, SK and XP44, respectively, which were transfected with 
huMETCAM and expressed a high level of huMETCAM. Statistical analysis was not 
possible because detailed data was not provided. 
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Fig. 2. Effect of over-expression of huMETCAM on tumor formation of two human 
melanoma cell lines, SK and XP-44 [17]. SK-METCAM and XP44-METCAM were two clones 
of human melanoma cell lines, SK and XP44, respectively, which were transfected with 
huMETCAM and expressed a high level of huMETCAM. Statistical analysis was not 
possible because detailed data was not provided. 
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2. Metcam and melanoma tumorigenesis 
Over-expression of METCAM had a slight tumor suppression effect on tumorigenesis of 
human melanoma cells in xenograft mice [17], as shown in Fig. 2, but it had no effect on 
tumorigenesis of two sublines, #3 (K3) and #10 (K10), of the mouse melanoma cell line 
K1735 in syngeneic mice [18]. Fig. 3 only shows the effect of moMETCAM on the 
tumorigenesis of K3. 
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Fig. 3. Effect of over-expression of moMETCAM on tumor formation of a mouse melanoma 
cell line K1735 subline #3 (K3) [18].  K3-METCAM (High) and K3-METCAM (Low) were 
two K3 clones transfected with moMETCAM cDNA that expressed a high and a low level of 
moMETCAM, respectively. K3-Vector, as a negative control, was one clone transfected with 
an empty vector and did not express any moMETCAM. Asterisks show the results of the 
clone used as the references for the P-value calculation. The P-values should be compared 
with the reference (asterisk) on the same row. 
 























Fig. 4. Effect of over-expression of huMETCAM on tumor formation of a human melanoma 
cell line SB-2 [3]. SB-2 is a human melanoma cell line, which did not express any 
huMETCAM. SB-2-neo is the SB-2 cells transected with the empty vector, as a negative 
control. SB-2-METCAM is a clone of the SB-2 cells which were transfected with huMETCAM 
cDNA and expressed a high level of huMETCAM. Since tumor formation was only shown 
in one nude mouse for each clone, statistical analysis was not possible. 
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Only one group showed that over-expression of METCAM increased tumorigenesis of a 
human melanoma cell line in xenograft mice [3]; however the results were questionable 
because only the tumorigenicity of one mouse injected with METCAM-expressing clone and 
one mouse with control cells was shown and thus no standard deviations were indicated 
and no statistical analysis done, as shown in Fig. 4.  
The most convincing evidence for its tumor suppressor effect is in the subline #9 of the 
mouse melanoma cell line K1735 (K1735-9 or K9) in syngeneic C3H mice. Over-expression of 
moMETCAM in the K9 cells significantly decreased subcutaneous tumorigenesis in 
immunocompetent syngeneic C3H mice [20-21], as shown in Fig. 5.   
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Fig. 5. Effect of over-expression of moMETCAM on tumor formation of a mouse melanoma 
K1735 subline #9 (K1735-9 or K9) in immune competent syngeneic C3H mice [20-21]. K9-
METCAM (High) and K9-METCAM (Low) were two transfected clones, which expressed a 
high and a low level of moMETCAM, respectively. K9-Vector was one clone transfected 
with the empty vector, as a negative control. K9 was the K1735 subline #9 cells, also as a 
negative control. Both K9-Vector and K9 did not express any moMETCAM. 
3. Metcam and melanoma metastasis 
HuMETCAM/MUC18 was originally found to be abundantly expressed on the cellular 
surface of most malignant human melanomas; since then, it has been postulated to play a 
role in the progression of human melanoma [1]. This notion is also supported by the positive 
correlation of moMETCAM expression with the metastatic ability of several mouse 
melanoma cells lines [9]. Definitive proof comes from the results that the stable, ectopic 
expression of the huMETCAM cDNA gene in three non-metastatic human cutaneous 
melanoma cell lines increases the metastatic abilities of these cell lines in immune-deficient 
mouse models [3, 17].  Furthermore, the stable, ectopic expression of moMETCAM cDNA in 
two low-metastatic mouse melanoma cell lines increases the metastatic abilities of these cell 
lines in immune-competent syngeneic mice [18], as shown in Figs. 6 & 7. 
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METCAM (High) and K9-METCAM (Low) were two transfected clones, which expressed a 
high and a low level of moMETCAM, respectively. K9-Vector was one clone transfected 
with the empty vector, as a negative control. K9 was the K1735 subline #9 cells, also as a 
negative control. Both K9-Vector and K9 did not express any moMETCAM. 
3. Metcam and melanoma metastasis 
HuMETCAM/MUC18 was originally found to be abundantly expressed on the cellular 
surface of most malignant human melanomas; since then, it has been postulated to play a 
role in the progression of human melanoma [1]. This notion is also supported by the positive 
correlation of moMETCAM expression with the metastatic ability of several mouse 
melanoma cells lines [9]. Definitive proof comes from the results that the stable, ectopic 
expression of the huMETCAM cDNA gene in three non-metastatic human cutaneous 
melanoma cell lines increases the metastatic abilities of these cell lines in immune-deficient 
mouse models [3, 17].  Furthermore, the stable, ectopic expression of moMETCAM cDNA in 
two low-metastatic mouse melanoma cell lines increases the metastatic abilities of these cell 
lines in immune-competent syngeneic mice [18], as shown in Figs. 6 & 7. 
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Fig. 6. Enforced expression of moMETCAM increased lung nodule formation of mouse 
melanoma K1735-3 (K3) cells in syngeneic C3H mice. K4, the highly tumorigenic and 
metastatic subline #4 of K1735 (Tumor+++/Methigh), was used as a positive control. K3-
METCAM clone expressed a high level of moMETCAM. K3, K3-Vector, and K3-METCAM 
(Rev), in which the moMETCAM cDNA was inserted into the expression vector in anti-
sense orientation, were the control clones that did not express any moMETCAM. 
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Fig. 7. Enforced expression of moMETCAM increased lung nodule formation of mouse 
melanoma K1735-10 (K10) cells in syngeneic C3H mice. The K10-METCAM clone expressed 
a high level of moMETCAM. K10, K10-Vector, and K10-METCAM (Rev), in which the 
moMETCAM cDNA was inserted into the expression vector in anti-sense orientation, were 
the control clones that did not express any moMETCAM. 
However, METCAM enables melanoma cells to establish pulmonary metastasis only when 
the cells are injected into the tail vein (experimental metastasis assay) [3, 17-18], thus 
bypassing the initial stages of metastasis. No metastasis was found when METCAM-
expressing melanoma cells were injected subcutaneously (spontaneous metastasis assay) 
either in immune-deficient mouse models [3, 17] or in immune-competent syngeneic mouse 
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models [18].  Taken together, METCAM promotes the metastasis of melanoma cells, but at 
later stages [7]; thus over-expression of METCAM did not initiate the metastasis of 
melanoma cells. This result is consistent with the recent observation that fibroblast growth 
factor 2, but not huMETCAM, nor integrin, actually initiates the malignant progression of 
subcutaneous melanocyte into melanoma [19].  
METCAM increases the progression of most melanoma cell lines with the exception of one 
mouse melanoma subline, K1735-9. We found over-expression of moMETCAM in one mouse 
melanoma K1735 subline #9 (K1735-9 or K9) decreased pulmonary lung nodule formation 
when cells were injected into tail veins (experimental metastasis test) [20-21], as shown in 
Fig. 8. 
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Fig. 8. Enforced expression of moMETCAM suppressed lung nodule formation of mouse 
melanoma K1735-9 (K9) cells in syngeneic C3H mice. Clones K9-METCAM (High) and K9-
METCAM (Low) clones expressed high and low levels of moMETCAM, respectively. K9-
Vector, K9, and K9-METCAM (Rev), in which the moMETCAM cDNA was inserted into the 
expression vector in anti-sense orientation, were the control clones that did not express any 
moMETCAM. 
Summary  
Table 1 summarizes the possible role of METCAM in the tumorigenesis and metastasis of 
various melanoma cells.  
 
Melanoma cells Tumorigenesis Metastasis References 
Clinical melanoma 
and human 
melanoma cell lines 
No effect Increasing (effect is in the late stages) 3, 17 
Mouse melanoma 
K1735 sublines #3 
and #10 
No effect or slight 
suppression 
Increasing (effect is 
in the late stages) 9, 18 
Mouse melanoma 
K1735 subline #9 Suppression Suppression 20, 21 
Table 1. The role of METCAM in the tumorigenesis and metastasis of melanoma cells. 
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Fig. 7. Enforced expression of moMETCAM increased lung nodule formation of mouse 
melanoma K1735-10 (K10) cells in syngeneic C3H mice. The K10-METCAM clone expressed 
a high level of moMETCAM. K10, K10-Vector, and K10-METCAM (Rev), in which the 
moMETCAM cDNA was inserted into the expression vector in anti-sense orientation, were 
the control clones that did not express any moMETCAM. 
However, METCAM enables melanoma cells to establish pulmonary metastasis only when 
the cells are injected into the tail vein (experimental metastasis assay) [3, 17-18], thus 
bypassing the initial stages of metastasis. No metastasis was found when METCAM-
expressing melanoma cells were injected subcutaneously (spontaneous metastasis assay) 
either in immune-deficient mouse models [3, 17] or in immune-competent syngeneic mouse 
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models [18].  Taken together, METCAM promotes the metastasis of melanoma cells, but at 
later stages [7]; thus over-expression of METCAM did not initiate the metastasis of 
melanoma cells. This result is consistent with the recent observation that fibroblast growth 
factor 2, but not huMETCAM, nor integrin, actually initiates the malignant progression of 
subcutaneous melanocyte into melanoma [19].  
METCAM increases the progression of most melanoma cell lines with the exception of one 
mouse melanoma subline, K1735-9. We found over-expression of moMETCAM in one mouse 
melanoma K1735 subline #9 (K1735-9 or K9) decreased pulmonary lung nodule formation 
when cells were injected into tail veins (experimental metastasis test) [20-21], as shown in 
Fig. 8. 
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Fig. 8. Enforced expression of moMETCAM suppressed lung nodule formation of mouse 
melanoma K1735-9 (K9) cells in syngeneic C3H mice. Clones K9-METCAM (High) and K9-
METCAM (Low) clones expressed high and low levels of moMETCAM, respectively. K9-
Vector, K9, and K9-METCAM (Rev), in which the moMETCAM cDNA was inserted into the 
expression vector in anti-sense orientation, were the control clones that did not express any 
moMETCAM. 
Summary  
Table 1 summarizes the possible role of METCAM in the tumorigenesis and metastasis of 
various melanoma cells.  
 
Melanoma cells Tumorigenesis Metastasis References 
Clinical melanoma 
and human 
melanoma cell lines 
No effect Increasing (effect is in the late stages) 3, 17 
Mouse melanoma 
K1735 sublines #3 
and #10 
No effect or slight 
suppression 
Increasing (effect is 
in the late stages) 9, 18 
Mouse melanoma 
K1735 subline #9 Suppression Suppression 20, 21 
Table 1. The role of METCAM in the tumorigenesis and metastasis of melanoma cells. 
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As shown in Table 1, huMETCAM does not affect the tumorigenesis of most melanoma cell 
lines, but it increases metastasis, thus is a metastatic gene, for most melanoma cell lines.  
However, in one case it acts as a tumor suppressor and a metastasis suppressor for a mouse 
melanoma subline.  
4. Mechanisms of metcam-mediated melanoma progression 
How does METCAM mediate or regulate tumorigenesis and metastasis of melanoma cells? 
We may be able to find some common clues to begin understanding its mechanisms by 
deducing knowledge learned from the tumorigenesis of other tumors [10-14, 22] and the 
huMETCAM-mediated progression of melanoma [23-25] and tumor angiogenesis [2, 26-29]. 
First, the transcriptional expression of METCAM gene may be regulated by PKA/CREB 
(cAMP-responsive element binding protein), AP-2 [24-25] and other transcription factors, 
such as SP-1, c-Myb, N-Oct2, ETs, CArG, Egr-1, and transcription factors binding to insulin 
response elements [7].  Among these potential regulators, it is well documented that the AP-
2transcription factor plays a crucial tumor suppressor role in the progression of 
melanoma [25]. However, the roles of other transcription regulators, tissue specific 
enhancers and repressors, epigenetic control, and control at the level of chromatin 
remodeling of the gene have still yet to be investigated [7]. 
Second, since the cytoplasmic tail of METCAM contains consensus sequences potentially to 
be phosphorylated by PKA, PKC, and CK2, it may manifest its functions by cross-talk with 
various signaling pathways mediated by these protein kinases [7]. For example, METCAM 
expression in melanoma cells is reciprocally regulated by AKT, in which AKT up-regulates 
the level METCAM and over-expression of METCAM activates endogenous AKT, which in 
turn inhibits apoptosis and increases survival ability [23]. However the detailed mechanism 
of how AKT up-regulates the expression of METCAM has not been worked out. PKA, PKC, 
and CK2 may phosphorylate the cytoplasmic tail of METCAM, which then facilitates its 
interaction with FAK, thus promoting cytoskeleton remodeling. Alternatively, after 
phosphorylation of its cytoplasmic tail by these protein kinases, METCAM may interact with 
the downstream effectors of Ras, activating ERK and JNK, which in turn may 
transcriptionally activate the expression of AKT or other genes that promote the 
proliferation and angiogenesis of tumor cells. Though METCAM has not been shown to be a 
substrate of CK2, which has been shown to phosphorylate other CAMs, such as CD44, E-
cadherin, L1-CAM, and vitronectin, it is also likely that CK2 may be able to phosphorylate 
METCAM and link it to AKT and affect the proliferation, survival and other tumorigenesis-
related functions of tumor cells [30]. 
Third, after the engagement of METCAM with the ligand(s) or extracellular matrix, it may 
transmit the outside-in signals into tumor cells by activating FAK and the downstream 
signaling components, promoting cytoskeleton remodeling and increasing tumor cell 
motility and invasiveness [2, 7].  
Fourth, from what we know about the roles of other CAMs in the progression of other 
tumors [10-14, 22], it is logical to postulate that METCAM may affect cancer cell progression 
by cross-talk with signaling pathways that affect apoptosis, survival and proliferation and 
angiogenesis of tumor cells [7, 13, 22]. Thus METCAM may affect tumorigenesis and 
metastasis by altering the expression of various indexes in apoptosis, survival signaling, 
proliferation signaling, and angiogenesis. To support this notion, we have found that 
METCAM promotes the progression of prostate cancer cells by increasing proliferative 
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ability (with elevated levels of Ki67 and PCNA), by increasing survival ability (with an 
elevated level of phosphorylated AKT), and by increasing angiogenic ability (with elevated 
levels of VEGF, VEGFR2, and CD31) [31]; but it has no effect on the process of apoptosis. In 
fact, METCAM promotes the progression of melanoma cells differently by preventing the 
apoptosis of melanoma cells [32] and reciprocally affecting the expression of a survival 
index, phospho-AKT [23]. Further systematic studies by using specific RNAi’s to 
knockdown the downstream effectors one by one in METCAM-expressing clones may be 
necessary to further understand this aspect of the mechanism.  
Fifth, METCAM may mediate the hematogenous spreading of melanoma cells, which had 
been implicated by its expression in endothelial cells, as well as in malignant melanoma cells 
[26]. Furthermore it has been shown to be present in the junctions of endothelial cells [27-28] 
and essential for tumor angiogenesis in at least three tumor cell lines [29] and human 
prostate cancer LNCaP cells [31, 33]. It is highly likely that METCAM expression may 
promote the hematogenous spreading of melanoma cells. However, it is not known if 
METCAM plays a role in the lymphatic spread of cancer cells. Recent results from one group 
showed that METCAM is one of the lymphatic metastasis-associated genes, which is up-
regulated in malignant mouse hepatocarcinoma [34]; suggesting that METCAM may also 
play a role in promoting lymphatic metastasis of melanoma cells. But the details of how 
METCAM mediates hematogenous or lymphatic spreading of melanoma cells have still yet 
to be investigated. Labeling the cells with viable dyes and following the process in real time 
by using a non-intruding, but highly photo-penetrating imaging method of photoacoustic 
tomography (PAT) [35-36] may be useful for monitoring each step in the METCAM-
mediated progression. For the METCAM-mediated dynamic spreading of melanoma cells in 
vivo, the PAT imaging method coupled with using hairless syngeneic mouse animal models 
[37] should reveal the process more clearly and in real time.  
Sixth, METCAM has been shown to express in normal mesenchymal cells (smooth muscle, 
endothelium, and Schwann cells) in the tissue stroma and to be a marker for the 
mesenchymal stem cells [38]. METCAM may play an important role in regulating melanoma 
dormancy or awakening, driving or preventing melanoma cells to pre-metastatic niche, and 
formatting a microenvironment for favorable or unfavorable melanoma growth in 
secondary sites. 
Seventh, METCAM may affect the progression of cancer cells by interactions with the host 
immune system, which, however, has been shown to have a paradoxical role in tumor 
progression [39]. Recently one group has shown that a subset of host B lymphocytes may 
control melanoma metastasis through METCAM-dependent interaction [40]. On the other 
hand, it is highly likely that the tumor suppression effect of METCAM expression in 
melanoma K1735-9 subline may be due to the interaction of METCAM-expressing cells with 
the host immune defense system in the immunocompetent syngeneic C3H brown mouse, 
since the intrinsic motility and invasiveness of mouse melanoma K1735-9 was increased by 
METCAM expression [20-21]. For example, the surface METCAM expressed in this 
particular melanoma cell line may have a homophilic interaction with the NK cells, which 
also express METCAM, and enhance the cytotoxic functions of NK cells [41]. This hypothesis 
should be testable by studying the METCAM-mediated progression of METCAM-
expressing K1735-9 cells in mice treated with antibodies against CD4+T cells, CD8+T cells, 
or NK cells, or mice with a combined treatment with the antibodies to impair the functions 
of these immune cells.   
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ability (with elevated levels of Ki67 and PCNA), by increasing survival ability (with an 
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levels of VEGF, VEGFR2, and CD31) [31]; but it has no effect on the process of apoptosis. In 
fact, METCAM promotes the progression of melanoma cells differently by preventing the 
apoptosis of melanoma cells [32] and reciprocally affecting the expression of a survival 
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regulated in malignant mouse hepatocarcinoma [34]; suggesting that METCAM may also 
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the host immune defense system in the immunocompetent syngeneic C3H brown mouse, 
since the intrinsic motility and invasiveness of mouse melanoma K1735-9 was increased by 
METCAM expression [20-21]. For example, the surface METCAM expressed in this 
particular melanoma cell line may have a homophilic interaction with the NK cells, which 
also express METCAM, and enhance the cytotoxic functions of NK cells [41]. This hypothesis 
should be testable by studying the METCAM-mediated progression of METCAM-
expressing K1735-9 cells in mice treated with antibodies against CD4+T cells, CD8+T cells, 
or NK cells, or mice with a combined treatment with the antibodies to impair the functions 
of these immune cells.   
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Eighth, malignant progression of cancer cells has been shown to associate with abnormal 
glycosylation, resulting in expression of altered carbohydrate determinants [42]. Thus, the 
glycosylated status of METCAM in different cancer types may be different from normal 
cells, thus manifesting positive or negative effect on the progression of melanoma cells. This 
aspect of the METCAM-mediate cancer progression has not been well studied, but is 
especially intriguing since METCAM possesses six conserved N-glycosylation sites in the 
extracellular domain [7-9].  
We should always keep in mind that the mechanisms of METCAM-mediated melanoma 
progression may be slightly different in different melanoma cell lines due to their different 
intrinsic properties, which provide different co-factors and/or different ligand(s) that either 
positively or negatively regulate the METCAM-mediated tumorigenesis and metastasis. To 
further understand the role of METCAM in these processes, it is essential to identify the co-
factors and the METCAM-cognate heterophilic ligand(s), which modulate the biological 
functions of METCAM. The endeavor in this direction appears to be promising: from our 
preliminary attempts we may have successfully found a possible candidate of METCAM’s 
heterophilic ligand in METCAM-expressing human melanoma SK-Mel-28 cells [7].  
Mechanisms of METCAM-mediated negative role in the progression of melanoma cells have 
not been studied at all. In some cancers does METCAM behave like E-cadherin, which 
always plays a negative role in the tumorigenesis and metastasis of melanoma as well as 
most epithelial cancer cells [13] But even E-cadherin may function differently in different 
cancer cells. For example, its expression is temporally different and correlates with different 
stages during the progression of ovarian cancer [43]: E-cadherin is not expressed in the 
ovarian surface epithelial cells, but is expressed in premalignant lesions and in well-
differentiated tumors, and finally is not expressed in late–stage invasive tumors [43]. 
Alternatively, METCAM may behave differently from E-cadherin by being modulated by 
different cofactors or ligands, which are expressed at different stages of the cancer. The 
tumor suppressor role of METCAM is not restricted to the mouse melanoma K9 subline and 
it was first suggested in breast cancer cells [44]; however, the tumor suppression of 
METCAM in breast cancer cell lines could not be reproduced [45]. Recently we also found 
the tumor suppressor role of METCAM in two human ovarian cancer cell lines [46]. The 
tumor suppressor role of METCAM in ovarian cancer cells is different from mouse 
melanoma subline K9 in that the METCAM expression suppressed the intrinsic motility and 
invasiveness of human ovarian cancer cells [46]. Our preliminary results appear to suggest 
an alternative mechanism that a soluble form of METCAM, which is produced by MMPs in 
the METCAM-expressing cells, may mediate the suppressive effect in ovarian cancer cells, 
similar to the production of a soluble form of P-cadherin by the induced MMPs in breast 
cancer cells, which then dictates, instead of suppresses, the aggressive behavior of the breast 
cancer cells [47]. 
5. Conclusion and clinical applications 
METCAM may have a key positive function in the progression of most melanoma cell lines. 
On the other hand, it may also have a key function in suppressing the progression of a few 
melanoma cell lines. To further understand its mechanisms in these processes, it is crucial to 
define its functional domains, identify its cognate ligand(s) and cofactor regulators, and 
study its cross-talk with members of various signaling pathways [7]. These model systems 
may be useful for real time observation of the dynamic process of cancer progression by 
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using a non-intrusive and high photo-penetrating imaging system, such as the newly 
developed photoacoustic tomography (PAT), to further understanding the process in mouse 
models [35-36]. The knowledge gained would also be useful for designing effective means to 
decrease or even to block the metastatic potential of these cancers. Along these lines, 
preclinical trials using a fully humanized anti-METCAM antibody against melanoma 
growth and metastasis [48-49] and using a mouse anti-METCAM monoclonal antibody 
against angiogenesis and tumor growth of hepatocarcinoma, leiomyosarcoma, and 
pancreatic cancer [29] have been successfully demonstrated. Alternatively, small soluble 
peptides derived from METCAM may also be useful for blocking the tumor formation and 
tumor angiogenesis of melanoma cells [33, 50-51]. The attachment of these reagents to 
nanoparticles may be another alternative for therapeutic use [52]. 
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glycosylated status of METCAM in different cancer types may be different from normal 
cells, thus manifesting positive or negative effect on the progression of melanoma cells. This 
aspect of the METCAM-mediate cancer progression has not been well studied, but is 
especially intriguing since METCAM possesses six conserved N-glycosylation sites in the 
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We should always keep in mind that the mechanisms of METCAM-mediated melanoma 
progression may be slightly different in different melanoma cell lines due to their different 
intrinsic properties, which provide different co-factors and/or different ligand(s) that either 
positively or negatively regulate the METCAM-mediated tumorigenesis and metastasis. To 
further understand the role of METCAM in these processes, it is essential to identify the co-
factors and the METCAM-cognate heterophilic ligand(s), which modulate the biological 
functions of METCAM. The endeavor in this direction appears to be promising: from our 
preliminary attempts we may have successfully found a possible candidate of METCAM’s 
heterophilic ligand in METCAM-expressing human melanoma SK-Mel-28 cells [7].  
Mechanisms of METCAM-mediated negative role in the progression of melanoma cells have 
not been studied at all. In some cancers does METCAM behave like E-cadherin, which 
always plays a negative role in the tumorigenesis and metastasis of melanoma as well as 
most epithelial cancer cells [13] But even E-cadherin may function differently in different 
cancer cells. For example, its expression is temporally different and correlates with different 
stages during the progression of ovarian cancer [43]: E-cadherin is not expressed in the 
ovarian surface epithelial cells, but is expressed in premalignant lesions and in well-
differentiated tumors, and finally is not expressed in late–stage invasive tumors [43]. 
Alternatively, METCAM may behave differently from E-cadherin by being modulated by 
different cofactors or ligands, which are expressed at different stages of the cancer. The 
tumor suppressor role of METCAM is not restricted to the mouse melanoma K9 subline and 
it was first suggested in breast cancer cells [44]; however, the tumor suppression of 
METCAM in breast cancer cell lines could not be reproduced [45]. Recently we also found 
the tumor suppressor role of METCAM in two human ovarian cancer cell lines [46]. The 
tumor suppressor role of METCAM in ovarian cancer cells is different from mouse 
melanoma subline K9 in that the METCAM expression suppressed the intrinsic motility and 
invasiveness of human ovarian cancer cells [46]. Our preliminary results appear to suggest 
an alternative mechanism that a soluble form of METCAM, which is produced by MMPs in 
the METCAM-expressing cells, may mediate the suppressive effect in ovarian cancer cells, 
similar to the production of a soluble form of P-cadherin by the induced MMPs in breast 
cancer cells, which then dictates, instead of suppresses, the aggressive behavior of the breast 
cancer cells [47]. 
5. Conclusion and clinical applications 
METCAM may have a key positive function in the progression of most melanoma cell lines. 
On the other hand, it may also have a key function in suppressing the progression of a few 
melanoma cell lines. To further understand its mechanisms in these processes, it is crucial to 
define its functional domains, identify its cognate ligand(s) and cofactor regulators, and 
study its cross-talk with members of various signaling pathways [7]. These model systems 
may be useful for real time observation of the dynamic process of cancer progression by 
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using a non-intrusive and high photo-penetrating imaging system, such as the newly 
developed photoacoustic tomography (PAT), to further understanding the process in mouse 
models [35-36]. The knowledge gained would also be useful for designing effective means to 
decrease or even to block the metastatic potential of these cancers. Along these lines, 
preclinical trials using a fully humanized anti-METCAM antibody against melanoma 
growth and metastasis [48-49] and using a mouse anti-METCAM monoclonal antibody 
against angiogenesis and tumor growth of hepatocarcinoma, leiomyosarcoma, and 
pancreatic cancer [29] have been successfully demonstrated. Alternatively, small soluble 
peptides derived from METCAM may also be useful for blocking the tumor formation and 
tumor angiogenesis of melanoma cells [33, 50-51]. The attachment of these reagents to 
nanoparticles may be another alternative for therapeutic use [52]. 
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1. Introduction 
The cellular signaling pathways that respond to Wnts control numerous processes ranging 
from gastrulation to aging and govern cell fate determination and patterning (Clevers, 2006). 
Wnt signaling abnormalities often lead to developmental disorders and lethal malignancies. In 
melanoma aberrant activation of Wnt signaling is often observed. Wnt signaling pathway is a 
very complex process. Its ligands, called Wnts, can signal via several pathways referred to as 
the canonical Wnt signaling and two noncanonical Wnt signaling pathways. According to the 
modern view, the canonical Wnt signaling branch is predominately involved in control of 
proliferation and differentiation acting at a transcriptional level, whereas the noncanonical 
ones affect cell motility and cytoskeletal rearrangements. In the case of melanoma, the 
canonical and the noncanonical Wnt pathways can play opposite roles. The noncanonical Wnt 
cascade promotes metastasis. Overexpression of Wnt5a correlates with a poor prognosis for 
patients. The canonical Wnt cascade has long been considered as fully oncogenic. However, a 
lot of data confirms that it can act as a tumor suppressor by promoting cell differentiation. 
2. Wnt proteins and their interactions 
Wnt genes were identified both in vertebrates and invertebrates whereas plants, unicellular 
eukaryotes and prokaryotes appear to lack them (Miller, 2001). In humans, the Wnt family 
encompasses 19 members. All of them are defined by sequence homology rather than by 
functional properties (Wnt homepage). Wnt genes encode highly modified glycoproteins of 
38-43 kDa that have typical features of the secreted growth factors, including a hydrophobic 
signal sequence, lack of transmembrane domains, an N-glycosilation site and a sustained 
spacing of conserved cysteine residues (McMahon, 1992). It is considered that 
posttranslational lipid modifications are essential for the Wnt function. Treatment of Wnts 
with the acylprotein thioesterase that removes palmitates leads to both hydropathy and 
signaling activity reduction (Willert et al., 2003). Moreover, mutations that prevent 
palmitoylation of cysteine residues in Wnt1, Wnt3a, Wnt5a result in significant decrease of 
their biological activity, presumably due to inability to bind Frizzled (Fz) receptors. These 
mutations do not affect secretion. In contrast, a mutation of the conserved serine in Wnt3a 
abrogates palmitoleic acid addition and blocks secretion. Considering these observations, it 
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1. Introduction 
The cellular signaling pathways that respond to Wnts control numerous processes ranging 
from gastrulation to aging and govern cell fate determination and patterning (Clevers, 2006). 
Wnt signaling abnormalities often lead to developmental disorders and lethal malignancies. In 
melanoma aberrant activation of Wnt signaling is often observed. Wnt signaling pathway is a 
very complex process. Its ligands, called Wnts, can signal via several pathways referred to as 
the canonical Wnt signaling and two noncanonical Wnt signaling pathways. According to the 
modern view, the canonical Wnt signaling branch is predominately involved in control of 
proliferation and differentiation acting at a transcriptional level, whereas the noncanonical 
ones affect cell motility and cytoskeletal rearrangements. In the case of melanoma, the 
canonical and the noncanonical Wnt pathways can play opposite roles. The noncanonical Wnt 
cascade promotes metastasis. Overexpression of Wnt5a correlates with a poor prognosis for 
patients. The canonical Wnt cascade has long been considered as fully oncogenic. However, a 
lot of data confirms that it can act as a tumor suppressor by promoting cell differentiation. 
2. Wnt proteins and their interactions 
Wnt genes were identified both in vertebrates and invertebrates whereas plants, unicellular 
eukaryotes and prokaryotes appear to lack them (Miller, 2001). In humans, the Wnt family 
encompasses 19 members. All of them are defined by sequence homology rather than by 
functional properties (Wnt homepage). Wnt genes encode highly modified glycoproteins of 
38-43 kDa that have typical features of the secreted growth factors, including a hydrophobic 
signal sequence, lack of transmembrane domains, an N-glycosilation site and a sustained 
spacing of conserved cysteine residues (McMahon, 1992). It is considered that 
posttranslational lipid modifications are essential for the Wnt function. Treatment of Wnts 
with the acylprotein thioesterase that removes palmitates leads to both hydropathy and 
signaling activity reduction (Willert et al., 2003). Moreover, mutations that prevent 
palmitoylation of cysteine residues in Wnt1, Wnt3a, Wnt5a result in significant decrease of 
their biological activity, presumably due to inability to bind Frizzled (Fz) receptors. These 
mutations do not affect secretion. In contrast, a mutation of the conserved serine in Wnt3a 
abrogates palmitoleic acid addition and blocks secretion. Considering these observations, it 
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is believed that the palmitoleic acid modification is required for secretion, whereas the 
palmitate modification is critical for receptor binding (Cadigan & Peifer, 2009). 
Complexity of the Wnt signaling is greatly enhanced by abundance of potential receptors. 
There are several groups of receptor molecules that can bind Wnts. The first group found to 
transduce the Wnt signal is the Frizzled (Fz) receptor family. The Fz proteins were identified 
both in vertebrates and invertebrates. In human and mice, the Fz family includes ten members 
(Wnt homepage). It is believed that Fz proteins are the real G-protein-coupled receptors that 
can activate the heterotrimeric G-protein to transmit signal from Wnts. Like typical GPCR, 
they have seven hydrophobic transmembrane domains, glycosylation and phosphorylation 
sites for cyclic AMP-dependent protein kinase (PKA), protein kinase C (PKC) and casein 
kinase 2 (CK2), and are able to form homomeric and heteromeric complexes with other 
members of the Fz family. However, there are several differences between the Fz receptors and 
other GPCRs. The Fz receptors lack two conserved motifs, Asp-Arg-Tyr and Asn-Pro-X-X-Tyr. 
The Asp-Arg-Tyr motif is located in the second intracellular loop of several GPCRs and is 
crucial for G protein coupling. The Asn-Pro-X-X-Tyr motif is present at the end of the seventh 
transmembrane segment of GPCRs (Angers & Moon, 2009). The classical Fz receptor consists 
of a long highly glycosilated N-terminal extension, that is positioned outside of the cell, seven 
transmembrane domains and a short cytoplasmic tail. An amino terminal region called a 
cysteine-rich domain (CRD) is intended for the direct Wnt binding. The carboxyl terminus 
contains a consensus PDZ domain-binding motif (S/T-X-V) that is important for interaction 
with cytoplasmic proteins (Miller, 2001). Wnt/Fz combination at the surface of the cell 
determinates the type of G-protein subunits to be utilized and the kind of cellular response to 
occur (Liu et al., 1999; Malbon et al., 2001). 
In addition to the Fz receptors, Wnt can bind to molecules of the low density lipoprotein 
(LDL) receptor-related protein (LRP) family. The Wnt-LRP coupling is considered to induce 
or stabilize the formation of the Fz-LRP-Wnt ternary complex. Wnts have a low affinity to 
LRP, as compared to Fz, so there is an idea that the coupling occurs between LRP and the 
Wnt–Fz complex (Tamai et al., 2000). Two members of the vertebrate LRP family, LRP5 and 
LRP6, are able to bind Wnts. The LRP6 mutant mice phenotype resembles defects caused by 
several individual Wnt genes deficiency (Pinson et al., 2000). LRP overexpression in Xenopus 
leads to activation of the Wnt signaling (Tamai et al., 2000). Moreover, binding of some 
extracellular inhibitors to LRP leads to abrogation of the Wnt signaling transduction (Itasaki 
et al., 2003; Glinka et al., 1998). Unlike to the Fz receptors, LRP6 is a single-pass 
transmembrane protein. It has a highly modular structure consisting of the extracellular 
domain (ECD) that mediates LRP6-ligand interactions, and the intracellular domain (ICD) 
that transduces extracellular signals to cytoplasmic effectors. ECD contains the extracellular 
proteins binding YWTD domains, EGF-like repeats, and LDL repeats. ECD is supposed to 
act as an autoinhibitory signal, since LRP6 lacking the ECD can constitutively activate the 
Wnt pathway. In contrast, the ICD domain is sufficient for the activation of the Wnt 
signalling pathway. The overexpression of the isolated ICD induces constitutive activation 
of the canonical Wnt signaling. The ICD domain is rich in proline, serine, and threonine and 
has a conserved PPSPXS motif critical for its function (Niehrs & Shen, 2010). 
Repertoire of the Wnt receptor molecules is broader than that of the Fz and LRP proteins. 
The Wnt ligands can also signal through alternative receptors, structurally related homologs 
Ror1 and Ror2 that belong to the receptor tyrosine kinase (RTK) superfamily, and Ryk that 
is an atypical tyrosine kinase receptor. Transgenic mice with the Ror2 loss-of-function 
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mutations demonstrate very similar phenotype to mice with the Wnt5a depletion (Oishi et 
al., 1999). Ror2 contains extracellular Fz-like cysteine-rich domains (CRDs), membrane-
proximal Kringle domains and immunoglobulin (Ig)-like domains. While CRDs and the Ig-
like domains participate in ligand binding, function of the Kringle domains is still unclear. 
However, it is assumed that the Kringle domains in Ror act as recognition modules for 
binding of the Wnt regulatory proteins (Minami et al., 2010). Another receptor molecule Ryk 
is thought to mediate the Wnt signaling. Unlike to Ror2, Ryk is an atypical Tyr kinase 
receptor. It lacks kinase activity due to amino acid substitutions in the evolutionarily 
conserved residues of the intracellular kinase domains (Halford et al., 1999; Hovens et al., 
1992). In addition to the intracellular kinase domain, Ryk contains a single transmembrane 
domain and an extracellular Wnt inhibitory factor (WIF) domain. The last one mediates 
binding of various Wnt ligands (Halford & Stacker, 2001). The choice of a ligand for 
interaction is rather controversial. According to different data, Ryk can bind both canonical 
and noncanonical Wnts. The physical interaction between Ryk and Wnt1 and Wnt3a with 
subsequent activation of the canonical Wnt signaling was demonstrated in the HEK293T 
cells (Lu et al., 2004). On the contrary, the noncanonical Wnt5a serves as a binding partner 
for Ryk in the Wnt5a-mediated axon guidance (Keeble et al., 2006). 
To complete the description of the Wnt-interacting partners, a special group of proteins that 
can bind Wnt ligands but unable to participate in signal transduction should be mentioned. 
These proteins act as inhibitors blocking the Wnt functional activity. The soluble Frizzled-
Related Proteins (sFRPs) represent a typical example of the extracellular Wnt inhibitors. 
They bind to Wnt proteins preventing them from coupling with their receptors. sFRPs are 
able to block both canonical and noncanonical Wnt signaling pathway. Another soluble Wnt 
inhibitor is called WIF-1 (Wnt inhibitory factor). Unlike to sFRPs, it does not contain a CRD 
domain. However, it can bind to Wnts through a unique domain that is similar to 
extracellular region of the Ryk receptors (Patthy, 2000).  
Another group of the Wnt signaling inhibitors consists of secreted Wnt antagonists. The 
Dickkopf (Dkk) family of the Wnt antagonists inhibits the Wnt signaling by direct binding to 
LRP5/6 (Glinka et al.,1998). It is considered that Dkk can form a ternary complex with 
LRP5/6 and a single-pass transmembrane receptor Kremen-1 in order to promote LRP5/6 
internalization with subsequent inactivation of the Wnt signaling (Mao et al., 2002). Binding 
of LRP by soluble Wnt signaling inhibitors is not a unique feature of Dkk. Some other 
secreted Wnt inhibitors (Wise and SOST) use the same mechanism (Itasaki et al., 2003; 
Semenov et al., 2005). 
Availability of different receptors, co-receptors and inhibitors create cellular context. An effect 
of the Wnt signaling pathway depends not on the Wnt ligand itself, but on the Wnt ligand in 
the cellular context. The same Wnt ligand can activate different Wnt signaling branches, and 
classification of Wnt ligands based on a type of Wnt signaling activated seems artificial.  
2.1 Different branches of the Wnt signaling 
The Wnt signaling is commonly considered as a combination of at least three different 
signaling branches: the β-catenin pathway, the Wnt/Ca2+ pathway and the planar cell 
polarity (PCP) pathway. There is evidence of significant crosstalk between them. 
2.1.1 The canonical Wnt signaling pathway 
The canonical Wnt signaling pathway, or the β-catenin pathway, was the first Wnt signaling 
discovered. It participates in multiple biological processes including embryogenesis, cell 
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is believed that the palmitoleic acid modification is required for secretion, whereas the 
palmitate modification is critical for receptor binding (Cadigan & Peifer, 2009). 
Complexity of the Wnt signaling is greatly enhanced by abundance of potential receptors. 
There are several groups of receptor molecules that can bind Wnts. The first group found to 
transduce the Wnt signal is the Frizzled (Fz) receptor family. The Fz proteins were identified 
both in vertebrates and invertebrates. In human and mice, the Fz family includes ten members 
(Wnt homepage). It is believed that Fz proteins are the real G-protein-coupled receptors that 
can activate the heterotrimeric G-protein to transmit signal from Wnts. Like typical GPCR, 
they have seven hydrophobic transmembrane domains, glycosylation and phosphorylation 
sites for cyclic AMP-dependent protein kinase (PKA), protein kinase C (PKC) and casein 
kinase 2 (CK2), and are able to form homomeric and heteromeric complexes with other 
members of the Fz family. However, there are several differences between the Fz receptors and 
other GPCRs. The Fz receptors lack two conserved motifs, Asp-Arg-Tyr and Asn-Pro-X-X-Tyr. 
The Asp-Arg-Tyr motif is located in the second intracellular loop of several GPCRs and is 
crucial for G protein coupling. The Asn-Pro-X-X-Tyr motif is present at the end of the seventh 
transmembrane segment of GPCRs (Angers & Moon, 2009). The classical Fz receptor consists 
of a long highly glycosilated N-terminal extension, that is positioned outside of the cell, seven 
transmembrane domains and a short cytoplasmic tail. An amino terminal region called a 
cysteine-rich domain (CRD) is intended for the direct Wnt binding. The carboxyl terminus 
contains a consensus PDZ domain-binding motif (S/T-X-V) that is important for interaction 
with cytoplasmic proteins (Miller, 2001). Wnt/Fz combination at the surface of the cell 
determinates the type of G-protein subunits to be utilized and the kind of cellular response to 
occur (Liu et al., 1999; Malbon et al., 2001). 
In addition to the Fz receptors, Wnt can bind to molecules of the low density lipoprotein 
(LDL) receptor-related protein (LRP) family. The Wnt-LRP coupling is considered to induce 
or stabilize the formation of the Fz-LRP-Wnt ternary complex. Wnts have a low affinity to 
LRP, as compared to Fz, so there is an idea that the coupling occurs between LRP and the 
Wnt–Fz complex (Tamai et al., 2000). Two members of the vertebrate LRP family, LRP5 and 
LRP6, are able to bind Wnts. The LRP6 mutant mice phenotype resembles defects caused by 
several individual Wnt genes deficiency (Pinson et al., 2000). LRP overexpression in Xenopus 
leads to activation of the Wnt signaling (Tamai et al., 2000). Moreover, binding of some 
extracellular inhibitors to LRP leads to abrogation of the Wnt signaling transduction (Itasaki 
et al., 2003; Glinka et al., 1998). Unlike to the Fz receptors, LRP6 is a single-pass 
transmembrane protein. It has a highly modular structure consisting of the extracellular 
domain (ECD) that mediates LRP6-ligand interactions, and the intracellular domain (ICD) 
that transduces extracellular signals to cytoplasmic effectors. ECD contains the extracellular 
proteins binding YWTD domains, EGF-like repeats, and LDL repeats. ECD is supposed to 
act as an autoinhibitory signal, since LRP6 lacking the ECD can constitutively activate the 
Wnt pathway. In contrast, the ICD domain is sufficient for the activation of the Wnt 
signalling pathway. The overexpression of the isolated ICD induces constitutive activation 
of the canonical Wnt signaling. The ICD domain is rich in proline, serine, and threonine and 
has a conserved PPSPXS motif critical for its function (Niehrs & Shen, 2010). 
Repertoire of the Wnt receptor molecules is broader than that of the Fz and LRP proteins. 
The Wnt ligands can also signal through alternative receptors, structurally related homologs 
Ror1 and Ror2 that belong to the receptor tyrosine kinase (RTK) superfamily, and Ryk that 
is an atypical tyrosine kinase receptor. Transgenic mice with the Ror2 loss-of-function 
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mutations demonstrate very similar phenotype to mice with the Wnt5a depletion (Oishi et 
al., 1999). Ror2 contains extracellular Fz-like cysteine-rich domains (CRDs), membrane-
proximal Kringle domains and immunoglobulin (Ig)-like domains. While CRDs and the Ig-
like domains participate in ligand binding, function of the Kringle domains is still unclear. 
However, it is assumed that the Kringle domains in Ror act as recognition modules for 
binding of the Wnt regulatory proteins (Minami et al., 2010). Another receptor molecule Ryk 
is thought to mediate the Wnt signaling. Unlike to Ror2, Ryk is an atypical Tyr kinase 
receptor. It lacks kinase activity due to amino acid substitutions in the evolutionarily 
conserved residues of the intracellular kinase domains (Halford et al., 1999; Hovens et al., 
1992). In addition to the intracellular kinase domain, Ryk contains a single transmembrane 
domain and an extracellular Wnt inhibitory factor (WIF) domain. The last one mediates 
binding of various Wnt ligands (Halford & Stacker, 2001). The choice of a ligand for 
interaction is rather controversial. According to different data, Ryk can bind both canonical 
and noncanonical Wnts. The physical interaction between Ryk and Wnt1 and Wnt3a with 
subsequent activation of the canonical Wnt signaling was demonstrated in the HEK293T 
cells (Lu et al., 2004). On the contrary, the noncanonical Wnt5a serves as a binding partner 
for Ryk in the Wnt5a-mediated axon guidance (Keeble et al., 2006). 
To complete the description of the Wnt-interacting partners, a special group of proteins that 
can bind Wnt ligands but unable to participate in signal transduction should be mentioned. 
These proteins act as inhibitors blocking the Wnt functional activity. The soluble Frizzled-
Related Proteins (sFRPs) represent a typical example of the extracellular Wnt inhibitors. 
They bind to Wnt proteins preventing them from coupling with their receptors. sFRPs are 
able to block both canonical and noncanonical Wnt signaling pathway. Another soluble Wnt 
inhibitor is called WIF-1 (Wnt inhibitory factor). Unlike to sFRPs, it does not contain a CRD 
domain. However, it can bind to Wnts through a unique domain that is similar to 
extracellular region of the Ryk receptors (Patthy, 2000).  
Another group of the Wnt signaling inhibitors consists of secreted Wnt antagonists. The 
Dickkopf (Dkk) family of the Wnt antagonists inhibits the Wnt signaling by direct binding to 
LRP5/6 (Glinka et al.,1998). It is considered that Dkk can form a ternary complex with 
LRP5/6 and a single-pass transmembrane receptor Kremen-1 in order to promote LRP5/6 
internalization with subsequent inactivation of the Wnt signaling (Mao et al., 2002). Binding 
of LRP by soluble Wnt signaling inhibitors is not a unique feature of Dkk. Some other 
secreted Wnt inhibitors (Wise and SOST) use the same mechanism (Itasaki et al., 2003; 
Semenov et al., 2005). 
Availability of different receptors, co-receptors and inhibitors create cellular context. An effect 
of the Wnt signaling pathway depends not on the Wnt ligand itself, but on the Wnt ligand in 
the cellular context. The same Wnt ligand can activate different Wnt signaling branches, and 
classification of Wnt ligands based on a type of Wnt signaling activated seems artificial.  
2.1 Different branches of the Wnt signaling 
The Wnt signaling is commonly considered as a combination of at least three different 
signaling branches: the β-catenin pathway, the Wnt/Ca2+ pathway and the planar cell 
polarity (PCP) pathway. There is evidence of significant crosstalk between them. 
2.1.1 The canonical Wnt signaling pathway 
The canonical Wnt signaling pathway, or the β-catenin pathway, was the first Wnt signaling 
discovered. It participates in multiple biological processes including embryogenesis, cell 
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proliferation and differentiation in adults, stem cell renewal in multiple tissues 
(hematopoietic, epidermal, and intestinal) and tumorigenesis (Clevers, 2006). A lot of 
growth genes (c-myc, cyclin D1, PPARδ) are under control of this signaling (He et al., 1998, 
1999; Tetsu & McCormick, 1999). Other target genes include the matrix metalloproteinase, 
fibronectin and the transcription factors AP-1, c-jun and fra1 (Brabletz et al., 1999; Gradl et 
al., 1999; Mann et al., 1999). The canonical Wnt signaling pathway can be activated by Wnts, 
such as Wnt1, Wn3a and Wnt8. In the absence of Wnts, concentration of the cytoplasmic β-
catenin is maintained at a low level by a special destruction complex. The destruction 
complex consists of the scaffolding proteins Axin and APC (adenomatous polyposis coli), 
GSK3β (glycogen synthase kinase 3β), CKI (casein kinase I), PP2A (protein phosphatase 2A) 
and, probably, ubiquitin ligase β-TrCP. When the destruction complex is active, β-catenin is 
phosphorylated by GSK3β. The phosphorylated β-catenin in turn is recognized by the 
ubiquitin ligase β-TrCP, which targets it for ubiquitin-mediated proteosomal degradation 
(Weeraratna, 2005). The canonical Wnt signaling is initiated by simultaneous binding of the 
Wnt ligand both to Fz receptor and LRP-5/6 coreceptor (Tamai et al., 2000). The ternary 
complex formation recruits a group of proteins including Disheveled (Dvl), Axin and 
GSK3β to the plasma membrane, where they form the Lrp6 signalosomes (Bilic et al., 2007). 
Aggregation causes CK1γ and GSK3β-mediated LRP6 phosphorylation. According to the 
modern view, the cytoplasmic scaffolding protein Dvl is required for the LRP6 aggregation 
and phosphorylation (Niehrs & Shen, 2010). Wnt-stimulated Dvl becomes hyper-
phosphorylated and forms polymers that are recruited to the plasma membrane, providing 
a platform for the Axin-GSK3β relocation (Cliffe et al., 2003). This relocation in turn results 
in inhibition of the β-catenin phosphorylation and further signaling transduction (Mao et al., 
2001). The β-catenin stabilization is a key event in activation of the canonical Wnt signaling. 
The stabilized β-catenin accumulates in the cytoplasm, translocates into the nucleus and 
participates in target gene regulation. β-catenin by itself is unable to bind DNA, but it can 
induce transcriptional activity of Tcf/Lef1 (Behrens et al., 1996). In the absence of β-catenin, 
Tcf/Lef1 acts as a transcriptional repressor. It can bind to the consensus motif 
(A/T)(A/T)CAA(A/T)G on DNA but has no trans-activation domain to induce 
transcription. In the β-catenin/Tcf/Lef1 complex, Tcf/Lef1 facilitates DNA-binding whereas 
β-catenin provides transactivation domains (Brantjes et al., 2002). 
2.1.2 The noncanonical Wnt signaling pathways 
At least two additional signaling pathways activated by Wnt ligands have been identified: 
the Wnt/Ca2+ pathway and the PCP pathway. Both of them are β-catenin-independent and 
are referred to as the noncanonical signaling pathways. Similar to the β-catenin signaling, 
the noncanonical pathways are essential for embryogenesis. They regulate multiple 
morphogenetic processes including gastrulation and neural tube closure (Jenny & Mlodzik, 
2006; Kohn & Moon, 2005). 
2.1.2.1 The Wnt/Ca2+ pathway 
The Wnt/Ca2+ pathway includes calcium release from the intracellular stores and induction 
of enzymatic activity of Ca2+-dependent protein kinases like calmodulin kinases, protein 
kinase C (PKC) and calcineurin (Kohn & Moon, 2005). The first ligand identified to induce 
transient spikes of the intracellular calcium is Wnt5a. In Xenopus embryos, it was shown that 
Wnt5a expression blocked the ability of the canonical Wnt8 to induce axis duplication. 
These data confirmed an idea of existence of multiple Wnt signaling pathways. The more 
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precise data came from studies in Xenopus and zebrafish models. It was revealed that Wnt5a 
overexpression phenocopied overexpression of a serpentine receptor that stimulates the 
intracellular calcium release in a G-protein-dependent manner. Later, an appropriate Fz 
receptor Rfz-2 was identified (Kuhl et al., 2000). The Wnt coupling to receptor (Fz, Rfz2) 
leads to dissociation of the Gα and Gβ/γ subunits. Gβ/γ activates phospholipase C (PLC), 
which translocates to the membrane and hydrolyzes phosphotidylinositol 4,5- biphosphate 
(PIP2) into inositol 1,4,5- triphosphate (IP3) and di-acyl glycerol (DAG). DAG activates PKC, 
while IP3 induces Ca2+ release from the intracellular stores. Elevation of the intracellular 
calcium level in turn stimulates the Ca2+-dependent effector molecules. Reminiscent of the 
canonical Wnt signaling-mediated Dvl translocation, Wnt5a expression results in PKC 
translocation to the plasma membrane where it is able to interact with its target proteins 
(Weeraratna, 2005). There is a positive feedback loop between PKC and Wnt5a. Inhibition of 
PKC can result in decrease of Wnt5a expression, whereas PKC activation leads to Wnt5a 
upregulation (Jonsson et al., 1998). Signaling cascades activated by PKC affect cytoskeletal 
organization and cell motility. 
2.1.2.2 The Planar Cell Polarity pathway 
Another noncanonical Wnt signaling pathway is the Planar Cell Polarity, or PCP, pathway. It 
was initially discovered in Drosophila melanogaster, but later found to control some critical 
biological processes in vertebrates (Mlodzik, 2002; Wang & Nathans, 2007). Polarity is an 
important feature in living organisms, underlying the proper performance of many functions. 
There are several kinds of polarity. Epithelial cells are polarized in two different manners. 
Besides apical-basal polarity, they also display polarization along the plane of the epithelial 
layer orthogonal to the apical-basal axis. This kind of polarization is called tissue polarity, or 
planar cell polarity (PCP). It is notable that, besides the epithelial cell polarity, the PCP 
proteins also provide mesenchymal cell intercalation during axis elongation process in 
vertebrates (Xenopus and zebrafish). The principal mechanism for tissue elongation is an 
insertion of mesenchymal cells between their neighbors along one axis. In this case, the 
mesenchymal cells have no apical-basal polarity but are able to extend polarized protrusions 
in the same direction. Thus, these cells are oriented with respect to direction of movement 
(Zallen, 2007). The transmembrane PCP proteins Frizzled, Strabismus, and Flamingo and the 
cytoplasmic PCP proteins Dvl and Prickle are critical for proper intercalation (Keller, 2002; 
Myers et al., 2002; Wallingford et al., 2002). Reestablishing of cell polarity after a mitotic cell 
division is also dependent on the PCP pathway (Nechiporuk & Vasioukhin, 2006). The 
Wnt/PCP pathway controls activity of the small GTPases Rho and Rac. The Rho signaling 
branch requires activation of the Dvl-Daam-1 (Dishevelled-associated activator of 
morphogenesis 1) complex and results in the Rho-associated kinase (ROCK) and myosin 
activation (Habas et al., 2001; Marlow et al., 2002; Weiser et al., 2007). Daam-1 is a member of 
the Formin protein family. It mediates an assembly of the Dvl-RhoA complex acting as a 
scaffolding protein (Habas et al., 2001). The Rac branch of signaling is Daam-1-independent. It 
requires another domain of Dvl to induce activity of small Rac GTPase. Activated Rac in turn 
stimulates Jun kinase (JNK) (Habas et al., 2003; Li et al., 1999). The PCP pathway regulates 
modifications of actin cytoskeleton structures and, as a consequence, provides cytoskeletal 
rearrangements and directed migration. In addition, it is considered that, unlike to the above 
mentioned pathways, the PCP cascade appears to function independently of transcription.  
Actually, the majority of molecular cascades connected with Rho/Rac GTPases and PKC 
mostly affect cell motility. This observation allows to suggest that the noncanonical Wnt 
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proliferation and differentiation in adults, stem cell renewal in multiple tissues 
(hematopoietic, epidermal, and intestinal) and tumorigenesis (Clevers, 2006). A lot of 
growth genes (c-myc, cyclin D1, PPARδ) are under control of this signaling (He et al., 1998, 
1999; Tetsu & McCormick, 1999). Other target genes include the matrix metalloproteinase, 
fibronectin and the transcription factors AP-1, c-jun and fra1 (Brabletz et al., 1999; Gradl et 
al., 1999; Mann et al., 1999). The canonical Wnt signaling pathway can be activated by Wnts, 
such as Wnt1, Wn3a and Wnt8. In the absence of Wnts, concentration of the cytoplasmic β-
catenin is maintained at a low level by a special destruction complex. The destruction 
complex consists of the scaffolding proteins Axin and APC (adenomatous polyposis coli), 
GSK3β (glycogen synthase kinase 3β), CKI (casein kinase I), PP2A (protein phosphatase 2A) 
and, probably, ubiquitin ligase β-TrCP. When the destruction complex is active, β-catenin is 
phosphorylated by GSK3β. The phosphorylated β-catenin in turn is recognized by the 
ubiquitin ligase β-TrCP, which targets it for ubiquitin-mediated proteosomal degradation 
(Weeraratna, 2005). The canonical Wnt signaling is initiated by simultaneous binding of the 
Wnt ligand both to Fz receptor and LRP-5/6 coreceptor (Tamai et al., 2000). The ternary 
complex formation recruits a group of proteins including Disheveled (Dvl), Axin and 
GSK3β to the plasma membrane, where they form the Lrp6 signalosomes (Bilic et al., 2007). 
Aggregation causes CK1γ and GSK3β-mediated LRP6 phosphorylation. According to the 
modern view, the cytoplasmic scaffolding protein Dvl is required for the LRP6 aggregation 
and phosphorylation (Niehrs & Shen, 2010). Wnt-stimulated Dvl becomes hyper-
phosphorylated and forms polymers that are recruited to the plasma membrane, providing 
a platform for the Axin-GSK3β relocation (Cliffe et al., 2003). This relocation in turn results 
in inhibition of the β-catenin phosphorylation and further signaling transduction (Mao et al., 
2001). The β-catenin stabilization is a key event in activation of the canonical Wnt signaling. 
The stabilized β-catenin accumulates in the cytoplasm, translocates into the nucleus and 
participates in target gene regulation. β-catenin by itself is unable to bind DNA, but it can 
induce transcriptional activity of Tcf/Lef1 (Behrens et al., 1996). In the absence of β-catenin, 
Tcf/Lef1 acts as a transcriptional repressor. It can bind to the consensus motif 
(A/T)(A/T)CAA(A/T)G on DNA but has no trans-activation domain to induce 
transcription. In the β-catenin/Tcf/Lef1 complex, Tcf/Lef1 facilitates DNA-binding whereas 
β-catenin provides transactivation domains (Brantjes et al., 2002). 
2.1.2 The noncanonical Wnt signaling pathways 
At least two additional signaling pathways activated by Wnt ligands have been identified: 
the Wnt/Ca2+ pathway and the PCP pathway. Both of them are β-catenin-independent and 
are referred to as the noncanonical signaling pathways. Similar to the β-catenin signaling, 
the noncanonical pathways are essential for embryogenesis. They regulate multiple 
morphogenetic processes including gastrulation and neural tube closure (Jenny & Mlodzik, 
2006; Kohn & Moon, 2005). 
2.1.2.1 The Wnt/Ca2+ pathway 
The Wnt/Ca2+ pathway includes calcium release from the intracellular stores and induction 
of enzymatic activity of Ca2+-dependent protein kinases like calmodulin kinases, protein 
kinase C (PKC) and calcineurin (Kohn & Moon, 2005). The first ligand identified to induce 
transient spikes of the intracellular calcium is Wnt5a. In Xenopus embryos, it was shown that 
Wnt5a expression blocked the ability of the canonical Wnt8 to induce axis duplication. 
These data confirmed an idea of existence of multiple Wnt signaling pathways. The more 
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precise data came from studies in Xenopus and zebrafish models. It was revealed that Wnt5a 
overexpression phenocopied overexpression of a serpentine receptor that stimulates the 
intracellular calcium release in a G-protein-dependent manner. Later, an appropriate Fz 
receptor Rfz-2 was identified (Kuhl et al., 2000). The Wnt coupling to receptor (Fz, Rfz2) 
leads to dissociation of the Gα and Gβ/γ subunits. Gβ/γ activates phospholipase C (PLC), 
which translocates to the membrane and hydrolyzes phosphotidylinositol 4,5- biphosphate 
(PIP2) into inositol 1,4,5- triphosphate (IP3) and di-acyl glycerol (DAG). DAG activates PKC, 
while IP3 induces Ca2+ release from the intracellular stores. Elevation of the intracellular 
calcium level in turn stimulates the Ca2+-dependent effector molecules. Reminiscent of the 
canonical Wnt signaling-mediated Dvl translocation, Wnt5a expression results in PKC 
translocation to the plasma membrane where it is able to interact with its target proteins 
(Weeraratna, 2005). There is a positive feedback loop between PKC and Wnt5a. Inhibition of 
PKC can result in decrease of Wnt5a expression, whereas PKC activation leads to Wnt5a 
upregulation (Jonsson et al., 1998). Signaling cascades activated by PKC affect cytoskeletal 
organization and cell motility. 
2.1.2.2 The Planar Cell Polarity pathway 
Another noncanonical Wnt signaling pathway is the Planar Cell Polarity, or PCP, pathway. It 
was initially discovered in Drosophila melanogaster, but later found to control some critical 
biological processes in vertebrates (Mlodzik, 2002; Wang & Nathans, 2007). Polarity is an 
important feature in living organisms, underlying the proper performance of many functions. 
There are several kinds of polarity. Epithelial cells are polarized in two different manners. 
Besides apical-basal polarity, they also display polarization along the plane of the epithelial 
layer orthogonal to the apical-basal axis. This kind of polarization is called tissue polarity, or 
planar cell polarity (PCP). It is notable that, besides the epithelial cell polarity, the PCP 
proteins also provide mesenchymal cell intercalation during axis elongation process in 
vertebrates (Xenopus and zebrafish). The principal mechanism for tissue elongation is an 
insertion of mesenchymal cells between their neighbors along one axis. In this case, the 
mesenchymal cells have no apical-basal polarity but are able to extend polarized protrusions 
in the same direction. Thus, these cells are oriented with respect to direction of movement 
(Zallen, 2007). The transmembrane PCP proteins Frizzled, Strabismus, and Flamingo and the 
cytoplasmic PCP proteins Dvl and Prickle are critical for proper intercalation (Keller, 2002; 
Myers et al., 2002; Wallingford et al., 2002). Reestablishing of cell polarity after a mitotic cell 
division is also dependent on the PCP pathway (Nechiporuk & Vasioukhin, 2006). The 
Wnt/PCP pathway controls activity of the small GTPases Rho and Rac. The Rho signaling 
branch requires activation of the Dvl-Daam-1 (Dishevelled-associated activator of 
morphogenesis 1) complex and results in the Rho-associated kinase (ROCK) and myosin 
activation (Habas et al., 2001; Marlow et al., 2002; Weiser et al., 2007). Daam-1 is a member of 
the Formin protein family. It mediates an assembly of the Dvl-RhoA complex acting as a 
scaffolding protein (Habas et al., 2001). The Rac branch of signaling is Daam-1-independent. It 
requires another domain of Dvl to induce activity of small Rac GTPase. Activated Rac in turn 
stimulates Jun kinase (JNK) (Habas et al., 2003; Li et al., 1999). The PCP pathway regulates 
modifications of actin cytoskeleton structures and, as a consequence, provides cytoskeletal 
rearrangements and directed migration. In addition, it is considered that, unlike to the above 
mentioned pathways, the PCP cascade appears to function independently of transcription.  
Actually, the majority of molecular cascades connected with Rho/Rac GTPases and PKC 
mostly affect cell motility. This observation allows to suggest that the noncanonical Wnt 
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signaling branches are implicated exactly in these processes. Contrariwise, the canonical 
Wnt signaling controls predominately proliferation and differentiation acting at a 
transcriptional level. 
2.2 Wnt signaling in skin biology 
In embryogenesis, components of the Wnt cascade are involved in multiple processes 
including neural crest induction, specification and differentiation (Dorsky et al., 1998). 
Neural crest cells arise from a region called neural folds at the border of the neural plate and 
non-neural ectoderm. During neurulation, neural folds converge at the dorsal midline of an 
embryo to form the neural tube. According to the conventional view, this process is 
mediated by molecular signals emanating from the ectoderm and receiving by the 
neuroepithelium. Numerous experiments in amphibian, zebrafish, avian and murine 
embryos revealed Wnt signaling as a driving force in this process (Garćia-Castro et al., 2002; 
Huang & Saint-Jeannet, 2004; Lewis et al., 2004). Depletion of the main effector component 
of the canonical Wnt signaling, β-catenin, abrogates the neural crest induction (Wu et al., 
2005), and the promoter region of neural crest-specific gene Slug contains a binding site for 
Lef/β-catenin complex (Vallin et al., 2001).  
The fate of the neural crest cells is also under control of the Wnt signaling pathway. Some 
reports confirm that Wnt6 and Wnt8 are required both for the neural crest induction and its 
expansion (Labonne & Bronner-Fraser, 1998; Sakai et al., 2005). After neurulation, neural 
crest cells from the roof plate of the neural tube undergo an epithelial-to-mesenchymal 
transition and migrate to the peripheral sites. This migration is an elaborate process, tightly 
controlled on a molecular level. It is believed that, unlike to the neural crest induction 
controlled by the canonical Wnt signaling, migration of neural crest cells mostly depends on 
another kind of the Wnt signaling called the noncanonical or the Planar Cell Polarity (PCP). 
Inhibition of the PCP factors like Wnt11, Frizzled7 (Fz7) and Dishevelled (Dvl) results in a 
failure of the neural crest cells migration, indicating that the noncanonical Wnt signaling is 
essential for the neural crest migration in vivo (De Calisto et al., 2005). 
The neural crest cells give rise to diverse cell types, including neurons, glia and 
melanocytes. Neurogenic and melanogenic populations of the neural crest cells have distinct 
migratory specificities governed by expression of different surface receptors and signaling 
moleculars, including Wnts (Thomas & Erickson, 2008). The Wnt signaling is supposed to be 
important for the neural crest cells specification. Neuroblasts and glioblasts show strong 
expression of the Wnt signaling inhibitor protein called Frzb-1. Conversely, the Frzb-1 
expression level in melanoblasts is decreased (Jin et al., 2001). Other evidence of the Wnt 
signaling participation in the neural crest cells specification comes from knockout studies. 
The Wnt1 and Wnt3a double-knockout mice exhibit defects in the neural crest cell 
derivatives, including melanocytes (Ikeya et al., 1997). The β-catenin knockout in the neural 
crest cells leads to loss of both melanocytes and sensory neurons (Hari et al., 2002). In the 
presence of Wnt3a in conditioned medium, the cultured quail neural crest cells evolve into 
melanoblasts (Jin et al., 2001). Injection of mRNA encoding cytoplasmic β-catenin into the 
neural crest cells of a zebrafish embryo targets them to a pigment cell fate at the expense of 
neurons and glia (Dorsky et al., 1998). In melanocytes, the canonical ligand Wnt3a promotes 
up-regulation of the microphthalmia-associated transcription factor (MITF), the master 
regulator of melanogenesis. The MITF expression starts in melanoblasts soon after their 
migration from the neural tube, and loss of MITF results in the absence of melanocytes 
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(Thomas & Erickson, 2009). Interestingly, the MITF expression is abolished in the fibroblasts 
derived from skin treated with the Wnt signaling inhibitor Dkk-1. Along with the MITF 
inhibition, these samples also show the decreased β-catenin expression level. Dkk-1 is 
supposed to be a key molecular determinant for a regional specificity in human skin 
pigmentation. Hands and feet express Dkk-1 at a higher level comparing to a trunk, and are 
less pigmented due to a lower melanocyte density. It is believed that in epidermis Dkk-1 
inhibits both melanocyte differentiation and melanin production (Yamaguchi et al., 2007). 
The terminal cell differentiation can be inhibited in a β-catenin-independent manner. A way 
to keep cells in a precursor state is provided by a member of the Tcf/Lef family, Tcf-3, that 
acts as a repressor of the Wnt-mediated transcription. Tcf-3 is normally expressed in the hair 
follicle bulge and basal layer of the outer root sheath. Ectopic expression of Tcf-3 in 
interfollicular epidermis inhibits terminal keratinocytes differentiation and induces a shift to 
progenitor-like molecular phenotype (Nguyen et al., 2006). The noncanonical Wnt signaling 
activated by Wnt5a also can antagonize the canonical signaling and inhibit expression of 
melanogenic antigens (Dissanayake et al., 2008). This observation leads to an idea that, 
whereas the canonical Wnt signaling is important for melanoblasts positioning and 
differentiation, the other Wnt signaling type serves for maintenance of the de-differentiated 
cell state. The idea is supported by data from the hematopoetic stem cells (HSCs). These 
cells are maintained in a quiescent state by Wnt5a, and the canonical Wnt signaling, 
contrariwise, makes them differentiate (Nemeth et al., 2007). The melanocyte stem cells 
express receptors for the Wnt signaling pathway on their surfaces (Yamada et al., 2010). 
Taking into account these data and the data from melanocytes regulation, it was speculated 
that Wnt5a could be involved in the quiescence maintenance of the melanocyte stem cells 
(MSCs), keeping them in their niche environment (Nishikawa & Osawa, 2007; O’Connell & 
Weeraratna, 2009). Stem cells committed to the melanocyte lineage reside in the bulge area 
of hair follicles (Nishimura et al., 2002). Being a source of melanoblasts and melanocytes, in 
adults they are most likely to be related to hyperpigmentation and age-associated hair 
graying (Yamada et al., 2010). 
Mammalian skin serves many critical biological functions to maintain homeostasis. 
Evidence indicates that the Wnt signaling is implicated in this process. The protective 
function of skin can be disturbed by wounding. The only way to restore skin integrity and, 
as a result, its protective function is healing of the wound. Unfortunately, wound healing 
and true regeneration are not the same. Cutaneous repair after the loss of full-thickness skin 
usually leads to scarring. The healed tissue contains a collagen-rich dermal matrix with a 
stratified epithelial covering. It is less elastic, has a lower tensile strength level and unable to 
form skin appendages. Interestingly, skin actually has a potential to regenerate, since it 
contains the multipotent epidermal stem cells in hair follicles and the undifferentiated 
mesenchymal cells in the dermis. Thus, it is postulated that scar repairing is more favorable 
than regeneration due to molecular context in the affected area. It is considered that the Wnt 
signaling pathway contributes significantly to this molecular context. To elucidate the role 
of the Wnt signaling in wound healing, the Wnt expression is examined at various times 
after wounding. Wnt-4 is expressed early in the process, while Wnt-5a and Wnt-11 
expression peaks are at the time of wound remodeling. The "TOPGAL" mice experiments 
reveal that the canonical Wnt signaling activity is increased in the hair follicles adjacent to 
the lesion, but not within the wound or overlying epithelium. Furthermore, the stabilized β-
catenin expression results in epithelial appendages formation like hair follicles and sebaceous 
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signaling branches are implicated exactly in these processes. Contrariwise, the canonical 
Wnt signaling controls predominately proliferation and differentiation acting at a 
transcriptional level. 
2.2 Wnt signaling in skin biology 
In embryogenesis, components of the Wnt cascade are involved in multiple processes 
including neural crest induction, specification and differentiation (Dorsky et al., 1998). 
Neural crest cells arise from a region called neural folds at the border of the neural plate and 
non-neural ectoderm. During neurulation, neural folds converge at the dorsal midline of an 
embryo to form the neural tube. According to the conventional view, this process is 
mediated by molecular signals emanating from the ectoderm and receiving by the 
neuroepithelium. Numerous experiments in amphibian, zebrafish, avian and murine 
embryos revealed Wnt signaling as a driving force in this process (Garćia-Castro et al., 2002; 
Huang & Saint-Jeannet, 2004; Lewis et al., 2004). Depletion of the main effector component 
of the canonical Wnt signaling, β-catenin, abrogates the neural crest induction (Wu et al., 
2005), and the promoter region of neural crest-specific gene Slug contains a binding site for 
Lef/β-catenin complex (Vallin et al., 2001).  
The fate of the neural crest cells is also under control of the Wnt signaling pathway. Some 
reports confirm that Wnt6 and Wnt8 are required both for the neural crest induction and its 
expansion (Labonne & Bronner-Fraser, 1998; Sakai et al., 2005). After neurulation, neural 
crest cells from the roof plate of the neural tube undergo an epithelial-to-mesenchymal 
transition and migrate to the peripheral sites. This migration is an elaborate process, tightly 
controlled on a molecular level. It is believed that, unlike to the neural crest induction 
controlled by the canonical Wnt signaling, migration of neural crest cells mostly depends on 
another kind of the Wnt signaling called the noncanonical or the Planar Cell Polarity (PCP). 
Inhibition of the PCP factors like Wnt11, Frizzled7 (Fz7) and Dishevelled (Dvl) results in a 
failure of the neural crest cells migration, indicating that the noncanonical Wnt signaling is 
essential for the neural crest migration in vivo (De Calisto et al., 2005). 
The neural crest cells give rise to diverse cell types, including neurons, glia and 
melanocytes. Neurogenic and melanogenic populations of the neural crest cells have distinct 
migratory specificities governed by expression of different surface receptors and signaling 
moleculars, including Wnts (Thomas & Erickson, 2008). The Wnt signaling is supposed to be 
important for the neural crest cells specification. Neuroblasts and glioblasts show strong 
expression of the Wnt signaling inhibitor protein called Frzb-1. Conversely, the Frzb-1 
expression level in melanoblasts is decreased (Jin et al., 2001). Other evidence of the Wnt 
signaling participation in the neural crest cells specification comes from knockout studies. 
The Wnt1 and Wnt3a double-knockout mice exhibit defects in the neural crest cell 
derivatives, including melanocytes (Ikeya et al., 1997). The β-catenin knockout in the neural 
crest cells leads to loss of both melanocytes and sensory neurons (Hari et al., 2002). In the 
presence of Wnt3a in conditioned medium, the cultured quail neural crest cells evolve into 
melanoblasts (Jin et al., 2001). Injection of mRNA encoding cytoplasmic β-catenin into the 
neural crest cells of a zebrafish embryo targets them to a pigment cell fate at the expense of 
neurons and glia (Dorsky et al., 1998). In melanocytes, the canonical ligand Wnt3a promotes 
up-regulation of the microphthalmia-associated transcription factor (MITF), the master 
regulator of melanogenesis. The MITF expression starts in melanoblasts soon after their 
migration from the neural tube, and loss of MITF results in the absence of melanocytes 
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(Thomas & Erickson, 2009). Interestingly, the MITF expression is abolished in the fibroblasts 
derived from skin treated with the Wnt signaling inhibitor Dkk-1. Along with the MITF 
inhibition, these samples also show the decreased β-catenin expression level. Dkk-1 is 
supposed to be a key molecular determinant for a regional specificity in human skin 
pigmentation. Hands and feet express Dkk-1 at a higher level comparing to a trunk, and are 
less pigmented due to a lower melanocyte density. It is believed that in epidermis Dkk-1 
inhibits both melanocyte differentiation and melanin production (Yamaguchi et al., 2007). 
The terminal cell differentiation can be inhibited in a β-catenin-independent manner. A way 
to keep cells in a precursor state is provided by a member of the Tcf/Lef family, Tcf-3, that 
acts as a repressor of the Wnt-mediated transcription. Tcf-3 is normally expressed in the hair 
follicle bulge and basal layer of the outer root sheath. Ectopic expression of Tcf-3 in 
interfollicular epidermis inhibits terminal keratinocytes differentiation and induces a shift to 
progenitor-like molecular phenotype (Nguyen et al., 2006). The noncanonical Wnt signaling 
activated by Wnt5a also can antagonize the canonical signaling and inhibit expression of 
melanogenic antigens (Dissanayake et al., 2008). This observation leads to an idea that, 
whereas the canonical Wnt signaling is important for melanoblasts positioning and 
differentiation, the other Wnt signaling type serves for maintenance of the de-differentiated 
cell state. The idea is supported by data from the hematopoetic stem cells (HSCs). These 
cells are maintained in a quiescent state by Wnt5a, and the canonical Wnt signaling, 
contrariwise, makes them differentiate (Nemeth et al., 2007). The melanocyte stem cells 
express receptors for the Wnt signaling pathway on their surfaces (Yamada et al., 2010). 
Taking into account these data and the data from melanocytes regulation, it was speculated 
that Wnt5a could be involved in the quiescence maintenance of the melanocyte stem cells 
(MSCs), keeping them in their niche environment (Nishikawa & Osawa, 2007; O’Connell & 
Weeraratna, 2009). Stem cells committed to the melanocyte lineage reside in the bulge area 
of hair follicles (Nishimura et al., 2002). Being a source of melanoblasts and melanocytes, in 
adults they are most likely to be related to hyperpigmentation and age-associated hair 
graying (Yamada et al., 2010). 
Mammalian skin serves many critical biological functions to maintain homeostasis. 
Evidence indicates that the Wnt signaling is implicated in this process. The protective 
function of skin can be disturbed by wounding. The only way to restore skin integrity and, 
as a result, its protective function is healing of the wound. Unfortunately, wound healing 
and true regeneration are not the same. Cutaneous repair after the loss of full-thickness skin 
usually leads to scarring. The healed tissue contains a collagen-rich dermal matrix with a 
stratified epithelial covering. It is less elastic, has a lower tensile strength level and unable to 
form skin appendages. Interestingly, skin actually has a potential to regenerate, since it 
contains the multipotent epidermal stem cells in hair follicles and the undifferentiated 
mesenchymal cells in the dermis. Thus, it is postulated that scar repairing is more favorable 
than regeneration due to molecular context in the affected area. It is considered that the Wnt 
signaling pathway contributes significantly to this molecular context. To elucidate the role 
of the Wnt signaling in wound healing, the Wnt expression is examined at various times 
after wounding. Wnt-4 is expressed early in the process, while Wnt-5a and Wnt-11 
expression peaks are at the time of wound remodeling. The "TOPGAL" mice experiments 
reveal that the canonical Wnt signaling activity is increased in the hair follicles adjacent to 
the lesion, but not within the wound or overlying epithelium. Furthermore, the stabilized β-
catenin expression results in epithelial appendages formation like hair follicles and sebaceous 
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glands within the wound (Fathke et al., 2006). The rate of wound closure is not affected by the 
β-catenin expression. Interestingly, the TGFβ-induced wound healing is partially regulated by 
β-catenin. Expression of Mmp-3 and Mmp-14 stimulated by TGFβ requires the β-catenin 
expression (Cheon et al., 2005). The noncanonical Wnt signaling is also able to direct adult skin 
progenitor cells toward regeneration. Wound transduction with the retrovirus expressing the 
typical noncanonical Wnt ligand Wnt-5a leads to even more abundant epithelial appendage 
formation in the wound, as compared with the stabilized β-catenin expression. Moreover, the 
authors report that the noncanonical Wnt signaling activation in epidermis is not associated 
with epithelial tumors, in contrast to the β-catenin-dependent signaling whose activation 
sometimes results in tumor formation (Fathke et al., 2006). 
Skin development and homeostasis are considerably dependent on regulation by the Wnt 
signaling. It is implicated in the neural crest induction and specification, determining of 
epidermal and melanocyte stem cells fate, hair follicle establishment and entry of its cells into 
the active growth phase and wound healing. Considering significance of the Wnt signaling in 
skin biology, it is not surprising that its malfunctions are often seen in different pathological 
conditions. Expression pattern of many Wnts is affected in malignant melanoma. 
2.3 Wnt signaling in melanoma 
Aberrant activation of the Wnt signaling pathways is often observed in melanoma. The 
cutaneous melanoma is considered as a neural crest-derived malignancy. It originates from 
the melanocyte progenitor cells or from the pigment-producing melanocytes. Taking into 
account that the Wnt signaling cascades play a crucial role in the neural crest induction, 
specification and melanocyte differentiation, implication of the different Wnt signaling 
branches in melanoma pathogenesis seems quite natural. 
The cutaneous melanoma is a common skin cancer characterized by high aggressiveness, 
morbidity and mortality. The melanoma development is a multistep process. It includes a 
congenital or acquired nevus, a dysplastic atypical nevus, a radial growth phase (RGP) 
melanoma, a vertical growth phase (VGP) melanoma and a metastatic melanoma (Larue & 
Beermann, 2007). Uncontrolled cell proliferation leads to the mole formation. It is considered 
that further immortalization is required for melanoma induction (Larue et al., 2009). A 
fraction of atypical nevi undergoes malignant transformation into a RGP melanoma with 
low probability to metastasize. Unlike to RGP, a VGP melanoma has high invasive and 
metastatic capabilities. A metastatic melanoma is usually resistant to chemotherapy and 
radiation (Govindarajan et al., 2007). It is believed that components of the Wnt signaling 
cascades can contribute to all stages of melanoma progression. There are several hypotheses 
describing potential roles of the canonical and noncanonical Wnt signaling branches in 
melanomagenesis. Thus, according to one of them, aberrations in the canonical signaling 
lead to melanoma formation, whereas the noncanonical Wnt signaling malfunctions are 
associated with metastatic progression. Furthermore, during melanoma progression, the β-
catenin signaling serves as a negative regulator of tumor growth. Numerous data confirms 
this idea. However, it is worth mentioning that some researchers argue against this 
conception. They consider the canonical Wnt signaling as a fully oncogenic. Anyway, the 
Wnt signaling is somehow implicated in melanoma progression. In the case of melanoma, 
Wnt1, Wnt3a and Wnt5a are best described. Wnt1 and Wnt3a are considered as the 
canonical ligands and Wnt5a as an activator of the Wnt/Ca2+ pathway. 
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2.3.1 Implication of the canonical Wnt signaling in melanoma cell fate 
In normal skin, melanocytes are interspersed among keratinocytes at the epidermal-dermal 
border. Physical and functional interaction with keratinocytes provides control of 
melanocyte proliferation and differentiation. In the absence of this control, melanocytes tend 
to rapid proliferation and expression of cell surface molecules normally associated with 
melanoma (McGary et al., 2002). A transmembrane protein E-cadherin is considered as the 
major mediator of human melanocyte adhesion to keratinocytes. Loss of E-cadherin is often 
associated with tumorigenesis including melanoma (Haass et al., 2005). Interestingly, E-
cadherin does not only act as a cell-cell adhesion molecule, but also mediates intracellular 
signaling through β-catenin. Indeed, β-catenin was originally identified as an interlink 
between E-cadherin and α-catenin in the adherens junctions (Cowin, 1994; Gumbiner & 
Neuron, 1993; Nagafuchi & Takeichi, 1989; Ozawa et al., 1989). Downregulation of E-
cadherin leads to release of β-catenin from the membrane-associated pool and to increase of 
its transcriptional activity. The activated canonical Wnt signaling is found in approximately 
one third of melanomas (Larue et al., 2009). Keeping in mind that the β-catenin signaling 
promotes expression of many "growth" genes, including cyclin D and c-myc, constitutive 
activation of this cascade can potentially stimulate tumor formation. For example, c-myc is a 
well-known oncogene. Its overexpression is found in a variety of human cancers including 
colorectal cancer, breast cancer, leukemia and melanoma (Dang, 1999). Inhibition of c-myc is 
supposed to be an important step in tumor growth restriction. Supporting this idea, the c-
myc antisense oligonucleotides have been shown to decrease proliferation of different cancer 
cells (Iversen et al., 2003). 
Expression of the canonical Wnt signaling negative regulators is often reduced in 
melanoma. Thus, Dkk-1, -2 and -3 are downregulated or lost both in melanoma cell lines 
and tumor samples (Kuphal et al., 2006). Dkk-1 and Dkk-2 inhibit the β-catenin signaling by 
binding to LRP5/6 coreceptor. It has been shown that Dkk-1 can suppress melanocyte 
growth and melanogenesis (Yamaguchi et al., 2004). Activation of the Dkk-1 expression 
results in inhibition of tumorigenicity and induction of apoptosis in melanoma cells during 
in vivo growth in the athymic nude mice (Mikheev et al., 2007). Another Wnt signaling 
inhibitor repressed in melanoma is WIF-1 (Wnt inhibitory factor-1) (Haqq et al., 2005). 
Unlike to Dkk, WIF-1 binds directly to the Wnt ligand blocking its signaling activity. 
Unfortunately, it remains unknown, which type of the Wnt signaling is inhibited by WIF-1. 
Anyway, the WIF-1 silencing may be a critical event in constitutive activation of the 
canonical Wnt pathway in melanoma cells. It is reported that melanoma cell growth is 
suppressed by WIF-1 overexpression, and the suppression is related to transcriptional and 
translational inhibition of the canonical Wnt signaling components, including β-catenin, 
Dvl-3, and cyclin D1 (Lin et al., 2007). 
Besides extracellular inhibitors of the canonical Wnt signaling, like Dkk and WIF-1, 
expression of the cytoplasmic CK1α in melanoma is frequently decreased or completely lost. 
CK1α is responsible for initial phosphorylation of β-catenin that is required for the GSK3β-
mediated β-catenin degradation (Liu et al., 2002). CK1α expression in invasive melanoma 
cells decreases growth rate and induces cell cycle arrest and apoptosis, whereas suppression 
of CK1α in primary melanomas has an opposite effect. Evidence confirming β-catenin 
implication in this effect comes from the β-catenin downregulation experiments. Inhibition 
of the β-catenin expression in the nonmetastatic melanoma cell lines results in inhibition of 
invasive growth (Sinnberg et al., 2010). 
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glands within the wound (Fathke et al., 2006). The rate of wound closure is not affected by the 
β-catenin expression. Interestingly, the TGFβ-induced wound healing is partially regulated by 
β-catenin. Expression of Mmp-3 and Mmp-14 stimulated by TGFβ requires the β-catenin 
expression (Cheon et al., 2005). The noncanonical Wnt signaling is also able to direct adult skin 
progenitor cells toward regeneration. Wound transduction with the retrovirus expressing the 
typical noncanonical Wnt ligand Wnt-5a leads to even more abundant epithelial appendage 
formation in the wound, as compared with the stabilized β-catenin expression. Moreover, the 
authors report that the noncanonical Wnt signaling activation in epidermis is not associated 
with epithelial tumors, in contrast to the β-catenin-dependent signaling whose activation 
sometimes results in tumor formation (Fathke et al., 2006). 
Skin development and homeostasis are considerably dependent on regulation by the Wnt 
signaling. It is implicated in the neural crest induction and specification, determining of 
epidermal and melanocyte stem cells fate, hair follicle establishment and entry of its cells into 
the active growth phase and wound healing. Considering significance of the Wnt signaling in 
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canonical ligands and Wnt5a as an activator of the Wnt/Ca2+ pathway. 
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2.3.1 Implication of the canonical Wnt signaling in melanoma cell fate 
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signaling through β-catenin. Indeed, β-catenin was originally identified as an interlink 
between E-cadherin and α-catenin in the adherens junctions (Cowin, 1994; Gumbiner & 
Neuron, 1993; Nagafuchi & Takeichi, 1989; Ozawa et al., 1989). Downregulation of E-
cadherin leads to release of β-catenin from the membrane-associated pool and to increase of 
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invasive growth (Sinnberg et al., 2010). 
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As mentioned above, β-catenin is a multifunctional protein, and its function is supposed to 
depend on cellular localization. At the membrane, β-catenin is a component of the cadherin 
adherens junctions and in the nucleus it acts as a transcriptional activator of the canonical 
Wnt signaling target genes. There are several reports that β-catenin is accumulated in the 
cytoplasm or nucleus of human melanoma cell lines and original tumors (Rubinfeld et al., 
1997). But unlike to other cancers, the elevated level of β-catenin in melanoma is rarely 
associated with mutations (Giles et al., 2003). Melanoma is very heterogeneous. The activity 
and regulation of the canonical Wnt signaling vary significantly among different patients. 
Nuclear β-catenin localization is not always sufficient for the canonical Wnt signaling 
activation.  Several cell lines with high nuclear β-catenin level are unable to activate this 
signaling (Kulikova et al., in press). 
According to some notions, β-catenin can induce melanocyte immortalization by bypassing 
the senescence barrier (Delmas et al., 2007). A growth arrest after a limited number of 
divisions represents a good way to protect cells from oncogenic transformation (Campisi, 
2005). Uncontrolled proliferation and delayed senescence are considered to be enough for 
melanoma transformation. Activating mutations in N-Ras and B-Raf (the MAP-kinase 
signaling pathway) can provide signals for proliferation, whereas β-catenin is believed to 
contribute to senescence escape (Delmas et al., 2007; Gray-Schopfer et al., 2005; Tsao et al., 
2000). Senescence is associated with the G0/G1-like cell cycle arrest induced by the tumor 
suppressor Rb1 that in turn is controlled by p16INK4a (Narita et al., 2003). In melanoma, the 
p16INK4a expression is often silenced by genetic and epigenetic mechanisms. It has been 
shown that in transgenic mice, the stabilized β-catenin decreases a number of melanoblasts 
and stimulates immortalization of primary skin melanocytes by silencing the p16INK4a 
promoter (Delmas et al., 2007). Transgenic animals expressing the stabilized form of β-
catenin demonstrate an elevated β-catenin level in the nucleus of target cells that mimics the 
constitutively active β-catenin in melanomas. Moreover, in human melanoma cells, this 
activated β-catenin represses p16INK4a directly in a TCF4-dependent manner. It should be 
noted that β-catenin by itself is unable to induce either melanocyte proliferation or 
melanoma formation. However, the double transgenic animals carrying both N-Ras and β-
catenin mutations show a high rate of melanoma incidences. Moreover, these double 
mutants are more subject to melanomagenesis than the single N-Ras transgenic mice. Thus, 
it has been postulated that the constitutively activated canonical Wnt signaling acts 
synergistically with the MAP kinase pathways in order to induce melanoma in the absence 
of the p16INK4a mutation (Delmas et al., 2007). 
The MAP kinase and β-catenin signaling cascades regulate activity of the master regulator 
of melanogenesis, MITF-M. In melanoma characterized by simultaneous activation of N-Ras 
and β-catenin, the MITF level is higher than in N-Ras-driven tumors (Larue et al., 2009). 
MITF-M regulates a wide range of biological processes including cell proliferation and 
differentiation (Palmieri et al., 2009). According to the current hypothesis, the β-catenin 
capacity to activate MITF-M underlies its ability to regulate the melanocyte number 
(Widlund et al., 2002; Larue & Delmas, 2006; Schepsky et al., 2006). A high level of MITF 
activity restricts cell division, whereas a low level is associated with proliferation (Carreira 
et al., 2005, 2006; Loercher et al., 2005; Wellbrock & Marais, 2005). Thus, β-catenin, being a 
direct regulator of the MITF-M expression, can affect melanocyte proliferation. In case of the 
β-catenin transgenic mice, the overactivated canonical Wnt signaling can lead to MITF 
activation and restriction of melanoblast proliferation. 
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In spite of numerous studies confirming the β-catenin implication in malignant 
transformation of melanocytes, the exact role of the Wnt/β-catenin signaling in melanoma 
and especially in melanoma metastasis remains quite controversial. Whereas a lot of papers 
claim that β-catenin is not associated with melanoma progression (not transformation), there 
is a report revealing a form of β-catenin that does correlate to the disease stage. Surprisingly, 
this phosphorylated form of β-catenin in human melanoma bioptic samples is accumulated 
in nucleus. However, as far as we know, the phosphorylated β-catenin is usually targeted 
for degradation in the cytoplasm (Kielhorn et al., 2003). Moreover, in contrast to the results 
from transgenic mice revealing no activation of proliferation in response to the stabilized β-
catenin, in human melanoma cell lines β-catenin induced melanoma growth mediated by 
the MITF upregulation (Widlund et al., 2002). On the other hand, a lot of data demonstrate 
that the β-catenin signaling actually acts as a negative regulator of melanoma progression. 
Almost all benign nevi are positive for the nuclear β-catenin, but the rate of nevi 
transformation into melanoma is very low (Tsao et al., 2003). Metastatic melanoma 
progression is associated with a loss of the nuclear β-catenin. Contrariwise, the nuclear 
accumulation of β-catenin is a good sign for patients (Bachmann et al., 2005; Chien et al., 
2009; Kageshita et al., 2001; Maelandsmo et al., 2003). The canonical Wnt signaling plays a 
crucial role in the pigment cell biology (Fang D et al., 2006). Wnt3a and Wnt1 are factors 
required for differentiation of pluripotent stem cells into functional melanocytes (Dorsky et 
al., 1998). Treatment of melanoma cells with Wnt3a results in increased pigmentation, 
transcriptional upregulation of melanogenic antigens and decreased metastatic ability 
(Chien et al., 2009). The Wnt3a-upregulated melanogenic antigens, including Trpm1, Kit, 
Met, and Mlana, are normally associated with melanocyte differentiation. They are 
frequently lost during metastatic tumor progression (Ryu et al., 2007). Transfection of the 
B16 melanoma cells with Wnt3a leads to decreased proliferation and induces differentiation 
(Chien et al., 2009). Moreover, silencing of β-catenin in this cell line actually promotes 
metastasis (Takahashi et al., 2008). Inhibition of negative regulators of the canonical Wnt 
signaling has a similar effect. The GSK3β suppression increases melanogenesis both in the 
B16 cells and melanocytes and decreases proliferation of the cultured B16 and human 
melanoma cells (Bellei et al., 2008; Chien et al., 2009). 
Thus, the canonical Wnt signaling pathway seems to play a dual role in melanomagenesis, 
depending on the context. On the one hand, it can somehow contribute to melanocyte 
transformation, and on the other, it can restrain tumor progression. Taking into 
consideration all these observations, it is possible that the Wnt/β-catenin signaling may be 
required to maintain a homeostasis (Lucero et al., 2010). The dysregulation of specific 
transcriptional programs in melanocytes or nevi can lead to early melanoma transformation. 
2.3.2 Contribution of the noncanonical Wnt signaling to melanoma metastasis 
Regarding the noncanonical Wnt cascades in melanoma, almost all data available at the 
moment is related to the Wnt5a and Wnt/Ca2+-signaling pathway. It is likely that  
Wnt/Ca2+-pathway is not implicated in melanocyte transformation, but rather contributes to 
melanoma progression. The Wnt5a overexpression is frequently observed in highly 
aggressive melanomas (Bittner et al., 2000; Dissanayake et al., 2007; Weeraratna et al., 2002). 
There is a positive correlation between its expression and a tumour stage (Weeraratna et al., 
2002). Moreover, Wnt5a was identified as a good criterion for melanoma division into 
highly aggressive tumors and less invasive counterparts (Bittner et al., 2000). Transfection of 
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less aggressive melanoma cells with Wnt5a converts them into more metastatic derivates. 
Moreover, in melanoma, Wnt5a is predominantly presented at the leading edge of invasion. 
It is considered that the conversion is connected with the PKC activation (Weeraratna et al., 
2002). The PKC signaling is often associated with alterations in cell motility, invasion and 
metastasis. Wnt5a can promote melanoma progression via the PKC-mediated mechanisms 
(Mapelli et al., 1994; Weeraratna et al., 2002). Another possible mechanism that can underlie 
the Wnt5a-dependent metastasis is the PCP pathway. Wnt5a, as well as Wnt1 and Wnt11, 
has been shown to activate the PCP pathway. Key components of this cascade, Rac, Rho and 
Cdc42, participate in melanoma metastasis (Choi & Han, 2002; Clark et al., 2000; Nakahara 
et al., 2003). But, unfortunately, there is no direct evidence supporting this idea. 
The Wnt5a signaling can antagonize the β-catenin signaling (Topol et al., 2003). As it was 
discussed before, silencing of the β-catenin signaling in melanoma cells actually promotes 
metastasis (Takahashi et al., 2008). Taken together, these observations provide a model 
where melanoma metastasis is at least partially associated with the Wnt5a-mediated 
repression of the β-catenin signaling. Notably, treatment of melanocytes with Wnt5a can 
induce their apoptosis but not transformation (O’Connell & Weeraratna, 2009). However, in 
melanoma, the Wnt5a-mediated increase in CamKII phosphorylation has been shown to 
protect cells against the Trail-induced apoptosis (Dissanayake et al., 2007; Xiao et al., 2005). 
Considering the tumor suppressor role of Wnt5a in other cancers, it is easy to speculate that 
a cellular context may be very important for the Wnt5a response determination. Moreover, 
balance between the canonical and noncanonical Wnt signaling pathways may be crucial for 
homeostasis maintenance (O’Connell & Weeraratna, 2009). In benign nevi, Wnt5a may 
prevent the β-catenin-dependent melanocyte transformation; in melanoma progression, the 
canonical Wnt signaling may inhibit the Wnt5a-driven metastasis. The opposite is true for 
melanomagenesis. The aberrantly activated canonical Wnt signaling is important for 
melanoma establishment, and, during cancer progression, it should be inhibited by the 
Wnt5a signaling in order to keep melanoma cells undifferentiated. 
Expression of Wnt5a in the nevi is quite controversial. While some researchers argue against 
the Wnt5a expression in the majority of benign nevi, others report the relatively strong 
Wnt5a expression (Da Forno et al., 2008; Mapelli et al., 1994; Pham et al., 2003). However, 
this disagreement can be explained by different sensitivity of methods used for Wnt5a 
detection. Considering high motility of the nevus cells and association of Wnt5a with 
decreased proliferation, the observation of a high Wnt5a level in the nevi is quite 
conforming to the behavior of these cells. 
Multiple data confirms that Wnt5a mediates its effects via the PKC activation (Dissanayake 
et al., 2007). In order to activate the noncanonical Wnt signaling in melanoma cells, Wnt5a 
must bind to a specific cohort of receptors, including Fz2, Fz5 and Ror2 (Billiard et al., 2005; 
Weeraratna et al., 2002). Treatment of melanoma cells with an antibody against Fz5 leads to 
inhibition of the PKC activation, reduced motility and invasion of melanoma cells (Sen et al., 
2001, Weeraratna et al., 2002). But the major Wnt5a receptor implicated in melanoma 
metastasis is supposed to be Ror2 (O’Connell et al., 2010). Like Wnt5a, it is upregulated 
predominantly in metastatic melanomas and has a negative correlation with melanoma 
patients survival (O’Connell et al., 2010). A knockdown of this receptor abrogates ability of 
Wnt5a to signal and mediate metastasis. Interestingly, overexpression or silencing of Wnt5a 
increases or decreases level of Ror2, respectively. However, downregulation of Ror2 has no 
effect on the Wnt5a expression (O’Connell et al., 2010). 
 
Dual Function of Wnts in Human Cutaneous Melanoma 
 
255 
Wnt5a can promote melanoma metastasis via different cellular mechanisms. First of all, it 
can induce morphological changes of melanoma cells. There is a report showing that 
transfection of melanoma cells (derived from an axillary lymph node) with the low 
endogenous Wnt5a expression with the Wnt5a-coding plasmid leads to shift from compact 
and roughly triangular cell shape into thin and spreading morphology. Cell shape changes 
were accompanied by increase in a number of contacts with the substrate (increased 
adhesion), actin cytoskeleton reorganization and PKC activation. Moreover, the transfected 
cells were more motile, as compared with the parent cells. Interestingly, the most affected 
PKC isoforms in the Wnt5a-transfected cells were PKCµ and PKCβII, that are considered to 
participate in cytoskeletal organization and invasion, respectively (Weeraratna et al., 2002).  
Morphological changes induced by the Wnt5a overexpression remind characteristics of the 
mesenchymal phenotype. Actually, cells with similar features are observed in many cancers. 
Mesenchymal motility is characterized by polarized and elongated cell morphology. It 
requires degradation of extracellular matrix (ECM) components in order to generate a "path" 
for moving cells (Parri et al., 2009). Wnt5a is considered to promote exactly this form of 
invasion. Thus, the Wnt5a overexpression stimulates production of matrix 
metalloproteinases like MMP-2 and MMP7 that degrade ECM (O’Connell et al., 2008; 
Pukrop et al., 2006). It also induces a shift in expression of cadherins, from E-cadherins to N-
cadherins (Hsu et al., 2002). This shift decreases cell-to-cell contacts and facilitates cell-to-
ECM interactions. Notably, Wnt5a also increases a level of an intermediate filament protein 
called vimentin and up-regulates expression of the transcriptional factor Snail, which are 
typical components of the mesenchymal cells. Wnt5a mediates its action on vimentin and 
Snail levels via the PKC activation (Dissanayake et al., 2007). Snail is a transcription factor 
capable of reducing the E-cadherin expression by binding to E-box elements in the cadherin 
promoter (Batlle et al., 2000). There is a positive feedback between Wnt5a and PKC. Wnt5a 
induces production of PKC, and vice versa (Jonsson et al., 1998). Thus, on the one hand, 
Wnt5a is able to support its own expression level, and on the other, it can affect cell motility 
through induction of the Snail-mediated E-cadherin repression.  
Besides the N-cadherin and vimentin expression, Wnt5a also stimulates expression of the 
glycosaminoglycan hyaluronan receptor CD44, a tumor cell homing and metastasis-
associated gene, and inhibits expression of the metastasis suppressor of melanoma KISS-1 
(Dissanayake et al., 2007). CD44 is a promigratory factor. In vitro study reveals its ability to 
enhance melanoma cell invasion in collagen gel (Albini, 1998). Inhibition of the Wnt5a-
induced PKC activation significantly reduces the CD44 expression (Dissanayake et al., 2007). 
Recently it has been shown that Wnt5a can increase the calpain protease-mediated cleavage of 
the cytoskeletal protein filamin. In the migratory osteoblast cells, filamin can induce filopodia 
formation. Overexpression of filamin is frequently observed in highly metastatic melanomas. 
In these cells filamin is distributed in a diffuse manner. Its cleavage is associated with 
enhanced cell motility (Nomachi et al., 2008; O’Connell et al., 2009). Inhibition of filamin in 
melanoma decreases cell migration. Calpain is a Ca2+-sensitive protein. Thus, Wnt5a promotes 
melanoma metastasis by induction of Ca2+ release and subsequent activation of calpain and 
calpain-mediated filamin cleavage (O’Connell et al., 2009). 
Another mechanism underlying melanoma metastasis is associated with alterations in cell 
adhesion. In the case of melanoma, adhesion predicts a less favorable outcome for patients. 
Many cell adhesion molecules are upregulated during tumor progression (O’Connell & 
Weeraratna, 2009). There is a notion explaining a positive correlation between enhanced 
adhesion and invasion. It is considered that for efficient tumor dissemination cancer cells 
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Recently it has been shown that Wnt5a can increase the calpain protease-mediated cleavage of 
the cytoskeletal protein filamin. In the migratory osteoblast cells, filamin can induce filopodia 
formation. Overexpression of filamin is frequently observed in highly metastatic melanomas. 
In these cells filamin is distributed in a diffuse manner. Its cleavage is associated with 
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must bind to endothelial cells (Albini, 1998; Cardones et al., 2003). Activated endothelial 
cells expose numerous adhesion molecules (VCAM-1, ICAM-1, E-selectin) on their surfaces 
(Chirivi et al., 1996). These adhesion molecules present good binding partners for cancer cell 
receptors. Cancer cells can both promote endothelial cells activation by production of IL-1α 
and enhance expression of its receptors for interaction with endothelial cells (Albini, 1998). 
Thus, melanoma is pushed towards invasion by enhanced adhesion. β1 integrins promote 
the CXCR4-mediated interaction between tumor and endothelial cells (Cardones et al., 
2003). And α3β1 integrin has been shown to provide migration and invasion of several 
melanoma cell lines (Melchiori et al., 1995). Wnt5a overexpression can lead to increase in 
substrate adhesion (Weeraratna et al., 2002). Moreover, melanoma cells exposed to the 
CXCL12 chemokine gradient demonstrate redistribution of the melanoma cell adhesion 
molecules (MCAM) into a polarized structure. And this process is controlled by the Wnt5a 
signaling (Witze et al., 2008). 
At last, the Wnt5a signaling has been shown to modulate immunogenicity of melanoma 
cells. The melanoma-associated antigens important for the cytotoxic T lymphocyte (CTL) 
response include MART-1, DCT, TYRP-1 (GP75) and GP100 (SILV). All of them are 
regulated by the transcription factors Sox10, Pax3 and MITF. Wnt5a can decrease 
melanosomal antigen expression by activation of PKC and STAT3 (Dissanayake et al., 2008) 
It is believed that PKC stimulated by Wnt5a is implicated in the STAT3 phosphorylation 
(Gartsbein et al., 2006; Sheldahl et al., 1999). Phosphorylated STAT3 is active and can reduce 
the Pax3 expression (Kamaraju et al., 2002). Inhibition of the Pax3 expression in turn results 
in the MITF repression and subsequent MART-1 silencing. Treatment of melanoma cells 
with phorbol ester has the same effect as the Wnt5a stimulation, and in the presence of 
STAT3 or PKC inhibitors, Wnt5a loses its ability to decrease the MART-1 expression 
(Dissanayake et al., 2008). Ratio of the Wnt5a-positive to the MART-1-negative tumors is 
increasing dramatically in metastasis (Dissanayake et al., 2008). Initially, it was 
demonstrated that melanoma patients could be separated into several cohorts according to 
their Wnt5a and MITF status (Hoek et al., 2006). A cohort with the high Wnt5a and low 
MITF expression has a weak proliferative, but a high metastatic potential. And cohort with 
the low Wnt5a and high MITF demonstrates opposite features: a high ability to proliferate 
and a low ability to metastasize. It is useful to remember that MITF is considered as a target 
of the Wnt/β-catenin signaling. And loss of the nuclear transcriptionally active β-catenin is 
frequently observed at the advanced stages of melanoma. Thus, an opposite correlation 
between the canonical and noncanonical Wnt signaling functions in melanomas can be 
revealed. During metastasis, melanoma cells prefer to downregulate their antigen expression 
in order to escape from immune surveillance of the tumors. The evidence for the notion comes 
from the experiment with MART-1 positive/negative cells presented to cytotoxic T-cells. The 
cytotoxic T-lymphocytes could be activated by melanoma cells expressing MART-1. Treatment 
of these cells with the recombinant Wnt5a abrogates their ability to activate the cytotoxic T-
cells and makes them more resistant to cytolysis. The opposite is also true. Silencing of Wnt5a 
by siRNA in Wnt5a high-leveled cells enhances the MART-1 expression and susceptibility to 
the T-cells-mediated cytolysis (Dissanayake et al., 2008). 
3. Conclusion 
The Wnt signaling pathways compose a really complex network both in melanocytes and in 
melanoma. Multiple receptors, coreceptors, inhibitors and agonists create a cellular context 
 
Dual Function of Wnts in Human Cutaneous Melanoma 
 
257 
that can vary significantly in benign nevi and tumors. The context determines a kind of a 
response to the Wnt ligand stimulation and gives a key to understanding why the canonical 
and noncanonical Wnt signaling cascades can act both as oncogenic and tumor suppressor 
factors. The Wnt5a and β-catenin signaling cascades play opposite roles in 
melanomagenesis. The canonical Wnt signaling is critical at the early stages of tumor 
development, but in advanced melanoma it serves as a tumor suppressor by promoting 
more differentiated phenotype. The Wnt5a signaling pathway does not participate in 
melanoma formation. On the contrary, it can control the canonical signaling preventing its 
aberrant activation. However, overexpression of Wnt5a is often associated with aggressive 
melanoma phenotype and is believed to promote metastasis. Thus, normally melanocyte 
homeostasis is maintained by tightly regulated system, and aberrations in the system 
regulation result in melanomagenesis. 
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1. Introduction  
Malignant melanoma is one of the most aggressive human cancers. Metastatic melanoma is 
highly resistant to genotoxic radiotherapy and chemotherapeutic treatments and patients have 
a median survival of under a year from diagnosis. As primary melanoma tumours can 
metastasise very early in tumour development (Chin et al., 2006), rapid diagnosis and curative 
surgery remain the best hopes for control of the disease. Early surgery that removes radial 
growth phase tumours that have not yet initiated vertical growth phase can be very effective 
and prevent further development. However, once the primary tumour has begun to invade the 
local epidermal and dermal environment treatment becomes much more complicated  
Why melanoma has such a high propensity to invade and metastasize is not well 
understood, but may be related to the developmental characteristics of the melanocyte 
lineage. Melanocytes derive from pluripotent neural crest cells as non-pigmented 
melanoblasts (Dupin et al., 2007; Dupin et al., 2006; Thomas and Erickson, 2008). During 
embryogenesis melanoblasts migrate via the dorso-lateral pathway to populate the basal 
layer of the epidermis and hair follicles, as well as a number of other sites including the 
inner ear and the heart (Yajima and Larue, 2008). The ability of transformed melanoma cells 
to rapidly invade and migrate away from the primary tumour perhaps reflects an inherent 
characteristic inherited from their embryonic state. 
Neural crest-derived cells are specified as melanoblasts by expression of MIcrophthalmia-
associated Transcription Factor (MITF), a basic helix-loop-helix transcription factor 
belonging to the MYC superfamily (Goding, 2000a; Goding, 2000b; Hemesath et al., 1994). 
The MITF locus encodes multiple isoforms generated by alternate splicing and use of 
internal promoters (Steingrimsson, 2008). The MITF-M isoform (hereafter designated simply 
as MITF) is produced specifically in the melanocyte lineage from an intronic promoter.  
MITF is required for melanoblast survival and differentiation of the retinal pigment 
epithelium (RPE) (Hou and Pavan, 2008; McGill et al., 2002). Consequently, MITF-null mice 
exhibit a white coat colour due to the loss of the melanocyte lineage and a small 
(microphthalmic) eye phenotype due to loss of the RPE (Hodgkinson et al., 1993; Hughes et 
al., 1993; Moore, 1995; Steingrimsson et al., 1994).  In humans, mutation of the MITF gene is 
responsible for Waardenburg syndrome type 2 (WS2) ((Tassabehji et al., 1994), a syndrome 
characterised by pigmentary defects and hearing loss highlighting the important role of the 
 
Research on Melanoma – A Glimpse into Current Directions and Future Trends 
 
268 
Xiao, C., Yang, B.F., Song, J.H., Schulman, H., Li, L., & Hao, C. (2005). Inhibition of CaMKII-
mediated c-FLIP expression sensitizes malignant melanoma cells to TRAIL-induced 
apoptosis. Exp Cell Res, Vol. 304, No. 1, (March 2005), pp. (244–255), ISSN 0014-4827 
Yamada, T., Akamatsu, H., Hasegawa, S., Inoue, Y., Date, Y., Mizutani, H., Yamamoto, N., 
Matsunaga, K., & Nakata, S. (2010). Melanocyte stem cells express receptors for 
canonical Wnt-signaling pathway on their surface. Biochem Biophys Res Commun, 
Vol. 396, No. 4, (June 2010), pp. (837–842), ISSN 0006-291X 
Yamaguchi, Y., Brenner, M., & Hearing, V.J. (2007). The regulation of skin pigmentation. J 
Biol Chem, Vol. 282, No. 38, (September 2007), pp. (27557-27561), ISSN 0021-9258 
Yamaguchi, Y., Morita, A., Maeda, A., & Hearing, V.J. (2009). Regulation of skin 
pigmentation and thickness by Dickkopf 1 (DKK1). J Investig Dermatol Symp Proc, 
Vol. 14, No. 1, (August 2009), pp. (73–75), 19675559 
Zallen, J.A. (2007). Planar Polarity and Tissue Morphogenesis. Cell, Vol. 129, No. 6, (June 
2007), pp. (1051-1063), ISSN 0092-8674 
13 
A POU3F2-MITF-SHC4 Axis in Phenotype 
Switching of Melanoma Cells  
Thomas Strub, Dominique Kobi,  
Dana Koludrovic and Irwin Davidson 
Institut de Génétique et de Biologie Moléculaire et Cellulaire 
CNRS; INSERM; Université de Strasbourg 
France 
1. Introduction  
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responsible for Waardenburg syndrome type 2 (WS2) ((Tassabehji et al., 1994), a syndrome 
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melanocytes located in the inner ear. MITF is thus the master regulator specifying the 
identify and properties of the melanocyte lineage.  
It is now commonly accepted that exposure to solar UV irradiation and consequent DNA 
damage and mutation, especially during childhood, is the primary cause of most forms of 
melanoma (Bennett, 2008b). Melanoma can arise spontaneously, but often result from a 
stepwise process via accumulations of genetic changes leading first to formation of a benign 
naevus (mole) which can remain stable throughout the individual’s life. If one of the cells in 
the naevus then acquires additional mutations it can go on and form the malignant tumour.  
In contrast to many other tumours where a diversity of mutations can be found, melanoma 
formation is tightly associated with specific genetic changes. Activating mutations in BRAF 
especially the BRAFV600E mutation or mutations in NRAS are found in more than 60% of 
primary melanomas. (Bennett, 2008a). The resulting constitutive activation of the MAP 
kinase pathway promotes melanocyte proliferation, but cells with activated BRAF or NRAS 
eventually arrest proliferation in what is assumed to be a senescent state in the form of  
benign nevi. Escape from this arrested state involves additional mutations one of the most 
frequent of which is inactivation of the CDKN2A locus encoding the cyclin dependent 
kinase inhibitor p16INK4 (Larue and Beermann, 2007). This inactivation can occur through 
genetic lesions (Bennett, 2008a) or DNA hypermethylation and epigenetic silencing  
(Richards and Medrano, 2009; Rothhammer and Bosserhoff, 2007), or repression via 
activation of Wntbeta-catenin signalling (Delmas et al., 2007).  The accumulation of these 
genetic and epigentic changes allows normal melanocytes to become immortal, escape 
senescence and go on to form malignant tumours.   
2. Phenotype switching versus genetic changes in tumour formation  
Following the genetic and epigentic changes described above, transformed melanoma cells 
enter the radial then the vertical growth phase where they acquire invasive properties. This 
is a critical event in tumour formation and two models have been put forward to account for 
how cells acquire the ability to invade neighbouring tissues, the lymphatic system and 
eventually form distant metastasis.  Cells in the primary tumour may acquire further genetic 
changes that promote invasion and metastasis. This would be an essentially irreversible 
genetic event that, unless additional mutations arise, would fix the properties of these cells. 
An alternate model that has been put forward in the case of melanoma is ‘phentoype 
switching’ which postulates that cells can reversibly switch from proliferative to invasive 
states (Hoek and Goding, 2010). This process involves a specific set of changes in gene 
expression and hence altered transcription factor activity and can take place dynamically 
within a population of cells in response to signals from the tumour microenvironment. 
The ‘phentoype switching’ model is based on two sets of observations. Firstly, analysis of 86 
cultured melanoma cell lines showed that they could be divided into two classes ; highly 
proliferative cells with low invasive potential and slowly dividing cells with much higher 
migratory and invasive potential (Hoek et al., 2008; Hoek et al., 2006). Gene expression 
profiling of these different cell types defined two distinct expression signatures in which a 
collection of 105 genes show the highest differential expression.  The invasive signature is 
characterised by up regulation of genes such as INHBA, COL5A1, and SERPINE1 that are 
involved in modifying the extracellular environment and are often known targets of TGFb 
signalling. In contrast, many of the proliferative signature genes are targets of Wnt 
signaling. Importantly however, a key feature of the two profiles revealed that invasive 
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phenotype cells exhibited low levels of MITF, while proliferative phenotype cells expressed 
high levels of MITF (Hoek et al., 2008; Hoek et al., 2006). These observations define at least 
two cell populations that differ in proliferative and invasive properties and are defined by 
distinct gene expression profiles including differential MITF expression.  
The second set of observations supporting this model are derived from experiments 
showing that when MITF high and MITF low cells are used to make xenografts, the 
resulting tumours comprise cell expressing both high and low MITF expression levels (Hoek 
et al., 2008). Hence, while the original cells were rather homogenous with respect to MITF 
expression, the resulting tumours are heterogenous.   The tumour microenvironment may  
therefore modify the gene expression profile allowing cells to switch from one state to the 
other in a dynamic way.  
This model is complicated by the observation that a low abundance subpopulation of cells 
that have strongly reduced MITF expression arise spontaneously in in vitro cultures of high-
MITF expressing cell lines (Cheli et al., 2011).  Depletion of these cells from the population 
leads to a strong reduction in tumour formation, whereas the purified low-MITF expressing 
population has high tumour formation potential and rapidly recovers higher MITF 
expression after subcutaneous injection. These observations confirm that cells can 
dynamically and even spontaneously switch their MITF expression and that low-MITF 
expressing cells have much higher tumour initiating capacity.  
These observations made from xenografted tumour cell lines have been confirmed in 
primary human tumours. Staining of primary tumours with antibodies against MITF 
showed a heterogenous pattern with cells that exhibited high levels of MITF and others that 
showed lower levels or were completely negative (Goodall et al., 2008). These results 
highlight the heterogeneity of cell populations within human tumours. This idea is 
reinforced by the observation that cells in human tumours with no MITF staining expressed 
high levels of a second transcription factor POU3F2 (also known as N-OCT3 or BRN2), 
while cells expressing high MITF showed low levels of POU3F2 (Goodall et al., 2008). Thus, 
these two transcription factors can act as markers for different cell populations within 
tumours. In an elegant approach, Pinner et al, (Pinner et al., 2009) used intravital imaging to 
follow the fate of xenografted human melanoma cells engineered to express green 
fluorescent protein under the control of the POU3F2 promoter. They were clearly able to 
show that the POU3F2 promoter was upregulated in motile cells and that these cells 
exhibited a de-differentiated phenotype with diminished pigmentation.  
Together the above results are consistent with the idea that cells expressing high levels of 
MITF are proliferative, but poorly motile and invasive, while those expressing low levels of 
MITF, but high levels of POU3F2 are highy motile and invasive and that this phenotype is 
acquired in a dynamic and reversible fashion in tumours. Spontaneous switching can also 
take place to a certain extent in cell culture, however, the low frequency of this event makes 
it a difficult process to follow. More recently however, Thurber et al (Thurber et al., 2011), 
showed that growth of high MITF expressing cells as non-adherent ‘melanospheres’ 
dramatically enhanced the frequency of low MITF/high POU3F2 expressing cells. Similarly, 
when we grew 501Mel cells expressing high levels of MITF in human embryonic stem cell 
medium under non-adherent conditions they readily form melanospheres, where we 
observe the appearance of a significant fraction of low MITF expressing cells in the spheres 
(Fig. 1). Thus, the change from monolayer to 3 dimensional culture in stem cells medium 
strongly influences MITF expression. Thurber et al, (Thurber et al., 2011) also showed using 
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siRNA silencing that POU3F2 was an activator and MITF a repressor of the Notch pathway. 
Loss of POU3F2-MITF signaling resulted in decreased capacity to form melanospheres and 
invasion through a collagen matrix. This in vitro model appears to recapitulate some of the 
characteristics of MITF and POU3F2 signaling seen in tumours and may therefore facilitate 
the identification of the signals and mechanisms that regulate melanoma cell heterogeneity 
in tumours.  
 
 
Fig. 1. Heterogenous MITF expression in 501Mel cells grown as melanospheres. The upper 
panels show phase contrast, MITF-labelling, nuclear Hoechst staining and the merge 
between the MITF and Hoechst signals of 501Mel cells grown as adherent monolayers under 
standard conditions. Almost all nuclei are stongly stained with MITF antibody.  In the lower 
panels, the cells were grown as melanospheres in human stem cell medium and a significant 
number of low-MITF expressing cells can now be seen. Representative low-MITF expressing 
cells are indicated by arrows. 
3. The MITF-POU3F2 axis in melanoma   
The results described above show that high levels of MITF promote melanoma cell 
proliferation and that MITF and POU3F2 show reciprocal levels of expression. Key 
questions are therefore how does MITF promote proliferation and how does POU3F2 
regulate MITF expression, proliferation and motility.  
i. POU3F2 an activator and a repressor of critical target genes in melanoma.  
POU (Pit, Oct1, Unc86) domain transcription factors play diverse functions in many 
physiological processes. The POU family factors have a bipartite DNA binding domain 
formed by the conserved POU-specific domain (POUs) and the POU homeodomain (POUh) 
that are joined by a linker region of variable length (Phillips and Luisi, 2000; Ryan and 
Rosenfeld, 1997). The POUs and POUh domains each comprise a helix-turn-helix structure 
of which the third helix recognises the DNA and provides sequence specificity (Cook and 
Sturm, 2008; Klemm et al., 1994).  
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POU3F2 and POU4F1 (BRN3) are involved in development of the central nervous system 
(Schonemann et al., 1998). Genetic studies in mice have demonstrated that POU3F2 is 
required for generation of specific neuronal lineages in the endocrine hypothalamus and the 
posterior pituitary gland (Nakai et al., 1995; Schonemann et al., 1995). POU3F2 also plays a 
role in the production and positioning of neocortical neurons (Sugitani et al., 2002). In 
addition to the nervous system, several studies have reported that POU3F2 is expressed in 
normal melanocytes and is upregulated in malignant melanoma cells where its expression is 
regulated by the Wnt/-catenin and activated BRAF signalling pathways (Cook et al., 2003; 
Eisen et al., 1995; Goodall et al., 2004a; Goodall et al., 2004b; Thomson et al., 1995). However, 
POU3F2 has not yet been selectively inactivated in the melanocyte lineage and genetic 
dissection of its role in normal melanocyte physiology and in melanoma will be a welcome 
and important addition to the field.  
POU3F2 directly represses MITF in melanoma cells through binding directly to the proximal 
internal promoter driving expression of the MITF-M isoform (Goodall et al., 2008). At least 3 
POU3F2 binding sites have been identified at the MITF-M locus, two in the proximal 
promoter region upstream of the transcription start site (TSS) and a third intronic site 
downstream of the TSS (Kobi et al., 2010). Wellbrock et al., (Wellbrock et al., 2008) have 
shown that in some melanoma cell types POU3F2 mediates the regulatory effect of the 
BRAFV600E mutation and induces MITF expression. As discussed above, this suggestion is at 
odds with what is observed in tumours and melanospheres. To reconcile what may appear 
to be contradictory observations, we have suggested that the POU3F2 binding to the site 
closest to the TATA element may repress MITF-M transcription through steric hindrance of 
the basal transcription machinery, for example TFIID, while POU3F2 may activate MITF-M 
transcription via binding to the other sites in the proximal promoter and downstream intron 
(Kobi et al., 2010). The ability to activate or repress may then be modulated by POU3F2 
concentration being able to efficiently compete with TFIID binding and repress MITF 
expression only at high concentrations. This model would reconcile the observation that 
POU3F2 is a transcription activator with the reciprocal MITF/POU3F2 expression seen in 
melanoma tumours (Goodall et al., 2008; Pinner et al., 2009). 
Another means by which POU3F2 and MITF may regulate each others expression is through 
control by miR-211. Boyle et al., (Boyle et al., 2011) have compared miRNA expression 
profiles and identified miR-211 as down-regulated in melanoma cell lines compared to 
normal melanocytes. MiR-211 is derived from the TRPM1 gene whose expression is directly 
regulated by MITF and it targets POU3F2 expression. Thus MITF driven expression of 
TRPM1/miR-211 provides a mechanism by which high MITF levels maintain low POU3F2 
levels. MiR-211 may also have other targets in melanoma. Levy et al., (Levy et al., 2010) have 
shown that  expression of miR-211 reduced migration and invasion in human melanomas 
with low miR-211 levels. They propose IGF2R, TGFBR2, and NFAT5 as miR-211 targets that 
mediate the phenotypic effects of its overexpression. In contrast, Mazar et al., (Mazar et al., 
2010) identified KCNMA1, encoding a calcium ion-regulated potassium channel protein, as 
a miR-211 target that influences melanoma cell aggressivity. MiR-211 has therefore many 
potential targets that influence melanoma cell properties. 
Can all of the effects of POU3F2 in melanoma be ascribed to its ability to repress MITF or 
does it regulate other target genes involved in melanoma development? Genome wide 
chromatin immunoprecipitation (ChIP) coupled to array hybridisation (ChIP-chip) profiling 
of POU3F2 promoter occupancy identified target genes that may be involved in modulating 
the properties of melanoma cells (Kobi et al., 2010). For example, siRNA-mediated 
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knockdown and transfection of reporter genes indicates that POU3F2 regulates expression 
of stem cell factor (Kit ligand, Kitl or Steel) via a cluster of 4 closely spaced binding sites 
located in the proximal promoter. Amplification and/or activating mutations of the KIT 
gene, encoding the KITL receptor, have been frequently found in mucosal, acral, and chronic 
sun-damaged melanomas (Garrido and Bastian, 2009), where it appears to promote 
melanoma development. The KITL/KIT pathway is also critical for promoting melanocyte 
migration during embryogenesis and hence may also be important in regulating the 
migratory/invasive properties of melanoma cells (Wehrle-Haller, 2003). POU3F2 may 
therefore modulate the properties of melanoma cells via autocrine KITL signalling.  
A second mechanism by which POU3F2 may enhance the motile and malignant properties 
of melanoma cells is through regulation of the cGMP-specific phosphodiesterase PDE5A. 
Arozarena et al (Arozarena et al., 2011) have shown that POU3F2 binds to two sites in the 
PDE5A proximal promoter upstream of the TSS to repress its expression. PDE5A down-
regulation has only a minor effect on proliferation, but potently increases melanoma cell 
invasion. Diminished PDE5A levels lead to an increase in cGMP and in cytosolic Ca2+, 
stimulating contractility and inducing invasion. In agreement with this idea, PDE5A levels 
are also down-regulated in human melanoma tumours. Hence, this model postulates that in 
melanoma cells, oncogenic BRAF promotes invasion through POU3F2-mediated repression 
of PDE5A. The ability of POU3F2 to act as a repressor at the PDE5A promoter is 
nevertheless surprising considering that it acts as a potent transcriptional activator in many 
other promoter contexts (Kobi et al., 2010).  
ii. MITF activates genes required for proliferation and represses genes involved in invasion. 
As described above, evidence from cell based models and human tumours suggest that 
MITF is a major regulator of melanoma cell proliferation. SiRNA-mediated silencing of 
MITF in proliferative melanoma cells leads to a rapid growth arrest confirming that it is 
indeed a critical regulator of proliferation (Carreira et al., 2006). Acute loss of MITF through 
siRNA mediated silencing has been reported to arrest cells at the G1/S phase transition 
through indirect regulation of CDKN1B (p27Kip1) via direct regulation of Diaphanous related 
formin DIAPH1. DIAPH1 promotes actin polymerization and coordinates the actin 
cytoskeleton and microtubule networks at the cell periphery (Carreira et al., 2006). MITF 
directly regulates DIAPH1 expression leading to reorganization of the actin cytoskeleton, 
accounting at least in part for the dramatic change in cell morphology seen upon MITF 
silencing, and increased ROCK-dependent invasiveness. MITF regulation of DIAPH1 also 
indirectly controls CDNK1B degradation leading to a G1 cell cycle arrest.  
While the above model accounts for many of the changes seen upon MITF silencing, it has 
been shown more recently that loss of MITF also leads to defects in mitosis and induces cell 
senescence (Giuliano et al., 2010; Strub et al., 2011). MITF silenced cells exhibit many 
characteristics of senescence such as enlarged and flattened cell morphology and 
senescence-associated β-galactosidase staining and heterochromatin foci.  Giuliano et al 
(Giuliano et al., 2010) showed that acute MITF silencing induced the DNA damage response 
leading to activation of ATM and CHK2 resulting in p53 phosphorylation and stabilization. 
SiRNA depletion and pharmacologic inhibition showed that the DNA-damage response is 
required for entry into senescence.  
How does MITF regulate both the proliferative and invasive properties of melanoma cells, 
and why does loss of MITF result in DNA damage? To answer these questions, Strub et al 
(Strub et al., 2011) used ChIP coupled to high throughput seqencing (ChIP-seq) to profile 
genomic MITF occupancy and RNA-seq following MITF silencing to identify MITF 
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regulated genes. As currently available antibodies do not efficiently ChIP MITF, 501Mel 
cells expressing 3HA-tagged MITF were used. ChIP-seq was perfomed not only for tagged 
MITF, but also for RNA polymerase II (Pol II) and trimethylation of lysine 4 of histone H3 
(H3K4me3), a covalent histone modification found at the 5’-end of transcribed genes 
(Ruthenburg et al., 2007).  An example of MITF occupancy of the highly expressed 
Tyrosinase locus is shown in Fig. 2, where at least 5 MITF-occupied sites can be detected 
both upstream and downstream of the TSS along with transcribing RNA Pol II. Overall, 
12139 MITF occupied loci were identified, 9447 of which could be annotated to more than 
5000 potential target genes.  
 
 
Fig. 2. Example of MITF-occupancy at the Tyrosinase locus. UCSC genome browser view of 
MITF and Pol II-occupancy and H3K4me3 at the TYR locus. The principal MITF occupied 
sites are indicated by arrows. TSS shows the engaged Pol II at the transcription start site, PS, 
enhanced Pol II occupany at an intronic pause site, and TTS, the transcription termination 
site downstream of the TYR polyadenylation site.  The data are adapted from the data set of 
Strub et al, (Strub et al., 2011). 
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To determine which of these potential targets are regulated by MITF in 501Mel cells, RNA-
seq was performed following MITF silencing identifying a large collection of both up and 
down-regulated genes (Strub et al., 2011). Amongst the genes that appear positively 
regulated by MITF are at least 31 genes involved in DNA replication, recombination and 
repair including LIG1 encoding DNA ligase 1, involved in the religation of Okazaki 
fragments during DNA replication, as well as religation during DNA repair and 
maintenance of genome stability (Bentley et al., 2002; Tomkinson and Mackey, 1998), and 
TERT (Telomerase reverse transcriptase) required for the proper replication of telomeres 
and frequently expressed in human tumours, (Artandi and DePinho, 2000; Artandi and 
DePinho, ; Kim et al., 1994; Rudolph et al., 1999). In addition, MITF regulates a set of 39 
genes involved in centromere organisation and mitosis including the G2-specific cyclins B1 
and F (CCNB1, CCNF) that promote entry into mitosis, as well as polo-like kinase 1 (PLK1) 
(Schmit et al., 2009), the CENPA-nucleosome associated and CENPA-nucleosome distal 
complexes and the chromosomal passenger complex. Consequently, siMITF silencing leads 
to mitotic defects with a high frequency of  binucleate and micronuclei containing cells.   
Together these results provide a more comprehensive picture of how MITF promotes 
proliferation by activating genes involved in DNA replication and repair as well as mitosis. 
Loss of expression of genes like LIG1 and TERT leads to incomplete DNA replication and 
telomere exposition activating the DNA damage and the senescence responses. We propose 
that, acute siMITF silencing in rapidly proliferating cells induces replication and mitotic 
defects too severe to be repaired and cells enter in senescence. However, the existence of 
senescent cells in human melanoma tumours has not yet been investigated and our results 
do not exclude the possibility that in vivo, decreased MITF expression could be offset by up-
regulation of other pathways that suppress senescence to produce slow-cycling invasive 
cells. Alternatively, a more gradual reduction of MITF expression such as may take place in 
tumours would allow cells to adapt progressively to slower growth due to diminished levels 
of replication and mitosis factors and not accumulate the high levels of DNA damage that 
trigger the senescence response.  
In contrast to the above, genomic profiling of MITF occupancy revealed genes that appear to 
be directly repressed by MITF. Amongst these are genes influencing metastasis such as 
MCAM (Ouhtit et al., 2009), SHC4 (Fagiani et al., 2007). Comparison of the ChIP-seq and 
mRNA-seq data shows the presence of at least 3 upstream and two intronic MITF occupied 
sites at the SHC4 locus and enhanced mRNA expression upon MITF knockdown (Figs. 3A 
and B). Increased SHC4 protein expression can also be seen upon MITF silencing (Fig 3C). 
SHC4 therefore appears to be directly repressed by MITF suggesting that MITF both 
activates and represses transcription in a promoter context-dependent manner similar to 
POU3F2 discussed above.  
SHC4 (also known as SHCD (Hawley et al., 2011), or RaLP, retinoic acid-like inducible like 
protein) belongs to the family of SRC homology and collagen (Shc) signal transduction 
adaptor proteins. These proteins share a common organisation with an N-terminal 
phosphotyrosine-binding (PTB) domain, a central region rich in proline and glycine residues 
(CH1) and a C-terminal SRC homologue 2 (SH2) domain (Pasini et al., 2009). A second N-
terminal collagen homology (CH2) region is present in the longest isoform of SHC4. SHC4 is 
of particular interest in melanoma as its expression is tightly correlated with tumour stage. 
SHC4 expression is low or undetectable in benign nevi and in early radial growth phase 
tumours, but is strongly expressed in the vertical growth phase and in metastases. SHC4 
functions as a substrate of activated IGF-1 and EGF receptors to enhance MAPK signaling 
and cell migration (Fagiani et al., 2007; Pasini et al., 2009). In contrast, SHC4 silencing in 
metastatic cells reduces their migration in vitro and inhibits tumour growth in vivo. 
 




Fig. 3. MITF occupies sites at SHC4 locus and represses its expression. A. UCSC genome 
browser view of MITF occupancy and H3K4me3 at the SHC4 locus. The principal MITF 
occupied sites are indicated by arrows. B. UCSC genome browser view of mRNA-seq data 
from 501Mel cells treated with control Luciferase or MITF siRNAs.  Increased expression of 
the SHC4 gene can be clearly observed in the siMITF cells.  C. Immunoblot showing 
increased SHC4 protein expression in total extracts from 501Mel cells following MITF 
silencing with 20 or 50 nM of siRNA (lanes 2 and 3, respectively). ChIP- and mRNA-seq data 
are adapted from Strub et al, (Strub et al., 2011). 
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Together with the results of the ChIP- and RNA-seq, these observations suggest a novel 
MITF-SHC4 axis in the control of melanoma cell invasion. Proliferating cells express high 
levels of MITF that repress SHC4 expression, but the loss of MITF that takes place during 
phenotype switching de-represses SHC4 expression to promote migration and metastasis 





Fig. 4. Summary of regulatory interactions. in the POU3F2-MITF-SHC4 axis. As described in 
the main text, activated BRAF induces POU3F2 expression which in turn has been described 
to either activate or repress MITF expression. POU3F2 also activates KITL expression but 
represses PDE5A to promote motility and migration.  MITF activates a series of genes 
involved in DNA replication and repair, mitosis and critical cyclin genes, but represses 
expression of SHC4 and MCAM that promote invasion and metastasis.  
4. Future perspectives  
In this review, we have limited our discussion to the hypothesis that POU3F2, MITF and 
SHC4 form a regulatory axis that controls the proliferative and invasive properties of 
melanoma cells. These are of course not the only transcription factors that regulate the 
properties of melanoma cells.  For example, recent studies have shown that GLI2 and ATF2 
modulate the invasive properties of melanoma cells. GLI2 is a transcription factor normally 
associated with Sonic Hedgehog (SHH) signaling is present in melanoma cells where its 
expression is rather controlled by TGFbeta and SMAD signaling (Alexaki et al., 2010; 
Dennler et al., 2009; Santiago-Walker and Herlyn, 2010). GLI2 is overexpressed in 
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subpopulations of cells and these GLI2-high cells metastasise to bone more readily than 
GLI2-low cells. GLI2 appears to promote invasion and metastasis through suppression of E-
cadherin expression leading to a mesenchymal-like phenotype. Also, the transcription factor 
ATF2 has been shown to attenuate melanoma susceptibility to apoptosis and to promote its 
ability to form tumors in xenografts (Bhoumik and Ronai, 2008; Shah et al., 2011). In mouse 
melanoma models, expression of mutant ATF2 in melanocytes strongly attenuated tumour 
formation. ATF2 appears to modulate MITF expression through ATF2-JunB-dependent 
suppression of expression of SOX10 a factor that binds to and activates the MITF-M 
promoter. Morevover, on melanoma tissue microarrays, a high nuclear ATF2 to MITF ratio 
was associated with metastatic disease and poor prognosis. In the future it will important to 
develop more complex mouse melanoma models in which POU3F2 and/or MITF, GLI2 and 
ATF2 are (in)activated or mutated to study combinatorial control by multiple transcription 
factors in melanoma. This will be a challenging, but important task.    
We have discussed the proposition that the regulatory interactions between POU3F2-
MITF-SHC4 explain in part the phenotype switching of melanoma cells. However, one 
important and outstanding question concerns the signal(s) in the tumour 
microenvironment responsible for modulating the expression of POU3F2 and MITF. Are 
these diffusable signals emanating from cells within or outside the tumour or are cell-cell 
contacts between the tumour cells and the stroma or amongst tumour cells involved ? An 
alternative possibility is that phenotype switching may take place spontaneously through 
transient stochastic changes in the expression of POU3F2 or MITF in single cells that set 
up a reinforcing positive feedback loop to establish a novel stable state. For example, 
down-regulation of MITF leads to up-regulation of POU3F2 (Strub et al., 2011), but 
elevated levels of POU3F2 repress MITF. Given this situation, a transient reduction in 
MITF could set up a reinforcing loop of POU3F2-mediated MITF repression.  This would 
explain the spontaneous appearance of cells low-MITF expressing cells in in vitro cultures 
of otherwise high-MITF expressing cell types. It remains possible that in the tumour 
environment, extracellular signals may influence the expression of MITF or POU3F2, but 
the important point is that the effect of these signals can be amplified by the positive and 
negative feedback loops between these factors.  The role that stochastic changes in 
transcriptional ‘noise’ may play in biological processes is only just beginning to be 
considered (Kashyap et al., 2009; Leisner et al., 2008). Whatever the mechanism involved,  
key features of melanoma cells are their plasticity and heterogeneity. As discussed above, 
Cheli et al (Cheli et al., 2011) identified low-MITF expression as a criteria for selecting 
cells with enhanced tumour initiating properties. This fits with the previously proposed 
‘rheostat’ model of MITF expression where high levels of MITF drive a G1/S arrest and 
differentiation, while low levels are associated with slow cycling tumour initiating cells, 
and intermediate levels are optimum for proliferation (Carreira et al., 2006; Hoek and 
Goding, 2010).  
However, MITF is not the only biomarker that has been used to select slow cycling tumour 
initiating cells. Roesch et al., (Roesch et al., 2010) have used the JARID1B histone 
demethylase as a marker to identify a population of slow cycling cells within the tumour 
population. Similar to purified low-MITF cells, purified JARID1B-positive cells give rise to a 
highly proliferative progeny showing the dynamics of their expression. Moreover, JARID1B 
silencing promotes a transient acceleration of tumor growth that is followed by exhaustion. 
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This observation suggests that the continuous dynamic appearance of a JARID1B-positive 
subpopulation is essential to maintain tumor growth. There are thus a number of parallels 
between JARID1B and MITF expression both in terms of the dynamics of their expression 
and the properties they confer to tumour cells. Unfortunately, Roesch et al, did not 
specifically assess MITF expression in the slow cycling JARID1B-positive cells, that one 
would predict to have low MITF expression or at least low levels of ‘active’ MITF. Cheli et 
al, (Cheli et al., 2011) however,  did not observe a consistent increase in JARID1B expression 
in the MITF low population. Previousy other markers such as CD133 (Monzani et al., 2007) 
or ABCB5 (Schatton et al., 2008; Zabierowski and Herlyn, 2008), have been used to 
characterise stem-like subpopulations in melanomas. Does this mean that there are multiple 
distinct slow cycling tumour cell populations characterised by different transcriptional 
programmes? Future studies should answer these questions.  
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1. Introduction  
1.1 Defining differentiation and cell fate in cancer 
In the setting of embryonic development, terms such as “cell fate“ and “cellular 
differentiation“ are relatively easy to grasp, since they refer to a straightforward linear 
model whereby progenitor cells give rise sequentially to various distinct and identifiable 
lineages, eventually resulting in a terminally differentiated cell that has until recently been 
thought to possess very little cellular plasticity or multipotent capacity. The sequences of 
events that regulate this process are extremely well conserved within a species, and even 
across species in many instances. In the setting of cancer, cell fate and cellular differentiation 
are often used descriptively to convey an observed phenotype rather than a defined and 
well-understood molecular process. How accurate is it to refer to “differentiation“ in cancer 
when the so-called end-point for this process results in cellular heterogeneity that is 
antithetical to the regulated and predictable differentiated cells that result from embryonic 
development? What does it mean to refer to “cell fate“ during the inherently dysregulated 
series of events involved in oncogenesis, which may not result in a distinct endpoint even 
across cells within the same tumor?   
Our review uses these terms in reference to the dynamic processes that constantly shape the 
function and properties of melanoma cells, which coincidentally utilize many of the same 
pathways involved in the regulated process of differentiation and determination of cell fate 
during embryonic development. While the label of being a differentiated cell may imply a 
terminal nature that might be viewed as less tumorigenic or lethal in the setting of cancer, this 
concept requires further experimental confirmation. Undoubtedly, these terms will become 
more refined as our understanding of the molecular events underlying melanoma progression 
comes into clearer focus. For now, they are the best terms available to describe some of the 
events and processes that help determine the behavior and response of tumor cells, and we use 
them with the full knowledge that years from now, advances in our understanding of cancer 
could render these terms woefully inadequate, or worse yet inaccurate. 
1.2 Differentiation in nevi and melanomas 
At one time, the classification of melanomas at the cellular level was largely limited to cell 
morphology, the expression profile of selected melanocytic or neuronal markers by 
 
Research on Melanoma – A Glimpse into Current Directions and Future Trends 
 
286 
Yajima, I. and Larue, L. (2008) The location of heart melanocytes is specified and the level of 
pigmentation in the heart may correlate with coat color. Pigment Cell Melanoma Res, 
21, 471-476. 
Zabierowski, S.E. and Herlyn, M. (2008) Learning the ABCs of melanoma-initiating cells. 
Cancer Cell, 13, 185-187. 
14 
The Role of Cellular Differentiation and  
Cell Fate in Malignant Melanoma 
Paul Kuzel1 and Andy J. Chien2 
1The University of Alberta School of Medicine and Dentistry and 
2The University of Washington School of Medicine  
1Canada 
2U.S.A. 
1. Introduction  
1.1 Defining differentiation and cell fate in cancer 
In the setting of embryonic development, terms such as “cell fate“ and “cellular 
differentiation“ are relatively easy to grasp, since they refer to a straightforward linear 
model whereby progenitor cells give rise sequentially to various distinct and identifiable 
lineages, eventually resulting in a terminally differentiated cell that has until recently been 
thought to possess very little cellular plasticity or multipotent capacity. The sequences of 
events that regulate this process are extremely well conserved within a species, and even 
across species in many instances. In the setting of cancer, cell fate and cellular differentiation 
are often used descriptively to convey an observed phenotype rather than a defined and 
well-understood molecular process. How accurate is it to refer to “differentiation“ in cancer 
when the so-called end-point for this process results in cellular heterogeneity that is 
antithetical to the regulated and predictable differentiated cells that result from embryonic 
development? What does it mean to refer to “cell fate“ during the inherently dysregulated 
series of events involved in oncogenesis, which may not result in a distinct endpoint even 
across cells within the same tumor?   
Our review uses these terms in reference to the dynamic processes that constantly shape the 
function and properties of melanoma cells, which coincidentally utilize many of the same 
pathways involved in the regulated process of differentiation and determination of cell fate 
during embryonic development. While the label of being a differentiated cell may imply a 
terminal nature that might be viewed as less tumorigenic or lethal in the setting of cancer, this 
concept requires further experimental confirmation. Undoubtedly, these terms will become 
more refined as our understanding of the molecular events underlying melanoma progression 
comes into clearer focus. For now, they are the best terms available to describe some of the 
events and processes that help determine the behavior and response of tumor cells, and we use 
them with the full knowledge that years from now, advances in our understanding of cancer 
could render these terms woefully inadequate, or worse yet inaccurate. 
1.2 Differentiation in nevi and melanomas 
At one time, the classification of melanomas at the cellular level was largely limited to cell 
morphology, the expression profile of selected melanocytic or neuronal markers by 
 
Research on Melanoma – A Glimpse into Current Directions and Future Trends 
 
288 
immunohistochemistry, and the presence or absence of phenotypic characteristics such as 
pigmentation. These early clinical and histological observations provide relevant insight into 
the role of cellular differentiation in both benign nevi and in melanoma (Barnhill et al., 2004). 
The phenomenon of “maturation with depth“ was described histologically in nevi well before 
the advent of molecular genetics (Winkelmann and Rocha, 1962), and highlights the capacity 
of certain nevus cells to dynamically evolve and undergo changes in cell fate, either through 
autologous signaling or in response to stromal factors. Maturation with depth is also seen in 
certain subsets of melanomas (sometimes termed “nevoid melanomas“), which reflects some 
of the cellular and molecular plasticity seen across tumors (Schmoeckel et al., 1985).  
Within the past decade, the sequencing of the human genome and the rapid development of 
technologies such as microarrays and deep sequencing has markedly advanced our 
understanding of cellular transcriptomes and led to the use of gene expression signatures as 
indicators of cell fate and cellular differentiation. It has become increasingly clear from 
studies in melanoma and across all cancers that the gene expression profile of a tumor or cell 
line can provide important information regarding the origin of the cancer cells, the status of 
various signal transduction pathways, and even the potential therapeutic susceptibility of 
cells to specific therapies. Furthermore, these analytic advances have confirmed the 
heterogeneity of melanoma that was already well-described histologically. 
1.3 Objectives 
Because cellular phenotype represents a primary measure of the state of melanoma cell 
differentiation, the focus of our discussion will center on some of the accumulated data 
regarding the characterization of phenotype by various experimental measures. Our overall 
goal is to summarize the literature on  differentiation and cell fate in melanoma, focusing on 
the gene expression profiles of both proliferative as well as invasive melanoma cells, along 
with discussing the mechanisms by which these profiles result in the described phenotypes. 
We will also review how gene signatures relate to the dynamic process of cellular 
differentiation in melanoma cells, including the evidence for the existence of phenotype 
switching, and how this phenomena may contribute to melanoma heterogeneity. Finally, we 
will examine how genetic mutations, phenotypic instability and therapeutic susceptibility 
affect efforts to treat this deadly disease. In the end, we hope that this review will stimulate 
thought and discussion on the viability of directed differentiation in melanoma and other 
cancers as a potential therapeutic strategy. By exploiting the powerful regulatory effects of 
the morphogen pathways utilized by cancer cells during oncogenesis, these types of 
strategies could potentially alter not only the behavior of these cells, but also their 
susceptibility and response to current and emerging cancer therapies. 
2. Global genetic regulation of melanoma differentiation 
2.1 Historical observations and recent advances 
2.1.1 The challenge of melanoma treatment 
Melanoma is the most lethal form of skin cancer, and both the incidence and consequent 
mortality rates of this deadly disease have increased globally in recent decades (Lens and 
Dawes, 2004). Death from this cutaneous neoplasm usually occurs as a result of distant 
metastasis, most commonly affecting the lungs, liver and brain. Its ability to become 
invasive and metastasize within months of the initial lesion developing makes melanoma 
one of the most aggressive forms of all human cancers (Miller and Mihm, 2006). Recent 
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advances in radio-, chemo- and immunotherapies have resulted in improved prognoses and 
prolonged survival times in many different types of malignancies.  Melanoma however, has 
remained largely resistant to treatment by any combination of these three therapeutic 
modalities, with current cancer treatment options still resulting in a median survival time of 
12 months or less in patients diagnosed with metastatic disease (Tsao et al., 2004). 
2.1.2 The intersection between developmental biology and cancer 
In recent years, we have gained a deeper understanding of the mechanisms underlying 
melanoma progression from a primary melanocyte to metastatic disease. Classically, this 
transformation has been viewed as the step-wise accumulation of genetic and epigenetic 
aberrations which results in an increasingly more malignant phenotype (Singh et al., 2008). 
A key feature of this progression model is the explicitly one-way nature of gene mutation. 
Based on this view of melanoma progression, a theory reminiscent of Darwinian natural 
selection has been conceived to explain the inevitable development of cellular heterogeneity 
and therapeutic resistance in melanoma tumors. Specifically, it is commonly believed that 
melanoma cells are constantly accumulating novel, prometastatic genetic mutations, which 
inevitably lead to the development of dominant subpopulations of tumor cells with a 
distinct survival advantage. As new dominant subpopulations are generated from ongoing 
genomic instability, the constantly evolving tumor is able to both maintain cellular 
heterogeneity, as well as develop dynamic resistance to chemotherapeutic agents.  
As tumor cells acquire more mutations, their properties dynamically change, as measured 
by changes in global gene expression or by changes in their capacity for relevant functions 
such as motility, proliferation, or invasion. By convention, these changes in cellular 
phenotype define a new cell fate, and reflect a process of differentiation (albeit 
dysregulated) that parallels the observed maturation of non-cancerous cells during 
development. To appreciate concepts such as differentiation and cell fate in the 
dysregulated setting of melanoma, one needs to have some contextual understanding of 
differentiation and cell fate determination in the normal development of cells that may serve 
as precursors for this deadly cancer. While the cell of origin for melanoma is almost 
certainly of neural crest origin, and likely in the melanocytic lineage, the recent unexpected 
finding that murine epidermal melanocytes can arise from a niche of Schwann cell 
precursors highlights the incomplete nature of our current understanding (Adameyko et al., 
2009). This finding suggests that an understanding of Schwann cell biology could be 
potentially relevant for identifying and treating melanomas that may arise from this distinct 
precursor population, since these melanomas could conceivably display different cellular 
phenotypes than melanomas derived from non-Schwann cell-derived melanocytes.  
While previous models of development have depicted differentiation as primarily a one-
way event, the observation that differentiated Schwann cells can be induced to form 
progenitor cells that subsequently give rise to glia and melanocytes provides evidence that 
so-called “terminal differentiation” does not preclude the ability to acquire pluripotency 
and/or the initiation of broad changes in cellular programming (Dupin et al., 2003). 
Likewise, the observation that melanocytes can de-differentiate to a precursor cell that gives 
rise to mature glia (Dupin et al., 2000) may further reflect a plasticity or instability of cell fate 
that is fundamentally relevant for melanoma and the exceptional resistance of this cancer to 
treatment.  
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immunohistochemistry, and the presence or absence of phenotypic characteristics such as 
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advances in radio-, chemo- and immunotherapies have resulted in improved prognoses and 
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2.1.2 The intersection between developmental biology and cancer 
In recent years, we have gained a deeper understanding of the mechanisms underlying 
melanoma progression from a primary melanocyte to metastatic disease. Classically, this 
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finding that murine epidermal melanocytes can arise from a niche of Schwann cell 
precursors highlights the incomplete nature of our current understanding (Adameyko et al., 
2009). This finding suggests that an understanding of Schwann cell biology could be 
potentially relevant for identifying and treating melanomas that may arise from this distinct 
precursor population, since these melanomas could conceivably display different cellular 
phenotypes than melanomas derived from non-Schwann cell-derived melanocytes.  
While previous models of development have depicted differentiation as primarily a one-
way event, the observation that differentiated Schwann cells can be induced to form 
progenitor cells that subsequently give rise to glia and melanocytes provides evidence that 
so-called “terminal differentiation” does not preclude the ability to acquire pluripotency 
and/or the initiation of broad changes in cellular programming (Dupin et al., 2003). 
Likewise, the observation that melanocytes can de-differentiate to a precursor cell that gives 
rise to mature glia (Dupin et al., 2000) may further reflect a plasticity or instability of cell fate 
that is fundamentally relevant for melanoma and the exceptional resistance of this cancer to 
treatment.  
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2.1.3 Insight from gene expression profiling studies 
An emerging body of evidence is re-defining the conventional genetic model of melanoma 
progression. Gene expression profiling studies using multi-center cohorts of patient tumors 
have previously revealed the existence of two major expression signatures (Hoek, 2007; 
Hoek et al., 2006). These signatures correlate to two distinct populations of melanoma cells, 
one with a predominantly proliferative phenotype and the other with a predominantly 
invasive phenotype. Subsequent transcriptional profiling studies in melanoma cells have 
revealed two discrete states of differentiation (Hoek, 2007; Tap et al., 2010). The first state 
results in a phenotype closely resembling primary human melanocytes, while the second 
results in a phenotype resembling neuronal stem cells (Hoek, 2007; Tap et al., 2010). Further, 
melanoma cells with a proliferative phenotype tend to be in a melanocytic differentiation 
state, while cells which acquire an invasive phenotype tend to dedifferentiate into a 
neuronal state. Several studies have demonstrated that melanoma has the ability to switch 
back-and-forth between these two phenotypes and/or differentiation states, triggered by 
factors such as microenvironmental conditions and therapeutic intervention (Hoek et al., 
2008; Hoek and Goding, 2010). The ability of melanoma cells to constantly switch 
phenotypes undoubtedly contributes to the resistance of melanoma to treatment. 
2.1.4 Cancer stem cells and melanoma 
Traditional chemotherapy operates largely under the premise that all cancer cells have equal 
malignant potential, with drug therapy focused on decreasing the population of cells within 
the tumor. Recently, studies looking at melanoma and other cancers have introduced the 
concept that certain populations within the tumor, often referred to as cancer stem cells 
(CSCs), have increased tumor initiating capabilities along with increased resistance to 
traditional chemotherapeutic approaches (Dou et al., 2007; Grichnik et al., 2006; Schatton et 
al., 2008). Consequently, the ability to identify, study and manipulate cells with the highest 
tumor-initiating capacity will be critical for developing effective therapeutic strategies. 
In the case of melanoma, the exact nature of CSCs remains controversial, with several 
putative CSC markers having been proposed in the literature (Zabierowski and Herlyn, 
2008). These markers include ABCB5 (Schatton et al., 2008), CD271/NGFR (Boiko et al., 
2010), and CD34 (Held et al., 2010). However, additional reports have demonstrated that 
tumor initiating capacity may actually be quite common among melanoma cells, and does 
not depend on the expression of any of the published putative melanoma CSC markers 
(Quintana et al., 2010; Quintana et al., 2008). In the context of cellular differentiation, studies 
have also  found that like other cancers, melanoma exhibits similarities to embryonic stem 
cells (Klein et al., 2007; Postovit et al., 2007).  The ability to correlate features of melanoma 
cells such as gene expression profiles with functional phenotypes such as tumor-initiating 
capacity (a hallmark of CSCs) will further delineate the role of cell fate in regulating 
melanoma progression. 
2.1.5 Tumor heterogeneity and plasticity 
While the cellular heterogeneity of tumors is a long-recognized phenomenon (Fidler, 1978), 
these recent studies highlight the variability within populations highlight regarding both 
gene signature and phenotypic plasticity. The concepts of phenotype switching and cancer 
stem cells in melanoma may both represent what happens within the tumor environment.  
Cancer stem cells may not be a fixed population, but rather a dynamically changing one 
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resulting from the phenotype switching of more “differentiated” cells in a tumor. This type 
of model could reconcile both sets of observations, and implies an inherent plasticity of 
melanoma cells that would undoubtedly complicate therapeutic efforts and potentially 
contribute to the variability seen with the use of cell surface markers to isolate CSC 
populations. While the use of the term differentiated in this model may again conjure up 
pre-conceptions that this population may be either more terminal/benign or less lethal in 
the long term, this assumption requires further experimental confirmation. 
2.2 The proliferative phenotype of melanoma cells 
Since cell fate and differentiation in the setting of cancer most closely parallels phenotype, 
this review will focus in particular on phenotypic characteristics that have been the center of 
efforts to understand melanoma at the molecular level. The first of the two major 
phenotypes expressed by malignant melanoma cells is the proliferative phenotype. As the 
name suggests, this phenotype is associated with a high rate of proliferation, as well as 
minimal invasive potential (Hoek et al., 2008; Hoek et al., 2006). Two key features of this 
group of cells help to account for their proliferative nature, including the activity of 
microphthalmia-associated transcription factor (MITF) (Levy et al., 2006) as well as the 
activity of the canonical Wnt/β-catenin pathway (Chien et al., 2009a). 
2.2.1 Microphthalmia transcription factor (MITF) 
MITF is a transcription factor that plays a critical role in the differentiation of melanoblasts 
from other cells derived from the neural crest (Levy et al., 2006), and severe mutations of MITF 
impede the embryonic development of melanocytes (Goding, 2000). It also plays a critical role 
in the normal functioning of differentiated primary melanocytes, regulating genes involved in 
the manufacture of melanosomes and melanin (Hornyak, 2006). This multi-tasking potential 
has been summarized using a proposed “rheostat model“ of MITF function (Carreira et al., 
2006; Hoek and Goding, 2010), which describes three different scenarios: MITF function in 
normal, differentiated melanocytes; MITF function in proliferative melanoma cells; and 
decreased MITF expression as seen in invasive melanoma cells.  
As previously mentioned, the primary role of MITF in a normally functioning melanocyte 
cell, where MITF expression is highest, is the regulation of genes involved in melanosome 
and melanin production (Lekmine et al., 2007; Levy et al., 2006). Some examples of the broad 
range of genes that affect pigmentation, whose expression is regulated by MITF, include 
melanocortin 1 receptor (MC1R), melanocortin 4 receptor (MC4R), tyrosinase (TYR) and 
melan-A (Lekmine et al., 2007; Levy et al., 2006). Other genes essential for normal 
melanocyte development, such as endothelin receptor type B (EDNRB) (Sato-Jin et al., 2008), 
p21cip1 (Carreira et al., 2005; Sestakova et al., 2010) and p16INK4 (Loercher et al., 2005), have 
also been shown to depend on MITF expression. Significantly, p21cip1 and p16INK4 are both 
regulators of the cell cycle, and are expressed when MITF levels are at their highest. 
As melanocytes acquire activating mutations in critical signalling pathways such as the 
MAPK pathway, the cellular effects of MITF change. Although the exact mechanism of this 
change is still not clear, it is primarily thought to be the result of altered post-translational 
modification of MITF, causing MITF to be targeted towards a different set of genes (Hoek 
and Goding, 2010). According to the rheostat model, overall MITF activity is also thought to 
be lower in malignant melanoma cells as compared to melanocytes (Hoek and Goding, 
2010). Consequently, MITF expression in this cell population results in suppression of 
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resulting from the phenotype switching of more “differentiated” cells in a tumor. This type 
of model could reconcile both sets of observations, and implies an inherent plasticity of 
melanoma cells that would undoubtedly complicate therapeutic efforts and potentially 
contribute to the variability seen with the use of cell surface markers to isolate CSC 
populations. While the use of the term differentiated in this model may again conjure up 
pre-conceptions that this population may be either more terminal/benign or less lethal in 
the long term, this assumption requires further experimental confirmation. 
2.2 The proliferative phenotype of melanoma cells 
Since cell fate and differentiation in the setting of cancer most closely parallels phenotype, 
this review will focus in particular on phenotypic characteristics that have been the center of 
efforts to understand melanoma at the molecular level. The first of the two major 
phenotypes expressed by malignant melanoma cells is the proliferative phenotype. As the 
name suggests, this phenotype is associated with a high rate of proliferation, as well as 
minimal invasive potential (Hoek et al., 2008; Hoek et al., 2006). Two key features of this 
group of cells help to account for their proliferative nature, including the activity of 
microphthalmia-associated transcription factor (MITF) (Levy et al., 2006) as well as the 
activity of the canonical Wnt/β-catenin pathway (Chien et al., 2009a). 
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MITF is a transcription factor that plays a critical role in the differentiation of melanoblasts 
from other cells derived from the neural crest (Levy et al., 2006), and severe mutations of MITF 
impede the embryonic development of melanocytes (Goding, 2000). It also plays a critical role 
in the normal functioning of differentiated primary melanocytes, regulating genes involved in 
the manufacture of melanosomes and melanin (Hornyak, 2006). This multi-tasking potential 
has been summarized using a proposed “rheostat model“ of MITF function (Carreira et al., 
2006; Hoek and Goding, 2010), which describes three different scenarios: MITF function in 
normal, differentiated melanocytes; MITF function in proliferative melanoma cells; and 
decreased MITF expression as seen in invasive melanoma cells.  
As previously mentioned, the primary role of MITF in a normally functioning melanocyte 
cell, where MITF expression is highest, is the regulation of genes involved in melanosome 
and melanin production (Lekmine et al., 2007; Levy et al., 2006). Some examples of the broad 
range of genes that affect pigmentation, whose expression is regulated by MITF, include 
melanocortin 1 receptor (MC1R), melanocortin 4 receptor (MC4R), tyrosinase (TYR) and 
melan-A (Lekmine et al., 2007; Levy et al., 2006). Other genes essential for normal 
melanocyte development, such as endothelin receptor type B (EDNRB) (Sato-Jin et al., 2008), 
p21cip1 (Carreira et al., 2005; Sestakova et al., 2010) and p16INK4 (Loercher et al., 2005), have 
also been shown to depend on MITF expression. Significantly, p21cip1 and p16INK4 are both 
regulators of the cell cycle, and are expressed when MITF levels are at their highest. 
As melanocytes acquire activating mutations in critical signalling pathways such as the 
MAPK pathway, the cellular effects of MITF change. Although the exact mechanism of this 
change is still not clear, it is primarily thought to be the result of altered post-translational 
modification of MITF, causing MITF to be targeted towards a different set of genes (Hoek 
and Goding, 2010). According to the rheostat model, overall MITF activity is also thought to 
be lower in malignant melanoma cells as compared to melanocytes (Hoek and Goding, 
2010). Consequently, MITF expression in this cell population results in suppression of 
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senescence and increased proliferation, as well as decreased invasiveness, both hallmarks of 
melanoma cells in the proliferative gene expression cluster.  
There have been many mechanisms proposed to help explain how MITF expression leads to 
increased proliferation of melanoma cells. For example, suppression of p27kip1, or cyclin-
dependent kinase inhibitor 1B (CDKN1B), is thought to be of primary importance in this 
process . The main function of p27kip1 is to impede cell cycle progression at G1. In melanoma 
cells with a proliferative phenotype, there is decreased p27kip1 expression (Carreira et al., 
2006). This is thought to be the result of increased expression of diaphanous-related formin 
DIA1, a protein which is upregulated by MITF and has a role in the regulation of a wide 
variety of cellular functions, including actin polymerization and E-cadherin organization. 
DIA1 in turn increases degradation of p27kip1 by S-phase kinase-associated protein 2 (SKP2), 
a gene which is regulated by DIA1 (Carreira et al., 2006). In addition, other genes 
upregulated by MITF in proliferative melanoma cells include BCL2 and CDK2 (Cheli et al., 
2010). While BCL2 upregulation imparts apoptotic resistance on melanoma cells, increased 
expression of cyclin-dependent kinase 2 results in cell cycle dysregulation and thus 
increased proliferation (Cheli et al., 2010).  
Besides increasing proliferation, MITF also contributes to the low invasive potential 
characteristic of melanoma cells in the “proliferative state”. Based on the results of Carreira et 
al., the ability of MITF to inhibit invasion is likely dependent on its DIA1-mediated regulation 
of the RHO/ROCK pathway, a known promoter of invasiveness (Carreira et al., 2006). MITF 
also appears to be a negative regulator of the Notch signalling cascade, which is itself a driver 
of invasive potential (Thurber et al., 2011). The frequent dysregulation of MITF by gene 
amplification in melanoma cells (Garraway et al., 2005) further highlights the critical nature of 
MITF in melanoma progression, and in the regulation of melanoma cell fate. 
2.2.2 Wnt/β-catenin signaling 
The Wnt/β-catenin signaling pathway represents a morphogenic pathway that is critical for 
development and almost always dysregulated in the context of cancers (Chien et al., 2009a) . 
Constitutive activation of the Wnt/β-catenin pathway is a common feature of many cancers, 
and increased activity of this pathway in general is a feature which distinguishes 
proliferative melanoma cells from invasive ones (Hoek et al., 2006). In the context of cellular 
differentiation and melanoma, which is neural crest-derived, Wnt/β-catenin signaling is 
particularly relevant since this pathway plays a pivotal role in regulating the differentiation 
of precursor cells into either neurons or melanocytes (Dorsky et al., 1998) .  
The key mediator of canonical Wnt/β-catenin pathway signalling is β-catenin, a protein 
whose degradation is inhibited upon Wnt ligand bidning, allowing its translocation to the 
nucleus where it regulates target gene expression (Chien et al., 2009a) . Wnt/β-catenin and 
MITF are intimately related in that β-catenin increases MITF expression (Dorsky et al., 
2000b), while MITF can interact with β-catenin in cultured malignant melanoma cells to alter 
its downstream gene-targeting (Widlund et al., 2002). Like MITF, Wnt/β-catenin signalling 
is critical to the normal embryonic development of melanocytes, so much so that the Wnt3a 
ligand is one of only three factors needed to stimulate the development of a pluripotent 
human embryonic stem cell into a mature melanocyte (Fang et al., 2006).  
The exact role of Wnt/β-catenin signaling in melanoma remains controversial, in part due to 
some differences in observed patient data and data obtained from murine models. Overall, 
increased activation of this pathway in approximately one-third of all melanomas is suggested 
by the presence of increased nuclear localization of β-catenin (Chien et al., 2009b), a surrogate 
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marker for Wnt/β-catenin activation. More importantly, the activation of Wnt/β-catenin 
signaling has been unexpectedly associated with improved patient survival (Bachmann et al., 
2005; Chien et al., 2009b). In addition, the presence of nuclear β-catenin in the majority of 
benign nevi (Bachmann et al., 2005; Kageshita et al., 2001; Maelandsmo et al., 2003) implicates a 
role for Wnt/β-catenin signaling in maintaining normal cellular homeostasis, and suggests 
that the dysregulaton of this pathway may contribute to the process of melanoma progression. 
The interpretation of these observations in patients is complicated by studies using a mouse 
model expressing a constitutively-active β-catenin mutant under the transcriptional control 
of a melanocyte-specific promoter. This transgenic mouse model suggests that increased 
Wnt/β-catenin signalling contributes to the initial immortalizaton of melanoma cells by 
inhbiting the expression of p16INK4a, a tumor suppressing protein which plays a key role in 
the induction of G1 cell cycle arrest in response to DNA damage (Delmas et al., 2007). 
Interestingly, although immortalization is often associated with proliferation, Delmas et al. 
show that in fact these two processes are effectively uncoupled during the process of 
malignant transformation in melanocytes (Delmas et al., 2007). However, despite facilitating 
the immortalization of melanocytes, the presence of a constitively-active β-catenin mutant 
was by itself not sufficient to generate spontaneous melanomas, which required 
concommitant activation of MAPK signaling through Nras mutation (Delmas et al., 2007).  
With regards to the issue of differentiation and questions surrounding the cell of origin for 
melanoma, the comparison of Wnt/β-catenin signaling in both human patients and mice 
raise two interesting points. First, melanomas from the mouse model appear to originate 
from the bulge region of the hair follicle, which is the proposed niche for melanocytic stem 
cells (Delmas et al., 2007); by contrast, most patient melanomas arise from interfollicular 
epidermis rather than from the hair follicle. Second, while these studies utilize a 
constitutively active mutant of β-catenin (Delmas et al., 2007), these types of activating 
mutations are quite rare in patient melanomas (Lucero et al., 2010), where Wnt/β-catenin 
activation is thought to result primarily from secreted Wnt ligand. Intuitively, the activation 
of signaling by secreted Wnt ligand is subject to modulation by extrinsic factors including 
endogenous inhibitors (i.e. DKK1, SFRPs) (Chien et al., 2009a), which would permit a model 
more akin the the MITF rheostat. Interestingly, the activation of Wnt/β-catenin signaling 
through the forced expression of WNT3A rather than a mutant β-catenin results in 
decreased proliferation in vitro and in vivo, correlating with the increased expression of 
genes associated with melanocyte differentiation (Chien et al., 2009b). 
2.3 The invasive phenotype of melanoma cells 
The second major gene expression signature of melanoma cells results in a phenotype 
characterized by a high degree of invasiveness and relatively lower rates of proliferation. 
Both MITF as well as canonical Wnt/β-catenin signalling are markedly downregulated in 
this population of cells, with a concomitant upregulation of a variety of pro-invasive 
mediators (Hoek et al., 2006). Notably, invasive melanoma cells are defined by genes 
suggestive of increased noncanonical WNT5A signalling, increased Notch1 signaling, 
upregulation of TGF-β and Brn-2 transcription factor as well as loss of the AP-2 
transcription factor, all of which are reviewed below.  
2.3.1 WNT5A and non-canonical Wnt signaling 
Whereas the canonical Wnt pathway is reliant on β-catenin signaling, the noncanonical Wnt 
pathway uses calcium-dependent mediators such as protein kinase C (PKC) to propagate 
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and increased activity of this pathway in general is a feature which distinguishes 
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particularly relevant since this pathway plays a pivotal role in regulating the differentiation 
of precursor cells into either neurons or melanocytes (Dorsky et al., 1998) .  
The key mediator of canonical Wnt/β-catenin pathway signalling is β-catenin, a protein 
whose degradation is inhibited upon Wnt ligand bidning, allowing its translocation to the 
nucleus where it regulates target gene expression (Chien et al., 2009a) . Wnt/β-catenin and 
MITF are intimately related in that β-catenin increases MITF expression (Dorsky et al., 
2000b), while MITF can interact with β-catenin in cultured malignant melanoma cells to alter 
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human embryonic stem cell into a mature melanocyte (Fang et al., 2006).  
The exact role of Wnt/β-catenin signaling in melanoma remains controversial, in part due to 
some differences in observed patient data and data obtained from murine models. Overall, 
increased activation of this pathway in approximately one-third of all melanomas is suggested 
by the presence of increased nuclear localization of β-catenin (Chien et al., 2009b), a surrogate 
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marker for Wnt/β-catenin activation. More importantly, the activation of Wnt/β-catenin 
signaling has been unexpectedly associated with improved patient survival (Bachmann et al., 
2005; Chien et al., 2009b). In addition, the presence of nuclear β-catenin in the majority of 
benign nevi (Bachmann et al., 2005; Kageshita et al., 2001; Maelandsmo et al., 2003) implicates a 
role for Wnt/β-catenin signaling in maintaining normal cellular homeostasis, and suggests 
that the dysregulaton of this pathway may contribute to the process of melanoma progression. 
The interpretation of these observations in patients is complicated by studies using a mouse 
model expressing a constitutively-active β-catenin mutant under the transcriptional control 
of a melanocyte-specific promoter. This transgenic mouse model suggests that increased 
Wnt/β-catenin signalling contributes to the initial immortalizaton of melanoma cells by 
inhbiting the expression of p16INK4a, a tumor suppressing protein which plays a key role in 
the induction of G1 cell cycle arrest in response to DNA damage (Delmas et al., 2007). 
Interestingly, although immortalization is often associated with proliferation, Delmas et al. 
show that in fact these two processes are effectively uncoupled during the process of 
malignant transformation in melanocytes (Delmas et al., 2007). However, despite facilitating 
the immortalization of melanocytes, the presence of a constitively-active β-catenin mutant 
was by itself not sufficient to generate spontaneous melanomas, which required 
concommitant activation of MAPK signaling through Nras mutation (Delmas et al., 2007).  
With regards to the issue of differentiation and questions surrounding the cell of origin for 
melanoma, the comparison of Wnt/β-catenin signaling in both human patients and mice 
raise two interesting points. First, melanomas from the mouse model appear to originate 
from the bulge region of the hair follicle, which is the proposed niche for melanocytic stem 
cells (Delmas et al., 2007); by contrast, most patient melanomas arise from interfollicular 
epidermis rather than from the hair follicle. Second, while these studies utilize a 
constitutively active mutant of β-catenin (Delmas et al., 2007), these types of activating 
mutations are quite rare in patient melanomas (Lucero et al., 2010), where Wnt/β-catenin 
activation is thought to result primarily from secreted Wnt ligand. Intuitively, the activation 
of signaling by secreted Wnt ligand is subject to modulation by extrinsic factors including 
endogenous inhibitors (i.e. DKK1, SFRPs) (Chien et al., 2009a), which would permit a model 
more akin the the MITF rheostat. Interestingly, the activation of Wnt/β-catenin signaling 
through the forced expression of WNT3A rather than a mutant β-catenin results in 
decreased proliferation in vitro and in vivo, correlating with the increased expression of 
genes associated with melanocyte differentiation (Chien et al., 2009b). 
2.3 The invasive phenotype of melanoma cells 
The second major gene expression signature of melanoma cells results in a phenotype 
characterized by a high degree of invasiveness and relatively lower rates of proliferation. 
Both MITF as well as canonical Wnt/β-catenin signalling are markedly downregulated in 
this population of cells, with a concomitant upregulation of a variety of pro-invasive 
mediators (Hoek et al., 2006). Notably, invasive melanoma cells are defined by genes 
suggestive of increased noncanonical WNT5A signalling, increased Notch1 signaling, 
upregulation of TGF-β and Brn-2 transcription factor as well as loss of the AP-2 
transcription factor, all of which are reviewed below.  
2.3.1 WNT5A and non-canonical Wnt signaling 
Whereas the canonical Wnt pathway is reliant on β-catenin signaling, the noncanonical Wnt 
pathway uses calcium-dependent mediators such as protein kinase C (PKC) to propagate 
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the signal of its primary extracellular ligand, WNT5A (Chien et al., 2009a). Normally, 
WNT5A signalling plays an important role in the regulation of cell fate, embryogenic 
patterning and cell motility (Chien et al., 2009a). In many forms of cancer, including colon, 
breast and liver cancer, WNT5A acts as a tumor suppressor (Chien and Moon, 2007). In the 
context of melanoma cell differentiation, which is assessed largely through gene signatures, 
the continued appearance of WNT5A as a major determinant of melanoma clusters in 
transcriptional profiling studies speaks to its likely importance as a genetic marker (Bittner 
et al., 2000; Hoek, 2007; Hoek et al., 2006; Weeraratna et al., 2004).  
Functionally, WNT5A is thought to contribute significantly to the invasive phenotype by 
regulating cellular migration, both through PKC and the re-distribution of cellular adhesion 
molecules (Dissanayake et al., 2007; Weeraratna et al., 2002; Witze et al., 2008). In addition, 
WNT5A signalling has been shown to inhibit the canonical Wnt/β-catenin pathway and 
consequently cause the downregulation of the downstream target genes of β-catenin (Chien 
et al., 2009b; Dissanayake et al., 2008), which may further contribute to its role in melanoma 
progression. The observation that WNT5A can be involved in the specification of 
dopaminergic neuronal cells (Castelo-Branco et al., 2003) and specification of axonal or 
synaptic function (Agalliu et al., 2009; Bodmer et al., 2009; Varela-Nallar et al., 2010) may 
also indicate a previously under-appreciated role of this pathway in the control of cellular 
differentiation. Conceivably, the role of WNT5A in neuronal cells may overlap with the 
phenotypic effects seen with WNT5A activation in melanoma cells, thereby contributing to 
whether these cells may display a phenotype that is neuronal as opposed to melanocyte-like. 
Alternatively, the expression of WNT5A in melanoma may simply be a reflection of cellular 
differentiation state, which would be consistent with transcriptional profiling studies where 
WNT5A is enriched in melanoma cells with a gene signature suggestive of neuroprogenitor 
cells (Tap et al., 2010). 
2.3.2 Notch signaling 
Another pathway implicated in melanoma is the Notch signaling cascade, which is one of 
the prototypical regulators of cell fate determination during embryonic development 
(Kopan and Ilagan, 2009). Like other primary transforming mutations in melanoma such as 
BRAF and NRAS, constitutive activation of the Notch1 receptor was in itself sufficient for 
the malignant transformation of human melanocytes (Pinnix et al., 2009). In fact, Notch1 
signaling is also required for β-catenin-induced proliferation in melanoma cells with a 
proliferative phenotype (Balint et al., 2005). However, the expression of Notch is negatively 
regulated by MITF, and thus its contribution to cellular phenotype is most pronounced in 
invasive melanoma cells where MITF is down-regulated (Thurber et al., 2011). Reports that 
these Notch effects in melanoma are mediated through regulation of the MAPK and PI3K-
Akt pathways (Liu et al., 2006a; Liu et al., 2006b) further highlight the convergence of critical 
pathways during melanoma progression.  
Like Wnt signaling, the Notch pathway plays a critical role in the specification of cell fate 
during neural crest development, making it particularly relevant to melanoma biology 
(Cornell and Eisen, 2005). During embryonic development, Notch signaling is thought to 
regulate both the specification of neural crest, as well as the subsequent determination of 
secondary cell fate through differentiation into glial-based lineages (Cornell and Eisen, 
2005). Engagement of Notch signaling can inhibit neurogenesis and neural differentiation, 
which may play some part in the role of this pathway in melanoma. Likewise in the context 
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of stem- and progenitor cells, Notch signaling can have varied roles in regulating either the 
maintenance of stem cell phenotype or the differentiation of stem cells into mature lineages 
(Liu et al., 2010). Understanding the interplay between Notch and other signaling pathways 
will be vital to effectively leveraging this important regulator of cellular differentiation for 
therapeutic benefit.  
2.3.3 Transforming growth factor-beta (TGFB) 
The morphogen-based Nodal signaling pathway, representing a subset of transforming 
growth factor β (TGFB) signaling pathways, was perhaps the initial pathway of interest in 
melanoma with regards to the concept of ‘differentiation therapy’ (Hardy et al., 2010; 
Postovit et al., 2008a; Postovit et al., 2008b; Strizzi et al., 2009). Like many of the other 
pathways that participate in melanoma biology, Nodal is a morphogen ligand involved the 
determination of cell fate during development. Melanoma is characterized by the presence 
of increased levels of Nodal ligand coinciding with decreased expression of the secreted 
Nodal antagonist Lefty (Postovit et al., 2008a). Typical benign nevi appear to express low 
levels of Nodal, although a subset of congenital nevi express levels of Nodal by 
immunohistochemistry that are comparable to what is observed in melanoma (Yu et al., 
2010). Analogous to its role in maintaining human embryonic stem cells in the 
undifferentiated state, Nodal signaling in melanoma is thought to regulate or facilitate the 
plasticity of tumor cells (Postovit et al., 2008a), thus eliciting considerable interest in the 
targeting of this pathway for therapeutic purposes.   
Overall, the role of TGFB in melanoma pathogenesis is complex, given the variability of its 
effects based on a cell’s stage of progression (Javelaud et al., 2008; Lasfar and Cohen-Solal, 
2010). Whereas normal human melanocytes are exquisitely sensitive to the anti-proliferative 
effects of TGF-β, resistance to this effect begins to develop as malignant transformation 
occurs. However, proliferative melanoma cells do retain sensitivity to TGF-β, and thus in 
this population of melanoma cells TGF-β actually acts as a tumor suppressor (Hoek et al., 
2006). Hoek et al. demonstrated that melanoma cells which clustered into the invasive, low 
MITF gene expression group also showed upregulation of many downstream targets of 
TGF-β (Hoek et al., 2006). Further, specific inhibition of the TGF-β signaling cascade via 
exogenous Smad7 significantly reduces the capacity of melanoma cells for anchorage-
independent growth, a characteristic intrinsic to metastatic potential (Javelaud et al., 2005). 
An important mechanism by which TGF-β signaling is able to increase invasive potential is 
likely its ability to decrease MITF expression, which results in upregulation of the pro-
invasive RHO/ROCK and Notch signaling cascades (Carreira et al., 2006; Thurber et al., 
2011). It also induces the expression of factors which inhibit canonical Wnt signaling (Hoek 
et al., 2006), promotes angiogenesis through factors such as VEGF, and has broad 
immunosuppressive effects which may contribute to the therapeutic resistance of TGF-β 
expressing tumor cells (Javelaud et al., 2008). 
A small but accumulating body of literature has also characterized the involvement in 
melanoma of bone morphogenic proteins (BMPs), which represent another subset of the 
TGFB superfamily (Hsu et al., 2005). Like TGFB, BMP7 can act in an autocrine fashion to 
inhibit melanoma cell growth (Hsu et al., 2008).  Interestingly, the upregulation of BMP7 
with melanoma progression coincides with upregulation of Noggin, an antagonist of BMP 
(Hsu et al., 2008). This finding parallels the observed acquisition of resistance to autocrine 
TGFB seen in melanoma cells compared to melanocytes (Krasagakis et al., 1999). In contrast, 
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the signal of its primary extracellular ligand, WNT5A (Chien et al., 2009a). Normally, 
WNT5A signalling plays an important role in the regulation of cell fate, embryogenic 
patterning and cell motility (Chien et al., 2009a). In many forms of cancer, including colon, 
breast and liver cancer, WNT5A acts as a tumor suppressor (Chien and Moon, 2007). In the 
context of melanoma cell differentiation, which is assessed largely through gene signatures, 
the continued appearance of WNT5A as a major determinant of melanoma clusters in 
transcriptional profiling studies speaks to its likely importance as a genetic marker (Bittner 
et al., 2000; Hoek, 2007; Hoek et al., 2006; Weeraratna et al., 2004).  
Functionally, WNT5A is thought to contribute significantly to the invasive phenotype by 
regulating cellular migration, both through PKC and the re-distribution of cellular adhesion 
molecules (Dissanayake et al., 2007; Weeraratna et al., 2002; Witze et al., 2008). In addition, 
WNT5A signalling has been shown to inhibit the canonical Wnt/β-catenin pathway and 
consequently cause the downregulation of the downstream target genes of β-catenin (Chien 
et al., 2009b; Dissanayake et al., 2008), which may further contribute to its role in melanoma 
progression. The observation that WNT5A can be involved in the specification of 
dopaminergic neuronal cells (Castelo-Branco et al., 2003) and specification of axonal or 
synaptic function (Agalliu et al., 2009; Bodmer et al., 2009; Varela-Nallar et al., 2010) may 
also indicate a previously under-appreciated role of this pathway in the control of cellular 
differentiation. Conceivably, the role of WNT5A in neuronal cells may overlap with the 
phenotypic effects seen with WNT5A activation in melanoma cells, thereby contributing to 
whether these cells may display a phenotype that is neuronal as opposed to melanocyte-like. 
Alternatively, the expression of WNT5A in melanoma may simply be a reflection of cellular 
differentiation state, which would be consistent with transcriptional profiling studies where 
WNT5A is enriched in melanoma cells with a gene signature suggestive of neuroprogenitor 
cells (Tap et al., 2010). 
2.3.2 Notch signaling 
Another pathway implicated in melanoma is the Notch signaling cascade, which is one of 
the prototypical regulators of cell fate determination during embryonic development 
(Kopan and Ilagan, 2009). Like other primary transforming mutations in melanoma such as 
BRAF and NRAS, constitutive activation of the Notch1 receptor was in itself sufficient for 
the malignant transformation of human melanocytes (Pinnix et al., 2009). In fact, Notch1 
signaling is also required for β-catenin-induced proliferation in melanoma cells with a 
proliferative phenotype (Balint et al., 2005). However, the expression of Notch is negatively 
regulated by MITF, and thus its contribution to cellular phenotype is most pronounced in 
invasive melanoma cells where MITF is down-regulated (Thurber et al., 2011). Reports that 
these Notch effects in melanoma are mediated through regulation of the MAPK and PI3K-
Akt pathways (Liu et al., 2006a; Liu et al., 2006b) further highlight the convergence of critical 
pathways during melanoma progression.  
Like Wnt signaling, the Notch pathway plays a critical role in the specification of cell fate 
during neural crest development, making it particularly relevant to melanoma biology 
(Cornell and Eisen, 2005). During embryonic development, Notch signaling is thought to 
regulate both the specification of neural crest, as well as the subsequent determination of 
secondary cell fate through differentiation into glial-based lineages (Cornell and Eisen, 
2005). Engagement of Notch signaling can inhibit neurogenesis and neural differentiation, 
which may play some part in the role of this pathway in melanoma. Likewise in the context 
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of stem- and progenitor cells, Notch signaling can have varied roles in regulating either the 
maintenance of stem cell phenotype or the differentiation of stem cells into mature lineages 
(Liu et al., 2010). Understanding the interplay between Notch and other signaling pathways 
will be vital to effectively leveraging this important regulator of cellular differentiation for 
therapeutic benefit.  
2.3.3 Transforming growth factor-beta (TGFB) 
The morphogen-based Nodal signaling pathway, representing a subset of transforming 
growth factor β (TGFB) signaling pathways, was perhaps the initial pathway of interest in 
melanoma with regards to the concept of ‘differentiation therapy’ (Hardy et al., 2010; 
Postovit et al., 2008a; Postovit et al., 2008b; Strizzi et al., 2009). Like many of the other 
pathways that participate in melanoma biology, Nodal is a morphogen ligand involved the 
determination of cell fate during development. Melanoma is characterized by the presence 
of increased levels of Nodal ligand coinciding with decreased expression of the secreted 
Nodal antagonist Lefty (Postovit et al., 2008a). Typical benign nevi appear to express low 
levels of Nodal, although a subset of congenital nevi express levels of Nodal by 
immunohistochemistry that are comparable to what is observed in melanoma (Yu et al., 
2010). Analogous to its role in maintaining human embryonic stem cells in the 
undifferentiated state, Nodal signaling in melanoma is thought to regulate or facilitate the 
plasticity of tumor cells (Postovit et al., 2008a), thus eliciting considerable interest in the 
targeting of this pathway for therapeutic purposes.   
Overall, the role of TGFB in melanoma pathogenesis is complex, given the variability of its 
effects based on a cell’s stage of progression (Javelaud et al., 2008; Lasfar and Cohen-Solal, 
2010). Whereas normal human melanocytes are exquisitely sensitive to the anti-proliferative 
effects of TGF-β, resistance to this effect begins to develop as malignant transformation 
occurs. However, proliferative melanoma cells do retain sensitivity to TGF-β, and thus in 
this population of melanoma cells TGF-β actually acts as a tumor suppressor (Hoek et al., 
2006). Hoek et al. demonstrated that melanoma cells which clustered into the invasive, low 
MITF gene expression group also showed upregulation of many downstream targets of 
TGF-β (Hoek et al., 2006). Further, specific inhibition of the TGF-β signaling cascade via 
exogenous Smad7 significantly reduces the capacity of melanoma cells for anchorage-
independent growth, a characteristic intrinsic to metastatic potential (Javelaud et al., 2005). 
An important mechanism by which TGF-β signaling is able to increase invasive potential is 
likely its ability to decrease MITF expression, which results in upregulation of the pro-
invasive RHO/ROCK and Notch signaling cascades (Carreira et al., 2006; Thurber et al., 
2011). It also induces the expression of factors which inhibit canonical Wnt signaling (Hoek 
et al., 2006), promotes angiogenesis through factors such as VEGF, and has broad 
immunosuppressive effects which may contribute to the therapeutic resistance of TGF-β 
expressing tumor cells (Javelaud et al., 2008). 
A small but accumulating body of literature has also characterized the involvement in 
melanoma of bone morphogenic proteins (BMPs), which represent another subset of the 
TGFB superfamily (Hsu et al., 2005). Like TGFB, BMP7 can act in an autocrine fashion to 
inhibit melanoma cell growth (Hsu et al., 2008).  Interestingly, the upregulation of BMP7 
with melanoma progression coincides with upregulation of Noggin, an antagonist of BMP 
(Hsu et al., 2008). This finding parallels the observed acquisition of resistance to autocrine 
TGFB seen in melanoma cells compared to melanocytes (Krasagakis et al., 1999). In contrast, 
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others have reported that BMPs including BMP7 promote melanoma cell migration and 
invasion (Rothhammer et al., 2005), suggesting that the current model for how BMPs affect 
melanoma is still incomplete. The observation that nevi display relatively low levels of 
BMP4 and BMP7 may reflect that these cells retain sensitivity to these ligands (Rothhammer 
et al., 2005), and would be consistent with a potential oncogenic role for BMPs during 
melanoma progression.  
2.3.4 Brn-2 
Brn-2 is a POU domain transcription factor which regulates melanocytic growth (Cook and 
Sturm, 2008; Thomson et al., 1995), and in the setting of melanoma, is upregulated by both 
the MAPK and β-catenin signaling pathways (Goodall et al., 2004a; Goodall et al., 2004b). 
Increased expression of Brn-2 is a hallmark of invasive melanoma cells, and its activity 
contributes to this phenotype through a variety of different mechanisms. For one, Brn-2 is a 
potent repressor of MITF expression, and downregulation of Brn-2 during melanoblast 
differentiation to a mature melanocyte is necessary to ensure adequate expression of MITF 
(Goodall et al., 2004a). In invasive melanoma cells however, Brn-2 is upregulated, leading to 
MITF depletion and increased metastatic potential. Pinner et al. demonstrated that Brn-2 
upregulation is a key feature of invasive and metastatic melanoma cells through intravital 
imaging of GFP-tagged Brn-2 levels in melanoma (Pinner et al., 2009). The invasive and 
metastatic tumor cells also showed decreased pigmentation, a surrogate marker for de-
differentiation as a result of a Brn-2-induced decrease in MITF expression. Besides acting as 
a repressor of MITF expression, Brn-2 increases invasive potential through its role as an 
activator of the Notch pathway. With siRNA knockdown of Brn-2 in the A2058 melanoma 
cell line, there is a resultant decrease in the expression of several Notch1-related target genes 
(Thurber et al., 2011). Interestingly, Brn-2 is one of only three factors necessary to facilitate 
the conversion of mouse fibroblasts into functional neurons (Vierbuchen et al., 2010), 
demonstrating the importance of this pathway not only in melanocyte biology, but also in 
neuronal biology. This observation is not entirely surprising given close links 
developmentally between melanocytes and other neural crest-derived cell types. 
2.3.5 AP-2 
The activity of AP-2, a 52kDa transcription factor, is vital to the normal embryonic 
development of neural crest cells, and also appears to play an important role in the 
differentiation of adult cells (Bar-Eli, 2001; Tellez et al., 2003). In normal human 
melanocytes, AP-2 is responsible for the regulation of a host of normal cellular functions, 
including DNA repair, cell cycle arrest and cell adhesion (Zhuang et al., 2007). However, in 
melanoma cells, the loss of AP-2 is a prominent feature associated with a switch to an 
invasive phenotype (Braeuer et al., 2011). It appears that this downregulation is the result of 
the increased activity of cAMP-responsive element binding (CREB) protein, a common 
feature in melanoma progression due to dysregulation of the MAPK pathway (Melnikova et 
al., 2010). Melnikova et al. showed that activation of PKA-dependent CREB signaling down-
regulates AP-2 in invasive melanoma cells, while re-introduction of AP-2 into these cells 
restores a non-metastatic phenotype (Melnikova et al., 2010). By our definition, this effect of 
AP-2 would constitute forced differentiation, resulting in an altered cell fate. Further studies 
will be needed to address whether AP-2 and its regulation by PKA/CREB can utilized as a 
viable therapeutic strategy. 
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2.4 Classification of melanoma by states of differentiation 
2.4.1 Relating gene signatures to the differentiation of cell lineages 
Melanocytes develop from embryonic stem cells along two distinct lineages (Dorsky et al., 
2000a; Thomas and Erickson, 2008). The classical lineage involves migration of neural crest 
cells (NCC) from the dorsal aspect of the neural tube. These pluripotent NCC initially have 
the ability to differentiate into a wide variety of cell types, including smooth muscle cells, 
peripheral neurons and glia, as well as melanocytes (Dorsky et al., 2000a; Thomas and 
Erickson, 2008). Certain extrinsic factors are necessary in order to induce melanocytic 
differentiation of these stem cells, and several have been identified, including mast cell 
growth factor (MGF/KITLG), endothelin 3 (EDN3) and SOX10.  
Intriguingly, in the search for key intrinsic modulators of melanocytic differentiation, it 
appears as though one transcription factor acts as the universal regulator of this process: 
MITF (Goding, 2000). Mutations of the MITF gene cause neural crest cell dysfunction and 
marked impairment of normal pigmentation, as reflected in patients with a variant of 
Waardenburg Syndrome (Goding, 2000). Some typical markers of melanocytic 
differentiation include tyrosinase (TYR), melanoma antigen recognized by T-cells 1 (MART-
1) and transmembrane glycoprotein NMB (GPNMB).  
Not all melanocytes follow the same path of differentiation from the neural crest.  If the 
transcription factor HMX1 is expressed in the dorsal root ganglia, NCCs instead migrate 
along the ventral aspect of the dorsal root, and are induced to differentiate towards a 
neuronal phenotype (Adameyko et al., 2009; Krispin et al., 2010). These neuronal and glial 
cells are then directed to expanding branches of peripheral neurons throughout the body. 
Among this population of ventrally-derived neuronal cells is a group of pluripotent stem 
cells known as Schwann Cell Precursors (SCPs). Adameyko et al. demonstrated that 
although these cells are fully capable of differentiating into Schwann cells, SCPs are also 
capable of differentiating along a melanocytic lineage, under the influence of growth factors 
such as IGF-1 and PDGF (Adameyko et al., 2009). Melanocytes spawned from this neuronal 
lineage have a gene expression profile defined by a lack of MITF or Wnt/β-catenin 
influence, and thus lack expression of many melanocyte-specific genes (Tap et al., 2010). 
Thus, the transcriptional profile closely parallels (and in fact may represent) invasive or 
stem cell-like melanoma cells (Hoek et al., 2006).  
2.4.2 Melanoma gene signatures resembling melanocytes or neuronal precursors 
Analogous to the two distinct clusters of gene expression profiles representing proliferative 
and invasive subpopulations of melanoma cells discussed in this chapter until now, there is 
also a large body of research which has used transcriptional profiling studies to identify two 
major differentiation states of melanoma cells. These differentiation states have previously 
been classified by Tap et al. as either the differentiated melanocyte group (DMG), or the 
neuronal precursor group (NPG) (Tap et al., 2010). Based on our description of the two 
distinct lineages of melanocytes, the differentiation state of melanoma cells in the DMG 
resembles melanocytes of the classical lineage, while the differentiation state of melanoma in 
the NPG resembles melanocytes of a neuronal lineage. The existence of these two distinct 
melanoma differentiation states is in keeping with the cancer stem cell theory, which is 
quickly gaining acceptance within the cancer research community as the missing link in our 
understanding of phenomena such as metastasis and therapeutic resistance (Zabierowski 
and Herlyn, 2008). This theory proposes that every tumor is made up of cells in various 
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others have reported that BMPs including BMP7 promote melanoma cell migration and 
invasion (Rothhammer et al., 2005), suggesting that the current model for how BMPs affect 
melanoma is still incomplete. The observation that nevi display relatively low levels of 
BMP4 and BMP7 may reflect that these cells retain sensitivity to these ligands (Rothhammer 
et al., 2005), and would be consistent with a potential oncogenic role for BMPs during 
melanoma progression.  
2.3.4 Brn-2 
Brn-2 is a POU domain transcription factor which regulates melanocytic growth (Cook and 
Sturm, 2008; Thomson et al., 1995), and in the setting of melanoma, is upregulated by both 
the MAPK and β-catenin signaling pathways (Goodall et al., 2004a; Goodall et al., 2004b). 
Increased expression of Brn-2 is a hallmark of invasive melanoma cells, and its activity 
contributes to this phenotype through a variety of different mechanisms. For one, Brn-2 is a 
potent repressor of MITF expression, and downregulation of Brn-2 during melanoblast 
differentiation to a mature melanocyte is necessary to ensure adequate expression of MITF 
(Goodall et al., 2004a). In invasive melanoma cells however, Brn-2 is upregulated, leading to 
MITF depletion and increased metastatic potential. Pinner et al. demonstrated that Brn-2 
upregulation is a key feature of invasive and metastatic melanoma cells through intravital 
imaging of GFP-tagged Brn-2 levels in melanoma (Pinner et al., 2009). The invasive and 
metastatic tumor cells also showed decreased pigmentation, a surrogate marker for de-
differentiation as a result of a Brn-2-induced decrease in MITF expression. Besides acting as 
a repressor of MITF expression, Brn-2 increases invasive potential through its role as an 
activator of the Notch pathway. With siRNA knockdown of Brn-2 in the A2058 melanoma 
cell line, there is a resultant decrease in the expression of several Notch1-related target genes 
(Thurber et al., 2011). Interestingly, Brn-2 is one of only three factors necessary to facilitate 
the conversion of mouse fibroblasts into functional neurons (Vierbuchen et al., 2010), 
demonstrating the importance of this pathway not only in melanocyte biology, but also in 
neuronal biology. This observation is not entirely surprising given close links 
developmentally between melanocytes and other neural crest-derived cell types. 
2.3.5 AP-2 
The activity of AP-2, a 52kDa transcription factor, is vital to the normal embryonic 
development of neural crest cells, and also appears to play an important role in the 
differentiation of adult cells (Bar-Eli, 2001; Tellez et al., 2003). In normal human 
melanocytes, AP-2 is responsible for the regulation of a host of normal cellular functions, 
including DNA repair, cell cycle arrest and cell adhesion (Zhuang et al., 2007). However, in 
melanoma cells, the loss of AP-2 is a prominent feature associated with a switch to an 
invasive phenotype (Braeuer et al., 2011). It appears that this downregulation is the result of 
the increased activity of cAMP-responsive element binding (CREB) protein, a common 
feature in melanoma progression due to dysregulation of the MAPK pathway (Melnikova et 
al., 2010). Melnikova et al. showed that activation of PKA-dependent CREB signaling down-
regulates AP-2 in invasive melanoma cells, while re-introduction of AP-2 into these cells 
restores a non-metastatic phenotype (Melnikova et al., 2010). By our definition, this effect of 
AP-2 would constitute forced differentiation, resulting in an altered cell fate. Further studies 
will be needed to address whether AP-2 and its regulation by PKA/CREB can utilized as a 
viable therapeutic strategy. 
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2.4 Classification of melanoma by states of differentiation 
2.4.1 Relating gene signatures to the differentiation of cell lineages 
Melanocytes develop from embryonic stem cells along two distinct lineages (Dorsky et al., 
2000a; Thomas and Erickson, 2008). The classical lineage involves migration of neural crest 
cells (NCC) from the dorsal aspect of the neural tube. These pluripotent NCC initially have 
the ability to differentiate into a wide variety of cell types, including smooth muscle cells, 
peripheral neurons and glia, as well as melanocytes (Dorsky et al., 2000a; Thomas and 
Erickson, 2008). Certain extrinsic factors are necessary in order to induce melanocytic 
differentiation of these stem cells, and several have been identified, including mast cell 
growth factor (MGF/KITLG), endothelin 3 (EDN3) and SOX10.  
Intriguingly, in the search for key intrinsic modulators of melanocytic differentiation, it 
appears as though one transcription factor acts as the universal regulator of this process: 
MITF (Goding, 2000). Mutations of the MITF gene cause neural crest cell dysfunction and 
marked impairment of normal pigmentation, as reflected in patients with a variant of 
Waardenburg Syndrome (Goding, 2000). Some typical markers of melanocytic 
differentiation include tyrosinase (TYR), melanoma antigen recognized by T-cells 1 (MART-
1) and transmembrane glycoprotein NMB (GPNMB).  
Not all melanocytes follow the same path of differentiation from the neural crest.  If the 
transcription factor HMX1 is expressed in the dorsal root ganglia, NCCs instead migrate 
along the ventral aspect of the dorsal root, and are induced to differentiate towards a 
neuronal phenotype (Adameyko et al., 2009; Krispin et al., 2010). These neuronal and glial 
cells are then directed to expanding branches of peripheral neurons throughout the body. 
Among this population of ventrally-derived neuronal cells is a group of pluripotent stem 
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states of differentiation, with one subgroup made up of quickly dividing tumor cells which 
remain highly differentiated and another subgroup made up of tumor cells which take on a 
stem-like phenotype.  
In relation to melanoma, the melanocytic subgroup of cells, or DMG, represents a population 
of tumor cells which express many of the markers of a differentiated melanocyte. These 
markers include TYR, MART-1, GPNMB, endothelin receptor type B (EDNRB) and neurturin 
(Tap et al., 2010). Melanoma cells belonging to the DMG are increasingly being referred to as 
the fast-growing, differentiated counterparts to stem cell-like tumor initiating melanoma cells. 
As with melanocytes which develop from NCC via the classical lineage under strong SOX10 
influence, the well-differentiated population of melanoma tumor cells express a transcriptional 
profile which reflects the influence of MITF and Wnt/β-catenin signalling. Tap et al. postulate 
that melanoma cells belonging to the DMG develop as per the typical pattern of melanocyte 
development from the dorsal aspect of the neural tube (Tap et al., 2010). It would appear that  
melanoma cells in the DMG may in fact represent the same subgroup of highly proliferative, 
minimally invasive melanoma cells described by Hoek & Goding, and refered to as 
proliferative melanoma cells (Hoek and Goding, 2010; Tap et al., 2010).  
The existence of a distinct subpopulation of cells within malignant tumors which retain key 
stem cell-like properties such as the capacity for self-renewal and differentiation is a hallmark 
of the cancer stem cell theory, and indeed melanoma tumors do contain populations of de-
differentiated cells which resemble neuronal stem cells (Barnhill et al., 2004). Much like the 
neuronal melanocyte lineage which develops from NCC under the strong influence of the 
HMX1 transcription factor and a lack of SOX10 signalling, the stem-like NPG melanoma 
population expresses a relative lack of MITF and Wnt/β-catenin influence in its transrciptional 
profile (Tap et al., 2010). Instead, several cellular markers asociated with neuronal and not 
melanocytic cells are expressed, including neural crest nerve growth factor receptor CD271, 
glial fibrillary acidic protein (GFAP), neurofilament protein (NFP) and synaptophysin (Syn) 
(Boiko et al., 2010). Further, melanoma cells which express stem-like properties are highly 
invasive and minimally proliferative. Add to all of this the fact the transcriptional profile of the 
NPG reflects the strong influence of noncanonical WNT5A signalling, and we come to the 
reasonable conclusion that the de-differentiated population of neuronal melanoma cells 
identified by Tap et al. May in fact be equivalent to the invasive melanoma population 
described by Hoek & Goding (Hoek and Goding, 2010; Tap et al., 2010).  
2.5 Phenotype switching and tumor heterogeneity 
In contrast to the unidirectional genetic theory of melanoma progression is the fact that the 
proliferative transcriptional grouping is comprised of cell lines originating from primary 
tumors as well as from distant secondary metastases, while the invasive grouping 
predominantly contains pre-metastatic cells taken from the outer margins of a melanoma 
lesion, or metastatic melanoma cells collected during the actual process of intravascular 
migration (Eichhoff et al., 2010; Hoek et al., 2008). A Clark-like model of melanoma 
progression would instead predict that the proliferative grouping would be made up entirely 
of pre-metastatic cells, while the invasive grouping would contain mainly metastatic and post-
metastatic cells (Miller and Mihm, 2006). However, evidence derived from several in vivo 
studies instead suggests that melanoma cells have the ability to cycle from a predominantly 
proliferative to a predominantly invasive phenotype, based on such influences as the tumor 
microenvironment and pharmaceutical therapies (Hoek and Goding, 2010).  
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One compelling study in support of phenotype switching as a source of melanoma 
heterogeneity was conducted by Pinner et al., in which it was shown through the use 
intravital imaging of melanoma cells that highly motile, intravasated metastatic melanoma 
cells reverted back to their pre-metastatic, proliferative phenotype once seeding at the site of 
secondary tumor metastasis occurred (Pinner et al., 2009). Specifically, whereas melanoma 
cells in the primary tumor as well as the secondary metastatic tumor were shown to have a 
phenotype defined by low levels of the transcription factor Brn-2 and a high level of 
pigmentation, highly motile, actively metastasizing melanoma cells were shown to express a 
predominantly Brn-2-high/pigment-low phenotype (Pinner et al., 2009).  
In a patient-matched analysis of both a primary metastatic lesion and distant metastases, 
Eichhoff et al. demonstrated that, consistent with our description of proliferative and 
invasive melanoma phenotypes, cells in the primary and distant tumors expressed high 
levels of MITF and Melan-A, while cells in the "unstructured" regions of these tumors (areas 
from which metastatic cells are most likely to be derived) stained heavily for WNT5A and 
far less for Mitf and Melan-A (Eichhoff et al., 2010). Strikingly, this study also revealed late-
stage metastatic melanoma cells adopted phenotypes and morphologies nearly identical to 
early-phase cells, indicating that melanoma cells have significant plasticity with regards to 
their gene expression profile (Eichhoff et al., 2010).  
Lending further support to the existence of phenotype switching are the findings of Hoek et 
al., in which seed melanoma cells of either an exclusively proliferative or exclusively 
invasive phenotype were injected subcutaneously into immunocompromised mice (Hoek et 
al., 2008). Regardless of seed cell phenotype, the resultant tumors expressed both major gene 
signatures, and furthermore the signatures appeared to adhere to a strict geographic 
localization pattern within the tumor. Specifically, melanoma cells expressing a proliferative 
phenotype were predominantly found on the periphery of melanoma tumors, while the 
invasive melanoma cells were found within the core of the tumor. As the tumor invades to 
deeper levels of tissue, the cells within the tumor core are brought into contact with 
microenvironmental factors such as Nodal signaling proteins, which in turn drive 
melanoma invasion (Hoek et al., 2008).  
2.6 Cell fate as a determinant of therapeutic response 
2.6.1 The advent of targeted BRAF inhibitors for metastatic melanoma 
One of the most promising targeted molecular therapies currently under development are 
small-molecule targeted kinase inhibitors such as PLX4720 (Tsai et al., 2008) and PLX4032 
(Flaherty et al., 2010a; Halaban et al., 2010; Yang et al., 2010). This drug works by inhibiting 
the mutated form of BRAF, a key serine/threonine protein kinase in the mitogen-activated 
protein kinase (MAPK) pathway (Singh et al., 2008). Up to 40-60% of melanomas harbor 
activating BRAF mutations (Goel et al., 2006; Gorden et al., 2003; Greene et al., 2009), and of 
these mutations, most are the result of a single amino acid substitution in the activation loop 
of exon 15. The most common mutation is BRAFV600E mutation, which results in a 500-fold 
increase in kinase activity, and is the target of PLX4032 inhibition (Flaherty et al., 2010b). 
Indeed, the results of Phase I/II trials have been promising, with a demonstrated response 
rate of up to 80% (Roukos, 2011).  
Exposure to drugs such as PLX4720 or PLX4032 results in a variety of anti-melanoma effects 
through the inhibition of the MAPK pathway and more specifically by mitigating aberrant 
activation of extracellular signal-regulated kinase (ERK), a downstream target of BRAF. As a 
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result, the use of PLX4720 or PLX4032 in cells harbouring activating mutations of BRAF 
such as BRAFV600E demonstrate decreased levels of proliferation, impaired colony-forming 
capability and the induction of apoptosis (Tsai et al., 2008). Despite obvious excitement over 
the demonstrated response rate of PLX4032 thus far, talk of accelerated FDA approval and 
current Phase III clinical trials, questions still remain regarding the potential benefit of this 
drug on overall patient survival (Roukos, 2011).  
2.6.2 The impact of cell fate on response to targeted BRAF inhibition 
Despite producing startling initial results in some patients and achieving an overall 
response rate of around 80%, all melanomas sensitive to treatment with the V600 BRAF 
inhibitor PLX4032 eventually develop resistance, and some melanomas with the V600 BRAF 
mutation are resistant from the outset of treatment (Flaherty et al., 2010a). Thus, melanoma 
cells treated with PLX4032 make for an ideal model of mechanisms underlying the process 
of therapeutic resistance. 
Transcriptional profiling provides some insight into the role of cell fate and PLX4032 
resistance (Tap et al., 2010). In general, BRAF-mutant melanomas with a DMG 
(differentiated melanocyte group) gene expression signature had the least amount of 
resistance to growth inhibition by PLX4032, while melanoma cells with the NPG (neuronal 
precursor group) gene expression signature displayed the highest level of resistance to 
growth inhibition by PLX4032. However, the most interesting findings of this study stem 
from the characterization of initially sensitive cells which later acquired resistance. Contrary 
to the obvious conclusion that BRAF must have undergone further mutations thereby 
rendering PLX4032 unable to maintain its inhibitory effect, what investigators found instead 
was that the activity of several parallel signaling pathways was upregulated to compensate 
for the BRAF inhibition. Of note, levels of acquired drug resistance were highest in 
melanoma cells with mutated NRAS, a GTPase signaling molecule which allows for cross-
talk between the PI3K-AKT and MAPK pathways.  
In more general terms, it appears as though BRAF-mutated melanoma cells sensitive to 
PLX4032 uniformly revert to a less differentiated transcriptional profile resembling neuronal 
stem cells (Tap et al., 2010). Future studies will likely illuminate the exact role of cell fate in 
regulating the response to targeted BRAF inhibition. Understanding how the exact 
differentiation state of a cell (reflected by gene signature) affects phenotypes such as 
dependence on MAPK signaling, drug metabolism, and susceptibility to apoptosis will 
provide the foundation for developing therapies aimed at manipulating cell fate to 
therapeutic advantage. 
3. Conclusion 
Recent developments in our understanding of melanoma are particularly interesting with 
regards to thinking about forced differentiation as a potential therapeutic approach. Can we 
employ strong morphogen pathways to forcibly alter or refine melanoma cell fate in a 
manner that renders them more susceptible to therapies like targeted BRAF inhibition?  Are 
morphogen pathways able to act as a ‘master override’ within a large tumor cell population 
to effectively decrease the heterogeneity that arises from dynamic phenotype switching?  Is 
there a “differentiated” cancer cell state that is truly more benign and manageable compared 
to a parallel “undifferentiated” state?   
 




Fig. 1. A summary of cell fate and differentiation in melanoma. This model attempts to 
reconcile findings in the literature regarding cell fate and differentiation. In the middle, 
melanoma cells are shown transitioning dynamically between two states: 1) a 
neuroprogenitor-like state (left) highlighted by gene signatures enriched for inhibitors of 
Wnt/β-catenin signaling such as WNT5A and DKK1; and 2) a more melanocyte-like state 
(right) exhibiting a gene signature consistent with active Wnt/β-catenin signaling, and 
reflecting increased expression of melanocytic markers. Note that the continued exposure of 
cells to PLX4032 can promote the development of cells with largely a neuronal or invasive 
signature (left). The increased survival denoted on the right side (upper part of panel) 
reflects the clinical observation that increased Wnt/β-catenin signaling correlates with 
increased patient survival (Bachmann et al., 2005; Chien et al., 2009b).  
Our traditional understanding of melanoma progression was based on the presumption that 
once a melanocyte acquired malignant potential, the constant accumulation of novel 
mutations conferred a progressively more aggressive phenotype as well as an increasing 
survival advantage to newly generated cancer cells. While it is true that key mutations such 
as the BRAF mutation targeted by PLX4032 are critical to melanoma pathogenesis, the 
sequence of intracellular events underlying the processes of tumor proliferation and 
metastasis in melanoma is far more dynamic than previously thought.  
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The recent characterization of distinct gene expression signatures in melanoma challenges 
our traditional model of melanoma progression. For one, two discreet transcriptional 
profiles would not be predicted by this model. Instead, we would expect a continuous 
spectrum of signatures representing the accumulation of new genetic mutations as 
melanoma became more aggressive. Secondly, we would expect that the transcriptional 
profiles of melanoma cells from secondary metastatic sites would bear less resemblance to 
cells in the primary tumor. Instead, proliferative melanoma cells from both primary and 
secondary sites are virtually identical, while the majority of invading and metastasizing 
melanoma cells express an invasive gene signature. Consequently, cell fate and the process 
of cellular differentiation are important for understanding the plasticity of melanoma cells 
and developing effective treatment strategies with durable long-term results. 
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The recent characterization of distinct gene expression signatures in melanoma challenges 
our traditional model of melanoma progression. For one, two discreet transcriptional 
profiles would not be predicted by this model. Instead, we would expect a continuous 
spectrum of signatures representing the accumulation of new genetic mutations as 
melanoma became more aggressive. Secondly, we would expect that the transcriptional 
profiles of melanoma cells from secondary metastatic sites would bear less resemblance to 
cells in the primary tumor. Instead, proliferative melanoma cells from both primary and 
secondary sites are virtually identical, while the majority of invading and metastasizing 
melanoma cells express an invasive gene signature. Consequently, cell fate and the process 
of cellular differentiation are important for understanding the plasticity of melanoma cells 
and developing effective treatment strategies with durable long-term results. 
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1. Introduction 
The growth, survival and proliferation of cancer cells are guaranteed by a crosstalk between 
cancer cells themselves and surrounding host cells and extracellular matrix. An intense area 
of research has contributed to a better understanding of the pathophysiological modification 
of tumour progression, e.g., the role of microenvironment.  
Human malignant melanoma is a highly metastatic tumour with poor prognosis and 
extreme resistance to treatment. It progresses through different steps: nevocellular nevi, 
dysplastic nevi (when these two entity can be identified as primary events in melanocytic 
neoplasia progression), in situ melanoma, radial growth phase melanoma (Breslow index 
≤0.75 mm), vertical growth phase melanoma (index >0.75 mm), and metastatic melanoma 
(Breslow, 1970). Primary tumour grows horizontally through the epidermis; over time, a 
vertical growth phase component intervenes and melanoma increases its thickness and 
invades the dermis. Once a vertical growth phase has developed, there is a direct correlation 
between the tumour thickness and the number of metastases (Heasley et al., 1996). 
Parallel with progression, melanoma acquires a rich vascular network. Melanoma 
neovascularization has been correlated with poor prognosis, shorter overall survival, 
ulceration and increased rate of relapse (Srivastava et al., 1988, 1989). This 
neovascularization is initiated and maintained by mean the secretion of various angiogenic 
cytokines, i.e. Vascular Endothelial Growth Factor-A (VEGF-A), Fibroblast Growth Factor-2 
(FGF-2), Placental Growth Factor (PGF) -1 and -2, Interleukin (IL) -8, Transforming Growth 
Factor-1 (TGF-1), by melanoma cells. Moreover cytokines production has been correlated to 
the transition from the radial to the vertical growth phase, and to the metastatic phase 
(Erhard et al., 1997; Marcoval et al., 1997; Salven et al., 1997). 
2. Human melanoma 
Human malignant melanoma originates from the melanocytes and manifests mainly on the 
skin. Rarely, melanomas can occur on the eye, the meninges, and the mucosa in different 
locations. The incidence of melanoma in white populations worldwide is increasing, 
especially in light skinned people with sun exposure. Melanomas are rare in populations 
with pigmented skin and almost always located on the mucosa or the palms of the hands or 
soles of the feet (Garbe et al., 2008).  
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≤0.75 mm), vertical growth phase melanoma (index >0.75 mm), and metastatic melanoma 
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Factor-1 (TGF-1), by melanoma cells. Moreover cytokines production has been correlated to 
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(Erhard et al., 1997; Marcoval et al., 1997; Salven et al., 1997). 
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especially in light skinned people with sun exposure. Melanomas are rare in populations 
with pigmented skin and almost always located on the mucosa or the palms of the hands or 
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The most important etiological factor for the development of a melanoma is UV radiation. 
Even in childhood, the influence of UV radiation results in the development of benign 
melanocytic neoplasms, in the form of melanocytic nevi. These are indicators of acquired 
mutations in the melanocytic system. The more melanocytic nevi someone has, the higher 
their risk of developing melanoma. Melanomas develop primarily in sites with the highest 
numbers of melanocytic nevi (Garbe et al., 2008). 
Clinically and histologically, four different subtypes of melanoma can be distinguished, 
which have different patterns of mutation: superficially spreading melanoma; nodular 
melanoma; lentigo maligna melanoma; acral lentiginous melanoma. The criteria of the 
ABCDE rule are the main diagnostic criteria (Asymmetry; Border irregularity; Color; 
Diameter; Evolving). Staging (American Joint Committee on Cancer Staging System) is 
important for selecting the best therapeutic approach (Balch et al., 2001, 2009). 
3. Tumour angiogenesis 
Angiogenesis is the sprouting of new blood vessels from a pre-existing vasculature and it is 
a tightly regulated process (Stasi & Amadori, 2002). During embryogenesis two major 
processes of blood vessel formation are implicated in the development of the vascular 
system: vasculogenesis and angiogenesis (Risau, 1988). 
Vasculogenesis starts from mesodermal-derived cells, the hemangioblasts, which 
differentiate both into angioblasts-endothelial cells and into hematopoietic stem cells. 
Vasculogenesis prevails in the embryo but it may have physiological roles in health and 
disease in adults (Iruela-Arispe & Dvorak, 1997). Both mechanisms, angiogenesis and 
vasculogenesis, occur in ischemic and tumour tissues in response to growth factors, such as 
VEGF and FGF-2, produced by tumour and stromal cells (Folkman et al., 2001). In some 
aggressive tumours the vessel wall is lined with only cancer cells as a mosaic of cancer cells 
and endothelial cells. This phenomenon is called “vasculogenesis mimicry” (Dome et al., 
2007).  
Angiogenesis is uncontrolled and unlimited in time, and essential for tumour growth, 
invasion and metastasis during the transition from the avascular to the vascular phase, the 
so-called angiogenic switch, in which the balance between angiogenesis inducers and 
inhibitors leans towards the former. The vascular phase is characterized by the new 
formation of vascular channels that enhance tumour cell proliferation, local invasion, and 
hematogenous metastasis.  
3.1 Angiogenesis and human melanoma 
New blood vessel formation is a prominent feature of human melanomas, indicating that 
these tumours have angiogenic activity (Mihm et al., 1975). The observation that cutaneous 
melanoma cells acquire the capacity to actively induce the growth of new blood vessels 
dates back to the earliest days of tumour angiogenesis research, when Warren and Shubik 
observed it after transplantation of human melanoma fragments into a hamster cheek pouch 
(Warren & Shubik, 1966). These studies were confirmed in later studies (Hubler & Wolf, 
1976). Rapid angiogenesis of cutaneous melanomas dramatically enhances the risk of 
lethality and contributes to the progression of the most common type of young adults (Streit 
& Detmar, 2003). 
 









Fig. 1. Processes implied in neovessel formation tumor-induced 
3.1.1 The role of angiogenic cytokines 
Tumour angiogenesis depends mainly on the release by neoplastic cells of growth factors 
specific for endothelial cells, able to stimulate the growth of the host’s blood vessels. 
VEGF is expressed in most solid tumours and the VEGF receptors (VEGF-Rs) are 
predominant in endothelial cells surrounding or penetrating malignant tissue, but are 
absent from vascular cells in the surrounding normal tissue. This finding suggests that 
VEGF-Rs expression is induced in endothelial cells during tumour angiogenesis by VEGF 
secreted by tumour cells.  
Secretion of VEGF-A isoform by melanoma cells has been correlated to the transition from 
the radial to the vertical growth phase, and to the metastatic phase (Erhard et al., 1997; 
Marcoval et al., 1997; Salven et al., 1997). Our previous studies indicated that increased 
microvascular density, strong VEGF-A tumour immunoreactivity, increased vascular 
diameter, and high number of vascular pillars—expression of the intussusceptive 
microvascular growth—are correlated to a high Breslow index (>3.6 mm).  
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Fig. 2. Angiogenesis extent parallel with melanoma progression: A) common nevi, B) 
displastic nevi, C) microvessels under the base of melanoma, D) melanoma breslow 0.45 
mm, E) melanoma breslow 1 mm, F) melanoma breslow >3 mm, G) advanced melanoma 
with inflammatory infiltrate, H) bowel metastasis of advanced melanoma 
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Salven et al. (1997) have demonstrated that up-regulation of VEGF-A expression in 
metastatic melanoma is associated with an increase in the number of tumour-infiltrating 
inflammatory cells expressing VEGF-A.  
FGF-2 regulates endothelial cell proliferation and angiogenesis by both autocrine and 
paracrine mechanisms. Since FGF-2 is devoid of the classic signal peptide for secretion, 
tumour cells release this factor by exocytosis from endoplasmic reticulum. Significant 
amounts of FGF-2 were found to be associated with extracellular matrix as well as with 
basement membrane of the newly formed blood vessels in human melanomas. Digestion of 
extracellular matrix by matrix metalloproteinases of melanoma or endothelial origin 
promotes release of matrix bound FGF-2, which, in turn, stimulates endothelial cell 
proliferation and vascular tube formation in melanomas. We and other authors (Salven et 
al., 1997) have demonstrated a significant correlation between melanoma progression, 
percentage of FGF-2-expressing tumour cells, and the number of mast cells which, in turn, 
secrete other angiogenic molecules, such as VEGF-A. 
Another important stimulator of melanoma angiogenesis is PGF. PGF-1 and -2 are expressed 
by melanoma cells and are known to bind neuropilin-1 and -2 receptors expressed on 
endothelial cells (Odorisio et al., 2006). In addition, PGF acts through binding VEGF-R1 
inducing the mobilization and recruitment of VEGF-R1+ hematopoietic precursors from 
bone marrow and enhancing blood vessel maturation by acting on VEGF-R1-expressing 
smooth muscle cells/pericytes (Donnini et al., 1999). Moreover, PGF forms heterodimers 
with VEGF-A and enhances melanoma angiogenesis by activating VEGF-R2 on endothelial 
cells (Donnini et al., 1999; Luttun et al., 2004). 
IL-8 expression was found to be very little in normal epidermis and benign melanocytic 
lesions. However, it is dramatically increased in the majority of cutaneous melanomas. Its 
serum levels in patients are significantly elevated compared to healthy individuals and 
correlate with advanced disease stage as well as with overall survival (Bar-Eli et al., 1999). 
Melanoma-derived IL-8 is able to induce endothelial cell migration, modulate vascular 
permeability, and enhance actin stress fiber formation. These activities resulted in enhanced 
angiogenesis, rapid tumour growth, and increased metastatic potential (Mahler et al., 2004; 
Melnikova & Bar-Eli, 2006). Liu et al. (2005) have demonstrated that TGF-1 is able to 
enhance expression of IL-8 in human melanoma cells and promote angiogenesis in several 
mouse xenograft models. 
Melanotransferrin, a member of the transferrin family, which is comprised of serum 
transferrin, lactoferrin and ovotransferrin, is highly expressed on melanoma cells compared 
to normal melanocytes. It exerts an angiogenic response quantitatively similar to that 
elicidated by FGF-2, and its angiogenic activity may depend on activation of endogenous 
VEGF. We have demonstrated that melanotransferrin contributes to angiogenesis during 
melanoma progression, and is likely associated with VEGF overexpression. 
4. Tumour microenvironment 
Neoplastic cells are influenced by their microenvironment and viceversa. The specific organ 
microenvironment determines the extent of cancer cell proliferation, angiogenesis, invasion 
and survival (Park et al., 2000; Liotta & Kohn, 2001). These data indicate that a permissive 
stromal environment is important in supporting tumour progression in combination with 
genetic alterations.  
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Tumour cells are surrounded by an infiltrate of inflammatory cells, namely lymphocytes, 
neutrophils, macrophages and mast cells, which communicate via a complex network of 
intercellular signalling pathways, mediated by surface adhesion molecules, cytokines and 
their receptors. 
The inflammatory cell infiltrate, particularly macrophages, may contribute to tumour 
angiogenesis, and there are many reports of associations between macrophage infiltration, 
vascularity and prognosis. Tumour-associated macrophages accumulate in poorly 
vascularized hypoxic or necrotic areas (Leek et al., 1999) and respond to experimental 
hypoxia by increasing the release of VEGF and FGF-2 and a broad range of other factors, 
such as Tumour Necrosis Factor-alpha (TNF-α), urokinase and matrix metalloproteinases 
(Bingle et al., 2002). Moreover, activated macrophages synthesize and release inducible 
nitric oxide synthase, which increases blood flow and promotes angiogenesis (Jenkins et al., 
1995). Lastly, the angiogenic factors secreted by macrophages stimulate mast cell migration 
(Gruber et al., 1995). 
Chemokines also have a role: some CXC chemokines, such as IL-8 are pro-angiogenic 
(Bernardini et al., 2003). Chemokines may exert their regulatory activity on angiogenesis 
directly or as a consequence of leucocyte infiltration and/or the induction of growth factor 
expression. Malignant melanoma is also associated with a dramatic host response composed 
of mast cells at the tumour periphery. 
Mast cells infiltrate hyperplasias, dysplasias and invasive fronts of carcinomas (but not the 
core of solid tumours), where they degranulate in close apposition to capillaries and 
epithelial basement membranes. Mast cells contain many angiogenic factors and a variety of 
cytokines, such as TGF-β, TNF-α, IL-8, FGF-2, VEGF, implicated in normal, as well as 
tumour-associated neoangiogenesis. 
Angiogenesis in human malignant melanoma, measured as microvessel counts, is highly 
correlated with both the percentage of tumour cells reactive to FGF-2 and mast cells counts 
(as total cell and tryptase-positive cell counts), and these parameters increase with tumour 
progression. 
Two distinct types of human mast cells have been described based on the protease 
composition of their secretory granules: mast cells containing chymase, carboxypeptidase, 
cathepsin and tryptase and mast cells containing tryptase only. Tryptase, a protease unique 
to the mast cells secretory granules, acts as a mitogen for fibroblasts, smooth muscle cells, 
and epithelial cells (Brown et al., 1995; Cairns & Walls, 1996). 
Blair and colleagues (Blair et al., 1997) have shown that mast cell-released tryptase plays an 
important role in neovascularization. Tryptase induces the formation of capillary structures 
by either directly acting on endothelial cells or by facilitating the early stages of 
angiogenesis. In fact, tryptase activates latent matrix metalloproteinases and plasminogen 
activator (Stack & Johnson, 1994), which degrade the extracellular matrix, a critical step in 
these stages (Mignatti & Rifkin, 1993). 
Mast cells are strikingly associated with angiogenesis in tumours, namely haemangioma, 
carcinomas, lymphoma and multiple myeloma where they are preferentially accumulated in 
the peripheral areas of the tumour, within the surrounding connective tissue, and rest near 
or around blood or lymphatic vessels. Mast cells are recruited and activated via several 
factors secreted by tumour cells: the c-kit receptor (Norrby & Woolley, 1993), FGF-2, VEGF-
A and Platelet-Derived Endothelial Cell Growth Factor (PD-ECGF), which are operative at 
picomolar concentrations (Gruber et al., 1995). 
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The fact that mast cells contribute to the induction of tumour angiogenesis stems from 
studies on mast cell-deficient mice, which display slow angiogenesis, and its restoration 
after local reconstitution of mast cells (Starkley et al., 1988; Toth et al., 2000). Moreover, in 
malignant breast lesions the number of mast cells with tryptase activity was significantly 
higher than in benign lesions (Kankunnen et al., 1997) and mast cells derived from human 
renal tumour tissues contained tryptase (Beil et al., 1998). 
Tryptase-positive mast cells may contribute, at least partly, to the melanoma-associated 
angiogenesis. Furthermore, tumour-derived FGF-2 may have pleiotropic influences, first on 
tumour invasion, by elevating proteolytic enzymes , second on angiogenesis, by paracrine 
stimulation of endothelial cell growth, and third on recruitment and activation of mast cells, 
which express the FGF-2 receptor. Mast cells, in their turn, secrete FGF-2 stored in their 
secretory granules, which further stimulates endothelial cell growth and amplifies the FGF-2 
paracrine stimulatory loop on angiogenesis. 
4.1 Integrin signalling and extracellular matrix enzymes 
Parallel with the angiogenic switch, an increasing number of tumour cells express the 
laminin receptor, which enables their adhesion to the vascular wall, favouring tumour cell 
extravasation and metastases. Our data indicate that melanoma cells express the 67-kDa 
laminin receptor in step with the progression from the nevocellular to the dysplastic nevi, 
and from the primary to the metastatic tumour. This expression enables melanoma cell 
adhesion to the vascular wall and together with the increased vascular network favours 
tumour cell extravasation and metastasis. 
Overexpression of αvβ3, αvβ5, α2β1, and α5β1 integrins has been correlated with the 
transition from primary to metastatic melanoma (Bosserhoff, 2006). In turn, integrins 
overexpression stimulates matrix metalloproteinases -2 and -7 in melanoma cells, increasing 
their invasive potential (Kuphal et al., 2005). 
Melanoma and tumour stromal cells express several matrix metalloproteinases, including 
matrix metalloproteinases -1, -2, -3, -7, -9, -14, -15, -16, as well as Tissue Inhibitors of Matrix 
Metalloproteinases such as TIMP-1, -2, and -3 (Hofmann et al., 2000a). Matrix metalloproteinases 
overexpression has been correlated with increased microvascular density, Bcl-2 
overexpression, and low survival rate. The most extensively studied matrix metalloproteinases 
in melanomas are the isoforms -2 and -9. 
The expression and activation of both enzymes have been correlated to the invasive and 
metastatic phenotypes of the tumours (Hofmann et al., 2000b; Kerkela & Saarialho-Kere, 
2003; Nikkola et al., 2005; Cotignola et al., 2007; Schnaeker et al., 2004) in which they are 
constitutively expressed and highly associated with atypia and dedifferentiation into 
melanocytic lesions. Matrix metalloproteinase -2 expression was highly correlated with the 
metastatic spread and low survival rates (Hofmann et al., 2000a). Moreover, functional 
activity of matrix metalloproteinases is required for tumour progression. Overexpression of 
Membrane-Type- Matrix Metalloproteinase in melanoma cells induced activation of matrix 
metalloproteinase -2 which is crucial for extracellular matrix degradation. Matrix 
metalloproteinase -2 and Membrane-Type- Matrix Metalloproteinase + tumour cells were 
often restricted to the interface between the tumour invasive part and stroma (Durko et al., 
1997; Hofmann et al., 2000b). 
Expression of matrix metalloproteinases is not restricted to tumour cells but is also found 
abundantly in stromal cells indicating a major contribution of host-derived proteases to 
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often restricted to the interface between the tumour invasive part and stroma (Durko et al., 
1997; Hofmann et al., 2000b). 
Expression of matrix metalloproteinases is not restricted to tumour cells but is also found 
abundantly in stromal cells indicating a major contribution of host-derived proteases to 
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tumour progression (Wojtowicz-Praga et al., 1998). Also matrix metalloproteinase -1 
expression is highly associated with melanoma progression (Nikkola et al., 2005). Matrix 
metalloproteinase -9 expression in melanoma cells was found exclusively during the 
horizontal growth phase but not during the vertical phase. This clearly suggests that 
expression of matrix metalloproteinase -9 is an early event in melanoma progression 
(Kerkela & Saarialho-Kere, 2003). 
Several studies using either cell lines or animal models have demonstrated that the balance 
between matrix metalloproteinases and their inhibitors finally determines melanoma 
progression (Hofmann et al., 2000b; Wojtowicz-Praga et al., 1998; Rudek et al., 2001; Jin et 
al., 2006; Wojtowicz-Praga et al., 1996; Bodey et al., 2001; Airola et al., 1999). Overexpression 
of TIMP-1, -2, and -3 significantly reduces melanoma tumour cell invasion, migration, 
growth and metastasis, and significantly reduces tumour neovascularization in several 
tumour models (Anand-Apte et al., 1996). Urokinase Plasminogen Activator and Its Receptor 
(uPA/uPAR) have been demonstrated to play a crucial role in several stages of melanoma 
progression including tumour cell migration, invasion, and metastasis. uPA secreted from 
melanoma cells is able to regulate endothelial cell functions including migration and the 
organization of endothelial cells into tube-like structures (Mueller, 1996; Delbaldo et al., 
1994; Hearing et al., 1988). 
The extracellular matrix enzymes and their inhibitors play also an important role in cancer 
dysregulated angiogenesis (Roy et al., 2009; Huang et al., 2009). These enzymes are the 
major degrading enzymes produced by angiogenic endothelial cells for migration through 
extracellular matrix during neovessel formation. Moreover, matrix metalloproteinases and 
TIMPs may act as regulators of signalling pathways through the cleavage of nonmatrix 
substrates, including cytokines, chemokines, and growth factors. In the last fifteen years, 
different extracellular matrix proteins and cleavage products have been identified. These 
molecules possess the ability to regulate vascular development, repair and function. 
Therefore, possible regulatory mechanisms in vascular biology controlled by different 
cleavage products of basement membrane proteins (e.g., endostatin and tumstatin, 
endorepellin), their activation by proteases and inhibitors, such as matrix metalloproteases, 
cathepsins, tissue inhibitors of matrix metalloproteinases and cystatin, have been reviewed 
in Suhr et al. (2009). 
Integrin-Linked Kinase (ILK) is a highly conserved serine-threonine protein kinase involved in 
cell-extracellular matrix interactions, cytoskeletal organization and cell signalling. 
Overexpression of ILK in epithelial cells leads to anchorage-independent growth with 
increased cell cycle progression. ILK upregulation strongly correlates with melanoma 
progression, invasion and inversely correlates with 5-year survival of melanoma patients 
(Wani et al., 2011). However, the molecular mechanism by which ILK enhances melanoma 
progression is currently unknown. The proangiogenic molecule IL-6 is the downstream 
target of ILK in melanoma cells. Wani et al. (2011) have demonstrated that ILK 
overexpression increases IL-6, whereas silencing of ILK suppressed IL-6 expression at both 
messenger RNA and protein levels. ILK also alteres the activity and subcellular localization 
of Nuclear Factor-KappaB (NF-κB) subunit p65. ILK enhances the IL-6 gene transcription by 
promoting the binding of NF-κB p65 to IL-6 promoter. Moreover, ILK overexpression in 
melanoma cells enhances the tube-forming ability of endothelial cells in vitro and 
microvessel formation in vivo (Wani et al., 2011). 
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5. Hypoxia in melanoma progression 
Solid tumours, including melanomas, are characterized by areas of hypoxia/anoxia that 
result from an imbalance between oxygen supply and consumption in proliferating tumour 
cells. This imbalance is further exacerbated by a compromised tumour vasculature (Vaupel 
& Mayer, 2007).  
The presence of hypoxia within a tumour is an independent marker of a poor prognosis for 
patients with various cancer types including cutaneous melanomas. Because stringent 
hypoxia/anoxia (<0.5% O2) is toxic for normal and tumour cells, it can promote tumour 
progression by selecting cells with mutations that allow them to survive in these extreme 
conditions. Furthermore, hypoxia activates signalling pathways that trigger 
neovascularization and that facilitate tumour cell invasion, migration, adhesion, and 
metastasis (Bedogni & Broome Powell, 2009). 
Metastasis is a complex multi-step process in which tumour cells have to acquire an 
invasive/migratory phenotype, enter the blood and lymphatic flow, survive anoikis and the 
immune response, and once localized to a distant site, survive in a likely hostile 
environment and proliferate. This process is relatively inefficient and only few cells within a 
tumour mass will have all the requirements that will allow them to successfully metastasize. 
Tumour hypoxia can influence most of the stages of metastasis (Bedogni & Broome Powell, 
2009). 
Hypoxia has been involved in a Epithelial-Mesenchymal Transition-like process where 
tumour cells change from an epithelial non-motile phenotype to a mesenchymal migratory 
phenotype and gain the ability to invade other tissues. Epithelial-Mesenchymal Transition is 
accompanied by specific changes in gene expression, such as down-regulation of E-
cadherin. Tumour hypoxia or loss of von Hippel-Lindau (VHL) which leads to Hypoxia-
Inducible Factor (HIF) stabilization, down-regulates E-cadherin (Yang & Wu, 2008). 
Furthermore, hypoxia through HIF-1, increases invasion by regulating genes, such as matrix 
metalloproteinase-2, that are involved in the degradation and remodelling of the 
extracellular matrix (Krishnamachary et al., 2003).  
Via induction of pro-angiogenic factors such as VEGF, IL-8 and angiopoietin- 2, tumour 
hypoxia contributes to tumour angiogenesis providing cancer cells with access to blood 
vessels which is made easier by the leakiness of the tumour vasculature. HIF-1 can also 
increase resistance to anoikis by down-regulating the expression of α5 integrin which 
mediates survival signals in the presence of extracellular matrix and apoptotic signals when 
cells lack adhesion to a substrate. Finally, by increasing the expression of lysyl oxidase, 
hypoxia/HIF-1 contributes to cancer metastasis in part by facilitating the recruitment of 
bone marrow derived cells to the metastatic niche, which prepares a receptive environment 
for cancer cells (Erler et al., 2009, 2006). 
A direct role of hypoxia in advanced melanoma is slowly starting to emerge. HIF-1 has been 
shown to play a critical role in uveal melanoma progression by increasing the expression of 
a number of target genes involved in invasion. HIF-1 is regarded as one of the critical 
biomarkers that most accurately can predict uveal melanoma metastasis. Furthermore, a 
recent study by Qi et al. (2008), supports a role in melanomagenesis and metastasis of Siah2. 
Siah2, recently found to be regulated by the Serine/Threonine Protein Kinase Akt, is an 
inhibitor of Prolyl Hydroxylase Domain Protein function and therefore enhances hypoxia 
dependent HIF-1α stabilization by further inhibiting Prolyl Hydroxylase Domain Protein -1 
and -3 in hypoxia. The authors found that blocking the axis Siah2-Spry2 leads to decreased 
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tumour progression (Wojtowicz-Praga et al., 1998). Also matrix metalloproteinase -1 
expression is highly associated with melanoma progression (Nikkola et al., 2005). Matrix 
metalloproteinase -9 expression in melanoma cells was found exclusively during the 
horizontal growth phase but not during the vertical phase. This clearly suggests that 
expression of matrix metalloproteinase -9 is an early event in melanoma progression 
(Kerkela & Saarialho-Kere, 2003). 
Several studies using either cell lines or animal models have demonstrated that the balance 
between matrix metalloproteinases and their inhibitors finally determines melanoma 
progression (Hofmann et al., 2000b; Wojtowicz-Praga et al., 1998; Rudek et al., 2001; Jin et 
al., 2006; Wojtowicz-Praga et al., 1996; Bodey et al., 2001; Airola et al., 1999). Overexpression 
of TIMP-1, -2, and -3 significantly reduces melanoma tumour cell invasion, migration, 
growth and metastasis, and significantly reduces tumour neovascularization in several 
tumour models (Anand-Apte et al., 1996). Urokinase Plasminogen Activator and Its Receptor 
(uPA/uPAR) have been demonstrated to play a crucial role in several stages of melanoma 
progression including tumour cell migration, invasion, and metastasis. uPA secreted from 
melanoma cells is able to regulate endothelial cell functions including migration and the 
organization of endothelial cells into tube-like structures (Mueller, 1996; Delbaldo et al., 
1994; Hearing et al., 1988). 
The extracellular matrix enzymes and their inhibitors play also an important role in cancer 
dysregulated angiogenesis (Roy et al., 2009; Huang et al., 2009). These enzymes are the 
major degrading enzymes produced by angiogenic endothelial cells for migration through 
extracellular matrix during neovessel formation. Moreover, matrix metalloproteinases and 
TIMPs may act as regulators of signalling pathways through the cleavage of nonmatrix 
substrates, including cytokines, chemokines, and growth factors. In the last fifteen years, 
different extracellular matrix proteins and cleavage products have been identified. These 
molecules possess the ability to regulate vascular development, repair and function. 
Therefore, possible regulatory mechanisms in vascular biology controlled by different 
cleavage products of basement membrane proteins (e.g., endostatin and tumstatin, 
endorepellin), their activation by proteases and inhibitors, such as matrix metalloproteases, 
cathepsins, tissue inhibitors of matrix metalloproteinases and cystatin, have been reviewed 
in Suhr et al. (2009). 
Integrin-Linked Kinase (ILK) is a highly conserved serine-threonine protein kinase involved in 
cell-extracellular matrix interactions, cytoskeletal organization and cell signalling. 
Overexpression of ILK in epithelial cells leads to anchorage-independent growth with 
increased cell cycle progression. ILK upregulation strongly correlates with melanoma 
progression, invasion and inversely correlates with 5-year survival of melanoma patients 
(Wani et al., 2011). However, the molecular mechanism by which ILK enhances melanoma 
progression is currently unknown. The proangiogenic molecule IL-6 is the downstream 
target of ILK in melanoma cells. Wani et al. (2011) have demonstrated that ILK 
overexpression increases IL-6, whereas silencing of ILK suppressed IL-6 expression at both 
messenger RNA and protein levels. ILK also alteres the activity and subcellular localization 
of Nuclear Factor-KappaB (NF-κB) subunit p65. ILK enhances the IL-6 gene transcription by 
promoting the binding of NF-κB p65 to IL-6 promoter. Moreover, ILK overexpression in 
melanoma cells enhances the tube-forming ability of endothelial cells in vitro and 
microvessel formation in vivo (Wani et al., 2011). 
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5. Hypoxia in melanoma progression 
Solid tumours, including melanomas, are characterized by areas of hypoxia/anoxia that 
result from an imbalance between oxygen supply and consumption in proliferating tumour 
cells. This imbalance is further exacerbated by a compromised tumour vasculature (Vaupel 
& Mayer, 2007).  
The presence of hypoxia within a tumour is an independent marker of a poor prognosis for 
patients with various cancer types including cutaneous melanomas. Because stringent 
hypoxia/anoxia (<0.5% O2) is toxic for normal and tumour cells, it can promote tumour 
progression by selecting cells with mutations that allow them to survive in these extreme 
conditions. Furthermore, hypoxia activates signalling pathways that trigger 
neovascularization and that facilitate tumour cell invasion, migration, adhesion, and 
metastasis (Bedogni & Broome Powell, 2009). 
Metastasis is a complex multi-step process in which tumour cells have to acquire an 
invasive/migratory phenotype, enter the blood and lymphatic flow, survive anoikis and the 
immune response, and once localized to a distant site, survive in a likely hostile 
environment and proliferate. This process is relatively inefficient and only few cells within a 
tumour mass will have all the requirements that will allow them to successfully metastasize. 
Tumour hypoxia can influence most of the stages of metastasis (Bedogni & Broome Powell, 
2009). 
Hypoxia has been involved in a Epithelial-Mesenchymal Transition-like process where 
tumour cells change from an epithelial non-motile phenotype to a mesenchymal migratory 
phenotype and gain the ability to invade other tissues. Epithelial-Mesenchymal Transition is 
accompanied by specific changes in gene expression, such as down-regulation of E-
cadherin. Tumour hypoxia or loss of von Hippel-Lindau (VHL) which leads to Hypoxia-
Inducible Factor (HIF) stabilization, down-regulates E-cadherin (Yang & Wu, 2008). 
Furthermore, hypoxia through HIF-1, increases invasion by regulating genes, such as matrix 
metalloproteinase-2, that are involved in the degradation and remodelling of the 
extracellular matrix (Krishnamachary et al., 2003).  
Via induction of pro-angiogenic factors such as VEGF, IL-8 and angiopoietin- 2, tumour 
hypoxia contributes to tumour angiogenesis providing cancer cells with access to blood 
vessels which is made easier by the leakiness of the tumour vasculature. HIF-1 can also 
increase resistance to anoikis by down-regulating the expression of α5 integrin which 
mediates survival signals in the presence of extracellular matrix and apoptotic signals when 
cells lack adhesion to a substrate. Finally, by increasing the expression of lysyl oxidase, 
hypoxia/HIF-1 contributes to cancer metastasis in part by facilitating the recruitment of 
bone marrow derived cells to the metastatic niche, which prepares a receptive environment 
for cancer cells (Erler et al., 2009, 2006). 
A direct role of hypoxia in advanced melanoma is slowly starting to emerge. HIF-1 has been 
shown to play a critical role in uveal melanoma progression by increasing the expression of 
a number of target genes involved in invasion. HIF-1 is regarded as one of the critical 
biomarkers that most accurately can predict uveal melanoma metastasis. Furthermore, a 
recent study by Qi et al. (2008), supports a role in melanomagenesis and metastasis of Siah2. 
Siah2, recently found to be regulated by the Serine/Threonine Protein Kinase Akt, is an 
inhibitor of Prolyl Hydroxylase Domain Protein function and therefore enhances hypoxia 
dependent HIF-1α stabilization by further inhibiting Prolyl Hydroxylase Domain Protein -1 
and -3 in hypoxia. The authors found that blocking the axis Siah2-Spry2 leads to decreased 
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HIF-1α stabilization, and results in a significant reduction of metastasis in a metastatic 
melanoma mouse model. This observation correlated with findings in human samples 
where reduced expression of the Siah2 substrates Prolyl Hydroxylase Domain Protein-3 and 
Spry2 and increased HIF-1α are characteristic of more advanced melanoma (Bedogni & 
Broome Powell, 2009). 
A role of HIF signalling in melanomagenesis is further supported by the work of 
Giatromanolaki et al. (2003). In this study, HIF-1α and HIF-2α were found to be expressed in 
28 and 65% of melanoma samples respectively, and HIF-2α, together with VEGF and 
vascular density, was associated with poor overall disease survival. 
In summary, these observations strongly support a role of hypoxia and HIF signalling in 
melanomagenesis and melanoma metastasis (Bedogni & Broome Powell, 2009). 
6. Antiangiogenic therapies 
Different molecular targets of antiangiogenic molecules can be recognized, so various 
antiangiogenic agents are currently in clinical trials for melanoma.  
Thalidomide was withdrawn from the market due to its teratogenecity, but in recent years 
its use has been focused on its anti-angiogenic properties (Frankset al., 2004; Kirchmair et al., 
2007; Son et al., 2006). In fact, Thalidomide has been found to have antiangiogenic and anti-
inflammatory properties, and accordingly it has been used as a therapeutic agent in some 
malignant tumours including liver, renal cell, and breast carcinomas (Singhal & Mehta, 
2002).  
We ourselves demonstrated that Thalidomide inhibits many genes which codify for 
angiogenic cytokines and their relative receptors in endothelial cells. Moreover, we have 
demonstrated that Thalidomide reduce the fundamental activity of activated endothelial 
cells (i.e. proliferation, migration, chemotaxis) as well as vessel formation in the Matrigel 
assay. It has been also proposed that the teratogenic property of Thalidomide involves in  
production of Reactive Oxygen Species (ROS), leading to subsequent DNA damage (Maniotis 
et al., 1999). When Thalidomide-induced ROS formation is inhibited, the anti-angiogenesis 
properties of Thalidomide will be reduced. 
Thalidomide inhibits vasculogenic mimicry channel and mosaic vessels formation in 
melanoma through the regulation of vasculogenic factors, and it can induce necrosis of 
tumour cells, which may be related with the NF-kB signalling pathway (Zhang et al., 2008). 
In advanced melanoma Thalidomide has obtained some promising results when used as 
single agent. Pawlak and Legha (Pawlak & Legha, 2004), published a study evaluating 
single-agent Thalidomide in metastatic malignant melanoma, showing no objective 
responses, but seven cases of stable disease.  
Other single agent phase II studies (Reiriz et al., 2004; Eisen et al., 2000) demonstrated stable 
disease in a few patients, with 30% of the patients included in these trials having ocular 
melanoma. In another phase II study Thalidomide has shown limited activity in patients 
with metastatic melanoma against melanoma metastases in the Central Nervous System 
(CNS) (Lene et al., 2008). However, the minor effects founded on peripheral tumour 
manifestations, has led to the conclusion that Thalidomide might be part of the treatment 
strategy for these patients. 
On the basis of these promising but non optimal results and since Thalidomide exhibits low 
oral bioavailability due to limitations in solubility, some experimental modification of oral 
preparation have been tested to improve the delivery of Thalidomide and its therapeutical 
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activity (Kale et al., 2008). Its complexation with sulfobutyl ether-7 beta-cyclodextrin has 
demonstrated to increase stability, oral bioavailability, drug absorption, and distribution 
through solubilization of Thalidomide in experimental animals. 
The safety and tolerability of adjuvant treatment with subcutaneous Granulocyte Macrophage 
Colony-Stimulating Factor (GM-CSF) administered in combination with escalating doses of 
Thalidomide in patients with surgically resected stage II (T4), III, or IV melanoma at high 
risk for recurrence has been also evaluated (Lutzky et al., 2009). This therapy has obtained 
promising results with a 42% overall survival at 2.6 years. However, the high incidence of 
life-threatening events, particularly thrombosis, that are unacceptable in the adjuvant 
setting, render the up-front antithrombotic prophylaxis necessary for further evaluation of 
this combination. 
Many studies are also focused on the effects of Thalidomide on advanced melanoma in 
combination with Interferon alpha 2 b (Hutchins et al., 2007; Vaishampayan et al., 2007), 
Temozolomide (Quirt et al., 2007; Atkins et al., 2008), and Dacarbazine (Ott et al., 2009) with 
encouraging results. The combination of Pegylated Interferon and Thalidomide was 
evaluated in a phase II trial (Vaishampayan et al., 2007). Pegylated Interferon was 
administered at a dose of 0.5 microg/kg subcutaneously weekly and Thalidomide 200 mg 
orally daily. Dose escalation of Thalidomide to 300 mg daily was feasible in some patients. 
This combination was well tolerated but failed to demonstrate clinical efficacy in pretreated 
metastatic melanoma. In fact, no objective responses were obtained, and only three patients 
achieved disease stabilization.  
The addition of Thalidomide to Temozolomide with or without whole brain irradiation does 
not appear to provide a substantial advantage in the treatment of patients with CNS 
metastasis from melanoma but seems to add only toxicity. An initial study (Hwu et al., 2003) 
reported considerable activity (32%response rate) for the Temozolomide and Thalidomide 
combination in the treatment of patients with systemic metastases from melanoma. This 
study combining Temozolomide in the prolonged administration schedule and Thalidomide 
at 200 mg/day with dose escalation to 400 mg/day produced 1 complete response and 11 
partial responses in 38 patients with advanced melanoma and a median survival of 9.5 
months. Evidence of response in CNS metastases was also reported in this setting. 
Subsequent results in a combined 53 evaluable patients in the Cytokine Working Group 
(CWG) and Cancer and Leukemia Group B (CALGB) studies are clearly disappointing (Quirt et 
al., 2007). Fatigue and an increased risk of thromboembolic events, without meaningfully 
increasing the modest CNS antitumour activity previously noted with the Temozolomide 
and whole brain irradiation combination (Margolin et al., 2002) or either Temozolomide 
(Agarwala et al., 2004) or whole brain irradiation alone (Fife et al., 2004). The conclusions of 
this study are consistent with the results of a CALGB trial using a similar regimen (Krown et 
al., 2006). This trial was stopped after 16 patients were enrolled because of excessive toxicity 
that included severe fatigue and sudden death in 1 patient and thromboembolic events 
(pulmonary embolism and deep vein thrombosis) in 4 patients. No tumour responses were 
observed in 14 evaluable patients. 
Given the virtual lack of efficacy observed for the Temozolomide and Thalidomide 
combination against systemic disease in these 2 studies, the lack of significant CNS tumour 
response or major impact on overall survival is not surprising. 
Similar results have been obtained when Thalidomide has been combined with 
Temozolomide alone in patients with stage IV malignant melanoma without active brain 
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HIF-1α stabilization, and results in a significant reduction of metastasis in a metastatic 
melanoma mouse model. This observation correlated with findings in human samples 
where reduced expression of the Siah2 substrates Prolyl Hydroxylase Domain Protein-3 and 
Spry2 and increased HIF-1α are characteristic of more advanced melanoma (Bedogni & 
Broome Powell, 2009). 
A role of HIF signalling in melanomagenesis is further supported by the work of 
Giatromanolaki et al. (2003). In this study, HIF-1α and HIF-2α were found to be expressed in 
28 and 65% of melanoma samples respectively, and HIF-2α, together with VEGF and 
vascular density, was associated with poor overall disease survival. 
In summary, these observations strongly support a role of hypoxia and HIF signalling in 
melanomagenesis and melanoma metastasis (Bedogni & Broome Powell, 2009). 
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Different molecular targets of antiangiogenic molecules can be recognized, so various 
antiangiogenic agents are currently in clinical trials for melanoma.  
Thalidomide was withdrawn from the market due to its teratogenecity, but in recent years 
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2007; Son et al., 2006). In fact, Thalidomide has been found to have antiangiogenic and anti-
inflammatory properties, and accordingly it has been used as a therapeutic agent in some 
malignant tumours including liver, renal cell, and breast carcinomas (Singhal & Mehta, 
2002).  
We ourselves demonstrated that Thalidomide inhibits many genes which codify for 
angiogenic cytokines and their relative receptors in endothelial cells. Moreover, we have 
demonstrated that Thalidomide reduce the fundamental activity of activated endothelial 
cells (i.e. proliferation, migration, chemotaxis) as well as vessel formation in the Matrigel 
assay. It has been also proposed that the teratogenic property of Thalidomide involves in  
production of Reactive Oxygen Species (ROS), leading to subsequent DNA damage (Maniotis 
et al., 1999). When Thalidomide-induced ROS formation is inhibited, the anti-angiogenesis 
properties of Thalidomide will be reduced. 
Thalidomide inhibits vasculogenic mimicry channel and mosaic vessels formation in 
melanoma through the regulation of vasculogenic factors, and it can induce necrosis of 
tumour cells, which may be related with the NF-kB signalling pathway (Zhang et al., 2008). 
In advanced melanoma Thalidomide has obtained some promising results when used as 
single agent. Pawlak and Legha (Pawlak & Legha, 2004), published a study evaluating 
single-agent Thalidomide in metastatic malignant melanoma, showing no objective 
responses, but seven cases of stable disease.  
Other single agent phase II studies (Reiriz et al., 2004; Eisen et al., 2000) demonstrated stable 
disease in a few patients, with 30% of the patients included in these trials having ocular 
melanoma. In another phase II study Thalidomide has shown limited activity in patients 
with metastatic melanoma against melanoma metastases in the Central Nervous System 
(CNS) (Lene et al., 2008). However, the minor effects founded on peripheral tumour 
manifestations, has led to the conclusion that Thalidomide might be part of the treatment 
strategy for these patients. 
On the basis of these promising but non optimal results and since Thalidomide exhibits low 
oral bioavailability due to limitations in solubility, some experimental modification of oral 
preparation have been tested to improve the delivery of Thalidomide and its therapeutical 
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activity (Kale et al., 2008). Its complexation with sulfobutyl ether-7 beta-cyclodextrin has 
demonstrated to increase stability, oral bioavailability, drug absorption, and distribution 
through solubilization of Thalidomide in experimental animals. 
The safety and tolerability of adjuvant treatment with subcutaneous Granulocyte Macrophage 
Colony-Stimulating Factor (GM-CSF) administered in combination with escalating doses of 
Thalidomide in patients with surgically resected stage II (T4), III, or IV melanoma at high 
risk for recurrence has been also evaluated (Lutzky et al., 2009). This therapy has obtained 
promising results with a 42% overall survival at 2.6 years. However, the high incidence of 
life-threatening events, particularly thrombosis, that are unacceptable in the adjuvant 
setting, render the up-front antithrombotic prophylaxis necessary for further evaluation of 
this combination. 
Many studies are also focused on the effects of Thalidomide on advanced melanoma in 
combination with Interferon alpha 2 b (Hutchins et al., 2007; Vaishampayan et al., 2007), 
Temozolomide (Quirt et al., 2007; Atkins et al., 2008), and Dacarbazine (Ott et al., 2009) with 
encouraging results. The combination of Pegylated Interferon and Thalidomide was 
evaluated in a phase II trial (Vaishampayan et al., 2007). Pegylated Interferon was 
administered at a dose of 0.5 microg/kg subcutaneously weekly and Thalidomide 200 mg 
orally daily. Dose escalation of Thalidomide to 300 mg daily was feasible in some patients. 
This combination was well tolerated but failed to demonstrate clinical efficacy in pretreated 
metastatic melanoma. In fact, no objective responses were obtained, and only three patients 
achieved disease stabilization.  
The addition of Thalidomide to Temozolomide with or without whole brain irradiation does 
not appear to provide a substantial advantage in the treatment of patients with CNS 
metastasis from melanoma but seems to add only toxicity. An initial study (Hwu et al., 2003) 
reported considerable activity (32%response rate) for the Temozolomide and Thalidomide 
combination in the treatment of patients with systemic metastases from melanoma. This 
study combining Temozolomide in the prolonged administration schedule and Thalidomide 
at 200 mg/day with dose escalation to 400 mg/day produced 1 complete response and 11 
partial responses in 38 patients with advanced melanoma and a median survival of 9.5 
months. Evidence of response in CNS metastases was also reported in this setting. 
Subsequent results in a combined 53 evaluable patients in the Cytokine Working Group 
(CWG) and Cancer and Leukemia Group B (CALGB) studies are clearly disappointing (Quirt et 
al., 2007). Fatigue and an increased risk of thromboembolic events, without meaningfully 
increasing the modest CNS antitumour activity previously noted with the Temozolomide 
and whole brain irradiation combination (Margolin et al., 2002) or either Temozolomide 
(Agarwala et al., 2004) or whole brain irradiation alone (Fife et al., 2004). The conclusions of 
this study are consistent with the results of a CALGB trial using a similar regimen (Krown et 
al., 2006). This trial was stopped after 16 patients were enrolled because of excessive toxicity 
that included severe fatigue and sudden death in 1 patient and thromboembolic events 
(pulmonary embolism and deep vein thrombosis) in 4 patients. No tumour responses were 
observed in 14 evaluable patients. 
Given the virtual lack of efficacy observed for the Temozolomide and Thalidomide 
combination against systemic disease in these 2 studies, the lack of significant CNS tumour 
response or major impact on overall survival is not surprising. 
Similar results have been obtained when Thalidomide has been combined with 
Temozolomide alone in patients with stage IV malignant melanoma without active brain 
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metastases (Joseph et al., 2010). In this phase II study patients received Thalidomide 
(200mg/d escalated to 400mg/d for patients <70, or 100mg/d escalated to 250mg/d for 
patients ≥70) plus Temozolomide (75mg/m2/d × 6 weeks then 2 weeks rest). The 
progression free survival was 15% at 6 month and the overall survival was 35% at 1 year. 
Enrolled patients obtained only partial response with a response rate of 13%. Authors 
conclude that this combination of Thalidomide and Temozolomide does not appear to have 
a clinical benefit that exceeds Dacarbazine alone and they not recommend it further for 
phase III trials or for standard community use. 
Similar results have been obtained when Thalidomide has been associated to Dacarbazine in 
the treatment of patients with advanced melanoma (Ott et al., 2009). Of the 13 patients 
evaluable for response of that enrolled in this phase II trial, 1 patient had a partial response, 3 
patients had stable disease and 9 patients had progressive disease. No complete responses 
were achieved. 1 patient withdrew due to toxicity. Grade III/IV constipation, peripheral 
neuropathy, fatigue, edema and rash were attributed to Thalidomide addition. The authors 
conclude that Thalidomide dose escalation beyond 200 mg/day was limited by unacceptable 
toxicity and this combination yielded activity insufficient to proceed with additional trials. 
In the last years Lenalidomide, a less toxic analogue of Thalidomide, has been tested in vitro 
and in vivo. Lenalidomide has been showed good efficacy in hematologic and non 
hematologic cancer with a good toxicity profile (Zeldis et al., 2011). Promising preliminary 
results have been obtained in a study recruit 13 patients with stage IV malignant melanoma 
(Bartlett et al., 2004). Despite the fact that clinical response was not the primary end-point of 
the study and that the patients had not responded to prior therapy, clear evidence of drug 
activity in rapidly progressing malignant melanoma with one partial response and two 
minor responses of visceral disease have been obtained.  
Subsequent studies (Glaspy et al., 2009; Eisen et al., 2010) have demonstrated that treatment 
with Lenalidomide (25 mg/d) has a manageable safety profile in patients with previously 
treated metastatic malignant melanoma. Although no benefit in tumour response, time to 
progression, or overall survival has been achieved in these patients, future trials for 
treatment of metastatic malignant melanoma with Lenalidomide should be conduct which 
focus its use in combination therapies (Lu et al., 2009). 
On the basis of preclinical findings indicating that continuous low dose (metronomic) 
chemotherapy is thought to inhibit tumour angiogenesis, the evaluation of antiangiogenic 
potency of various chemotherapeutic drugs for metronomic chemotherapy, particularly 
Taxol, is ongoing for its efficacy (Drevs et al., 2004). In a pivotal study, 20 patients received 
paclitaxel 10 mg/m2 for 96 hours weekly as a continuous intravenous infusion and oral 
celecoxib 400 mg twice daily. One patient achieved a partial response, and 3 of 20 patients 
(15%) had stable disease for >6 months. The median time to progression was 57 days, and 
the median overall survival was 212 days. These findings support a role for metronomic 
therapy in patients with advanced melanoma. (Bhatt et al., 2010). 
A newest approach to cancer therapy is to target the multicellular biological entity of the 
tumour microenvironment. This type of combination causes an inhospitable 
microenvironment for tumour cells and represent a great promise for clinical use. 
(Blansfield et al., 2008). 
Semaxanib, a small molecule inhibitor of the VEGFR-2 tyrosine kinase, has shown 
encouraging results in patients with metastatic melanoma (Kuenen et al., 2003; Peterson, et 
al., 2004) in whom it has also been evaluated in combination with Thalidomide to assess the 
efficacy, tolerability, pharmacokinetic, and pharmacodynamic characteristics (Mita et al., 
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2007). This last study has demonstrated that the combination Semaxanib-Thalidomide is 
feasible and has also demonstrated antitumour activity in patients with metastatic melanoma 
who had failed prior therapy. Twelve patients were enrolled in this study and received 44 
courses of Semaxanib at the fixed dose of 145 mg/m2 intravenously twice-weekly in 
combination with Thalidomide, commencing at 200 mg daily with intrapatient dose escalation 
as tolerated. The principal toxicities included deep venous thrombosis, headache, and lower 
extremity edema. Out of ten patients evaluable for response, one complete response lasting 20 
months and one partial response lasting 12 months were observed. Additionally, four patients 
had stable disease lasting from 2 to 10 months. These results indicate that the combination of 
Semaxanib and Thalidomide is feasible and demonstrated anti-tumour activity in patients 
with metastatic melanoma who had failed prior therapy.  
Another way to inhibit angiogenesis is the inhibition of matrix metalloproteinase activity. In 
the early 1990, matrix metalloproteinase inhibitors generated great enthusiasm among 
several research groups wishing to take them to clinical trials. Preclinical trials of matrix 
metalloproteinase inhibitors were very promising, showing minimum side effects compared 
to other drugs available at the time. Several current inhibitors, which have been tested in 
preclinical and clinical trials, are broad category matrix metalloproteinase inhibitors. 
Pharmacological inhibitors such as Prinomastat, Batimastat, and its analog Marimastat, 
which interfere with the catalytic site of the matrix metalloproteinases, were the first 
inhibitors studied in detail. Most of the inhibitors tested in clinical trials were not very 
promising due to the lack of positive outcomes and the appearance of substantial drug side 
effects, which were not observed in preclinical studies. Therefore, most of the inhibitor 
clinical trials were terminated following phase 3 clinical trials (Quirt et al., 2002; Pavlaki & 
Zucker, 2003; Coussens et al., 2002).  
Good therapeutic effects have been obtained in little studies with the combination of 
Bevacizumab (the anti-VEGF monoclonal antibody) and chemotherapy in advanced 
melanoma. Moreover, preclinical data strongly support the use of a combination of 
Bevacizumab and Erlotinib, a tyrosine kinase receptors inhibitor (Varker et al., 2007; Perez et 
al., 2009; Vásquez et al., 2009; Schicher et al., 2009). 
PI-88, a potent inhibitor of heparanase, demonstrates an overall survival and time to 
progression similar to standard chemotherapy (Basche et al., 2006). In a phase II trial (Lewis 
et al., 2008) a total of 44 patients were enrolled with about 60% of them previously treated. 
The median time to progression and overall survival was 1.7 months and 9 months, 
respectively. One (2.4%) patient achieved a partial response and six (14.6%) had stable disease 
as best response. At the end of six cycles of treatment, three of the 41 evaluable patients had 
non-progressive disease. Treatment was generally well tolerated with serious bleeding 
occured in two patients and positive anti-platelet antibody test in three patients. One of these 
four patients experienced an associated thrombosis. These results indicate that in patients with 
advanced melanoma, PI-88 demonstrates an overall survival and time to progression similar to 
standard chemotherapy with evidence of activity that warrantee further investigation. 
Preclinical data suggest that the ectopic expression of alphaIIb beta3 in melanoma cells can 
be exploited as a novel target of antibody therapy (Mitjans et al., 2000).  
Although most of these study have obtained encouraging results, further evaluations of 
therapeutic strategies that target multiple angiogenesis pathways may be warranted in 
patients with advanced melanoma and other malignancies. 
Finally, antiangiogenic therapy might have the unintended effect of promoting tumour 
metastasis by increasing vasculogenic mimicry as an alternative circulatory system (Qu et 
al., 2010). When the endothelium-dependent vessels are inhibited by the effective 
angiogenesis inhibitors, the hypoxia of tumour cells caused by antiangiogenesis may 
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increase vasculogenic mimicry compensatively which can replace the job of endothelium-
dependent vessels to maintain the tumour blood supply and provide a convenient route of 
tumour metastasis.  
7. Conclusion 
Tumour microenvironment plays a crucial role in the pathophysiology of human melanoma. 
It is involved in the crosstalk between melanoma cells and the microenvironment cells, 
which increases the survival, proliferation and migration of tumour cells themselves, and 
represents the substrate for angiogenesis which favours disease progression. Due to 
interaction with active microenvironment, neoplastic cells also acquire drug resistance 
giving less opportunity to therapy response. 
Many research studies have tried to better understand the biological mechanisms and the 
genetic basis of all the interactions between tumour cells and the microenvironment cells. 
VEGF, FGF-2, IL-6, IL-8, macrophages, mast cells, and many others cells and molecules, play 
important roles in this process.  
State the important role of angiogenesis in melanoma progression and diffusion, it 
represents a good target for biological therapies. Several molecules targeting the tumour 
microenvironment are actually evaluated in clinical trials and other compounds are in 
preclinical developing. However the initial results obtained with these compounds are 
promising, these approaches should be further developed. 
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1. Introduction  
The stromal microenvironment has become recognized as a major factor maintaining 
physiological functions of the cells and tissue integrity and it sensitively responds 
to pathological conditions including malignant transformation. The development of an altered 
stromal microenvironment in response to carcinoma is a common feature of many tumours. 
Induced stromal changes significantly contribute to malignant cell invasion and cancer 
progression. The chapter concerns about the most important stromal alterations involved in 
progression of malignant melanoma. It has been documented that one of the reasons, why 
melanoma cells escape apoptosis is a result of multicellular nature of the disease, in which 
melanoma cells are embedded in a tissue microenvironment of multiple cell types.  
2. Malignant melanoma 
Malignant melanoma is known as a highly aggressive tumour, the prognosis of which is 
difficult to predict. This tumour represents a paradox among all solid tumours because, 
despite the fact that many prognostic markers have been identified, there is very little 
understanding of their biological significance. In fact, the prognosis of malignant melanoma 
is still only based on histological criteria such as tumour size, depth of invasion, ulcerations 
and mitotic activity. However, these parameters do not allow precise prognosis. A small-
sized tumour can metastasize very early, and, on the other hand, tumours of advanced 
stages may remain localized for many years (Heenen & Laporte, 2003). Many 
epidemiological, clinical, in vitro and in vivo studies have provided insight into the biology 
of the disease. In melanoma cells, numbers of mutations and/or deregulated expression of 
B-Raf, N-Ras, CDK2A, MDM2, PTEN, p53 have been recognised, but in addition to genetic 
abnormalities, it has been shown that interactions between tumour cells and surrounding 
stromal environment are significant. Melanoma cells are embedded in a tissue 
microenvironment of multiple cell types including keratinocytes, fibroblasts, endothelial 
cells and immunoregulatory cells.  
2.1 Tumour stroma and malignant melanoma  
The interactive signalling between tumour and stroma is very heterogeneous and 
contributes to the formation of the so-called “tumour organ”. Stroma is a compilation of 
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cells including fibroblasts/myofibroblasts, epithelial, fat, immune, vascular and smooth 
muscle cells along with extracellular matrix and extracellular molecules (Fig.1). While none 
of these cells are malignant themselves, due to their interactions with each other and directly 
or indirectly with cancer cells, they acquire an abnormal phenotype and altered function to 
form a permissive and supportive environment for tumour, known as the reactive tumour 
stroma, which largely determines the phenotype of the tumour. This abnormal interplay 
consisting of cell-cell contact and active molecular crosstalk further drives the cancer stroma 
phenotype and may result in permanent alterations in cell function. The whole process is 
similar to wound healing; in fact, tumours are called never-healed wounds. The relative 
amount of stroma and its composition vary considerably from tumour to tumour and do not 
correlate with the degree of tumour malignancy.  
 
 
Fig. 1. Interactions between melanoma cells and activated stromal microenvironment are 
complicated  and complex, and include changes in cell-cell adhesions, cell- matrix and cell-
cell interactions and angiogenesis. 
2.1.1 Stromal microenvironment 
A large range of molecules including growth factors and their receptors, degradation and 
remodelling enzymes, extracellular matrix (ECM) molecules, cytokines, interleukins, 
formation of bioactive fragments are produced to disrupt normal tissue homeostasis and act 
in a paracrine manner to induce angiogenesis, the inflammatory response, changes in 
extracellular matrix composition and increased protease activity (Bhowmick et al., 2004), 
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which affect differentiation, proliferation, migration and invasion of malignant cells, and 
support tumour spread and invasion. There is also increasing evidence that tumour stroma 
can have a more direct role in tumorigenesis by acting as a mutagen. As tumours progress, 
the cells display increased genetic instability. Conditions in the tumour microenvironment 
including oxidative stress, low pH environment and nutrient deprivation contribute to 
genetic instability through the induction of enhanced mutagenesis and an impaired DNA 
damage pathway (Bindra & Glazar, 2005). Alterations of the microenvironment are not the 
same within the whole tumour mass, conditions in the central region, where hypoxia and 
necrosis occur, differ from more viable areas found toward the periphery.  
2.1.2 Carcinoma-associated fibroblasts  
One of the most important components of stromal microenvironment are stromal 
fibroblasts. The main function of normal fibroblasts is synthesis of fibrillar extracellular 
matrix including collagens I, III, V and fibronectin. They also contribute to basal membrane 
formation by secretion of collagen IV and laminin. Carcinoma-associated fibroblasts (CAFs) 
can form a foetal-like environment. Through production of a variety of growth factors 
including basic fibroblast growth factor (bFGF), platelet-derived growth factor (PDGF), 
epidermal growth factor (EGF), transforming growth factor alpha (TGF-alpha) and the 
family of vascular endothelial growth factors (VEGFs) A, B and C. Fibroblasts are capable of 
modulating complicated interactions between epithelial and mesenchymal cells. Fibroblasts 
can also act as antigen-presenting cells and so importantly regulate the immune response. 
Besides maintaining homeostasis and integrity of healthy tissues, fibroblasts fundamentally 
contribute to tissue healing by formation of granulation tissue and scarring. In cancers, 
CAFs or myofibroblasts are believed to be a major part of a tumorous stroma. Such 
fibroblasts are phenotypically and genotypically different from normal fibroblasts 
(Bhowmick et al., 2004). They become highly proliferating cells with decreased apoptotic 
potential and increased migratory capacity.  
CAFs promote tumour progression by secreting growth factors and pro-migratory ECM 
components, as well as up-regulating the expression of serine proteases and matrix 
metalloproteinases that degrade and remodel the ECM. They also contribute to tumorous 
neoangiogenesis. Moreover, CAFs can promote progression of pre-malignant lesions or 
even act as a direct mutagen stimulating the progression of a non-tumorigenic cell 
population to a tumorigenic one (Bhowmick et al., 2004). On the other hand, fibroblasts may 
also inhibit tumour growth. However, only normal fibroblasts possess these abilities. The 
mechanisms are still not clear, though the reduction of TGF or modulation of the immune 
response via interleukin-1 (IL-1), interleukin-6 (IL-6) or inhibition of T-lymphocyte 
apoptosis have been described (Silzle et al., 2004). In in vivo models of melanoma genesis, 
both the early vertical phase and the late radial phase were repressed (Proia & Kuperwasser, 
2005). Thus normalization of the stromal microenvironment should be able to slow or even 
reverse tumour progression. 
2.2 Tumour changes in malignant melanoma 
In skin, under normal condition, tissue homeostasis determines whether a cell remains 
quiescent, proliferates, differentiates, or undergoes apoptosis. Melanocytes, after cell 
division, separate and migrate along the basement membrane; finally, they extend their 
dendrites and establish multiple contacts with keratinocytes and Langerhans cells. In the 
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state of homeostasis, keratinocytes control growth and behaviour of melanocytes through 
a complicated and complex system of paracrine growth factors and cell-cell adhesion 
molecules. Once this delicate homeostatic balance is altered, melanocyte proliferation and 
migration is stimulated, which can lead to nevi or even malignant melanoma development. 
Melanoma cells escape from the control of keratinocytes through several mechanisms 
including a decrease or loss of intercellular adhesions by down-regulation of receptors and 
proteins important for their communication with keratinocytes (E-cadherin, P-cadherin), 
loss of their anchorage to the basement membrane, because of altered expression of the 
extracellular matrix-binding integrin family, and up-regulation of receptors and signalling 
molecules important for melanoma-melanoma and melanoma-fibroblast interaction such as 
N-cadherin.  
The growth of melanoma is associated with cumulating stromal alterations. The molecular 
changes associated with the transformation of melanoma cells from the radial growth phase 
(RGP) to the vertical growth phase (VGP) and the metastatic phenotype are not very well 
defined. However, some of the genes that are critical for melanoma progression have been 
demonstrated. For example, the switch from RGP to VGP and the metastatic phenotype are 
associated with loss of the AP-2 alpha transcription factor. This loss resulted in 
overexpression of MCAM/UC18, MMP, and lack of c-KIT expression (Leslie & Bar-Eli, 
2005). AP-2 alpha also regulates two G protein-coupled receptors (GPCRs), the thrombin 
receptor protease-activated receptor (PAR-1) and platelet-activating factor receptor (PAFR). 
In turn, PAR-1 regulates the expression of gap junction protein connexin 43 and the tumour 
suppressor maspin. Activation of PAR-1 also leads to overexpression and secretion of 
proangiogenic factors such as IL-8, VEGFs, PDGF, as well as certain integrins. The ligands 
for these GPCRs, thrombin and PAF, are secreted by stromal cells, emphasizing the 
importance of the melanoma microenvironment for the progression of the disease (Braeuer 
et al., 2010). Other studies have shown that AP-2 alpha regulates additional genes involved 
in melanoma growth including E-cadherin, p21/WAF-1, Her2, Bcl-2, FAS/APO-1, 
plasminogen activator inhibitor-1 (PAI-1), hepatocyte growth factor (HGF) and insulin-like 
growth factor receptor 1 (IGFR-1). The factor is a p53 binding partner, and has been shown 
to stimulate p53-dependent transcription (Melnikova & Bar-Eli, 2008). Additionally, the 
transition of melanoma cells from RGP to VGP is associated with overexpression of 
transcription factors CREB/ATF-1 (cAMP-responsive element binding protein/activating 
transcription factor-1). Two mechanisms how overexpression of CREB and ATP-1 
contributes to the aggressive phenotype have been identified. The first one is overexpression 
of the metalloproteinase MMP-2 and the adhesion molecule MCAM/UC18; in the second 
mechanism  both proteins act as survival factors for melanoma cells. 
In malignant melanoma, tumour stroma interactions involve five main mechanisms 
influencing the growth and invasion of malignant cells, activation of which determine each 
other reciprocally: (1) changes in intercellular adhesion such as the  cadherin, catenin, Snail 
and claudin families, (2) up-regulation of growth factors and their receptors, (3) activation of 
transcription factors (the family of signal transducers and activators of transcription, 
STATs), (4) stimulation of angiogenesis, and (5) immune cell response. 
2.2.1 Cell-cell adhesions 
In normal epithelial structures, cell-cell junctions play an important role in the maintenance, 
integrity and morphology of the epithelium (Alami et al., 2003). It has been reported that the 
E-cadherin/beta-catenin system of adhesion molecules plays a crucial role in these processes 
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(Weis & Nelson, 2006). E-cadherin is a cell adhesion transmembrane molecule, a member of 
a family of functionally related transmembrane glycoproteins that mediate Ca2+-dependent 
intercellular adhesion. The adhesion is mediated via interaction with adjacent cells through 
their N-terminal ectodomains and the cytoplasmic terminal tail of E-cadherin links 
specifically to beta-catenin that binds directly to the cytoskeletal actin. A deficiency in  
E-cadherin causes loss of adherent junctions (AJs), which leads to impaired intercellular 
signalling, but not to direct tumour transformation. It has been reported that dysfunction or 
disruption of cell adhesion molecules accompanies the invasiveness and metastatic 
behaviour of malignant cells. Protein beta-catenin is a molecular sensor that integrates cell-
cell junctions and cytoskeletal dynamics with signalling pathways affecting morphogenesis, 
tissue homeostasis, and intercellular communication within tissues (Perez-Moreno & Fuchs, 
2006). Generally, beta-catenin has a dual function. It plays a key role in cell-cell adhesion by 
linking cadherins to alpha-catenin and cytoskeletal actin (Weis & Nelson, 2006). In the 
absence of Wnt signal, beta-catenin is constitutively down-regulated by a multicomponent 
destruction complex containing GSK3 beta (glycogen synthase kinase 3 beta), axin and the 
tumour suppressor APC (adenomatous polyposis coli). These proteins promote the 
phosphorylation of serine and threonine residues in the NH2-terminal region of beta-
catenin. Beta-catenin is then degraded by casein kinase CK1 and protein phosphatases PP2A 
and PP2C through the ubiquitin-proteasome pathway. Wnt signalling inhibits this process, 
leading to an accumulation of beta-catenin in the nucleus, which promotes the formation of 
transcriptionally active complexes with members of the Tcf/lef family (T-cell 
factor/lymphoid enhancer factor). The Tcf/beta-catenin heterodimers act as bipartite 
transcription factors and activate expression of the specific Wnt responsive genes that 
encode proteins regulating cell cycle, e.g. c-Myc, cyclin D1 and Pitx2 (Tetsu & McCormick, 
1999). Alterations in beta-catenin-mediated regulation have been demonstrated mainly 
during cancer development, where mutations of the beta-catenin gene CTNNB1 result in 
disruption of a large number of cellular functions leading to loss of growth control and 
neoplastic change (Voeller et al., 1998; Garcia-Rostan et al., 1999). 
The classical E-, N- and P- cadherins are expressed during various stages of melanoma 
progression. In the skin environment, E-cadherin expressed by keratinocytes and 
melanocytes prevents melanocytes from division without killing the cells, and P-cadherin is 
expressed only on the surfaces of basal layer, but not by keratinocytes or melanocytes 
(Satyamoorthy & Herlyn, 2002). During embryonic development, expression of cadherin 
subtypes correlates with the migration and segregation of different cell layers and the cell 
populations. An increase of E–cadherin expression is induced on the surfaces of 
melanoblasts prior to their entry into the epidermis, thereby forming an E-cadherin-
high/P-cadherin-low population. The cadherin expression pattern then diversifies, giving 
rise to three populations: (1) an E-cadherin-/P-cadherin-negative dermal population, (2) an 
E-cadherin-high/P-cadherin-low epidermal population, and (3) an E-cadherin-/P-cadherin-
mediate to -high follicular population. In all three populations, the patterns of expression 
are region specific. During melanoma development, expression of E-cadherin is 
progressively lost and becomes heterogeneous. In nevus cells, it is predominantly 
distributed diffusely in the cytoplasm, while in melanoma cells, it is completely absent. This 
may impair loss of terminal differentiation to melanocytes by disrupting the complex 
formation between cadherin, catenin and cytoskeleton required for strong intercellular 
adhesion. Despite the loss of E-cadherin by melanoma cells, these cells express high levels of 
N-cadherin and this switching of the profile is thought to promote their interaction with 
fibroblasts and endothelial cells. This may facilitate melanoma cells to migrate into the 
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(Weis & Nelson, 2006). E-cadherin is a cell adhesion transmembrane molecule, a member of 
a family of functionally related transmembrane glycoproteins that mediate Ca2+-dependent 
intercellular adhesion. The adhesion is mediated via interaction with adjacent cells through 
their N-terminal ectodomains and the cytoplasmic terminal tail of E-cadherin links 
specifically to beta-catenin that binds directly to the cytoskeletal actin. A deficiency in  
E-cadherin causes loss of adherent junctions (AJs), which leads to impaired intercellular 
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disruption of cell adhesion molecules accompanies the invasiveness and metastatic 
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tumour suppressor APC (adenomatous polyposis coli). These proteins promote the 
phosphorylation of serine and threonine residues in the NH2-terminal region of beta-
catenin. Beta-catenin is then degraded by casein kinase CK1 and protein phosphatases PP2A 
and PP2C through the ubiquitin-proteasome pathway. Wnt signalling inhibits this process, 
leading to an accumulation of beta-catenin in the nucleus, which promotes the formation of 
transcriptionally active complexes with members of the Tcf/lef family (T-cell 
factor/lymphoid enhancer factor). The Tcf/beta-catenin heterodimers act as bipartite 
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disruption of a large number of cellular functions leading to loss of growth control and 
neoplastic change (Voeller et al., 1998; Garcia-Rostan et al., 1999). 
The classical E-, N- and P- cadherins are expressed during various stages of melanoma 
progression. In the skin environment, E-cadherin expressed by keratinocytes and 
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E-cadherin-high/P-cadherin-low epidermal population, and (3) an E-cadherin-/P-cadherin-
mediate to -high follicular population. In all three populations, the patterns of expression 
are region specific. During melanoma development, expression of E-cadherin is 
progressively lost and becomes heterogeneous. In nevus cells, it is predominantly 
distributed diffusely in the cytoplasm, while in melanoma cells, it is completely absent. This 
may impair loss of terminal differentiation to melanocytes by disrupting the complex 
formation between cadherin, catenin and cytoskeleton required for strong intercellular 
adhesion. Despite the loss of E-cadherin by melanoma cells, these cells express high levels of 
N-cadherin and this switching of the profile is thought to promote their interaction with 
fibroblasts and endothelial cells. This may facilitate melanoma cells to migrate into the 
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dermis and enter the vasculature (Perlis & Herlyn, 2004). In malignant melanoma, each of 
three cadherin molecules has been evaluated as a prognostic marker in multiple 
retrospective cohort studies of varying quality with different results. In multivariable 
analysis, decreased levels of P-cadherin have been shown to be associated with faster 
disease progression in thin (<2mm) lesions, but did not reach significance for all-cause 
mortality in another study (Pacifico et al., 2005). Gain of N-cadherin expression was 
significantly associated with increased all-cause mortality in one univariate long-rank 
analysis and did not retain its significance. Decreased levels of E-cadherin have been 
associated with a metastatic phenotype, where lower mean levels of the protein were shown 
in metastatic melanomas. Significant negative trends of E-cadherin were also shown with 
Breslow thickness (Kreizenbeck et al., 2008) On the other hand, improved survival was 
described in a group of patients with retained E-cadherin expression. Interesting data were 
published by Kreizenbeck et al. (2008) who evaluated simultaneous expression of cadherins. 
Worse outcomes were described in a subset of melanomas that successfully completed 
epithelial-mesenchymal transition (EMT) – down-regulation of E- and P-cadherins and 
up-regulation of N-cadherin. But unexpectedly, one group, despite having the highest levels 
of N-cadherin in the entire cohort, displayed the best survival. In this group, E-cadherin 
continued to be expressed. Thus, high levels of N-cadherin should not always be a feature of 
EMT, but high levels of the protein may recapitulate a very early but noninvasive, 
developmental phenotype.  
In malignant melanoma, both the loss of E-cadherin and mutations of beta-catenin, leading 
to a more stable non-degradable protein, have been reported. Patients with N-cadherin and 
beta-catenin co-expression yielded a 3.29-fold increased risk of death (Kreizenbeck et al., 
2008). The impact of beta-catenin expression depends on its subcellular distribution, where 
nuclear translocation of the protein represents an unfavourable prognosis, while 
cytoplasmic locations were associated with increased disease-free survival. 
The mechanism of down-regulation of E-cadherin in malignant melanoma is still unknown. 
One possibility involves promoter inactivation attributable to hypermethylation. 
Furthermore, loss of activating protein-2 transcription factor expression as a potential 
activator of E-cadherin has been suggested. Also mutations in E-cadherin gene resulting in 
a functionally inactive protein have been detected. Ultraviolet irradiation leading to 
secretion of endothelin 1 can also down-regulate E-cadherin in melanocytes and melanoma 
cells (Jamal & Schneider, 2002), as well as tumour invasion. One of the strongest E-cadherin 
repressors is the protein Snail 1. Snail is a zinc-finger transcription factor involved in the 
process that facilitates cell movement during embryonic development. Snail 1 expression 
leads to the acquisition of fibroblastic properties by epithelial cells, facilitating their 
migration. In malignant melanoma, up-regulation of Snail 1 has been observed.  Besides 
down-regulation of E-cadherin, Snail 1 is also known to promote the nuclear localization of 
beta-catenin. Furthermore, Snail suppresses the expression of claudins and occludins (De 
Craene et al., 2005). Snail has been described to affect transcriptional expression of CYLD 
(a tumour suppressor) in melanoma cells, which finally results in N-cadherin and cyclin D1 
overexpression.  The Snail family is activated by TGF-beta. Other known Snail inductors 
manifesting high metastatic potential and often exhibiting loss of functional tight junctions 
(TJs) include RAS or ILK (integrin-linked kinase) (Massoumi et al., 2009). Furthermore, 
mutation of BRAF can lead to up-regulation of Snail as well (Massoumi et al., 2009). 
Besides AJs, cell-cell adhesions are maintained through tight junctions. In contrast to the role 
of AJs, the role of TJ proteins in cancer is less well understood. TJs are the most apical cell-
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cell contacts and are important for a barrier function that regulates the passage of ions, 
water, macromolecules, and a fence function that maintains cell polarity. A number of 
integral membrane proteins associated with TJs have been identified including occludin, 
junctional adhesion molecules and the claudin family consisting of at least 24 members 
(Dhawan et al., 2005). Tumour cells, particularly in those cancers that manifest high 
metastatic potential, often exhibit loss of functional TJs. For example, levels of zonula 
occludens (ZO-1, ZO-2) and occludins are decreased during tumour formation and 
metastasis. There are differences in claudin family expression in various tumours. While 
a decrease of claudin-7 has been found, levels of claudin-1, -2 and -3 are frequently elevated. 
Claudins encode proteins with 4 transmembrane domains, and their N- and C-terminal ends 
are located in the cytoplasm. Members of the claudin family interact with each other. In 
addition, the C-terminal domain of claudins also serves as a binding site for interactions 
with other TJs that are potentially involved in signalling. Furthermore, claudins have been 
reported to recruit and promote the activation of MMP-2, suggesting potential involvement 
in invasion and metastasis. Claudin-1 was also recently identified as a probable target of 
beta-catenin/Tcf signalling. It has also been demonstrated that claudin-1 inhibition increases 
E-cadherin expression. Expression of various claudins is regulated by EGF and TGF-beta.  
As claudins regulate paracellular transport, they are usually found at the cell membrane. 
However, these proteins have been shown to alter their subcellular localization during 
malignant progression. Benign lesions and less aggressive melanomas express claudin-1 in 
the nucleus, whereas aggressive melanomas have an abundance of the protein in the 
cytoplasm. It has been reported that for the regulation and cytoplasmic localization of 
claudin expression, protein kinases such as protein kinase A (PKA) and protein kinase C 
(PKC) are important. In benign nevi and early stage melanomas, claudin is largely 
expressed in the nucleus, while highly metastatic melanoma cells tend to have increased 
claudin-1 in the cytoplasm and at the membrane  (French et al., 2009). It is curious that in 
cases where claudin-1 is low, it is predominantly nuclear, despite abundant active PKA. This 
observation implies that the levels of claudin-1 may need to reach a certain threshold prior 
to being shuttled out of the nucleus. The significance of claudin-1 in the nucleus is unclear. It 
is known that the nuclear expression of other TJs can inhibit proliferation. But different 
results were obtained by others, claiming that nuclear translocation correlates with 
oncogenic transformation and proliferation. Cytoplasmic claudin-1 location can induce 
dramatic EMT, resulting in increased cell motility and metastatic potential.  
2.2.2 Epithelial-mesenchymal transition 
All the above-mentioned proteins (cadherins, catenin, Snail and claudins) are crucially 
involved in epithelial-mesenchymal transition. EMT refers to the process, in which an 
epithelial cell disengages from its parent tissue by losing mediators of homotypic and/or 
heterotypic cell-cell interactions in exchange for morphology and adhesions marker profiles 
consistent with a mesenchymal cell and is regarded as the first necessary step for invasion 
and metastasis (Kreizenbeck et al., 2008). This pathway is especially appropriate for 
melanoma, because EMT recapitulates a pivotal phase of melanocyte development. Normal 
melanocyte precursors are derived from the neural crest. During embryogenesis, these cells 
undergo the first EMT to disengage from the neural crest and then subsequently migrate 
through the embryonic mesenchyme until they reach their terminal locations distributed 
throughout the dermal/epidermal junction where they subsequently undergo reverse EMT 
to facilitate interactions with local keratinocytes.   
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nuclear translocation of the protein represents an unfavourable prognosis, while 
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repressors is the protein Snail 1. Snail is a zinc-finger transcription factor involved in the 
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(Dhawan et al., 2005). Tumour cells, particularly in those cancers that manifest high 
metastatic potential, often exhibit loss of functional TJs. For example, levels of zonula 
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are located in the cytoplasm. Members of the claudin family interact with each other. In 
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with other TJs that are potentially involved in signalling. Furthermore, claudins have been 
reported to recruit and promote the activation of MMP-2, suggesting potential involvement 
in invasion and metastasis. Claudin-1 was also recently identified as a probable target of 
beta-catenin/Tcf signalling. It has also been demonstrated that claudin-1 inhibition increases 
E-cadherin expression. Expression of various claudins is regulated by EGF and TGF-beta.  
As claudins regulate paracellular transport, they are usually found at the cell membrane. 
However, these proteins have been shown to alter their subcellular localization during 
malignant progression. Benign lesions and less aggressive melanomas express claudin-1 in 
the nucleus, whereas aggressive melanomas have an abundance of the protein in the 
cytoplasm. It has been reported that for the regulation and cytoplasmic localization of 
claudin expression, protein kinases such as protein kinase A (PKA) and protein kinase C 
(PKC) are important. In benign nevi and early stage melanomas, claudin is largely 
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is known that the nuclear expression of other TJs can inhibit proliferation. But different 
results were obtained by others, claiming that nuclear translocation correlates with 
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dramatic EMT, resulting in increased cell motility and metastatic potential.  
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involved in epithelial-mesenchymal transition. EMT refers to the process, in which an 
epithelial cell disengages from its parent tissue by losing mediators of homotypic and/or 
heterotypic cell-cell interactions in exchange for morphology and adhesions marker profiles 
consistent with a mesenchymal cell and is regarded as the first necessary step for invasion 
and metastasis (Kreizenbeck et al., 2008). This pathway is especially appropriate for 
melanoma, because EMT recapitulates a pivotal phase of melanocyte development. Normal 
melanocyte precursors are derived from the neural crest. During embryogenesis, these cells 
undergo the first EMT to disengage from the neural crest and then subsequently migrate 
through the embryonic mesenchyme until they reach their terminal locations distributed 
throughout the dermal/epidermal junction where they subsequently undergo reverse EMT 
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EMT plays an important role not only in skin morphology but also in wound repair, tissue 
fibrosis and cancer progression (Nakamura & Tokura, 2011). In malignant melanoma, EMT 
contributes to the promotion of metastatic phenotype in primary tumour by supporting 
specific adhesive, invasive, and migratory properties, and it is important for promoting 
transition to the VGP. EMT is the result of the expression of mesenchymal gene products 
such as fibronectin, vimentin and metalloproteinases, and the invasion and inhibition of 
E-cadherin. For EMT induction in melanomas, all genetic abnormalities including common 
mutations and/or deregulated expression of B-Raf, N-Ras and PTEN seem to synergize with 
microenvironmental factors including cell-cell interaction and angiogenic efficiency. In 
addition, it has been shown that hypoxia promotes melanocyte transdifferentiation and 
melanoma migratory and invasive abilities through up-regulating of genes normally 
associated with the extracellular matrix remodelling and invasion. These genes include 
laminin, urokinase and genes encoding matrix metalloproteinases. Furthermore, different 
microenvironments may be selective for higher levels of B-Raf-dependent and B-Raf-
independent ERK1/2 activation. These microenvironments are critical for tumour cell 
proliferation and spread. It has been shown that expression levels of phosphorylated 
ERK1/2 are not always correlated with the station status of B-Raf or N-Ras, suggesting that 
other factors promote ERK1/2 activation. Among these factors are growth factor autocrine 
loops such as the CDF-dependent activation of c-Kit, and extracellular signals. The above 
findings exemplify how the microenvironment can complement aberrant genetic changes to 
promote melanomagenesis and to support an invasive cell phenotype (Lin et al., 2010). In 
contrast to a general conception that invasion and dissemination occur during the later 
vertical phase, recent findings show that early dissemination of tumour cells that have not 
fully progressed contributes to subsequent development of metastasis. Moreover, B-RAF 
mutation is associated with constitutive hyperactivation of survival/antiapoptotic pathways 
such as the MAPK, NF-kappaB, and PI3K/AKT, which may also initiate EMT. All pathways 
cross-talk and regulate each other’s activities and functions. For instance, the NF-kappaB 
pathway directly regulates EMT through the transcription of gene products involved in 
EMT such as COX-2. Metalloproteinases and VEGFs in metastatic lesions directly and 
indirectly induce Snail through the transcriptional up-regulation. Snail in turn suppresses 
the expression of the metastasis suppressor gene product Raf kinase inhibitor protein RKIP 
(inhibits the MAPK and NF-kappaB pathways) as well as PTEN (inhibits the PI3K/AKT 
pathway). Hyperactivation of NF-kappaB greatly increases the metastatic potential, while 
knockdown of NF-kappaB reverses the mesenchymal-like phenotype and suppresses the 
motility and invasion capacity of melanoma cells (Lin et al., 2010). 
EMT accelerates cancer metastasis through not only enhanced invasion but also via 
induction of immunosuppression. Human melanocytes with typical EMT features after Snail 
transduction induce regulatory T cells and impair dendritic cells in vitro and in vivo. 
Intratumoral injection with a Snail-specific monoclonal antibody inhibits tumour growth 
and metastasis followed by an increase of tumour-specific tumour-infiltrating lymphocytes 
and systemic immune response (Kudo-Saito et al., 2009). 
Moreover, there are several new theories that EMT may also contribute to formation of 
malignant stroma when normal or cancer epithelial cells may be a source of carcinoma-
associated fibroblasts largely involved in cancer progression. 
2.2.3 Growth factors in melanoma progression 
There is a large number of growth factors and their receptors and cytokines, which by 
means of autocrine and paracrine effects are associated with melanoma progression. Those 
considered to have the highest impact are dealt with in this review. 
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Fibroblast growth factors  
Fibroblast growth factors (FGFs) are proteins with diverse functions in development, repair, 
and metabolism. The 22-member human FGF gene family includes FGF 1 – FGF 23; FGF 15 
has not been identified in humans (Itoh, 2010). FGFs can be subdivided by their action 
mechanism into three groups: (1) the intracellular FGF 11/12/13/14 subfamily, (2) the 
hormone-like (endocrine) FGF 19/21 (23) subfamily, and (3) the canonical FGF subfamily 
comprising FGF 1/2/5, FGF 3/4/6, FGF 7/10/22, FGF 8/17/18 and FGF 9/16/20 (Itoh & 
Ornitz, 2008). Canonical FGFs mediate their biological responses as extracellular proteins by 
binding to and activating cell surface tyrosine kinase FGF receptors (FGFRs) including 
FGFR-1, -2 and -3 with heparin/heparan sulfate as a cofactor. They act as local signalling 
molecules in an autocrine/paracrine manner. Two members of the FGF family, acidic FGF 
(FGF1) and predominantly basic FGF (FGF-2), are related to melanoma progression. Basic 
FGF (bFGF) protein is known as a mitogen stimulating proliferation of mesenchymal, 
epithelial and neuroectodermal cells.  The protein has been shown to stimulate proliferation 
of human melanocytes and also to support the growth and invasion of melanoma cells. The 
aberrant expression of bFGF occurs at an early stage of melanocyte lesions affecting growth 
and cell dedifferentiation. The protein is expressed not only by melanocytes or 
melanoblasts, but also by stromal cells, especially by activated fibroblasts. It is believed that 
aberrant expression of the protein even belongs to early changes stimulating proliferation 
and dedifferentiation of melanocytic lesions.  Increased bFGF expression can be induced by 
exposure to UV radiation, with abnormal expression of the protein resulting in inactivation 
of some tumour suppressors. Halaban et al. (1988) found bFGF only in malignant melanoma 
cells and characterized it as a significant autocrine factor influencing melanoma growth. 
However, these findings have not been confirmed by other studies (Ugurel  et al., 2001), 
where bFGF has also been described in cells of conventional benign nevi, although 
significantly less often. It seems to be more probable that bFGF cannot be considered 
a marker of melanocyte transformation and it can stimulate cell growth under benign as 
well malignant conditions. On the other hand, when bFGF was cleaved by thrombin, which 
imparted its biological activity, proliferation, chemotaxis and invasion of melanoma cells 
were observed (Totta et al., 2009). The function of bFGF may also be influenced by varying 
subcellular localization. Whilst in malignant melanomas, the protein is localized in the 
cytoplasm, its nuclear expression predominates in nevus cells. Cytoplasmic localization is 
associated with stimulation of VEGF and HIF expression in tumorous and stromal cells via 
activation of a variety of kinases such as PI-3K and MAPK. This location may reflect an 
aberrant form of the bFGF molecule, which is either incapable of nuclear transport or 
a possible defect in the bFGF-driven cascade may exist. It is possible that the different 
localization may be a key to another effect of bFGF, for example on the growth of malignant 
lesions and/or stimulation of fibrotization and maturation of benign nevi. In advanced stage 
III or IV melanomas, a significant increase in plasma bFGF levels has been found. These 
results even show that increased bFGF is a more sensitive parameter than detection of S-100 
protein or VEGF. The protein bFGF is suggested to be one of the candidates of early 
detection of lymph node metastases (Kurschat et al., 2007). 
Hepatocyte growth factor 
Hepatocyte growth factor/scatter factor (HGF/SF) is a potent angiogenic factor and 
mediator of epithelial cell motility, morphogenesis and angiogenesis. HGF is a mediator of 
mesenchymal-epithelial interactions that stimulates cell proliferation, migration and 
morphogenesis through its receptor c-met. HGF/SF is an essential mesenchyme-derived 
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of some tumour suppressors. Halaban et al. (1988) found bFGF only in malignant melanoma 
cells and characterized it as a significant autocrine factor influencing melanoma growth. 
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factor in epithelial–mesenchymal (or stromal) interactions during organogenesis, 
maintaining homeostasis and regeneration of a variety of normal tissues. Moreover, 
HGF/SF is involved in tumorigenesis in vivo (Bellusci et al., 2004). The protein is considered 
to be expressed by CAFs and contributes to the microenvironment alteration (Dali et al., 
2007). Delehedde et al. (2001) showed that HGF/SF is secreted by melanoma cells. HGF 
induces fibronectin expression and its extracellular assembly on the surface of melanoma 
cells through activation of the mitogen-activated protein (MAP) kinase pathway, and 
induction and transcriptional activation of early growth response 1. Altogether this 
autocrine HGF signalling seems to have important implications in regulation of melanoma 
progression.  
Transforming growth factor beta 
TGF-beta is a paracrine growth factor, which under normal physiological conditions maintains 
tissue homeostasis via proliferation and apoptosis. It also has strong immunosuppressive 
effects. On the contrary, in cancers, this factor stimulates cell proliferation and growth and can 
protect malignant cells from the attack by the immune system.  
TGF-beta modulates the microenvironment to the benefit of tumour growth and invasion 
(Lázár-Molnár et al., 2000). TGF-beta stimulates angiogenesis, CAF proliferation, and 
extracellular matrix and cytokine production. It is also considered to be involved in EMT 
(Prud’homme, 2007). TGF-beta is generally secreted in an inactive form and requires prior 
activation. It has been documented that most mammalian cells including melanoma cells, 
express TGF-beta (Moretti et al., 1999), while melanocytes can produce latent TGF-beta only 
after stimulation by exogenous growth factors such as insulin-like growth factor 1. TGF-beta 
is a marker of advanced progression of malignant melanomas (Moretti et al., 1999). TGF-
beta has an inhibitory effect on melanocytes and early lesions, but not on advanced stage 
melanomas. In some cases, it switches to an autocrine stimulator (Lázár-Molnár et al., 2000). 
However, the role of TGF-beta as a potential autocrine growth factor is more complex. 
Experimentally, factors such as TGF-beta can induce normal fibroblasts to become activated 
and express alpha SMA (smooth muscle actin), but it is not clear if these cells acquire other 
characteristics of CAFs, and if the phenotype is stable, or if they can recover again to 
a normal state. 
Platelet-derived growth factor  
PDGF drives cellular responses including proliferation, survival, migration and deposition of 
extracellular matrix and tissue remodelling factors (Hoch & Soriano, 2003). Besides its 
mitogenic activity, this factor has its own transforming ability. The important sources of the 
protein are not only malignant cells themselves, but also activated macrophages, fibroblasts, 
smooth muscle and endothelial cells and epidermal keratinocytes. PDGF acts through the 
platelet-derived growth factor receptor (PDGFR) family of receptors tyrosine kinases. These 
receptors are expressed by a range of cell types, in which they regulate cell growth and 
proliferation by activation of signalling pathways that include BRAF-MAPK and PI-3 
pathways. PDGF is a known stimulator of tumorous stroma especially by its ability to 
modulate and activate stromal fibroblasts. Also important is its role in stimulation of 
angiogenesis. But PDGF contributes to morphological changes of new blood and lymph 
vessels, which are typical for tumorous microcirculation. It has been reported that molecules 
activated by PDGF via its receptors increase interstitial fluid pressure and in this way 
contribute to tumour chemoresistance. On the other hand, when PDGFRs and their ligands are 
blocked, there is increased therapeutic drug delivery to a tumour region (Ogawa et al., 2008).  
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Expression of PDGF in benign melanocytic lesions is low, a significant increase has been 
described in melanomas. Higher PDGF expression is documented not only in cells of 
primary skin melanomas but also in their metastases, emphasizing its importance as 
a growth factor in melanoma progression.  Thus, PDGF has become a potential aim in anti-
melanoma therapy that not only influences melanoma cells themselves but also importantly 
modulates a stromal response. 
Epidermal growth factor receptor  
EGFR belongs to the family of tyrosine kinase receptors governing cell proliferation, 
differentiation and transformation in a range of malignancies, mainly through activation of 
PI-3KAKT and MAPK pathways. EGFR also inhibits apoptosis and stimulates cell 
migration. EGFR has a direct effect on the stromal microenvironment including stimulation 
of angiogenesis and an increase of MMP-1 levels, which potentiate invasion of cancer cells. 
EGFR may also raise metastatic potential including inhibition of TGF-beta or MMP 
activation. 
The main EGFR ligands include EGF and TGF-alpha. While increased expression of EGFR 
has been well described in many cancers such as colon, stomach, lung and breast 
carcinomas, where it correlates with a worse prognosis, its role in melanoma biology is less 
clear. EGFR is one of factors whose phosphorylation and activation are influenced by UV 
radiation. But in some cases, induction of apoptosis in cells exposed to UV radiation 
accompanied by inhibition of EGFR expression has been demonstrated. Transactivation of 
EGFR may also lead to increased stability of poly(ADP-ribose) polymerase (PARP) protein 
involved in DNA repair and associated with UV stress. In vitro studies have shown increased 
cell proliferation, when EGFR was transfected to melanoma cell lines. This is in contrast to in 
vivo studies using implantation of melanoma cells, where decreased EGFR together with 
growth inhibition have been documented. It seems that EGFR levels are modulated during 
melanoma growth, with one of important modulators being the immune system (Diaz et al., 
2009).  EGFR is increased not only in melanoma lesions including both early- and late-stage 
melanomas but also in benign nevi. It seems probable that different effector pathways are 
activated. Anti-apoptotic and proliferating effects predominate in melanoma cells while in 
nevi, DNA repairs are stimulated. What conditions and mechanisms determine the function is 
not clear. FGF 1 is related to the achievement of an angiogenic phenotype of melanoma cells. 
Vascular endothelial growth factors  
VEGFs possess the leading role among the factors regulating tumour angiogenesis. VEGFs 
and their receptors have been established as distinctive proteins playing a role in endothelial 
cell proliferation and/or elongation, migration and vascular morphogenesis. VEGFs are 
produced by a variety of cell types including keratinocytes, macrophages, mast cells, 
smooth muscle cells, endothelial cells and fibroblasts. VEGF-A is the most well-
characterized member of the family of structurally related proteins that act as endothelial 
cell (EC) mitogens and angiogenic factors. VEGF-A is a dimeric glycoprotein with structural 
homology to PDGF (Ferrara et al., 1991). One of the most striking characteristics of the factor 
is its ability to induce vascular permeability. This enhanced permeability leads to 
subsequent fibrin deposition in the extracellular matrix that can then serve as a scaffold for 
migrating endothelial cells. VEGF-C, a structural homologue with VEGFs and PDGF, has 
been shown to stimulate the growth of the lymphatic endothelium and thus induce 
lymphangiogenesis.  
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The known responses of VEGFs are mediated through their receptors (VEGFRs) including 
VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1) and VEGFR-3. The activation of VEGFRs by its 
ligands results in enhanced permeability of the vasculature and increased migration and 
proliferation of endothelial cells, making them also major targets for therapy (Rosen, 2002). 
VEGFs bind and activate two receptors, VEGFR-1 and VEGFR-2. The binding-affinity of 
VEGFR-1 for VEGF-A is one order of magnitude higher than that of VEGFR-2, whereas the 
kinase activity of VEGFR-1 is about 10-fold weaker than that of VEGFR-2 (Shibuya, 2006). 
VEGFR-1 plays a dual role: (1) a negative role in angiogenesis in the embryo most likely by 
tramping VEGF, and (2) a positive role in adulthood in a tyrosine kinase-dependent manner. 
VEGFR-2 has strong tyrosine kinase activity and it transduces the major signals for 
angiogenesis. VEGFR-2 is a direct signal transducer for pathological angiogenesis including 
cancer (Shibuya, 2006). VEGF-C binds and activates VEGFR-2 and VEGFR-3. VEGFR-3 is 
essential for the development of the lymphatic vasculature. Experimental tumours that 
overexpress VEGFR-3 ligands induce lymphatic vessel sprouting and enlargement and 
show enhanced metastasis to regional lymph nodes (Laakkonen et al., 2007). In melanocytic 
lesions, VEGF-A was shown to be expressed in benign as well malignant lesions, but 
malignant melanomas product the protein in significantly higher levels. However, there are 
different findings considering VEGF-A expression in moles, and some authors strictly deny 
their expression in nevus cells and they correlate increased production of the protein only 
with malignant transformation (Gorski et al., 2003; Goydos et al., 2003). Moreover, VEGF-A 
has been correlated to the transition from the radial to vertical growth phase. But it seems 
more likely that the factors can regulate angiogenesis under benign and malignant 
conditions and their detection can serve for differentiation of biological character of the 
lesion . The most important impact has deregulated and prolonged expression of VEGF-A in 
melanomas. Contrary to this, VEGF-C was shown to be mostly negative in nevi, and its 
expression seems to be directly associated with malignant transformation. Both factors are 
expressed already in early-stage melanomas, and it has been documented  that the 
expression is regulated not only by hypoxia-inducible factor (HIF) caused by hypoxic 
conditions in larger tumours but also by numbers of cytokines and growth factors (Kyzas et 
al., 2005). VEGFs are significantly increased in stromal elements surrounding melanoma 
cells, especially in advanced melanomas. Local levels of VEGFs precede their serological 
levels described in stage IV melanoma (Pelletier et al., 2005). 
VEGFRs are specific not only for endothelial cells but also for fibroblasts, tumour and immune 
cells. The role of VEGFRs is well recognised during embryonic development, but their impact 
in tumours is less clear (Shibuya, 2006). While some melanomas express increased levels of the 
receptors, others are completely negative. VEGFs are likely to be at least partly independent on 
their receptors. On the other hand, there are results exhibiting better prognosis of tumours, 
which express VEGFR-1. One explanation may be that VEGFs may bound-out free VEGFs and 
thus block their effector pathway (Yamaguchi et al., 2007). From this point of view, it may be 
possible that VEGFR-negative melanomas would have a worse prognosis. 
2.2.4 Activation of transcriptional factors 
In melanoma progression, a variety of transcriptional factors have been described. The 
leading role is believed to belong to the c-Myc oncoprotein and STAT family.  
c-Myc 
It is known that the c-Myc proto-oncogene stimulates cell proliferation and inhibits 
differentiation. The protein has also its own transforming potential. Increased expression of 
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c-Myc was described already in early stages of melanoma development, but significant 
deregulation was mostly bound to advanced stages. Autocrine production of c-Myc by 
melanoma cells stimulates their growth and dedifferentiation, but simultaneously c-Myc 
may stimulate proliferation of fibroblasts in a paracrine way and thus form tumorous 
stroma (Gu et al., 2001). Moreover, c-Myc has been found to be expressed in increased levels 
by stromal fibroblasts. Such production markedly contributes to stromal autoregulation. 
In tissues, the c-Myc oncoprotein is stabilized and its effector function is therefore 
potentiated by FGF (Lepigue et al., 2004). It has been demonstrated that oncogenic signals 
outgoing from CAFs may stimulate transformation of a non-tumorous cell population to 
a tumorous one. c-Myc is one of molecules that through the stromal compartment may 
transform cells and/or contribute to accumulation of mutations and to selection of more 
aggressive cell clones. 
Signal transducers and transcriptional activators  
STATs form a family of 7 proteins (STAT 1, 2, 3, 4, 5A, 5B and 6), which are involved in 
activation of a variety of genes. Some of them are involved in malignant transformation (Yu 
& Jove, 2004). These proteins have dual roles as cytoplasmic signalling proteins and as 
nuclear transcriptional factors that activate a diverse set of genes including some that are 
implicated in malignant progression. In normal cells, STAT proteins transmit cytoplasmic 
signals from polypeptide cytokines, specifically interferon (IFN) and IL-6, and growth 
factors that have receptors with intrinsic or associated tyrosine kinase activity, especially 
EGFR and PDGF. 
STATs are activated by phosphorylation at TYR 701, which results in their dimerization and 
translocation to the nucleus, where they directly regulate gene expression. The 
phosphorylation may also be mediated by some non-receptor kinases such as SRC and BCR-
ABL. Physiologically, ligand-dependent activation of STATs is a transient process lasting for 
several minutes to several hours. In tumours, their constitutive activation associated with 
their increased transcriptional initiation and stimulation of cell proliferation has been 
described. STATs have been shown to inhibit apoptosis by an increase of anti-apoptotic 
proteins such as BCL-XL and surviving, or a decrease by p53 protein. Moreover, STATs may 
stimulate expression of cyclins D1 and D2 and c-Myc oncoprotein.  
STATs markedly regulate tumour angiogenesis by increased expression of VEGFs and  
HIF-1. They may also modulate the immune response, when both decrease of pro-
inflammatory and stimulation of anti-inflammatory cytokines and chemokines have been 
demonstrated. STATs are also able to inhibit dendritic cell differentiation, which may result 
in an induction of cell tolerance. STATs may stimulate migration and invasion of malignant 
cells via induction of MMP-2 as well. Despite close structural homology of the STAT family, 
the responses of its individual members differ, depending on activating ligands.  
STAT 1 and STAT 2 respond to interferons, STAT 3 to IL-6, STAT 4 and STAT 6 to IL-12/16, 
whereas STAT 5 is activated mainly by growth factors and prolactin. In malignant 
melanoma, increased levels of STAT 3 have been found, in comparison with moles, where 
their concentrations are generally low (Messina et al., 2008).  STAT 3 is associated with 
an increased metastatic potential as its deregulated levels were observed in advanced and 
metastatic melanomas. In several STAT- negative cell lines, increased apoptosis or G1 arrest 
have been demonstrated. STAT 3 may affect the response to IFN-alpha adjuvant therapy in 
melanoma cells. On the one hand, a decreased antiproliferative effect of the cytokine may be 
observed. On the other hand, its activation may stimulate tumour progression. Similar 
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Research on Melanoma – A Glimpse into Current Directions and Future Trends 
 
348 
effects on melanoma formation and progression are seen in STAT 5, which is associated 
with Bcl-2 overexpression. STAT 1 seems to have an opposite role with its pro-apoptotic and 
anti-angiogenic effects (Ho et al., 2006). Inducibility of STAT 1 activation significantly and 
favourably influences disease-free interval and overall survival. By contrast, low expression 
of STAT 1 after administration of IFN-alpha may mean that the tumour is resistant to the 
therapy. Wang et al. (2007) suggested to evaluate the STAT 1/STAT 3 ratio, with a high ratio 
referring to a favourable clinical response. The critical antitumour action seems to be the 
activation of STAT 1 in immune effector cells. 
2.3 Angiogenesis 
Angiogenesis is an example of how tumour stroma differs from normal connective tissue. 
The induction of new blood vessel growth into tumours from pre-existing vascular beds has 
been reported as a parameter of potential prognostic value in solid tumours, as it may 
facilitate tumour growth and metastasis (Miller, 2004). By contrast, normal adult vasculature 
is generally quiescent in nature, with endothelial cells dividing approximately every 10 
years. Extensive angiogenesis occurs normally only during the female reproductive cycle 
and in body repair processes such as wound healing. 
It has been shown that for their growth beyond 1-2 mm in size, solid tumours require 
constant vascular growth and remodelling (Folkman, 1990). In tumour growth, angiogenesis 
is uncontrolled and unlimited in the time and the transition from the avascular to the 
vascular phase is called the angiogenic switch, in which the balance between angiogenesis 
inducers and inhibitors lean towards the former (Ribatti et al., 2007). Studies on human 
breast carcinomas have even shown that vascular stroma formation occurs before invasion 
by tumour cells (Gallagher  et al., 2005). Tumour vasculature differs from non-tumour not 
only by an increased number of newly formed vessels, but also by their different structure, 
organization and function, instead of regular arrangement. The vessels are distributed 
irregularly, being morphologically heterogeneous and typically thin-walled. The basal 
membranes are incomplete, partly degraded, with a reduced amount of laminin. They have 
activated endothelial cells and often lack pericytes in the periphery. The typical hallmark of 
tumour vasculature is its increased permeability. The origin of the vessels is mostly in 
activated and proliferating endothelial cells, but they may also be formed from circulation 
bone marrow progenitor cells.  
In melanoma, parallel with progression, tumours acquire a rich vascular network, whereas 
an increasing number of tumour cells express the laminin receptor, which enables their 
adhesion to the vascular wall, favouring tumour cells extravasation and metastases 
(Mahabeleshwar & Byzova, 2007). Melanoma neovascularization has been correlated with 
poor overall survival, ulceration and increased rate of relapse (Ribatti et al., 2005). 
Numerous cytokines, growth factors and extracellular matrix enzymes are associated with 
neoangiogenesis. They are produced by tumour cells themselves, but their important 
sources also include stromal elements such as fibroblasts, macrophages, mast cells and 
endothelial cells, as well as epidermal keratinocytes. The central role is played by the VEGF 
family via direct stimulation of endothelial cell migration and proliferation, permeability 
and adhesion among endothelial and tumour cells (Fig. 2).  
Very important in tumour angiogenesis is bFGF, which can stimulate vascularization by 
activation of HIF-1 and the subsequent release of VEGFs or it may also act synergistically 
with VEGFs, but with distinctive effects on vessel function and with different consequences 
on tumour oxygenation and viability. Tumours with bFGF expression are characterized by 
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a striking heterology in blood vessel diameter with numerous large-calibre vessels. FGF 
down-regulation has a profound impact on microvessel morphology, causing a significant 
decrease in diameter heterogeneity and disappearance of large-calibre vessels. FGFs do not 
possess the ability to mediate a chemotactic response for pericytes and myofibroblasts, as is 
known for VEGFs (Giavazzi et al., 2003). 
Other important stimulators of melanoma angiogenesis are PDGF and TGF-beta that 
directly stimulate VEGF-A secretion, or IGF 2, EGFR, HSP 90, STAT 3 acidosis and hypoxia 
that stimulate VEGF indirectly through activation of  HIF  gene transcription. 
An important role is also played by placental growth factor (PGF), which binds neuropilin-1 
and neuropilin-2 receptors expressed on endothelial cells. In addition, PGF acts through 
binding to VEGFR-1 inducing the mobilization and recruitment of hematopoietic precursors 
from bone marrow. Moreover, PGF forms heterodimers with VEGF-A and enhances 
melanoma angiogenesis by activating VEGFR-2 on endothelial cells (Ria et al., 2010). 
Endothelial cell migration and vascular permeability may also be induced by IL-6 derived 
from melanoma cells. It is known that levels of the cytokine dramatically increase in 
majority of melanomas and are correlated with rapid tumour growth and increased 
metastatic potential. Integrins overexpressed on melanoma cells may also contribute to 
melanoma progression and increased metastatic potential by stimulating MMP-2 and  
MMP-7 (Kuphal et al., 2005). MMP overexpression has been correlated with increased 
microvascular density, Bcl-2 overexpression and low survival rate. Several studies using 
either cell lines or animal models have demonstrated that the balance between MMPs and 
their inhibitors (TIMPs) finally determines melanoma progression. Overexpression of TIMPs 
reduces melanoma cell invasion, migration, tumour neovascularization and risk of 
metastases. MMPs and TIMPs may act as regulators of signalling pathways through the 
cleavage of non-matrix substrates including cytokines, chemokines and growth factors. 
 
 
Fig. 2. Main factors involved in melanoma angiogenesis. 
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2.4 Therapy of malignant melanoma 
Up to now, there has been no effective curative treatment of malignant melanoma beyond 
surgical excision of the primary lesion. Chemotherapy and immunotherapy have thus failed 
to make an impact on survival in the metastatic setting, while immunotherapy leads to 
modest improvement in survival in the adjuvant setting. Recent data have shed light on 
anti-melanoma targeted therapies, whereas successful management of malignant melanoma 
treatment will benefit from the identification of essential regulatory pathways and 
molecular switches underlying the plastic tumour cell phenotype and its unique interactions 
with the microenvironment.  
This review presents data on the most promising agents in development. However, it is 
important to note that all these agents have been used singly or in combination with 
chemotherapy. It has become quite apparent that the inhibition of one pathway can lead to 
up-regulation of other related or redundant pathways. This may negatively affect its activity 
or likely lead to resistance. Therefore, combination of therapies utilizing these agents seems 
to be most promising approach in the future. Targeted molecular therapeutics are tailored to 
genetic abnormalities that are associated with tumour progression. These possible targets in 
melanoma include the RAS-MAPK and PI3K/AKT signal transduction pathways, resistance 
to apoptosis, the proteasome, melanoma-induced angiogenesis, and immunotherapy 
(Tab.1). Most agents are in early phase trials, although some have already reached phase III 
evaluation. As knowledge and experience with targeted therapy advance, new challenges 
appear to be arising particularly in terms of resistance and appropriate patient selection. 
 
Inhibitors of RAS-MAPK signal transductor 
pathway Sorafenib 
Inhibitors of the PI3K/AKT signal 
transduction pathway 
 
Rapamycin and its analogues RAD001, 
AP23573m and CCI-779 
Imatinib mesylat 
R115777 (Lonafarnib) 









Anti-angiogenic  isoforms of VEGF 
Vitaxin (MEDI-552)  
Immunotherapy 
Interleukin-2 
Interluekin-2 with peptide vaccination 
Ipilimumab 
Table 1. Targeted therapy in malignant melanoma 
2.4.1 Inhibitors of the RAS-MAPK signal transduction pathway 
The importance of the RAS-MAPK signal transduction pathway for the genesis of 
melanoma has been highlighted by the discovery of activating BRAF mutations in 60% of 
cutaneous melanoma. Constitutive activation of the RAS pathway occurs through 
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mutational activation of the RAS oncogene and of downstream components. Numerous 
inhibitors have been developed including direct inhibitors of RAF such as sorafenib. 
Sorafenib 
Currently, only preliminary results of small- to medium sized phase II clinical trials are 
available for metastatic melanoma.  In addition to blocking BRAF in tumour cells, it was also 
found that sorafenib blocks other receptors effectively, including VEGFR2, PDGFR, Flt3 
(FMS-like tyrosine kinase), c-Kit and RET receptor kinases.  As a single agent, however, 
Sorafenib seems to have little or no antitumour activity in advanced melanoma patients (Ott 
et al., 2010). The most promising results so far have been observed for combination of 
multikinase inhibitor sorafenib and chemotherapy, whereas sorafenib has been found to 
enhance the response of melanoma to regional chemotherapy. The main toxicities observed 
were grade 3/4 chemotherapy-related neutropenia and thrombocytopenia. No serious 
additional toxicity of sorafenib added to carboplatin and paclitaxel was obvious (Kirkwood 
et al., 2006). Discovery of markers for predicting response to sorafenib might be useful. In 
melanomas, it has been documented that high VEGFR2 expression is associated with 
response, whereas high ERK1/2 is associated with resistance (Jilaveanu et al., 2011). 
2.4.2 Inhibitors of the PI3K/AKT signal transduction pathway 
The phosphoinositide 3-kinase (PI3K) pathway is responsible for the production of 
3-phosphoinositide lipid molecules that serve as second messengers in the cells. The 
pathway controls a cascade of signals that regulates basic cellular properties including 
survival, motility and apoptosis resistance. Multiple mechanisms for activation of the 
pathway have been identified such as amplification and overexpression of tyrosine kinase 
receptors and their ligands, c-kit or mutation of the PTEN tumour suppressor gene. 
Molecular cloning identified an additional family, whose catalytic domains bear 
resemblance to PI3K. Based on their sequence homology, the kinases were named PI3K-
related kinases (PIKKs). They include several subfamilies such as the TOR family, ataxia 
telangiectasia gene product and the DNA-dependent protein kinase (Kirkwood et al., 2006). 
In melanoma therapy, the TOR subfamily is targeted by rapamycin and its analogues 
RAD001, AP23573m and CCI-779, from which especially the last molecule seems to have 
a promising therapeutic effect. Toxicity is mild, predominantly comprised of stomatitis, 
diarrhoea, a skin rash and hyperlipidemia. 
R115777 (tipifarnib) 
Farnesyl transferase inhibitors (FTIs) inhibit the farnesylation of proteins, which are 
involved in RAS downstream signalling pathway including the RAF-MEK-ERK (MAPK) 
and PI3K-AKT-mTOR (AKT). They have a major role in melanoma progression. Current 
findings suggest that R115777 inhibits mTOR signalling and may therefore represent an 
effective alternative for melanoma treatment. In particular, the combination of the FTI with 
the RAS inhibitor sorafenib synergistically inhibited melanoma cell growth, significantly 
enhanced sorafenib-induced apoptosis and completely suppressed invasive tumour growth. 
Imatinib 
The presence of c-kit and PDGF on the surface of at least some melanomas encouraged the 
exploration of these agents in melanoma patients. Imatinib is known as a c-kit and PDGF 
inhibitor.  But an imatinib phase II study showed no objective clinical responses and no 
patient was progression-free at 6 months. Moreover, significant grade 3 and 4 toxicity was 
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observed (Sosman & Puzanov, 2011). Based on the results, it was concluded that imatinib is 
inactive as single-agent therapy for metastatic melanoma. 
Erlotinib 
Erlotinib is a small-molecule inhibitor specific for the EGFR kinase, based on competing 
with ATP for binding to the intracellular catalytic domain of the receptor kinase, thereby 
inhibiting autophosphorylation of the receptor critical for binding to downstream signalling 
proteins. Whereas no influence on tumour cell proliferation was seen with erlotinib 
monotherapy, preclinical studies demonstrated decreased invasive potential of its 
combination with bevacizumab (anti-VEGF therapy), providing promising rationale for 
clinical studies. 
2.4.3 Reversing resistance to apoptosis 
One of the major consequences of the constitutive activation of the MAPK and PI3K/AKT 
pathways is the induction of tumour cell resistance to apoptosis. This resistance is believed 
to be an element of the resistance of melanoma to the classical therapy. Members of the anti-
apoptotic Bcl-2 family have been successfully targeted to render tumour cells more 
susceptible to apoptosis. 
Oblimersen sodium is an anti-Bcl-2 oligonucleotide that selectively targets Bcl-2 RNA for 
degradation by RNase H, thereby decreasing Bcl-2 protein production. Although the drug 
did not increase overall survival, the application was associated with a significant increase 
of durable response (exceeding 6 months). The use of oblimersen can improve multiple 
outcomes in patients with advanced melanoma in combination with dacarbazine. The 
adverse effects of the therapy include fever, neutropenia and thrombocytopenia (Tawbi & 
Nimmagadda, 2009). 
Another targeted molecule of this class is survivin, which has been found to be highly 
expressed in most cancers. YM155 is a small molecule that has been demonstrated in 
preclinical models to suppress the function of survivin. 
2.4.4 Inhibitors of the proteasome 
The proteasome is a multienzyme complex that serves as a major protein in degradation 
pathway. The proteasome controls the levels of proteins that are important for cell cycle 
progression and apoptosis including cyclins, caspases, Bcl-2, and NF-kappaB. In cancers, 
deregulation of the ubiquitin-proteasome pathway may contribute to tumour progression, 
drug resistance and altered immune surveillance. Bortezomib was identified as a leading 
candidate of proteasome inhibitors correlated with growth-inhibitory effect. But a phase II 
study of bortezomib was terminated due to a lack of responses, and it was concluded that 
single-agent bortezomib administration was not efficacious in metastatic melanoma. 
Patients demonstrated grade 3 toxicity including sensory neuropathy, thrombocytopenia, 
constipation, fatigue, ileus and infections without neutropenia. 
2.4.5 Anti-angiogenic therapy 
Targeting tumour angiogenesis has several advantages over standard chemotherapy 
including independence on tumour cell resistance, broad applicability to tumour of different 
histogenesis and the potential to develop very specific therapies with minimal toxicities, 
because neoangiogenesis is not required for normal adult tissues. Because VEGF has a key 
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role in tumour angiogenesis, numerous compounds have been developed to counteract its 
angiogenic effect. 
Bevacizumab 
Bevacizumab is an anti-VEGF monoclonal antibody, received FDA approval for colorectal 
cancer therapy in US in 2005 (Kirkwood et al., 2006).  Bevacizumab is currently being tested 
in metastatic melanoma. The effect of bevacizumab on tumour cells is indirect and not 
necessarily lethal with no direct anti-proliferative effect. This is probably why as a single 
agent it is not very active, but bevacizumab therapy seems to be promising when combined 
with anti-proliferative agents. It is combined with low- and high-dose IFN-alpha. This  
chemotherapy is comprised of  carboplatin and paclitaxel, imatinib mesylate, and lastly with 
erlotinib. The addition of bevacizumab to conventional chemotherapy has been shown to 
control tumour growth and progression more effectively than chemotherapy alone. This is 
probably explained by bevacizumab´s ability to dampen the effect of VEGF up-regulation 
induced by chemotherapy. Adverse response include infrequently increased risk of grade 
3/4 hypertension, but also bleeding relating death was documented (Yang et al., 2010). 
Anti-angiogenic  isoforms of VEGF 
These isoforms are generated by differential splicing of exon 8 being widely expressed in 
normal human tissue but down-regulated in cancer. Endogenous anti-angiogenic VEGF 
isoforms are cytoprotective for endothelial, epithelial and neuronal cells suggesting both an 
improved safety profile and an explanation for unpredictable anti-VEGF side effects. It has 
been demonstrated that administration of recombinant VEGF(165)b inhibits angiogenesis in 
colorectal carcinoma and malignant melanoma. Splicing factors and their regulatory 
molecules alter splice site selection and cells can switch from the anti-angiogenic VEGF 
isoforms to the pro-angiogenic ones. Splice site selection in cancer opens up the possibility 
of using splicing factor inhibitors as novel anti-angiogenic therapeutics. 
Thalidomide  
The precise mechanism of thalidomide anti-angiogenic activity remains unknown, however 
some of its effect may result from blocking angiogenic factors such as VEGF. Thalidomide 
has also been suggested to have immunomodulating effect by decreasing cyclooxygenase-2 
activity. Thalidomide is a potent inhibitor TNF-alpha and decreases the density of 
TNF-alpha induced adhesion molecules such as ICAM-1 and VCAM. Thalidomide also 
causes induction of NK (natural killer) cells and increases the levels of IL-1, IL-2 receptors 
and INF-gamma leading to tumour cell lysis and modulates immune system to induce 
anticancer activity. Thalidomide has also antiproliferative and proapototic properties 
through induction of cell growth arrest at the G1 phase, downregulation of NF-kappaB and 
activation of caspase 8 (Tawbi & Nimmagada, 2009). Because thalidomide alone showed 
poor activity, various combination have been used in metastatic melanoma. 
The combinations, however, failed to demonstrate clinical efficacy. 
The main toxicities are dose-dependent neuropathy, constipation, anorexia, skin rash, 
fatigue, but to the most serious belong deep venous thrombosis and pulmonary embolism. 
Vitaxin (MEDI-552) 
Vitaxin is a monoclonal antibody targeted against the αvβ3 integrin expressed by 
endothelial and melanoma cells but not by normal melanocytes. Tumours from patients 
with stage IV melanoma seem to express  the integrin more intensely. MEDI-552 potentially 
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role in tumour angiogenesis, numerous compounds have been developed to counteract its 
angiogenic effect. 
Bevacizumab 
Bevacizumab is an anti-VEGF monoclonal antibody, received FDA approval for colorectal 
cancer therapy in US in 2005 (Kirkwood et al., 2006).  Bevacizumab is currently being tested 
in metastatic melanoma. The effect of bevacizumab on tumour cells is indirect and not 
necessarily lethal with no direct anti-proliferative effect. This is probably why as a single 
agent it is not very active, but bevacizumab therapy seems to be promising when combined 
with anti-proliferative agents. It is combined with low- and high-dose IFN-alpha. This  
chemotherapy is comprised of  carboplatin and paclitaxel, imatinib mesylate, and lastly with 
erlotinib. The addition of bevacizumab to conventional chemotherapy has been shown to 
control tumour growth and progression more effectively than chemotherapy alone. This is 
probably explained by bevacizumab´s ability to dampen the effect of VEGF up-regulation 
induced by chemotherapy. Adverse response include infrequently increased risk of grade 
3/4 hypertension, but also bleeding relating death was documented (Yang et al., 2010). 
Anti-angiogenic  isoforms of VEGF 
These isoforms are generated by differential splicing of exon 8 being widely expressed in 
normal human tissue but down-regulated in cancer. Endogenous anti-angiogenic VEGF 
isoforms are cytoprotective for endothelial, epithelial and neuronal cells suggesting both an 
improved safety profile and an explanation for unpredictable anti-VEGF side effects. It has 
been demonstrated that administration of recombinant VEGF(165)b inhibits angiogenesis in 
colorectal carcinoma and malignant melanoma. Splicing factors and their regulatory 
molecules alter splice site selection and cells can switch from the anti-angiogenic VEGF 
isoforms to the pro-angiogenic ones. Splice site selection in cancer opens up the possibility 
of using splicing factor inhibitors as novel anti-angiogenic therapeutics. 
Thalidomide  
The precise mechanism of thalidomide anti-angiogenic activity remains unknown, however 
some of its effect may result from blocking angiogenic factors such as VEGF. Thalidomide 
has also been suggested to have immunomodulating effect by decreasing cyclooxygenase-2 
activity. Thalidomide is a potent inhibitor TNF-alpha and decreases the density of 
TNF-alpha induced adhesion molecules such as ICAM-1 and VCAM. Thalidomide also 
causes induction of NK (natural killer) cells and increases the levels of IL-1, IL-2 receptors 
and INF-gamma leading to tumour cell lysis and modulates immune system to induce 
anticancer activity. Thalidomide has also antiproliferative and proapototic properties 
through induction of cell growth arrest at the G1 phase, downregulation of NF-kappaB and 
activation of caspase 8 (Tawbi & Nimmagada, 2009). Because thalidomide alone showed 
poor activity, various combination have been used in metastatic melanoma. 
The combinations, however, failed to demonstrate clinical efficacy. 
The main toxicities are dose-dependent neuropathy, constipation, anorexia, skin rash, 
fatigue, but to the most serious belong deep venous thrombosis and pulmonary embolism. 
Vitaxin (MEDI-552) 
Vitaxin is a monoclonal antibody targeted against the αvβ3 integrin expressed by 
endothelial and melanoma cells but not by normal melanocytes. Tumours from patients 
with stage IV melanoma seem to express  the integrin more intensely. MEDI-552 potentially 
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blocks tumour growth causing cell apoptosis and impairment of angiogenesis. The drug 
alone showed no objective response, whereas the combination with chemotherapy 
demonstated mild response rate. Grade 3  and 4 adverse events were chiefly neutropenia 
and thrombocytopenia (Sosman & Puzanov, 2011). 
2.4.6 Immunotherapy   
IL-2 is a potent immune modulator that stimulates activation and proliferation of 
T lymphocytes. Treatment with high-dose IL-2 leads to objective tumour responses. 
Treatment is typically reserved for younger, fitter patients and requires intensive 
monitoring. The therapy is associated with substantial toxicity including oliguria, renal 
failure, hepatotoxicity, edema, sepsis, and death  (Algazi et al., 2010). 
IL-2 with peptide vaccination 
Recent data suggest that vaccination against the melanoma peptide antigen gp-100 may 
improve the efficacy of high-dose IL-2 (Algazi et al., 2010). 
Anti-CTLA4 antibodies 
The T cell surface protein, CTLA4, competes with CD28 for B7. It is a second surface protein of 
antigen presenting cells that acts as a costimulatory molecule for T lymphocytes. Binding of 
CTLA4 to B7 inhibits T-cell proliferation, thus anti-CTLA4 antibodies have been developed to 
abrogate these inhibitory interactions and break immune tolerance to melanoma. Ipilimumab 
is an anti-CTLA4 antibody that have led to modest rates of objective tumour response. 
Common observed toxicities included grade 3 and 4 immune-related events such as colitis, 
dermatitis, hepatitis, acute pancreatitis and hypophysitis (Di Giacomo et al., 2011). 
Combined approaches are already being tested. Some of the most promising combination 
development are listed in Table 2. All trials are planned with an emphasis on tumour 
biology. Molecular characterization of the tumour before the therapy followed by treatment 
examining inhibitory effects on the targets will be critical to understand the clinical results. 
 
Sorafenib + bevacizumab 
Sorafenib + CCI-779 
Sorafenib + R115777 
Bevacizumab + CCI-779 
Bevacizumab + R115777  
Table 2. The most promising combinations  for melanoma therapy 
3. Conclusions 
Stroma alterations in malignant melanoma are observed already in early stage tumours and 
are further cumulated as tumours progress. A deeper understanding the factors modulating 
melanoma microenvironment is necessary and would potentially lead to a new therapeutic 
approach. 
4. Acknowledgement 
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1. Introduction   
Tumour metastasis is the primary cause of death in cancer patients, and cutaneous 
melanoma is one of the most highly metastatic cancers. While early stage melanomas are 
almost always curable, despite new and promising treatments (Flaherty et al., 2010; Hodi et 
al., 2010), advanced unresectable melanomas (Stage III and IV) have a much worse 
prognosis (Shivers et al., 1998). Similarly, once uveal melanomas have metastasized, they are 
irremediably lethal (Kivela et al., 2006).  
Until recently, tumour cell dissemination was thought to be a late event in cancer 
progression (Fearon and Vogelstein, 1990). But the advent of sensitive and reliable 
techniques for detecting circulating tumour cells has revealed that tumour cells can 
disseminate long before the primary tumour reaches a clinically detectable size. A growing 
body of convergent studies, including those from our laboratory, confirms this finding in 
both mice and humans. 
If some cancer cells disseminate before diagnosis and if metastases develop from these 
disseminated cancer cells, how can the treatment of the primary tumour impact disease 
progression? Or might it be more efficient to focus therapeutic intervention on the control of 
the disseminated cancer cells? 
This new paradigm of early dissemination implies that disseminated cancer cells remain 
dormant or under control for prolonged periods of time, often for decades, before 
developing into overt metastases. It is not yet clear why only some disseminated cancer cells 
develop into metastases and why not all patients with disseminated cancer cells develop 
metastatic disease. Tumour-initiating cells may only represent a small fraction of 
disseminated cancer cells, as proposed by the cancer stem cell hypothesis. Alternatively, 
disseminated cancer cells may require additional adaptation to their new environment or 
specific signals delivered by their new environment to exit from dormancy (the metastatic 
niche model). It is certain that the immune system plays a crucial role in controlling the 
dormancy of disseminated cancer cells, since both acquired and iatrogenic immune 
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suppression accelerates the development of metastases. A better understanding of the 
immune mechanisms keeping disseminated melanoma cells in a state of dormancy could 
lead to the development of interventions to help to slow down cancer progression, improve 
the treatment of advanced melanomas and increase patient survival. In this regard, 
immunotherapies such as cancer vaccines or anti-CTLA4 monoclonal antibodies (which 
prevent T lymphocyte anergy) are likely to be most successful if used to delay the onset of 
metastasis in patients with dormant disseminated cancer cells and minimal disease. 
In this chapter, we will review our current understanding of the metastatic process and 
discuss possible therapeutic implications. We will address some of the key questions arising 
from recent data, and their relevance to the treatment of patients. For example, if metastases 
derive from cancer cells that have already disseminated at the time of diagnosis, how do the 
size of the primary tumour and the extent of lymph node invasion still predict survival? Are 
there any features of the primary tumour that correlate with early dissemination, or does the 
primary tumour itself contribute to the growth of disseminated cancer cells? And how do 
the answers to these questions impact on our ability to understand which individuals will 
develop metastatic disease and how to best manage patients for maximum survival benefit? 
2. The process of metastasis 
Metastasis is a multistep process in which cancer cells derived from the primary tumour 
migrate to regional or distant sites where they reinitiate their development (Chiang and 
Massague, 2008). Cancer cells can disseminate directly through the blood or may enter the 
circulatory system via the lymphatics (Wong and Hynes, 2006). While tumour cells are 
reliant on the blood for their dissemination, the circulatory system is essentially a hostile 
environment; intravenously injected cancer cells are cleared after just a few days. To 
successfully use the blood circulation to colonize a new site, cancer cells must enter the 
vessel, brave the substantial shear forces of the blood flow and then arrest their movement 
in order to extravasate and invade the tissue. Lymph may be gentler to disseminated cancer 
cells, in part because shearing forces there are lower, but lymph nodes may serve as filters. 
Each type of cancer exhibits a preferred metastatic profile. For example ocular melanomas 
typically metastasize to the liver; cutaneous melanomas prefer the skin, lungs, liver, bones 
and brain; while prostate cancers often spread to the bones, liver, brain and lung (Weinberg, 
2007). The reasons underlying such preferences for different metastatic sites are important to 
understand. In some cases the sites where circulating cancer cells stop may be determined 
by physical restrictions imposed by the vasculature. For example, large cancer cells might be 
more likely to be arrested in small lung capillaries. Alternatively, chemokines may be 
exploited by tumour cells in order to actively target specific organs; breast cancer cells 
expressing CXCR4 are preferentially attracted to organs expressing the CXCR4 ligand 
CXCL12 (Helbig et al., 2003; Muller et al., 2001). Similarly, expression of CCR7 by B16 
melanoma cells increases their homing to lymph nodes and the outgrowth of lymph node 
metastases (Wiley et al., 2001). However, homing is only a small part of determining the 
eventual pattern of metastasis, as the ability of the cancer cells to survive and proliferate in 
their ectopic location is a key factor. This is evidenced by the fact that less than 0.01% of 
circulating cancer cells will successfully develop into metastases (Chambers et al., 2002; 
Luzzi et al., 1998). As originally hypothesized in 1889 by Paget, circulating cancer cells will 
only develop into overt metastasis if they encounter a favourable environment (Paget, 1989). 
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This has been clearly demonstrated in the RETAAD model of melanoma. RETAAD mice are 
transgenic for the human RET oncogene, which is specifically expressed in melanocytes. 
These fully immune-competent mice develop spontaneous uveal melanoma. While cancer 
cells derived from the primary eye tumor disseminate to all tested organs and tissues, 
metastases develop almost exclusively in the skin, muscles, lungs and reproductive tract 
(Eyles et al., 2010). 
3. Initial routes of dissemination 
Cancer cells disseminate through the blood and the lymph, although it can be challenging to 
discern which route is preferred by different tumours. Cutaneous melanomas were thought 
to disseminate mainly through the lymph, but some visceral metastases occur without 
lymph node invasion. In addition, it had been claimed that ocular melanoma disseminates 
exclusively through the blood (Clarijs et al., 2001), however, data from both humans and 
mice now indicate dissemination via the lymph as well (Boonman et al., 2004; Harris et al., 
2007). Tumour growth itself is associated with profound alterations of the blood and lymph 
vessels that may be advantageous to disseminating cells. The growth of a tumour requires 
the development of new blood vessels in and around the lesion. These newly-generated 
vessels convey nutrients and oxygen to the growing tumour, but are also used by cancer 
cells to escape the primary tumour and disseminate. The relatively high leakiness of 
tumour-associated blood vessels may also facilitate cancer cell intravasation. Similarly, 
tumour growth is associated with lymphangiogenesis (the growth of lymphatic vessels) 
both within and around the tumour and in the tumour-draining lymph node. Using the 
RETAAD model of spontaneous melanoma, we found that the growth of lymphatic vessels 
precedes melanoma cell migration to the draining lymph node and correlates with the size 
of the primary tumour. This suggests that the primary tumour secretes factors which favour 
lymphangiogenesis in the draining lymph node. Tumour tissues are also chronically 
inflamed, and inflammation encourages both angiogenesis and lymphangiogenesis. This 
may, at least in part, contribute to the well-established link between tumour inflammation 
and cancer progression. It is therefore reasonable to consider that melanomas can 
disseminate through the lymph or through the blood and that the actual route of 
dissemination may vary according to local conditions. 
4. Early cancer cell dissemination 
Until recently, cancer cell dissemination was thought to be a late event in disease 
progression (Fearon and Vogelstein, 1990; Fidler and Hart, 1982; Fidler and Kripke, 1977). 
Metastasis was believed to occur once the primary tumour had reached a certain size.  
Indeed the risk of metastatic disease increases with the size of the primary tumour. The 
recent advent of sensitive and reliable techniques to detect circulating tumour cells has 
revealed that tumour cells can in fact disseminate long before the primary tumour reaches a 
clinically detectable size (Pantel and Brakenhoff, 2004; Wharton et al., 1999). In the RETAAD 
model, melanoma cells can be detected in all tissues and organs by the time mice are two 
weeks of age, while the primary tumour is only visible after 5 to 8 weeks. In human uveal 
melanoma, calculation of tumour doubling times also suggests that metastases derive from 
tumour cells that disseminate on average three years before the primary tumour is 
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suppression accelerates the development of metastases. A better understanding of the 
immune mechanisms keeping disseminated melanoma cells in a state of dormancy could 
lead to the development of interventions to help to slow down cancer progression, improve 
the treatment of advanced melanomas and increase patient survival. In this regard, 
immunotherapies such as cancer vaccines or anti-CTLA4 monoclonal antibodies (which 
prevent T lymphocyte anergy) are likely to be most successful if used to delay the onset of 
metastasis in patients with dormant disseminated cancer cells and minimal disease. 
In this chapter, we will review our current understanding of the metastatic process and 
discuss possible therapeutic implications. We will address some of the key questions arising 
from recent data, and their relevance to the treatment of patients. For example, if metastases 
derive from cancer cells that have already disseminated at the time of diagnosis, how do the 
size of the primary tumour and the extent of lymph node invasion still predict survival? Are 
there any features of the primary tumour that correlate with early dissemination, or does the 
primary tumour itself contribute to the growth of disseminated cancer cells? And how do 
the answers to these questions impact on our ability to understand which individuals will 
develop metastatic disease and how to best manage patients for maximum survival benefit? 
2. The process of metastasis 
Metastasis is a multistep process in which cancer cells derived from the primary tumour 
migrate to regional or distant sites where they reinitiate their development (Chiang and 
Massague, 2008). Cancer cells can disseminate directly through the blood or may enter the 
circulatory system via the lymphatics (Wong and Hynes, 2006). While tumour cells are 
reliant on the blood for their dissemination, the circulatory system is essentially a hostile 
environment; intravenously injected cancer cells are cleared after just a few days. To 
successfully use the blood circulation to colonize a new site, cancer cells must enter the 
vessel, brave the substantial shear forces of the blood flow and then arrest their movement 
in order to extravasate and invade the tissue. Lymph may be gentler to disseminated cancer 
cells, in part because shearing forces there are lower, but lymph nodes may serve as filters. 
Each type of cancer exhibits a preferred metastatic profile. For example ocular melanomas 
typically metastasize to the liver; cutaneous melanomas prefer the skin, lungs, liver, bones 
and brain; while prostate cancers often spread to the bones, liver, brain and lung (Weinberg, 
2007). The reasons underlying such preferences for different metastatic sites are important to 
understand. In some cases the sites where circulating cancer cells stop may be determined 
by physical restrictions imposed by the vasculature. For example, large cancer cells might be 
more likely to be arrested in small lung capillaries. Alternatively, chemokines may be 
exploited by tumour cells in order to actively target specific organs; breast cancer cells 
expressing CXCR4 are preferentially attracted to organs expressing the CXCR4 ligand 
CXCL12 (Helbig et al., 2003; Muller et al., 2001). Similarly, expression of CCR7 by B16 
melanoma cells increases their homing to lymph nodes and the outgrowth of lymph node 
metastases (Wiley et al., 2001). However, homing is only a small part of determining the 
eventual pattern of metastasis, as the ability of the cancer cells to survive and proliferate in 
their ectopic location is a key factor. This is evidenced by the fact that less than 0.01% of 
circulating cancer cells will successfully develop into metastases (Chambers et al., 2002; 
Luzzi et al., 1998). As originally hypothesized in 1889 by Paget, circulating cancer cells will 
only develop into overt metastasis if they encounter a favourable environment (Paget, 1989). 
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This has been clearly demonstrated in the RETAAD model of melanoma. RETAAD mice are 
transgenic for the human RET oncogene, which is specifically expressed in melanocytes. 
These fully immune-competent mice develop spontaneous uveal melanoma. While cancer 
cells derived from the primary eye tumor disseminate to all tested organs and tissues, 
metastases develop almost exclusively in the skin, muscles, lungs and reproductive tract 
(Eyles et al., 2010). 
3. Initial routes of dissemination 
Cancer cells disseminate through the blood and the lymph, although it can be challenging to 
discern which route is preferred by different tumours. Cutaneous melanomas were thought 
to disseminate mainly through the lymph, but some visceral metastases occur without 
lymph node invasion. In addition, it had been claimed that ocular melanoma disseminates 
exclusively through the blood (Clarijs et al., 2001), however, data from both humans and 
mice now indicate dissemination via the lymph as well (Boonman et al., 2004; Harris et al., 
2007). Tumour growth itself is associated with profound alterations of the blood and lymph 
vessels that may be advantageous to disseminating cells. The growth of a tumour requires 
the development of new blood vessels in and around the lesion. These newly-generated 
vessels convey nutrients and oxygen to the growing tumour, but are also used by cancer 
cells to escape the primary tumour and disseminate. The relatively high leakiness of 
tumour-associated blood vessels may also facilitate cancer cell intravasation. Similarly, 
tumour growth is associated with lymphangiogenesis (the growth of lymphatic vessels) 
both within and around the tumour and in the tumour-draining lymph node. Using the 
RETAAD model of spontaneous melanoma, we found that the growth of lymphatic vessels 
precedes melanoma cell migration to the draining lymph node and correlates with the size 
of the primary tumour. This suggests that the primary tumour secretes factors which favour 
lymphangiogenesis in the draining lymph node. Tumour tissues are also chronically 
inflamed, and inflammation encourages both angiogenesis and lymphangiogenesis. This 
may, at least in part, contribute to the well-established link between tumour inflammation 
and cancer progression. It is therefore reasonable to consider that melanomas can 
disseminate through the lymph or through the blood and that the actual route of 
dissemination may vary according to local conditions. 
4. Early cancer cell dissemination 
Until recently, cancer cell dissemination was thought to be a late event in disease 
progression (Fearon and Vogelstein, 1990; Fidler and Hart, 1982; Fidler and Kripke, 1977). 
Metastasis was believed to occur once the primary tumour had reached a certain size.  
Indeed the risk of metastatic disease increases with the size of the primary tumour. The 
recent advent of sensitive and reliable techniques to detect circulating tumour cells has 
revealed that tumour cells can in fact disseminate long before the primary tumour reaches a 
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model, melanoma cells can be detected in all tissues and organs by the time mice are two 
weeks of age, while the primary tumour is only visible after 5 to 8 weeks. In human uveal 
melanoma, calculation of tumour doubling times also suggests that metastases derive from 
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diagnosed (Eskelin et al., 2000). Moreover, at the time of dissemination, the size of the 
primary tumour represents less than 1% of its final size at the time of diagnosis. Even 
though 98% of patients are free of metastasis at the time of surgery, about 50% of them will 
eventually succumb to metastatic disease (Eskelin et al., 2000). Similar conclusions have 
been reached in other types of cancer. For example, whole exome sequencing of pancreatic 
tumours has confirmed that metastases derive from cells that disseminate roughly three 
years before diagnosis (Luebeck, 2010). Strikingly, Vinokurava et al. reported five cases of 
patients with non-invasive cervical intraepithelial neoplasia (CIN) who relapsed 4 to 12 
years after radical hysterectomy. Cervical tumours are caused by random integration of the 
human papilloma virus (HPV) genome, and mapping the site of HPV integration confirmed 
a common clonal origin of the primary lesions (CIN) and  metachronous metastases 
(Vinokurova et al., 2005). Remarkably this implies that transformed cells can even spread 
from pre-invasive cervical lesions, and go on to cause clinical disease. In summary, a 
growing body of convergent findings in both mice and humans shows that tumour cell 
dissemination can be an early event in cancer progression and sometimes occurs even before 
the primary tumour is diagnosed. 
5. What drives cancer cell dissemination? 
Cancer cells within the primary tumour compete with each other for space and nutrients. 
The evolution of cancer cells is therefore likely to be affected by this competition, and 
selection should favour cancer cells with advantageous characteristics (Gatenby and Gillies, 
2008). What could be the selective pressure responsible for the early acquisition of a motile 
phenotype by the cancer cells in the primary tumour? If disseminated cancer cells remain 
dormant for prolonged periods of time, metastasis is unlikely to be positively selected: 
selection is blind to the future. Perhaps unexpectedly, hints may come from the analysis of 
tumour shapes. Primary tumours often display a multinodular, papilloma-like structure. 
The shape of the primary tumour correlates with the risk of disease progression (Goutzanis 
et al., 2008; Tambasco and Magliocco, 2008) and is therefore linked to metastatic propensity. 
In silico modelling suggests that tumour multinodularity results from the competition 
among cancer cells for nutrients (Ferreira et al., 2002; Mallet and De Pillis, 2006). This 
competition is particularly keen in non-vascularised tumours. We showed that such 
multinodular growth is determined by intercellular adhesion, adhesion between cells and 
the extra-cellular matrix and cancer cell motility (Narang, 2011). Importantly, these in silico 
models show that under nutrient-limited conditions, tumour growth is faster if it is 
multinodular. Therefore, acquisition of a metastatic phenotype could be selected because it 
favours the growth of the primary tumour (Norton, 2005); dissemination would be more of 
an accidental by-product resulting from the acquisition of cellular behaviours aimed at 
benefitting the primary tumour. This would explain why the risk of metastasis correlates 
with primary tumour size. 
6. Cancer cell dissemination and mesenchymal transition 
In order to disseminate, cancer cells need to detach from the primary tumour and become 
motile. Cancer cells must therefore decrease expression of various adhesion molecules such 
as cadherins and catenins, increase expression of proteases (e.g. matrix metalloproteinases 
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or MMP) able to degrade the extracellular matrix, and enhance their motility. So how do 
cancer cells simultaneously acquire this panel of phenotypic changes? Epithelial to 
Mesenchymal transition (EMT) is often considered the first step of cancer cell progression 
toward metastasis. The term EMT traditionally refers to the formation of mesenchymal cells 
(loosely adherent, often motile cells embedded in the extracellular matrix) from a primitive 
epithelium during embryonic development (Thiery, 2002). The process of EMT is associated 
with down-regulation of cell surface molecules involved in intercellular contacts and up-
regulation of mesenchymal markers (vimentin, N-cadherin). Similar changes are indeed 
observed during carcinoma progression. It is therefore likely that the mechanism by which 
sessile carcinoma cells become motile resembles EMT. Even though melanocytes are not of 
epithelial origin, expression of mesenchymal markers correlates with tumour aggressiveness 
and propensity to metastasize. 
Melanocytes and melanocyte stem cells derive from melanoblasts, a non-pigmented cell 
population which migrates from the neural crest during embryonic development (Thomas 
and Erickson, 2008). Therefore, acquisition of a motile phenotype by melanoma cells only 
requires re-expression of a previously silenced pathway. Weinberg and coll. have shown 
that ectopic expression of just a few genes in human melanocytes was sufficient to make 
them tumourigenic and highly metastatic (Gupta et al., 2005). The same set of genes 
transferred into fibroblasts or epithelial cells resulted in only localized tumour formation. 
Therefore, cells of melanocytic origin are more prone to undergo mesenchymal transition, 
and lineage-specific factors contribute to the tendency of melanoma to metastasize.  
7. Clinical relevance 
If cancer cell dissemination can occur early on during disease development, it is likely that 
many patients already have cancer cells disseminated throughout their body at diagnosis. A 
recent meta-analysis including 38,918 patients with cutaneous melanoma showed that patients 
whose primary tumour had a Breslow’s thickness above 1 mm, was ulcerated and/or had a 
mitotic index above 1 mitose /mm2 were at higher risk of melanoma-related death, even in the 
absence of invaded nodes and metastasis (Balch et al., 2009). Because metastases have a long 
latency period, it has been hypothesized that these early disseminating cancer cells were 
unable to develop into metastases, supporting the traditional notion that the spread of cells 
causing metastases occurred late during disease. Accordingly, accumulation of additional 
genetic changes would be required for the development of full-blown metastatic potential. 
However, recent studies in mouse models of breast cancer and melanoma have shown that 
early disseminating cancer cells are fully competent to develop into metastases (Eyles et al., 
2010; Husemann et al., 2008). Moreover, genetic comparison of primary human tumours, 
disseminated cancer cells and metastases confirmed that metastases do derive from early 
disseminating cancer cells (Klein, 2009). The interesting question of the factors controlling this 
long-term latency of early disseminated tumour cells is then raised. The immune system is 
likely to play a major role, but if so, does the treatment of the primary tumour impact disease 
progression and is there really any benefit from removing the tumour-draining lymph node? 
More than 30 years ago, B. Fisher predicted that if cancer (in this case, breast cancer) were a 
systemic disease from its inception, the extent of local treatment should not affect patient 
survival (Fisher, 1980). Several of his predictions also hold true for melanoma, in particular for 
primary tumours presenting with pejorative prognostic factors. 
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or MMP) able to degrade the extracellular matrix, and enhance their motility. So how do 
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(loosely adherent, often motile cells embedded in the extracellular matrix) from a primitive 
epithelium during embryonic development (Thiery, 2002). The process of EMT is associated 
with down-regulation of cell surface molecules involved in intercellular contacts and up-
regulation of mesenchymal markers (vimentin, N-cadherin). Similar changes are indeed 
observed during carcinoma progression. It is therefore likely that the mechanism by which 
sessile carcinoma cells become motile resembles EMT. Even though melanocytes are not of 
epithelial origin, expression of mesenchymal markers correlates with tumour aggressiveness 
and propensity to metastasize. 
Melanocytes and melanocyte stem cells derive from melanoblasts, a non-pigmented cell 
population which migrates from the neural crest during embryonic development (Thomas 
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that ectopic expression of just a few genes in human melanocytes was sufficient to make 
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transferred into fibroblasts or epithelial cells resulted in only localized tumour formation. 
Therefore, cells of melanocytic origin are more prone to undergo mesenchymal transition, 
and lineage-specific factors contribute to the tendency of melanoma to metastasize.  
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latency period, it has been hypothesized that these early disseminating cancer cells were 
unable to develop into metastases, supporting the traditional notion that the spread of cells 
causing metastases occurred late during disease. Accordingly, accumulation of additional 
genetic changes would be required for the development of full-blown metastatic potential. 
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disseminated cancer cells and metastases confirmed that metastases do derive from early 
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long-term latency of early disseminated tumour cells is then raised. The immune system is 
likely to play a major role, but if so, does the treatment of the primary tumour impact disease 
progression and is there really any benefit from removing the tumour-draining lymph node? 
More than 30 years ago, B. Fisher predicted that if cancer (in this case, breast cancer) were a 
systemic disease from its inception, the extent of local treatment should not affect patient 
survival (Fisher, 1980). Several of his predictions also hold true for melanoma, in particular for 
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8. Tumour excision 
It has been known for more than 50 years that melanoma cells often disseminate locally (up 
to 5 cm away) around the primary tumour. Initially it seemed logical to excise these distant 
cells by using a large enough surgical margin. A first randomised prospective trial was 
conducted in the 1970’s to determine whether there was any significant clinical benefit 
associated with a 5 cm margin excision compared to a 2 cm margin (Wargo and Tanabe, 
2009). No statistically significant difference was observed in distant metastases or overall 
survival. This conclusion was counter-intuitive and difficult to accept, and so at least four 
other prospective randomized studies were conducted between 1980 and 2000 to determine 
the optimal margin of excision for cutaneous melanomas (Balch et al., 2001; Balch et al., 
1993; Cohn-Cedermark et al., 2000; Ringborg et al., 1996; Thomas et al., 2004; Veronesi and 
Cascinelli, 1991; Veronesi et al., 1988). These trials compared various margins from 1 to 5 
cm, in melanomas of different thickness and in a total of 2,861 patients. None of these trials 
found any survival benefit associated with the larger excision. Similarly, the survival of 
patients with anal melanoma is not different whether they are treated by local tumour 
excision or rectal resection (Kiran et al., 2010). Regardless, the consensus in clinical practice 
is to use large margins to excise thick primary tumours.  
Besides their obvious implications for melanoma management, these observations lead to 
important theoretical conclusions. There is no doubt that some cancer cells are left behind 
after a narrow excision of the primary tumour, but the patient is able to control these cancer 
cells to the extent that they do not affect patient survival. Alternatively, these cells may not 
play a major role in the development of the distant metastases that cause patient death 
because metastases develop from cancer cells that have already disseminated at the time of 
surgery, and not from residual cancer cells left in the vicinity of the primary tumour. But 
since surgery cures most early stage patients, one has to conclude that only some primary 
tumours have the properties that favour metastases, and that most patients are able to 
control the disseminated cancer cells. A systemic biological process, for example the 
immune system, is therefore able to prevent the proliferation of cancer cells, provided they 
are not too numerous. 
9. Sentinel lymph node biopsy 
Infiltration of melanoma cells in the tumour-draining lymph node has also been extensively 
studied. The results of sentinel lymph node biopsy followed by examination using H&E 
stains and immunohistochemistry is one of the most reliable predictors of patient survival. 
However, it is now recognized that not all tumour-draining lymph nodes containing 
disseminated cancer cells will progress into palpable metastases. The number and 
localisation of the disseminated cancer cells within the lymph node seem to be important. In 
one study, 50% of patients with thin primary tumours had tumour-draining lymph nodes 
containing melanoma cells, as judged by RT-PCR, but 85% of them survived more than 5 
years (Shivers et al., 1998). In addition, the melanoma-specific survival of patients with 
subcapsular deposits less than 1 mm in diameter is the same as that of patients with 
negative lymph nodes (Starz et al., 2004). However it is not clear whether these few cells are 
fully-fledged melanoma cells or whether they represent sub-capsular nevi. In any case, the 
patient’s own immune system is probably able to cope with a limited number of cancer cells 
disseminated in the draining lymph node. One could even argue that the presence of cancer 
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cells in the draining lymph node might facilitate the induction of an anti-melanoma immune 
response (Ochsenbein et al., 2001). Using various mouse tumour models, including the B16 
melanoma model, these authors suggested that tumour-specific induction of protective 
cytotoxic T cells (CTLs) could depend on sufficient tumour cells reaching secondary 
lymphatic organs. However, whether this finding holds for human tumours is unclear. 
For almost 20 years, patients with intermediate or thick primary melanomas (Breslow’s 
depth above 1 mm) have been advised to undergo sentinel lymph node biopsy (SLNBx) and 
this procedure has become a standard approach (Wargo and Tanabe, 2009). When metastatic 
cells are identified in the sentinel lymph node, a complete regional lymph node dissection 
(CRLND) is performed. Indeed, the result of SLNBx and CRLND accurately predicts patient 
survival. The 5-year survival of patients with positive SLNBx (72.3%) is significantly shorter 
than that of patients with negative SLNBx (90.2%; p<0.001) (Baldwin et al., 2010). In 
addition, the efficacy of adoptive immune therapy depends on the number of metastatic 
lymph nodes (Khammari et al., 2007). Patients presenting with a single metastatic lymph 
node benefit from adoptive treatment with tumour-infiltrating lymphocytes (prolonged 
overall survival p=0.0125; decreased relapse rate p=0.022), but not those with more than one 
invaded node. However, four controlled studies have shown that there is no survival benefit 
associated with early removal of non-palpable lymph nodes (Balch et al., 2000; Cascinelli et 
al., 1998; Sim et al., 1986; Veronesi et al., 1982; Zitelli, 2008). The prospective randomized 
Multi-centre Selective Lymphadenectomy Trial (MSLT-1), conducted between 1994 and 2002 
with 1269 patients, clearly confirmed that there is no survival benefit for patients 
undergoing wide excision and SLNBx with immediate CRLND if nodal micrometastases 
were detected compared to those undergoing wide excision and postoperative observation 
of regional lymph nodes with therapeutic lymph node dissection (lymphadenectomy) if 
nodal relapse occurred (Baldwin et al., 2010; Morton et al., 2006). The Sunbelt Melanoma 
trial analysed the survival of patients with minimal infiltration of the sentinel lymph node 
by melanoma cells. Patients whose SLNBx was negative by standard 
immunopathology/immunochemistry methods, but positive by RT-PCR, were randomized 
to observation or CRLND treatment; but interestingly, no difference in overall survival was 
found between the two groups (McMasters et al., 2001). In conclusion, while lymph node 
invasion correlates with shorter survival, early removal of non-palpable lymph nodes 
containing micrometastases does not improve survival. It is still unknown whether removal 
of palpable metastatic lymph nodes improves survival, but this question is being addressed 
by the MSLT-II trial.  
Similar conclusions have been reached in studies on other types of cancer. For example, 
Sleeman et al. analysed 7 randomized clinical studies, totalling 3,351 patients with breast 
cancer (Sleeman et al., 2011). None of these studies showed any overall survival or disease-
free survival benefit from removing tumour-draining lymph nodes. A recent report also 
compared 891 breast cancer patients with metastasis-containing sentinel lymph nodes 
undergoing either sentinel lymph node dissection alone or complete axillary lymph node 
dissection (Giuliano et al., 2011). Five years after surgery, no significant difference in the 
rates of overall survival (91.8% vs 92.5%) or disease-free survival (82.2% vs 83.9%) was 
observed.  In the same indication, Bidart et al. found that 82% of patients with tumour cells 
in the bone marrow do not relapse at least for the 6 years of the study (Bidard et al., 2008). 
Veronesi et al. performed a meta-analysis with an average follow up of 30 years. While the 
presence of tumour cells in the internal lymph nodes was a strong predictor of patient 
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8. Tumour excision 
It has been known for more than 50 years that melanoma cells often disseminate locally (up 
to 5 cm away) around the primary tumour. Initially it seemed logical to excise these distant 
cells by using a large enough surgical margin. A first randomised prospective trial was 
conducted in the 1970’s to determine whether there was any significant clinical benefit 
associated with a 5 cm margin excision compared to a 2 cm margin (Wargo and Tanabe, 
2009). No statistically significant difference was observed in distant metastases or overall 
survival. This conclusion was counter-intuitive and difficult to accept, and so at least four 
other prospective randomized studies were conducted between 1980 and 2000 to determine 
the optimal margin of excision for cutaneous melanomas (Balch et al., 2001; Balch et al., 
1993; Cohn-Cedermark et al., 2000; Ringborg et al., 1996; Thomas et al., 2004; Veronesi and 
Cascinelli, 1991; Veronesi et al., 1988). These trials compared various margins from 1 to 5 
cm, in melanomas of different thickness and in a total of 2,861 patients. None of these trials 
found any survival benefit associated with the larger excision. Similarly, the survival of 
patients with anal melanoma is not different whether they are treated by local tumour 
excision or rectal resection (Kiran et al., 2010). Regardless, the consensus in clinical practice 
is to use large margins to excise thick primary tumours.  
Besides their obvious implications for melanoma management, these observations lead to 
important theoretical conclusions. There is no doubt that some cancer cells are left behind 
after a narrow excision of the primary tumour, but the patient is able to control these cancer 
cells to the extent that they do not affect patient survival. Alternatively, these cells may not 
play a major role in the development of the distant metastases that cause patient death 
because metastases develop from cancer cells that have already disseminated at the time of 
surgery, and not from residual cancer cells left in the vicinity of the primary tumour. But 
since surgery cures most early stage patients, one has to conclude that only some primary 
tumours have the properties that favour metastases, and that most patients are able to 
control the disseminated cancer cells. A systemic biological process, for example the 
immune system, is therefore able to prevent the proliferation of cancer cells, provided they 
are not too numerous. 
9. Sentinel lymph node biopsy 
Infiltration of melanoma cells in the tumour-draining lymph node has also been extensively 
studied. The results of sentinel lymph node biopsy followed by examination using H&E 
stains and immunohistochemistry is one of the most reliable predictors of patient survival. 
However, it is now recognized that not all tumour-draining lymph nodes containing 
disseminated cancer cells will progress into palpable metastases. The number and 
localisation of the disseminated cancer cells within the lymph node seem to be important. In 
one study, 50% of patients with thin primary tumours had tumour-draining lymph nodes 
containing melanoma cells, as judged by RT-PCR, but 85% of them survived more than 5 
years (Shivers et al., 1998). In addition, the melanoma-specific survival of patients with 
subcapsular deposits less than 1 mm in diameter is the same as that of patients with 
negative lymph nodes (Starz et al., 2004). However it is not clear whether these few cells are 
fully-fledged melanoma cells or whether they represent sub-capsular nevi. In any case, the 
patient’s own immune system is probably able to cope with a limited number of cancer cells 
disseminated in the draining lymph node. One could even argue that the presence of cancer 
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cells in the draining lymph node might facilitate the induction of an anti-melanoma immune 
response (Ochsenbein et al., 2001). Using various mouse tumour models, including the B16 
melanoma model, these authors suggested that tumour-specific induction of protective 
cytotoxic T cells (CTLs) could depend on sufficient tumour cells reaching secondary 
lymphatic organs. However, whether this finding holds for human tumours is unclear. 
For almost 20 years, patients with intermediate or thick primary melanomas (Breslow’s 
depth above 1 mm) have been advised to undergo sentinel lymph node biopsy (SLNBx) and 
this procedure has become a standard approach (Wargo and Tanabe, 2009). When metastatic 
cells are identified in the sentinel lymph node, a complete regional lymph node dissection 
(CRLND) is performed. Indeed, the result of SLNBx and CRLND accurately predicts patient 
survival. The 5-year survival of patients with positive SLNBx (72.3%) is significantly shorter 
than that of patients with negative SLNBx (90.2%; p<0.001) (Baldwin et al., 2010). In 
addition, the efficacy of adoptive immune therapy depends on the number of metastatic 
lymph nodes (Khammari et al., 2007). Patients presenting with a single metastatic lymph 
node benefit from adoptive treatment with tumour-infiltrating lymphocytes (prolonged 
overall survival p=0.0125; decreased relapse rate p=0.022), but not those with more than one 
invaded node. However, four controlled studies have shown that there is no survival benefit 
associated with early removal of non-palpable lymph nodes (Balch et al., 2000; Cascinelli et 
al., 1998; Sim et al., 1986; Veronesi et al., 1982; Zitelli, 2008). The prospective randomized 
Multi-centre Selective Lymphadenectomy Trial (MSLT-1), conducted between 1994 and 2002 
with 1269 patients, clearly confirmed that there is no survival benefit for patients 
undergoing wide excision and SLNBx with immediate CRLND if nodal micrometastases 
were detected compared to those undergoing wide excision and postoperative observation 
of regional lymph nodes with therapeutic lymph node dissection (lymphadenectomy) if 
nodal relapse occurred (Baldwin et al., 2010; Morton et al., 2006). The Sunbelt Melanoma 
trial analysed the survival of patients with minimal infiltration of the sentinel lymph node 
by melanoma cells. Patients whose SLNBx was negative by standard 
immunopathology/immunochemistry methods, but positive by RT-PCR, were randomized 
to observation or CRLND treatment; but interestingly, no difference in overall survival was 
found between the two groups (McMasters et al., 2001). In conclusion, while lymph node 
invasion correlates with shorter survival, early removal of non-palpable lymph nodes 
containing micrometastases does not improve survival. It is still unknown whether removal 
of palpable metastatic lymph nodes improves survival, but this question is being addressed 
by the MSLT-II trial.  
Similar conclusions have been reached in studies on other types of cancer. For example, 
Sleeman et al. analysed 7 randomized clinical studies, totalling 3,351 patients with breast 
cancer (Sleeman et al., 2011). None of these studies showed any overall survival or disease-
free survival benefit from removing tumour-draining lymph nodes. A recent report also 
compared 891 breast cancer patients with metastasis-containing sentinel lymph nodes 
undergoing either sentinel lymph node dissection alone or complete axillary lymph node 
dissection (Giuliano et al., 2011). Five years after surgery, no significant difference in the 
rates of overall survival (91.8% vs 92.5%) or disease-free survival (82.2% vs 83.9%) was 
observed.  In the same indication, Bidart et al. found that 82% of patients with tumour cells 
in the bone marrow do not relapse at least for the 6 years of the study (Bidard et al., 2008). 
Veronesi et al. performed a meta-analysis with an average follow up of 30 years. While the 
presence of tumour cells in the internal lymph nodes was a strong predictor of patient 
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survival, extensive lymphadenectomy did not change survival (Veronesi et al., 1999). 
Collectively, these observations confirm that patients are able to control disseminated cancer 
cells for prolonged period of times, provided they are not too numerous. 
10. Reasons to remove the tumour-draining lymph nodes 
Despite the lack of clinical evidence supporting a benefit of extensive lymph node 
dissection, there are theoretical reasons to believe that removal of invaded draining lymph 
nodes may be beneficial. Firstly, cancer cells secrete factors that facilitate metastasis. 
Cytokines such as TGF- which is abundantly secreted by tumours can suppress the anti-
tumour immune response. Tumours also secrete GM-CSF which plays a crucial role in the 
accumulation of myeloid-derived suppressor cells (MDSC). We found that tumours in 
RETAAD mice also secrete chemokines that attract MDSC. MDSC favour tumour cell 
proliferation, metastasis, and dampen the immune response. In melanoma patients, 
regulatory T cells, which suppress the immune response, are twice as frequent in metastatic 
lymph nodes as in tumour-free nodes (Viguier et al., 2004). Primary tumours also secrete 
growth factors that directly stimulate the proliferation of disseminated cancer cells or 
micrometastases. Tumour supernatants have also been involved in the development of the 
cellular clusters of non-tumoural cells that facilitate organ colonization by the cancer cells. 
These clusters have been referred to as pre-metastatic niches (Kaplan et al., 2005). In 
summary, large tumour masses participate in immunosuppression to favour tumour 
growth, and some studies show that surgery to remove such masses could improve the 
functionality of the anti-tumour response (Tatsumi et al., 2002). It is therefore difficult to 
argue against the removal of any detectable tumour cell. 
11. Reasons not to remove tumour-draining lymph nodes 
There are also theoretical reasons explaining why lymph node removal does not improve 
survival, or could even be deleterious. Surgery may sometimes result in the spread of cancer 
cells into the circulation, as has been shown in colorectal and prostate cancers (Yamaguchi et 
al., 2000). This has also been reported for cutaneous and uveal melanoma (De Giorgi et al., 
2010). Surgery also induces inflammation, and the link between inflammation and cancer 
progression is well established. Wound healing is known to induce local production of 
TGF and bFGF, which promotes the growth of B16 tumours in experimental models (Hofer 
et al., 1998). Similarly, trauma facilitates the implantation of mammary carcinoma cells 
(Murthy et al., 1989). Alteration of the lymphatic drainage may further worsen these effects. 
Lymph node removal reduces fluid drainage and favours oedema development which may 
also cause increased inflammation. While inflammation stimulates lymphangiogenesis 
(Angeli and Randolph, 2006), inhibitors of lymphangiogenesis have been shown to increase 
local inflammation. Conversely, stimulation of lymphangiogenesis reduces chronic skin 
inflammation (Huggenberger et al., 2010). All these studies are consistent with the idea that 
inefficient drainage increases inflammation. Inflammation induced by extensive surgery 
could then favour angiogenesis and suppress the anti-tumour immune response. Since 
suppression of angiogenesis (Holmgren et al., 1995; Naumov et al., 2006) and the immune 
response (Eyles et al., 2010) are considered the main mechanisms controlling dormancy of 
disseminated cancer cells, this would explain how surgery can influence the outgrowth of 
distant micrometastases. 
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In fact, there is substantial evidence, especially in colorectal cancer, that surgery contributes 
to metastasis (van der Bij et al., 2009). In melanoma patients, similar observations have been 
reported. Tseng et al noted the cases of two patients with giant upper extremity melanomas 
and no sign of progression for years. However, six months after surgery, both patients 
developed extensive metastatic disease (Tseng et al., 2009). Using the RETAAD model of 
uveal melanoma, we found that early removal of the primary eye tumour does not always 
reduce metastasis. In a few instances, incomplete enucleation was followed by rapid local 
recurrence, accelerated tumour growth and increased dissemination. Similarly, removal of 
the mandibular lymph node which drains the primary eye tumour resulted in increased 
angiogenesis and accelerated melanoma cell dissemination in this model. Taken together, 
these observations indicate that surgery aimed at removing the primary tumour and cancer 
cells disseminated locally could stimulate the growth of distant metastases. To address this 
issue and the considerable morbidity associated with CRLND, Murali et al. recently 
established a set of clinical and histo-pathological features predicting the negativity of non-
sentinel lymph nodes (Murali et al., 2010). Murali et al. recommend low risk patients to be 
spared unnecessary surgery. 
12. Immune surveillance and immune control of disseminated cancer cells 
The immune surveillance theory originally proposed by L. Thomas (Thomas, 1959) and F. 
Burnet (Burnet, 1970) in the 50’s proposes that the immune system plays a critical role in 
preventing cancer development and progression. This idea was initially broadly accepted, 
and then almost universally rejected, until the last decade when R. Schreiber, M. Smyth and 
their colleagues conclusively showed that the immune system controls not only the 
incidence of specific cancers in mice, but also interacts in a complex way with the tumour to 
shape its immune profile (Dunn et al., 2004). It is now recognized that both immunodeficient 
animals (Swann and Smyth, 2007) and patients under immunosuppression (Peto, 2001) have 
a higher incidence of cancer. The immune system is not only important to eliminate 
subclinical primary tumours. It plays a crucial role in controlling the dormancy of 
disseminated cancer cells, since immune suppression also accelerates the development of 
metastases. While pregnancy does not increase the risk of melanoma (Lens and Bataille, 
2008), it may accelerate the development of metastatic disease (Sato et al., 2008; Youn et al., 
2010). We also showed that RETAAD mice depleted of CD8+ T cells develop visceral 
metastases much earlier than control mice (Eyles et al., 2010; Lengagne et al., 2008). 
Pathological examination of the lungs of CD8-depleted animals revealed a higher density of 
proliferating cancer cells. This suggests that CD8+ T cells control metastatic dormancy 
through their anti-proliferative activity (for example by secreting cytostatic cytokines) rather 
than by direct cytotoxicity. Striking evidence for a role of the immune system in controlling 
disseminated cancer cells in humans comes from iatrogenic cases of allogeneic melanoma 
after organ transplantation (Penn, 1996). MacKie et al. reported two cases of such melanoma 
developing in patients grafted with the kidneys of a donor who had been treated for 
superficial melanoma without any detectable metastases 16 years before the transplantation 
(MacKie et al., 2003). Some disseminated melanoma cells apparently survived in the donor 
for this long period of time and escaped from dormancy only after transplantation into the 
immune-suppressed recipients. Tumour cells can escape immune control through a variety 
of mechanisms (Mapara and Sykes, 2004; Zou, 2005). In fact, the development of metastases 
in cancer patients with active anti-tumour immune responses is one of the most disturbing 
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survival, extensive lymphadenectomy did not change survival (Veronesi et al., 1999). 
Collectively, these observations confirm that patients are able to control disseminated cancer 
cells for prolonged period of times, provided they are not too numerous. 
10. Reasons to remove the tumour-draining lymph nodes 
Despite the lack of clinical evidence supporting a benefit of extensive lymph node 
dissection, there are theoretical reasons to believe that removal of invaded draining lymph 
nodes may be beneficial. Firstly, cancer cells secrete factors that facilitate metastasis. 
Cytokines such as TGF- which is abundantly secreted by tumours can suppress the anti-
tumour immune response. Tumours also secrete GM-CSF which plays a crucial role in the 
accumulation of myeloid-derived suppressor cells (MDSC). We found that tumours in 
RETAAD mice also secrete chemokines that attract MDSC. MDSC favour tumour cell 
proliferation, metastasis, and dampen the immune response. In melanoma patients, 
regulatory T cells, which suppress the immune response, are twice as frequent in metastatic 
lymph nodes as in tumour-free nodes (Viguier et al., 2004). Primary tumours also secrete 
growth factors that directly stimulate the proliferation of disseminated cancer cells or 
micrometastases. Tumour supernatants have also been involved in the development of the 
cellular clusters of non-tumoural cells that facilitate organ colonization by the cancer cells. 
These clusters have been referred to as pre-metastatic niches (Kaplan et al., 2005). In 
summary, large tumour masses participate in immunosuppression to favour tumour 
growth, and some studies show that surgery to remove such masses could improve the 
functionality of the anti-tumour response (Tatsumi et al., 2002). It is therefore difficult to 
argue against the removal of any detectable tumour cell. 
11. Reasons not to remove tumour-draining lymph nodes 
There are also theoretical reasons explaining why lymph node removal does not improve 
survival, or could even be deleterious. Surgery may sometimes result in the spread of cancer 
cells into the circulation, as has been shown in colorectal and prostate cancers (Yamaguchi et 
al., 2000). This has also been reported for cutaneous and uveal melanoma (De Giorgi et al., 
2010). Surgery also induces inflammation, and the link between inflammation and cancer 
progression is well established. Wound healing is known to induce local production of 
TGF and bFGF, which promotes the growth of B16 tumours in experimental models (Hofer 
et al., 1998). Similarly, trauma facilitates the implantation of mammary carcinoma cells 
(Murthy et al., 1989). Alteration of the lymphatic drainage may further worsen these effects. 
Lymph node removal reduces fluid drainage and favours oedema development which may 
also cause increased inflammation. While inflammation stimulates lymphangiogenesis 
(Angeli and Randolph, 2006), inhibitors of lymphangiogenesis have been shown to increase 
local inflammation. Conversely, stimulation of lymphangiogenesis reduces chronic skin 
inflammation (Huggenberger et al., 2010). All these studies are consistent with the idea that 
inefficient drainage increases inflammation. Inflammation induced by extensive surgery 
could then favour angiogenesis and suppress the anti-tumour immune response. Since 
suppression of angiogenesis (Holmgren et al., 1995; Naumov et al., 2006) and the immune 
response (Eyles et al., 2010) are considered the main mechanisms controlling dormancy of 
disseminated cancer cells, this would explain how surgery can influence the outgrowth of 
distant micrometastases. 
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In fact, there is substantial evidence, especially in colorectal cancer, that surgery contributes 
to metastasis (van der Bij et al., 2009). In melanoma patients, similar observations have been 
reported. Tseng et al noted the cases of two patients with giant upper extremity melanomas 
and no sign of progression for years. However, six months after surgery, both patients 
developed extensive metastatic disease (Tseng et al., 2009). Using the RETAAD model of 
uveal melanoma, we found that early removal of the primary eye tumour does not always 
reduce metastasis. In a few instances, incomplete enucleation was followed by rapid local 
recurrence, accelerated tumour growth and increased dissemination. Similarly, removal of 
the mandibular lymph node which drains the primary eye tumour resulted in increased 
angiogenesis and accelerated melanoma cell dissemination in this model. Taken together, 
these observations indicate that surgery aimed at removing the primary tumour and cancer 
cells disseminated locally could stimulate the growth of distant metastases. To address this 
issue and the considerable morbidity associated with CRLND, Murali et al. recently 
established a set of clinical and histo-pathological features predicting the negativity of non-
sentinel lymph nodes (Murali et al., 2010). Murali et al. recommend low risk patients to be 
spared unnecessary surgery. 
12. Immune surveillance and immune control of disseminated cancer cells 
The immune surveillance theory originally proposed by L. Thomas (Thomas, 1959) and F. 
Burnet (Burnet, 1970) in the 50’s proposes that the immune system plays a critical role in 
preventing cancer development and progression. This idea was initially broadly accepted, 
and then almost universally rejected, until the last decade when R. Schreiber, M. Smyth and 
their colleagues conclusively showed that the immune system controls not only the 
incidence of specific cancers in mice, but also interacts in a complex way with the tumour to 
shape its immune profile (Dunn et al., 2004). It is now recognized that both immunodeficient 
animals (Swann and Smyth, 2007) and patients under immunosuppression (Peto, 2001) have 
a higher incidence of cancer. The immune system is not only important to eliminate 
subclinical primary tumours. It plays a crucial role in controlling the dormancy of 
disseminated cancer cells, since immune suppression also accelerates the development of 
metastases. While pregnancy does not increase the risk of melanoma (Lens and Bataille, 
2008), it may accelerate the development of metastatic disease (Sato et al., 2008; Youn et al., 
2010). We also showed that RETAAD mice depleted of CD8+ T cells develop visceral 
metastases much earlier than control mice (Eyles et al., 2010; Lengagne et al., 2008). 
Pathological examination of the lungs of CD8-depleted animals revealed a higher density of 
proliferating cancer cells. This suggests that CD8+ T cells control metastatic dormancy 
through their anti-proliferative activity (for example by secreting cytostatic cytokines) rather 
than by direct cytotoxicity. Striking evidence for a role of the immune system in controlling 
disseminated cancer cells in humans comes from iatrogenic cases of allogeneic melanoma 
after organ transplantation (Penn, 1996). MacKie et al. reported two cases of such melanoma 
developing in patients grafted with the kidneys of a donor who had been treated for 
superficial melanoma without any detectable metastases 16 years before the transplantation 
(MacKie et al., 2003). Some disseminated melanoma cells apparently survived in the donor 
for this long period of time and escaped from dormancy only after transplantation into the 
immune-suppressed recipients. Tumour cells can escape immune control through a variety 
of mechanisms (Mapara and Sykes, 2004; Zou, 2005). In fact, the development of metastases 
in cancer patients with active anti-tumour immune responses is one of the most disturbing 
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paradoxes of cancer immunology. Indeed, in most cancer patients, anti-tumour T cell 
responses can be detected. For the first time in 2010, the US Food and Drug Administration 
approved a therapeutic cancer vaccine, Provenge, to treat asymptomatic or minimally 
symptomatic metastatic hormone-refractory prostate cancer (Kantoff et al., 2010). While 
significant progress has been made in increasing the strength and quality of the immune 
response induced by candidate cancer vaccines, clinical benefits are still limited (Rosenberg 
et al., 2004). Cancer vaccines have most frequently been tested in advanced cancer patients 
with bulky tumours. Work in preclinical models however, suggests that such vaccines may 
be more efficient at controlling the dormancy of disseminated cancer cells. 
13. Conclusion  
Most patients with early stage melanoma are cured by local surgery. However, extensive 
surgical treatment of more advanced patients may not always be beneficial because some 
primary tumour cells have the capacity to disseminate early during disease progression. 
Distant metastases may not develop from nodal metastases detected at diagnosis but rather 
from cancer cells already disseminated throughout the body. Once the main tumoural mass 
has been removed, the immune system of the patient should be able to cope with the 
residual cancer cells. In these patients, extensive surgery may even accelerate the outgrowth 
of distant metastases by adversely affecting the immune response and favouring the escape 
of disseminated cancer cells from dormancy. Collectively, the data presented in this review 
plead for a limited surgery of the primary tumour combined with systemic adjuvant 
therapy. 
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paradoxes of cancer immunology. Indeed, in most cancer patients, anti-tumour T cell 
responses can be detected. For the first time in 2010, the US Food and Drug Administration 
approved a therapeutic cancer vaccine, Provenge, to treat asymptomatic or minimally 
symptomatic metastatic hormone-refractory prostate cancer (Kantoff et al., 2010). While 
significant progress has been made in increasing the strength and quality of the immune 
response induced by candidate cancer vaccines, clinical benefits are still limited (Rosenberg 
et al., 2004). Cancer vaccines have most frequently been tested in advanced cancer patients 
with bulky tumours. Work in preclinical models however, suggests that such vaccines may 
be more efficient at controlling the dormancy of disseminated cancer cells. 
13. Conclusion  
Most patients with early stage melanoma are cured by local surgery. However, extensive 
surgical treatment of more advanced patients may not always be beneficial because some 
primary tumour cells have the capacity to disseminate early during disease progression. 
Distant metastases may not develop from nodal metastases detected at diagnosis but rather 
from cancer cells already disseminated throughout the body. Once the main tumoural mass 
has been removed, the immune system of the patient should be able to cope with the 
residual cancer cells. In these patients, extensive surgery may even accelerate the outgrowth 
of distant metastases by adversely affecting the immune response and favouring the escape 
of disseminated cancer cells from dormancy. Collectively, the data presented in this review 
plead for a limited surgery of the primary tumour combined with systemic adjuvant 
therapy. 
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1. Introduction  
Vasculogenic mimicry (VM) patterns are present in a wide variety of malignant tumors, 
represent the formation of perfusion pathways by tumor cells, and their presence in tumors 
is associated with adverse outcome (Maniotis et al., 1999; Folberg et al., 2000; Hendrix et al., 
2003; Folberg and Maniotis, 2004; Döme et al., 2007). Mechanisms by which VM may 
contribute to adverse outcome are not well understood. Previous observations in our 
laboratory indicated that VM-forming tumor cells have increased resistance to herpes 
simplex virus-mediated oncolysis in three-dimensional (3D) uveal melanoma cultures 
(Valyi-Nagy et al., 2010). To determine whether VM-forming tumor cell subpopulations also 
have increased resistance against cytotoxic drugs, traditional two-dimensional (2D) and 
extracellular matrix (ECM, Matrigel)-containing 3D cultures of C918 uveal melanoma cells 
were established. In 2D cultures, C918 cells grew in monolayers. In 3D cultures, C918 cells 
formed a number of morphologically distinct tumor cell subpopulations that included cells 
that grew in monolayers on the Matrigel surface, cells that formed VM patterns, and cells 
that formed monolayers on the bottom of the culture dish. Following exposure to cisplatin 
or cadmium chloride, VM-forming tumor cells demonstrated prolonged survival relative to 
other tumor cell subpopulations in 3D cultures and cells grown in 2D. As presented in detail 
below, these findings suggest that increased drug resistance is a mechanism by which VM-
forming tumor cells contribute to adverse outcome. 
1.1 Vasculogenic mimicry 
VM patterns represent the formation of perfusion pathways by tumor cells (Maniotis et al., 
1999). VM is composed of patterned networks of laminin-rich basement membranes lined by 
tumor cells. VM patterns are present in a wide variety of malignant tumors and the presence 
of VM in tumors is associated with adverse outcome (Folberg et al., 1992 and 1993; Folberg 
and Maniotis, 2004; Gosh et al., 2005; Folberg et al., 2000 and 2007; Hendrix et al., 2003; 
Döme et al., 2007). While VM formation is clearly a marker of highly invasive tumor 
phenotype, mechanisms by which these structures may contribute to adverse outcome are 
not well understood. It has been proposed that VM formation may facilitate tumor 
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perfusion and the physical connection between VM and blood vessels may also facilitate 
hematogeneous dissemination of tumor cells (Folberg and Maniotis, 2004).  Interestingly, 
uveal melanoma cells within VM patterns assume a spindle A morphology and the 
expression of the Ki67 proliferation marker is significantly reduced in these cells (Folberg et 
al., 2006). These findings raise the possibility that VM-forming tumor cells have increased 
resistance against radiation and chemotherapeutic agents that target highly proliferative 
tumor cell populations. 
Recent studies also indicate that malignant melanoma initiating cells (MMIC) are 
specifically associated with VM and it has been proposed that one mechanism by which 
MMIC promote tumor growth is by the induction of VM formation by MMIC (Frank et al., 
2011). Previous work in our laboratory indicated that VM-forming tumor cells in 3D tumor 
cell cultures have increased resistance against at least one form of therapy: oncolytic 
virotherapy (Valyi-Nagy et al., 2010). To test the hypothesis that VM-forming tumor cells 
also have increased resistance against cytotoxic agents, in the current study we utilized 3D 
cultures of uveal melanoma cells as an experimental platform.  
1.2 Three-dimensional tumor cultures 
The introduction of 3D tumor cultures has revolutionized anticancer drug research as these 
cultures allow for the study of drug resistance mechanisms that can not be explored in 
traditional two dimensional (2D) monolayer cultures. The behavior of cells in vivo is 
controlled by their interactions with neighboring cells and with the ECM (Abbott, 2003; 
Friedrich, 2003; Nelson and Bissel, 2004; Smalley et al., 2006; Schmeichel and Bissel, 2005; 
Sandal et al., 2007; Wang et al., 1988; Weaver et al., 1997). Cancer cells grown in 3D cultures 
in a polymeric ECM closely mimic the biology of tumor development in vivo and numerous 
studies indicate that 3D cultures are superior to traditional 2D monolayer cultures for 
studies of key cellular behaviors like differentiation, proliferation, invasion and apoptosis 
(Xu and Burg, 2007). Cancer cells grown in 3D culture are more resistant to 
chemotherapeutic agents and radiation than cells in 2D culture and 3D tumor cell cultures 
are useful for preclinical evaluation of the cytotoxic effect of anticancer agents (Smalley et 
al., 2006). It is well established that multiple cell types within individual tumors have 
differential sensitivities to drugs and radiation both in vivo and in 3D cultures (Schmidmaier 
and Baumann, 2008; Jacks and Weinberg, 2002; Vescio et al., 1987). 
Uveal melanoma cells form several morphologically distinct cell populations under 3D 
culture conditions (Maniotis et al., 1999, 2005; Valyi-Nagy et al., 2010). Importantly for our 
current study, the several morphologically distinct cell populations formed by highly 
invasive uveal melanoma cells under 3D culture conditions include cells that form VM 
(Maniotis et al., 1999; Folberg and Maniotis, 2004). To determine whether VM-forming 
tumor cell subpopulations have increased resistance against cytotoxic drugs, traditional 
two-dimensional (2D) and extracellular matrix (Matrigel)-containing 3D cultures of C918 
uveal melanoma cells were established and were then exposed to cytotoxic agents. 
2. Experimental approach 
2.1 Cells 
C918 uveal melanoma cells of high invasive potential were maintained in Eagle’s Minimal 
Essential Medium (EMEM, BioWhittaker Inc., Walkersville, MD) supplemented with heat 
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inactivated 15% fetal bovine serum (Fisher, Ontario, Canada) without the addition of 
exogenous extracellular matrix molecules or growth factors. This cell line has been described 
in detail previously (Folberg et al., 2008).  
2.2 Establishment of 2D and 3D melanoma cultures  
For  the establishment of 2D and 3D cultures used in experiments, C918 uveal melanoma 
cells were grown on 24-well plates in EMEM medium either in the presence (3D cultures) or 
in the absence (2D cultures) of extracellular matrix rich in laminin (Matrigel, BD Biosciences, 
Bedford, MA) as described previously (Valyi-Nagy et al., 2007 and 2010). For 3D cultures, 
Matrigel was poured onto the bottom of the tissue culture wells to a depth of approximately 
0.2 mm and was allowed to polymerize for 1 hour at 37oC. Following polymerization, C918 
melanoma cells were placed on the Matrigel surface and the cultures were incubated in 
repeatedly refreshed culture medium for up to 4 weeks. Cultures were observed daily under 
an inverted microscope (Leica, Bannockburn, IL). 
2.3 Exposure of 2D and 3D melanoma cultures to cytotoxic agents  
Cells were first exposed to various concentrations of cytotoxic agents four to five days after 
the initiation of cultures, when 2D cultures formed monolayers and cells in 3D cultures 
formed morphologically distinct tumor cell subpopulations including VM patterns. Tested 
cytotoxic agents included cisplatin [cis-diammineplatinum(II)dichloride, Sigma] and 
cadmium chloride [CdCl2 hemi (pentahydrate), Sigma]. Culture media containing either 
cisplatin or cadmium chloride were changed daily. Cultures were observed daily under an 
inverted fluorescence microscope (Leica, Bannockburn, IL) for evidence of drug toxicity. The 
day when at least 99% of a given morphologically distinct tumor cell subpopulation was 
destroyed was noted. Cell death was confirmed by the uptake of the charged cationic dye 
Trypan blue (Mediatech Inc., Manassas, VA) by more than 99% of cells following incubation 
of cultures with Trypan blue (0.2%) for 10 minutes at 37 °C. 
3. Results 
3.1 Uveal melanoma cells form morphologically distinct cell populations under 3D 
conditions 
As expected based on previous observations (Valyi-Nagy et al, 2010), C918 cells grew in 
monolayers in 2D cultures (Fig.1) and formed several morphologically distinct cell 
populations under 3D culture conditions (Fig.2). In 3D cultures, morphologically distinct 
tumor cell subpopulations included cells that grew in monolayers on the Matrigel surface, 
cells that formed VM patterns, and cells that formed monolayers on the bottom of the 
culture dish (Fig.2). The growth of 3D cultures demonstrated the following course:  
when C918 cells were placed on the Matrigel surface, the cells started to grow on the 
Matrigel surface in a single layer and focally formed circular vasculogenic mimicry patterns 
that surrounded round matrix surfaces free of tumor cells. Next, tumor cells started to  
grow into the Matrigel at the line defined by the vasculogenic mimicry patterns and 
migrated to the bottom of the culture plate where they formed monolayers. The formation 
of these bottom monolayers was restricted to areas that were in the center of VM patterns 
(Fig. 2).  
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(Xu and Burg, 2007). Cancer cells grown in 3D culture are more resistant to 
chemotherapeutic agents and radiation than cells in 2D culture and 3D tumor cell cultures 
are useful for preclinical evaluation of the cytotoxic effect of anticancer agents (Smalley et 
al., 2006). It is well established that multiple cell types within individual tumors have 
differential sensitivities to drugs and radiation both in vivo and in 3D cultures (Schmidmaier 
and Baumann, 2008; Jacks and Weinberg, 2002; Vescio et al., 1987). 
Uveal melanoma cells form several morphologically distinct cell populations under 3D 
culture conditions (Maniotis et al., 1999, 2005; Valyi-Nagy et al., 2010). Importantly for our 
current study, the several morphologically distinct cell populations formed by highly 
invasive uveal melanoma cells under 3D culture conditions include cells that form VM 
(Maniotis et al., 1999; Folberg and Maniotis, 2004). To determine whether VM-forming 
tumor cell subpopulations have increased resistance against cytotoxic drugs, traditional 
two-dimensional (2D) and extracellular matrix (Matrigel)-containing 3D cultures of C918 
uveal melanoma cells were established and were then exposed to cytotoxic agents. 
2. Experimental approach 
2.1 Cells 
C918 uveal melanoma cells of high invasive potential were maintained in Eagle’s Minimal 
Essential Medium (EMEM, BioWhittaker Inc., Walkersville, MD) supplemented with heat 
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inactivated 15% fetal bovine serum (Fisher, Ontario, Canada) without the addition of 
exogenous extracellular matrix molecules or growth factors. This cell line has been described 
in detail previously (Folberg et al., 2008).  
2.2 Establishment of 2D and 3D melanoma cultures  
For  the establishment of 2D and 3D cultures used in experiments, C918 uveal melanoma 
cells were grown on 24-well plates in EMEM medium either in the presence (3D cultures) or 
in the absence (2D cultures) of extracellular matrix rich in laminin (Matrigel, BD Biosciences, 
Bedford, MA) as described previously (Valyi-Nagy et al., 2007 and 2010). For 3D cultures, 
Matrigel was poured onto the bottom of the tissue culture wells to a depth of approximately 
0.2 mm and was allowed to polymerize for 1 hour at 37oC. Following polymerization, C918 
melanoma cells were placed on the Matrigel surface and the cultures were incubated in 
repeatedly refreshed culture medium for up to 4 weeks. Cultures were observed daily under 
an inverted microscope (Leica, Bannockburn, IL). 
2.3 Exposure of 2D and 3D melanoma cultures to cytotoxic agents  
Cells were first exposed to various concentrations of cytotoxic agents four to five days after 
the initiation of cultures, when 2D cultures formed monolayers and cells in 3D cultures 
formed morphologically distinct tumor cell subpopulations including VM patterns. Tested 
cytotoxic agents included cisplatin [cis-diammineplatinum(II)dichloride, Sigma] and 
cadmium chloride [CdCl2 hemi (pentahydrate), Sigma]. Culture media containing either 
cisplatin or cadmium chloride were changed daily. Cultures were observed daily under an 
inverted fluorescence microscope (Leica, Bannockburn, IL) for evidence of drug toxicity. The 
day when at least 99% of a given morphologically distinct tumor cell subpopulation was 
destroyed was noted. Cell death was confirmed by the uptake of the charged cationic dye 
Trypan blue (Mediatech Inc., Manassas, VA) by more than 99% of cells following incubation 
of cultures with Trypan blue (0.2%) for 10 minutes at 37 °C. 
3. Results 
3.1 Uveal melanoma cells form morphologically distinct cell populations under 3D 
conditions 
As expected based on previous observations (Valyi-Nagy et al, 2010), C918 cells grew in 
monolayers in 2D cultures (Fig.1) and formed several morphologically distinct cell 
populations under 3D culture conditions (Fig.2). In 3D cultures, morphologically distinct 
tumor cell subpopulations included cells that grew in monolayers on the Matrigel surface, 
cells that formed VM patterns, and cells that formed monolayers on the bottom of the 
culture dish (Fig.2). The growth of 3D cultures demonstrated the following course:  
when C918 cells were placed on the Matrigel surface, the cells started to grow on the 
Matrigel surface in a single layer and focally formed circular vasculogenic mimicry patterns 
that surrounded round matrix surfaces free of tumor cells. Next, tumor cells started to  
grow into the Matrigel at the line defined by the vasculogenic mimicry patterns and 
migrated to the bottom of the culture plate where they formed monolayers. The formation 
of these bottom monolayers was restricted to areas that were in the center of VM patterns 
(Fig. 2).  
 




Fig. 1. Morphology of 2D C918 uveal melanoma cultures. In traditional 2D cultures, C918 
uveal melanoma cells formed a monolayer of cells on the bottom surface of the tissue culture 
wells (200x magnification). 
 
Cells on matrigel surface
VM
Cells surrounded by VM on bottom of plate  
Fig. 2. Morphology of 3D C918 uveal melanoma cultures. Pictures of a 3D C918 uveal 
melanoma culture with focus either on cells growing on the Matrigel surface (left panel) or 
on cells growing on the bottom of the tissue culture well (right panel). Vasculogenic 
mimicry (VM) patterns are also marked by arrows (200x magnification). 
3.2 VM-forming melanoma cells have increased resistance against cisplatin  
Starting 4 to 5 days after the initiation of cultures, when 2D cultures formed monolayers and 
cells in 3D cultures formed morphologically distinct tumor cell subpopulations including 
VM patterns, cultures were exposed to various concentrations of cisplatin (Del Bello et al., 
2003; Feldman et al., 2004; Bowden et al., 2010) and observed daily for toxicity. Cisplatin 
concentrations tested in the experiments ranged from 30 to 300 µM and fresh culture media 
containing cisplatin were added to the cultures daily. Control cultures not exposed to 
cisplatin remained viable and demonstrated growth. However, cultures exposed to cisplatin 
demonstrated dose dependant toxicity (Table 1). Interestingly, we found that VM-forming 
tumor cells demonstrated prolonged survival following cisplatin treatment relative to other 
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tumor cell subpopulations in 3D cultures and relative to cells grown in 2D (Table 1, Figs 3 to 
8). For instance, it took 6 days until 300 µM cisplatin destroyed more than 99% of cells forming 
VM in 3D cultures while other cell subpopulations in 3D cultures and cells grown in 2D 
cultures were destroyed by 4 and 3 days, respectively (Table 1). Even more pronounced 
differences were detected at 100 µM cisplatin concentrations as destruction of VM-forming 
tumor cells never reached 99% in 3D cultures during a 7-day observation period while other 
cell subpopulations in 3D cultures and cells grown in 2D cultures were destroyed by 4 and 3 
days, respectively (Table 1). These findings indicate that VM-forming tumor cells have 















NA (>7 days) NA (>7 days) NA (>7 days) NA (>7 days)
CPL 30 µM NA (>7 days) NA (>7 days) NA (>7 days) NA (>7 days)
CPL 100 
µM
3 days 4 days NA (>7 days) 4 days
CPL 300 
µM
3 days 4 days 6 days 4 days
 
Table 1. Time (days) elapsed from the initiation of cisplatin treatment to destruction of more 
than 99% of C918 uveal melanoma cells in 2D cultures and destruction of more than 99% of 
various C918 cell subpopulations in 3D cultures during a 7-day observation period. 
Abbreviations: 2D = two-dimensional cultures; 3D = three-dimensional cultures; VM = cells 
forming vasculogenic mimicry patterns; CPL = cisplatin; NA (>7 days) = not applicable, cell 




Fig. 3. Destruction of 2D C918 uveal melanoma cultures following exposure to cisplatin for 
four days. Panel A shows cultures grown in regular culture medium. Panel B shows 
destruction of cells that were cultured in medium containing 100 µM cisplatin. 
Magnification: 100x. 
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Fig. 3. Destruction of 2D C918 uveal melanoma cultures following exposure to cisplatin for 
four days. Panel A shows cultures grown in regular culture medium. Panel B shows 
destruction of cells that were cultured in medium containing 100 µM cisplatin. 
Magnification: 100x. 
 








Fig. 4. Trypan blue staining in 2D C918 uveal melanoma cultures following 100 µM cisplatin 
treatment for seven days. While the majority of cells are viable (negative for trypan blue) in 
untreated control cultures (panel A), no viable (trypan blue-negative) C918 uveal melanoma 
cells are detected after 100 µM cisplatin treatment (panel B) (200x magnification). 
 
 
Fig. 5. Effect of 100 µM cisplatin on 3D C918 uveal melanoma cultures. All cells but those 
forming VM patterns demonstrate extensive destruction by 100 µM cisplatin in 3D cultures 
of C918 uveal melanoma cells three days after initiation of cisplatin treatment. Arrows point 
to VM (100x magnification). 
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Fig. 6. Effect of 100 µM cisplatin on the morphology of 2D and 3D C918 uveal melanoma 
cultures. All cells but those forming VM patterns (arrows) are destroyed by 100 µM cisplatin 
in 3D cultures exposed for four days to cisplatin (panels A, B, and D). Destruction of 2D 




Fig. 7. Trypan blue staining in 3D C918 uveal melanoma cultures exposed for four days to 
regular medium (panel A) or to medium containing 100 µM cisplatin (panel B). Note that the 
majority of cells are viable (negative for trypan blue) in the control cultures in panel A. In 
contrast, only some of the cells associated with VM formation are viable (negative for trypan 
blue) in 3D cultures four days after 100 µM cisplatin treatment. Arrow in panel B points to 
VM (200x magnification). 
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Fig. 8. Trypan blue staining in a 3D C918 uveal melanoma culture following 100 µM 
cisplatin treatment for seven days. Only some of the cells associated with VM formation 
(arrows) are viable (negative for trypan blue). Magnification: 200x. 
3.3 VM-forming melanoma cells have increased resistance against cadmium 
Starting 4 to 5 days after the initiation of cultures, when 2D cultures formed monolayers and 
cells in 3D cultures formed morphologically distinct tumor cell subpopulations including 
VM patterns, cultures were exposed to various concentrations of cadmium chloride 
(Yokouchi et al., 2007) and observed daily for toxicity. Cadmium chloride concentrations 
tested in the experiments ranged from 20 to 1000 µM. Fresh culture media containing 
cadmium chloride were added to the cultures daily for up to 4 weeks. Control cultures not 
exposed to cadmium chloride remained viable and demonstrated growth for several weeks. 
However, cultures exposed to cadmium chloride in the culture medium demonstrated dose 
dependant toxicity (Table 2). Similarly to the observations made with cisplatin, VM-forming 
tumor cells demonstrated prolonged survival following cadmium treatment relative to other 
tumor cell subpopulations in 3D cultures and cells grown in 2D (Table 2, Figs 9 through 14). 
Specifically, at 200 µM cadmium chloride concentration, destruction of VM-forming tumor 
cells never reached 99% in 3D cultures during a 16-day observation period while other cell 
subpopulations in 3D cultures and cells grown in 2D cultures were completely destroyed by 
4 and 3 days, respectively (Table 2). Interestingly, as presented in the next section in detail, if 
cadmium chloride treatment was stopped sixteen days after initiation of drug treatment, 
residual still viable cells in VM patterns served as foci of new tumor growth (Fig. 16 through 
18). These findings indicate that VM-forming tumor cells have increased resistance against 
the cytotoxic effects of cadmium chloride in 3D uveal melanoma cultures. 
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No Cd Control NA (>16 days) NA (>16 days) NA (>16 days) NA (>16 days)
Cd 20 µM NA (>16 days) NA (>16 days) NA (>16 days) NA (>16 days)
Cd 200 µM 4 days 4 days NA (>16 days) 4 days
Cd 400 µM 2 days 2 days 2 days 2 days




Table 2. Time (days) elapsed from the initiation of cadmium chloride (CdCl2) treatment to 
destruction of more than 99% of C918 uveal melanoma cells in 2D cultures and destruction 
of more than 99% of various C918 cell subpopulations in 3D cultures during a 16-day 
observation period. Abbreviations: 2D = two-dimensional cultures; 3D = three-dimensional 
cultures; VM = cells forming vasculogenic mimicry patterns; Cd = cadmium chloride 






Fig. 9. Effect of 200 µM cadmium chloride on 2D C918 uveal melanoma cultures. Panel A 
shows cultures grown in regular culture medium. Panel B shows destruction of cells that 
were cultured in medium containing 200 µM cadmium chloride for four days. 
Magnification: 100x. 
 






Fig. 8. Trypan blue staining in a 3D C918 uveal melanoma culture following 100 µM 
cisplatin treatment for seven days. Only some of the cells associated with VM formation 
(arrows) are viable (negative for trypan blue). Magnification: 200x. 
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Fig. 9. Effect of 200 µM cadmium chloride on 2D C918 uveal melanoma cultures. Panel A 
shows cultures grown in regular culture medium. Panel B shows destruction of cells that 
were cultured in medium containing 200 µM cadmium chloride for four days. 
Magnification: 100x. 
 





Fig. 10. Trypan blue staining in 2D C918 uveal melanoma cultures following 200 µM 
cadmium treatment for four days. While the majority of cells are viable (negative for trypan 
blue) in untreated control cultures (panel A), no viable (trypan blue-negative) C918 uveal 






Fig. 11. Effect of 200 µM cadmium chloride on 3D C918 uveal melanoma cultures. Panel A 
shows a 3D culture grown in regular medium for nine days and is notable for an abundance 
of viable-appearing cells. Panels B through D show 3D cultures grown in medium 
containing 200 µM cadmium chloride for nine days. Note that all but some cells forming VM 
patterns are destroyed by the cadmium chloride treatment. Arrows point to VM in panels B, 
C, and D. Magnification: 200x. 
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Fig. 12. Effect of exposure of 3D C918 uveal melanoma cultures to 200 µM cadmium chloride 
for nine days (A) or ten days (B). Note that all but some cells forming VM patterns (arrows) 




Fig. 13. Trypan blue staining in 3D C918 uveal melanoma cultures exposed for  four  days to 
regular medium (A) or to medium containing 200 µM cadmium chloride (B). The majority of 
cells are viable in the control cultures (A). Only some cells associated with VM formation are 




Fig. 14. Trypan blue staining in 3D C918 uveal melanoma cultures exposed for four days to 
200 µM cadmium chloride. Only some tumor cells associated with VM formation (arrows) 
are viable (negative for trypan blue). 200x magnification. 
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Fig. 12. Effect of exposure of 3D C918 uveal melanoma cultures to 200 µM cadmium chloride 
for nine days (A) or ten days (B). Note that all but some cells forming VM patterns (arrows) 




Fig. 13. Trypan blue staining in 3D C918 uveal melanoma cultures exposed for  four  days to 
regular medium (A) or to medium containing 200 µM cadmium chloride (B). The majority of 
cells are viable in the control cultures (A). Only some cells associated with VM formation are 




Fig. 14. Trypan blue staining in 3D C918 uveal melanoma cultures exposed for four days to 
200 µM cadmium chloride. Only some tumor cells associated with VM formation (arrows) 
are viable (negative for trypan blue). 200x magnification. 
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3.4 VM-forming melanoma cells may serve as foci of renewed growth once drug 
treatment is stopped 
Findings presented above indicate that VM-forming tumor cells have increased resistance 
against the cytotoxic effects of cadmium chloride in 3D uveal melanoma cultures. 
Interestingly, if cadmium chloride treatment was stopped sixteen days after initiation of 
drug treatment, residual still viable cells associated with VM patterns appeared to serve as 




Fig. 15. Morphology of a 3D C918 melanoma culture one day after cadmium chloride 
treatment was stopped. Three-dimensional cultures of C918 uveal melanoma cells were 
exposed for sixteen days to medium containing 200 µM cadmium chloride resulting in the 
destruction of all cells but some cells forming VM (arrows). There is no evidence of cell 





Fig. 16. Cells growing out from VM patterns four days following withdrawal of cadmium 
chloride treatment.  Three-dimensional cultures of C918 uveal melanoma cells were exposed 
for sixteen days to medium containing 200 µM cadmium chloride resulting in the 
destruction of all cells but some forming VM (arrows). Note focus of resumed melanoma cell 
growth (arrowheads) from VM. Magnification: 200x. 
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Fig. 17. Cells growing out from VM patterns four days following withdrawal of cadmium 
chloride treatment.  Three-dimensional cultures of C918 uveal melanoma cells were exposed 
for sixteen days to medium containing 200 µM cadmium chloride resulting in the 
destruction of all cells but some forming VM (arrows). Note focus of resumed melanoma cell 
growth (arrowheads) from VM. Magnification: 100x (A), 200x (B). 
 
 
Fig. 18. Cells growing out from VM patterns following withdrawal of cadmium chloride 
treatment.  Three-dimensional cultures of C918 uveal melanoma cells were exposed for 
sixteen days to medium containing 200 µM cadmium chloride resulting in the destruction of 
all cells but some of those associated with VM. Panel A shows cultures two days after drug 
withdrawal. Focus of resumed melanoma cell growth (arrow) is associated with VM 
(arrowhead). Panel B shows cultures nine days after drug withdrawal (200 x magnification). 
4. Conclusions 
While VM formation is clearly a marker of highly invasive tumor phenotype in vivo, 
mechanisms by which VM may contribute to adverse outcome are not well understood 
(Folberg et al., 1993; Maniotis et al., 1999; Folberg et al., 2000; Hendrix et al., 2003; Folberg 
and Maniotis, 2004; Lin et al., 2005; Döme et al, 2007). We have shown here that in 2D 
cultures, C918 uveal melanoma cells grow in monolayers and in 3D cultures, C918 cells form 
a number of morphologically distinct tumor cell subpopulations that include cells that form 
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VM patterns. Importantly, we found that following exposure to cytotoxic agents, VM-
forming tumor cells demonstrate prolonged survival relative to other tumor cell 
subpopulations in 3D cultures and cells grown in 2D. Additional observations suggested 
that drug resistant VM-forming tumor cells may serve as foci of new tumor growth once 
cytotoxic drug levels drop. While confirmation of these observations in in vivo studies and 
other tumor types will be essential, our findings reported here suggest that increased drug 
resistance is a mechanism by which VM-forming tumor cells contribute to adverse outcome. 
As VM patterns have been described in a wide variety of malignant neoplasms, 
observations of this current report are of great potential significance. 
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VM patterns. Importantly, we found that following exposure to cytotoxic agents, VM-
forming tumor cells demonstrate prolonged survival relative to other tumor cell 
subpopulations in 3D cultures and cells grown in 2D. Additional observations suggested 
that drug resistant VM-forming tumor cells may serve as foci of new tumor growth once 
cytotoxic drug levels drop. While confirmation of these observations in in vivo studies and 
other tumor types will be essential, our findings reported here suggest that increased drug 
resistance is a mechanism by which VM-forming tumor cells contribute to adverse outcome. 
As VM patterns have been described in a wide variety of malignant neoplasms, 
observations of this current report are of great potential significance. 
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1. Introduction 
The metastatic spread of solid tumors is the most fatal complication in malignant diseases 
and the major cause of tumor-related mortality. This is of high relevance for malignant 
melanoma which are highly proliferating tumors with aggressive metastatic tendency. The 
majority of melanoma cells tend to metastasize primary via the lymph system and 
secondary into different organs, most likely distant skin regions, liver, lungs, brain, and 
heart via hematogenous distribution, which is associated with bad prognosis. The molecular 
mechanisms of the metastatic processes are complex and not fully elucidated. Although 
cytostatic agents or anti-angiogenetic drugs (e.g. Avastin/bevacizumab) affect, beside their 
effects on the primary tumors, also the growth and development of metastases, there is at 
present no antimetastatic pharmacological strategy in the clinics to interfere with tumor cell 
dissemination or spread. 
Adhesion receptors are strongly involved in the process of tumor cell metastasis, either by 
deregulation of adhesive functions and subsequently the detachment of tumor cells from the 
primary tumor and the overcoming of tissue borders, or by mediating manifold cell contacts 
with blood components in the phase of hematogenous distribution. An intensive and 
ongoing preclinical research provided essential insight and several postulated factors and 
mechanisms for the hematogenous dissemination, i.e. the interaction of tumor cells with the 
different blood elements, soluble factors and cells. P- and L-selectin, members of a family of 
carbohydrate binding adhesion receptors are regarded as functional key players in the 
contact formation of tumor cells with platelets and leukocytes, thus facilitating microemboli 
formation and accelerating metastatic dissemination. The antimetastatic activities of 
heparin, confirmed by a number of prospective clinical trials, are to a large extent ascribed 
to the inhibition of these two selectins.  
Besides the important role of selectins, integrins as ubiquitary cell adhesion receptors are 
also involved in the mediation of manifold adhesive interactions in the metastasis of tumor 
cells. Integrins bind ligands of the extracellular matrix (ECM), such as fibronectin, collagen, 
laminin and vitronectin to stabilize cell attachment with the surrounding tissues or to 
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mediate migration in the metastatic cascade. Furthermore, integrins mediate cellular 
contacts of the tumor cells to platelets, leukocytes, and endothelium. However, in contrast to 
the selectins, the integrin function has hardly been considered as target for antimetastatic 
approaches.  
Integrins possess important tasks in cell signalling that can be summarized as defining the 
cellular shape, mobility, invasion and cell cycle regulation. The regulation of these processes 
via contribution of the actin and microtubule cytoskeletons is well known to be controlled 
by Rho-GTPases (Ras homologue; guanosintriphosphatases), which belong to the 
superfamily of Ras-GTPases (Rat adeno sarcoma). GTPases of the Ras-superfamily are 
important for cell proliferation, metastasis, migration, apoptosis, gene expression and 
multiple other functions in the cell. Since the integrin signalling is also cross-linked to the 
function of GTPases, a therapeutic influence on the GTPase activity could be a novel and 
attractive approach to control integrin bindings. Recent data on the treatment of melanoma 
cells with lysophosphatidylcholine (LysoPC) referred to reduced integrin functions, which 
might be related to reduced GTPase signalling.  
This book chapter will deal with the molecular function of adhesion receptors in the process 
of hematogenous metastasis of melanoma cells and the therapeutic potential and prospects 
to interfere with adhesion receptor activity as an antimetastatic approach. The focus was put 
on the integrins, which will be explained with their functions, abilities and connections to 
other indispensable proteins, such as cytoskeletal components in the context of cancer and 
metastasis. Finally the hypothesis to influence the integrin functions in metastatic cascade at 
a signalling level will be introduced and discussed as an interesting novel target for 
antimetastatic approaches. 
2. The metastasis of melanoma cells 
2.1 The course of the metastatic cascade  
Tumor cell metastasis is a complex cascade which consists of various molecular events. 
Metastatic cells have to exit the primary tumor by a deregulation of the cellular contacts, 
have to migrate the basement membrane of the tumor, degrade the extracellular matrix and 
intravasate lymphatic vessels or local post capillary veins. Several factors are known which 
contribute to the malignant transformation of melanocytes and melanoma development and 
progression, including microenvironmental influences, or UV radiation for triggering a 
cascade of proinflammatory factors and mediators (Lee & Herlyn 2006; Schwarz & Luger 
1989).  
Once in the blood system, the tumor cells have to escape the immune surveillance and 
physical stress of the blood stream to finally seed at the vascular bed at distant organs. This 
is the rate-limiting step of the metastatic cascade before they can extravasate and form 
metastases (Figure 1).   
An insight into the hematogenous phase of tumor cell distribution is given by numerous 
animal models of experimental metastasis, which dominantly used melanoma cell lines due 
to their rapid metastatic colonization tendency (Ludwig et al., 2004; Bereczky et al., 2005; 
Ludwig et al., 2006; Mousa et al., 2006; Niers et al. 2009). Although these models do not 
completely recapitulate the natural processes of metastatic spread, the timely defined 
presence of tumor cells in the blood systems allows for characterization and evaluation of 
cellular contacts within the phase of hematogenous distribution.  
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Fig. 1. Schematic representation of the hematogenous metastasis.  
The illustration give insights into the step-by-step process of the hematogenous metastasis: 
Detachment of tumor cells from primary tumor; overcoming of ECM, intravasation into the 
blood system, association with platelets and leukocytes to prevent shear forces and immune 
defense, transport through the organism, physical arrest or arrest via interaction with the 
vascular endothel, extravasation, generation of micrometastases and angiogenesis to the 
blood supply.  
Modified from (Guo W. & Giancotti F. G., 2004) 
The massive interaction of tumor cells forming a platelet cloak is a vital strategy to evade the 
immune defense and was shown to correlate with metastatic progression. Furthermore, the 
recruitment of leukocytes to form microemboli is thought to support microvascular arrest at 
distant sites and contributes to activation of endothelial cells. In general, tumor cell and/or 
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leukocyte interaction with the microenvironment at site of colonization induces an 
inflammatory-like activation of endothelial cells during the initial steps of metastasis 
progression, including the chemokine network and different procoagulative factors 
(Lazennec & Richmond, 2010). However, cellular adhesion receptors play a pivotal role for 
this complex cellular communication.  
2.2 The impact of selectins on the hematogenous tumor cell dissemination 
The selectins, a family of carbohydrate binding proteins, represent the crucial importance 
linked with hematogenous metastasis (Läubli & Borsig, 2010). P-selectin, expressed by 
platelets is dominant for the platelet contact of tumor cells. Its role for protecting the tumor 
cells and facilitating metastatic progression is confirmed by experiments using P-selectin 
knock-out mice, which displayed strongly attenuated experimental metastasis (Ludwig et al., 
2004; Kim et al., 1998). It became evident that P-selectin, expressed by activated endothelial 
cells also contributes to the metastatic progression (Ludwig et al., 2004). L-selectin, which is 
constitutively expressed by all types of leukocytes, supports the comprehension of leukocyte 
into the microemboli and vascular contact formation and activation (Laubli et al., 2006). 
Endothelial activation is associated with the upregulation of other adhesion receptors, such as 
E-selectin or the integrin ligand vascular cell adhesion molecule-1 (VCAM-1), which again 
advises to the inflammatory-like reaction (Auguste et al., 2007).  
Consequently, the competitive blocking of the selectin function appears as a promising 
therapeutic approach to interfere with the metastatic cascade.  
2.3 The role of heparin for antimetastatic approaches 
The evidence for those selectin-blocking approaches came indirectly from clinical efforts to 
treat cancer-associated thromboembolic events, which are frequent complications in 
malignant diseases. Heparin, or low molecular weight heparin (LMWH) are the 
anticoagulant drug of choice in the clinical treatment or prophylactic treatment of cancer-
associated thrombosis. Based on the retrospective evaluation of clinical data, which referred 
to a survival benefit of heparin treated cancer patients, a number of prospective clinical 
trials have been lauchned (Zacharski & Lee, 2008). Animal experiments supported the 
assumption that heparin hardly affects the primary tumor but interferes with the process of 
metastasis. Several molecular mechanisms exist to explain the antimetastatic efficiency of 
heparin. The reader is referred to excellent reviews in this field (Borsig, 2010; Casu et al. 
2008) from which the inhibitory capacity of heparin towards P- and L-selectin binding 
should be highlighted here. 
Heparin as a highly sulfated, acidic polysaccharide has the ability to compete with the natural 
mucin-like selectin ligands. The capacity of heparin to interfere with P- and L-selectin binding 
has already been described in the early 90th (Skinner et al., 1991), but in the context of tumor 
cell metastasis the heparin effects as competitors of P- and L-selectins were accumulated 
during the last decade. Further insight was obtained into the structural requirements of 
heparin for selectin binding (Hostettler et al., 2007), and binding affinities of heparin to both 
selectins were shown to be in the low micromolar range (Simonis et al., 2007). 
2.4 Integrins as targets for heparin 
The platelet integrin IIb IIIa also contributes to the bond formation between platelets and 
melanoma cells via fibronectin or vWF to melanoma integrins. A recent study reported that 
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heparin has also an inhibitory capacity to this binding (Zhang et al., 2009). Thrombin, 
interacting with its receptor PAR-1 on melanoma cells (protease-activated receptors-1) has a 
strong impact for regulating this interaction. PAR-1, which is predominantly overexpressed 
in malignant melanoma cells induces diverse procoagulant and metastatic events, such as 
matrix degradation, secretion of angiogenetic factors or integrin activation (Melnikova et al., 
2008).  
Melanoma integrins can also directly contribute to the firm adhesion to the vasculature. The 
integrin 41 (very late activation antigen-4, VLA-4), which interacts with the VCAM-1 as 
counter receptor, is described as another pathway for endothelial arrest of malignant 
melanoma cells (beside osteosarcoma and rhabdomyosarcoma cells), thereby promoting the 
transmigration (Okahara et al., 1994; Liang & Dong, 2008) and metastasis (Garofalo et al., 
1995; Schadendorf et al., 1995). Although these finding suggest that the inhibition of VLA-4 
could be promising in the treatment of melanoma metastasis, and despite VLA-4 inhibition 
by antibodies or small molecules is a vital strategy to interfere with pathological 
inflammations, such approaches have not been described so far in the cancer field. We could 
recently show that the VLA-4/VCAM-1 interaction of murine or human melanoma cell lines 
can be efficiently blocked by heparin (Schlesinger et al., 2009). Nevertheless, beside those 
approaches for a competitive blockade of integrin receptor function, the manifold signalling 
functions of integrins open a new way for a therapeutic interference, which will be 
discussed below.   
3. The biology of integrins in the context of cell adhesion processes and 
metastasis 
In addition to the selectin-mediated cell adhesion processes in metastasis, the protein 
families of immunoglobulins (IGs), cadherins and integrins play important roles – in the 
case of malfunction - in the development and progression of melanoma metastasis.  
Several members of the IG superfamily such as ICAM-1, L1CAM and MCAM/MUC18 are 
significantly associated with progression of melanoma metastasis (Meier et al., 2006; Yamada 
et al., 2006; Johnson et al., 1997). The MUC18/MCAM expression confers metastatic potential 
and increased tumorigenicity to human melanoma cells (Johnson et al., 1999). A switch of the 
cadherin molecules from E-cadherin to N-cadherin is responsible for the disassociation of 
melanoma cells from keratinocytes. The loss of E-cadherin function is connected with the 
upregulation/induction of MUC18/MCAM and v3 integrin in melanocytic cells in vitro 
and with changes in the levels and the cellular distribution of the transcriptional regulator -
catenin in melanomas in vivo (Johnson et al., 1999). Thus, melanoma cell invasion through the 
dermis is mediated by this change (Hsu et al., 1996; Hsu et al., 2000).  
One of the most prominent examples that is frequently associated with the progression of 
melanoma is the integrin 41 (VLA-4) (Braeuer et al, 2011). It was observed that VLA-4 
overexpression and interaction with VCAM-1 is clearly correlated with experimental lung 
metastasis and the tumor stage (Schadendorf et al., 1995; Okahara et al., 1994). Due to the 
fact that the interaction of VLA-4 and VCAM-1 and other integrins are of great interest as 
possible targets for melanoma cancer therapy, the following chapter will handle with details 
on the integrin family and their structural and functional connections in the context of 
cancer metastasis. 
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3.1 The general structure of integrins 
The integrins are large and complex transmembrane glycoproteins which act as adhesion 
receptor molecules that are responsible for the mediation of attachment and anchorage 
between cells or to the underlying extracellular matrix (ECM) (Morgan et al., 2007). In detail 
they span the plasma membrane and work alongside other proteins such as cadherins and 
selectins to mediate cell-cell and cell-matrix interaction and communication. One important 
task of integrins is the binding of the cell surface and ECM components such as fibronectin, 
vitronectin, collagen, and laminin.  
Many cells have multiple types of integrins on their surface. That means the use of integrin-
targeted reagents is not specific for all but for a few or one specific integrin. This provides 
additional mechanistic insights into the functions of integrin adhesion receptors.  
The structure of integrins can be divided in two distinct chains, the α- and β-subunit (Figure 
2) which form a non-covalent heterodimer (Morgan et al., 2007; Lau et al., 2009; Shattil et al., 
2010). In mammals, 18 α- and 8 β-integrin genes have been characterized that encode 
polypeptides that combine to form 24 unique, canonical α/β receptors out of 144 possible 
combinations. The Drosophila genome encodes only five α- and two β-subunits, and the 
Caenorhabditis nematodes possess two α and one β genes (Shattil et al., 2010; Morgan et al., 
2007; Humphries, 2000). In addition, variants of some integrin subunits are formed by 
differential splicing, for example four variants of the beta-1 subunit exist (Hynes, 2002).  
Both the α- and β-subunits form separate tails, which penetrate the plasma membrane and 
possess small cytoplasmic domains (Nermut et al., 1988; Lau et al., 2009). The extracellular 
α/β-domains are relatively huge compared to the short cytoplasmic domain and the 
structure of each subunit is conserved between isoforms, excluding a subset of α-subunits, 
which include an inserted ‘A-domain’ in their ligand-binding pocket (Shattil et al., 2010; 
Morgan et al., 2007). The pathway of extracellular binding of integrins to intracellular 
transformation of the binding is most often mediated by the cytoplasmic tail of the β-
subunit (Morgan et al., 2007).  
3.2 The cellular functions of integrins 
Concerning the function, integrins are involved in a wide range of biological activities, 
including immune patrolling, cell migration, defining cellular shape, cell cycle regulation, 
growth, invasion, proliferation, differentiation, survival/apoptosis and binding to cells by 
certain viruses (Desgrosellier & Cheresh, 2010; Assoian & Klein, 2008).  
The integrin proteins act as receptors which are able to communicate between the ECM and 
the cell. They also transport information from the status inside the cell to the extracellular 
space. This allows rapid and flexible responses in both directions. Thus integrin tasks can be 
divided into two main functions: Attachment of the cell to the ECM and signal transduction 
from the ECM to the cell. Within the past decade it has become apparent that adhesion 
molecules such as integrins play an important role for the mediation of critical cytosolic 
signalling events in the cell (Stupack, 2007).  
Integrins act to regulate complex processes in cancer disease such as angiogenesis, tumor 
growth and metastasis (Hynes, 2002), and the signalling has a dramatic impact on cell 
proliferation, survival and motility. For this reason they have become attractive therapeutic 
targets for the development of pharmaceutical compounds. Several effective integrin 
antagonists are now under clinical evaluation (Stupack, 2007).  
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Fig. 2. Domain architecture of the heterodimeric transmembrane domains which show how 
integrins are designed to act as bidirectional signalling machines. Integrins are 
heterodimeric adhesive receptors consisting of an α- and a β-subunit. The ligand binding 
site is provided by the N-terminal domain of the α- and β-integrin subunits (the β-propeller 
and the βA domain, respectively) which are assembled in most integrins by non-covalent 
interactions to form a “head”. It is known that in 8 α integrin subunits (α1, α2, α10, α11, αL, 
αM, αX and αD), the αA domain, which is homologous to the βA domain of the β-integrin 
subunit, is inserted into the β-propeller domain. This is the main ligand-binding site in these 
integrins. Integrins that lack an A domain (e.g. the depicted schematic architecture of αIIbβ3 
integrin), the βA domain forms the main ligand-binding site. The PSI-domain (plexin, 
semaphorin and integrin) is at the N terminus of the β-integrin subunit, but is joined by 
disulfide bonds to more C-terminal residues. The remaining C-terminal extracellular 
domains of the α- and β-subunit comprise two long ‘legs’ which are anchored in the PM. 
The low affinity state of the integrin for its ligands is maintained by non-covalent 
interactions between the α- and β-integrin transmembrane and cytoplasmic domains. Figure 
is modified from (Shattil et al., 2010); α-subunit and β-subunit 
In particular integrins operate as mechanistic biosensors in a context-dependent manner. On 
one hand, integrins that ligate substrate-immobilized ligands typically transduce positive 
signals into the cell. On the other hand, antagonized or unligated integrins promote negative 
signalling into the cell, which leads to cell cycle arrest or apoptosis. Thus, integrins constantly 
interrogate the local ECM and modulate cell behaviour accordingly. Typically, receptors 
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inform a cell of the molecules in its environment and the cell evokes a response. Integrin 
receptors have two ways of signalling. They are able to perform outside-in signalling - 
response to molecules in its environment - and they also operate in an inside-out mode 
(Huveneers & Danen, 2009; Shattil et al., 2010; (Figure 3)). Therefore they are known as 
bidirectional, allosteric molecular signalling machines, although the relationship between 
specific conformations and activation remains controversial (Hynes, 2002; Shattil et al., 2010).  
 
 
Fig. 3. Cellular signalling modes of integrins. 
The two ways of integrin signalling can be divided in “outside-in” (left) and “inside-out” 
(right) modes. Both directions have different biological and biochemical consequences. In 
the case of “outside-in” signalling, binding of integrins to their extracellular ligands changes 
the conformation of the integrin and - because many of the ligands are multivalent - 
contributes to integrin clustering. The combination of these two events leads to intracellular 
signals that control cell polarity, cytoskeletal structure, gene expression, cell survival and 
proliferation. During ‘inside–out’ signalling, an intracellular activator, such as talin or 
kindlins, binds to the β-integrin tail, leading to conformational changes that result in 
increased affinity for extracellular ligands (integrin ‘activation’). Inside–out signalling 
controls adhesion strength and enables sufficiently strong interactions between integrins 
and ECM proteins to allow integrins to transmit the forces required for cell migration and 
ECM remodelling and assembly. Both modes of signalling are often closely linked; for 
example, integrin activation can increase ligand binding, resulting in outside–in signalling. 
Conversely, ligand binding can generate signals that cause inside–out signalling.  
Modified from (Shattil et al., 2010) 
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As mentioned before, the cytoplasmic tail of the β-subunit is known to be the main region of 
mediating protein interaction (e.g. talin, a cytoskeletal protein), signal transduction and 
direct integrin activation (Shattil et al., 2010; Morgan et al., 2007).  
4. The integrins in the context of signal transduction processes 
The mechanisms of integrin interaction at the cytoplasmic side are strongly connected to the 
regulation of GTPases. For example, activated Rac1 and RhoA transduce signals to integrin 
activation via phospholipase D (PLD) and phosphatidylinositol-4-phosphate 5-kinase 1γ 
(PIP5K1γ) (Tybulewicz & Henderson, 2009). Furthermore it is known that integrin signalling 
is inhibited by RhoH through an unknown mechanism. In this case, integrin signalling leads to 
the activation of the GEF αPIX (PAK-interacting exchange factor-α) and the following 
activation of Rac1 and PAK (p21-activated kinase) (Tybulewicz & Henderson, 2009). PAKs are 
well known to serve as targets for the small GTPases Cdc42 and Rac and they have been 
implicated in a wide range of biological activities, such as regulating the cell motility and 
morphology (PAK1), involvement in apoptotic processes (PAK2), or in the rapid cytoskeletal 
reorganization in dendritic spines (PAK3) or mediation of filopodia formation (PAK4).  
Integrin signalling works predominantly through the recruitment and activation of Src-family 
kinases (SFKs). Most integrins recruit focal adhesion kinase (FAK) through their cytoplasmic 
domain of the β-subunit (Guo & Giancotti, 2004). FAK works as a phosphorylation-regulated 
scaffold to recruit Src to focal adhesions. From this important point of origin, several signal 
pathways influence the cell proliferation, survival and migration (Figure 4). Activating 
signalling via FAK, phosphatidylinositol 3-kinase (PI3K) over phosphatidylinositol-3,4,5-
trisphosphate (PtdIns(3,4,5)P3) to AKT and protein kinase B (PKB) can induce the mentioned 
effects (e.g. adhesion, cell proliferation, etc.). In addition, there is a direct crosstalk via GEF to 
activate Rac (another possibility for activation is from SFK via CAS, Crk and DOCK180 to Rac) 
which in turn can activate PAK, Jun amino-terminal kinase (JNK) and nuclear factor kappa-B 
(NFκB) (Parsons & Parsons, 1997; Schlaepfer & Hunter, 1998; Cary et al, 1999). Furthermore 
FAK can activate extracellular signal-regulated kinase/mitogen-activated protein kinase 
(ERK/MAPK) by recruiting the Rap1 GEF C3G through Crk. Rap1 is then able to activate 
ERK/MAPK through B-Raf. An alternative way for ERK/MAPK activation is via the direct 
recruitment of growth-factor-receptor-bound-2 (GRB2) and son-of-sevenless (SOS) complex. 
Here, certain integrins, including α5β1, α1β1 and αvβ3, are coupled to palmitoylated SFKs 
through their α-subunits. The palmitoylated SFKs recruit and phosphorylate the adaptor Shc, 
which combines with GRB2–SOS to activate ERK/MAPK signalling from Ras (Wary et al., 
1996; 1998).  
Beside the interaction of integrins with SFKs mentioned before, some integrins are able to 
interact directly with SFKs via the cytoplasmic tail of their β-subunits (Arias-Salgado et al., 
2003). As an example, the α6β4 integrin is palmitoylated at its β-subunit. This 
palmitoylation is required for the incorporation of the complete α6β4 integrin in lipid rafts 
where the receptor is able to interact with SFKs that are similarly palmitoylated (Gagnoux-
Palacios et al., 2003). Here, the SFKs phosphorylate several tyrosine residues in the 
cytoplasmic domain of β4, which causes the recruitment of SHC and activation of Ras–
ERK/MAPK and PI3K signalling (Mainiero et al., 1995; 1997; Shaw et al., 1997; 2001). The 
known pathways that integrins can activate through SFKs are sufficient for the induction of 
cell migration, invasion and proliferation or to confer some protection from apoptosis on 
cells.  
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Fig. 4. General overview of alternative integrin signalling pathways.  
The figure shows a section of the possible signalling cascades which lead to the activation of 
cellular survival proliferation and migration. Further details to the interactions are 
explained in the main text.  
Modified from (Guo & Giancotti, 2004).  
In addition to the α6β4 integrin, α4β1 (VLA-4) and αLβ2 have been identified to colocalize 
with the lipid raft marker GM-1 in T-cells. Disruption of raft integrity through depletion of 
membrane cholesterol with methyl--cyclodextrin (MbCD) completely disrupted α4β1 
cluster formation, implying that the lipid rafts are required for α4 integrin clusters (Leitinger 
& Hogg, 2002). The integrins αvβ3, αIIbβ3 and α2β1 are associated with specific integrin 
interacting proteins in cholesterol-dependent microdomains distinct from classical rafts 
(Green et al., 1999). These results hypothesize that the mechanism of membrane 
compartmentalization – as identified for the mentioned integrins – also operates in other 
integrin-signalling systems, which might be an explanation for several specific aspects of 
diverse integrins.  
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5. Possible ways for pharmacological antimetastatic approaches by 
intervention with integrins on the plasma membrane and signalling level 
The integrins, especially the integrin VLA-4 has been for longer time in the interest as target 
for the design of small molecule competive inhibitors as potential antiinflammatory drugs 
(Singh et al, 2004).  
Concerning the “non-competitive” influence on integrins, there basically exist two different 
ways for integrin modulation: An interference with the signal transduction at the 
cytoplasmatic site or an influence on the integrin compartmentalization at the plasma 
membrane. As mentioned before the influence on integrins is mainly mediated via the 
cytoplasmatic tail of their β-subunits which allows the inside-out signalling (Arias-Salgado 
et al., 2003).   
In general, integrins essentially need the specific membrane positioning and membrane 
anchorage of signalling proteins like GTPases of the Ras-superfamily for their signalling 
processes. The distribution of Ras proteins is determined by different C-terminal lipid 
modifications. Extensive experimental studies on Ras-GTPases have revealed that the 
proteins only operate at the plasma membrane (Meder & Simons, 2005; Pechlivanis & 
Kuhlmann, 2006). Several publications have pointed out the importance of Ras 
compartmentalization for signal transduction (Roy et al. 2002; Chiu et al., 2002). In 
particular, the palmitoylation allows the anchorage for H-Ras / N-Ras and the spatial and 
temporal organization plus segregation of the GTPases signal transfer duration. The time of 
PM-Golgi apparatus cycling, for N-Ras the transfer time from the PM to the Golgi apparatus 
during cycling, was remarkably shortened compared to H-Ras (Rocks et al., 2010; Rocks et 
al., 2005). This is in line with their palmitoylation status – two palmitoyl anchors for H-Ras 
and one palmitoyl anchor for N-Ras. Therefore, impact on the GTPase localization by 
affecting the membrane characteristics might have strong consequences for the integrin 
activity too. 
In addition to the α6β4 integrin mentioned before, which possesses as laminin-5 receptor 
unique functions in epithelial growth and carcinoma invasion (Mainiero et al., 1997; Shaw et 
al., 1997) a palmitoylation of the β4-subunit as a prerequisite for the incorporation of α6β4 in 
rafts and the compartmentalization with SFKs  (Gagnoux-Palacios et al., 2003), other 
integrins were also reported to depend critically on their membrane localization. The α4β1 
integrin (VLA-4) was also identified to be localized in lipid rafts, which revealed that lipid 
rafts also play a key role in regulating integrin activity, function and its further downstream 
signalling (Leitinger & Hogg, 2002; Schadendorf et al., 1995; Okahara et al., 1994). Non-raft 
integrins are excluded from the rafts by cytoskeletal constraints and are no more able to 
perform signalling from raft microdomains (Leitinger & Hogg, 2002). Thus, the positioning 
of integrins inside or outside of rafts for their physical interaction with important signalling 
switches, such as GTPases or FAKs depends critically on the surrounding lipid composition. 
Consequently, an influence on the membrane characteristics and lipid composition of tumor 
cells appears as attractive way to influence integrin activities. 
In a recent study, such an aspect of attenuated melanoma metastasis has been reported 
(Jantscheff et al., 2011), which refers to reduced receptor mediated binding by non-
competively interfering with integrin function. This study is based on earlier findings that 
empty liposomes consisting of saturated phosphatidylcholine (PC) displayed strong 
antimetastatic effects in a murine pancreatic mice model (Graeser et al., 2009). Jantscheff et 
al. (2011) postulated that liposomes, passively accumulated in the tumor, release LysoPC as 
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a degradation product of the saturated PC which affects the capability of tumor cells for 
metastases. In order to follow this hypothesis, the authors incubated murine melanoma 
B16.F10 cells with physiological and increased concentrations of saturated LysoPC. The 
melanoma cells fastly removed the LysoPC from the medium which was accompanied by a 
radical shift in tumor cell membrane fatty acid composition towards saturated fatty acids. 
This had strong morphological and functional consequences for the tumor cells. Electron 
microscopic images suggested that the changed membrane composition leads to a strong 
increase in number and size of filopodial-like membrane protrusions. It became evident that 
these morphological changes are based on cytoskeletal contractions. However, these 
concentrations of LysoPC used did not possess direct cytotoxicity. An induction of apoptosis 
could also be excluded.  
The functional basis for antimetastatic effects of LysoPC became exposed by investigating 
the adhesion receptor binding. As mentioned before, melanoma cells make use of their 
integrin VLA-4 binding the endothelial ligand VCAM-1 for vascular arrest in the metastatic 
cascade. LysoPC incubation affected crucially the VLA-4 activity in a concentration 
dependent manner, although the expression levels of this integrin were not changed. 
Exceeding the physiological LysoPC concentration, the melanoma cells lost their ability for 
VCAM-1 binding. Furthermore, even though the treated cells exhibited a remarkably 
augmented number of protrusions, the cell motility on fibronectin as essential requirement 
for distinct steps of metastasis, e.g. tissue transmigration was significantly attenuated. In 
addition, the interaction with platelets via P-selectin was also strongly diminished, which is 
a further factor for reduced metastasis. These in vitro findings were totally reflected in a 
syngenic intravenous lung-invasion model. Using ex vivo-treated B16.F10 cells, LysoPC 
concentrations above the threshold (450 µM) resulted in significantly reduced metastasis-
like lesions in lung tissue.  
The search for the molecular basis of these promising data is ongoing yet, but might lead to 
some preliminary postulations. On the one hand, biophysical aspects of membrane 
properties and their change by the saturated lipids can be discussed to affect integrin 
function. On the other hand, an interference of LysoPC with the integrin signalling at the 
level of GTPases can be assumed.  
Referring to the first assumption, a balance between saturated and unsaturated fatty acids is 
a fundamental biophysical determinant of membrane fluidity (Mansilla et al., 2008). The so-
called homeoviscous adaptation is highly regulated and influences important membrane 
properties as flexibility, and lipid raft composition (Mansilla et al., 2008; Stulnig et al., 2001; 
Callaghan et al., 1993; Hac-Wydro et al., 2007). This strongly indicates that the addition of 
exogenous fully hydrogenated LysoPC and the subsequent change of membrane 
composition might have a clear impact on the deregulation of these factors. Since the 
integrin function is dependent on several aspects of membrane compartmentation (as 
described before), a reduced VLA-4 function could result from changes in e.g. raft domains.  
Concerning the expression of important signalling proteins, we observed slightly reduced 
gene expression of the GTPases RhoA, RhoB and others after LysoPC exposition (300 µM 
and 450 µM) indicating an altered signal transduction in the context of membrane shape and 
adhesion (Alexander M. et al., 2010; 2011). RhoA and RhoB are known to participate in the 
regulaton of cytoskeleton, proliferation, formation of filopodia, lamellipodia, stress fibers 
and adhesion complexes (Hall A., 1998; Bishop & Hall, 2000; Etienne-Manneville & Hall, 
2002; Etienne-Manneville & Hall, 2001; Hall A., 2009). Thus, activation of Rho GTPases is 
necessary for signalling between cells and ECM and for maintenance of cell shape and 
associated focal adhesion complexes (Burridge & Wennerberg, 2004). 
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Furthermore, one main part of cellular crosstalk and adhesion is the signal transduction via 
the integrins and SFKs (Mainiero et al., 1995; 1997; Shaw et al., 1997; 2001). In addition, to 
the reduced gene expression of GTPases, we also identified that several integrin subunits 
(ITGA4, ITGA2 and ITGB1) are reduced in transcription by LysoPC exposition in a 
concentration-dependent manner (Alexander M. et al., 2010). Thus, one can assume 
interplay between the LysoPC incubation and the altered adhesion, membrane morphology 
and gene expression of the examined melanoma cells. 
The exact signal pathway that is affected by LysoPC exposition has to be investigated in 
future analyses due to the fact that not only one or a few defined signal pathways are 
triggering the adhesion process via integrins (Figure 4). Nevertheless it is suggested that – 
due to the kind of deregulated genes – the ERK/MAPK pathway may be one key part of the 
promising antimetastatic effects initiated by LysoPC.  
Genes which are regulated in expression levels by the ERK/MAPK pathway could influence 
the processes of invasion and adhesion. It is not completely understood if ERK/MAPK is 
activated or inhibited by LysoPC but specific kinases such as the dual-specificity 
phosphatase 1 (DUSP1) – a member of the threonine-tyrosine dual-specificity phosphatases - 
are deregulated by LPC treatment. Several members of the dual-specificity phosphatase 
(DUSPs) family are able to dephosphorylate MAPK isoforms with different specificity, 
cellular and tissue localization (Bermundez et al., 2010; Calvisi et al., 2008; Liu et al., 2007). 
The MAP kinases phosphatase (MKP) DUSP1/MKP-1 was shown to dephosphorylate ERKs 
(extracellular-regulated kinases), JNK and p38MAPKs (Liu et al., 2007). DUSP1 displays a 
rather broad specificity for inactivation of the ERK, p38 and JNK MAP kinases (Keyse, 2008). 
In addition, DUSP1 has detectable binding to ERK in vivo and is suggested to act as a 
positive activator of ERK in EGFR-mutant lung cancer cell lines independent of the ability to 
bind to ERK (Britson et al., 2009). Recent findings support the involvement of DUSPs in 
cancer progression and resistance (Bermundez et al., 2010) due to the fact that abnormalities 
in MAPK signalling have important consequences for processes critical to the development 
and progression of human cancer.   
LysoPC exhibit a comparable chemical structure to the experimental anticancer drugs 
miltefosine and edelfosine (Figure 5). The treatment of cancer cells with those 
alkylphosphocholines (APCs), which are able to incorporate into specific membrane 
compartments can disturb the well balanced and organized lipid network and thus 
influence the signalling of associated proteins. Such effects were reported for edelfosine and 
miltefosine, which are known to induce changes in receptor interaction and consequently 
signalling processes (Ausili et al., 2008; Gajate et al., 2009; Mollinedo & Gajate, 2010).  
Since LysoPC possess a remarkably rapid uptake in the membranes of cancer cells, a 
comparable cellular mechanism by the critical alteration of the integrity and functionality of 
specific membrane microdomains could be hypothesized for LysoPC with regard to the 
global gene expression data. Although LysoPC possesses an evident similarity in chemical 
structure compared to the APCs, LysoPC seems to activate different signalling pathways. 
One difference is that exposition with edelfosine leads to selective promotion of apoptosis in 
leukemic cells (Mollinedo et al., 1997; Gajate et al., 2000; 2004).  
Edelfosine was tested as a pharmaceutical compound against prostate cancer (Berdel et al., 
1981), human brain tumors, lung tumors and other cancer types (Berdel et al. 1984; Denizot 
et al., 2001; Haugland et al., 1999; Houlihan et al., 1987; Kosano & Takatani, 1988; Ausili et 
al., 2008). In detail, edelfosine exposition leads to accumulation in lipid rafts (van der Luit et 
al., 2002; Gajate et al., 2004) and to a reorganization of the lipid and protein composition of 
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Fig. 5. Chemical structures of: Lysophosphatidylcholine (1), Miltefosine (2), Edelfosine (3) 
and Ilmofosine (4). 
membrane caveolae (Gajate et al., 2004; Zaremberg et al., 2005; Gajate & Mollinedo, 2007). In 
a multiple myeloma animal model, oral administration of edelfosine showed a potent in 
vivo anti-myeloma activity and the drug accumulated preferentially in the tumor 
(Mollinedo et al., 2010). These data suggest that edelfosine incorporation in lipid rafts leads 
to a redistribution of sterols from the plasma membrane (Zaremberg et al., 2005). The 
redistribution of a major lipid raft component - they consist of cholesterol, glycolipids und 
sphingolipids - is likely to alter the biophysical properties of the lipid raft microdomain with 
putative important consequences for cell fate, due to the fact that the association of raft-
targeted proteins is strongly assumed to be altered. However, there are no data available 
how edelfosine affects the integrin status of tumor cells. 
In addition, the APC analog miltefosine (hexadecylphosphocholine) acts as another 
membrane-directed anti-tumoral and also anti-leishmanial drug (Santa-Rita et al., 2004). It 
activates anti-tumor effects against a broad spectrum of established tumor cell lines and 
solid tumors (Boggs et al., 1998; Wieder et al., 1998; Rybczynska et al., 2001; Jendrossek et al., 
2002). Initial clinical studies have shown promising results: for example, miltefosine may be 
used for the treatment of cutaneous metastases of mammary carcinomas (Clive et al., 1999; 
Jimenez-Lopez et al., 2010).  
Presently it remains open whether the antimetastatic effects and the serious affect on 
integrin activity by LysoPC are in line or on a comparable mechanistic level with the APC 
membrane effects. Future studies will provide insight into the hypotheses on membrane 
effects and the consequences for integrin localization and signalling. However, the non-
competitive influence on the integrin activity by changing the lipid microenvironment 
appears as an interesting approach to interfere with integrin function in tumor cell 
metastasis. 
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The book Research on Melanoma: A Glimpse into Current Directions and Future 
Trends, is divided into sections to represent the most cutting-edge topics in melanoma 
from around the world. The emerging epigenetics of disease, novel therapeutics 
under development and the molecular signaling aberrations are explained in detail. 
Since there are a number of areas in which unknowns exist surrounding the complex 
development of melanoma and its response to therapy, this book illuminates and 
comprehensively discusses such aspects. It is relevant for teaching the novice 
researcher who wants to initiate projects in melanoma and the more senior researcher 
seeking to polish their existing knowledge in this area. Many chapters include visuals 
and illustrations designed to easily guide the reader through the ideas presented.
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